<SEC-DOCUMENT>0001493152-24-011210.txt : 20240326
<SEC-HEADER>0001493152-24-011210.hdr.sgml : 20240326
<ACCEPTANCE-DATETIME>20240325205745
ACCESSION NUMBER:		0001493152-24-011210
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240326
DATE AS OF CHANGE:		20240325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38286
		FILM NUMBER:		24780735

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ENVB="http://enveric.com/20231231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_ENVB_enveric.com_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000890821 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_063_AUD_0_iso4217%2D%2DAUD -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0000890821</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="xdx2ixbrl0071" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0104" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0110" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0111" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="AsOf2023-12-31" id="xdx2ixbrl0135" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="AsOf2023-12-31" id="xdx2ixbrl0138" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0144" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0145" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0194" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:InducementExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0302" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0438" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0440" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0453" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0455" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0468" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0470" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0540" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0543" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0546" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0549" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0555" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0556" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0576" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0577" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0578" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0583" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0585" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0587" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0588" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0593" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0594" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0595" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0596" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0597" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0598" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0602" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0603" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0604" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0605" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0606" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0608" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0620" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0626" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0635" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ENVB:InducementExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0663" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0665" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:NoncashIncomeTaxExpense" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0668" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0681" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0705" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0713" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0717" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0720" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0722" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0743" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0747" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:WarrantsIssuedInConjunctionWithCommonStockIssuance" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0749" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:IssuanceOfEmbeddedDerivative" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0752" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:StockSubscriptionReceivable" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0756" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:OfferingCostsAccruedNotPaid" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0759" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:WarrantsIssuedForOfferingCosts" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0762" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0765" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:InducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0768" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0773" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:ModificationOfWarrantsAsPartOfShareCapitalRaise" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0776" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" contextRef="AsOf2022-12-31" id="xdx2ixbrl0816" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember" id="xdx2ixbrl0893" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_CommonStockInAbeyanceMember" id="xdx2ixbrl0897" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2022-12-31" id="xdx2ixbrl0939" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:PrepaidFranchiseTaxReceivable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0942" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0945" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:GoodwillImpairmentLossGross" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0962" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:GoodwillCurrencyTranslationImpairmentLoss" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0966" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:GoodwillForeignCurrencyTranslationGainLossGross" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0970" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0972" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31" id="xdx2ixbrl0984" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2022-12-31" id="xdx2ixbrl0994" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:AccruedRestructuringCosts" contextRef="AsOf2022-12-31" id="xdx2ixbrl1050" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl1053" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1180" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1182" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1315" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1349" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl1377" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2021-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl1379" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2021-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl1381" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2022-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl1393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl1405" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl1413" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="AsOf2023-12-31" id="xdx2ixbrl1560" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="AsOf2023-12-31" id="xdx2ixbrl1564" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember" id="xdx2ixbrl1582" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1585" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember" id="xdx2ixbrl1591" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember" id="xdx2ixbrl1594" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1614" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1616" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_WainwrightInvestmentOptionsMember" id="xdx2ixbrl1658" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_RDInvestmentOptionsMember" id="xdx2ixbrl1660" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PIPEInvestmentOptionsMember" id="xdx2ixbrl1662" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1706" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1716" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1718" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1752" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1754" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1756" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="xdx2ixbrl1788" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1853" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1854" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1857" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1859" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1860" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1863" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1865" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1866" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1868" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1869" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1871" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1874" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1900" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1901" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ENVB:EffectiveIncomeTaxRateReconciliationDeferredTrueup" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1937" unitRef="Pure" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="envb-20231231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesCRedeemablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityDistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:EquityDistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-012024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-01</xbrli:startDate>
        <xbrli:endDate>2024-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-152023-06-16_custom_KanubaddiSeparationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:KanubaddiSeparationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-15</xbrli:startDate>
        <xbrli:endDate>2023-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-16_custom_KanubaddiSeparationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:KanubaddiSeparationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-152023-06-16_custom_MrKanubaddiEmploymentAgreementMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:MrKanubaddiEmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-15</xbrli:startDate>
        <xbrli:endDate>2023-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-16_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_country_CA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MinimumMember_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MaximumMember_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:PrefundedCommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RestrictedStockUnitsUnvestedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RestrictedStockUnitsUnvestedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockAwardsVestedAndUnIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockAwardsVestedAndUnIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonStockInAbeyanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:CommonStockInAbeyanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CommonStockInAbeyanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:CommonStockInAbeyanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvstmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvstmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:ComputerEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:ComputerEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegistrationRightsAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-03</xbrli:startDate>
        <xbrli:endDate>2023-11-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-03_custom_RegistrationRightsAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegistrationRightsAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-132022-02-15_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-13</xbrli:startDate>
        <xbrli:endDate>2022-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-132022-02-15_custom_UnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENVB:UnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-13</xbrli:startDate>
        <xbrli:endDate>2022-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_UnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENVB:UnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-21</xbrli:startDate>
        <xbrli:endDate>2022-07-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-21</xbrli:startDate>
        <xbrli:endDate>2022-07-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-22_custom_PIPESecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDOfferingAndPIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-25</xbrli:startDate>
        <xbrli:endDate>2022-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-022022-05-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-02</xbrli:startDate>
        <xbrli:endDate>2022-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-02_custom_TwoThousandTwentyLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-102022-02-11_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-10</xbrli:startDate>
        <xbrli:endDate>2022-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-11_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-11_us-gaap_CommonStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-11_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-14_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-22_custom_WarrantAmendmentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-14_custom_WarrantAmendmentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RDOfferingAndPIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDOfferingAndPIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PIPESecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PIPESecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-252022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:PlacementAgentPreferredInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-25</xbrli:startDate>
        <xbrli:endDate>2022-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:PlacementAgentPreferredInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-282023-12-28_custom_FebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-28</xbrli:startDate>
        <xbrli:endDate>2023-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-282023-12-28_custom_FebruaryWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-28</xbrli:startDate>
        <xbrli:endDate>2023-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FebruaryWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-28_custom_FebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PreModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputOptionVolatilityMember_custom_PreModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PreModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PreModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PreModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_ExistingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:ExistingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PostModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PostModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_ExistingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:ExistingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-282023-12-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-28</xbrli:startDate>
        <xbrli:endDate>2023-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-132022-07-14_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-13</xbrli:startDate>
        <xbrli:endDate>2022-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-14_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:RothAndInducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-28</xbrli:startDate>
        <xbrli:endDate>2023-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-28_custom_RothAndInducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:RothAndInducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-04</xbrli:startDate>
        <xbrli:endDate>2022-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-04</xbrli:startDate>
        <xbrli:endDate>2022-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-04</xbrli:startDate>
        <xbrli:endDate>2022-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-04</xbrli:startDate>
        <xbrli:endDate>2022-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENVB:AkosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-042022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENVB:AkosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-04</xbrli:startDate>
        <xbrli:endDate>2022-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_InitialMeasurementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SubsequentMeasurementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_custom_MeasurementInputMarketRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ENVB:MeasurementInputMarketRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-25</xbrli:startDate>
        <xbrli:endDate>2022-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-25</xbrli:startDate>
        <xbrli:endDate>2022-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-25</xbrli:startDate>
        <xbrli:endDate>2022-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AvanceClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AvanceClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_OneTimeMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:VogalNathanPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:OneTimeMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-25</xbrli:startDate>
        <xbrli:endDate>2017-12-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_AdditionalMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:VogalNathanPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:AdditionalMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-25</xbrli:startDate>
        <xbrli:endDate>2017-12-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:VogalNathanPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-25</xbrli:startDate>
        <xbrli:endDate>2017-12-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_OtherConsultingAndVendorAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:OtherConsultingAndVendorAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-292024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-29</xbrli:startDate>
        <xbrli:endDate>2024-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-08</xbrli:startDate>
        <xbrli:endDate>2024-03-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-02</xbrli:startDate>
        <xbrli:endDate>2024-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="AUD">
      <xbrli:measure>iso4217:AUD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20230101__20231231_zNGN3YLdfTuf"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000012" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.2in"><span id="xdx_90F_edei--DocumentAnnualReport_c20230101__20231231_zIO3QXCJctzd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000013" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b>Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the annual period ended: <span id="xdx_902_edei--DocumentPeriodEndDate_c20230101__20231231_z5V2ybsC764h"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayyearen" id="Fact000014" name="dei:DocumentPeriodEndDate"><span id="xdx_903_edei--CurrentFiscalYearEndDate_c20230101__20231231_zlxjSQ2nAmp7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayen" id="Fact000015" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_909_edei--DocumentFiscalYearFocus_c20230101__20231231_zhrJusYzdCBa"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000016" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_909_edei--DocumentTransitionReport_c20230101__20231231_z6eogpRhPa5a"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from ___ to ___</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number <span id="xdx_903_edei--EntityFileNumber_c20230101__20231231_zREwOsNEsoi1"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000018" name="dei:EntityFileNumber">001-38286</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90F_edei--EntityRegistrantName_c20230101__20231231_ztejnNclOSm9"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000019" name="dei:EntityRegistrantName">ENVERIC
BIOSCIENCES, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20230101__20231231_zBRAPEWbviSl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20230101__20231231_zACjABTzU3o2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000021" name="dei:EntityTaxIdentificationNumber">95-4484725</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20230101__20231231_zmtnRptkQxii"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000022" name="dei:EntityAddressAddressLine1">4851
                                            Tamiami Trail N</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20230101__20231231_zqUAfa7yBqki"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000023" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20230101__20231231_z0cE7A6shhdk"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000024" name="dei:EntityAddressCityOrTown">Naples</ix:nonNumeric></span>,
    <span id="xdx_909_edei--EntityAddressStateOrProvince_c20230101__20231231_zOgfQdyamudl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000025" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressPostalZipCode_c20230101__20231231_zc9pC8YP7uQc"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">34103</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--CityAreaCode_c20230101__20231231_zWBF5A6a0Qk"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000027" name="dei:CityAreaCode">(239)</ix:nonNumeric></span>
<span id="xdx_90A_edei--LocalPhoneNumber_c20230101__20231231_zCj4lZi3AYEc"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000028" name="dei:LocalPhoneNumber">302-1707</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20230101__20231231_z32f3kyteW89"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000029" name="dei:Security12bTitle">Common
    Stock, $0.01 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--TradingSymbol_c20230101__20231231_zRlZc0cw1GA3"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000030" name="dei:TradingSymbol">ENVB</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_90E_edei--SecurityExchangeName_c20230101__20231231_zlSKgdjGLNak"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act: None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_903_edei--EntityWellKnownSeasonedIssuer_c20230101__20231231_z0W3IHIBuF4e"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000032" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; <span id="xdx_908_edei--EntityVoluntaryFilers_c20230101__20231231_zUzS1jI4CIq1"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000033" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
- Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act
from their obligations under those Sections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_90E_edei--EntityCurrentReportingStatus_c20230101__20231231_zzPKBCeAtJc5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000034" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746;  No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was
required to submit such files). <span id="xdx_901_edei--EntityInteractiveDataCurrent_c20230101__20231231_zhA9URL46kh3"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000035" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746;  No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityFilerCategory_c20230101__20231231_zpU9GqReYDR7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000036" name="dei:EntityFilerCategory">Non-accelerated
filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_908_edei--EntitySmallBusiness_c20230101__20231231_zTxc50xhvb54"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000037" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20230101__20231231_zFvDUvowRr53"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation of its management&#8217;s assessment of the effectiveness
of its internal controls over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_90C_edei--IcfrAuditorAttestationFlag_c20230101__20231231_zbjBhpWQytEk"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000039" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_905_edei--DocumentFinStmtErrorCorrectionFlag_c20230101__20231231_znqdTbHfRNi7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No
<span id="xdx_908_edei--EntityShellCompany_dbF_c20230101__20231231_zRt9Nweff7J"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000041" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, the last day of the registrant&#8217;s most recently completed second fiscal quarter; the aggregate market value of
the registrant&#8217;s common stock held by non-affiliates of the registrant, based on a closing price of $3.37 per share, was approximately
$<span id="xdx_90D_edei--EntityPublicFloat_iI_pn5n6_c20230630_zQTIbecrXvQd"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-06-30" id="Fact000042" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.1</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 21, 2024, there were <span id="xdx_900_edei--EntityCommonStockSharesOutstanding_iI_pid_c20240321_ziwjPDwym5n8"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-03-21" id="Fact000043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,294,005</ix:nonFraction></span> shares outstanding of Registrant&#8217;s Common Stock (par value $0.01 per share).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DOCUMENTS
INCORPORATED BY REFERENCE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--DocumentsIncorporatedByReferenceTextBlock_c20230101__20231231_zrTFuxnmCYt2" title="Documents Incorporated By Reference"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000045" name="dei:DocumentsIncorporatedByReferenceTextBlock">Portions
of the Company&#8217;s proxy statement for the Annual Meeting of Stockholders to be held May 28, 2024 are incorporated by reference into
Part III of this report. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s
fiscal year ended December 31, 2023. Additionally, portions of the Annual Report are incorporated by reference in this Form 10-K in response
to Items within Part II.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 13.5pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ar_001">PART I - FINANCIAL INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_003">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_001">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_002">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_003">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_004">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_005">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ku_006">PART II - OTHER INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_007">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_008">[Reserved]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_009">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_010">Quantitative and Qualitative Disclosure About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_011">Financial Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_012">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_013">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_014">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_015">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ku_016">PART III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_017">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_018">Executive Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_019">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_020">Certain Relationships and Related Transactions and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_021">Principal Accountant Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ku_022">PART IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_023">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_024">Form 10&#8211;K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ku_025">SIGNATURES</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD LOOKING STATEMENTS;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
FACTOR SUMMARY </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K, including the documents that we incorporate by reference herein, contains forward-looking statements within
the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;). Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical
facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as &#8220;anticipate,&#8221;
&#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221;
&#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions, or the negative of these
terms, or similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual
results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference
to the factors discussed throughout this Annual Report on Form 10-K, and in particular those factors referenced in the section entitled
&#8220;Risk Factors.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements are based on our management&#8217;s belief and assumptions and on information currently available to our management.
These statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and
other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any
future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Numerous factors
could cause our actual results to differ materially from those described in forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the principal risk factors that make investing in our securities risky and might cause our actual results to differ materially
from those projected in these forward-looking statements is set forth below. If any of the following risks occur, our business, financial
condition, results of operations, cash flows, cash available for distribution, ability to service our debt obligations and prospects
could be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependence on the success of our prospective product candidates, which are in early stages of development and may not reach a particular
    stage in development, receive regulatory approval or be successfully commercialized;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    difficulties that may delay, suspend, or scale back our efforts to advance additional early research programs through preclinical
    development and investigational new drug (&#8220;IND&#8221;) application filings and into clinical development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that the cost savings, synergies and growth from our combination with MagicMed Industries Inc. and the successful use of the
    rights and technologies acquired in the combination may not be fully realized or may take longer to realize than expected;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    limited study on the effects of psychedelics, and the chance that future clinical research studies may lead to conclusions that dispute
    or conflict with our understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing, and social acceptance
    of psychedelics;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expensive, time-consuming, and uncertain nature of clinical trials, which are susceptible to change, delays, termination, and differing
    interpretations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to establish that potential products are efficacious or safe in preclinical or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    fact that our current and future preclinical and clinical studies may be conducted outside the United States, and the United States
    Food and Drug Administration may not accept data from such studies to support any new drug applications we may submit after completing
    the applicable developmental and regulatory prerequisites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to effectively and efficiently build, maintain and legally protect our molecular derivatives library so that it can be an
    essential building block from which those in the biotech industry can develop new patented products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish or maintain collaborations on the development of therapeutic candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain appropriate or necessary governmental approvals to market potential products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to manufacture product candidates on a commercial scale or in collaborations with third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    significant and increasing liquidity needs and potential requirements for additional funding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain future funding for developing products and working capital and to obtain such funding on commercially reasonable
    terms;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislative
    changes related to and affecting the healthcare system, including, without limitation, changes and proposed changes to the Patient
    Protection and Affordable Care Act (&#8220;PPACA&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    intense competition we face, often from companies with greater resources and experience than us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain key executives and scientists;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to secure and enforce legal rights related to our products, including intellectual property rights and patent protection;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">political,
    economic, and military instability in Israel which may impede our development programs; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    factors described in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have included important factors in the cautionary statements included in this Annual Report on Form 10-K and the documents we incorporate
by reference herein and, particularly in the &#8220;Risk Factors&#8221; sections of these documents, that we believe could cause actual
results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect
the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. No forward-looking
statement is a guarantee of future performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this Annual Report on Form 10-K and the documents that we incorporate by reference herein completely and with the understanding
that our actual future results may be materially different from what we expect. The forward-looking statements in this Annual Report
on Form 10-K and the documents we incorporate by reference herein represent our views as of the date of this Annual Report on Form 10-K.
We anticipate that subsequent events and developments will cause our views to change. However, we undertake no obligation to publicly
update or revise any forward-looking statements, whether from new information, future events or otherwise, except as required by law.
You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of
this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unless
the context indicates otherwise, references in this Annual Report on Form 10-K to the &#8220;Company,&#8221; &#8220;Enveric,&#8221; &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to Enveric Biosciences, Inc. and its subsidiaries.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_002"></span>Item
1. Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated under the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was a shell
company immediately prior to the completion of a &#8220;reverse merger&#8221; transaction on May 26, 2015, whereby Ameri100 Acquisition,
Inc., a Delaware corporation and newly created, wholly owned subsidiary, was merged with and into Ameri and Partners Inc. (&#8220;Ameri
and Partners&#8221;), a Delaware corporation (the &#8220;2015 Merger&#8221;). In connection with the 2015 Merger, we changed our name
to AMERI Holdings, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ameri business ceased to be part of the Company on December 30, 2020, pursuant to a spin-off transaction. On December 30, 2020, we completed
a tender offer to purchase all of the outstanding common shares of Jay Pharma Inc., a Canada corporation, for shares of Company common
stock or certain preferred stock (the &#8220;Offer&#8221;), and changed our name to &#8220;Enveric Biosciences, Inc.&#8221; Our principal
corporate office is located at Enveric Biosciences, Inc., 4851 Tamiami Trail N, Suite 200, Naples, Florida 34103, telephone (239) 302-1707.
Our internet address is https://www.enveric.com/, and the information included in, or linked to our website is not part of this Annual
Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as a textual reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2021, the Company entered into an Amalgamation Agreement (the &#8220;Amalgamation Agreement&#8221;) with 1306432 B.C. Ltd., a
corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of the Company (&#8220;HoldCo&#8221;),
1306436 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of HoldCo
(&#8220;Purchaser&#8221;), and MagicMed Industries Inc., a corporation existing under the laws of the Province of British Columbia (&#8220;MagicMed&#8221;),
pursuant to which, among other things, the Company, indirectly through Purchaser, acquired all of the outstanding securities of MagicMed
in exchange for securities of the Company by way of an amalgamation under the British Columbia Business Corporations Act, upon the terms
and conditions set forth in the Amalgamation Agreement, such that, upon completion of the Amalgamation (as defined herein), the amalgamated
corporation (&#8220;Amalco&#8221;) became an indirect wholly-owned subsidiary of the Company. The Amalgamation was completed on September
16, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2023, the Company established Enveric Therapeutics, an Australia-based subsidiary, to support the Company&#8217;s plans to
advance its lead program, the EVM201 Series, comprised of the next generation synthetic prodrugs of the active metabolite, psilocin (&#8220;EVM201
Series&#8221;), towards the clinic. Enveric Therapeutics will oversee the Company&#8217;s preclinical, clinical, and regulatory activities
in Australia, including ongoing interactions with the local Human Research Ethics Committees (&#8220;HREC&#8221;) and the Therapeutic Goods Administration
(&#8220;TGA&#8221;), Australia&#8217;s regulatory authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to file Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q with the Securities and Exchange Commission (the
&#8220;SEC&#8221;) on a regular basis, and are required to disclose certain material events in Current Reports on Form 8-K. The SEC maintains
an Internet website that contains reports, proxy and information statements and other information regarding issuers that file electronically
with the SEC. The SEC&#8217;s Internet website is located at http://www.sec.gov. We also make available, free of charge, our Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to these reports on our website at https://www.enveric.com/
as soon as reasonably practicable after those reports and other information is electronically filed with, or furnished to, the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Overview </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression,
anxiety, and addiction disorders. Leveraging our unique discovery and development platform, The Psybrary&#8482;, we have created a robust
intellectual property portfolio of new chemical entities for specific mental health indications. Our lead program, the EVM201 Series,
comprises next generation synthetic prodrugs of the active metabolite, psilocin. We are developing the first product from the EVM201
Series &#8211; EB-002 &#8211; for the treatment of psychiatric disorders. We are also advancing its second program, the EVM301 Series
&#8211; EB 003 &#8211; expected to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders,
mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Psychedelics</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
our amalgamation with MagicMed completed in September 2021 (the &#8220;Amalgamation&#8221;), we have continued to pursue the development
of MagicMed&#8217;s proprietary psychedelic derivatives library, the Psybrary&#8482; which we believe will help us to identify and develop
the right drug candidates needed to address mental health challenges, including anxiety. We synthesize novel versions of classic psychedelics,
such as psilocybin, N,N-Dimethyltryptamine (&#8220;DMT&#8221;), mescaline and MDMA, using a mixture of chemistry and synthetic biology, resulting in
the expansion of the Psybrary&#8482;, which includes 15 patent families with over a million potential variations and hundreds of synthesized
molecules. Within the Psybrary&#8482; we have three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs),
and Generation 3 (new chemical entities). The Company has created over 1,000 novel psychedelic molecular compounds and derivatives (&#8220;Psychedelic
Derivatives&#8221;) that are housed in the Psybrary&#8482;. Our current focus is develop our lead molecules EB-002 and EB-003 and to
out-license other molecules from the Psybrary&#8482;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Akos
Spin-Off </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2022, the Company announced plans to transfer and spin-off its cannabinoid clinical development pipeline assets to Akos Biosciences,
Inc. (formerly known as Acanna Therapeutics, Inc.), a majority-owned subsidiary of the Company (hereafter referred to as &#8220;Akos&#8221;),
which was incorporated on April 13, 2022, by way of dividend to Enveric shareholders (the &#8220;Spin-Off&#8221;). As of May 12, 2023,
the holders of the Company&#8217;s Akos Series A Preferred Stock, par value $0.01 per share (&#8220;Akos Series A Preferred Stock&#8221;)
have exercised this right to force redemption of all of the Akos Series A Preferred Stock for $1,000 per share, plus accrued but unpaid
dividends of $52,057 for a total of $1,052,057. The Company made full payment on May 19, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pipeline of product candidates and key ongoing development programs are shown in the tables below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 46%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    Candidates</b></span></td>
    <td style="text-align: left; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 16%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Targeted
    Indications</b></span></td>
    <td style="text-align: left; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 16%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="text-align: left; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 16%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expected
    Next Steps</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EB-002</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Second-generation
    psychedelic asset: prodrug of psilocin</i></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anxiety</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Clinical
    Development</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing
    of HREC for FIH study in Australia</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EB-003</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Third-generation
    psychedelic-inspired new chemical entity</i></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mental
    health indication</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Clinical
    Development</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND
    Filing</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a party to certain license agreements as described below, and going forward we intend to both develop intellectual property and license
intellectual property from pharmaceutical and biotechnology companies and research institutions which would cover research stage and
clinical stage assets to build a pipeline of product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current focus of Enveric&#8217;s intellectual property is in psychedelics, including multiple portfolios of psychedelic-inspired compounds
and formulations and methods of making, using, and treating mental and neurological disorders. In addition, Enveric has intellectual
property related to computer assisted methods of discovering promising novel psychedelic-inspired compounds. The Enveric intellectual
property estate includes several portfolios of cannabinoid-related patents and patent applications related to the treatment of pain and
treatment of cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Psychedelics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own full rights to 22 patent families related to psychedelic inspired compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Psilocybin
Derivatives</span>. A portfolio of ten patent families, represented by five United States patents and 33 pending United States and non-United
States patent applications, related to psilocybin derivatives, methods of making psilocybin derivatives, and methods for treatment of
mental disorders, such as anxiety, post-traumatic-stress disorder (&#8220;PTSD&#8221;), and other psychiatric conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Psilocybin
Prodrugs</span>. A portfolio of four patent families, represented by three United States patents, three pending United States applications,
and four pending Patent Cooperation Treaty (&#8220;PCT&#8221;) applications related to prodrugs of psilocin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Mescaline
Derivatives &#8211; EVM 501 Series.</span> A portfolio of four patent families represented by four pending United States patent applications
and four PCT applications related to mescaline derivatives and methods of treatment using mescaline derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Mescaline
Derivatives &#8211; EVM 401 Series</span>. A portfolio of four patent families represented by four pending PCT applications related to MDMA
derivatives and methods of treatment using MDMA derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
portfolios include the following published and unpublished applications:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Psilocybin
Derivatives.</span> These ten patent families include applications and patents related to different psilocybin derivative compounds, methods
for making the compounds, methods for modulating a 5-HT2A cell surface receptor, and methods for treating psychiatric disorders:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Glycosylated
    Psilocybin Derivatives and Methods of Using (WO 2022/040802)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Halogenated
    Psilocybin Derivatives and Methods of Using (WO2022047579)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Hydroxylated
    Psilocybin Derivatives and Methods of Using (WO2022047580)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nitrated
    Psilocybin Derivatives and Methods of Using (WO 2022/047583) </i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Aminated
    Psilocybin Derivatives and Methods of Using (WO2023044556A1) </i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nitrilated
    Psilocybin Derivatives and Methods of Using (WO2022104475A1)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Carboxylated
    Psilocybin Derivatives and Methods of Using (WO2022115944) </i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Aldehyde
    and Ketone Derivatives of Psilocybin and Methods of Using (WO2022115960)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prenylated
    Psilocybin Derivatives and Methods of Using (WO2022155751)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Multi-substituent
    Psilocybin Derivatives and Methods of Using (WO2022170438) </i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Psilocybin
Prodrugs.</span> These four patent families include applications and patents related to novel tryptamine derivative compounds which serve
as prodrugs for psilocin, and methods for making and using the prodrugs for treatment of psychiatric disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>C-4
    Substituted Tryptamine Derivatives and Methods of Using (WO2023/173227A1) - </i>This application relates to several groups of novel
    C4-substituted tryptamine derivative compounds and pharmaceutical drug formulations containing C4-ether-substituted tryptamine derivative
    compounds, C4-carbonic ester- substituted tryptamine derivative compounds, C4-polyether substituted tryptamine derivative compounds,
    and C4-phosphate substituted tryptamine derivative compounds. These pharmaceutical formulations may be used to treat psychiatric
    disorders. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>C-4
    Carboxylic Acid Substituted Tryptamine Derivatives and Methods of Using (WO2023/173196A1)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>C-4
    Carbanothioate Substituted Tryptamine Derivatives and Methods of Using (WO 2023/173197)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Salts
    of C4-Carboxylic Acid and C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using (WO 2023/173229)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Mescaline
Derivatives &#8211; EVM 501 Series.</span> These four patent families include applications related to novel mescaline derivative compounds
and pharmaceutical formulations, methods for making and using those compounds and formulations, and methods for treating a neurological
disorder. One is published, and three are currently unpublished PCT applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fused
    Heterocyclic Mescaline Derivatives</i> (<i>WO2024026568A1)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Three
    unpublished applications directed to three other groups of novel Mescaline Derivatives, described in PCT/CA2023/051422, PCT/CA2023/051548,
    and PCT/CA2023/051670</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Four
    unpublished United States Track One Patent Applications, one each corresponding to each of the four PCT application in this family</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Mescaline
Derivatives &#8211; EVM 401 Series. </span>These four patent families include applications related to novel mescaline derivative compounds
and pharmaceutical formulations, methods for making and using those compounds and formulations, and methods for treating a neurological
disorder. One is published, and three are currently unpublished PCT applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Glycosylated
    Mescaline Derivatives and Methods of Using (WO2023/102658)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Isopropylamine
    Analogues of Glycosylated Mescaline Derivatives (WO2023/102659)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phosphorylated
    and Sulfonated Mescaline Derivatives and Methods of Using (WO 2023/044574)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Isopropylamine
    Analogues of Phosphorylated and Sulfonated Mescaline Derivatives (WO 2023/108296)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Computer
Assisted Drug Discovery</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Computer
    Implemented Methods and Systems for Identifying Tryptamine Derivative Compounds Capable of Interacting with a 5-HT2A Receptor (Provisional
    patent application) </i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cannabinoids
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own rights to six families of cannabinoid-related intellectual property. All cannabinoid-related technology, intellectual property, and
agreements are held by Enveric&#8217;s subsidiary, Akos Biosciences, Inc. The Akos cannabinoid portfolios have three focus areas: conjugate
molecules for the treatment of pain; cancer treatment comprising combination treatment; and topical creams for treating the effects of
cancer radiation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cannabinoid-Conjugates</span>.
A portfolio of three patent families discloses and variously claims novel conjugate molecules of cannabinoids linked with either COX-2
inhibitors or steroids for treatment of pain, osteoarthritis, rheumatoid arthritis, and other diseases. Two patent families in-licensed
from Diverse Biotech (see detail below) comprise of one United States patent and twelve pending United States and non-United States patent
applications. The third and wholly owned patent family comprises two United States patents, four pending United States and non-United
States patent applications, and one pending PCT application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cannabinoid
    Conjugate Molecules (WO2020263888A1) (In-licensed)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conjugate
    Molecules (WO2021076197A1) (In-licensed)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cannabinoid
    Conjugate Molecules (WO2023150057A1) (wholly owned by Enveric&#8217;s subsidiary Akos Biosciences, Inc.)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cancer
Treatment.</span> A portfolio of two patent families addresses the treatment of cancer using a combination of a cannabinoid and a chemotherapeutic
agent. The two patent families are represented by one United States patent and five pending United States and non-United States patent
applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Combination
    of a cannabinoid and a chemotherapeutic agent for the treatment of breast cancer (WO2019193112A1)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration
    regimes of cannabinoids in combination with chemotherapeutics against cancer (WO2021028646A1</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cannabinoid
Cr&#232;me</span>. A portfolio comprising a single patent family focuses on cremes for the treatment of radiation dermatitis, a frequent
side effect of cancer treatment which needs a higher standard of care for patients. The patent family includes one pending United States
patent application and one pending PCT application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compositions
    for Topical Treatment of Radiation Dermatitis (WO2023154264A1)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Diverse
Biotech, Inc. In-License</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold limited rights to patent applications owned by Diverse Biotech, Inc. for the use of cannabinoids in conjugate form with five existing,
standard-of-care drugs (celecoxib and four selected steroids) via Diverse Biotech&#8217;s patent pending conjugate drug delivery platform.
Our rights extend to all fields of use. The intended target for development of such conjugates is alleviating pain, specifically the
pain of osteoarthritis, rheumatoid arthritis, and cancer, with the goal of achieving improved and novel therapeutic outcomes for patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
in-licensed Diverse Biotech, Inc. portfolio includes two patent families comprising one issued and 12 pending national applications. Those
patents and applications disclose conjugate chemistry that combines cannabinoids with existing drugs in conjugate form that we believe
will provide differentiation in use and efficacy from combination therapy of drugs and cannabinoids. The license extends for as long
as Enveric intends to develop and commercialize the licensed Agents and Products. The patent applications, should they issue, may expire
as late as 2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
&amp; Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
view of the urgent need for new and more effective mental health treatments, we intend to combine innovative scientific discoveries and
bio-chemical synthesis, along with accelerated clinical development plans to create, develop and progress novel therapies using psychedelic-inspired
medications and similar compounds. Our current research and development efforts are focused on developing novel molecules structurally
related to certain naturally occurring psychedelics with improved pharmaceutical characteristics. Some of the naturally occurring psychedelic
molecules are currently being investigated by researchers around the world as potential treatments for a broad range of psychiatric and
neurologic disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Studies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently pursuing drug discovery and pre-clinical activities in order to advance a number of novel psychedelic-inspired molecules
towards the clinic. Enveric&#8217;s lead programs are EB-002 and EB-003. EB-002 is a next generation prodrug of psilocin, the active
metabolite of psilocybin. It is the lead drug candidate from the EVM201 Series currently advancing through preclinical development with
the aim of initiating first-in-human studies, followed by clinical trials targeting the treatment of anxiety disorders. EB-003 is a next
generation analog of DMT. It is the lead drug candidate from the EVM301 Series currently advancing through preclinical
development with the aim of initiating first-in-human studies, followed by clinical trials targeting the treatment of depression disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to assemble a team of principal investigators with clinical experience across multiple mental health and central nervous system
indications to be responsible for the management, monitoring, and integrity of the clinical research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to submit filings with regulatory agencies including Clinical Trial Applications (&#8220;CTA&#8221;), Investigational New Drug (&#8220;IND&#8221;)
applications and, eventually, new drug applications (&#8220;NDA&#8221;) to seek approval with the US FDA and other jurisdictions, in
connection with our product candidates. The selection, timing, duration, and design of any prospective studies are subject to regulatory
filings, approval and finalization of commercial plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2023, we issued a press release announcing the selection of Australian CRO, Avance Clinical, in preparation for Phase 1 Study
of EB-002, our lead candidate targeting the treatment of anxiety disorders. Under the agreement, Avance Clinical will manage the Phase
1 clinical trial of EB-002 in coordination with our newly established Australian subsidiary, Enveric Therapeutics Pty, Ltd. The Phase
1 clinical trial is designed as a multi-cohort, dose-ascending study to measure the safety and tolerability of EB-002. EB-002, a next-generation
proprietary psilocin prodrug, has been recognized as a New Chemical Entity (&#8220;NCE&#8221;) by Australia&#8217;s TGA and is currently
in preclinical development targeting the treatment of anxiety disorder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2023, we issued a press release announcing the selection of EB-003 as the lead development candidate from our EVM 301 Series.
Our next step is to advance EB-003 into formal pre-clinical studies in support of a future IND filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Scientific
Advisory Board</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a scientific advisory board and plan to seek advice and input from these experienced clinical leaders on matters related
to our research and development programs. The members of our scientific advisory board consist of experts across a range of key disciplines
relevant to our programs. We intend to continue to leverage the broad expertise of our advisors by seeking their counsel on important
topics relating to our product development and clinical development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
scientific advisors are not our employees and do have commitments to, or consulting or advisory contracts with, other entities that may
limit their availability to us. In addition, our scientific advisors may have arrangements with other companies to assist those companies
in developing products or technologies that may compete with us. All of our scientific advisors are affiliated with other entities and
devote a limited portion of their time to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric&#8217;s
current scientific advisors are set forth in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 61%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Specialization</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maurizio
    Fava, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Director of the Clinical Trials Network and Institute</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Research</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    M. Stahl, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of Psychopharmacology for the California Department of State Hospitals</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Research</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sheila
    DeWitt, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair,
    President &amp; CEO of DeuteRx, LLC; COO of Neuromity Therapeutics, Inc.; Founder of RIFFIT, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutics R&amp;D</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Krystal, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of Yale Center for Clinical Investigation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Research</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Maurizio
Fava, M.D.</i> has served as a Scientific Advisor of Enveric since 2022. Dr. Maurizio
Fava is Psychiatrist-in-Chief of the Massachusetts General Hospital (&#8220;MGH&#8221;), executive director of the Clinical Trials Network
and Institute, associate dean for clinical and translational research, and the Slater Family Professor of Psychiatry at Harvard Medical
School. Dr. Fava is a world leader in the field of depression. He has edited eight books and authored or co-authored more than 900 original
articles published in medical journals with international circulation, articles which have been cited more than 95,000 times in the literature
and with an H index greater than 150. Dr. Fava founded and was director of MGH&#8217;s Depression Clinical and Research Program from 1990
until 2014. Under Dr. Fava&#8217;s direction, the Depression Clinical and Research Program became one of the most highly regarded depression
programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. In 2007, he
also founded and is now the executive director of the MGH Psychiatry Clinical Trials Network and Institute, the first academic CRO specialized
in the coordination of multi-center clinical trials in psychiatry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stephen
M. Stahl, M.D., Ph.D.</i> has served as a Scientific Advisor of Enveric since 2022. Dr. Stephen Stahl has held faculty positions at Stanford
University, the University of California at Los Angeles, the Institute of Psychiatry London, the Institute of Neurology London, and,
currently, as Clinical Professor of Psychiatry and Neuroscience at the University of California Riverside, Adjunct Professor of Psychiatry
at the University of California San Diego and as Honorary Fellow in Psychiatry at the University of Cambridge. Dr. Stahl serves as editor-in-chief
of CNS Spectrums and is Senior Academic Advisor and Director of Psychopharmacology for the California Department of State Hospitals (DSH)
where he has a leadership role in addressing violence and decriminalization of the seriously mentally ill. Author of over 575 articles
and chapters with an H index of 69, and more than 2000 scientific presentations and abstracts, Dr. Stahl is an internationally renowned
clinician, researcher, and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has written over 50 textbooks
and edited 15 others, including the best-selling and award-winning textbook, Stahl&#8217;s Essential Psychopharmacology, now in its fifth
edition, and the best-selling and award-winning clinical manual, Essential Psychopharmacology Prescriber&#8217;s Guide, now in its seventh
edition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sheila
DeWitt, M.D.</i> has served as a Scientific Advisor of Enveric since 2022. Dr. Sheila DeWitt is a Life Sciences Executive &amp; Serial
Entrepreneur with over 30 years of experience in pharmaceutical and biotechnology companies. She is currently the Chair, President &amp;
CEO of DeuteRx, LLC, the COO and Board Member of Neuromity Therapeutics, Inc., and a Founder and Board Member of RIFFIT, Inc. She also
collaborates with Poxel SA and Salarius Therapeutics, Inc. on deuterated drug candidates. Dr. DeWitt has founded and/or led the start-up
or turnaround of nine biotechnology companies or business units. Dr. DeWitt earned her B.A. in Chemistry from Cornell University and
Ph.D. in Synthetic Organic Chemistry from Duke University. She is internationally recognized for her pioneering contributions to pharmaceutical
R&amp;D in the areas of combinatorial chemistry, predictive ADMET, nanotechnology, computational chemistry, and deuterated drugs and
has received numerous awards in recognition for her innovation and entrepreneurship. She has authored over 60 publications and abstracts,
created and delivered over 20 short courses or symposia, and is an inventor on over 100 patents and/or patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>John
Krystal, M.D. </i>has served as a Scientific Advisor of Enveric since 2022. Dr. John Krystal
is the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience, and Psychology; Chair of the
Department of Psychiatry at Yale University; and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. He is a graduate
of the University of Chicago, Yale School of Medicine, and the Yale Psychiatry Residency Training Program. He has published extensively
on the neurobiology and treatment of schizophrenia, alcoholism, PTSD, and depression. Notably, his laboratory discovered the rapid antidepressant
effects of ketamine in humans. Dr. Krystal directs/co-directs the Yale Center for Clinical Investigation, NIAAA Center for the Translational
Neuroscience of Alcoholism, and Clinical Neuroscience Division of the National Center for PTSD (VA). He is a member of the U.S. National
Academy of Medicine; co-director of the Neuroscience Forum of the U.S. National Academies of Sciences, Engineering, and Medicine; Fellow
of the American Association for the Advancement of Science; and editor of Biological Psychiatry. Previously, Dr. Krystal chaired the NIMH
Board of Scientific Counselors and has served as a member of the NIMH National Mental Health Advisory Council and the NIAAA National Alcohol
Advisory Council. He also previously served as the president of the American College of Neuropsychopharmacology and the International
College of Neuropsychopharmacology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Academic
Partners </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also established relationships with certain academic partners, whom we believe have the potential to accelerate product development,
market entry, data collection, analysis and advancement of clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary academic partner is the University of Calgary which brings excellence into advancing brain and mental health research and education.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis
on proprietary products. While we believe that our scientific knowledge and technology and development experience provide us with competitive
advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology
companies, academic institutions, governmental agencies, and public and private research institutions. Any product candidates that we
successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to focus on the development of novel and viable Psychedelic Derivatives for mental illnesses and unmet medical needs, and partner
with pharmaceutical and other drug development and biotechnology companies in developing and commercializing psychedelic-derived drugs
for diverse psychological and neuropsychiatric indications, of which will be fundamentally composed of the Psychedelic Derivatives contained
in the Psybrary&#8482;. While we believe that our technology, knowledge and experience as well as the scientific resources at our disposal
provide us with significant competitive advantages, we face potential competition from many different sources. Any product candidates
we successfully identify will compete not only with existing therapies but also new therapies that may become available in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunities could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, more effective,
have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Our
competitors also may obtain approval from the FDA or other regulatory agencies for their medicines more rapidly than us, which could
result in our competitors establishing a strong market position before we are able to enter the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
our Psybrary&#8482; and the intellectual property kept and developed therein, our success depends on our ability to protect our intellectual
property and our ability to achieve and maintain key partnerships aimed at the development, licensing and marketing of Psychedelic Derivatives
without infringing on the proprietary rights of others. Patent positions within the pharmaceutical field can be highly uncertain and
involve complex legal, scientific and factual questions for which important legal principles remain unresolved. Patents issued to us
may be challenged, invalidated or circumvented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation and Product Approvals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
companies are subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic
Act, or the FDCA, and, to a lesser extent, by state and local governments. Before our prescription products may be marketed in the U.S.,
they must be approved by the FDA for commercial distribution. Certain OTC products must comply with applicable FDA regulations, known
as OTC Monographs, in order to be marketed, but do not have the benefit of FDA review and approval before marketing. We are also subject
to regulation under federal, state and local laws, including requirements regarding occupational safety, laboratory practices, environmental
protection and hazardous substance control, and may be subject to other present and future local, state, federal and foreign regulations.
We cannot predict the extent to which we may be affected by legislative and other regulatory developments concerning our products and
the healthcare industry in general.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDCA and other federal and state statutes and regulations govern the testing, manufacture, quality control, export and import, labeling,
storage, record keeping, approval, pricing, advertising, promotion, sale and distribution of pharmaceutical products. Noncompliance with
applicable requirements both before and after approval, can subject us, our third party manufacturers and other collaborative partners
to administrative and judicial sanctions, such as, among other things, warning letters, fines and other monetary payments, recall or
seizure of products, criminal proceedings, suspension or withdrawal of regulatory approvals, interruption or cessation of clinical trials,
total or partial suspension of production or distribution, injunctions, limitations on or the limitation of claims we can make for our
products, and refusal of the government to enter into supply contracts for distribution directly by governmental agencies, or delay in
approving or refusal to approve new drug applications. The FDA also has the authority to revoke or withhold approvals of new drug applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
approval is required before any &#8220;new drug,&#8221; can be marketed. Our products are new drugs and require prior FDA approval. Such
approval must be based on extensive information and data submitted in a NDA, including, but not limited to, adequate and well controlled
laboratory and clinical investigations to demonstrate the safety and effectiveness of the drug product for its intended use(s) as well
as the manufacturing suitability of the product. In addition to providing required safety and effectiveness data for FDA approval, a
drug manufacturer&#8217;s practices and procedures must comply with current Good Manufacturing Practices (&#8220;cGMPs&#8221;), which
apply to manufacturing, receiving, holding and shipping, and include, among other things, demonstration of product purity, consistent
manufacturing and quality and at least six months of data supporting product expiration dating based on clinical registration batches.
Accordingly, manufacturers must continue to expend time, money and effort in all applicable areas relating to quality assurance and regulatory
compliance, including production and quality control to comply with cGMPs. Failure to so comply risks delays in approval of drug products
and possible FDA enforcement actions, such as an injunction against shipment of products, the seizure of non-complying products, criminal
prosecution and/or any of the other possible consequences described above. We are subject to periodic inspection by the FDA and the Drug
Enforcement Administration (&#8220;DEA&#8221;), which inspections may or may not be announced in advance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intellectual property kept and developed in our Psybrary&#8482; is focused solely on developing and commercializing non-hallucinogenic
synthetic derivatives of psychedelic substances. While we use psychedelic inspired compounds and classic psychedelics as our starting
point for our research and identification of compounds, we do not have any direct or indirect involvement in the illegal selling, production
or distribution of any substances in the jurisdictions in which we operate. Enveric is a neuro-pharmaceutical scientific company and
as such we do not advocate for the legalization of psychedelic substances nor do we deal with psychedelic substances except within laboratory
and clinical trial settings conducted within approved regulatory frameworks. Our products will not be commercialized prior to applicable
regulatory approval and this approval will only be granted if clinical evidence of safety and efficacy for the specific intended use
is successfully developed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
execution of our strategy is in part contingent upon compliance with regulatory requirements enacted by governmental authorities and
obtaining regulatory approvals for the development and license of its Psychedelic Derivatives. The psychedelic therapy industry is a
new and emerging industry with ambiguous existing regulations and uncertainty as to future regulations; we cannot predict the impact
of the ever-evolving compliance regime in respect of this industry. The impact of compliance regimes, any delays in obtaining, or failure
to obtain regulatory approvals may significantly delay or impact our development of markets, our business, Psychedelic Derivatives, and
licensing initiatives and could have a material adverse effect on our business, financial condition and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FDA
New Drug Approval Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDCA,
and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage,
recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import
and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative
or judicial sanctions, such as imposition of clinical holds, FDA refusal to approve pending NDAs, warning letters, product recalls, product
seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution,
disgorgement, civil penalties and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
product development in the U.S. typically involves pre-clinical laboratory and animal tests and the submission to the FDA of an IND,
which must become effective before clinical testing may commence. For commercial approval, the sponsor must submit adequate tests by
all methods reasonably applicable to show that the drug is safe for use under the conditions prescribed, recommended or suggested in
the proposed labeling. The sponsor must also submit substantial evidence, generally consisting of adequate, well-controlled clinical
trials to establish that the drug will have the effect it purports or is represented to have under the conditions of use prescribed,
recommended or suggested in the proposed labeling. In certain cases, the FDA may determine that a drug is effective based on one clinical
study plus confirmatory evidence. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time
required may vary substantially based upon the type, complexity and novelty of the product or disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics
and potential safety and efficacy of the product. The conduct of the pre-clinical tests must comply with federal regulations and requirements,
including the FDA&#8217;s good laboratory practices regulations and the U.S. Department of Agriculture&#8217;s (USDA&#8217;s) regulations
implementing the Animal Welfare Act. The results of pre-clinical testing are submitted to the FDA as part of an IND application along
with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol.
Long-term pre-clinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND application
is submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
30-day waiting period after the submission of each IND application is required prior to the commencement of clinical testing in humans.
If the FDA has not imposed a clinical hold on the IND application or otherwise commented or questioned the IND application within this
30-day period, the clinical trial proposed in the IND application may begin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the IND to healthy volunteers or patients under the supervision of a qualified investigator. Clinical
trials must be conducted: (i) in compliance with federal regulations, (ii) in compliance with GCP (&#8220;Good Clinical Practice&#8221;),
an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators
and monitors, and (iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the
effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted
to the FDA as part of the IND application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time or impose other sanctions if it believes that
the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical
trial patients. The trial protocol and informed consent information for patients in clinical trials must also be submitted to an institutional
review board, or IRB, for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently,
for failure to comply with the IRB&#8217;s requirements or may impose other conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In general,
in Phase 1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics,
pharmacological actions, side effects associated with increasing doses and, if possible, early evidence on effectiveness. Phase 2 usually
involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance
and optimum dosage, and to identify common adverse effects and safety risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken
to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed
clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information
for the labeling of the drug. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate
the efficacy of the drug. The FDA may, however, determine that a drug is effective based on one clinical study plus confirmatory evidence.
Only a small percentage of investigational drugs complete all three phases and obtain marketing approval. In some cases, the FDA may
require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval in order to gather additional information
on the drug&#8217;s effect in various populations and any side effects associated with long-term use. Depending on the risks posed by
the drugs, other post-market requirements may be imposed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completion of the required clinical testing, an NDA is prepared and submitted to the FDA. The FDA approval of the NDA is required before
marketing of the product may begin in the U.S. The NDA must include the results of all pre-clinical, clinical, and other testing and
a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting
an NDA is substantial. Under federal law, the submission of most NDAs is additionally subject to a substantial application user fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s
threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the
FDA begins an in-depth review. Under the statute and implementing regulations, the FDA has 180 days (the initial review cycle) from the
date of filing to issue either an approval letter or a complete response letter, unless the review period is adjusted by mutual agreement
between the FDA and the applicant or as a result of the applicant submitting a major amendment. In practice, the performance goals established
pursuant to the Prescription Drug User Fee Act have effectively extended the initial review cycle beyond 180 days. The FDA&#8217;s current
performance goals call for the FDA to complete review of 90 percent of standard (non-priority) NDAs within 10 months of receipt and within
six months for priority NDAs, but two additional months of review are added to standard and priority NDAs for a new molecular entity
(NME).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to
an advisory committee, which is typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation
as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally
follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance
with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve
the product unless compliance with current GMP is satisfactory and the NDA contains data that provide substantial evidence that the drug
is safe and effective in the indication studied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete
response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information,
in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction
in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing 90 percent of resubmissions within
two to six months depending on the type of information included.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition
of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug
outweigh the potential risks. REMS can include medication guides, communication plans for health care professionals, and elements to
assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing,
dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially
affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and
surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory
standards is not maintained or problems are identified following initial marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disclosure
of Clinical Trial Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsors
of clinical trials of certain FDA-regulated products, including prescription drugs, are required to register and disclose certain clinical
trial information on a public website maintained by the U.S. National Institutes of Health. Information related to the product, patient
population, phase of investigation, study sites and investigator, and other aspects of the clinical trial is made public as part of the
registration. Sponsors are also obligated to disclose the results of these trials after completion. Disclosure of the results of these
trials can be delayed for up to two years if the sponsor certifies that it is seeking approval of an unapproved product or that it will
file an application for approval of a new indication for an approved product within one year. Competitors may use this publicly available
information to gain knowledge regarding the design and progress of our development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Special
Protocol Assessment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
company may reach an agreement with the FDA under the Special Protocol Assessment, or &#8220;SPA&#8221;, process as to the required design
and size of clinical trials intended to form the primary basis of an efficacy claim. According to its performance goals, the FDA is supposed
to evaluate the protocol within 45 days of the request to assess whether the proposed trial is adequate, and that evaluation may result
in discussions and a request for additional information. A SPA request must be made before the proposed trial begins, and all open issues
must be resolved before the trial begins. If a written agreement is reached, it will be documented and made part of the administrative
record. Under the FDCA and FDA guidance implementing the statutory requirement, an SPA is generally binding upon the FDA except in limited
circumstances, such as if the FDA identifies a substantial scientific issue essential to determining safety or efficacy after the study
begins, public health concerns emerge that were unrecognized at the time of the protocol assessment, the sponsor and the FDA agree to
the change in writing, or if the study sponsor fails to follow the protocol that was agreed upon with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advertising
and Promotion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-approval
promotion of investigational drug candidates is prohibited by the FDA. Therefore, sponsors must ensure that any pre-approval communications
disseminated about its drug candidates do not state or imply that such candidates have been proven safe or effective for the applicable
use(s) or that they have been approved for commercialization in the United States. Further, once an NDA for a given candidate is approved,
if ever, the product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval
marketing and promotion of drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of
the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities,
require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new
indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions
in reviewing NDA supplements as it does in reviewing NDAs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adverse
Event Reporting and GMP Compliance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-marketing
testing, known as Phase 4 testing, may require under a REMS special communication regarding the safety of the drug or heightened surveillance
to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or
use of the product. In addition, quality-control, drug manufacture, packaging, and labeling procedures must continue to conform to GMP,
after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and
certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the
agency inspects manufacturing facilities to assess compliance with GMP. Accordingly, manufacturers must continue to expend time, money
and effort in the areas of production and quality control to maintain compliance with GMP. Regulatory authorities may withdraw product
approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial
marketing or if previously unrecognized problems are subsequently discovered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pediatric
Exclusivity and Pediatric Use</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Best Pharmaceuticals for Children Act, or &#8220;BPCA&#8221;, provides NDA holders a six-month period of exclusivity attached to any
other exclusivity listed with the FDA&#8201;&#8212;&#8201;patent or non-patent&#8201;&#8212;&#8201;for a drug, if certain conditions
are met. Conditions for pediatric exclusivity include a determination by the FDA that information relating to the use of a new drug in
the pediatric population may produce health benefits in that population; a written request by the FDA for pediatric studies; and agreement
by the applicant to perform the requested studies and the submission to the FDA, completion of the studies in accordance with the written
request, and the acceptance by the FDA, of the reports of the requested studies within the statutory time frame. Applications under the
BPCA are treated as priority applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Pediatric Research Equity Act, or &#8220;PREA&#8221;, NDAs or supplements to NDAs must contain data to assess the
safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration
for each pediatric subpopulation for which the drug is safe and effective, unless the sponsor has received a deferral or waiver from
the FDA. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has
been granted. The sponsor or the FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral
may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric studies
are complete or that additional safety or effectiveness data need to be collected before the pediatric studies begin. Under PREA, the
FDA must send a noncompliance letter requesting a response within 45 days to any sponsor that fails to submit the required assessment,
keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Controlled
Substances</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Controlled Substances Act of 1970, or &#8220;CSA&#8221;, and its implementing regulations establish a &#8220;closed system&#8221;
of regulations for controlled substances. The CSA imposes registration, security, recordkeeping and reporting, storage, manufacturing,
distribution, importation and other requirements under the oversight of the Drug Enforcement Agency (&#8220;DEA&#8221;). The DEA is the
federal agency responsible for regulating controlled substances, and requires those individuals or entities that manufacture, import,
export, distribute, research, or dispense controlled substances to comply with the regulatory requirements in order to prevent the diversion
of controlled substances to illicit channels of commerce.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DEA categorizes controlled substances into one of five schedules&#8201;&#8212;&#8201;Schedule I, II, III, IV or V&#8201;&#8212;&#8201;with
varying qualifications for listing in each schedule. Schedule I substances by definition have a high potential for abuse, have no currently
accepted medical use in treatment in the U.S., and lack accepted safety for use under medical supervision. Marijuana and psychedelics
such as psilocybin, DMT, mescaline and MDMA are currently Schedule I controlled substances, which means that no preclinical or clinical
studies of product candidates containing these substances may be conducted in the United States without the required DEA registration(s)
and related approvals, as applicable. Pharmaceutical products having a currently accepted medical use that are otherwise approved for
marketing may be listed as Schedule II, III, IV or V substances, with Schedule II substances presenting the highest potential for abuse
and physical or psychological dependence, and Schedule V substances presenting the lowest relative potential for abuse and dependence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facilities
that manufacture, distribute, import, or export any controlled substance must register annually with the DEA. The DEA registration is
specific to the particular location, activity(ies) and controlled substance schedule(s). For example, separate registrations are required
for importation and manufacturing activities, and each registration authorizes which schedules of controlled substances the registrant
may handle. However, certain coincidental activities are permitted without obtaining a separate DEA registration, such as distribution
of controlled substances by the manufacturer that produces them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DEA inspects all manufacturing facilities to review security, recordkeeping, reporting, and handling prior to issuing a controlled substance
registration. The specific security requirements vary by the type of business activity and the schedule and quantity of controlled substances
handled. The most stringent requirements apply to manufacturers of Schedules I and Schedule II substances. Required security measures
commonly include background checks on employees and physical control of controlled substances through storage in approved vaults, safes
and cages, and through use of alarm systems and surveillance cameras. An application for a manufacturing registration as a bulk manufacturer
(not a dosage form manufacturer or a repacker/relabeler) for a Schedule I or II substance must be published in the Federal Register,
and is open for 60 days to permit interested persons to submit comments, objections or requests for a hearing. A copy of the notice of
the Federal Register publication is simultaneously forwarded by DEA to all those registered, or applicants for registration, as bulk
manufacturers of that substance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
registered, manufacturing facilities must maintain records documenting the manufacture, receipt and distribution of all controlled substances.
Manufacturers must submit periodic reports to the DEA of the distribution of Schedules I and II controlled substances, Schedule III narcotic
substances, and other designated substances. Registrants must also report any controlled substance thefts or significant losses, and
must obtain authorization to destroy or dispose of controlled substances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
with applications for registration as a bulk manufacturer, an application for an importer registration for a Schedule I or II substance
must also be published in the Federal Register, which remains open for 30 days for comments. Imports of Schedules I and II controlled
substances for commercial purposes are generally restricted to substances not already available from a domestic supplier or where there
is not adequate competition among domestic suppliers. In addition to an importer or exporter registration, importers and exporters must
obtain a permit for every import or export of a Schedules I and II substance or Schedules III, IV and V narcotic, and submit import or
export declarations for Schedules III, IV and V non-narcotics. In some cases, Schedule III non-narcotic substances may be subject to
the import/export permit requirement, if necessary to ensure that the U.S. complies with its obligations under international drug control
treaties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
drugs manufactured in the U.S., the DEA establishes annually an aggregate quota for the amount of substances within Schedules I and II
that may be manufactured or produced in the U.S. based on the DEA&#8217;s estimate of the quantity needed to meet legitimate medical,
scientific, research and industrial needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
states also maintain separate controlled substance laws and regulations, including licensing, recordkeeping, security, distribution,
and dispensing requirements. State Authorities, including Boards of Pharmacy, regulate use of controlled substances in each state. Failure
to maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can
result in enforcement action that could have a material adverse effect on our business, operations and financial condition. The DEA may
seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances,
violations could lead to criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Europe/Rest
of World Government Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the U.S., we are and will be subject, either directly or through our distribution partners, to a variety of
regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales (including pricing and reimbursement)
and distribution of our product candidates, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries
prior to the commencement of clinical trials or marketing of the product in those countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, medicinal products are subject to extensive pre- and post-marketing regulation by regulatory authorities at both
the European Union and national levels. Additional rules also apply at the national level to the manufacture, import, export, storage,
distribution and sale of controlled substances. In many European Union member states the regulatory authority responsible for medicinal
products is also responsible for controlled substances. Responsibility is, however, split in some member states. Generally, any company
manufacturing or distributing a medicinal product containing a controlled substance in the European Union will need to hold a controlled
substances license from the competent national authority and will be subject to specific record-keeping and security obligations. Separate
import or export certificates are required for each shipment into or out of the member state.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trials and Marketing Approval</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable regulatory authorities
of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies
from country to country and can involve additional product testing and additional administrative review periods. The time required to
obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in
one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may
negatively impact the regulatory process in others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
countries outside of the U.S. have a process that requires the submission of a clinical trial application much like an IND application
prior to the commencement of human clinical trials. In Europe, for example, a clinical trial application, or &#8220;CTA&#8221;, must
be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends
to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s requirements and a company has received favorable
ethics committee approval, clinical trial development may proceed in that country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
requirements and process governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to
country, even though there is already some degree of legal harmonization in the European Union member states resulting from the national
implementation of underlying European Union legislation. In all cases, the clinical trials must be conducted in accordance with the International
Conference on Harmonization, or &#8220;ICH&#8221;, guidelines on GCP and other applicable regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain regulatory approval to place a drug on the market in European Union countries, Enveric must submit a marketing authorization application.
This application is similar to the NDA in the U.S., with the exception of, among other things, country-specific document requirements.
All application procedures require an application in the common technical document, or CTD, format, which includes the submission of
detailed information about the manufacturing and quality of the product, and nonclinical and clinical trial information. Drugs can be
authorized in the European Union by using (i) the centralized authorization procedure, (ii) the mutual recognition procedure, (iii) the
decentralized procedure, or (iv) national authorization procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
European Commission created the centralized procedure for the approval of human drugs to facilitate marketing authorizations that are
valid throughout the European Union and, by extension (after national implementing decisions) in Iceland, Liechtenstein and Norway, which,
together with the European Union Member States, comprise the European Economic Area, or &#8220;EEA&#8221;. Applicants file marketing
authorization applications with the EMA (European Medicines Agency), where they are reviewed by a relevant scientific committee, in most
cases the Committee for Medicinal Products for Human Use (the &#8220;CHMP&#8221;). The EMA forwards CHMP opinions to the European Commission,
which uses them as the basis for deciding whether to grant a marketing authorization. This procedure results in a single marketing authorization
granted by the European Commission that is valid across the European Union, as well as in Iceland, Liechtenstein and Norway. The centralized
procedure is compulsory for human drugs that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain
a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases,
autoimmune and other immune dysfunctions and viral diseases, (iii) officially designated &#8220;orphan drugs&#8221; (drugs used for rare
human diseases), and (iv) advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines. The
centralized procedure may at the voluntary request of the applicant also be used for human drugs that do not fall within the above-mentioned
categories if the CHMP agrees that the human drug (a) contains a new active substance not yet approved on November 20, 2005; (b) constitutes
a significant therapeutic, scientific or technical innovation, or (c) authorization under the centralized procedure is in the interests
of patients at the European Union level. Since the U.K. exited the E.U., it no longer falls under these regulations, however, it has
been decided it will follow EMA as it is transitioning to regulations as defined by the Medicines and Healthcare products Regulatory
Agency (MHRA). The MHRA has temporary arrangements in place to partially align with EU regulations around medical technology including
the sale of CE-marked medical devices until June 2023 and approval of EU-authorized medicines using a mutual recognition procedure until
the end of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the centralized procedure in the European Union, the maximum time frame for the evaluation of a marketing authorization application by
the EMA is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response
to questions asked by the CHMP), with adoption of the actual marketing authorization by the European Commission thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest
from the point of view of therapeutic innovation, defined by three cumulative criteria: the seriousness of the disease to be treated;
the absence of an appropriate alternative therapeutic approach, and anticipation of exceptional high therapeutic benefit. In this circumstance,
EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion issued thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
those medicinal products for which the centralized procedure is not available, the applicant must submit marketing authorization applications
to the national medicines regulators through one of three procedures: (i) the mutual recognition procedure (which must be used if the
product has already been authorized in at least one other European Union member state, and in which the European Union member states
are required to grant an authorization recognizing the existing authorization in the other European Union member state, unless they identify
a serious risk to public health), (ii) the decentralized procedure (in which applications are submitted simultaneously in two or more
European Union member states), or (iii) national authorization procedures (which results in a marketing authorization in a single European
Union member state).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mutual
Recognition Procedure</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
mutual recognition procedure, or &#8220;MRP&#8221;, for the approval of human drugs is an alternative approach to facilitate individual
national marketing authorizations within the European Union. Fundamentally, the MRP may be applied for all human drugs for which the
centralized procedure is not obligatory. The MRP is applicable to the majority of conventional medicinal products, and must be used if
the product has already been authorized in one or more European Union member states.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MRP functions by building on an already-existing marketing authorization in a member state of the European Union which is used as a reference
in order to obtain marketing authorizations in other European Union member states. Under the MRP, if a marketing authorization for a
drug already exists in one or more member states of the European Union and subsequently marketing authorization applications are made
in other European Union member states by referring to the initial marketing authorization. The member state in which the marketing authorization
was first granted will then act as the reference member state. The member states where the marketing authorization is subsequently applied
for act as concerned member states. The concerned member states are required to grant an authorization recognizing the existing authorization
in the reference member state, unless they identify a serious risk to public health.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MRP is based on the principle of the mutual recognition by European Union member states of their respective national marketing authorizations.
Based on a marketing authorization in the reference member state, the applicant may apply for marketing authorizations in other member
states. In such case, the reference member state shall update its existing assessment report about the drug in 90 days. After the assessment
is completed, copies of the report are sent to all member states, together with the approved summary of product characteristics, labeling
and package leaflet. The concerned member states then have 90 days to recognize the decision of the reference member state and the summary
of product characteristics, labeling and package leaflet. National marketing authorizations shall be granted within 30 days after acknowledgement
of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any European Union member state refuse to recognize the marketing authorization by the reference member state, on the grounds of potential
serious risk to public health, the issue will be referred to a coordination group. Within a time frame of 60 days, member states shall,
within the coordination group, make all efforts to reach a consensus. If this fails, the procedure is submitted to an EMA scientific
committee for arbitration. The opinion of this EMA Committee is then forwarded to the European Commission, for the start of the decision-making
process. As in the centralized procedure, this process entails consulting various European Commission Directorates General and the Standing
Committee on Human Medicinal Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
Exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, marketing authorization applications for generic medicinal products do not need to include the results of pre-clinical
and clinical trials, but instead can refer to the data included in the marketing authorization of a reference product for which regulatory
data exclusivity has expired. If a marketing authorization is granted for a medicinal product containing a new active substance, that
product benefits from eight years of data exclusivity, during which generic marketing authorization applications referring to the data
of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity, during which such generic
products may not be placed on the market. The two-year period may be extended to three years if during the first eight years a new therapeutic
indication with significant clinical benefit over existing therapies is approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
Medicinal Products</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EMA&#8217;s Committee for Orphan Medicinal Products (&#8220;COMP&#8221;) may recommend orphan medicinal product designation to promote
the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating
conditions affecting not more than 5 in 10,000 persons in the European Union. Additionally, designation is granted for products intended
for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without
incentives, it is unlikely that sales of the product in the European Union would be sufficient to justify the necessary investment in
developing the medicinal product. The COMP may only recommend orphan medicinal product designation when the product in question offers
a significant clinical benefit over existing approved products for the relevant indication. Following a positive opinion by the COMP,
the European Commission adopts a decision granting orphan status. The COMP will reassess orphan status in parallel with EMA review of
a marketing authorization application and orphan status may be withdrawn at that stage if it no longer fulfills the orphan criteria (for
instance because in the meantime a new product was approved for the indication and no convincing data are available to demonstrate a
significant benefit over that product). Orphan medicinal product designation entitles a party to financial incentives such as reduction
of fees or fee waivers and ten years of market exclusivity is granted following marketing authorization. During this period, the competent
authorities may not accept or approve any similar medicinal product, unless it offers a significant clinical benefit. This period may
be reduced to six years if the orphan medicinal product designation criteria are no longer met, including where it is shown that the
product is sufficiently profitable not to justify maintenance of market exclusivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pediatric
Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, companies developing a new medicinal product must agree to a Pediatric Investigation Plan, or &#8220;PIP&#8221;,
with the EMA and must conduct pediatric clinical trials in accordance with that PIP unless a waiver applies, for example, because the
relevant disease or condition occurs only in adults. The marketing authorization application for the product must include the results
of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which
case the pediatric clinical trials must be completed at a later date. Products that are granted a marketing authorization on the basis
of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six-month extension of the protection under
a supplementary protection certificate (if the product covered by it qualifies for one at the time of approval). This pediatric reward
is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical
trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, most countries are parties to the Single Convention on Narcotic Drugs 1961, which governs international trade and domestic
control of narcotic substances. Countries may interpret and implement their treaty obligations in a way that creates a legal obstacle
to us obtaining marketing approval for our product candidates in those countries. These countries may not be willing or able to amend
or otherwise modify their laws and regulations to permit our product candidates to be marketed, or achieving such amendments to the laws
and regulations may take a prolonged period of time. In that case, we would be unable to market our product candidates in those countries
in the near future or perhaps at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have consolidated our employee base to save capital and focus on development of our leading candidates EB-002 and EB-003. As of the date
of this report, we employ 7 full-time employees. We also work with scientific advisors, consultants and service providers, mainly through
academic institutions and contract research organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never had a work stoppage and none of its employees are covered by collective bargaining agreements or represented by a labor union.
We believe that we have good relationships with our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_003"></span>Item
1A. Risk factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business and Financial Condition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern as of
December 31, 2023. We will be unable to continue to operate for the foreseeable future without additional capital.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our independent registered public accounting firm issued a report dated
March 25, 2024 in connection with the audit of our consolidated financial statements as of December 31, 2023, which included an explanatory
paragraph describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern including
our recurring losses, cash used in operations, and need to raise additional funds to meet our obligations and sustain our operations.
In addition, the notes to our financial statements for the year ended December 31, 2023, included in this Annual Report on Form 10-K,
contain a disclosure describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern.
Our ability to continue as a going concern is dependent upon our ability to obtain substantial additional funding in connection with our
continuing operations. Adequate additional financing may not be available to us in the necessary timeframe, in the amounts we require,
on terms that acceptable to us, or at all. If we are unable to raise additional capital our business, prospectus, financial condition
and results of operations will be materially and adversely affected and we may be unable to continue as a going concern. For example,
we anticipate that our existing cash, including funds raised during the first quarter of 2024, will enable us to maintain our current
operations into the fourth quarter of fiscal year 2024, but not beyond. If we are not able to continue as a going concern, we may have
to liquidate our assets and may receive less than the value at which those assets are carried on our consolidated financial statements
and/or seek protection under federal bankruptcy law, and it is likely that holders of our common stock and holders of securities convertible
into our common stock will lose all of their investment. If we seek additional financing to fund our business activities in the future
and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling
to provide additional funding on commercially reasonable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial
doubt about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on the success of our prospective product candidates, which are in early stages of development, and there can be no assurances
that any such prospects will reach a particular stage in development, receive regulatory approval or be successfully commercialized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend on our ability to successfully develop and commercialize our prospective product candidates through our development
programs. We intend to develop at least two product candidates, currently EB-003 and EB-002, by undergoing the long, costly clinical-trial
process for each candidate under an IND application and, eventually, obtaining FDA approval under an NDA before proceeding to market.
In order to proceed with development of our pharmaceutical product candidates under the NDA pathway, we must obtain the FDA&#8217;s approval
of our IND application and conduct preclinical and clinical trials in compliance with the applicable IND regulations, clinical-study
protocols, and other applicable regulations and related requirements. We may never be able to develop products which are commercially
viable or receive regulatory approval in the U.S. or elsewhere. There can be no assurance that the FDA or any other regulatory authority
will approve of our current or future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or &#8220;FDCA,&#8221; and implementing regulations.
Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and
the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial
time and financial resources. The process required by the FDA before a new drug or biological product may be marketed in the United States
generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of preclinical laboratory tests, animal studies, and formulation studies according to Good Laboratory Practices and other applicable
    regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission
    to the FDA of an IND application, which must become effective before human clinical trials may begin in the United States;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    of adequate and well-controlled human clinical trials according to the FDA&#8217;s current good clinical practices, or GCPs, which
    sufficiently demonstrate the safety and efficacy of the proposed drug or biologic for its intended uses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission
    to the FDA of a New Drug Application, or an NDA, for a new drug product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory
    completion of an FDA inspection of the manufacturing facility or facilities where the drug or biologic is to be produced to assess
    compliance with the FDA&#8217;s current good manufacturing practice standards, or cGMP, to assure that the facilities, methods and
    controls are adequate to preserve the drug&#8217;s or biologic&#8217;s identity, strength, quality and purity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
    FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA or biologics license application;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and, potentially, approval of the NDA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require
the expenditure of substantial resources. There can be no certainty that approvals will be granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter difficulties that may delay, suspend or scale back our efforts to advance additional early research programs through preclinical
development and IND application filings and into clinical development.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to advance early research programs through preclinical development and to file an IND application for human clinical trials evaluating
the prospective product candidates in our pipeline. The preparation and submission of IND applications requires rigorous and time-consuming
preclinical testing, the results of which must be sufficiently documented to establish, among other things, the toxicity, safety, manufacturing,
chemistry and clinical protocol of the product candidates. We may experience unforeseen difficulties that could delay or otherwise prevent
us from successfully executing our current development strategy. In addition, our ability to complete and file certain IND applications
may depend on the support of our partners and the timely performance of their obligations under relevant collaboration agreements. If
our relevant partners are not able to perform such obligations, or if they otherwise delay the progress, we may not be able to prepare
and file the intended IND applications on a timely basis or at all. Any delay, suspension or reduction of our efforts to pursue our preclinical
and IND strategy could have a material adverse effect on our business and cause our share price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Catastrophic
events could have a material adverse effect on our business, including current plans for product development, as well as any currently
ongoing preclinical studies and clinical trials and any future studies or other development or commercialization activities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations and business could be disrupted by natural disasters; industrial accidents; public health issues and global pandemics such
as COVID 19; cybersecurity incidents; interruptions of service from utilities, transportation restrictions or disruptions, telecommunications,
or IT systems providers; manufacturing equipment failures; geopolitical conflict; terrorism; or other catastrophic events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Catastrophic
events could severely impact our business, including, but not limited to, our current or future preclinical studies, clinical trials,
regulatory progress, or any other development or commercialization activities, including (among others):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in enrolling patients in clinical trials, specifically since many of the patients are considered immunocompromised;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial
    sites and hospital staff supporting the conduct of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by
    federal or state governments, employers and others;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees
    or their families or the desire of employees to avoid contact with large groups of people;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical
    trials</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in local regulations as part of a response to a catastrophic event which may require us to change the ways in which our clinical
    trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations
    in employee resources or forced furlough of government employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    in the timing of interactions with the FDA due to absenteeism by federal employees or by the diversion of their efforts and attention
    to approval of other therapeutics or other activities related ; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a catastrophic event could disrupt our operations due to absenteeism by infected or ill members of management or other employees,
or absenteeism by members of management and other employees who elect not to come to work due to the illness affecting others in our
office or laboratory facilities, or due to quarantines. A catastrophic event could also impact members of our board of directors, resulting
in absenteeism from meetings of the directors or committees of directors, and making it more difficult to convene the quorums of the
full board of directors or our committees needed to conduct meetings for the management of our affairs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have significant and increasing liquidity needs and may require additional funding.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development, management and administrative expenses and cash used for operations will continue to be significant and may increase
substantially in the future in connection with new and continued research and development initiatives and our pursuit of IND authorization(s)
for some or all of our product candidates, as is required to initiate clinical trials in human subjects in the United States. We will
need to raise additional capital to fund our operations, continue to conduct clinical trials to support potential regulatory approval
of marketing applications, and to fund commercialization of our current and future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount and timing of our future funding requirements will depend on many factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, number, initiation, progress, timing, costs, design, duration, delays (if any), and results of preclinical and clinical studies
    for our current or future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA,
    and comparable foreign regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and amount of revenue generated or received, including any revenue from grants or other sources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate of progress and cost of our clinical trials and other product development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights associated with our current
    and future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing technological and market developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">personnel,
    facilities and equipment requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and timing of any additional collaborative, licensing, co-promotion or other arrangements that we may establish.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we expect to fund our future capital requirements from financing arrangements, we cannot assure you that any such financing arrangements
will be available to it on favorable terms, or at all. Even if we can raise funds from financing arrangements, the amounts raised may
not be sufficient to meet our future capital requirements. Additionally, the Company does not have sufficient unreserved, authorized
shares to secure an equity investment of a sufficient amount, based on the Company&#8217;s currently traded price per share, and the
Company will require shareholder approval to increase the amount of authorized shares. If we are not able to raise capital, we could
be required to postpone, scale back or eliminate some, or all, of our development objectives or commercialization efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on our current key personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have consolidated our employee base to save capital and focus on development of our leading candidates EB-002 and EB-303. As of the date
of this report, we employ 7 full-time employees. We are highly dependent on our current management and scientific personnel, including
Joseph Tucker, Ph.D., Peter Facchini, Ph.D., and Kevin Coveney, CPA. The inability to hire or retain experienced management personnel
could adversely affect our ability to execute our business plan and harm our operating results. Due to the specialized scientific and
managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial
personnel. The competition for qualified personnel in the pharmaceutical field is intense and we may be unable to continue to attract
and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
has been limited study on the effects of psychedelics, and future clinical research studies may lead to conclusions that dispute or conflict
with our understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing, and social acceptance of psychedelics.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
relating to the medical benefits, viability, safety, efficacy, and dosing of psychedelics remains in relatively early stages. There have
been few clinical trials on the benefits of psychedelics conducted by us or by others. Future research and clinical trials may draw opposing
conclusions to statements contained in the articles, reports and studies we have relied on, or could reach different or negative conclusions
regarding the medical benefits, viability, safety, efficacy, dosing or other facts and perceptions related to cannabinoids and psychedelics,
which could adversely affect social acceptance of psychedelics and the demand for our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
limited resources have lead us to focus on a particular candidate. As a result, we may fail to capitalize on product candidates that
may be more profitable or for which there is a greater likelihood of medical and commercial success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
result of our limited financial, managerial and scientific leadership resources we have focused on developing product candidates that
we have identified as most likely to succeed. As such, we have elected to forego or delay for the time being the development of other
candidates that may prove to have greater potential. Our resource allocation decisions may cause us to fail to capitalize on viable medical
solutions, therapeutic enhancements and commercial potentials for viable markets when our spending on our current and future defined
candidates with the indications specified therein may not yield any commercially viable products. Inaccurate evaluation of potential
may result in relinquishment of valuable product candidate opportunity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to face intense competition, often from companies with greater resources and experience than us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical industry is highly competitive, with an emphasis on proprietary products and subject to rapid change. The industry continues
to expand and evolve as an increasing number of competitors and potential competitors enter the market. Many of these competitors and
potential competitors have substantially greater financial, technological, managerial and research and development resources and experience
than us. Some of these competitors and potential competitors have more experience than us in the development of pharmaceutical products,
including validation procedures and regulatory matters. In addition, our future product candidates, if successfully developed, will compete
with product offerings from large and well-established companies that have greater marketing and sales experience and capabilities than
us or our collaboration partners have. Other companies with greater resources than we may announce similar plans in the future. In addition,
small or early stage companies may prove to be competitors, particularly through collaborative arrangements with large and established
companies. If we are unable to compete successfully, our commercial opportunities will be reduced and our business, results of operations
and financial conditions may be materially harmed. In addition, we compete with these companies in recruiting and retaining scientific
personnel as well as establishing clinical trial sites and patient registration for clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current and future preclinical and clinical studies may be conducted outside the United States, and the FDA may not accept data from
such studies to support any NDAs we may submit after completing the applicable developmental and regulatory prerequisites.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are conducting, or may conduct, preclinical and/or clinical studies outside the United States. For example, we have conducted preclinical
studies in Israel, and plan to conduct clinical studies for one or more product candidates in Israel or other non-U.S. countries. To
the extent we do not conduct these clinical trials in accordance under an IND application, the FDA may not accept data from such trials.
Although the FDA may accept data from clinical trials conducted outside the United States that are not conducted under an IND application,
the FDA&#8217;s acceptance of the data is subject to certain conditions. For example, the clinical trial must be well designed and conducted
and performed by qualified investigators in accordance with ethical principles and all applicable FDA regulations. The trial population
must also adequately represent the intended U.S. population, and the data must be applicable to the U.S. population and U.S. medical
practice in ways that the FDA deems clinically meaningful. In general, the patient population for any clinical trials conducted outside
of the United States must be representative of the population for whom we intend to market the product candidate in the United States,
if approved. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent
upon our ability to verify the data and our determination that the trials also complied with all applicable U.S. laws and regulations.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and foreign statutes and
regulations requires the expenditure of substantial time and financial resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data
from such clinical trials, we would likely result in the need for additional trials and the completion of additional regulatory steps,
which would be costly and time-consuming and could delay or permanently halt our development of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
the results of preclinical studies and earlier clinical trials are not necessarily predictive of future results, we may not have favorable
results in our planned and future clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
development of therapeutic products is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Drug
development involves long lead times and involves many variables of uncertainty. Product candidates that appear promising in the early
phases of development may fail to reach the market for several reasons including, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical
    study results that may show the product to be less effective than desired (e.g., the study failed to meet our primary objectives)
    or to have harmful or problematic side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may be caused
    by slow enrollment in clinical studies, length of time to achieve study endpoints, additional time requirements for data analysis
    or an IND and later NDA, preparation, discussions with the FDA, an FDA request for additional preclinical or clinical data or unexpected
    safety or manufacturing issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    costs, pricing, or reimbursement issues or other factors that make the product not economical; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proprietary rights of others and their competing products and technologies that may prevent the product from being commercialized.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
positive results from our preclinical testing of our prospective product candidates may not necessarily be predictive of the results
from planned or future clinical trials for such product candidates. Many companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in clinical trials after achieving positive results in preclinical and early clinical development,
and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical
findings while clinical trials were underway or safety or efficacy observations in clinical trials, including adverse events. Moreover,
our interpretation of clinical data or our conclusions based on the preclinical in vitro and in vivo models may prove inaccurate, as
preclinical and clinical data can be susceptible to varying interpretations and analyses, and many companies that believed their product
candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other regulatory approvals.
Similarly, undesirable side effects caused by our product candidates could cause us or regulatory authorities to limit dosage in development
or interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval
by the FDA or other comparable foreign authorities. Restrictive label applications may include but are not limited to a Boxed Warning,
Risk Evaluation and Mitigation Strategies, or REMS, or other limitations of use. Drug-related side effects during one clinical trial
furthermore could affect patient recruitment or the ability of enrolled patients to complete the trial, result in potential product liability
claims or our ability to ensure enrollment for future trials. Any of these occurrences may harm our business, financial condition and
prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulatory
approval is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated,
and we may be subject to fines, penalties or injunctions if we are determined to be promoting the use of our products for unapproved
or &#8220;off-label&#8221; uses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory approval is limited
to those specific indications for which a product is approved. If we are not able to obtain FDA approval for any desired future indications
for our products and product candidates, our ability to effectively market and sell our products may be reduced and our business may
be adversely affected. While physicians may choose to prescribe drugs for uses that are not described in the product&#8217;s labeling
and for uses that differ from those tested in clinical studies and approved by the regulatory authorities, we are prohibited from marketing
and promoting the products for indications that are not specifically approved by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
&#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied
circumstances. Regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their
choice of treatment within the practice of medicine. Regulatory authorities do, however, restrict communications by pharmaceutical companies
on off-label use. If the FDA determines that our promotional activities constitute promotion of an off-label use, it could request that
we modify our promotional materials or subject us to regulatory or enforcement actions by other agencies, including issuance of warning
letters, suspension or withdraw an approved product from the market, additional reporting requirements and/or oversight if we become
subject to a corporate integrity agreement or similar agreement, any of which could significantly harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
interruptions could delay us in the process of developing our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
of our stored materials or facilities through fire, theft, or other causes could have an adverse effect on our ability to continue product
development activities and to conduct our business. Even if we obtain insurance coverage to compensate us for such business interruptions,
such coverage may prove insufficient to fully compensate us for the damage to our business resulting from any significant property or
casualty loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and legal requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
FDA, SEC or Office of Inspector General regulations, or regulations of any other applicable regulatory authority, failure to provide
accurate information to the FDA or the SEC, comply with applicable manufacturing standards, other federal, state or foreign laws and
regulations, report information or data accurately or disclose unauthorized activities. Employee misconduct could also involve the improper
use of confidential or protected information, including information obtained in the course of clinical trials, or illegal pre-approval
promotion of drug candidates, which could result in government investigations, enforcement actions and serious harm to our reputation.
We have adopted a Corporate Code of Conduct and Ethics and Whistleblower Policy, but employee misconduct is not always possible to identify
and deter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
precautions we take to detect and prevent these prohibited activities may not be effective in controlling unknown or unmanaged risks
or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance
with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending our Company or asserting
our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we expect to collect and store sensitive data, including valuable and commercially sensitive intellectual
property, clinical trial data, our proprietary business information and that of our future customers, suppliers and business partners,
and personally identifiable information of our customers, clinical trial subjects and employees, patients, in our data centers and on
our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security
measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance
or other disruptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any
such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the
privacy of personal information, regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence
in our products and our ability to conduct clinical trials, which could adversely affect our business and reputation and lead to delays
in gaining regulatory approvals for our future product candidates. Although we may obtain business interruption insurance coverage in
the future, our insurance might not cover all losses from any future breaches of our systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
of our information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt
the operation of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business depends on the use of information technologies. Our ability to execute our business plan and to comply with regulators&#8217;
requirements with respect to data control and data integrity, depends, in part, on the uninterrupted performance of our information technology
systems, or IT systems and the IT systems supplied by third-party service providers. Our IT systems are vulnerable to damage from a variety
of sources, including telecommunications or network failures, malicious human acts, natural disasters and more sophisticated and targeted
cyber-related attacks that pose a risk to the security of our information systems and networks and the confidentiality, availability
and integrity of data and information. A successful cybersecurity attack or other data security incident could result in the misappropriation
and/or loss of confidential or personal information, create system interruptions, or deploy malicious software that attacks our systems.
It is also possible that a cybersecurity attack might not be noticed for some period of time. In addition, sustained or repeated system
failures or problems arising during the upgrade of any of our IT systems that interrupt our ability to generate and maintain data could
adversely affect our ability to operate our business. The occurrence of a cybersecurity attack or incident could result in business interruptions
from the disruption of our IT systems, or negative publicity resulting in reputational damage with our shareholders and other stakeholders
and/or increased costs to prevent, respond to or mitigate cybersecurity events. In addition, the unauthorized dissemination of sensitive
personal information or proprietary or confidential information could expose us or other third-parties to regulatory fines or penalties,
litigation and potential liability, or otherwise harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Security
breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent it from accessing
critical information or expose it to liability, which could adversely affect our business and its reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we expect to collect and store sensitive data, including legally protected patient health information,
credit card information, personally identifiable information about our employees, intellectual property, and proprietary business information.
We expect to manage and maintain this data utilizing on-site systems. This data includes a wide variety of business-critical information
including research and development information, commercial information and business and financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy,
and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized
access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers, or viruses, breaches or
interruptions due to employee error, malfeasance or other disruptions, or lapses in compliance with privacy and security mandates. Any
such virus, breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties,
publicly disclosed, lost or stolen. In the future, any such access, disclosure or other loss of information could result in legal claims
or proceedings, liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability
Act and European Union General Data Protection Regulation, government enforcement actions and regulatory penalties. Unauthorized access,
loss or dissemination could also disrupt our operations, including our ability to process samples, provide test results, share and monitor
safety data, bill payors or patients, provide customer support services, conduct research and development activities, process and prepare
company financial information, manage various general and administrative aspects of our business and may damage our reputation, any of
which could adversely affect our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operating results may vary significantly in future periods.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the early stages of product development and expect to focus substantial efforts for, at least, the next several years on preclinical
and clinical trials and other research and development activities. We have not obtained regulatory approval for any product candidates.
Our revenues, expenses and operating results are likely to fluctuate significantly in the future. We expect to incur substantial additional
operating expenses over the next several years as our research, development, and preclinical and clinical study activities increase.
Our financial results are unpredictable and may fluctuate, for among other reasons, due to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, number, progress, duration, endpoints, cost, results, and timing of our preclinical testing and clinical studies of current
    or potential future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain additional funding to develop product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in the commencement, enrollment and timing of clinical studies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
high portion of our costs are predetermined on an annual basis, due in part to our significant research and development costs. Thus,
small declines in revenue could disproportionately affect financial results in a quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
ongoing costs and obligations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a neuro-pharmaceutical drug discovery and development platform company, the Company expects to spend substantial funds on the research,
development and testing of psychedelic molecular derivatives. In addition, the Company expects to incur significant ongoing costs and
obligations related to its investment in infrastructure and growth and for regulatory compliance, which could have a material adverse
impact on the Company&#8217;s results of operations, financial condition and cash flows. The Company will also require significant additional
funds if it expands the scope of current plans for research and development or if it were to acquire any other assets and advance their
development. It is possible that future financing will not be available or, if available, may not be on favorable terms. The availability
of financing will be affected by the achievement of the Company&#8217;s corporate goals, the results of scientific and clinical research,
the need and ability to obtain regulatory approvals and the state of the capital markets generally. If adequate funding is not available,
the Company may be required to delay, reduce or eliminate one or more of its research and development programs, or obtain funds through
corporate partners or others who may require the Company to relinquish significant rights to its Psychedelic Derivatives or compounds
or obtain funds on less favorable terms than the Company would otherwise accept. To the extent that external sources of capital become
limited or unavailable or available on onerous terms, the Company&#8217;s intangible assets and its ability to continue its business
plans may become impaired, and the Company&#8217;s assets, liabilities, business, financial condition and results of operations may be
materially or adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, future changes in regulations, changes in legal status of psychedelic products, more vigorous enforcement thereof or other
unanticipated events could require extensive changes to the Company&#8217;s operations, increased compliance costs or give rise to material
liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company.
The Company&#8217;s efforts to grow its business may be costlier than expected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may rely on third parties to plan and conduct preclinical and clinical trials</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may rely on third parties to conduct preclinical development activities and intends to partner with third parties who may conduct clinical
development activities with our Psychedelic Derivatives and other product candidates. Preclinical activities include &#8220;in vivo&#8221;
studies providing access to specific disease models, pharmacology and toxicology studies, and assay development. Clinical development
activities include trial design, regulatory submissions, clinical patient recruitment, clinical trial monitoring, clinical data management
and analysis, safety monitoring and project management. If there is any dispute or disruption in its relationship with third parties,
or if such third parties are unable to provide quality services in a timely manner and at a feasible cost, or if such third parties fail
to meet certain development milestones, our active development programs may face delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
if any of these third parties fails to perform as we expect or if their work fails to meet regulatory requirements, the testing and eventual
development of viable Psychedelic Derivative drug candidates could be delayed, cancelled or rendered ineffective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reliance on third party contract manufacturers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
our completion of the &#8220;in vitro&#8221; portion of the preclinical testing we intend to conduct, when only lab-grade and lab-scale
psychedelic molecules are required, we intend to manufacture the required psychedelic molecules at our facilities in Calgary. However,
when larger quantities and higher quality psychedelic molecules are required (e.g., for animal model testing), we intend to contract
with appropriate third party contract manufacturing organizations (&#8220;CMOs&#8221;) to, among other things, supply the active pharmaceutical
ingredients (&#8220;API&#8221;) used in its Psychedelic Derivatives over which we may have limited control. We intend to rely on CMOs
to supply APIs in compliance with local GMP regulations applicable to its Psychedelic Derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
applicable jurisdictions, including Health Canada, and the FDA, ensure the quality of drug products by carefully monitoring drug manufacturers&#8217;
compliance with GMP regulations. The GMP regulations for drugs contain minimum requirements for the methods, facilities and controls
used in manufacturing, processing and packing of a drug product. There can be no assurances that CMOs will be able to meet our timetable
and requirements or carry out their contractual obligations in accordance with the applicable regulations. In addition, the API they
supply to us may not meet our specifications and quality policies and procedures or they may not be able to supply the API in commercial
quantities. If we are unable to arrange for alternative third-party supply sources on commercially reasonable terms or in a timely manner,
it may delay the development of its Psychedelic Derivatives and could have a material adverse effect on our business operations and financial
condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the failure of CMOs to operate in compliance with GMP regulations could result in, among other things, certain product liability claims
in the event such failure to comply results in defective products (containing our Psychedelic Derivatives) that caused injury or harm.
In general, our dependence upon third parties for the supply of our APIs may adversely affect profit margins and our ability to develop
and deliver viable Psychedelic Derivatives on a timely and competitive basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Termination
or non-renewal of key licenses and agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is highly dependent on key licenses and agreements which expire in a short time period. Specifically, in conducting research
and preclinical studies in compliance with current legislation, we substantially rely on the Facchini Drug License ,which expires on
December 31, 2024. Health Canada renews drug licenses annually and Dr. Facchini has held the Facchini Drug License since October 5, 1995
and it has been renewed each year without issue. Until Enveric obtains its own Dealer&#8217;s License or Section 56 Exemption necessary
for its business, the termination, non-renewal or hinderance of use of the Facchini Drug License would have a material adverse effect
on Enveric&#8217;s ability to develop Psychedelic Derivatives, conduct research or operate its business as it currently does. This could
have a material adverse impact on Enveric&#8217;s financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Negative
results from clinical trials or studies of others and adverse safety events involving our Psychedelic Derivatives</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, studies or clinical trials on various aspects of biopharmaceutical or natural health products (&#8220;NHPs&#8221;) are
conducted by academic researchers, competitors or others. The results of these studies or trials, when published, may have a significant
effect on the market for the biopharmaceutical or NHP that is the subject of the study. The publication of negative results of studies
or clinical trials or adverse safety events related to the psychedelic compounds used by us in the development of our Psychedelic Derivatives,
or the therapeutic areas in which our Psychedelic Derivatives compete, could adversely affect our share price and our ability to finance
future development of our Psychedelic Derivatives, and our business and financial results could be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
trials of our Psychedelic Derivatives may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or not
otherwise produce positive results</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
third parties are able to obtain marketing approval from regulatory authorities for the sale of products containing our Psychedelic Derivatives,
the completion of preclinical studies in animals and extensive clinical trials in humans to demonstrate the safety and efficacy of the
Psychedelic Derivatives will be required. Clinical testing is expensive and difficult to design and implement, can take many years to
complete and has uncertain outcomes. The outcome of preclinical studies and early clinical trials may not predict the success of later
clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical,
NHP and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable
safety profiles, notwithstanding promising results in earlier trials. We do not know whether the clinical trials that third parties may
conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any products containing our Psychedelic
Derivatives in any jurisdiction. A product/compound candidate may fail for safety or efficacy reasons at any stage of the testing process.
A major risk we face is the possibility that none of the products containing our Psychedelic Derivatives will successfully gain market
approval from Health Canada, the FDA or other regulatory authorities, resulting in our inability to derive any royalty-based revenue
from them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raw
materials requiring regulatory approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
raw materials used by us will require regulatory approval by Health Canada and the FDA because the plant or fungi may contain a controlled
substance. While we believe that we can acquire, or indirectly make use of, the requisite licenses to conduct our intended research and
development activities, there is a risk that Health Canada and the FDA can either reject or require further action to approve the requisite
licenses which would cause delays or result in losses for us and could result in the abandonment of a specific research programs. Raw
materials and supplies are generally available in quantities to meet the needs of our business. An inability to obtain raw materials
or product supply could have a material adverse impact on our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Possible
increase in costs beyond what is currently expected as a result of regulatory review</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
Canada and the FDA have not yet determined whether our Psychedelic Derivatives will be scheduled as controlled substances. In the event
Health Canada or the FDA determine that these products are controlled substances and therefore, require regulatory approval, (a) our
licensees will be required to obtain such approval; and (b) to the extent that we produce Psychedelic Derivatives, we will require similar
regulatory approval. Such additional regulatory requirements may increase our costs and cause a delay in our operations. Further, if
Health Canada or the FDA require that we perform additional preclinical studies, or if we determine that additional preclinical studies
are required for our Psychedelic Derivatives, our expenses would further increase beyond what is currently expected and the anticipated
timing of any potential approval of our Psychedelic Derivatives or licensing out agreements would likely be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have never been profitable, have no products approved for commercial sale, and to date have not generated any revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never been profitable and we do not expect to be profitable in the foreseeable future. Neither us, nor any third-party partner,
have submitted any products containing our products for approval by regulatory authorities in Canada, the United States or elsewhere.
Since inception, we have an accumulated deficit of $96.5 million and accumulated other comprehensive losses of $0.6 million. To date,
we have devoted most of our financial resources to research and development, including drug discovery research, preclinical development
activities, patent application filing and media relation efforts, as well as corporate overhead.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any revenues since inception, we expect to continue to incur losses for the foreseeable future, and expect these losses
to increase as we continue our product development activities. If our Psychedelic Derivatives and other products developed do not achieve
market acceptance, we may never become profitable. As a result of the foregoing, we expect to continue to experience net losses and negative
cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect
on our stockholders&#8217; equity and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of
increased expenses or when, or if, we will be able to achieve profitability. In addition, our expenses could increase if we are required
by the FDA or Health Canada to perform preclinical studies or trials in addition to those currently expected, or if there are any delays
in completing our preclinical studies or the development of any of our Psychedelic Derivatives or other products. The amount of future
net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have no licensing, marketing or distribution experience and will have to invest significant resources to develop those capabilities or
enter into acceptable third-party sales and marketing transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no licensing, marketing or distribution experience. To develop licensing, distribution and marketing capabilities, we will have
to invest significant amounts of financial and management resources, some of which will need to be committed prior to any confirmation
that our Psychedelic Derivatives will be approved by the FDA and Health Canada for Psychedelic Derivatives where we decide to perform
licensing, marketing and distribution functions itself or through third parties, we could face a number of additional risks, including
that we or our third-party collaborators may not be able to build and maintain an effective marketing or sales force. If we use third
parties to market and license our Psychedelic Derivatives, we may have limited or no control over our licensing, marketing and distribution
activities on which our future revenues may depend.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may from time to time seek to enforce our intellectual property rights against infringers when we determine that a successful outcome
is probable and may lead to an increase in the value of the intellectual property. If we choose to enforce our patent rights against
a party, then that individual or company has the right to ask the court to rule that such patents are invalid or should not be enforced.
Additionally, the validity of our patents and the patents we have licensed may be challenged if a petition for post grant proceedings
such as inter-partes review and post grant review is filed within the statutorily applicable time with the Canadian Intellectual Property
Office or the United States Patent and Trademark Office. These lawsuits and proceedings are expensive and would consume time and resources
and divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there is a risk that the court will decide that such patents are not valid and that we do not have the right to stop the other
party from using the inventions. There is also the risk that, even if the validity of such patents is upheld, the court will refuse to
stop the other party on the ground that such other party&#8217;s activities do not infringe our intellectual property rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in patent law and its interpretation could diminish the value of patents in general, thereby impairing our ability to protect our Psychedelic
Derivatives</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other NHP, biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property rights,
particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves technological and legal complexity,
and obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. The Supreme Court of Canada
and the U.S. Supreme Court have ruled on several patent cases in recent years, either narrowing the scope of patent protection available
in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard
to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents,
once obtained. Depending on decisions by the Canadian House of Representative, the Federal Court of Canada, the Canadian Intellectual
Property Office, U.S. Congress, the federal courts, and the U.S. Patent and Trademark Office and international treaties entered into
by these nations, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain
patents or to enforce patents we may obtain in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to manage growth</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we advance our Psychedelic Derivatives through preclinical studies and seek business arrangements and partnerships with third parties
to advance our Psychedelic Derivatives through clinical development, we will need to increase our preclinical development, scientific,
management and administrative headcount to manage these programs and negotiate these arrangements. In addition, to meet obligations as
a public company, we may need to increase our general and administrative capabilities and improve our operational and financial controls
and reporting procedures. Our management, personnel and systems currently in place may not be adequate to support this future growth.
In managing our growing operations, we are also subject to the risks of over-hiring and/or overcompensating our employees and over-expanding
our operating infrastructure. As a result, we may be unable to manage our expenses effectively in the future, which may negatively impact
our gross profit or operating expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Insurance
and uninsured risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks and hazards generally, including adverse preclinical trial results, accidents, labor disputes
and changes in the regulatory environment. Such occurrences could result in damage to assets, personal injury or death, environmental
damage, delays in operations, monetary losses and possible legal liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
insurance may not cover all the potential risks associated with our operations. We may also be unable to maintain insurance to cover
these risks at economically feasible premiums. Insurance coverage may not be available or may not be adequate to cover any resulting
liability. Moreover, insurance against risks such as environmental pollution or other hazards encountered in our operations is not generally
available on acceptable terms. We might also become subject to liability for pollution or other hazards which may not be insured against
or which we may elect not to insure against because of premium costs or other reasons. Losses from these events or any significant uninsured
liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may become party to litigation from time to time in the ordinary course of business which could adversely affect our business. Should
any litigation in which we become involved be determined against us such a decision could adversely affect our ability to continue operating
and the market price for our shares and could use significant resources. Even if we are involved in litigation and win, litigation can
redirect significant company resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conflicts
of interest</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our directors and officers do not devote their full time to the affairs of the Company and certain of our directors and officers are
also directors, officers and shareholders of other biotechnology and research and development companies or other public companies in
general, and as a result they may find themselves in a position where their duty to another company conflicts with their duty to the
Company. There is no assurance that any such conflicts will be resolved in favor of the Company. If any such conflicts are not resolved
in our favor we may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
psychedelic therapy industry and market are relatively new and this industry and market may not continue to exist or grow as anticipated</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate our business in a relatively new industry and market. In addition to being subject to general business risks, we must continue
to build brand awareness in this industry and market through significant investments in our strategy, our operational capacity, quality
assurance and compliance with regulations. In addition, there is no assurance that the industry and market will continue to exist and
grow as currently estimated or anticipated or function and evolve in the manner consistent with management&#8217;s expectations and assumptions.
Any event or circumstance that adversely affects the psychedelic therapy industry and market could have a material adverse effect on
our business, financial conditions and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
psychedelic medicine market will face specific marketing challenges given the products&#8217; status as a controlled substance which
resulted in past and current public perception that the products have negative health and lifestyle effects and have the potential to
cause physical and social harm due to psychoactive and potentially addictive effects. Any marketing efforts by us would need to overcome
this perception to build consumer confidence, brand recognition and goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
psychedelics industry and market are relatively new, and the industry may not succeed in the long term.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate our business in a relatively new industry and market. The use of psychedelics for medicinal purposes has shown promise in various
studies and we believe that both regulators and the public have an increasing awareness and acceptance of this promising field. Nevertheless,
psychedelics remain a controlled substance in the United States, Canada, and most other jurisdictions and their use for research and
therapeutic purposes remains highly regulated and narrow in scope. There is no assurance that the industry and market will continue to
grow as currently estimated or anticipated or function and evolve in the manner consistent with management&#8217;s expectations and assumptions.
Any event or circumstance that adversely affects the psychedelic manufacturing and medicines industry and market could have a material
adverse effect on our business, financial condition and results of operations. We have committed and expect to continue committing significant
resources and capital to the development of psychedelic products for therapeutic uses. As a category of products, medical-grade psychedelics
raw materials and psychedelic-derived APIs, and research into such substances, represent relatively untested offerings in the marketplace,
and we cannot provide assurance that psychedelics as a category, or that our prospective products, in particular, will achieve market
acceptance. Moreover, as a relatively new industry, there are not many established players in the psychedelic-based medicines industry
whose business model we can emulate. Similarly, there is little information about comparable companies available for potential investors
to review in making a decision about whether to invest in our common shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
psychedelic product candidates may generate public controversy. Adverse publicity or public perception regarding the psychedelic APIs
we intend to utilize may negatively influence our success and that of our prospective investigational therapies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to establish and grow our business is substantially dependent on the success of the emerging market for psychedelics-based medicines,
which will depend upon, among other matters, pronounced and rapidly changing public preferences, factors which are difficult to predict
and over which we have little, if any, control. We and our clients will be highly dependent upon consumer perception of psychedelic-based
therapies and other products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapies
containing controlled substances may generate public controversy. Political and social pressures and adverse publicity could lead to
delays in approval of, and increased expenses for any future therapeutic candidates we may develop. Opponents of these therapies may
seek restrictions on marketing and withdrawal of any regulatory approvals. In addition, these opponents may seek to generate negative
publicity in an effort to persuade the medical community to reject these therapies. For example, we may face media-communicated criticism
directed at our clinical development program. Adverse publicity from psilocybin misuse may adversely affect the commercial success or
market penetration achievable by our product candidates. Anti-psychedelic protests have historically occurred and may occur in the future
and generate media coverage. Political pressures and adverse publicity could lead to delays in, and increased expenses for, and limit
or restrict the introduction and marketing of any future therapeutic candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
expansion of the use of psychedelics in the medical industry may require new clinical research into effective medical therapies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
in United States and internationally regarding the medical benefits, viability, safety, efficacy, addictiveness, dosing and social acceptance
of psychedelic and psychoactive products remains in early stages. There have been relatively few clinical trials on the benefits of such
products. Although we believe that the articles, reports and studies support our beliefs regarding the medical benefits, viability, safety,
efficacy, dosing and social acceptance of psychedelic and psychoactive products, future research and clinical trials may prove such statements
to be incorrect, or could raise concerns regarding, and perceptions relating to, psychedelic and psychoactive products. Given these risks,
uncertainties and assumptions, readers should not place undue reliance on such articles and reports. Future research studies and clinical
trials may draw opposing conclusions to those stated in this Annual Report on Form 10-K or reach negative conclusions regarding the medical
benefits, viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to psychedelic and psychoactive
products, which could have a material adverse effect on the demand for our Psychedelic Derivatives with the potential to lead to a material
adverse effect on the Company&#8217;s business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
psychedelic therapy industry is difficult to quantify and investors will be reliant on their own estimates of the accuracy of market
data</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the psychedelic therapy industry is in a nascent stage with uncertain boundaries, there is a lack of information about comparable companies
available for potential investors to review in deciding about whether to invest in us and, few, if any, established companies whose business
model we can follow or upon whose success we can build. Accordingly, investors will have to rely on their own estimates in deciding about
whether to invest in us. There can be no assurance that our estimates are accurate or that the market size is sufficiently large for
our business to grow as projected, which may negatively impact our financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
psychedelic therapy and biotechnology industries are experiencing rapid growth and increased competition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
psychedelic therapy and biotechnology industries are undergoing rapid growth and substantial change, which has resulted in an increase
in competitors, consolidation and formation of strategic relationships. Acquisitions or other consolidating transactions could harm us
in a number of ways, including, without limitation, by losing strategic partners if they are acquired by or enter into relationships
with a competitor, losing customers, revenue and market share, or forcing us to expend greater resources to meet new or additional competitive
threats, all of which could harm our operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change.
We have competitors in Canada, the United States, Europe and other jurisdictions, including, without limitation, major multinational
pharmaceutical companies, established biotechnology companies, specialty pharmaceutical and generic drug companies and universities and
other research institutions. Many of our competitors have greater financial and other resources, such as larger research and development
staff and more experienced marketing and manufacturing organizations than we do. Large pharmaceutical companies, in particular, have
extensive experience in, and substantial capital resources for, conducting research, molecular derivative development, obtaining regulatory
approvals, obtaining intellectual property protection and establishing key relationships. These companies also have significantly greater
sales and marketing capabilities and experience in completing collaborative transactions in our target markets with leading companies
and research institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors may introduce new Psychedelic Derivatives or develop technological advances that compete with us. We cannot predict the timing
or impact of competitors introducing new Psychedelic Derivatives or technological advances. Such competing Psychedelic Derivatives may
be safer, more effective, more effectively marketed, licensed or sold or have lower prices or superior performance features than our
Psychedelic Derivatives, and this could negatively impact our business and results of operations. Established pharmaceutical companies
may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the
Psychedelic Derivatives that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent
protection or discovering, developing and commercializing Psychedelic Derivatives before we do or may develop Psychedelic Derivatives
that are deemed to be more effective or gain greater market acceptance than those of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
or early-stage companies may also prove to be significant competitors, particularly through collaborative transactions with large, established
companies. In addition, many universities and private and public research institutes may become active in the development of novel compounds.
Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies and Psychedelic Derivatives that
are more effective or less costly than any of the Psychedelic Derivatives that we are currently developing or that we may develop, which
could render our Psychedelic Derivatives obsolete or non-competitive. If our competitors market Psychedelic Derivatives that are more
effective, safer or less expensive or that reach the market sooner than our Psychedelic Derivatives, if any, we may not achieve commercial
success. In addition, because of our limited resources, it may be difficult for us to stay abreast of the rapid changes in each technology.
If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products
developed by our competitors may render our technologies or Psychedelic Derivatives obsolete, less competitive or not economical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in legislation, regulations and guidelines</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to various laws, regulations and guidelines relating to, among other things, drug research, development, marketing
practices, health and safety, the conduct of operations and preclinical trials. In addition to FDA and Health Canada restrictions on
the marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain marketing
practices in the pharmaceutical and medical industries in recent years, as well as consulting or other service agreements with physicians
or other potential referral sources. While to the knowledge of management, we are currently in compliance with all such laws, changes
to applicable laws, regulations and guidelines may cause adverse effects to its operations. The risks to the business of the Company
represented by this or similar risks are that they could significantly reduce the addressable market for our Psychedelic Derivatives
and could materially and adversely affect the business, financial condition and results of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Regulatory Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current and prospective product candidates, and the development thereof, are or will be subject to the various federal and state laws
and regulations relating to the safety and efficacy of health products, such as drugs and medical devices.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the process of developing investigational new drugs for which we intend to pursue FDA approval via the NDA process. In these product
candidates and synthetic molecules based on psychedelics, such as psilocybin, N,N-dimethyltryptamine (&#8220;DMT&#8221;), mescaline and
MDMA, will be the active pharmaceutical ingredients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our development and future commercialization (if applicable) of our prospective products, we, and each contemplated product
candidate, are subject to the Federal Food Drug and Cosmetic Act (FDCA). The FDCA is intended to assure the consumer, in part, that drugs
and devices are safe and effective for their intended uses and that all labeling and packaging is truthful, informative, and not deceptive.
The FDCA and the U.S. Food and Drug Administration (FDA) regulations define the term &#8220;drug,&#8221; in part, by reference to its
intended use, as &#8220;articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease&#8221; and
&#8220;articles (other than food) intended to affect the structure or any function of the body of man or other animals.&#8221; The definition
also includes components of drugs, such as active pharmaceutical ingredients. To be lawfully marketed in the United States, drugs must
generally either receive premarket approval by FDA through the NDA process or conform to a &#8220;monograph&#8221; for a particular drug
category, as established by FDA&#8217;s Over-the-Counter (OTC) Drug Review. If the FDA does not award premarket approval for our product
candidates through the NDA process, this will have a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the nature of the active ingredients we intend to utilize in our product candidates subjects us and our development and future commercialization
(as applicable) activities to additional regulatory scrutiny and oversight. In connection with our development and future commercialization
(if applicable) of psychedelic-based product candidates, we and each contemplated product candidate will be subject to the federal Controlled
Substances Act (CSA) and the Controlled Substances Import and Export Act in the United States and analogous state and foreign laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that any of our investigational drugs will ever be approved as medicines in any jurisdiction in which the Company operates,
as there are currently very few FDA-approved drugs containing the psychedelic ingredients we intend to utilize as active ingredients.
And, the laws and regulations generally applicable to the industry in which the Company is involved are subject to constant evolution
and may change in ways currently unforeseen. Any amendment to or replacement of existing laws or regulations, including the re-classification
of the substances the Company is developing or with which it is working, which are matters beyond the Company&#8217;s control, may cause
the Company&#8217;s business, financial condition, results of operations and prospects to be adversely affected or may cause the Company
to incur significant costs in complying with such changes or it may be unable to comply therewith. A violation of any applicable laws
and regulations of the jurisdictions in which the Company operates could result in significant fines, penalties, administrative sanctions,
convictions or settlements arising from civil proceedings initiated by either government entities in the jurisdictions in which the Company
operates, or private citizens or criminal charges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
psychedelic-derived therapeutic candidates we are developing or may develop in the future are subject to controlled substance laws and
regulations in the United States and other countries where the product will be marketed, and failure to comply with these laws and regulations,
or the cost of compliance with these laws and regulations, may adversely affect the results of our business operations and our financial
condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, psychedelics, such as psilocybin (and its active metabolite, psilocin), DMT, mescaline and MDMA, are classified by
the DEA as a Schedule I substances under the CSA. The DEA regulates chemical compounds as Schedule I, II, III, IV or V substances. Schedule
I substances by-definition have a high potential for abuse, have no currently accepted medical use in the United States, lack accepted
safety for use under medical supervision, and may not be prescribed marketed or sold in the United States. Pharmaceutical products approved
for use in the United States may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest
potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse among such substances. Schedule I and II
substances are subject to the strictest controls under the CSA, including manufacturing and procurement quotas, security requirements
and criteria for importation. In addition, dispensing of Schedule II substances is further restricted. For example, they may not be refilled
without a new prescription and may have a black box warning. Further, most, if not all, state laws in the United States classify the
psychedelic active ingredients we intend to utilize as Schedule I controlled substances. For any product containing active ingredients
that are Schedule I controlled substances to be available for commercial marketing in the United States, the product must be scheduled
by the DEA to Schedule II, III, IV or V, which requires scheduling-related legislative or administrative action, which can further delay
the path to market. There can be no assurance that the DEA will make a favorable scheduling decision. Even assuming categorization as
a Schedule II or lower controlled substance (i.e., Schedule III, IV or V), at the federal level, such substances would also require scheduling
determinations under state laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
approval is also a prerequisite to commercialization, and the controlled-substance status of our psychedelic APIs may negatively impact
the FDA&#8217;s decision regarding whether to approve the applicable product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the pre-market review process, the FDA may determine that additional data is needed for one or more of our psychedelic candidates, either
from non-clinical or clinical studies, including with respect to whether, or to what extent, the substance has abuse potential. This
may introduce a delay into the approval and any potential rescheduling process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, therapeutic candidates containing controlled substances are subject to DEA regulations relating to manufacturing, storage,
distribution and physician prescription procedures, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEA
    registration and inspection of facilities. Facilities conducting research, manufacturing, distributing, importing or exporting, or
    dispensing controlled substances must be registered (licensed) to perform these activities and have the security, control, recordkeeping,
    reporting and inventory mechanisms required by the DEA to prevent drug loss and diversion. All these facilities must renew their
    registrations annually, except dispensing facilities, which must renew every three years. The DEA conducts periodic inspections of
    certain registered establishments that handle controlled substances. Obtaining and maintaining the necessary registrations may result
    in delay of the importation, manufacturing or distribution of product candidates. Furthermore, failure to maintain compliance with
    the CSA, particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse
    effect on our business, financial condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary
    registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could
    lead to criminal proceedings.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    controlled-substances laws. Individual U.S. states have also established controlled substance laws and regulations. Though state-controlled
    substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule product candidates.
    While some states automatically schedule a drug based on federal action, other states schedule drugs through rule making or a legislative
    action. State scheduling may delay commercial sale of any product for which we obtain federal regulatory approval and adverse scheduling
    could have a material adverse effect on the commercial attractiveness of such product. We or any partners must also obtain separate
    state registrations, permits or licenses in order to be able to obtain, handle, and distribute controlled substances for clinical
    trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the
    states in addition to those from the DEA or otherwise arising under federal law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    trials. Because some of our current and future product candidates contain Schedule I controlled substances, to conduct clinical trials
    in the United States prior to approval, each of our research sites must submit a research protocol to the DEA and obtain and maintain
    a DEA researcher registration that will allow those sites to handle and dispense such product candidates and to obtain the product
    from our importer. If the DEA delays or denies the grant of a researcher registration to one or more research sites, the clinical
    trial could be significantly delayed, and we could lose clinical trial sites.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Importation.
    If any of our product candidates is approved and classified as a Schedule II, III or IV substance, an importer can only import it
    for commercial purposes if it obtains an importer registration and files an application for an import permit for each import. The
    DEA provides annual assessments/estimates to the International Narcotics Control Board, which guides the DEA in the amounts of controlled
    substances that the DEA authorizes to be imported. The failure to identify an importer or obtain the necessary import authority,
    including specific quantities, could affect the availability of our product candidates and have a material adverse effect on our
    business, results of operations and financial condition. In addition, an application for a Schedule II importer registration must
    be published in the Federal Register, and there is a waiting period for third-party comments to be submitted. It is always possible
    that adverse comments may delay the grant of an importer registration.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacture.
    If, because of a Schedule II classification or voluntarily, we were to conduct manufacturing or repackaging/relabeling in the United
    States, our contract manufacturers would be subject to the DEA&#8217;s annual manufacturing and procurement quota requirements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution.
    If any of our product candidates is approved for marketing and scheduled under Schedule II, III or IV, we would also need to identify
    wholesale distributors with the appropriate DEA registrations and authority to possess and distribute or dispense such products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
psychedelic APIs we intend to utilize are listed as Schedule I controlled substances under the CSA in the United States and under similar
controlled-substance legislation in other countries, and any significant violations of these laws and regulations, or changes in the
laws and regulations, may result in interruptions to our development activity or business continuity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
psychedelic APIs we intend to utilize are categorized as Schedule I controlled substances under the CSA and are similarly categorized
by most states and foreign governments. Even assuming any future therapeutic candidates containing such APIs are approved and scheduled
by regulatory authorities to allow their commercial marketing, the ingredients in such therapeutic candidates will likely continue to
be listed under Schedule I, or the state or foreign equivalent and, thus, illegal without the requisite regulatory authorizations (e.g.,
to allow for the use of such substances in clinical trials under an IND and in compliance with all applicable FDA, DEA, and other regulatory
requirements). Violations of any federal, state or foreign laws and regulations could result in significant fines, penalties, administrative
sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens,
or criminal charges and penalties, including, but not limited to, disgorgement of profits, cessation of business activities, divestiture
or prison time. This could have a material adverse effect on us, including on our reputation and ability to conduct business, our financial
position, operating results, profitability or liquidity, the potential listing of our shares or the market price of our shares. In addition,
it is difficult for us to estimate the time or resources that would be needed for the investigation or defense of any such matters or
our final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information
requested by the applicable authorities involved, and such time or resources could be substantial. It is also illegal to aid or abet
such activities or to conspire or attempt to engage in such activities. An investor&#8217;s contribution to and involvement in such activities
may result in federal civil and/or criminal prosecution, including, but not limited to, forfeiture of his, her or its entire investment,
fines and/or imprisonment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
federal, state, provincial and local laws govern our business in any jurisdictions in which we may operate, and to which we may export
our products, including laws relating to health and safety, the conduct of our operations, and the production, storage, sale and distribution
of our products. Complying with these laws requires that we comply concurrently with complex federal, state, provincial and/or local
laws. These laws change frequently and may be difficult to interpret and apply. To ensure our compliance with these laws, we will need
to invest significant financial and managerial resources. It is impossible for us to predict the cost of such laws or the effect they
may have on our future operations. A failure to comply with these laws could negatively affect our business and harm our reputation.
Changes to these laws could negatively affect our competitive position and the markets in which we operate, and there is no assurance
that various levels of government in the jurisdictions in which we operate will not pass legislation or regulation that adversely impacts
our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we or third parties were to conduct activities in compliance with U.S. state or local laws or the laws of other countries
and regions in which we conduct activities, potential enforcement proceedings could involve significant restrictions being imposed upon
us or third parties, while diverting the attention of key executives. Such proceedings could have a material adverse effect on our business,
revenue, operating results and financial condition as well as on our reputation and prospects, even if such proceedings conclude successfully
in our favor. In the extreme case, such proceedings could ultimately involve the criminal prosecution of our key executives, the seizure
of corporate assets, and consequently, our inability to continue business operations. Strict compliance with state and local laws with
respect to psilocybin and psilocin does not absolve us of potential liability under U.S. federal law, the Canadian law or EU law, nor
provide a defense to any proceeding which may be brought against us. Any such proceedings brought against us may adversely affect our
operations and financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
prospective products will be subject to the various federal and state laws and regulations relating to health and safety.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the process of developing investigational new drugs for which we intend to pursue FDA approval via the NDA process. In connection
with our development and future commercialization (if applicable) of our products, we and each contemplated product candidate are subject
to the Federal Food Drug and Cosmetic Act (FDCA). The FDCA is intended to assure the consumer, in part, that drugs and devices are safe
and effective for their intended uses and that all labeling and packaging is truthful, informative, and not deceptive. The FDCA and FDA
regulations define the term &#8220;drug,&#8221; in part, by reference to its intended use, as &#8220;articles intended for use in the
diagnosis, cure, mitigation, treatment, or prevention of disease&#8221; and &#8220;articles (other than food) intended to affect the
structure or any function of the body of man or other animals.&#8221; Therefore, almost any ingested or topical or injectable product
that, through its label or labeling (including internet websites, promotional pamphlets, and other marketing material), that is claimed
to be beneficial for such uses will be regulated by FDA as a drug. The definition also includes components of drugs, such as active pharmaceutical
ingredients. Drugs must generally either receive premarket approval by FDA through the NDA process or conform to a &#8220;monograph&#8221;
for a particular drug category, as established by FDA&#8217;s Over-the-Counter (OTC) Drug Review. If the FDA does not award premarket
approval for our product candidates through the NDA process, this could have a material adverse effect on our business, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
trials are expensive, time-consuming, uncertain and susceptible to change, delay or termination. The results of clinical trials are open
to differing interpretations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have two product candidates that are in preclinical development for indications such as Radiation Dermatitis and other side-effects
of cancer, including anxiety. We intend to develop additional drug candidates targeting other indications, including, for example, pain
and PTSD. After completing the requisite preclinical testing, submissions to FDA (namely IND applications), internal review board (&#8220;IRB&#8221;)
review, and any other applicable obligations that must be completed before clinical testing may begin in the United States, we must conduct
extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, time consuming,
and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, or at
all. Failures in connection with one or more clinical trials can occur at any stage of testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other applicable regulatory agencies may analyze or interpret the results of clinical trials differently than us. Even if the
results of our clinical trials are favorable, the clinical trials for a number of our product candidates are expected to continue for
several years and may take significantly longer to complete. Events that may prevent successful or timely completion of clinical development
include (without limitation):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching a consensus with regulatory authorities on trial design;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching agreement on acceptable terms with prospective contract research organization (&#8220;CRO&#8221;) and clinical trial
    sites;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in sourcing materials and research animals for preclinical testing and correlated testing windows at the appropriate CRO facilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in opening clinical trial sites or obtaining required IRB or independent ethics committee approval at each clinical trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or perceived lack of effectiveness of any product candidate during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discovery
    of serious or unexpected toxicities or side effects experienced by trial participants or other safety issues, such as drug interactions,
    including those which cause confounding changes to the levels of other concomitant medications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected rates of subject recruitment and enrollment rates in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in retaining subjects for the entire duration of applicable clinical studies (as study subjects may withdraw at any time due to adverse
    side effects from the therapy, insufficient efficacy, fatigue with the clinical trial process or for any other reason;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or inability in manufacturing or obtaining sufficient quantities of materials for use in clinical trials due to regulatory and manufacturing
    constraints;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequacy
    of or changes in our manufacturing process or product candidate formulation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining regulatory authorizations, such as INDs and any others that must be obtained, maintained, and/or satisfied to commence
    a clinical trial, including &#8220;clinical holds&#8221; or delays requiring suspension or termination of a trial by a regulatory
    agency, such as the FDA, before or after a trial is commenced;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable regulatory policies and regulation, including changes to requirements imposed on the extent, nature or timing of studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainty
    regarding proper dosing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to supply product for use in clinical trials which conforms to regulatory specification;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    results from ongoing preclinical studies and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our CROs, or other third-party contractors to comply with all contractual requirements or to perform their services in a timely
    or acceptable manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us, our employees, our CROs or their employees to comply with all applicable FDA or other regulatory requirements relating to
    the conduct of clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">scheduling
    conflicts with participating clinicians and clinical institutions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to design appropriate clinical trial protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    concerns with psychedelics, generally, and the potential for abuse;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    data to support regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    or unwillingness of medical investigators to follow our clinical protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in maintaining contact with patients during or after treatment, which may result in incomplete data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    clinical holds placed on company by regulatory agencies during review process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to supply psychedelic product for use in clinical trials due to cross-border or inter-continental shipment or customs
    handling and processing of controlled substances; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    finding clinical trials sites whose investigators possess the requisite credentials to oversee clinical trials involving a Schedule
    I substance.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
third-parties we rely on to conduct our operations are subject to regulatory requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third parties to conduct our preclinical studies and expect to use clinical studies in the future. We rely on CROs and clinical
data management organizations to design, conduct, supervise and monitor our preclinical studies and clinical trials. We and our CROs
are required to comply with various regulations, including GCP, which are enforced by regulatory agencies, to ensure that the health,
safety and rights of patients are protected in clinical development and clinical trials, and that trial data integrity is assured. Regulatory
authorities ensure compliance with these requirements through periodic inspections of trial sponsors, principal investigators and trial
sites. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. If we or
any of our CROs fail to comply with applicable requirements, the clinical data generated in our clinical trials may be deemed unreliable
and the FDA or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving
our marketing applications. Because we rely on third parties, our internal capacity to perform these functions is limited. Outsourcing
these functions involves risk that third parties may not perform to our standards, may not produce results in a timely manner or may
fail to perform at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third parties to supply the materials for, and manufacture, our research and development, and preclinical and clinical trial
supplies and APIs, and we expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate.
To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third
parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related
to quality control and assurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Difficulty
or delays in enrolling patients in clinical trials may result in delay or prevention of necessary regulatory approvals.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to locate and enroll a sufficient number of eligible patients to participate in our clinical trials for our product candidates
as required by the FDA or similar regulatory authorities outside the United States, we may not be able to initiate or conduct our trials.
Our inability to enroll a sufficient number of patients for our trials would result in significant delays could require us to postpone
or abandon clinical trials. Enrollment delays may result in increased development costs for our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
failure by us to comply with existing regulations could harm our reputation and operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to extensive regulation by U.S. federal and state and foreign governments in each of the U.S., European and Canadian markets,
in which we plan to sell our product candidates. We must adhere to all regulatory requirements, including FDA&#8217;s Good Laboratory
Practice (&#8220;GLP&#8221;), GCP, and GMP requirements, pharmacovigilance requirements, advertising and promotion restrictions, reporting
and recordkeeping requirements, and their European equivalents. If we or our suppliers fail to comply with applicable regulations, including
FDA pre-or post-approval requirements, then the FDA or other foreign regulatory authorities could sanction our Company. Even if a drug
is approved by the FDA or other competent authorities, regulatory authorities may impose significant restrictions on a product&#8217;s
indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of our product candidates which may be approved in the U.S. will be subject to ongoing regulatory requirements for manufacturing, labeling,
packaging, storage, distribution, import, export, advertising, promotion, sampling, recordkeeping and submission of safety and other
post-market information, including both federal and state requirements. In addition, manufacturers and manufacturers&#8217; facilities
are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform
to GMP. As such, we and our contract manufacturers (in the event contract manufacturers are appointed in the future) are subject to continual
review and periodic inspections to assess compliance with GMP. Accordingly, we and others with whom we work will have to spend time,
money and effort in all areas of regulatory compliance, including manufacturing, production, quality control and quality assurance. We
will also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements
concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a
variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. Similar
restrictions and requirements exist in the European Union and other markets where we operate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency,
or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of the product,
it may impose restrictions on that product or on us, including requiring withdrawal of the product from the market. If we fail to comply
with applicable regulatory requirements, a regulatory agency or enforcement authority may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    warning letters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    civil or criminal penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any of our ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to approved applications submitted by us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    restrictions on our operations, including by requiring us to enter in to a Corporate Integrity Agreement or closing our contract
    manufacturers&#8217; facilities, if any; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain products or require a product recall.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to federal, state and foreign healthcare laws and regulations and implementation of or changes to such healthcare laws
and regulations could adversely affect our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we successfully complete the requisite preclinical and clinical testing, make the required regulatory submissions and obtain any corresponding
authorizations or licenses (as applicable), fulfill all other applicable development-related regulatory obligations, and, eventually,
obtain FDA approval to market one or more of our current or future product candidates in the United States, we may be subject to certain
healthcare laws and regulations. In both the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory
proposals to change the healthcare system in ways that could impact our ability to sell our future product candidates. If we are found
to be in violation of any of these laws or any other federal, state or foreign regulations, we may be subject to administrative, civil
and/or criminal penalties, damages, fines, individual imprisonment, exclusion from federal health care programs and the restructuring
of our operations. Any of these could have a material adverse effect on our business and financial results. Since many of these laws
have not been fully interpreted by the courts, there is an increased risk that we may be found in violation of one or more of their provisions.
Any action against us for violation of these laws, even if we are ultimately successful in our defense, will cause us to incur significant
legal expenses and divert our management&#8217;s attention away from the operation of our business. In addition, in many foreign countries,
particularly the countries of the European Union, the pricing of prescription drugs is subject to government control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing
drug pricing vary widely from country to country. For example, some European Union jurisdictions operate positive and negative list systems
under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some
of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate
to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company
profits. Such differences in national pricing regimes may create price differentials between European Union member states. There can
be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable
reimbursement and pricing arrangements for any of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
products launched in the European Union do not follow price structures of the U.S.. In the European Union, the downward pressure on healthcare
costs in general, particularly prescription medicines, has become intense. As a result, barriers to entry of new products are becoming
increasingly high and patients are unlikely to use a drug product that is not reimbursed by their government.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition,
the importation of foreign products may compete with any future product that we may market, which could negatively impact our profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically
in the U.S., we expect that the 2010 Affordable Care Act (&#8220;ACA&#8221;), as well as other healthcare reform measures that may be
adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive
for any approved product. There have been judicial challenges to certain aspects of the ACA and numerous legislative attempts to repeal
and/or replace the ACA in whole or in part, and we expect there will be additional challenges and amendments to the ACA in the future.
At this time, the full effect that the ACA will have on our business in the future remains unclear. An expansion in the government&#8217;s
role in the U.S. healthcare industry may cause general downward pressure on the prices of prescription drug products, lower reimbursements
or any other product for which we obtain regulatory approval, reduce product utilization and adversely affect our business and results
of operations. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments
from private payors. Several states have adopted or are considering adopting laws that require pharmaceutical companies to provide notice
prior to raising prices and to justify price increases. We expect that additional healthcare reform measures will be adopted in the future,
any of which could limit the amounts that federal and state governments will pay for healthcare products and services, and in turn could
significantly reduce the projected value of certain development projects and reduce our profitability. The implementation of such cost
containment measures and other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize
any of our future product candidates for which we may receive regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is a high rate of failure for drug candidates proceeding through clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no products on the market. None of our prospective products or investigational candidates have ever been tested in a human subject.
Our ability to achieve and sustain profitability with respect to our product candidates depends on obtaining regulatory approvals for
and, if approved, successfully commercializing our product candidates, either alone or with third parties. Before obtaining regulatory
approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical
tests and clinical trials to demonstrate the safety, purity and potency of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
there is a high rate of failure for drug candidates proceeding through clinical trials. We may suffer significant setbacks in our clinical
trials similar to the experience of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving
promising results in earlier trials. Further, even if we view the results of a clinical trial to be positive, the FDA or other regulatory
authorities may disagree with our interpretation of the data. In the event that we obtain negative results from clinical trials for product
candidates or other problems related to potential chemistry, manufacturing and control issues or other hurdles occur and our future product
candidates are not approved, we may not be able to generate sufficient revenue or obtain financing to continue our operations, our ability
to execute on our current business plan may be materially impaired, and our reputation in the industry and in the investment community
might be significantly damaged. In addition, our inability to properly design, commence and complete clinical trials may negatively impact
the timing and results of our clinical trials and ability to seek approvals for our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
testing, marketing and manufacturing of any new drug product for use in the United States will require approval from the FDA. We cannot
predict with any certainty the amount of time necessary to obtain such FDA approval and whether any such approval will ultimately be
granted. Preclinical and clinical trials may reveal that one or more products are ineffective or unsafe, in which event further development
of such products could be seriously delayed or terminated. Moreover, obtaining approval for certain products may require testing on human
subjects of substances whose effects on humans are not fully understood or documented. Delays in obtaining FDA or any other necessary
regulatory approvals of any proposed drug and failure to receive such approvals would have an adverse effect on the drug&#8217;s potential
commercial success and on our business, prospects, financial condition and results of operations. In addition, it is possible that a
proposed drug may be found to be ineffective or unsafe due to conditions or facts that arise after development has been completed and
regulatory approvals have been obtained. In this event, we may be required to withdraw such proposed drug from the market. To the extent
that our success will depend on any regulatory approvals from government authorities outside of the United States that perform roles
similar to that of the FDA, uncertainties similar to those stated above will also exist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Serious
adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of our prospective
products or current or future product candidates, limit the scope of any approved label or market acceptance, or cause the recall or
loss of marketing approval of products that are already marketed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our prospective products or current or future product candidates, prior to or after any approval for commercial sale, cause serious
or unexpected side effects, or are associated with other safety risks such as misuse, abuse or diversion, a number of potentially significant
negative consequences could result, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may interrupt, delay or halt clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may deny regulatory approval of our future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require certain labeling statements, such as warnings or contraindications or limitations on the indications for
    use, and/or impose restrictions on distribution in the form of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) in
    connection with approval or post-approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw their approval, require more onerous labeling statements, impose a more restrictive REMS, or require it
    to recall any product that is approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way the product is administered or conduct additional clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    relationships with our collaboration partners may suffer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer. The reputational risk is heightened with respect to those of our future product candidates that are being
    developed for pediatric indications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may voluntarily suspend or terminate our clinical trials if at any time we believe that the product candidates present an unacceptable
risk to participants, or if preliminary data demonstrates that our future product candidates are unlikely to receive regulatory approval
or unlikely to be successfully commercialized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completing preclinical testing and obtaining the requisite regulatory authorizations, as applicable, we may voluntarily suspend or terminate
our clinical trials for any number of reasons, including if we believe that a product&#8217;s use, or a person&#8217;s exposure to it,
may cause adverse health consequences or death. In addition, regulatory agencies, IRBs or data safety monitoring boards may at any time
recommend the temporary or permanent discontinuation of our clinical trials or request that we cease using investigators in the clinical
trials if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements, or that
they present an unacceptable safety risk to participants. Although we have never been asked by a regulatory agency, IRB or data safety
monitoring board to temporarily or permanently discontinue a clinical trial, if we elect or are forced to suspend or terminate a clinical
trial of any of our future product candidates, the commercial prospects for that product will be harmed and our ability to generate product
revenue from that product may be delayed or eliminated. Furthermore, any of these events may result in labeling statements such as warnings
or contraindications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, such events or labeling could prevent us or our partners from achieving or maintaining market acceptance of the affected product
and could substantially increase the costs of commercializing our future product candidates and impair our ability to generate revenue
from the commercialization of these products either by us or by our collaboration partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulatory
risks related to Psychedelic Derivatives</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
execution of our strategy is contingent, in part, upon compliance with regulatory requirements from time to time enacted by governmental
authorities and obtaining all regulatory approvals, where necessary, for the development and license of our Psychedelic Derivatives.
Health Canada and the FDA have not yet determined whether our Psychedelic Derivatives will be scheduled as controlled substances. The
psychedelic therapy industry is a new and emerging industry with ambiguous existing regulations and uncertainty as to future regulations;
We cannot predict the impact of the ever-evolving compliance regime in respect of this industry. In the event Health Canada or the FDA
determine that our Psychedelic Derivatives are controlled substances and therefore, require regulatory approval, to the extent that we
produce Psychedelic Derivatives, we will be required to obtain such regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we may not be able to predict the time required to secure all appropriate regulatory approvals for our Psychedelic Derivatives, or the
extent of testing and documentation that may, from time to time, be required by governmental authorities. The impact of compliance regimes,
any delays in obtaining, or failure to obtain regulatory approvals may significantly delay or impact the development of markets, our
business and Psychedelic Derivatives, and licensing initiatives and could have a material adverse effect on the business, financial condition
and operating results of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with regulations may result in additional
costs for corrective measures, penalties or result in restrictions on our operations. In addition, changes in regulations, more vigorous
enforcement thereof or other unanticipated events could require extensive changes to our operations, increased compliance costs or give
rise to material liabilities, which could have a material adverse effect on the business, financial condition and operating results of
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
management will be required to devote a substantial time to comply with public company regulations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley
Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), the Dodd-Frank Wall Street Reform and Consumer Protection Act as well as rules implemented
by the SEC and Nasdaq, impose various requirements on public companies, including those related to corporate governance practices. Our
management and other personnel must devote a substantial amount of time to these requirements. Moreover, these rules and regulations
increase our legal and financial compliance costs and make some activities more time consuming and costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure
controls and procedures. In particular, we must perform system and process evaluation and testing of our internal control over financial
reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section
404 of the Sarbanes-Oxley Act. Our compliance with these requirements will require that we incur substantial accounting and related expenses
and expend significant management efforts. We have engaged third party consultants to help satisfy the ongoing requirements of Section
404 of the Sarbanes-Oxley Act. The costs of this outsourcing may be material and there can be no assurance that such staff will be immediately
available to us. Moreover, if we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we identify
deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, investors could lose confidence
in the accuracy and completeness of our financial reports, the market price of our common stock could decline and we could be subject
to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities, which could require additional financial and management
resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have identified a material weakness in our internal control over financial reporting. If we are unable to remediate the material weakness,
or if we experience additional material weaknesses in the future, our business may be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting and for evaluating and
reporting on the effectiveness of our system of internal control. Internal control over financial reporting is a process used to provide
reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external
purposes in accordance with generally accepted accounting principles in the United States. As a public company, we are required to comply
with the Sarbanes-Oxley Act and other rules that govern public companies. In particular, we are required to certify our compliance with
Section 404 of the Sarbanes-Oxley Act, which requires us to furnish annually a report by management on the effectiveness of our internal
control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management performed an assessment of the Company&#8217;s significant processes and key controls. Based on this assessment, management
concluded that our internal control over financial reporting was not effective as of December 31, 2023 due to the material weakness related
to segregation of duties. As of December 31, 2023, there were control deficiencies which constituted a material weakness in our internal
control over financial reporting. Management has taken, and is taking steps to strengthen our internal control over financial reporting:
we have conducted evaluation of the material weakness to determine the appropriate remedy and have established procedures for documenting
disclosures and disclosure controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the small size of our Company, we do not maintain sufficient segregation of duties to ensure the processing, review and authorization
of all transactions including non-routine transactions. While we have taken certain actions to address the material weaknesses identified,
additional measures including engaging third party consultants may be necessary as we work to improve the overall effectiveness of our
internal controls over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remediation
efforts place a significant burden on management and add increased pressure to our financial resources and processes. If we are unable
to successfully remediate our existing material weakness or any additional material weaknesses in our internal control over financial
reporting that may be identified in the future in a timely manner, the accuracy and timing of our financial reporting may be adversely
affected; our liquidity, our access to capital markets, the perceptions of our creditworthiness may be adversely affected; we may be
unable to maintain or regain compliance with applicable securities laws, the listing requirements of the Nasdaq Stock Market; we may
be subject to regulatory investigations and penalties; investors may lose confidence in our financial reporting; our reputation may be
harmed; and our stock price may decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tax
risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to various taxes in either the United States, Canada and Australia, or all three, including, without limitation, the following:
income taxes, payroll taxes, workers compensation, goods and services tax, sales tax, and land transfer tax. Our tax filings will be
subject to audit by various taxation authorities. While we intend to base its tax filings and compliance on the advice of our tax advisors,
there can be no assurance that our tax filing positions will never be challenged by a relevant taxation authority resulting in a greater
than anticipated tax liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to adequately protect or enforce our intellectual property rights, which could harm our competitive position.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend, in part, on our ability to obtain and maintain additional patents, protect our trade secrets and operate without
infringing on the proprietary rights of others. We rely upon a combination of patents, trade secret protection (i.e., know-how), and
confidentiality agreements to protect the intellectual property of our future product candidates. The strengths of patents in the pharmaceutical
field involve complex legal and scientific questions and can be uncertain. Where appropriate, we seek patent protection for certain aspects
of our products and technology. Filing, prosecuting and defending patents globally can be prohibitively expensive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to look to patent technologies with commercial potential in jurisdictions with significant commercial opportunities. However,
patent protection may not be available for some of the products or technology we are developing. If we must spend significant time and
money protecting, defending or enforcing our patents, designing around patents held by others or licensing, potentially for large fees,
patents or other proprietary rights held by others, our business, results of operations and financial condition may be harmed. We may
not develop additional proprietary products that are patentable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of pharmaceutical products are complex and uncertain. The scope and extent of patent protection for our future product
candidates are particularly uncertain. Although we have sought, and will continue to seek, patent protection in the U.S., Europe and
other countries for our proprietary technologies, future product candidates, their methods of use, and methods of manufacture, any or
all of them may not be subject to effective patent protection. If any of our products is approved and marketed for an indication for
which we do not have an issued patent, our ability to use our patents to prevent a competitor from commercializing a non-branded version
of our commercial products for that non-patented indication could be significantly impaired or even eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
of information related to our future product candidates by us or others may prevent us from obtaining or enforcing patents relating to
these products and product candidates. Furthermore, others may independently develop similar products, may duplicate our products, or
may design around our patent rights. In addition, any of our issued patents may be opposed and/or declared invalid or unenforceable.
If we fail to adequately protect our intellectual property, we may face competition from companies who attempt to create a generic product
to compete with our future product candidates. We may also face competition from companies who develop a substantially similar product
to our future product candidates that is not covered by any of our patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting, defending and enforcing intellectual property rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other
intellectual property rights, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent
rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success depends on our ability to obtain additional intellectual property and operate without infringing the proprietary rights of others.
Infringement claims by third parties may result in liability for damages or prevent or delay our developmental and commercialization
efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success and ability to compete depend in part on our ability to obtain additional patents, protect our trade secrets, and operate without
infringing on the proprietary rights of others. If we fail to adequately protect our intellectual property, we may face competition from
companies who develop a substantially similar product to our future product candidates that is not covered by any of our intellectual
property. Many companies have encountered significant problems in protecting, defending, and enforcing intellectual property rights in
foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement
of patents and other intellectual property rights, particularly those relating to pharmaceuticals, which could make it difficult for
us to stop the infringement of our intellectual property and other proprietary rights. There is also a substantial amount of litigation,
both within and outside the U.S., involving patient and other intellectual property rights in the pharmaceutical industry. We may, from
time to time, be notified of claims that we are infringing upon the proprietary rights of third parties, and we cannot provide assurances
that other companies will not, in the future, pursue such infringement claims against it, our commercial partners, or any third-party
proprietary technologies we have licensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unsuccessful in licensing additional intellectual property to develop new product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may in the future seek to in-license additional intellectual property that we believe could complement or expand our product candidates
or otherwise offer growth opportunities. The pursuit of such licenses may cause us to incur various expenses in identifying, investigating
and pursuing suitable intellectual property. If we acquire additional intellectual property to develop new therapeutic product candidates,
we may not be able to realize anticipated cost savings or synergies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
third parties claim that intellectual property used by us infringes upon their intellectual property, our operating profits could be
adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the
pharmaceutical industry. We may, from time to time, be notified of claims that we are infringing upon patents, trademarks, copyrights
or other intellectual property rights owned by third parties, and we cannot provide assurances that other companies will not, in the
future, pursue such infringement claims against us, our commercial partners or any third-party proprietary technologies we have licensed.
If we were found to infringe upon a patent or other intellectual property right, or if we failed to obtain or renew a license under a
patent or other intellectual property right from a third party, or if a third party that we were licensing technologies from was found
to infringe upon a patent or other intellectual property rights of another third party, we may be required to pay damages, including
damages of up to three times the damages found or assessed, if the infringement is found to be willful, suspend the manufacture of certain
products or reengineer or rebrand our products, if feasible, or we may be unable to enter certain new product markets. Any such claims
could also be expensive and time-consuming to defend and divert management&#8217;s attention and resources. Our competitive position
could suffer as a result. In addition, if we have declined or failed to enter into a valid non-disclosure or assignment agreement for
any reason, we may not own the invention or our intellectual property, and our products may not be adequately protected. Thus, we cannot
guarantee that any of our future product candidates, or our commercialization thereof, does not and will not infringe any third party&#8217;s
intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and
products could be significantly diminished.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secrets to protect our proprietary technologies, especially where it does not believe patent protection is appropriate
or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our current and former
employees, consultants, outside scientific collaborators, sponsored researchers, contract manufacturers, vendors and other advisors to
protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential
information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition,
we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets. Any
party with whom we or they have executed such an agreement may breach that agreement and disclose our proprietary information, including
our trade secrets, and we may not be able to obtain adequate remedies for such breaches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforcing
a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome
is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.
If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent
them, or those to whom they disclose such trade secrets, from using that technology or information to compete with us. If any of our
trade secrets were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would
be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property rights effectively outside of the United States.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. Therefore,
we choose to file applications and/or obtained patents only in key markets. Competitors may use our technologies in jurisdictions where
we have not obtained patent protection to develop their own products and, further, may be able to export otherwise infringing products
to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may
compete with our products in jurisdictions where we do not have any issued patents and/or our patent claims or other intellectual property
rights may not be effective or sufficient to prevent them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other
intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent
rights in certain foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our
business and could be unsuccessful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
financial condition would be adversely impacted if our intangible assets become impaired</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangibles
are evaluated quarterly and are tested for impairment at least annually or when events or changes in circumstances indicate the carrying
value of each segment, and collectively the Company taken as a whole, might exceed its fair value. If we determine that the value of
our intangible assets is less than the amounts reflected on our balance sheet, we will be required to reflect an impairment of our intangible
assets in the period in which such determination is made. An impairment of our intangible assets would result in our recognizing an expense
in the amount of the impairment in the relevant period, which would also result in the reduction of our intangible assets and a corresponding
reduction in our stockholders&#8217; equity in the relevant period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Ownership of Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our common stock may be subject to significant fluctuations and volatility, and our stockholders may be unable to resell
their shares at a profit and incur losses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price our common stock could be subject to significant fluctuation. Market prices for securities of life sciences and biopharma
companies in particular have historically been particularly volatile and have shown extreme price and volume fluctuations that have often
been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general
economic, political and market conditions such as recessions or interest rate changes, may seriously affect the market price of our common
stock, regardless of our actual operating performance. Some of the factors that may cause the market price of our common stock to fluctuate
include, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors
    react negatively to the effect on our business and prospects;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    announcement of new products, new developments, services or technological innovations by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated quarterly increases or decreases in revenue, gross margin or earnings, and changes in our business, operations or
    prospects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    relating to strategic relationships, mergers, acquisitions, partnerships, collaborations, joint ventures, capital commitments, or
    other events by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    or trends in the life sciences and biopharma industries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the economic performance or market valuations of other life sciences and biopharma companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions or domestic or international macroeconomic and geopolitical factors unrelated to our performance or financial condition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
    of our common stock by stockholders, including executives and directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    and limitations in trading volumes of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    in the market prices and trading volumes of companies in the life sciences and biopharma industries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to finance our business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability
    to secure resources and the necessary personnel to pursue our plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failures
    to meet external expectations or management guidance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our capital structure or dividend policy, future issuances of securities, sales or distributions of large blocks of common stock
    by stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    cash position;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    and events surrounding financing efforts, including debt and equity securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analyst
    research reports, recommendation and changes in recommendations, price targets, and withdrawals of coverage;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">departures
    and additions of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    and litigation related to intellectual properties, proprietary rights, and contractual obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investigations
    by regulators into our operations or those of our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable laws, rules, regulations, or accounting practices and other dynamics; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which may be out of our control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, following periods of volatility in the overall market and the market prices of particular companies&#8217; securities, securities
class action litigations have often been instituted against these companies. Litigation of this type, if instituted against us, could
result in substantial costs and a diversion of our management&#8217;s attention and resources. Any adverse determination in any such
litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may issue additional equity securities in the future, which may result in dilution to existing investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may, from
time to time, sell additional equity securities in one or more transactions at prices and in a manner we determine. If we sell additional
equity securities, existing stockholders may be materially diluted. New investors could gain rights superior to existing stockholders,
such as liquidation and other preferences. In addition, the number of shares available for future grant under our equity compensation
plans may be increased in the future. Also, the exercise or conversion of outstanding options or warrants to purchase shares of capital
stock may result in dilution to our stockholders upon any such exercise or conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
stockholders could attempt to influence changes within our Company which could adversely affect our operations, financial condition and
the value of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stockholders may from time to time seek to acquire a controlling stake in our Company, engage in proxy solicitations, advance stockholder
proposals or otherwise attempt to effect changes. Campaigns by stockholders to effect changes at publicly-traded companies are sometimes
led by investors seeking to increase short-term stockholder value through actions such as financial restructuring, increased debt, special
dividends, stock repurchases or sales of assets or the entire company. Responding to proxy contests and other actions by activist stockholders
can be costly and time-consuming and could disrupt our operations and divert the attention of our board of directors and senior management
from the operation of our business. These actions could adversely affect our operations, financial condition and the value of our common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities analysts do not publish research or reports about our business, or if they publish negative evaluations, the price of our
common stock could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will rely in part on the availability of research and reports that third-party industry or financial
analysts publish about our Company. There are many large, publicly traded companies active in the life sciences and biopharma industries,
which may mean it will be less likely that we receive widespread analyst coverage. Furthermore, if one or more of the analysts who do
cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our Company, we
could lose visibility in the market, which in turn could cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions under Delaware corporate law may make it difficult for our stockholders to replace or remove our board of directors and could
deter or delay third parties from acquiring our Company, which may be beneficial to our stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our Amended and Restated Certificate of Incorporation, we are subject to the anti-takeover provisions of the Delaware General Corporation
Law (&#8220;DGCL&#8221;), including Section 203 of the DGCL. Under these provisions, if anyone becomes an &#8220;interested stockholder,&#8221;
we may not enter into a &#8220;business combination&#8221; with that person for three (3) years without special approval, which could
discourage a third party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 203 of
the DGCL, &#8220;interested stockholder&#8221; means, generally, someone owning fifteen percent (15%) or more of our outstanding voting
stock or an affiliate of ours that owned fifteen percent (15%) or more of our outstanding voting stock during the past three (3) years,
subject to certain exceptions as described in Section 203 of the DGCL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not anticipate paying any cash dividends in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result,
capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of gain, if any, for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
the event that we fail to regain compliance with the listing requirements of The Nasdaq Capital Market or satisfy any of the listing
requirements of Nasdaq, our common stock may be delisted, which could affect our market price and liquidity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on Nasdaq. For continued listing on Nasdaq, we will be required to comply with the continued listing requirements,
including the minimum market capitalization standard, the stockholders&#8217; equity requirement, the corporate governance requirements
and the minimum closing bid price requirement, among other requirements. On November 21, 2023, we received a letter from the Nasdaq staff
indicating that, based on our reported stockholders&#8217; equity of $2,435,646 reported on Form 10-Q for the period ended September
30, 2023, we were not in compliance with the stockholders&#8217; equity requirement of at least $2,500,000 pursuant to Listing Rule 5550(b)(1).
We intend to regain compliance with Listing Rule 5550(b)(1). On February 6, 2024, the Nasdaq staff notified us that based on a review
of the materials submitted by the Company to Nasdaq, we were granted us an extension to regain compliance with the minimum stockholders&#8217;
equity requirement. The Company must regain compliance by May 20, 2024 and further evidence its compliance upon filing its periodic report
for June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that we fail to regain compliance with Listing Rule 5550(b)(1) or satisfy any of the listing requirements of Nasdaq, our common
stock may be delisted. We will have an opportunity to appeal the determination to a Hearings Panel, but we cannot guarantee that such
appeal will be successful. If we are unable to list on Nasdaq, we would likely be more difficult to trade in or obtain accurate quotations
as to the market price of our common stock. If our common stock is delisted from trading on Nasdaq, and we are not able to list our common
stock on another exchange or to have it quoted on Nasdaq, our securities could be quoted on the OTC Bulletin Board or on the &#8220;pink
sheets.&#8221; As a result, we could face significant adverse consequences including, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability of market quotations for our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere
    to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of news and analyst coverage for our Company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability to issue additional securities (including pursuant to short-form registration statements on Form S-3 or obtain
    additional financing in the future).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to maintain an active trading market for our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
listing of our common stock on Nasdaq does not assure that a meaningful, consistent and liquid trading market exists. If an active market
for our common stock does continue, it may be difficult for investors to sell their shares without depressing the market price for the
shares or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
maintain our cash at financial institutions, often in balances that exceed federally insured limits.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
majority of our cash is held in accounts at U.S. banking institutions that we believe are of high quality. Cash held in non-interest-bearing
and interest-bearing operating accounts may exceed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If
such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations.
While the FDIC took control of one such banking institution, Silicon Valley Bank (&#8220;SVB&#8221;), on March 10, 2023, and the FDIC
also took control of Signature Bank (&#8220;Signature Bank&#8221;) on March 12, 2023, we did not have any accounts with SVB or Signature
Bank and therefore did not experience any specific risk of loss. The FDIC also announced that account holders would be made whole. Thus,
we do not view the risk as material to our financial condition. However, as the FDIC continues to address the situation with SVB, Signature
Bank and other similarly situated banking institutions, the risk of loss in excess of insurance limitations has generally increased.
Any material loss that we may experience in the future could have an adverse effect on our ability to pay our operational expenses or
make other payments and may require us to move our accounts to other banks, which could cause a temporary delay in making payments to
our vendors and employees and cause other operational inconveniences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe
will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able
to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and
company culture. We may encounter numerous difficulties in developing, manufacturing, and marketing any new products resulting from a
strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. There is
no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction, which
could result in a material adverse effect on our business and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_001"></span>Item
1B. Unresolved Staff Comments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_002"></span>Item
1C. Cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cybersecurity
Risk Management and Strategy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information
systems and protect the confidentiality, integrity, and availability of our data. We have established certain policies and procedures
for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these policies and procedures
into our overall risk management framework to promote a company-wide culture of cybersecurity risk management. Such procedures include
physical, procedural and technical safeguards, response methods, regular tests on our systems, and routine review of our processes to
identify risks and enhance our practices. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based
cybersecurity programs. We engage certain external parties, including consultants and computer security firms to enhance our cybersecurity
oversight and provide monthly trainings to our employees. We consider the internal risk oversight programs of third-party service providers
before engaging them in order to help protect our company from any related vulnerabilities. <span style="background-color: white">At
this time, we are not aware of any material cybersecurity incidents that have impacted the Company. For a description of the risks from
cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1 Item 1A Risk Factors in
this Annual Report.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Governance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our board of directors is acutely aware of the critical nature managing
risks associates with cybersecurity threats. Our board of directors has delegated authority to the Audit Committee to serve as the cybersecurity
oversight body. The Audit Committee is composed of board members with diverse expertise including, risk management, technology, and finance.
Our board of directors also works with the chief financial officer to assess and respond to cybersecurity threats. The chief financial
officer meets with the third-party vendors regularly to discuss any issues and updates related to the Company&#8217;s information technology
environment and reports to the chief executive officer and Audit Committee on a regular basis, with a minimum frequency of once per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_003"></span>Item
2. Properties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal corporate office is located at 4851 Tamiami Trail N, Suite 200 Naples, FL 34103 and our Canadian office is located at 3655
36 Street NW Calgary, Alberta T2L1Y8. The Company believes our offices are in good condition and are sufficient to conduct our operations.
Our principal corporate office is held under a month-to-month operating lease. Our Canadian office is held under a quarter-to-quarter
operating lease set to expire in March 2024. We do not plan to renew this lease following its expiration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_004"></span>Item
3. Legal proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is periodically involved in legal proceedings, legal actions and claims arising in the ordinary course of business. We do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management,
have a material adverse effect on our financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_005"></span>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_006"></span>PART
II. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_007"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is traded on the Nasdaq Capital Markets under the symbol &#8220;ENVB&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Holders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2024 the Company had approximately 202 stockholders of record.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividends</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has never declared or paid cash dividends on its common stock and has no intention to do so in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Sales of Unregistered Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuer
Purchases of Equity Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_008"></span>Item
6. [Reserved]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_009"></span>Item
7. Management&#8217;s discussion and analysis of financial condition and results of operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
to the &#8220;Company,&#8221; &#8220;Enveric&#8221; &#8220;our,&#8221; &#8220;us,&#8221; or &#8220;we&#8221; in this section titled
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of Enveric&#8221; refer to
Enveric Biosciences, Inc. The following discussion and analysis of our financial condition and results of operations should be read
together with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the
information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including
information with respect to our plans and strategy for our business and related financing, includes forward-looking statements
involving risks and uncertainties and should be read together with the &#8220;Risk Factors&#8221; and the &#8220;Cautionary
Statement Regarding Forward-Looking Statements&#8221; sections of this Annual Report on Form 10-K. Such risks and uncertainties
could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained
in the following discussion and analysis.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression,
anxiety, and addiction disorders. Leveraging our unique discovery and development platform, the Psybrary&#8482;, we have created a robust
intellectual property portfolio of new chemical entities for specific mental health indications. Our lead program, the EVM201 Series,
comprises next generation synthetic prodrugs of the active metabolite, psilocin. We are developing the first product from the EVM201
Series &#8211; EB-002 &#8211; for the treatment of psychiatric disorders. We are also advancing its second program, the EVM301 Series
&#8211; EB 003 &#8211; expected to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders,
mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Psychedelics</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
our amalgamation with MagicMed completed in September 2021 (the &#8220;Amalgamation&#8221;), we have continued to pursue the development
of MagicMed&#8217;s proprietary psychedelic derivatives library, the Psybrary&#8482; which we believe will help us to identify and develop
the right drug candidates needed to address mental health challenges, including anxiety. We synthesize novel versions of classic psychedelics,
such as psilocybin, DMT, mescaline and MDMA, using a mixture of chemistry and synthetic biology, resulting in
the expansion of the Psybrary&#8482;, which includes 15 patent families with over a million potential variations and hundreds of synthesized
molecules. Within the Psybrary&#8482; we have three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs),
and Generation 3 (new chemical entities). The Company has created over 1,000 novel psychedelic molecular compounds and derivatives (&#8220;Psychedelic
Derivatives&#8221;) that are housed in the Psybrary&#8482;. Our current focus is develop our lead molecules EB-002 and EB-003 and to
out-license other molecules from the Psybrary&#8482;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Akos
Spin-Off</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2022, the Company announced plans to transfer and spin-off its cannabinoid clinical development pipeline assets to Akos Biosciences,
Inc. (formerly known as Acanna Therapeutics, Inc.), a majority-owned subsidiary of the Company (hereafter referred to as &#8220;Akos&#8221;),
which was incorporated on April 13, 2022, by way of dividend to Enveric shareholders (the &#8220;Spin-Off&#8221;). As of May 12, 2023,
the holders of the Company&#8217;s Akos Series A Preferred Stock, par value $0.01 per share (&#8220;Akos Series A Preferred Stock&#8221;)
have exercised this right to force redemption of all of the Akos Series A Preferred Stock for $1,000 per share, plus accrued but unpaid
dividends of $52,057 for a total of $1,052,057. The Company made full payment on May 19, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Australian
Subsidiary</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2023, the Company established Enveric Therapeutics, Pty. Ltd. (&#8220;Enveric Therapeutics&#8221;), an Australia-based subsidiary,
to support the Company&#8217;s plans to advance its EVM201 Series towards the clinic. Enveric Therapeutics will oversee the Company&#8217;s
preclinical, clinical, and regulatory activities in Australia, including ongoing interactions with the local Human Research Ethics Committees
(HREC) and the Therapeutic Goods Administration (&#8220;TGA&#8221;), Australia&#8217;s regulatory authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2023, we issued a press release announcing the selection of Australian CRO, Avance Clinical, in preparation for Phase 1 Study
of EB-002, our lead candidate targeting the treatment of anxiety disorders. Under the agreement, Avance Clinical will manage the Phase
1 clinical trial of EB-002 in coordination with our newly established Australian subsidiary, Enveric Therapeutics Pty, Ltd. The Phase
1 clinical trial is designed as a multi-cohort, dose-ascending study to measure the safety and tolerability of EB-002. EB-002, a next-generation
proprietary psilocin prodrug, has been recognized as a New Chemical Entity (NCE) by Australia&#8217;s Therapeutic Goods Administration
(TGA) and is currently in preclinical development targeting the treatment of anxiety disorder. The total cost of the Avance Clinical
contract is approximately 3,000,000 AUD, which translates to approximately $2,000,000 as of December 31, 2023. As of December 31, 2023,
the Company has paid $1,036,940 of the Avance Clinical contract costs and has accrued $523,284 recorded as accrued liabilities and $239,320
as accounts payable. For the year ended December 31, 2023, the Company has expensed $1,751,444 in research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2023, we issued a press release announcing the selection of EB-003 as the lead development candidate from our EVM 301 Series.
Our next step is to advance EB-003 into formal pre-clinical studies in support of a future IND filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reduction
in Force/Restructuring</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Company entered into a cost reduction plan, including a reduction in force of approximately 35% of its full-time employees
to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that were focused on the Akos
cannabinoid spin-out were terminated. The Company recognized severance charges of $453,059 through December 31, 2023. The plan included
a focus on progressing the Company&#8217;s existing non-cannabinoid pipeline while reducing the rate of spend and managing cash flow.
As of December 31, 2023, the Company has completed the reduction in force, with such severance expenses recorded in salaries and wages
and legal accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 16, 2023, the Company entered into a separation agreement with Avani Kanubaddi, the Company&#8217;s President and Chief Operating
Officer (the &#8220;Kanubaddi Separation Agreement&#8221;). Mr. Kanubaddi&#8217;s 2023 salary and benefits of $550,974 was accrued and
will be paid out in twelve equal monthly installments beginning in July 2023. Upon termination, any unvested time-based RSU&#8217;s became
fully vested. The Company accelerated expense recognized related to these shares that vested upon termination of $231,273. All of the
11,278 market performance-based RSUs previously granted that were subject to the original terms and conditions of Mr. Kanubaddi&#8217;s
employment agreement were forfeited during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Distribution Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2023, the Company entered into a Distribution Agreement, with Canaccord Genuity, LLC (&#8220;Canaccord&#8221;), pursuant
to which the Company may offer and sell from time to time, through Canaccord as sales agent and/or principal, shares of common stock
of the Company, par value $0.01 per share having an aggregate offering price of up to $10.0 million. Due to the offering limitations
applicable to the Company and in accordance with the terms of the Distribution Agreement, the Company may offer common stock having an
aggregate gross sales price of up to $2,392,514 pursuant to the prospectus supplement dated September 1, 2023 (the &#8220;Prospectus
Supplement&#8221;). Subject to the terms and conditions of the Distribution Agreement, Canaccord may sell the common stock by any method
permitted by law deemed to be an &#8220;at-the-market offering&#8221;. The Company will pay Canaccord a commission equal to 3.0% of the
gross sales price of the common stock sold through Canaccord under the Distribution Agreement and has also agreed to reimburse Canaccord
for certain expenses. The Company may also sell common stock to Canaccord as principal for Canaccord&#8217;s own account at a price agreed
upon at the time of sale. Any sale of common stock to Canaccord as principal would be pursuant to the terms of a separate terms agreement
between the Company and Canaccord.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company has issued no shares of common stock through the Distribution Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inducement Letters (as defined below) prohibit the Company from entering into any variable rate transaction as defined in the Inducement
Letters, including the issuance of (1) any variable priced debt or equity securities or (2) transactions whereby the Company may issue
securities at a future determined price, such as through an at-the-market offering or an equity line of credit. The variable rate transaction
restriction expires after six-months from the closing date of December 28, 2023 for the Inducement Letters for an issuance through an
at-the-market offering, and one-year for the remaining variable rate transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct
offering of 228,690 shares of the Company&#8217;s common stock, par value $0.01 per share to the Holders (as defined below) of the
Inducement Warrants (as defined below). The issuance was made in exchange for the permanent and irrevocable waiver of the variable rate transaction
limitation solely with respect to the entry into and/or issuance of shares of common stock in an at-the-market offering contained in
the Inducement Letters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Line</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, the Company entered into an equity line by entering into a Purchase Agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln
Park&#8221;), pursuant to which the Company may offer and sell from time to time over a 24-month period, shares of common stock of the
Company, par value $0.01 per share, to receive gross proceeds of up to $10.0 million. As required under the Purchase Agreement, the Company
registered a resale of 1,140,477 shares of our common stock by Lincoln Park on a registration statement on Form S-1 dated November 8,
2023, which was declared effective by the SEC on December 5, 2023. Subject to the SEC rules and regulations, the Company may register
additional shares of our common stock for resale with the SEC pursuant to the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Inducements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#8220;Inducement Letters&#8221;) with
certain holders (the &#8220;Holders&#8221;) of the February 2022 Post-Modification Warrants and RD and PIPE preferred investment
options to purchase shares of the Company&#8217;s common stock (the &#8220;Existing Warrants and Investment Options&#8221;) pursuant
to which the Holders agreed to exercise for cash their Existing Warrants and Investment Options to purchase 1,122,000 shares of the
Company&#8217;s common stock, in the aggregate, at a reduced exercised price of $1.37 per share (from an original exercise price of
$7.78 per share), in exchange for the Company&#8217;s agreement to sell and issue new warrants (the &#8220;Inducement
Warrants&#8221;) to purchase up to 2,244,000 shares of the Company&#8217;s common stock (the &#8220;Inducement Warrant
Shares&#8221;), and the Holders to make a cash payment of $0.125 per Inducement Warrant share for total proceeds of $280,500. The Company received aggregate gross
proceeds of $1,817,640 from the exercise of the Existing Warrants and Investment Options by the Holders and the sale of the
Inducement Warrants on January 2, 2024. As of December 31, 2023, the exercised and unsettled Existing Warrants and Investment
Options by the Holders and the sale of the Inducement Warrants are included in the consolidated balance sheet as a subscription
receivable. Due to the beneficial ownership limitation provisions, 704,000 shares of Existing Warrants and Investment Options
exercised were initially unissued and held in abeyance for the benefit of the Holder until notice is received from the Holder that
the shares may be issued in compliance with such limitation. Subsequent to December 31, 2023, the Company issued all 704,000 shares
of common stock of the 704,000 shares of Existing Warrants and Investment Options exercised that were held in abeyance due to the
beneficial ownership limitation provisions. The Company engaged Roth Capital Partners, LLC (&#8220;Roth&#8221;) to act as its
financial advisor in connection with the transactions summarized above and will pay Roth approximately $144,000 for its services, in
addition to reimbursement for certain expenses. Roth was also issued warrants to purchase up to 67,320 shares of common stock. The
Roth Warrants have the same terms as the Inducement Warrants. The grant date fair value of these Roth Warrants was estimated to be
$77,991 on December 28, 2023 and were charged to additional paid in capital as issuance costs. The Company also incurred legal fees
of $17,254 related to the transactions above that were charged to additional paid in capital as issuance costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pre-revenue biotech company that has to date, not generated any revenues. During the years ended December 31, 2023 and 2022, we
raised approximately $18.2 million from the sales of common stock, warrants, preferred investment options, and redeemable non-controlling
interest, and from proceeds realized from the exercise of cash warrants. These amounts were the primary source of funds upon which our
operations were financed during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred for the research and development of our preclinical product candidates,
and include, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
    expenses, including salaries, benefits and share-based compensation expense;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred under agreements with contract research organizations, contract manufacturing organizations, and consultants and other entities
    engaged to support our product research and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of acquiring, developing and manufacturing materials and lab supplies used in research and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facility,
    equipment, depreciation and other expenses, which include, without limitation direct and allocated expenses for rent, maintenance
    of our facilities and equipment, insurance and other supplies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    associated with preclinical activities and regulatory operations, including, without limitation, patent related costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consulting
    and professional fees associated with research and development activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expense research and development costs to operations as incurred. Research and development activities are central to our business model.
We utilize a combination of internal and external efforts to advance product development from early-stage work to future clinical trial
manufacturing and clinical trial support. External efforts include work with consultants and increasingly substantial work at CROs and
CMOs. We support an internal research and development team at our facility in Calgary, Alberta, Canada. To move these programs forward
along our development timelines, a large portion (approximately 75%) of our staff are research and development employees. In January
2024, the Company reduced its discovery team in Calgary and is primarily focused on the development of EBV 002 and EBV 003 pipeline assets.
Sixty percent of the staff are focused on these development activities after the reduction in discovery team. Because of the numerous
risks and uncertainties associated with product development, however, we cannot determine with certainty the duration and completion
costs of these or other current or future preclinical studies and clinical trials. The duration, costs and timing of clinical trials
and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical and preclinical
studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation. In addition, the probability
of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial
viability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist principally of salaries, benefits and related costs such as stock-based compensation for personnel
and consultants in executive, finance, business development, corporate communications and human resource functions, facility costs not
otherwise included in research and development expenses, accounting and audit costs, tax compliance costs, SEC compliance costs, investor
relation costs, training and conference costs, insurance costs and legal fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our general and administrative expenses will decrease in the future due to the reduction in force during the year ended
December 31, 2023, which is expected to reduce expenses related to salaries and benefits, director and office liability insurance, and
other employee-related costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Intangible Assets and Goodwill</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the Psybrary&#8482; and Patent Applications, In Process Research and Development (&#8220;IPR&amp;D&#8221;) and license
agreements. Psybrary&#8482; and Patent Applications intangible assets are valued using the relief from royalty method. The cost of license
agreements is amortized over the economic life of the license. The Company assesses the carrying value of its intangible assets for impairment
each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performs an annual impairment test of intangible assets and goodwill as of December 31 of each fiscal year. As of December 31,
2022, the Company qualitatively assessed whether it is more likely than not that the respective fair value of the Company&#8217;s intangible
assets and goodwill is less than its carrying amount. Beginning in the fourth quarter of 2021 and throughout 2022, the Company experienced
a sustained decline in the quoted market price of its common stock and as a result the Company determined that as of December 31, 2022
it was more likely than not that the carrying value of these acquired intangibles exceeded their estimated fair value. Accordingly, the
Company performed an impairment analysis as of December 31, 2022 using the income approach. This analysis required significant judgments,
including primarily the estimation of future development costs, the probability of success in various phases of its development programs,
potential post launch cash flows and a risk-adjusted weighted average cost of capital. Pursuant to Accounting Standard Update (&#8220;ASU&#8221;)
2017-04, the Company recorded an impairment of intangible assets of approximately $6.0 million, and an impairment of goodwill of approximately
$1.5 million for the year ended December 31, 2022. There was no impairment of intangible assets or goodwill recorded for the year ended
December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant portion of our operating expenses is related to stock-based compensation costs. Stock-based compensation costs were approximately
$2.2 million and $2.6 million for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation consists of restricted stock units (&#8220;RSU&#8221;) and options to purchase shares of the Company&#8217;s common stock.
The Company follows Accounting Standards Codification (&#8220;ASC&#8221;) 718, Compensation - Stock Compensation, which addresses the
accounting for stock-based payment transactions, requiring such transactions to be accounted for using the fair value method. The fair
value of RSU or restricted stock awards (&#8220;RSAs&#8221;) is determined by the closing price per share of the Company&#8217;s common stock on the date of the award.
The Company uses the Black-Scholes option pricing model to determine the grant date fair value of options issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSU&#8217;s
may contain vesting conditions that include, without limitation, any or all of the following: immediate vesting, vesting over a defined
time period, vesting based on specific volume weighted average price levels being achieved by the Company&#8217;s common stock as publicly
traded within specified measurement periods, and vesting based on the achievement of specific performance milestones. Options contain
vesting conditions that provide for vesting over a defined time period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of RSU&#8217;s and options, is charged to expense, on a straight line basis over the vesting periods defined in the award
agreements, except for the fair value which is attributable to achievement of a specific performance milestones, which are charged to
expense upon achievement of such milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in fair value of warrant liabilities, investment options and derivative liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives
or contain features that qualify as embedded derivatives, pursuant to ASC 480. &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC
480&#8221;) and ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). The Company accounts for warrants for shares
of the Company&#8217;s common stock that are not indexed to its own stock as derivative liabilities at fair value on the consolidated
balance sheet. The Company adjusts this derivative liability at each reporting period, with the liability recorded on the balance sheet
being equal to fair value of such liability on the relevant balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value of derivative liabilities is determined in accordance with ASC 820-10 &#8220;Fair Value Measurement&#8221;. As of December 31,
2023 and 2022, the fair value of the embedded derivative liabilities was determined using weighted-average scenario analysis and the
fair value of warrant liabilities was determined using the Black-Scholes valuation model, both of which are level 3 methods, as defined
in ASC 820-10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
liabilities with an initial fair value of approximately $8.3 million were recorded during the year ended December 31, 2022, which were
attributable to certain warrants issued as part the Company&#8217;s sales of common stock and warrants in February 2022, embedded derivatives
issued as part of the Company&#8217;s convertible preferred stock issuance in May 2022, and investment options issued in July 2022. During
the year-end December 31, 2023, there were no derivative liabilities issued. During the years ended December 31, 2023 and 2022, an aggregate
decrease in value of derivative liabilities of approximately $1.0 million and $7.5 million, respectively, was recorded, resulting in
other income equal to such amount. The fair value of these derivative liabilities has a strong correlation to the price per share of
the Company&#8217;s common stock as publicly traded. Increases in the Company&#8217;s price per share will result in increased derivative
liabilities, with a corresponding other expense being recorded in the other income (expense) section of the statement of operations and
comprehensive loss. Decreases in the Company&#8217;s price per share will result in decreased derivative liabilities, with a corresponding
other income being recorded in the other income (expense) section of the statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the inducement to exercise warrants in accordance with ASC Subtopic 470-20-40 &#8220;Debt with Conversion and Other
Options&#8221; (&#8220;ASC 470-20-40&#8221;). ASC 470-20-40 requires the recognition through earnings of an inducement charge equal to
the fair value of the consideration delivered in excess of the consideration issuable under the original conversion terms. Therefore,
the Company recognized a loss on the warrant inducement for the issuance of new warrants. The inducement warrants were determined to
be equity classified and the fair value was determined using the Black-Scholes valuation model. The grant date fair value of the Inducement
Warrants was estimated to be $2,599,552 on December 28, 2023 and the proceeds of $280,500, which were received on January 2, 2024, for
the issuance of the Inducement Warrants is reflected as inducement expense, within other expenses on the Company&#8217;s consolidated
statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information comparing the components of net loss for the years ended December 31, 2023 and 2022:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,852,021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,605,761</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,252,437</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,027,773</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Impairment of intangible assets and goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,453,662</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">343,982</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">327,910</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,448,440</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">27,415,106</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(16,448,440</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(27,415,106</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other (expense) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Inducement expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,848,235</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,315,236</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,472,726</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">727,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(325,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Interest income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,708</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,249</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other (expense) income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(814,379</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,457,713</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(17,262,819</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(19,957,393</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax (expense) benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,913</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,486,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,291,732</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,471,333</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Known
Trends or Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current inflationary trend existing in the North American economic environment is considered by Management to be reasonably likely to
have a material unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior
levels of price inflation have caused a general increase in the cost of labor and materials. In addition, there is an increased risk
of the Company experiencing labor shortages as a result of a potential inability to attract and retain human resources due to increased
labor costs resulting from the current inflationary environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses decreased to $8,852,021 for the year ended December 31, 2023 from $11,605,761 for the year ended
December 31, 2022, a decrease of $2,753,740, or 24%. This change was primarily driven by decreases in insurance expenses of $1,112,059,
salaries and wages of $626,573, transaction expenses of $735,043, stock compensation expense of $351,898, marketing expense of $390,851,
and legal fees of $532,563. This is offset by an increase in consulting expenses of $381,786, Delaware Franchise Tax expenses of $247,389,
and accounting fees of $255,872. The decrease in insurance expense was due to a reduction in director and officer liability insurance
related to the Company&#8217;s reduction in force and restructuring during the year ended December 31, 2023. The decrease in salaries
and wages was due to the reduction in force during the year ended December 31, 2023. The decrease in transaction expenses was due to
the expenses related to non-recurring capital raises during the year ended December 31, 2022. The decrease in stock compensation expense
was due primarily to a reduction in expense related to restricted stock units as a result of forfeitures and decreased value of new grants
as a result of lower stock prices. The decrease in marketing and legal expenses was due to the termination of marketing efforts surrounding
the Akos cannabinoid spin-off. The increase in consulting expenses was due to increased outsourcing to contractors as a result of the
reduction in force during 2023. The increase in Delaware Franchise Tax expenses was due to taxes and penalty fees related to the 2022
franchise tax return. The increase in accounting fees was due to internal control deficiency remediation efforts related to deficiencies
identified in 2022 and technical accounting services related to 2023 transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expense for the year ended December 31, 2023 was $7,252,437 as compared to $8,027,773 for the year ended December
31, 2022 with a decrease of $775,336, or approximately 10%. This decrease was primarily driven by decreased salaries and wages of 1,608,437,
product development of $443,158, and lab expenses of $321,773, and increase in tax incentive of $141,185. This is slightly offset by
an increase in CRO costs of $1,674,958. The decrease in salaries and wages was primarily due to the reduction in force as a result of
the cost reduction plan that the Company entered into in May 2023 and the increase in CRO costs is due to contract in Australian Subsidiary
Research and Development that began in March 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of intangible assets and goodwill</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no impairment of intangible assets and goodwill for the year ended December 31, 2023 as compared to $7,453,662 for the year ended
December 31, 2022, as all recognized indefinite lived intangible assets and goodwill were fully impaired as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Depreciation
and Amortization Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization expense for the year ended December 31, 2023 was $343,982 as compared to $327,910 for the year ended December 31, 2022,
with a decrease of $16,072, or approximately 5%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Warrant Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of warrant liabilities for the year ended December
31, 2023 resulted in income of $94,396 as compared to $4,315,236 for the year ended December 31, 2022. The change in fair value of warrant
liabilities is significantly influenced by the change in the closing price of common stock at the end of each period, as compared to the
closing price of common stock at the beginning of each period with a strong inverse relationship between changes in fair value of warrant
liabilities and the trading price of common stock. The significant decrease in the Company&#8217;s stock price during the year ended December
31, 2023 compared to the year ended December 31, 2022, resulted in the significant decrease to the change in fair value of warrant liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Investment Option Liability</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
in fair value of investment option liability for the year ended December 31, 2023 resulted in income of $208,752 as compared to $3,472,726
for the year ended December 31, 2022. The change in fair value of investment option liability is significantly influenced by the change
in the closing price of common stock at the end of each period, as compared to the closing price of common stock at the beginning of
each period with a strong inverse relationship between changes in fair value of warrant liabilities and the trading price of common stock.
The significant decrease in the Company&#8217;s stock price during the year ended December 31, 2023 compared to the year ended December
31, 2022, resulted in the significant decrease to the change in fair value of warrant liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Derivative Liability</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s change in fair value of derivative liability increased by $1,052,000 for the year ended December 31, 2023, due primarily
to the termination of the planned spin-off of Akos and redemption of the underlying preferred stock in May 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inducement
Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inducement
expense was $1,848,235 for the year ended December 31, 2023. The expenses recorded were related to inducement incurred related to the
conversion of warrants and investment options that occurred in December 2023. The Company did not incur such expenses in the prior period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Tax (Expense) Benefi</i></b>t</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense was $28,913 for the year ended December 31, 2023, which primarily related to state excise taxes, compared to an income tax benefit of 1,486,060 for the year ended December
31, 2022 or a change of $1,514,973. For the year ended December 31, 2022, the Company recognized a benefit for the reversal of the deferred
tax liability for the indefinite lived intangible assets upon impairment, which is the primary reason for the change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern, Liquidity and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred a loss since inception resulting in an accumulated deficit of $96,499,518 as of December 31, 2023 and further losses
are anticipated in the development of its business. Further, the Company had operating cash outflows of $14,094,411 for the year ended
December 31, 2023. For the year ended December 31, 2023, the Company had a loss from operations of $16,448,440. Since inception, being
a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its
operations. The Company&#8217;s operations have been funded principally through the issuance of debt and equity. These factors raise
substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the Company&#8217;s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate
sufficient cash flow in the future to support its operating and capital expenditure commitments. At December 31, 2023, the Company had
cash of $2,287,977 and working capital of $1,238,027. The Company&#8217;s current cash on hand is insufficient to satisfy its operating
cash needs for the 12 months following the filing of this Annual Report on Form 10-K. These conditions raise substantial doubt regarding
the Company&#8217;s ability to continue as a going concern for a period of one year after the date the financial statements are issued.
Management&#8217;s plan to alleviate the conditions that raise substantial doubt include reducing the Company&#8217;s rate of spend,
managing its cash flow, advancing its programs, and raising additional working capital through public or private equity or debt financings
or other sources, which includes the Equity Distribution Agreement with Canaccord for proceeds of up to $2.4 million, the Purchase Agreement
with Lincoln Park, and the Inducement Letters and resulting sales of common stock under the Existing Warrants for net cash proceeds of
$1.5 million received in January 2024, and the exercise of warrants to purchase 1,954,000 shares of common stock for gross cash proceeds
of approximately $2.7 million in February 2024, and may include collaborations with additional third parties as well as disciplined cash
spending, to increase the Company&#8217;s cash runway. The Inducement Letters included variable rate transaction limitation, which prohibit
the issuance of shares under the Purchase Agreement with Lincoln Park until December 28, 2024. Adequate additional financing may not
be available to the Company on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the
Company may be required to undertake cost-cutting measures including delaying or discontinuing certain operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as
a going concern for a period of one year after the date of the financial statements. The Company&#8217;s consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reduction
in Force/Restructuring</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Company entered into a cost reduction plan, including a reduction in force of approximately 35% of its full-time employees
to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that were focused on the Akos
cannabinoid spin-out were terminated. The plan included a focus on progressing the Company&#8217;s existing non-cannabinoid pipeline
while reducing the rate of spend and managing cash flow. As of December 31, 2023, the Company has completed the reduction in force, with
such severance expenses recorded in salaries and wages and legal accounts. The Company recognized severance charges of approximately
$1,004,033 through December 31, 2023, with $572,628 of these charges paid and the reversal of Avani Kanubaddi&#8217;s 2023 performance
bonus of $129,760 as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
on June 16, 2023, the Company entered into the Kanubaddi Separation Agreement with Avani Kanubaddi, the Company&#8217;s President and
Chief Operating Officer. Upon termination, any unvested time-based RSU&#8217;s became fully vested. Mr. Kanubaddi&#8217;s 2023 salary
and benefits was accrued and were agreed to be paid out in twelve equal monthly installments beginning in July 2023, as well as his 2023
performance bonus in the amount of $129,760. As of December 31, 2023, the performance metrics were not achieved and the accrued bonus
was reversed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have primarily used our available cash to fund our product development and operations expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows for the Years Ended December 31, 2023 and 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of cash flows for the years presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(14,094,411</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(17,146,723</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(584,165</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash (used in) provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,343,141</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,180,137</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of Foreign Exchange Rate on Changes on Cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,022</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(81,364</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net (decrease) increase in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,435,907</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">367,885</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $14,094,411 during the year ended December 31, 2023, which consisted primarily of a net loss adjusted
for non-cash items of $13,919,661, an increase in prepaid expenses of $6,857, a decrease in accounts payable and accrued liabilities
of $103,848, and a decrease in right-of-use operating lease asset and obligation of $64,045.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $17,146,723 during the year ended December 31, 2022, which consisted primarily of a net loss adjusted
for non-cash items of $16,929,063, an increase in prepaid expenses and other current assets of $374,058, an increase in accounts payable
and accrued liabilities of $263,686, and a decrease in right-of-use operating lease asset and obligation of $107,288.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by investing activities was $11,667 during the year ended December 31, 2023, which consisted of the purchase of property
and equipment, offset by proceeds from sale of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $584,165 during the year ended December 31, 2022, which consisted of the purchase of property and
equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in financing activities was $1,343,141 during the year ended December 31, 2023, which consisted of $1,052,057 from the redemption
of Series A Preferred Stock and $291,084 for equity distribution offering costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $18,180,137 during the year ended December 31, 2022, which consisted of $17,222,099 in net
proceeds from the sale of common stock and warrants and warrant exercises, net of fees, and proceeds from the sale of redeemable non-controlling
interest, net of offering costs, of $958,038.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation
of our consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect
the reported amount of assets, liabilities, costs and expenses and related disclosures. Our critical accounting estimates are those estimates
that involve a significant level of uncertainty at the time the estimate was made, and changes in them have had or are reasonably likely
to have a material effect on our financial condition or results of operations. Accordingly, actual results could differ materially from
our estimates. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances,
and we evaluate these estimates on an ongoing basis. Our most critical accounting estimates include determining the accruals associated
with third party providers supporting research and development efforts and the fair value of the inducement warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accrued
Research and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses. This process involves reviewing purchase orders, open contracts, reconciling payments and invoices and communicating with our
personnel and suppliers to identify services that have been performed on our behalf. It also includes the research and development vendors
providing us milestone and percentage completion reports on the statuses within each active purchase order and contract along with estimating
the level of service performed and the associated cost incurred for the services when we have not yet been invoiced or otherwise notified
of the actual cost. Our vendors invoice us in various ways via advance payments, as contractual milestones are met or monthly in arrears
for services performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances
known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and adjust if necessary. The
significant estimates in our accrued research and development expenses include the costs incurred for services performed by clinical,
pre-clinical, and CMC vendors in connection with research and development activities for which we have not yet been invoiced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
contract with these vendors to conduct clinical, pre-clinical, or CMC research and development services on our behalf. We base our expenses
on our estimates of the services received and efforts expended pursuant to quotes and contracts with the research and development vendors.
The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows.
There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of
the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and
the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies
from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Non-refundable advance payments for goods and services
that will be used in future research and development activities are expensed when the activity has been performed or when the goods have
been received rather than when the payment is made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing
of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts
that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such
expenses and the amounts actually incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Inducement Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
inducement warrants are measured at estimated fair value using the Black Scholes valuation model. Inherent in this model are assumptions
related to expected stock price volatility, expected life, risk-free interest rate and dividend yield. We estimate the volatility of
our common stock at the date of issuance based on the historical implied volatility of our own stock price that matches the expected
remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the measurement
date for a maturity similar to the expected remaining life of the inducement warrants. The expected life of the inducement warrants is
assumed to be equivalent to their remaining contractual term. The dividend rate is based on our historical rate, which we anticipate
to remain at zero. The assumptions used in calculating the estimated fair value of the inducement warrants represent our best estimates.
However, these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and
different assumptions are used, the inducement warrants estimated fair value could be materially different.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_010"></span>Item
7A. Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through December 31, 2023, the Company&#8217;s reporting currency is the United States dollar while the functional currency
of certain of the Company&#8217;s subsidiaries were the Canadian dollar and Australian dollar. For the reporting periods ended December
31, 2023 and December 31, 2022, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars.
As a result, the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against
the U.S. dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_011"></span>Item
8. Financial Statements and Supplementary Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item 8 is included at the end of this Annual Report on Form 10-K beginning on page F-1 and is incorporated here by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_012"></span>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_013"></span>Item
9A. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Evaluation
of Disclosure Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures designed to ensure that the information we are required to disclose in reports we file or
submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified under the rules and
forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such
information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer,
as appropriate, to allow timely decisions regarding required disclosures. A material weakness is a deficiency, or combination of deficiencies,
in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual
or interim financial statements will not be prevented or detected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
required by paragraph (b) of Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer (our principal executive) and
Chief Financial Officer (our principal financial officer and principal accounting officer) carried out an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures as of December 31, 2023. Based on this evaluation, and in light
of the material weaknesses found in our internal controls over financial reporting, our Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures (as defined in paragraph (e) of Rules 13a-15 and 15d-15 under the Exchange Act)
were not effective as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Limitations
on Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
internal control system over financial reporting has inherent limitations and may not prevent or detect misstatements. Therefore, even
those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. However, these inherent limitations
are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though
not eliminate, this risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange
Act Rule 13a-15(f) and 15d-15(f). Internal control over financial reporting is a process used to provide reasonable assurance regarding
the reliability of our financial reporting and the preparation of our financial statements for external purposes in accordance with generally
accepted accounting principles in the United States. Internal control over financial reporting includes policies and procedures that
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our
assets; provide reasonable assurance that transactions are recorded as necessary to permit preparation of our financial statements in
accordance with generally accepted accounting principles in the United States, and that our receipts and expenditures are being made
only in accordance with the authorization of our board of directors and management; and provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive officer)
and Chief Financial Officer (our principal financial officer and principal accounting officer), we performed an assessment of the Company&#8217;s
significant processes and key controls. Based on this assessment, management concluded that our internal control over financial reporting
was not effective as of December 31, 2023 due to the material weaknesses described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material weakness in internal control over financial reporting is a deficiency or a combination of deficiencies, in internal control
over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim
financial statements will not be prevented or detected on a timely basis. We determined that our internal control over financial reporting
had the following material weaknesses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    were unable to document, formalize, implement and revise where necessary controls, policies and procedure documentation to evidence
    a system of controls, including testing of such controls that is consistent with our current personnel and available resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    failed to document, maintain and test effective control activities over our control environment, risk assessment, information technology
    and monitoring components;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    had insufficient segregation of duties, oversight of work performed and lack of compensating controls in our finance and accounting
    functions, including, without limitation, the processing, review and authorization of all routine and non-routine transactions, due
    to limited personnel and resources.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is evaluating these weaknesses to determine the appropriate remedy. Because disclosure controls and procedures include those
components of internal control over financial reporting that provide reasonable assurances that transactions are recorded as necessary
to permit preparation of financial statements in accordance with generally accepted accounting principles, management also determined
that its disclosure controls and procedures were not effective as a result of the foregoing material weaknesses in its internal control
over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company is in process of remediating its material weaknesses and designing an effective internal control environment,
however it has not yet remediated its material weaknesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Remediation
efforts to address material weaknesses in internal controls</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    engaged third party subject matter experts to assist in the design and documentation of an internal control environment meeting those
    requirements and criteria established in the COSO 2013 Internal Control Integrated Framework;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    engaged information technology experts who designed and implemented a secure, cloud based, server and IT environment with controlled
    access, monitoring, help desk and a user training protocol;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    installed and implemented third party software that provides improved control, approvals and segregation of duties over the purchase
    to pay operation cycle;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    engaged third party subject matter experts who are providing independent supervision of accounting staff, transaction processing,
    reconciliations and financial statement preparation, resulting in improved segregation of duties;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    engaged third party subject matter experts who are assisting in the financial reporting function, with such activities, including,
    without limitation, preparation, review and reconciliation of financial reports, research of technical accounting issues/transactions,
    performing various checklists to ensure compliance with GAAP and SEC requirements, with all such activities resulting in improved
    segregation of duties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_014"></span>Item
9B. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right requiring Akos to force redemption of all of the Akos Series A Preferred Stock for $1,000&#8239;per share, plus accrued
but unpaid dividends of approximately $50,000&#8239;for a total of approximately $1,052,057. The Company had 20 days following the receipt
of the Put Exercise Notice to make the payment and made payment on May 19, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, Akos, and the Akos Investor terminated the Akos Purchase Agreement in connection with the planned Spin-Off and that certain
registration rights agreement in connection with the Akos Private Placement in May 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Company entered into a cost reduction plan, including a reduction in force of approximately 35% of its full-time employees
to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that were focused on the Akos
cannabinoid spin-out will be terminated. The Company recognized severance charges of $874,273 through December 31, 2023. The plan included
a focus on progressing the Company&#8217;s existing non-cannabinoid pipeline while reducing the rate of spend and managing cash flow.
As of December 31, 2023, the Company has completed the reduction in force, with such severance expenses recorded in salaries and wages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_015"></span>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_016"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_017"></span>Item
10. Directors, Executive Officers and Corporate Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We incorporate by reference the information responsive to this Item under
the captions &#8220;Election of Directors,&#8221; &#8220;Corporate Governance &#8211; Executive Officers,&#8221; &#8220;Corporate Governance
&#8211; Family Relationships,&#8221; &#8220;Related Person Transactions and Section 16(a) Beneficial Ownership Reporting Compliance,&#8221;
&#8220;Corporate Code of Conduct and Ethics,&#8221; &#8220;Corporate Governance &#8211; Committees of the Board of Directors &#8211;
Audit Committee,&#8221; &#8220;Corporate Governance &#8211; Insider Trading Policy,&#8221; &#8220;Stockholder Proposals and Nominations
for Director&#8221; appearing in our definitive Proxy Statement on Schedule 14A for our 2024 Annual Meeting of Stockholders (&#8220;Proxy
Statement&#8221;), a copy of which will be filed no later than 120 days after December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_018"></span>Item
11. Executive Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We incorporate by reference the information responsive to this Item under
the captions &#8220;Executive Officer and Director Compensation&#8221; and &#8220;Corporate Governance &#8211; Committees of the Board
of Directors &#8211; Compensation Committee&#8221; appearing in our Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_019"></span>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We incorporate by reference the information responsive to this Item under
the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Executive Officer and Director Compensation
&#8211; Equity Compensation Plan Information&#8221; appearing in our Proxy Statement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_020"></span>Item
13. Certain Relationships and Related Transactions and Director Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference the information responsive to this Item under the captions &#8220;Related Person Transactions and Section 16(a)
Beneficial Ownership Reporting Compliance&#8221; and &#8220;Corporate Governance &#8211; Director Independence&#8221; appearing in our
Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_021"></span>Item
14. Principal Accountant Fees and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We incorporate by reference the information responsive to this Item under
the caption &#8220;Principal Accountant Fees and Services&#8221; appearing in our Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_022"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_023"></span>Item
15. Exhibits and Financial Statement Schedules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are filed as part of this Annual Report on Form 10-K:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Financial Statements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_001">Reports of Independent Registered Accounting Firm</a> (PCAOB Firm ID: <span>Marcum LLP</span> #<span id="xdx_907_edei--AuditorFirmId_c20230101__20231231_zokm5oksVph8"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000046" name="dei:AuditorFirmId">688</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_002">Consolidated Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#aj_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations and Comprehensive Loss</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#aj_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Mezzanine Equity and Shareholders&#8217; Equity</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#aj_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#Na_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Financial Statement Schedules:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.
Financial statement schedules have not been included because they are not applicable, or the information is included in the consolidated
financial statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Exhibits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Index to Exhibits&#8221; for a description of our exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_024"></span>Item
16. Form 10&#8211;K Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">2.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000114036120000667/ex2_1.htm" style="-sec-extract: exhibit">Share Purchase Agreement, dated January 10, 2020, by and between AMERI Holdings, Inc. and Ameri100, Inc. (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 13, 2020)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">2.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315220015383/ex10-1.htm" style="-sec-extract: exhibit">Tender Offer Support Agreement and Termination of Amalgamation Agreement, dated August 12, 2020, by and among AMERI Holdings, Inc., Jay Pharma Merger Sub, Inc., Jay Pharma Inc., 1236567 B.C. Unlimited Liability Company and Barry Kostiner, as the Ameri representative (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on August 12, 2020)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">2.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315220023958/ex10-1.htm" style="-sec-extract: exhibit">Amendment No. 1 To Tender Offer Support Agreement and Termination of Amalgamation Agreement, dated December 18, 2020, by and among Ameri, Jay Pharma Merger Sub, Inc., Jay Pharma Inc., 1236567 B.C. Unlimited Liability Company and Barry Kostiner, as the Ameri representative (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on December 18, 2020)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">2.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221012752/ex2-1.htm" style="-sec-extract: exhibit">Amalgamation Agreement, dated May 24, 2021, by and among Enveric Biosciences, Inc., 1306432 B.C. LTD., 1306436 B.C. LTD., and MagicMed Industries, Inc. (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on May 24, 2021)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">3.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex3-2.htm" style="-sec-extract: exhibit">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 6, 2021)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex3-3.htm" style="-sec-extract: exhibit">Certificate of Designations of Series B Preferred Stock of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.3 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex3-4.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.4 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221029223/ex3-1.htm" style="-sec-extract: exhibit">Amendment to the Amended and Restated Bylaws of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on November 18, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222012076/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Designation of the Series C Preferred Stock of the Company, dated May 4, 2022 (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on May 4, 2022, File No. 000-26460)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222014217/ex3-2.htm" style="-sec-extract: exhibit">Certificate of Amendment of Certificate of Designation of the Series C Preferred Stock of the Company, dated May 17, 2022 (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Registration Statement on Form 8-A/A, filed with the Securities and Exchange Commission on May 17, 2022, File No. 000 26460)</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222019341/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 14, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">4.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223010431/ex4-1.htm" style="-sec-extract: exhibit">Description of Securities (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000824/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant (issued in connection with January 2021 Registered Direct Offering) (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000824/ex4-2.htm" style="-sec-extract: exhibit">Form of Warrant (issued in connection with January 2021 Registered Direct Offering) (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221003373/ex4-1.htm" style="-sec-extract: exhibit">Form of Warrant (issued in connection with February 2021 Registered Direct Offering) (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on February 11, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221007757/ex4-5.htm" style="-sec-extract: exhibit">Form of Series B Warrant (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Annual Report on Form 10-K filed with the Commission on April 1, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/ex4-1.htm" style="-sec-extract: exhibit">Form of MagicMed Warrant Certificate (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 17, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222004649/ex4-1.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant (in connection with February 2022 Offering) (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on February 15, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex4-1.htm" style="-sec-extract: exhibit">Form of RD Pre-Funded Warrant (in connection with July 2022 Offering) (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex4-2.htm" style="-sec-extract: exhibit">Form of PIPE Pre-Funded Warrant (in connection with July 2022 Offering) (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex4-3.htm" style="-sec-extract: exhibit">Form of RD Preferred Investment Option (in connection with July 2022 Offering) (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex4-4.htm" style="-sec-extract: exhibit">Form of PIPE Preferred Investment Option (in connection with July 2022 Offering) (incorporated by reference to Exhibit 4.4 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex4-5.htm" style="-sec-extract: exhibit">Form of Wainwright Warrant (in connection with July 2022 Offering) (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">4.13</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223046601/ex4-1.htm" style="-sec-extract: exhibit">Form of Inducement Warrant (in connection with December 2023 Offering) (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on December 29, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223006267/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement between Kevin Coveney and the Company, effective March 13, 2023 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on February 28, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222012822/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (entered into in connection with the May 5, 2022 Private Placement) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on May 11, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222012822/ex10-2.htm" style="-sec-extract: exhibit">Certificate of the Designations, Preferences and Rights of Akos Series A Convertible Preferred Stock (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on May 11, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222012822/ex10-3.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement (entered into in connection with the May 5, 2022 Private Placement) (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on May 11, 2022)</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222012822/ex10-4.htm" style="-sec-extract: exhibit">Form of Warrant (entered into in connection with the May 5, 2022 Private Placement) (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on May 11, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex10-4.htm" style="-sec-extract: exhibit">Form of Warrant Amendment (in connection with the July 2022 Offerings) (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222019341/ex10-1.htm" style="-sec-extract: exhibit">First Amendment to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 14, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex10-4.htm" style="-sec-extract: exhibit">Form of Warrant Amendment (in connection with July 2022 Offering) (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (in connection with July 2022 Offering) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex10-2.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (in connection with July 2022 Offering) (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex10-3.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement (in connection with July 2022 Offering) (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex10-2.htm" style="-sec-extract: exhibit">Employment Agreement, dated December 2, 2020, by and between the Company and Avani Kanubaddi (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex10-5.htm" style="-sec-extract: exhibit">Enveric Biosciences, Inc. 2020 Long-Term Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex10-6.htm" style="-sec-extract: exhibit">Form of RSU Award Agreement (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000824/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated January 11, 2021, by and among the Company and the purchasers thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000824/ex10-2.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated January 11, 2021, by and among the Company and the purchasers thereto (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000824/ex10-3.htm" style="-sec-extract: exhibit">Letter Agreement, dated January 11, 2021, by and between the Company and Alpha Capital Anstalt (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221003373/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated February 9, 2021, by and among the Company and the purchasers thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on February 11, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221003373/ex10-2.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated February 9, 2021, by and among the Company and the purchasers thereto (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on February 11, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221011946/ex10-6.htm" style="-sec-extract: exhibit">Exclusive License Agreement, between the Company and Diverse Biotech, Inc., dated March 5, 2021 (incorporated by reference to Exhibit 10.6 the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on May 17, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221018886/form424b3.htm" style="-sec-extract: exhibit">Form of Voting and Support Agreement, dated as of May 24, 2021, by and among Enveric Biosciences, Inc. and certain shareholders of MagicMed Industries Inc. named therein (incorporated by reference to Annex B-1 to the Company&#8217;s Proxy Statement/Prospectus, filed with the Commission on August 6, 2021)</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221018886/form424b3.htm#o_154" style="-sec-extract: exhibit">Form of Voting Agreement, dated as of May 24, 2021, by and among MagicMed Industries Inc. and certain shareholders of Enveric Biosciences, Inc. named therein (incorporated by reference to Annex B-2 to the Company&#8217;s Proxy Statement/Prospectus, filed with the Commission on August 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221018886/form424b3.htm#ct_002" style="-sec-extract: exhibit">Form of Lock-Up Agreement, dated as of May 24, 2021, by and among Enveric Biosciences, Inc. and certain shareholders of MagicMed Industries Inc. named therein (incorporated by reference to Annex C-1 to the Company&#8217;s Proxy Statement/Prospectus, filed with the Commission on August 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221018886/form424b3.htm#ct_001" style="-sec-extract: exhibit">Form of Lock-Up/Leak-Out Agreement, dated as of May 24, 2021, by and among Enveric Biosciences, Inc. and certain shareholders of MagicMed Industries Inc. named therein (incorporated by reference to Annex C-2 to the Company&#8217;s Proxy Statement/Prospectus, filed with the Commission on August 3, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221012752/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement between Joseph Tucker and Enveric Biosciences, Inc. (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221012752/ex10-2.htm" style="-sec-extract: exhibit">Employment Agreement between Peter Facchini and Enveric Biosciences, Inc. (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221012752/ex10-3.htm" style="-sec-extract: exhibit">Employment Agreement between Jillian Hagel and Enveric Biosciences, Inc. (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/ex10-1.htm" style="-sec-extract: exhibit">MagicMed Stock Option Plan, as amended September 10, 2021 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 17, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.29</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223016990/ex10-2.htm" style="-sec-extract: exhibit">Form of Termination of Prior Agreements and Mutual Release (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on May 15, 2023)***</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.30</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223031526/ex1-1.htm" style="-sec-extract: exhibit">Equity Distribution Agreement, dated September 1, 20123, by and among the Company and Canaccord Genuity, LLC (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on September 1, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.31</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223039443/ex10-1.htm" style="-sec-extract: exhibit">Purchase Agreement, dated November 3, 2023, by and among the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the Commission on November 6, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.32</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223039443/ex10-2.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated November 3, 2023, by and among the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed with the Commission on November 6, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.33</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223046601/ex4-1.htm" style="-sec-extract: exhibit">Form of Inducement Warrant, dated December 28, 2023, by and among the investors thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on December 29, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">14</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex14.htm">Code of Ethics*</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">19</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex19.htm">Policy on Insider Trading*</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223010431/ex21-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries (incorporated by reference to Exhibit 21.1 of the Company&#8217;s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of independent registered public accountant &#8211; Marcum LLP*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification pursuant to Section 302 of the Sarbanes&#8211;Oxley Act of 2002 of Principal Executive Officer*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification pursuant to Section 302 of the Sarbanes&#8211;Oxley Act of 2002 of Principal Financial and Accounting Officer*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32.htm">Certification pursuant to Section 906 of the Sarbanes&#8211;Oxley Act of 2002 of Principal Executive Officer, Principal Financial and Accounting Officer**</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">97</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex97.htm">Clawback Policy*</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Labels Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">***</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (&#8220;[***]&#8221;) because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    contract or compensatory plan or arrangement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_025"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
    BIOSCIENCES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dr. Joseph Tucker</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Joseph Tucker</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dr. Joseph Tucker</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Joseph Tucker</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Kevin Coveney</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin
    Coveney</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael Webb</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Webb</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    George Kegler</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Kegler</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Marcus Schabacker</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcus
    Schabacker</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Frank Pasqualone</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    Pasqualone</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Enveric Biosciences, Inc. (the &#8220;Company&#8221;) as of December 31,
2023 and 2022, the related consolidated statements of operations and comprehensive loss, changes in mezzanine equity and shareholders&#8217;
equity and cash flows for the years ended December 31, 2023 and 2022, and the related notes (collectively referred to as the &#8220;financial
statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the
Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the two years in the period ended
December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Explanatory
Paragraph &#8211; Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described
in Note 1, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These
conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard
to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome
of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit<b>s</b>. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contracted
Research &amp; Development Cost Recognition:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Aptos; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Critical Audit Matter Description</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in Note 2 to the financial statements, the Company records costs for contracted research and development costs based upon estimates of costs incurred through the balance sheet date for services performed by contract research organizations, clinical study sites and other research and development related vendors.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditing the recognition of costs associated with contracted research and development organizations is challenging due to the significant judgment required to determine the nature and level of services that have been received, including determining the progress to completion of specific tasks and activities conducted in relation to what has been invoiced and recorded.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How We Addressed the Matter in Our Audit</i></span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The primary procedures we performed to address this critical audit matter included:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 2in">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtained an understanding of the design and implementation of internal controls for contracted research and development cost.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tested the completeness and accuracy of the underlying data used in the estimates including, but not limited to, the estimated costs per project milestone and duration.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed the reasonableness of the significant assumptions, corroborated the progress of the contracted research and development costs with the Company&#8217;s operations personnel and to information obtained by the Company directly from third parties, and to information in contracts or statements of work including costs for those activities and project duration.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examined subsequent invoices received from contracted research and development cost third parties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_90C_edei--AuditorName_c20230101__20231231_zC61WagbUw9h"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000047" name="dei:AuditorName">Marcum LLP</ix:nonNumeric></span><span style="font-variant: small-caps"></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--AuditorLocation_c20230101__20231231_zJlRLyvIArGh"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000048" name="dei:AuditorLocation">East
Hanover, New Jersey</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2024</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_002"></span>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_111_zNoDyIbk7d6e" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-left: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_494_20231231_z0aiWewdkgD2" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_494_20221231_zHVdYHfTPhj3" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_zuyasahyCNP8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsCurrentAbstract_i01B_zrClMKkAh7yl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Cash_i02I_maCzBWO_zyxYYxAAEQP4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; width: 68%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,287,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,723,884</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzBWO_zVz1e55wyfEa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,293,554</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">708,053</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrent_i02TI_mtCzBWO_maCzUBD_z229NEBugvEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,581,531</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,431,937</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsNoncurrentAbstract_i01B_zzoBKouyjvl4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Other assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCzcA6_zUHLIHlbqqr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507,377</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">677,485</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzcA6_zjLX3afz62Rd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Right-of-use operating lease asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0071">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,817</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maCzcA6_z6KIKksKFCPj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Intangible assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,932</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsNoncurrent_i02TI_mtCzcA6_maCzUBD_zeSLDOrZTyW2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,309</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2022-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,120,988</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Assets_i01TI_mtCzUBD_zV1gC1DqOUrc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 40pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,299,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,552,925</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z6U1n2O7ocuh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrentAbstract_i01B_z0Bq1nUo3ktg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_i02I_maCzp0K_z8L6ewqh31bb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,218,783</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzp0K_zZa944R3psp" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,075,643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,705,655</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzp0K_zUIRuAn8gjWi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current portion of right-of-use operating lease obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,820</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzp0K_zdcg8en7w8zi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,608</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">851,008</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--WarrantLiabilitiesCurrent_i02I_maCzp0K_zv3bpoy8gag8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:WarrantLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:WarrantLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maCzp0K_zq8XbSHBrqu2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0104">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesCurrent_i01TI_mtCzp0K_maLASEze7M_zarQUurgEM71" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,343,504</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,995,973</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommitmentsAndContingencies_i01I_maLASEze7M_zDBhSFmKHWci" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Commitments and contingencies (Note 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0110">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0111">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--TemporaryEquityAbstract_i01B_zGeD7eqHwSee" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Mezzanine equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_i02I_maCzcUj_zRiX4UyOKEph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Series C redeemable preferred stock, $<span id="xdx_908_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zsd9onDW2XGi" title="Temporary equity, par value"><span id="xdx_903_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zEYUM3rnrqN3" title="Temporary equity, par value"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000119" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000121" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_901_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zdbUrR6XRlvk" title="Temporary equity, shares authorized"><span id="xdx_904_eus-gaap--TemporaryEquitySharesAuthorized_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_pdd" title="Temporary equity, shares authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000123" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000125" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, and <span id="xdx_904_eus-gaap--TemporaryEquitySharesIssued_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zsLrMB9TFz74" title="Temporary equity, shares issued"><span id="xdx_901_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zf6ntM4K8Owf" title="Temporary equity, shares outstanding"><span id="xdx_90B_eus-gaap--TemporaryEquitySharesIssued_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zHvPNZlUbOV8" title="Temporary equity, shares issued"><span id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_znQOCIrf3p7c" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000127" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000129" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of December 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0116">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0117">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_i02I_maCzcUj_zuQPiB8No3Ed" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Redeemable non-controlling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0135">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="AsOf2022-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_i02TI_mtCzcUj_maLASEze7M_zr0RNxWG5Csi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total mezzanine equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0138">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="AsOf2022-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PreferredStockValue_i02I_maSEzCcC_zmjMd13jV02g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Preferred stock, $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zA4AGtI9pdq1" title="Preferred stock, par value"><span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231_zxSA7020YjIa" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zw9nDXcTfuO" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zb7UdIJ03pXl" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; Series B preferred stock, $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zV5YfohYgdu5" title="Preferred stock, par value"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znIQVh99GTP9" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000155" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000157" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDruAwhz4vXg" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbxwbBoNpEu3" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000159" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000161" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,600,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6kbYktmcB65" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzxTlHjt21I8" title="Preferred stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znava2C3DHWc" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDfHOSqiWmEh" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000163" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000165" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000167" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000169" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of December 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0144">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0145">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockValue_i02I_maSEzCcC_zK4DQjJMlTLg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock, $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zQpsnnKedWD8" title="Common stock, par value"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zzhPol3yvj8h" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zK1IPYmlrRIc" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20221231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20231231_zrBWV8QXS5gj" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_z0tI5A955xK3" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,739,315</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20221231_zChPxBooDE9k" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zYxiJ3yS0m64" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,078,271</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,392</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,782</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdditionalPaidInCapital_i02I_maSEzCcC_zmT1MJGeXBEj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,815,851</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,395,662</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_i02NI_di_msSEzCcC_zmQdB8isTLsb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock subscription receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2023-12-31" id="Fact000193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,817,640</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0194">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzCcC_z5SegL4empVk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,499,518</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">79,207,786</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maSEzCcC_zwZJLUR6I2d6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">569,749</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">536,734</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzCcC_maLASEze7M_zpH6a87QNJJk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total shareholders&#8217; equity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,956,336</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,671,924</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEze7M_zxzjgGvkoOCh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities, mezzanine equity, and shareholders&#8217; equity</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,299,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,552,925</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_003"></span>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_113_zpzYA4z3x626" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-left: 10pt; text-align: center">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_490_20230101__20231231_zmrtvzbIFTI1" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_493_20220101__20221231_ziTmNqBHZihb" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingCostsAndExpensesAbstract_iB_zNXzBq3N8eb1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzC9H_zRPCUH31POkg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,852,021</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,605,761</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzC9H_zHqcDFnG7eV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,252,437</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,027,773</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GoodwillAndIntangibleAssetImpairment_i01_maCzC9H_zKahbQpfEEe7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Impairment of intangible assets and goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0217">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2022-01-012022-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,453,662</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_i01_maCzC9H_zix1iK0Ytny8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-01to2023-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,982</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-012022-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">327,910</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingCostsAndExpenses_i01T_mtCzC9H_msCzzfK_zxDJBI3aERX9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2023-01-01to2023-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,448,440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2022-01-012022-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,415,106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_iT_mtCzzfK_maILFCOzRDq_zYNq1quOqiS6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,448,440</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,415,106</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zIKg6Mapn9dk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other (expense) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--InducementExpense_i01N_di_msNIEzd72_z9f0YN47cvlk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Inducement expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:InducementExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,848,235</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msNIEzd72_zavxJRG79X6l" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-01to2023-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,315,236</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GainLossOnInvestments_i01_maNIEzd72_zTBX2nczkMR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2023-01-01to2023-12-31" id="Fact000238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,752</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2022-01-012022-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,472,726</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maNIEzd72_ztxXVjO6x3Md" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-01to2023-12-31" id="Fact000241" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">325,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestIncomeExpenseNet_i01_maNIEzd72_zlWRyTwu9GG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Interest income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-01to2023-12-31" id="Fact000244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,708</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-01-012022-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,249</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzd72_maILFCOzRDq_zhq82Hx34RA2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other (expense) income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">814,379</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,457,713</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzRDq_maNILzfq7_zHrrDmK0K62c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,262,819</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,957,393</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iN_pp0p0_di_msNILzfq7_zIAevkLUHAF6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax (expense) benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact000253" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,913</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,486,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_iT_mtNILzfq7_maNILATzJ2K_z2qHnhQOMVoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,291,732</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000257" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,471,333</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--PreferredStockDividendsIncomeStatementImpact_msNILATzJ2K_za6LjvNffBJl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less preferred dividends attributable to non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-01to2023-12-31" id="Fact000259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2022-01-012022-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,014</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--TemporaryEquityAccretionToRedemptionValueAdjustment_msNILATzJ2K_zOQBk5x2GJR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less deemed dividends attributable to accretion of embedded derivative at redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="From2023-01-01to2023-12-31" id="Fact000262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,988</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="From2022-01-012022-12-31" id="Fact000263" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,976</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzJ2K_maCINOTz2bP_z8tl8hk0Vu8g" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net loss attributable to shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000265" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,458,761</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,800,323</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_iB_zk91A4M23sod" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01_maCINOTz2bP_znfTkIUjvych" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-01to2023-12-31" id="Fact000271" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,015</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000272" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505,932</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_mtCINOTz2bP_zv9utR0rMgah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-01to2023-12-31" id="Fact000274" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,491,776</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000275" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,306,255</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20230101__20231231_z8bC21dbmrv9" title="Net loss per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zXd8MnNC85vh" title="Net loss per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000277" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" id="Fact000279" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">8.09</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zfg11Udg3lqk" title="Net loss per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zxkrMmxfKDe9" title="Net loss per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" id="Fact000281" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" id="Fact000283" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">13.00</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average shares outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zQI874Ttr14e" title="Weighted average shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zvvPFxxRW191" title="Weighted average shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000285" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" id="Fact000287" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,159,063</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_zM2ysIxyStG1" title="Weighted average shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zBs8toeBmqn7" title="Weighted average shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" id="Fact000289" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,446,007</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_004"></span>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_114_zzd6nAUiwll1" summary="xdx: Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-left: 10pt; text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_custom--SeriesCRedeemablePreferredStockMember_z8oapZNiJjzh" style="display: none; text-align: center">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_custom--RedeemableNoncontrollingInterestMember_zg3U8TPm9Y7h" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_custom--MezzanineEquityMember_z7AF5sqiwnuk" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zq3M7CTsBF34" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zKRWnQZY8Sw" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--SubscriptionReceivableMember_znFiyoFadqLg" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zVoUE5hxVunc" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zrNmHeEF5OTl" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B6_zj7NWVEQSje6" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Non-controlling Interest</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Mezzanine Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Additional Paid-In Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Subscription Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Other Comprehensive Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Shareholders&#8217; Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43E_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zDtT7pw44ell" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font-weight: bold">Balance at January 1, 2023</td><td id="xdx_98A_ecustom--TemporaryEquityShares_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zzmZTTmCiIG4" style="text-align: center; width: 2%"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0293"><span style="-sec-ix-hidden: xdx2ixbrl0302">-</span></span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--TemporaryEquityShares_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zuwxrHNt0l55" title="Mezzanine equity balance, shares" style="width: 3%; text-align: right"><ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000304" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_MezzanineEquityMember" id="Fact000295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSZyE2pSKxeh" title="Beginning balance, shares" style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,078,271</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,782</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,395,662</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000299" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">79,207,786</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000300" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">536,734</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,671,924</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PreferredDividendsAttributableToRedeemableNoncontrollingInterest_iN_di_zmh64Dw85S73" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred dividends attributable to redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000309" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="Fact000310" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--AccretionOfEmbeddedDerivativeToRedemptionValue_iN_di_zKH0Zggsq2sg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accretion of embedded derivative to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000319" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">147,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="Fact000320" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">147,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,988</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-01to2023-12-31" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,988</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_zSXTBEtujUS3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Redemption of Series A preferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zAMxF1JFemKb" title="Redemption of Series A preferred, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000338" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000329" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,052,057</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="Fact000330" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,052,057</ix:nonFraction></td><td style="text-align: left">)</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zYioNQaT0pyk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,150,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-01to2023-12-31" id="Fact000348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,150,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zfDAiYSK2Vel" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common shares in exchange for RSU conversions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzUv3obJuiab" title="Issuance of common shares in exchange for RSU conversions, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,036</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000354" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,036</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z7doNkZPDHZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of common shares for deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhn7iV3Nkfvj" title="Issuance of common shares for deferred offering costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000372" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,403</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000365" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,394</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,713</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-01to2023-12-31" id="Fact000370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,107</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zmipmDmJPhI5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of Inducement Warrants, net of offering costs of $<span id="xdx_90F_ecustom--NetOfferingCosts_c20230101__20231231_zJ4PcfOtpN03" title="Net offering costs"><ix:nonFraction name="ENVB:NetOfferingCosts" contextRef="From2023-01-01to2023-12-31" id="Fact000384" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239,302</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,967,424</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="Fact000379" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">280,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-01to2023-12-31" id="Fact000382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,686,924</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_zIQlj6i9heX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Induced conversion of warrants and preferred investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">683,997</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-01to2023-12-31" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">683,997</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueOther_z4yDJ6HnPU0f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Exercise of warrants and preferred investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdprlierDny6" title="Exercise of warrants and preferred investment options, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000406" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">418,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,180</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,532,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="Fact000401" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,537,140</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zLceMYKxdzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange translation loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000415" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,015</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-01to2023-12-31" id="Fact000416" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,015</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zCkukq0a3ml2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000424" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,291,732</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,291,732</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zspP5OQWzPQj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td id="xdx_98F_ecustom--TemporaryEquityShares_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zb8A5oXTcvm3" title="Mezzanine equity ending balance, shares" style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0428"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></span></span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--TemporaryEquityShares_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zxz482BItqra" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAspnCvEcRui" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000442" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,739,315</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000431" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,392</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,815,851</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_SubscriptionReceivableMember" id="Fact000433" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,817,640</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000434" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,499,518</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000435" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">569,749</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,956,336</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_005"></span>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-left: 10pt; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--SeriesCRedeemablePreferredStockMember_z1VpA8Jszc3" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_custom--RedeemableNoncontrollingInterestMember_zkZF9hy2S6r2" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_custom--MezzanineEquityMember_z2ZzfyFDbZ61" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zzzkxTTZCIpi" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zXlIe0z8R6na" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zlzk67CHGmYg" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zUavTsFk6sFk" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B0_zcdBxuK4nQ1g" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series C Redeemable Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Non-controlling Interest</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Mezzanine Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Additional Paid-In Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Other Comprehensive Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Shareholders&#8217; Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43E_c20220101__20221231_eus-gaap--StockholdersEquity_iS_z7g8z2zFffR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--TemporaryEquityShares_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zIKW3Bbl1qka" title="Mezzanine equity balance, shares" style="width: 3%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0444">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--TemporaryEquityShares_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_z4mf2EoP8Zml" title="Mezzanine equity balance, shares" style="width: 3%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0445">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBqqv2azeEOl" title="Beginning balance, shares" style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000457" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">651,921</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,519</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000448" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,066,656</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000449" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,736,453</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000450" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,802</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact000451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,305,920</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zCxLol2au2qf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-weight: bold">Balance</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_985_ecustom--TemporaryEquityShares_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zTeTMDkTaRzi" title="Mezzanine equity balance, shares" style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8212;</span></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">&#8212;</span></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_984_ecustom--TemporaryEquityShares_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_z6AbyWo1Y7ll" title="Mezzanine equity balance, shares" style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8212;</span></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span></td><td style="display: none; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ1fVCJ5r20d" title="Beginning balance, shares" style="display: none; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000472" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">651,921</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,519</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,066,656</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000464" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,736,453</ix:nonFraction></td><td style="display: none; text-align: left">)</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000465" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,802</ix:nonFraction></td><td style="display: none; text-align: left">)</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,305,920</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_z8zrs1gtlKXb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">February 2022 registered direct offering, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0474">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjdHSCBWd0v7" title="February 2022 registered direct offering, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000483" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,798,464</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31" id="Fact000481" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,802,464</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z6X6iSnVDSL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,620,671</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31" id="Fact000492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,620,671</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_z9VaIwgvjYpk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Conversion of RSUs into common shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0494">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXo3Y7pagT33" title="Conversion of RSUs into common shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000503" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">899</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000498" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0501">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--RedeemableNoncontrollingInterestValue_z5FAl1j4FjFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Redeemable non-controlling interest, net of $<span id="xdx_906_ecustom--RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative_c20220101__20221231_z2XOUMLoT3ek" title="Issuance of embedded derivative"><ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" contextRef="From2022-01-012022-12-31" id="Fact000514" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,000</ix:nonFraction></span> embedded derivative and net of issuance costs of $<span id="xdx_90D_ecustom--RedeemableNoncontrollingInterestIssuanceCosts_c20220101__20221231_zCDgR6Lmc054" title="Redeemable noncontrolling interest issuance costs"><ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestIssuanceCosts" contextRef="From2022-01-012022-12-31" id="Fact000516" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,962</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--RedeemableNoncontrollingInterestShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zwDdnE4dClTa" title="Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962, shares" style="text-align: right"><ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestShares" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000518" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000506" format="ixt:numdotdecimal" decimals="0" unitRef="USD">556,038</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="Fact000507" format="ixt:numdotdecimal" decimals="0" unitRef="USD">556,038</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0508">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0512">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--IssuanceOfRedeemableNoncontrollingSeriesPreferredStock_zNzFqeQkIXc9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of redeemable Series C preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zdHhWjMI7lo" title="Issuance of redeemable Series C preferred stock, shares" style="text-align: right"><ix:nonFraction name="ENVB:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000529" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,685</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000524" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--PreferredDividendsAttributableToRedeemableNoncontrollingInterest_iN_di_zriilB6nx1ag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Preferred dividends attributable to redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000532" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="Fact000533" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000535" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,014</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,014</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--AccretionOfEmbeddedDerivativeToRedemptionValue_iN_di_ztCGCr23pN7g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accretion of embedded derivative to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0540">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000541" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">295,976</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="Fact000542" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">295,976</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0543">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,976</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0546">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31" id="Fact000547" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,976</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_zZHUZduvZfQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Conversion of RSAs into common shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI7m77FAVk1e" title="Conversion of RSAs into common shares, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000558" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000553" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_zWh7ERDdIMcd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgZ5smQ9iupb" title="July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000569" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000564" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,239,124</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31" id="Fact000567" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,249,124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IssuanceOfRoundedSharesAsResultOfReverseStockSplit_zZgii8ZxxVK7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of rounded shares as a result of the reverse stock split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0572">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhLD5wR6QJab" title="Issuance of rounded shares as a result of the reverse stock split, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000580" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,228</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000574" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000575" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">242</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0577">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0578">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_zMIWVckDCAU3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Redemption of Series C preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zjJzJq4HF5Oj" title="Redemption of Series C preferred stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000591" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">52,685</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000582" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0583">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="Fact000584" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">)</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0588">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31" id="Fact000589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zLHC6jkluDI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange translation loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0593">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0594">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0595">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0596">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0597">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0598">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000599" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505,932</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000600" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505,932</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zM553y8V6Wuk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0602">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0603">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0604">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0605">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0606">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000607" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,471,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0608">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000609" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,471,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43D_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zFMQrM2EBs8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--TemporaryEquityShares_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zSnsGirCEhzl" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0611">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--TemporaryEquityShares_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zw0SZS0jPX7f" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000622" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000612" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_MezzanineEquityMember" id="Fact000613" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAbgqmUKXnP4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000624" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,078,271</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000614" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,782</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,395,662</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000616" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">79,207,786</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000617" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">536,734</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,671,924</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zyDG6p1w0kTg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td id="xdx_984_ecustom--TemporaryEquityShares_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zwx8lrzErQn8" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0635">&#8212;</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0626">&#8212;</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td id="xdx_985_ecustom--TemporaryEquityShares_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zYmCLTl7ISkk" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000637" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000627" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_MezzanineEquityMember" id="Fact000628" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSuz7bZsOHAl" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000639" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,078,271</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,782</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000630" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,395,662</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000631" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">79,207,786</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">)</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000632" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">536,734</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">)</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000633" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,671,924</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_006"></span>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_112_zy7K5TjvrLk3" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_497_20230101__20231231_zMJRHF5q3T45" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_492_20220101__20221231_zWzAOuQfZ1R" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zyxPCgN0FaCl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_maNCPBUzuYE_zrmLL3Z3AAkh" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000644" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,291,732</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000645" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,471,333</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zFSGzYNhHRfe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i02_maNCPBUzuYE_zKZVK9B5xsth" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-01to2023-12-31" id="Fact000650" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,396</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000651" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,315,236</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--GainLossOnInvestments_i02N_di_msNCPBUzuYE_zoZKUocNnuof" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2023-01-01to2023-12-31" id="Fact000653" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,752</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2022-01-012022-12-31" id="Fact000654" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,472,726</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_msNCPBUzuYE_zOjnFNHODJv5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-01to2023-12-31" id="Fact000656" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact000657" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">325,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_i02_maNCPBUzuYE_za3Q3P6VkpD2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-12-31" id="Fact000659" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,150,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" id="Fact000660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,620,671</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--InducementExpense_i02_maNCPBUzuYE_zo9FmnyPrtVa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Inducement expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:InducementExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,848,235</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0663">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GoodwillAndIntangibleAssetImpairment_i02_maNCPBUzuYE_zGlbjnR2BkMa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt">Impairment of intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0665">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2022-01-012022-12-31" id="Fact000666" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,453,662</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--NoncashIncomeTaxExpense_i02_maNCPBUzuYE_zRxMqun2i3K5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Non-cash income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0668">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:NoncashIncomeTaxExpense" contextRef="From2022-01-012022-12-31" id="Fact000669" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,504,302</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maNCPBUzuYE_z0ZkPiDw5bl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of ROU asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-012022-12-31" id="Fact000672" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,291</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfIntangibleAssets_i02_maNCPBUzuYE_zgmM4OG4fe08" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">Amortization of intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000674" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31" id="Fact000675" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Depreciation_i02_maNCPBUzuYE_zNDck1Yj4CIf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-12-31" id="Fact000677" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,228</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="Fact000678" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i02N_di_msNCPBUzuYE_zQf8O9eDR4wf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gain on disposal of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-01-01to2023-12-31" id="Fact000680" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,206</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zTF64X1sapMi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzuYE_zxxDlr437bDc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000686" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,857</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-12-31" id="Fact000687" format="ixt:numdotdecimal" decimals="0" unitRef="USD">374,058</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maNCPBUzuYE_zesJZcLo5Y8h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts payable and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-12-31" id="Fact000689" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">103,848</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-12-31" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_i03N_di_msNCPBUzuYE_zRthgjOtPZY5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Right-of-use operating lease asset and obligation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" contextRef="From2023-01-01to2023-12-31" id="Fact000692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,045</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" contextRef="From2022-01-012022-12-31" id="Fact000693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,288</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzuYE_maCCERCzwov_zhDo1IkUA5lg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000695" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,094,411</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" id="Fact000696" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,146,723</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z9RlW89EOLh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzogo_zTlSHKq9ZdSf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-01to2023-12-31" id="Fact000701" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,180</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" id="Fact000702" format="ixt:numdotdecimal" decimals="0" unitRef="USD">584,165</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_maNCPBUzogo_zS2BWBaDZ0U3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from disposal of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-01-01to2023-12-31" id="Fact000704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,847</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzogo_maCCERCzwov_zWzk8v0OIKsi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,667</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" id="Fact000708" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">584,165</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zo1qlouUT50j" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzYQ2_zcbLoIJw2Tj2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of common stock, warrants, and investment options, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-12-31" id="Fact000714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,222,099</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_msNCPBUzYQ2_zEQVszV17HAd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payment for equity distribution offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-01-01to2023-12-31" id="Fact000716" format="ixt:numdotdecimal" decimals="0" unitRef="USD">291,084</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_i01N_di_msNCPBUzYQ2_zm9x2RsPGg92" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Redemption of Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock" contextRef="From2023-01-01to2023-12-31" id="Fact000719" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,057</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0720">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromRepurchaseOfRedeemablePreferredStock_i01_maNCPBUzYQ2_z9sq7kdQbbWh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from the sale of redeemable non-controlling interest, net of offering costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0722">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock" contextRef="From2022-01-012022-12-31" id="Fact000723" format="ixt:numdotdecimal" decimals="0" unitRef="USD">958,038</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzYQ2_maCCERCzwov_zpvHpWniaSY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash (used in) provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000725" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,343,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" id="Fact000726" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,180,137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCCERCzwov_zcNWeBg0E2a1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of Foreign Exchange Rate on Changes on Cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2023-01-01to2023-12-31" id="Fact000728" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2022-01-012022-12-31" id="Fact000729" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">81,364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzwov_zKZFAj35e885" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net (decrease) increase in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-12-31" id="Fact000731" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,435,907</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" id="Fact000732" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,885</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zMeS9FC6purf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash at beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000734" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,723,884</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" id="Fact000735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,355,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zbbjgCJeCg1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,287,977</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,723,884</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zboEshf3wyl2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash and non-cash transactions:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestPaidNet_i01_z5mAqmQaCHm8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0743">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-12-31" id="Fact000744" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,249</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxesPaidNet_i01_zwGypZx5Ofa8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income taxes paid</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-01to2023-12-31" id="Fact000746" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,507</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0747">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--WarrantsIssuedInConjunctionWithCommonStockIssuance_i01_zuNMCyAgVzr6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Warrants issued in conjunction with common stock issuance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0749">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:WarrantsIssuedInConjunctionWithCommonStockIssuance" contextRef="From2022-01-012022-12-31" id="Fact000750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,595,420</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr id="xdx_400_ecustom--IssuanceOfEmbeddedDerivative_i01_zH66ocqy1Yr7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left; padding-bottom: 2.5pt">Issuance of embedded derivative</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0752">&#8212;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><ix:nonFraction name="ENVB:IssuanceOfEmbeddedDerivative" contextRef="From2022-01-012022-12-31" id="Fact000753" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockSubscriptionReceivable_i01_z8pczcHQaQ59" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock subscription receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:StockSubscriptionReceivable" contextRef="From2023-01-01to2023-12-31" id="Fact000755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,817,640</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0756">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OfferingCostsAccruedNotPaid_i01_zG4LzB9Tets2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Offering costs accrued not paid</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:OfferingCostsAccruedNotPaid" contextRef="From2023-01-01to2023-12-31" id="Fact000758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,724</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0759">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--WarrantsIssuedForOfferingCosts_i01_zaF2Cxvvtqed" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Warrants issued for offering costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:WarrantsIssuedForOfferingCosts" contextRef="From2023-01-01to2023-12-31" id="Fact000761" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,991</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0762">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfCommonSharesForDeferredOfferingCosts_i01_ztTgXdib6AX3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Issuance of common shares for deferred offering costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts" contextRef="From2023-01-01to2023-12-31" id="Fact000764" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,107</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0765">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--InducedConversionOfWarrantsAndPreferredInvestmentOptions_i01_zGp8rtjisSe2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Induced conversion of warrants and preferred investment options</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:InducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-01to2023-12-31" id="Fact000767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">683,997</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PreferredDividendsAttributableToRedeemableNoncontrollingInterest_i01_zoyMIquVgGp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Preferred dividends attributable to redeemable non-controlling interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,041</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000771" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,014</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance_i01_zL3DevS7SeBl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Investment options issued in conjunction with common stock issuance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" contextRef="From2022-01-012022-12-31" id="Fact000774" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,323,734</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ModificationOfWarrantsAsPartOfShareCapitalRaise_i01_zPtxbNA5gZCg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Modification of warrants as part of share capital raise</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ModificationOfWarrantsAsPartOfShareCapitalRaise" contextRef="From2022-01-012022-12-31" id="Fact000777" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,357</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccretionOfEmbeddedDerivativeToRedemptionValue_i01_zy28eXaeLfFd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Accretion of embedded derivative to redemption value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-01to2023-12-31" id="Fact000779" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,988</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31" id="Fact000780" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_001"></span>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000782" name="us-gaap:NatureOfOperations"><p id="xdx_808_eus-gaap--NatureOfOperations_zcYw7bouB0pi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_827_zeGb70wjgan">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature
of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. (&#8220;Enveric&#8221; or the &#8220;Company&#8221;) is a biotechnology company developing novel neuroplastogenic small-molecule
therapeutics for the treatment of depression, anxiety, and addiction disorders. The head office of the Company is located in Naples,
Florida. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (&#8220;Jay Pharma&#8221;), 1306432 B.C. Ltd. (&#8220;HoldCo&#8221;),
MagicMed Industries, Inc. (&#8220;MagicMed&#8221;), Enveric Canada Inc., and Enveric Therapeutics, Pty. Ltd. (&#8220;Enveric Therapeutics&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging
its unique discovery and development platform, The Psybrary&#8482;, Enveric has created a robust Intellectual Property portfolio of New
Chemical Entities for specific mental health indications. Enveric&#8217;s lead program, the EVM201 Series, comprises next generation
synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series &#8211; EB-373
&#8211; for the treatment of psychiatric disorders. Enveric is also advancing its second program, the EVM301 Series, expected to offer
a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity
without also inducing hallucinations in the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Company&#8217;s amalgamation with MagicMed completed in September 2021 (the &#8220;Amalgamation&#8221;), the Company has continued
to pursue the development of MagicMed&#8217;s proprietary Psychedelic Derivatives library, the Psybrary&#8482; which the Company believes
will help to identify and develop the right drug candidates needed to address mental health challenges, including cancer-related distress.
The Company synthesizes novel versions of classic psychedelics, such as psilocybin, DMT, mescaline and MDMA, using a mixture of chemistry
and synthetic biology, resulting in the expansion of the Psybrary&#8482;, which includes 15 patent families with over a million potential
variations and hundreds of synthesized molecules. Within the Psybrary&#8482; the Company has three different types of molecules, Generation
1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). The Company is working to add novel psychedelic
molecular compounds and derivatives (&#8220;Psychedelic Derivatives&#8221;) on a regular basis through its work at the Company&#8217;s
labs in Calgary, Alberta, Canada, where the Company has a team of PhD scientists with expertise in synthetic biology and chemistry. To
date the Company has created over 500 molecules that are housed in the Psybrary&#8482;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company screens newly synthesized molecules in the Psybrary&#8482; through PsyAI&#8482;, a proprietary artificial intelligence (&#8220;AI&#8221;)
tool. Leveraging AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. The Company
believes it streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological
effects to help determine ideal drug candidates, tailored to each indication. Each of these molecules that the Company believes are patentable
can then be further screened to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New
compounds of sufficient purity are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal),
and ultimately clinical (human) evaluations. The Company intends to utilize the Psybrary&#8482; and the AI tool to categorize and characterize
the Psybrary&#8482; substituents to focus on bringing more psychedelics-inspired molecules from discovery to the clinical phase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Australian
Subsidiary</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2023, the Company established Enveric Therapeutics, an Australia-based subsidiary, to support the Company&#8217;s plans to
advance its lead program, the EVM201 Series, comprised of the next generation synthetic prodrugs of the active metabolite, psilocin (&#8220;EVM201
Series&#8221;), towards the clinic. Enveric Therapeutics will oversee the Company&#8217;s preclinical, clinical, and regulatory activities
in Australia, including ongoing interactions with the local Human Research Ethics Committees (HREC) and the Therapeutic Goods Administration
(TGA), Australia&#8217;s regulatory authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern, Liquidity and Other Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred a loss since inception resulting in an accumulated deficit of $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_zeXL2JVUG7I7" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000784" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,499,518</ix:nonFraction></span> as of December 31, 2023 and further losses
are anticipated in the development of its business. Further, the Company has operating cash outflows of $<span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20231231_zC9IEOtZAr8a" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000786" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,094,411</ix:nonFraction></span> for the year ended
December 31, 2023. For the year ended December 31, 2023, the Company had a loss from operations of $<span id="xdx_906_eus-gaap--OperatingIncomeLoss_iN_di_c20230101__20231231_zptySDPGyAxb" title="Loss from operations"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000788" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,448,440</ix:nonFraction></span>. Since inception, being
a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its
operations. The Company&#8217;s operations have been funded principally through the issuance of equity. These factors raise substantial
doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the Company&#8217;s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate
sufficient cash flow in the future to support its operating and capital expenditure commitments. At December 31, 2023, the Company had
cash of $<span id="xdx_906_eus-gaap--Cash_iI_c20231231_zvJyRYCpQVAi" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000790" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,287,977</ix:nonFraction></span> and working capital of $<span id="xdx_900_ecustom--WorkingCapital_iI_c20231231_znZyDndGCB39" title="Working capital"><ix:nonFraction name="ENVB:WorkingCapital" contextRef="AsOf2023-12-31" id="Fact000792" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,238,027</ix:nonFraction></span>. The Company&#8217;s current cash on hand is not sufficient enough to satisfy its
operating cash needs for the 12 months from the filing of this Annual Report on Form 10-K. These conditions raise substantial doubt regarding
the Company&#8217;s ability to continue as a going concern for a period of one year after the date the financial statements are issued.
Management&#8217;s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public
or private equity or debt financings or other sources, which has included the Equity Distribution Agreement with Canaccord for proceeds
of up to $<span id="xdx_901_eus-gaap--ProceedsFromShortTermDebt_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z37fhioYnxFk" title="Additional working capital"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2023-01-012023-12-31_custom_EquityDistributionAgreementMember" id="Fact000794" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million (see Note 7), the Purchase Agreement with Lincoln Park (see Note 7), subject to registration, the Inducement Letters
and resulting sales of common stock under the Existing Warrants for cash proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zz97PuFdcZcd" title="Warrants for cash proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-01-31_us-gaap_SubsequentEventMember" id="Fact000796" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction></span> million received in January 2024 (see Note
7), and the exercise of warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBnxG2jQtVMb" title="Exercise of warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact000798" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,954,000</ix:nonFraction></span> shares of common stock for cash proceeds of approximately $<span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240201__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zck6XEqy8KS5" title="Cash proceeds of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-02-012024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact000800" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million in February
2024 (see Note 12), and may include additional collaborations with third parties as well as disciplined cash spending. Adequate additional
financing may not be available to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital,
the Company may be required to undertake cost-cutting measures including delaying or discontinuing certain operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as
a going concern for a period of one year after the date of the financial statements are issued. The Company&#8217;s consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reduction
in Force/Restructuring</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Company entered into a cost reduction plan, including a reduction in force (&#8220;RIF&#8221;) of approximately 35% of
its full-time employees to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that
were focused on the Akos cannabinoid spin-out were terminated. The Company recognized severance charges of approximately $<span id="xdx_909_eus-gaap--SeveranceCosts1_c20230501__20230531_z8D58hHBUYA" title="Severance costs"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2023-05-012023-05-31" id="Fact000802" format="ixt:numdotdecimal" decimals="0" unitRef="USD">453,059</ix:nonFraction></span> through
December 31, 2023. The plan included a focus on progressing the Company&#8217;s existing non-cannabinoid pipeline while reducing the
rate of spend and managing cash flow. In June 2023, the Company completed the reduction in force, with such severance expenses recorded
in general and administrative accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 16, 2023, the Company entered into a separation agreement with Avani Kanubaddi, the Company&#8217;s President and Chief Operating
Officer (the &#8220;Kanubaddi Separation Agreement&#8221;). In accordance with the Kanubaddi Separation Agreement, Mr. Kanubaddi&#8217;s
outstanding restricted stock units (&#8220;RSUs&#8221;) will retain their vesting conditions. Mr. Kanubaddi&#8217;s 2023 salary and benefits
of $<span id="xdx_907_eus-gaap--SalariesAndWages_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_zMaUHcTYjBF4" title="Salaries and benefit"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2023-06-152023-06-16_custom_KanubaddiSeparationAgreementMember" id="Fact000804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,974</ix:nonFraction></span>, inclusive of the 2023 performance bonus in the amount of $<span id="xdx_90A_eus-gaap--AccruedBonusesCurrent_iI_c20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_ztd6F7MB8w7c" title="Performance bonus"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2023-06-16_custom_KanubaddiSeparationAgreementMember" id="Fact000806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,760</ix:nonFraction></span> were accrued and the salary and benefits, excluding the
2023 performance bonus will be paid out in twelve equal monthly installments beginning in July 2023. As of December 31, 2023, the performance
metrics for the 2023 performance bonus were not achieved and the accrued amount of amount of $<span id="xdx_906_eus-gaap--RestructuringReserve_iI_c20231231_zRuin27dgPvk" title="Reversed amount"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="AsOf2023-12-31" id="Fact000808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,760</ix:nonFraction></span> was reversed. Upon termination,
any unvested time-based RSUs became fully vested. The Company accelerated expense recognized related to these shares that vested was
$<span id="xdx_907_ecustom--ExpenseRelatedToAccelerationOfVesting_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--MrKanubaddiEmploymentAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLAvMlfADMU2" title="Expense related to acceleration of vesting"><ix:nonFraction name="ENVB:ExpenseRelatedToAccelerationOfVesting" contextRef="From2023-06-152023-06-16_custom_MrKanubaddiEmploymentAgreementMember_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,273</ix:nonFraction></span>. All of the <span id="xdx_906_ecustom--MarketPerformanceBasedShares_iI_c20230616__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmfQq6R0AFH7" title="Market performance based shares"><ix:nonFraction name="ENVB:MarketPerformanceBasedShares" contextRef="AsOf2023-06-16_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000812" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,278</ix:nonFraction></span> market performance-based RSUs previously granted that were subject to the original terms and conditions of
Mr. Kanubaddi&#8217;s employment agreement were forfeited during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000814" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z5glKSFld41e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_ztulwBwkUNX1" style="display: none">SCHEDULE
OF RESTRUCTURING COSTS PAYABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued<br/>
Restructuring Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>January 1, 2023 Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20230101__20231231_zAlZ6w4mtdef" title="Restructuring cost payable, beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Restructuring costs incurred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_ecustom--RestructuringCostsIncurred_c20230101__20231231_zWEiabbndsUi" title="Restructuring costs incurred" style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:RestructuringCostsIncurred" contextRef="From2023-01-01to2023-12-31" id="Fact000818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,004,033</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restructuring costs paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RestructuringCosts_c20230101__20231231_zH5WzRsnJSdh" title="Restructuring costs" style="text-align: right">(<ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="From2023-01-01to2023-12-31" id="Fact000820" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">572,628</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restructuring costs reversed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OtherRestructuringCosts_c20230101__20231231_zY0iQ8QQEIX6" title="Restructuring costs reversed" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherRestructuringCosts" contextRef="From2023-01-01to2023-12-31" id="Fact000822" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">129,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">December 31, 2023 ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20230101__20231231_z5ABeYZz2MK4" title="Restructuring cost payable, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" contextRef="AsOf2023-12-31" id="Fact000824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,645</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zbWxkJfj9qfh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers the current inflationary trend existing in the North American economic environment reasonably likely to have a material
unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price
inflation, have caused a general increase in the cost of labor and materials. In addition, there is an increased risk of the Company
experiencing labor shortages due to a potential inability to attract and retain human resources due to increased labor costs resulting
from the current inflationary environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Notice</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that as
of September 30, 2023, the Company did not meet the minimum of $<span id="xdx_90A_ecustom--MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_iI_c20231121_zRjXM8zUUidi" title="Minimum of stockholders equity required for continued listing pursuant to exchange"><ix:nonFraction name="ENVB:MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" contextRef="AsOf2023-11-21" id="Fact000826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span> in stockholders&#8217; equity required for continued listing
pursuant to Nasdaq Listing Rule 5550(b)(1). On February 6, 2024, the Company received a letter from Nasdaq, granting the Company an extension
to regain compliance with the minimum stockholders&#8217; equity requirement by May 20, 2024. If the Company fails to evidence compliance
upon filing its periodic report for June 30, 2024 with the SEC and Nasdaq, the Company may be subject to delisting. The Company plans
to regain and evidence compliance with the Stockholders&#8217; Equity Requirement by the required deadlines, but it is not assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000828" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_z1Usp4Epnijl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_827_z29VOpGCLrQb">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000830" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6VcoZZsSz29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zbIKrsz2JJMb">Basis
of Presentation and Principal of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance and in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and the applicable rules
and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) regarding consolidated financial information. All intercompany
transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000832" name="us-gaap:UseOfEstimates"><p id="xdx_846_eus-gaap--UseOfEstimates_zLE80GiwQAK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zMMySFR20SIc">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported.
By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such
estimates in future periods could be significant. Significant areas requiring management&#8217;s estimates and assumptions include determining
the fair value of transactions involving common stock, the valuation of warrants and preferred investment options, and the valuation
of stock-based compensation and accruals associated with third party providers supporting research and development efforts. Actual results
could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000834" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z5nptn10VcWl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zFKLsC1vhXHf">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through December 31, 2023, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#8217;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended December
31, 2023 and 2022, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the consolidated statements of operations and comprehensive loss as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000836" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6AeRnFPvu0k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zNjHpvv4Gia">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The
Company did not have any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000838" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zIej6k2jp2B1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z0Oa78Uy6iHe">Concentration
of Credit Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zB4bQGBLtGA6" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31_country_US" id="Fact000840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> in the United States and Australia and $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zGy542i4yAyf" title="Cash insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31_country_CA" id="Fact000842" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of December 31, 2023, the Company had greater than $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zQv2tJGpW28l" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31_country_US" id="Fact000844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> at United States financial institutions, less than $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--AU_zPZgCdbAQVk7" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31_country_AU" id="Fact000846" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>
at Australian financial institutions, and greater than $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zkz71lJ5798l" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31_country_CA" id="Fact000848" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> at Canadian financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000850" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zuPlfgRbEyZd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztBjC43QkT38">Comprehensive
Loss</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss consists of two components, net loss and other comprehensive income (loss). Other comprehensive loss refers to revenue, expenses,
gains, and losses that under GAAP are recorded as an element of shareholders&#8217; equity but are excluded from net loss. Other comprehensive
loss consists of foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000852" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziQD2CBAghZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zPkCB4Owiyud">Intangible
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the Psybrary&#8482; and Patent Applications, In Process Research and Development (&#8220;IPR&amp;D&#8221;) and license
agreements. Psybrary&#8482; and Patent Applications intangible assets are valued using the relief from royalty method. The cost of license
agreements is amortized over the economic life of the license. The Company assesses the carrying value of its intangible assets for impairment
each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IPR&amp;D
intangible assets are acquired in conjunction with the acquisition of a business and are assigned a fair value, using the multi-period
excess earnings method, related to incomplete research projects which, at the time of acquisition, have not reached technological feasibility.
The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion
or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then-useful
life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to
be generated, and begin amortization. The Company tests its intangible assets for impairment at least annually and whenever events or
circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator
of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company&#8217;s
expected future cash flows; a sustained, significant decline in the Company&#8217;s stock price and market capitalization; a significant
adverse change in legal factors or in the business climate of the Company&#8217;s segments; unanticipated competition; and slower growth
rates. If the fair value determined is less than the carrying amount, an impairment loss is recognized in operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000854" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy"><p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z32t25Ny06rb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zdX7mG65WS1b">Goodwill</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company tests goodwill for potential impairment at least annually, or more frequently if an event or other circumstance indicates that
the Company may not be able to recover the carrying amount of the net assets of the reporting unit. The Company has determined that the
reporting unit is the entire company, due to the integration of all of the Company&#8217;s activities. In evaluating goodwill for impairment,
the Company may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that
the fair value of a reporting unit is less than its carrying amount. If the Company bypasses the qualitative assessment, or if the Company
concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company performs
a quantitative impairment test by comparing the fair value of a reporting unit with its carrying amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000856" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zNmGyuL93vpj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z622SrpvFB74">Property
&amp; Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Major property additions, replacements, and betterments are capitalized, while maintenance and repairs
that do not extend the useful lives of an asset or add new functionality are expensed as incurred. Depreciation and amortization are
recorded using the straight-line method over the respective estimated useful lives of the Company&#8217;s long-lived assets. The estimated
useful lives are typically <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDXlWGeWzm" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MinimumMember_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear" id="Fact000858" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zuaBlK6Ilio2" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MaximumMember_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear" id="Fact000860" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years for office furniture and equipment and are depreciated on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000862" name="ENVB:DeferredOfferingCostsPolicyTextBlock"><p id="xdx_844_ecustom--DeferredOfferingCostsPolicyTextBlock_zI13qPYdFR16" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zmmelDy6vXh3">Deferred
Offering Costs</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocates offering costs to the different components of the capital raise on a pro rata basis. Any offering costs allocated to
common stock are charged directly to additional paid-in capital. Any offering costs allocated to warrant liabilities are charged to general
and administrative expenses on the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirements of ASC Topic 340, <i>Other Assets and Deferred Costs</i> (&#8220;ASC 340&#8221;) and SAB 5A <i>-
Expenses of Offering</i>. Offering costs, which consist mainly of legal, accounting and consulting fees directly attributable to the
issuance of an equity contract to be classified in equity are recorded as a reduction in equity. For the year ended December 31, 2023,
the Company incurred $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zOw3Bao897qf" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="Fact000864" format="ixt:numdotdecimal" decimals="0" unitRef="USD">567,603</ix:nonFraction></span> in deferred offering costs in connection with the Equity Distribution Agreement (the &#8220;Distribution
Agreement&#8221;), with Canaccord Genuity LLC (&#8220;Canaccord&#8221;) and the Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). These deferred offering costs will be proportionately offset against
the total proceeds from the issuance of common stock available under the agreements and the Company will expense any remaining balance
of deferred offering costs if the agreements are terminated. For the year ended December 31, 2023, there were no issuances of common
stock under the agreements resulting in the deferral of offering costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000866" name="ENVB:WarrantLiabilityPolicyTextBlock"><p id="xdx_84C_ecustom--WarrantLiabilityPolicyTextBlock_zanLVGGwng9c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zH6VWLIKl02j">Warrant
Liability and Investment Options</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its financial instruments, including issued stock purchase warrants and investment options, to determine if
such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 &#8220;Distinguishing
Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;) and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;).
The Company accounts for warrants and investment options for shares of the Company&#8217;s common stock that are not indexed to its own
stock as derivative liabilities at fair value on the consolidated balance sheets. The Company accounts for common stock warrants and
investment options with put options as liabilities under ASC 480. Such warrants and investment options are subject to remeasurement at
each consolidated balance sheet date and any change in fair value is recognized as a component of other expense on the consolidated statements
of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration
of such common stock warrants and investment options. At that time, the portion of the warrant liability and investment options related
to such common stock warrants will be reclassified to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000868" name="ENVB:ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock"><p id="xdx_846_ecustom--ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_zOLylevrf7oj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zHBF6D1y83y9">Modification
and Inducement of Warrants and Investment Options</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in any of the terms or conditions of warrants is accounted for as a modification. For a warrant modification accounted for under
ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over the fair
value of the original warrant immediately before its terms are modified, measured based on the fair value of the shares and other pertinent
factors at the modification date. The accounting for incremental fair value of warrants is based on the specific facts and circumstances
related to the modification. When a modification is directly attributable to equity offerings, the incremental change in fair value of
the warrants are accounted for as equity issuance costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the inducement to exercise warrants in accordance with ASC Subtopic 470-20-40 &#8220;Debt with Conversion and Other
Options&#8221; (&#8220;ASC 470-20-40&#8221;). ASC 470-20-40 requires the recognition through earnings of an inducement charge equal to
the fair value of the consideration delivered in excess of the consideration issuable under the original conversion terms. Therefore,
the Company recognized a loss on the warrant inducement for the incremental change of the warrants related to the reduced exercise price
and the issuance of new warrants as these components induced the holders to exercise the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000870" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_ze8NOutWO18c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zBwpH1gx3ZNb">Derivative
Liability</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as assets or liabilities, the derivative
instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the
fair value reported in the consolidated statements of operations. The classification of derivative instruments, including whether such
instruments should be recorded as assets or liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion
of the instrument could be required within 12 months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000872" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zL6shVmPF5Cf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zsORoSsW5NTg">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#8217;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liabilities. In management&#8217;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The
amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that
do not meet these recognition and measurement standards. As of December 31, 2023 and 2022, no liability for unrecognized tax benefits
was required to be recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy for recording interest and penalties associated with tax audits is to record such items as a component of operating
expenses. There were no amounts accrued for penalties and interest for the years ended December 31, 2023 and 2022. The Company does not
expect its uncertain tax positions to change during the next twelve months. Management is currently unaware of any issues under review
that could result in significant payments, accruals or material deviations from its position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified its United States, Canadian and Australian federal tax returns, and its state and provincial tax returns in Florida,
Massachusetts, New Jersey, Pennsylvania, and Ontario, CA as its &#8220;major&#8221; tax jurisdictions. The Company is in the process
of filing its United States federal and state and Australian federal corporate tax returns for the year ended December 31, 2023. The
Company is in the process of filing its Canadian corporate tax returns for the years ended December 31, 2023 and 2022. Net operating
losses for these periods will not be available to reduce future taxable income until the returns are filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000874" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zEsxkwpAfIyl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zVtfgEZ2LSf1">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows ASC 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions, requiring
such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded at the more
readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The Company uses the Black-Scholes
option-pricing model to determine the grant date fair value of certain stock-based awards under ASC 718. The assumptions used in calculating
the fair value of stock-based awards represent management&#8217;s reasonable estimates and involve inherent uncertainties and the application
of management&#8217;s judgment. Fair value of restricted stock units or restricted stock awards is determined by the closing price per
share of the Company&#8217;s common stock on the date of award grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value is amortized as a charge to earnings on a straight-line basis, for awards or portions of awards that do not require
specified milestones or performance criteria as a vesting condition and also depending on the terms and conditions of the award, and
the nature of the relationship of the recipient of the award to the Company. The Company records the grant date fair value in line with
the period over which it was earned. For employees and consultants, this is typically considered to be the vesting period of the award.
The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of awards that require specified milestones or recipient performance are charged to expense when such milestones
or performance criteria are probable to be met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
stock units, restricted stock awards, and stock options are granted at the discretion of the Compensation Committee of the Company&#8217;s
board of directors (the &#8220;Board of Directors&#8221;). These awards are restricted as to the transfer of ownership and generally
vest over the requisite service periods, typically over a 12 to 48-month period. A significant portion of these awards may include vesting
terms that include, without limitation, defined volume weighted average price levels being achieved by the Company&#8217;s common stock,
specific performance milestones, employment, or engagement by the Company, with no assurances of achievement of any such vesting conditions,
if applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RSU&#8217;s is equal to the product of the number of units awarded, multiplied by the closing price per share of the Company&#8217;s
common stock on the date of the award. The terms and conditions of each RSU is defined in the RSU agreement and includes vesting terms
that consist of any or all of the following: immediate vesting, vesting over a defined period of time, vesting based on achievement of
a defined volume weighted average price levels at specified times, vesting based on achievement of specific performance milestones within
a specific time frame, change of control, termination of the employee without cause by the Company, resignation of the employee with
good cause. The value assigned to each RSU is charged to expense based on the vesting terms, as follows: value of RSU&#8217;s that vest
immediately are charged to expense on the date awarded, value of RSU&#8217;s that vest based upon time, or achievement of stock price
levels over a period of time are charged to expense on a straight line basis over the time frame specified in the RSU and the value of
RSU&#8217;s that vest based upon achievement of specific performance milestones are charged to expense during the period that such milestone
is achieved. Vested RSU&#8217;s may be converted to shares of common stock of an equivalent number upon either the termination of the
recipient&#8217;s employment with the Company, or in the event of a change in control. If the recipient is not an employee, such person&#8217;s
engagement with the Company must either be terminated prior to such conversion of RSU&#8217;s to shares of common stock, or in the event
of a change in control. Furthermore, as required by Section 409A of the Internal Revenue Code, if the recipient is a &#8220;specified
employee&#8221; (generally, certain officers and highly compensated employees of publicly traded companies), such recipient may only
convert vested RSU&#8217;s into shares of common stock no earlier than the first day of the seventh month following such recipients termination
of employment with the Company, or the event of change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RSA&#8217;s is equal to the product of the number of restricted shares awarded, multiplied by the closing price per share of
the Company&#8217;s common stock on the date of the award. The terms and conditions of each RSA is defined in the RSA agreement and includes
vesting terms that consist of any or all of the following: immediate vesting, vesting over a defined period of time, or vesting based
on achievement of a defined volume weighted average price levels at specified times. Upon vesting, the recipient may receive restricted
stock which includes a legend prohibiting sale of the shares during a restriction period that is defined in the RSA agreement. Termination
of employment by or engagement with the Company is not required for the recipient to receive restricted shares of common stock. The value
assigned to each RSA is charged to expense based on the vesting terms, as follows: value of RSA&#8217;s that vest immediately are charged
to expense on the date awarded, value of RSA&#8217;s that vest based upon time, or achievement of stock price levels over a period of
time are charged to expense on a straight-line basis over the time frame specified in the RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000876" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z2bNPdQ0lNxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zX4N0aihbZJi">Net
Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the years ended December 31, 2023 and 2022 excludes
potentially dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully
diluted. In accordance with ASC 260 &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;), penny warrants were included in the calculation
of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022 the Company issued <span id="xdx_908_eus-gaap--StockIssued1_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zrEmdvuW4kc3" title="Stock and warrants issued"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember" id="Fact000878" format="ixt:numdotdecimal" decimals="0" unitRef="USD">767,500</ix:nonFraction></span> pre-funded common stock warrants, which were exercised on various dates during
the year ended December 31, 2022. The pre-funded common stock warrants became exercisable on July 26, 2022 based on the terms and conditions
of the agreements. As the pre-funded common stock warrants are exercisable for $<span id="xdx_90D_eus-gaap--WarrantExercisePriceDecrease_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zklaTLhZDQRk" title="Warrant exercise price"><ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>, these shares are considered outstanding common
shares and are included in the computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants
is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions
were met on July 26, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000882" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3HM0uaIm6yl" style="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,799,213</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000885" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">655,463</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember" id="Fact000887" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,848</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,492</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock units - unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsUnvestedMember" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">140,491</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_RestrictedStockUnitsUnvestedMember" id="Fact000891" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">64,053</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_z5qaULxH0YR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock awards - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0893">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">708</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_zqhcUe1s59cj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock in abeyance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_CommonStockInAbeyanceMember" id="Fact000896" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">704,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zq1067Obsksb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment options to purchase shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember" id="Fact000899" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,070,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zhYSctrl3dxd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase shares of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember" id="Fact000903" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-12-31" id="Fact000905" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,764,881</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31" id="Fact000906" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,901,045</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zJID65LmxDb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000908" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqetmarc655b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztG9Z6EAI5m2">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value
Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), approximates the carrying amounts in the balance sheets, excluding the derivative,
warrants, and preferred investment option liabilities, primarily due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000910" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zWzfZ1GdSou9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zKPLQOyArmx4">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and
liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by
other market participants. These valuations require significant judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, including cash and accounts payable, the carrying amounts approximate their fair values as of December
31, 2023 and 2022 because of their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000912" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ziSLQKNyYoCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zuz1Rz8vQhr9">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000914" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_zQ7ioewi5Gc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease assets are included within right-of-use operating lease asset and operating lease liabilities are included in current portion of
right-of-use operating lease obligation and non-current portion of right-of-use operating lease obligation on the consolidated balance
sheets as of December 31, 2023 and 2022. The Company has elected not to present short-term leases as these leases have a lease term of
12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise.
Lease payments for short-term leases are recognized on a straight-line basis over the term of the lease. All other lease assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the
Company&#8217;s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information
available at adoption date in determining the present value of lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain
a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset
and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company
has elected to account for non-lease components associated with its leases and lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes a right-of-use asset, which represents the Company&#8217;s right to use the underlying asset for the lease term, and
a lease liability, which represents the present value of the Company&#8217;s obligation to make payments arising over the lease term.
The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing
rate<b><i>.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of
ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset
that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset,
(iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v)
the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of
the lease term. All other leases are recorded as operating leases. Finance lease payments are bifurcated into (i) a portion that is recorded
as interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did not have any finance
leases as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000916" name="ENVB:RedeemableNoncontrollingInterestPolicyTextBlock"><p id="xdx_846_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zxsDQhAmPSMf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_za6xEu8hPKl1">Redeemable
Non-controlling Interest</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of Akos Series A Preferred Stock, the Akos Purchase Agreement (as defined below in Note 8) and certificate
of designation contain a put right guaranteed by the Company as defined in Note 8. Applicable accounting guidance requires an equity
instrument that is redeemable for cash or other assets to be classified outside of permanent equity if it is redeemable (a) at a fixed
or determinable price on a fixed or determinable date, (b) at the option of the holder, or (c) upon the occurrence of an event that is
not solely within the control of the issuer. As a result of this feature, the Company recorded the non-controlling interests as Redeemable
Non-Controlling Interests (&#8220;RNCI&#8221;) and classified them in mezzanine equity within its consolidated balance sheet initially
at its acquisition-date estimated redemption value or fair value. In addition, the Company has elected to recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument by accreting the embedded derivative at each reporting
period over 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right (as defined below) requiring Akos to force redemption of all of the Akos Series A Preferred Stock. See Note 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000918" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQ4s5yz0SOx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zww0mCbaLZc1">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines its reporting units in accordance with FASB ASC 280, &#8220;Segment Reporting&#8221; (&#8220;ASC 280&#8221;). The
Company evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated. The Company has multiple operations related
to psychedelics and cannabinoids. Both of these operations exist under one reporting unit: Enveric. The Company has one operating segment
and reporting unit. The Company is organized and operated as one business. Management reviews its business as a single operating segment,
using financial and other information rendered meaningful only by the fact that such information is presented and reviewed in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000920" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6VQKIWjEQ2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zwwObdI2aaB5">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>Debt&#8212;Debt with Conversion and Other Options</i> (Subtopic 470-20) and <i>Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</i> (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;) to simplify certain financial
instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features
from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2023, and should be applied on a full or modified retrospective basis. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06
effective January 1, 2023, and has determined that the adoption of this guidance had no impact on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently evaluating ASU 2023-07 to determine its impact on the Company&#8217;s
disclosures, however, as the Company currently has one reportable segment, the Company does not expect ASU 2023-07 to have a material
impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its consolidated financial statements
and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000922" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_80C_eus-gaap--OtherCurrentAssetsTextBlock_zaAAsItDs3Mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3.<span> <span id="xdx_82D_z7UD1gS7KARl">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000924" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3Gs4LNqtEXh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, the prepaid expenses and other current assets of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zTydFvT6Kuv4" style="display: none">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_z62twSxO8pL7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_z3hHr38UO7Tf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zIwSnFeaEsv8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:PrepaidResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact000926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,320</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:PrepaidResearchAndDevelopment" contextRef="AsOf2022-12-31" id="Fact000927" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,686</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_znbflNJJ4xcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid value-added taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2023-12-31" id="Fact000929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2022-12-31" id="Fact000930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,782</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_z3HJkewuOo16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-12-31" id="Fact000932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-12-31" id="Fact000933" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,406</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zRR1RvRhJGo5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000935" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,036</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2022-12-31" id="Fact000936" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,179</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_zv88yG4YKVt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="Fact000938" format="ixt:numdotdecimal" decimals="0" unitRef="USD">567,603</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0939">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zujCa29AAHXe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Franchise tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PrepaidFranchiseTaxReceivable" contextRef="AsOf2023-12-31" id="Fact000941" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,258</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zaRKpTVrRgM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">R&amp;D tax incentive receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable" contextRef="AsOf2023-12-31" id="Fact000944" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,349</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0945">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zieXSbV2rhJ5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,293,554</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">708,053</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<!-- Field: Split-Segment; Name: 001 -->
</ix:nonNumeric><p id="xdx_8A7_zesRhFyyZGE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000950" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_804_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_z9SCaXsACTk5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span id="xdx_824_zU9uwK220FDb">INTANGIBLE ASSETS AND GOODWILL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performs an annual impairment test at the reporting unit level as of December 31 of each fiscal year. As of December 31, 2022,
the Company&#8217;s goodwill and intangible assets were fully impaired, and thus no annual impairment test was necessary as of December
31, 2023. The following table provides the Company&#8217;s goodwill, indefinite and definite lives intangible assets as of December 31,
2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000952" name="us-gaap:ScheduleOfGoodwillTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zNA8zJSGKUU" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s goodwill consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_zywzBm3sR0Xd" style="display: none">SCHEDULE
OF GOODWILL</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Impairment Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Currency Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--GoodwillGross_iS_c20220101__20221231_zrL5hyJCBTck" title="Goodwill Gross, Beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:GoodwillGross" contextRef="AsOf2021-12-31" id="Fact000954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,834,855</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNS_di_c20220101__20221231_zoA3HbV75zY9" title="Accumulated Impairment Losses, Beginning balance" style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="AsOf2021-12-31" id="Fact000956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,225,862</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--GoodwillCurrencyTranslation_iS_c20220101__20221231_zsv05uR0T8P7" title="Currency Translation, Beginning balance" style="width: 11%; text-align: right">(<ix:nonFraction name="ENVB:GoodwillCurrencyTranslation" contextRef="AsOf2021-12-31" id="Fact000958" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,359</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Goodwill_iS_c20220101__20221231_zcXRwm58qzs1" title="Goodwill, Beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" id="Fact000960" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,587,634</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--GoodwillImpairmentLossGross_iN_di_c20220101__20221231_zkf3VkHhApy6" title="Goodwill Gross, Impairment losses" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0962">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--GoodwillAccumulatedImpairmentLoss_iN_di_c20220101__20221231_zUssTZVnGsp9" title="Accumulated Impairment Losses, Impairment losses" style="text-align: right">(<ix:nonFraction name="ENVB:GoodwillAccumulatedImpairmentLoss" contextRef="From2022-01-012022-12-31" id="Fact000964" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,486,060</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--GoodwillCurrencyTranslationImpairmentLoss_iN_di_c20220101__20221231_zl7mHTPCTDti" title="Currency Translation, Impairment losses" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0966">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zsSlcGVeDune" title="Goodwill, Impairment losses" style="text-align: right">(<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-012022-12-31" id="Fact000968" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,486,060</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--GoodwillForeignCurrencyTranslationGainLossGross_c20220101__20221231_zyhq88vbkWy9" title="Goodwill Gross, Loss on currency translation" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0970">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_c20220101__20221231_zyyjjekFt9Bh" title="Accumulated Impairment Losses, Loss on currency translation" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0972">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--GoodwillCurrencyTranslationLoss_c20220101__20221231_zapkiDJnziL9" title="Currency Translation, Loss on currency translation" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ENVB:GoodwillCurrencyTranslationLoss" contextRef="From2022-01-012022-12-31" id="Fact000974" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">101,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20220101__20221231_zMG8RIR4uUE4" title="Goodwill, Loss on currency translation" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="From2022-01-012022-12-31" id="Fact000976" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">101,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GoodwillGross_iE_c20220101__20221231_zs3uh3Cgc7W3" title="Goodwill Gross, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GoodwillGross" contextRef="AsOf2022-12-31" id="Fact000978" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,834,855</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNE_di_c20220101__20221231_zIXJIohBvg8a" title="Accumulated Impairment Losses, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="AsOf2022-12-31" id="Fact000980" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,711,922</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--GoodwillCurrencyTranslation_iE_c20220101__20221231_zW9O3fTzJnD2" title="Currency Translation, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ENVB:GoodwillCurrencyTranslation" contextRef="AsOf2022-12-31" id="Fact000982" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">122,933</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zvobPkbyOarl" title="Goodwill, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zxEPfyg8txe4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000986" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zUeFBNUXA8mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s indefinite lived intangible assets consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B7_zWEh1BmzLMM6" style="display: none">SCHEDULE
OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Indefinite lived intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iS_d0_c20220101__20221231_zYcj6o314Pg" title="Balance, Indefinite lived intangible assets" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2021-12-31" id="Fact000988" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,375,492</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetImpairmentCharges_iN_di_c20220101__20221231_z8wLJAfYqT8g" title="Impairment losses" style="text-align: right">(<ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2022-01-012022-12-31" id="Fact000990" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,967,602</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Loss on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20220101__20221231_z1veDDOEjT78" title="Loss on currency translation" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" contextRef="From2022-01-012022-12-31" id="Fact000992" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">407,890</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iE_c20220101__20221231_z7LKtTyUhh1h" title="Balance, Indefinite lived intangible assets" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0994">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023 and 2022, the definite lived intangible assets consisted of: &#160; &#160; &#160; &#160;</p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; width: 80%">Definite lived intangible assets</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 16%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold">Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20220101__20221231_ziSpokWclQNl" title="Balance, Definite lived intangible assets" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31" id="Fact000996" format="ixt:numdotdecimal" decimals="0" unitRef="USD">548,436</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20220101__20221231_zSxeeR1NJHi1" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31" id="Fact000997" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,750</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold">Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20230101__20231231_zoS9i0Nplzqe" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" id="Fact000998" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20231231_zNNExnK3q2ec" title="Amortization" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-01to2023-12-31" id="Fact001000" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,754</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20230101__20231231_zIT0j5Uxijbd" title="Balance, Definite lived intangible assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact001002" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,932</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zXWcVfQneWi8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
identified definite lived intangible assets, amortization expense amounted to $<span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zk2p8bhGkqR9" title="Intangible assets, amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-01to2023-12-31" id="Fact001004" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,754</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zyBCbH7OAWC" title="Intangible assets, amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31" id="Fact001006" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,750</ix:nonFraction></span> during the years ended December 31,
2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001008" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zqb59wU0hIE9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company amortizes definite lived intangible assets on a&#8239;straight-line basis over their estimated useful lives. Amortization expense
of identified intangible assets based on the carrying amount as of December 31, 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B8_zzVXkKpEcQPl" style="display: none">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231_zkDZQgKYy2ck">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzC0U_zTyAhx8Iihm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2023-12-31" id="Fact001010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,750</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzC0U_zWOFDxfsxxFe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2023-12-31" id="Fact001012" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,182</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzC0U_zC9XwcaOuro6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Finite lived assets amortization
    expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact001014" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,932</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zPK37hZCJdad" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001016" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXXYZu4HU6c9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_825_zaytaYVEUUm6">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001018" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVVGahhpzvNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following assets which are located in Calgary, Canada and placed in service by Enveric Biosciences Canada,
Inc. (&#8220;EBCI&#8221;), with all amounts translated into U.S. dollars:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BF_zxF5quYUvBz1" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zzCZHNQZFxvd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zvLPGndd0db5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zp4aNQNMWWri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Lab equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_LabEquipmentMember" id="Fact001020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">836,709</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_LabEquipmentMember" id="Fact001021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">831,123</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_z9JhYXtwNtFl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment and leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember" id="Fact001023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,379</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember" id="Fact001024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,137</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zPgLn2Oc6tvg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact001026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,711</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="Fact001027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,775</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zXt2mt3bMunh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net of accumulated depreciation</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact001029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507,377</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact001030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">677,485</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z2MshGQnoZt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_90D_eus-gaap--Depreciation_c20230101__20231231_zaY42joe7YG7" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-12-31" id="Fact001032" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,228</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--Depreciation_c20220101__20221231_z0vGnuRplH4c" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="Fact001034" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,160</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001036" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zBePLueQV7ve" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_828_zbdmk1JonaWe">ACCRUED LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001038" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zEC0nxuwQfD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and December 31, 2022, the accrued liabilities of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B6_z2CYiR69qip9" style="display: none">SCHEDULE
OF ACCRUED LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zIdUdedJs0bc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_ztfCG22lB8m6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_zzTIaLc6TzX6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Product development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:AccruedProductDevelopmentCost" contextRef="AsOf2023-12-31" id="Fact001040" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,981</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:AccruedProductDevelopmentCost" contextRef="AsOf2022-12-31" id="Fact001041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,104</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zxArVFIfjro7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued salaries, wages, and bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2023-12-31" id="Fact001043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,889</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2022-12-31" id="Fact001044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,175,963</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zmvujpsSA58g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" id="Fact001046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">584,810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2022-12-31" id="Fact001047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,255</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zGJabHMfEVH5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued restructuring costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccruedRestructuringCosts" contextRef="AsOf2023-12-31" id="Fact001049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,645</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_z6PA2plzHgPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued franchise taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2023-12-31" id="Fact001052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zTXa5jxvaF64" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Patent costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2023-12-31" id="Fact001055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2022-12-31" id="Fact001056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zHLlMDwwvI65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,075,643</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact001059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,705,655</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zfLwpnfUgaDl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001061" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zDwGAQBPdjdj" style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_821_zPkNv6EA0ckj">SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Authorized
Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--CommonStockVotingRights_c20230101__20231231_zyP7HBT2y9O4" title="Common stock voting rights"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact001063" name="us-gaap:CommonStockVotingRights">The
holders of the Company&#8217;s common stock are entitled to one vote per share</ix:nonNumeric></span>. Holders of common stock are entitled to receive ratably
such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Upon the liquidation, dissolution,
or winding up of the Company, holders of common stock are entitled to share ratably in all assets of the Company that are legally available
for distribution. As of December 31, 2023, <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_z3kEFDBFbKC" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares of common stock and <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zBU2P1eYPMuf" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact001067" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span> shares of Preferred Stock were authorized
under the Company&#8217;s articles of incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Distribution Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2023, the Company entered into the Distribution Agreement, with Canaccord, pursuant to which the Company may offer and sell
from time to time, through Canaccord as sales agent and/or principal, shares of common stock of the Company, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zzPld5phABZh" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact001069" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share
having an aggregate offering price of up to $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zV61LRnnxsQj" title="Common stock, offering price"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact001071" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million. Due to the offering limitations applicable to the Company and in accordance
with the terms of the Distribution Agreement, the Company may offer common stock having an aggregate gross sales price of up to $<span id="xdx_900_ecustom--SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zFsQ1hTkiWgf" title="Aggregate gross sales price"><ix:nonFraction name="ENVB:SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact001073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,392,514</ix:nonFraction></span>
pursuant to the prospectus supplement dated September 1, 2023 (the &#8220;Prospectus Supplement&#8221;). Subject to the terms and conditions
of the Distribution Agreement, Canaccord may sell the common stock by any method permitted by law deemed to be an &#8220;at-the-market
offering&#8221;. The Company will pay Canaccord a commission equal to <span id="xdx_909_ecustom--CommissionPercentage_pid_dp_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zXJHXmkSZzdf" title="Commission percentage"><ix:nonFraction name="ENVB:CommissionPercentage" contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact001075" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross sales price of the common stock sold through
Canaccord under the Distribution Agreement and has also agreed to reimburse Canaccord for certain expenses. The Company may also sell
common stock to Canaccord as principal for Canaccord&#8217;s own account at a price agreed upon at the time of sale. Any sale of common stock to Canaccord as principal would be pursuant to the terms of a separate terms agreement between the Company and Canaccord.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inducement Letters (as defined below within this Note 7) prohibits the Company from entering into any variable rate transaction as defined
in the Inducement Letters, including the issuance of (1) any variable priced debt or equity securities or (2) transactions whereby the
Company may issue securities at a future determined price, such as through an at-the-market offering or an equity line of credit. The
variable rate transaction restriction expires after six-month from the closing date of December 28, 2023 for the Inducement Letters for
an issuance through an at-the-market offering, and one-year for the remaining variable rate transactions. Subsequent to December 31, 2023, the limitation on the at-the-market offering was waived. See Note 12.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lincoln
Park Equity Line</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, the Company entered into a Purchase Agreement and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;),
with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $<span id="xdx_904_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zOOeNanEtQna" title="Purchase committment"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember" id="Fact001077" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million of the Company&#8217;s common stock,
par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zHrjprwA7De7" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-11-03_custom_RegistrationRightsAgreementMember" id="Fact001079" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share subject to certain limitations and satisfaction of the conditions set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln
Park, and Lincoln Park is obligated to purchase up to $<span id="xdx_90A_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zs6V54OtPzKd" title="Purchase committment"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember" id="Fact001081" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million of the Company&#8217;s common stock (the &#8220;Purchase Shares&#8221;).
However, such sales of common stock by the Company, if any, will be subject to important limitations set forth in the Purchase Agreement,
including limitations on number of shares that may be sold. Sales may occur from time to time, at the Company&#8217;s sole discretion,
over the 24-month period commencing on the date that the conditions to Lincoln Park&#8217;s purchase obligation set forth in the Purchase
Agreement are satisfied, including that a registration statement on Form S-1 covering the resale of the shares of our common stock that
have been and may be issued to Lincoln Park under the Purchase Agreement, which the Company has filed with the SEC pursuant to the Registration
Rights Agreement, is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the purchase price per share to be paid by Lincoln Park for the shares of common stock that we may elect to sell to Lincoln Park under
the Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock at the time we elect to sell shares to
Lincoln Park pursuant to the Purchase Agreement, if any, it is not possible for us to predict the number of shares of Common Stock that
we will sell to Lincoln Park under the Purchase Agreement, the purchase price per share that Lincoln Park will pay for shares purchased
from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by Lincoln Park under
the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company has issued no shares of common stock through the Equity Line or the Distribution Agreement.
The Company had capitalized deferred offering costs of $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zKz2gddhOKWe" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="Fact001083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">567,603</ix:nonFraction></span> related to establishing the Distribution Agreement with Canaccord and
the Purchase Agreement with Lincoln Park and no reductions to additional paid in capital. Of this amount, $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zPkUqxA8u6Vg"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-01to2023-12-31" id="Fact001084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,107</ix:nonFraction></span> represents the fair
value of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDJ8hpMn6Hwc"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001085" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,403</ix:nonFraction></span> shares of common stock issued to Lincoln Park as consideration for its commitment under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Activity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023 a total of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znp99CIqxNdk" title="Issuance of common shares in exchange for RSU conversions, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,641</ix:nonFraction></span> shares of common stock were issued pursuant to the conversion of restricted stock
units. During the year ended December 31, 2022, a total of <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVVRjjZ5Exei" title="Stock issued during period conversion of restricted stock award"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001089" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,223</ix:nonFraction></span> and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9r9oyNeumEg"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001090" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">899</ix:nonFraction></span> shares of common stock were issued pursuant to the conversion
of restricted stock awards and restricted stock units, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, the Company completed a public offering of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220213__20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zntTgZMDrl9k" title="Public offering"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-132022-02-15_us-gaap_IPOMember" id="Fact001092" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></span> shares of common stock and warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTUe4kaUETye" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-02-15_us-gaap_IPOMember" id="Fact001094" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></span> shares
of common stock for gross proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220213__20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6jFxLXor71f" title="Proceeds from common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-02-132022-02-15_us-gaap_IPOMember" id="Fact001096" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million, before deducting underwriting discounts and commissions and other
offering expenses. A.G.P./Alliance Global Partners acted as sole book-running manager for the offering. In addition, Enveric granted
the underwriter a 45-day option to purchase up to an additional <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zq0ZVhdNZHnc" title="Additional shares of common stock purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-132022-02-15_custom_UnderwritersMember" id="Fact001098" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span> shares of common stock and/or warrants to purchase up to an additional
<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zxA8e1kW3047" title="Additional warrants purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-02-15_custom_UnderwritersMember" id="Fact001100" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span> shares of common stock at the public offering price, which the underwriter has partially exercised for warrants to purchase up
to <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zX7UOxhPkFLc" title="Exercised of warrants"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2022-02-132022-02-15_custom_UnderwritersMember" id="Fact001102" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span> shares of common stock. At closing, Enveric received net proceeds from the offering of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zcX0o9TCANtj" title="Net proceeds from offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-02-132022-02-15_custom_UnderwritersMember" id="Fact001104" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.1</ix:nonFraction></span> million, after deducting
underwriting discounts and commissions and estimated offering expenses with $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zwY93X07Ejgd" title="Offering expenses"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2022-02-15_custom_UnderwritersMember" id="Fact001106" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span> million allocated to equity, $<span id="xdx_905_ecustom--WarrantLiability_iI_pn5n6_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zlHQkuaWT4Ck" title="Warrant liability"><ix:nonFraction name="ENVB:WarrantLiability" contextRef="AsOf2022-02-15_custom_UnderwritersMember" id="Fact001108" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.6</ix:nonFraction></span> million to warrant
liability and the remaining $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zNb2KWCaTJi7" title="Warrant expenses"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-02-132022-02-15_custom_UnderwritersMember" id="Fact001110" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million recorded as an expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, the Company entered into a securities purchase agreement (the &#8220;Registered Direct Securities Purchase Agreement&#8221;)
with an institutional investor for the purchase and sale of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zq67jFtpMDv2" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">116,500</ix:nonFraction></span> shares of the Company&#8217;s common stock, pre-funded warrants to
purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zjWAalEsmIM2" title="Purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001114" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">258,500</ix:nonFraction></span> shares of common stock (the &#8220;RD Pre-Funded Warrants&#8221;), and unregistered preferred investment options
(the &#8220;RD Preferred Investment Options&#8221;) to purchase up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_z19ToUBw98Gi" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">375,000</ix:nonFraction></span> shares of common stock (the &#8220;RD Offering&#8221;).
The gross proceeds from the RD Offering were approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zmk1U6vmH2Ck" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>. Subject to certain ownership limitations, the RD Pre-Funded Warrants
became immediately exercisable at an exercise price equal to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zsYLFes8tIh5" title="Share price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001120" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share of common stock. On August 3, 2022, all of the issued
RD Pre-Funded Warrants were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with the RD Offering, the Company entered into a securities purchase agreement (the &#8220;PIPE Securities Purchase Agreement&#8221;)
with institutional investors for the purchase and sale of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zo2AVAUxuI0k" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">116,000</ix:nonFraction></span> shares of common stock, pre-funded warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zjS5ykHZolGe" title="Purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-07-22_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001124" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">509,000</ix:nonFraction></span>
shares of common stock (the &#8220;PIPE Pre-Funded Warrants&#8221;), and preferred investment options (the &#8220;PIPE Preferred Investment
Options&#8221;) to purchase up to <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zdO9qNgWdtvg" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">625,000</ix:nonFraction></span> shares of the common stock in a private placement (the &#8220;PIPE Offering&#8221;). The gross
proceeds from the PIPE Offering were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zcihzISSJtPf" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span>. Subject to certain ownership limitations, the PIPE Pre-Funded Warrants
became immediately exercisable at an exercise price equal to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zaSq53mrSBkh" title="Share price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-22_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001130" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share of common stock. All of the issued PIPE Pre-Funded Warrants
were exercised on various dates prior to August 18, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RD Offering and PIPE Offering closed on July 26, 2022, with aggregate gross proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromOtherEquity_pn6n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zFQmF58p6Dzl" title="Proceeds from RD offerings"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember" id="Fact001132" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">8</ix:nonFraction></span> million. The aggregate net proceeds
from the offerings, after deducting the placement agent fees and other estimated offering expenses, were approximately $<span id="xdx_90D_ecustom--PaymentsOfStockIssuanceCost_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zUK66EqEgCdh" title="Offerings costs"><ix:nonFraction name="ENVB:PaymentsOfStockIssuanceCost" contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember" id="Fact001134" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.1</ix:nonFraction></span> million,
with $<span id="xdx_90F_ecustom--PaymentsOfAllocatedEquity_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_z7bhCebODrmj" title="Payments of allocated equity"><ix:nonFraction name="ENVB:PaymentsOfAllocatedEquity" contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember" id="Fact001136" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.2</ix:nonFraction></span> million allocated to equity, $<span id="xdx_90E_ecustom--PaymentsOfInvestmentOptionLiability_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zSkUFLNUdin9" title="Payments of investment option liability"><ix:nonFraction name="ENVB:PaymentsOfInvestmentOptionLiability" contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember" id="Fact001138" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.3</ix:nonFraction></span> million to investment option liability, and the remaining $<span id="xdx_901_ecustom--PaymentsOfStockIssuanceCostsRecordedExpense_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zmXneHwiVHlh" title="Payments of stock issuance costs recorded expense"><ix:nonFraction name="ENVB:PaymentsOfStockIssuanceCostsRecordedExpense" contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember" id="Fact001140" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million recorded as an expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment
to 2020 Long-Term Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2022, our board of directors (&#8220;Board&#8221;) adopted the First Amendment (the &#8220;Plan Amendment&#8221;) to the Enveric
Biosciences, Inc. 2020 Long-Term Incentive Plan (the &#8220;Incentive Plan&#8221;) to <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220502__20220503_zZJBKbAFKI05" title="Incentive plan description"><ix:nonNumeric contextRef="From2022-05-022022-05-03" id="Fact001142" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">(i) increase the aggregate number of shares available
for the grant of awards by 146,083 shares to a total of 200,000 shares, and (ii) add an &#8220;evergreen&#8221; provision whereby the
number of shares authorized for issuance pursuant to awards under the Incentive Plan will be automatically increased on the first trading
date immediately following the date the Company issues any share of common stock (defined below) to any person or entity, to the extent
necessary so that the number of shares of the Company&#8217;s common stock authorized for issuance under the Incentive Plan will equal
the greater of (x) 200,000 shares, and (y) 15% of the total number of shares of the Company&#8217;s common stock outstanding as of such
issuance date (the &#8220;Evergreen Provision&#8221;). The Plan Amendment was approved by the Company&#8217;s shareholders at a special
meeting of the Company&#8217;s shareholders held on July 14, 2022.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 2, 2023, the shareholders approved the amendments to the 2020 Long-Term Incentive Plan, which was approved by the Board on August
8, 2023 (the &#8220;Amended Incentive Plan&#8221;). The Amended Incentive Plan (i) increased the number of authorized shares reserved
for issuance under the Amended Incentive Plan to a maximum of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231102__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zlmk1poNjGA3" title="Authorized shares reserved"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2023-11-02_custom_TwoThousandTwentyLongTermIncentivePlanMember" id="Fact001144" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span>, subject to adjustment, and (ii) removed the Evergreen Provision
implemented in the Plan Amendment. As of December 31, 2023, the total number of shares available for grant under the Incentive Plan was
<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zwU3zwqNsFga" title="Shares available ofr grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyLongTermIncentivePlanMember" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">107,453</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001148" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8YtSqYx16Ag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity under the Company&#8217;s incentive plan for the years ended December 31, 2023 and 2022 is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zu3hZq6igFI4" style="display: none">SCHEDULE OF STOCK OPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Outstanding at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zlfachWgXyo4" title="Number of Shares, Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" id="Fact001150" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,829</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zBHipcjjafJb" title="Weighted Average Exercise Price, Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" id="Fact001152" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">79.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_z3KUiEblBS32" title="Weighted Average Grant Date Fair Value, Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31" id="Fact001154" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">103.50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zc6QHY3pugra" title="Weighted Average Remaining Contractual Term (years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" id="Fact001156" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.3</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zWsvXq7xXltk" title="Aggregate Intrinsic Value, Outstanding" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31" id="Fact001158" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,333</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zUwzel36BOnk" title="Number of Shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31" id="Fact001160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z5kJ7HfnP6pf" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" id="Fact001162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znh44xkmKi5a" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31" id="Fact001164" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin-top: 0; margin-bottom: 0"><span></span></p>
                                                                          <p style="margin-top: 0; margin-bottom: 0"><span>&#160;</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zMwQE9ty7cd5" title="Number of shares, forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31" id="Fact001166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zODjjvTnFKVd" title="Weighted average exercise price, forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" id="Fact001168" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">175.00</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znQpNtug7kVc" title="Weighted average grant date fair value, forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31" id="Fact001170" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">140.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span>&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_z8a4TyNt1Z85" title="Number of Shares, Outstanding at beginning" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" id="Fact001172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zg98NijbXZh" title="Weighted Average Exercise Price, Outstanding at beginning" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.05</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zIZUyOqQArtj" title="Weighted Average Grant Date Fair Value, Outstanding at beginning" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31" id="Fact001176" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">44.82</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5ShG7pIcpf5" title="Weighted Average Remaining Contractual Term (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" id="Fact001178" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.1</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zfbN7fLAAKpi" title="Number of Shares, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1180">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zvXECFVHHTLj" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231_z4H5Vu8Biz83" title="Number of shares, forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-01to2023-12-31" id="Fact001184" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zV15MinWPaA" title="Weighted average exercise price, forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-12-31" id="Fact001186" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.07</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zMCYL5FZJYyj" title="Weighted average grant date fair value, forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" contextRef="From2023-01-01to2023-12-31" id="Fact001188" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_z0vJtB0G1Poe" title="Number of Shares, Outstanding at end" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact001190" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zTWGbA0Nvv66" title="Weighted Average Exercise Price, Outstanding at end" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001192" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.17</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zUfoA887Azb9" title="Weighted Average Grant Date Fair Value, Outstanding at end" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31" id="Fact001194" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">77.22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_za3lss46TUsl" title="Weighted average remaining contractual term, outstanding balance"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" id="Fact001196" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.4</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231_zN4jPjsgp21g" title="Exercisable shares at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31" id="Fact001198" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,677</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_ziRZaH57gja8" title="Exercisable weighted average price at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001200" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">64.45</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zx8Su3tDvHy7" title="Weighted average grant date fair value, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31" id="Fact001202" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">88.72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z4vf0GnUomE9" title="Weighted average remaining contractual term, exercisable"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" id="Fact001204" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">2.9</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zXYm0PO3CNlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001206" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEutDXJS5oV9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted during the years ended December 31, 2022 were valued using the Black Scholes model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zR9P2uQxAng7" style="display: none">SCHEDULE OF STOCK OPTION ASSUMPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zj6iPtU5AHta" title="Term (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" id="Fact001208" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20221231_zlKRFdSy2ve2" title="Stock price"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" contextRef="AsOf2022-12-31" id="Fact001210" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.07</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231_zX3WUGe0AYX2" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2022-12-31" id="Fact001212" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.07</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z5lvwkDplOW2" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31" id="Fact001214" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_zXidb2KriXN1" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2022-01-012022-12-31" id="Fact001216" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">112.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_za8yif42LrIb" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31" id="Fact001218" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.9</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zSkXtPvxBb04" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above assumptions are determined by the Company as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    price &#8211; Based on closing price of the Company&#8217;s common stock on the date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average risk-free interest rate &#8212; Based on the daily yield curve rates for U.S. Treasury obligations with maturities, which
    correspond to the expected term of the Company&#8217;s stock options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield &#8212; The Company has not paid any dividends on common stock since its inception and does not anticipate paying dividends
    on its common stock in the foreseeable future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility &#8212; Based on the historical volatility of comparable companies in a similar industry.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term &#8212; The Company has had no stock options exercised since inception. The expected option term represents the period that
    stock-based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin (&#8220;SAB&#8221;)
    No. 107, Share-Based Payment, which averages an award&#8217;s weighted-average vesting period and expected term for &#8220;plain
    vanilla&#8221; share options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock based compensation expense, recorded within general and administrative expense, related to stock options for the
years ended December 31, 2023 and 2022 was $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zt08RojEH0Xh" title="General and administrative expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001220" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">156,075</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXVmi6fVuBdb" title="General and administrative expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001222" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">180,042</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za7OVdVnQO29" title="Unamortized stock option expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,774</ix:nonFraction></span> in unamortized stock option expense, which will be recognized over a weighted average period
of <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zN1HXhFc7nl6"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001225" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.00</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recorded $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoynQV9JMUSl" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember" id="Fact001227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWmTrUjkTZp7" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember" id="Fact001229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,363</ix:nonFraction></span>, respectively, in stock-based compensation expense within
general and administrative expense, related to restricted stock awards. There were no RSA grants during the years ended December 31,
2023 and 2022. As of December 31, 2022, there were no unvested RSA shares. As of December 31, 2023, there were no unamortized stock-based
compensation costs related to restricted share awards. During the year ended December 31, 2023 the Company settled the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1bnkYOkliK7" title="Common stock , shares issued restricted stock awards"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember" id="Fact001231" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">708</ix:nonFraction></span> vested and
unissued shares (as of December 31, 2022) for cash of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLFTi9qtv6r6" title="Unissued shares for cash"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember" id="Fact001233" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,250</ix:nonFraction></span>. There are <span id="xdx_900_ecustom--NumberOfVestedAndUnissuedShares_iI_do_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2mtX7G3wVJd" title="Number of vested and unissued shares"><ix:nonFraction name="ENVB:NumberOfVestedAndUnissuedShares" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockMember" id="Fact001235" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> restricted stock awards as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuance
of Restricted Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001237" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zeKrkjRh7dje" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activity in restricted stock units was as follows for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zOnUfbNkVcx6" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average<br/>
 fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Non-vested at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEDhw9y1hxZb" title="Number of shares, Non-vested beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001239" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,013</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaILPTwaljuj" title="Weighted average fair value, Non-vested beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001241" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">126.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zirQtPdDJsZi" title="Number of shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,445</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUYL7MfjSel" title="Weighted average fair value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">33.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxzxsA9U3MM5" title="Number of shares, Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001247" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,772</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoUqJoFo0SPa" title="Weighted average fair value, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001249" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">79.64</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCGHiACcoei3" title="Number of shares, Vested" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,633</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmbvrrJRPdT2" title="Weighted average fair value, Vested" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001253" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">130.55</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Non-vested at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3a70kwxF3V2" title="Number of shares, Non-vested beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001255" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">64,053</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLrYNbURiDu7" title="Weighted average fair value, Non-vested beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001257" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">92.57</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znLFWlg2TGh1" title="Number of shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001259" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">182,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfBGTV22anXd" title="Weighted average fair value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001261" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.73</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2mJgukWkvO9" title="Number of shares, Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001263" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,426</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxHfzIDptRA4" title="Weighted average fair value, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001265" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNyxeKRhEEJ3" title="Number of shares, vested" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001267" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrqPsZk6qtR7" title="Weighted average fair value, Vested" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001269" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.80</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIJwWAqEmkx2" title="Number of shares, non-vested ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001271" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">140,491</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJYYLsJCm9Q8" title="Weighted average fair value, Non-vested ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001273" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.97</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zBLyP5ujOgX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recorded $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaktYeVWKPm1" title="Stock based compensation, expenses"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,994,085</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJPvzY0F5oTg" title="Stock based compensation, expenses"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,416,266</ix:nonFraction></span>, respectively, in stock-based compensation
expense related to restricted stock units, which is a component of both general and administrative and research and development expenses
in the consolidated statement of operations and comprehensive loss. As of December 31, 2023, the Company had unamortized stock-based
compensation costs related to restricted stock units of $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRBdOX0w06He" title="Stock-based compensation, unamortized"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,021,021</ix:nonFraction></span> which will be recognized over a weighted average period of <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyktIo5qhnf1" title="Weighted average period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact001281" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.9</ix:nonNumeric></span> years
and unamortized stock-based costs related to restricted stock units which will be recognized upon achievement of specified milestones.
As of December 31, 2023, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxLDWxSkxrQi" title="Common stock vested restricted stock units"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember" id="Fact001283" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,848</ix:nonFraction></span> restricted stock units are vested without shares of common stock being issued, with all of these shares
due as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001285" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z3ex9jdX7Hgd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s recognition of stock-based compensation for restricted stock units for the following periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zwVhDWsRp68h" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zPQew5K1VjCh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zCbffNV9umPf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense for RSUs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zSOwB6VgYaZd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,085,791</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,389,359</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfdu3M9qPMBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">908,294</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,026,907</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zcduJChWGdHc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-12-31" id="Fact001293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,994,085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31" id="Fact001294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,416,266</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_zgOmbiRFAoQe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock-based compensation expense for RSUs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-12-31" id="Fact001296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,994,085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31" id="Fact001297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,416,266</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A3_zs23cTYn7Nd8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants
and Preferred Investment Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001299" name="ENVB:ScheduleOfWarrantsOutstandingTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zCwAZnLGDADf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about shares issuable under warrants outstanding at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_z8ZFdYdYVEvf" style="display: none">SCHEDULE
OF WARRANTS OUTSTANDING</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrant shares outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTfdpCfJmiBi" title="Warrant shares outstanding at beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="Fact001301" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">195,463</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3fi1daRxsLi" title="Weighted average exercise Price, Outstanding at beginning" style="width: 11%; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="Fact001303" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">131.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z54Yv7nvu7W9" title="Weighted average remaining life, Outstanding"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001305" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">3.4</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVKnQZX3WT3" title="Intrinsic Value, Outstanding beginning" style="width: 11%; text-align: right"><ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="Fact001307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">801,024</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoHdcQoSVWS2" title="Warrant shares outstanding, Issued" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,227,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq4CkgY3nmbb" title="Weighted average exercise price, Issued" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001311" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoCiirvRQcd1" title="Warrant shares outstanding, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001313" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">767,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchanged for common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPYXssDy289d" title="Exchanged for common stock" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1315">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziP88dUalGL3" title="Warrant shares outstanding at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact001317" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">655,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgN4PA0LOL52" title="Weighted average exercise Price, Outstanding at beginning" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact001319" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">58.36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNat7GYdCief" title="Weighted average remaining life, Outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001321" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">3.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zif7UujrkK8h" title="Intrinsic Value, Outstanding beginning" style="text-align: right"><ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact001323" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,514</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF9wfK13hB3a" title="Warrant shares outstanding, Issued" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,311,320</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzzaBhPs6fcj" title="Weighted average exercise price, Issued" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001327" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFg4HAtR0Uo3" title="Warrant shares outstanding, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">122,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjBdEmkvsgQ3" title="Weighted average exercise price, Exercised" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001331" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWsO7MCiRq3g" title="Warrant shares outstanding, Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001333" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,570</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0n5xO3Jttvj" title="Weighted average exercise price, Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001335" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">111.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG0zfcvh1EB" title="Warrant shares outstanding at end" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,799,213</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVykSWQShf2c" title="Weighted average exercise Price, Outstanding at end" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact001339" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.79</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo234JlDnvN9" title="Weighted average remaining life, Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001341" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">4.6</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TQKNs9s47l" title="Warrant shares outstanding, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact001343" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,799,213</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxF5xDyqxuv9" title="Weighted average exercise price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact001345" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.79</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziBL756oG0Sj" title="Weighted average remaining life, Exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001347" name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption">4.6</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znZZJLvwpd7" title="Intrinsic Value, Outstanding end" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1349">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A4_zPsrElVeMZDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 11, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;)
with A.G.P./Alliance Global Partners (the &#8220;Underwriter&#8221;). Pursuant to the Underwriting Agreement, the Company agreed to sell,
in a firm commitment offering, <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220210__20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBeMIQlREhB9" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-02-102022-02-11_us-gaap_CommonStockMember" id="Fact001351" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></span> shares of the Company&#8217;s common stock and accompanying warrants to purchase up to an aggregate
of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwRjsuVzK6ll" title="Warrant exercises, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-02-11_us-gaap_WarrantMember" id="Fact001353" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></span> shares of its common stock (&#8220;February 2022 Warrants&#8221;), as well as up to <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220210__20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4yI7NRdWlc6" title="Additional shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-102022-02-11_us-gaap_CommonStockMember" id="Fact001355" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span> additional shares of common stock
and/or warrants to purchase an aggregate of up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zCnVO8Hipssf" title="Warrant exercises, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-02-11_us-gaap_CommonStockMember_srt_MaximumMember" id="Fact001357" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span> shares of its common stock that may be purchased by the Underwriter pursuant
to a 45-day option granted to the Underwriter by the Company (the &#8220;Offering&#8221;). Each share of common stock was sold together
with a common warrant to purchase one share of common stock, at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt7SQbdnlyZ9" title="Warrant, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-02-11_us-gaap_CommonStockMember" id="Fact001359" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.50</ix:nonFraction></span> per share. Such common warrants were immediately
exercisable and will expire five years from the date of issuance. There is not expected to be any trading market for the common warrants
issued in the Offering. The combined public offering price of each share of common stock and accompanying common warrant sold in the Offering
was $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUsxAEI45Quk" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-02-11_us-gaap_WarrantMember" id="Fact001361" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.00</ix:nonFraction></span>. On February 14, 2022, the Underwriter exercised its option to purchase an additional <span id="xdx_905_ecustom--ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_iI_c20220214__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5i9uo6XMQy" title="Purchase of additional warrants"><ix:nonFraction name="ENVB:ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-02-14_us-gaap_WarrantMember" id="Fact001363" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span> warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Registered Direct (&#8220;RD&#8221;) Offering and the Private Investment in Public Entity (&#8220;PIPE&#8221;) Offering
entered into on July 22, 2022, the Company entered into Warrant Amendment (the &#8220;Warrant Amendments&#8221;) with the investors in
both offerings to amend certain existing warrants to purchase up to an aggregate of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220722__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zBOpNG8waIyk" title="Purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-07-22_custom_WarrantAmendmentAgreementsMember" id="Fact001365" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">122,000</ix:nonFraction></span> shares of common stock that were previously
issued to the investors, with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220714__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zphVdaVhW65b" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-14_custom_WarrantAmendmentAgreementsMember" id="Fact001367" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.50</ix:nonFraction></span> per share (subsequent to the 1-for-50 reverse stock split that occurred on
July 14, 2022) and expiration date of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220714__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zgyCnvlpoemb" title="Warrant expiration"><ix:nonNumeric contextRef="AsOf2022-07-14_custom_WarrantAmendmentAgreementsMember" format="ixt:datemonthdayyearen" id="Fact001369" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">February 15, 2027</ix:nonNumeric></span>. Pursuant to the Warrant Amendments, the previously issued warrants were amended,
effective upon the closing of the offerings, so that the amended warrants have a reduced exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220722__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_znAWYBaoUBq9" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-22_custom_WarrantAmendmentAgreementsMember" id="Fact001371" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.78</ix:nonFraction></span> per share and expire
five and one-half years following the closing of the offerings. In connection with this transaction, the Company determined the fair
value of the February 2022 Warrants immediately prior to the Warrant Amendment and the fair value of the amended warrants immediately
after the Warrant Amendment. For the year ended December 31, 2022, the incremental change in fair value was deemed to be $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zSNM3dV6YnM1" title="Offerings costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-012022-12-31_custom_RDOfferingAndPIPEInvestmentOptionsMember" id="Fact001373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,357</ix:nonFraction></span>, which was included as equity issuance costs
related to the RD and PIPE financing transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants assumed pursuant to the acquisition of MagicMed contain certain down round features, which were not triggered by the February
2022 and July 2022 public offerings, that would require adjustment to the exercise price upon certain events when the offering price
is less than the stated exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001375" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z00XmdXvzoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about investment options outstanding at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B7_zXmcUZK6ggX1" style="display: none">SCHEDULE
OF WARRANTS  AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Investment options outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zEwvcLEoJfDe" title="Investment options Outstanding, beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1377">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zxaDKk1asuL5" title="Weighted average exercise price, Outstanding beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1379">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zlJw8znfo0I4" title="Intrinsic value, Outstanding beginning" style="text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1381">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; padding-bottom: 1.5pt">Issued</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zDF48VFSv1A7" title="Investment options outstanding, Issued" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" contextRef="From2022-01-012022-12-31_custom_InvestmentOptionsMember" id="Fact001383" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,070,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVx10hGW7qx2" title="Weighted average exercise price, Issued" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" contextRef="From2022-01-012022-12-31_custom_InvestmentOptionsMember" id="Fact001385" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.93</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zqwHo3jONiyh" title="Investment options outstanding, beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_InvestmentOptionsMember" id="Fact001387" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,070,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVu0eC11XHn7" title="Weighted average exercise price, Outstanding beginning" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2022-12-31_custom_InvestmentOptionsMember" id="Fact001389" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7cYhlQli82i" title="Weighted average remaining life, Outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_InvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001391" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">5.1</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zW78kJ5dKbha" title="Intrinsic value, Outstanding beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1393">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLWd0NriqTJ9" title="Investment options outstanding, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember" id="Fact001395" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zJbc1b45aUy4" title="Weighted average exercise price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember" id="Fact001397" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.37</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z1lexvtMAU48" title="Investment options outstanding, end" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="Fact001399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z64Vkjb4vBD2" title="Weighted average exercise price, Outstanding end" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="Fact001401" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zo3u42JYc9hg" title="Weighted average remaining life, Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001403" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">4.1</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLfLYOEFU04b" title="Intrinsic value, Outstanding end" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1405">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zSZT9LEs53K1" title="Investment options outstanding, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="Fact001407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zaDEqPn9Z6kf" title="Weighted average exercise price, Outstanding end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="Fact001409" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zyrHBnlcTyT6" title="Weighted average remaining life, Exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001411" name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption">4.1</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zhirJurCktSd" title="Intrinsic value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1413">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zN7RQXnULVth" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Registered Direct Securities Purchase Agreement the Company issued unregistered preferred investment options to purchase
up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zZV69Zq59PW2" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001415" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">375,000</ix:nonFraction></span> shares of common stock. Subject to certain ownership limitations, the RD Preferred Investment Options became immediately
exercisable at an exercise price equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zntitPn12CAh" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001417" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.78</ix:nonFraction></span> per share of common stock. The RD Preferred Investment Options are exercisable for five
and one-half years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the PIPE Securities Purchase Agreement the Company issued unregistered preferred investment options to purchase up to
<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zLjlPihd61Y1" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001419" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">625,000</ix:nonFraction></span> shares of the common stock. Subject to certain ownership limitations, PIPE Preferred Investment Options became immediately exercisable
at an exercise price equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zOI44kWNylt2" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001421" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.78</ix:nonFraction></span> per share of common stock. The PIPE Preferred Investment Options are exercisable for five and one-half
years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2022, in connection with the RD Offering and PIPE Offering, the Company issued preferred investment options (the &#8220;Placement
Agent Preferred Investment Options&#8221;) to an entity to purchase up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220725__20220726__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_z4HuoSUpk0bk" title="Purchase of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-252022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember" id="Fact001423" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,000</ix:nonFraction></span> shares of the common stock for acting as a placement
agent. The Placement Agent Preferred Investment Options have substantially the same terms as the RD Preferred Investment Options and
the PIPE Preferred Investments Options, except the Placement Agent Preferred Investment Options have an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220726__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_zZKCojjEaSb2" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember" id="Fact001425" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per
share. The Placement Agent Preferred Investment Options are exercisable for five years from the date of the commencement of the RD Offering
and PIPE Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#8220;Inducement Letters&#8221;) with
certain holders (the &#8220;Holders&#8221;) of the February 2022 Post-Modification Warrants and RD and PIPE preferred investment
options to purchase shares of the Company&#8217;s common stock (the &#8220;Existing Warrants and Investment Options&#8221;) pursuant
to which the Holders agreed to exercise for cash their Existing Warrants and Investment Options to purchase <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_z8kGZoMo5WF2" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember" id="Fact001427" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,122,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock, in the aggregate, at a reduced exercised price of $<span id="xdx_90B_eus-gaap--WarrantExercisePriceDecrease_pid_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MinimumMember_zmre4xpOatuj" title="Share price"><ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember_srt_MinimumMember" id="Fact001429" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.37</ix:nonFraction></span>
per share (from an original exercise price of $<span id="xdx_903_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MaximumMember_zHGTrhQQ6C24" title="Share price"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2023-01-012023-12-31_custom_FebruaryWarrantsMember_srt_MaximumMember" id="Fact001431" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.78</ix:nonFraction></span>
per share), in exchange for the Company&#8217;s agreement to issue new warrants (the &#8220;Inducement Warrants&#8221;) to purchase
up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zZZklwjzMRFc" title="Issued shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-12-28_custom_FebruaryWarrantsMember" id="Fact001433" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,244,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock (the &#8220;Inducement Warrant Shares&#8221;), and the Holders to make a cash payment of
$<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zLm5mALpc9N2" title="Cash payment"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-28_custom_FebruaryWarrantsMember" id="Fact001435" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.125</ix:nonFraction></span>
per Inducement Warrant share for total proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zD00dqXJGv56" title="Proceeds from inducement warrant"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember" id="Fact001437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,500</ix:nonFraction></span>. In January 2024, the Company received aggregate gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGk6Yg4XAvBi" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-01-31_us-gaap_SubsequentEventMember" id="Fact001439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,817,640</ix:nonFraction></span>
from the exercise of the Existing Warrants and Investment Options by the Holders and the sale of the Inducement Warrants. Because
the Existing Warrants and Investment Options by the Holders and the sale of the Inducement Warrants that exercised on December 28,
2023 and unsettled until January 2024, the proceeds are included in the consolidated balance sheet as a subscription receivable as
of December 31, 2023. As of December 31, 2023, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOGsXVkNBqP9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001440" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">418,000</ix:nonFraction></span>
shares of the Existing Warrants and Investment Options exercised were considered issued as the Company had the enforceable right to
the obtain the cash proceeds, which were in-transit, and the Holders were no longer able to rescind the exercise election. Due to
the beneficial ownership limitation provisions, <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zhAJrEorEKnf" title="Issued shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-12-31_custom_FebruaryWarrantsMember" id="Fact001442" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">704,000</ix:nonFraction></span>
shares of the Existing Warrants and Investment Options exercised were initially unissued and held in abeyance for the benefit of the
Holder until notice is received from the Holder that the shares may be issued in compliance with such limitation. <span id="xdx_903_ecustom--ClassOfWarrantOrRightReasonForIssuing_c20230101__20231231_zwnPNtnbyEcl" title="Warrant issued description"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact001444" name="ENVB:ClassOfWarrantOrRightReasonForIssuing">The
Company engaged Roth Capital Partners, LLC (&#8220;Roth&#8221;) to act as its financial advisor in connection with the transactions
summarized above and will pay Roth approximately $144,000 for its services, in addition to reimbursement for certain expenses. Roth
was also issued warrants to purchase up to 67,320 shares of common stock. The Roth Warrants have the same terms as the Inducement
Warrants. The grant date fair value of these Roth Warrants was estimated to be $77,991 on December 28, 2023 and were charged to
additional paid in capital as issuance costs. The Company also incurred legal fees of $17,254 related to the transactions above that
were charged to additional paid in capital as issuance costs.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also agreed to file a registration statement on Form S-3 covering the resale of the Inducement Warrant Shares issued or issuable
upon the exercise of the Inducement Warrants (the &#8220;Resale Registration Statement&#8221;) by January 8, 2024 (filed January 11,
2024). In the Inducement Letters, the Company agreed not to issue any shares of common stock or common stock equivalents or to file any
other registration statement with the SEC (in each case, subject to certain exceptions) for a period ending on February 26, 2024. The
Company also agreed not to effect or agree to effect any variable rate transaction (as defined in the Inducement Letters) until December
28, 2024. See the <i>Equity Distribution Agreement</i> section of this Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company determined the fair value of the Existing Warrants and Investment Options immediately
prior to the Inducement Letters and the fair value of the amended warrants and investment options immediately after the Inducement
Letters. The pre-modification measurement of fair value of the Existing Warrants and Investment Options were determined utilizing a
Black-Scholes model considering all relevant assumptions current at the date of modification (i.e. for the Existing Warrants share
price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_z4IjDXLBbkR3" title="Warrants share price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember" id="Fact001446" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.56</ix:nonFraction></span>,
exercise price of $<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zXyDya2udmf7" title="Exercise price"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember" id="Fact001448" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.78</ix:nonFraction></span>,
term of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_z18G9NhjUGR9" title="Term (years)"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember" format="ixt-sec:duryear" id="Fact001450" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.6</ix:nonNumeric></span>
years, volatility of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zAwHYm59mTXh" title="Warrants outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputOptionVolatilityMember_custom_PreModificationWarrantsMember" id="Fact001452" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">94</ix:nonFraction></span>%,
risk-free rate of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zm3bbvuCJqC7" title="Warrants outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PreModificationWarrantsMember" id="Fact001454" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.96</ix:nonFraction></span>%,
and expected dividend rate of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zl0yVDmgmajc" title="Warrants outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PreModificationWarrantsMember" id="Fact001456" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%,
resulting in a fair value per share of $<span id="xdx_904_eus-gaap--SharePrice_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zhUcl0TXRUT1" title="Warrants outstanding, per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember" id="Fact001458" decimals="INF" unitRef="USDPShares">.54</ix:nonFraction></span> and for the Investment Options share price of $<span id="xdx_90D_ecustom--InvestmentOptionSharePrice_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zGpacZ3BNDs9" title="Share price"><ix:nonFraction name="ENVB:InvestmentOptionSharePrice" contextRef="From2023-01-012023-12-31_custom_PreModificationWarrantsMember" id="Fact001460" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1.56</ix:nonFraction></span>,
exercise price of $<span id="xdx_907_ecustom--InvestmentOptionExercisePrice_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zKnYAoUxhJdj" title="Exercise price"><ix:nonFraction name="ENVB:InvestmentOptionExercisePrice" contextRef="From2023-01-012023-12-31_custom_PreModificationWarrantsMember" id="Fact001462" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.78</ix:nonFraction></span>,
term of <span id="xdx_903_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zhEXHdObGO13" title="Term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_PreModificationWarrantsMember" format="ixt-sec:duryear" id="Fact001464" name="ENVB:InvestmentOptionTerm">4.1</ix:nonNumeric></span> years,
volatility of <span id="xdx_907_ecustom--InvestmentOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zYBQ1dLbufLc" title="Investment outstanding, measurement input"><ix:nonFraction name="ENVB:InvestmentOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputOptionVolatilityMember_custom_PreModificationWarrantsMember" id="Fact001466" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">95</ix:nonFraction></span>%,
risk-free rate of <span id="xdx_90F_ecustom--InvestmentOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zntwM6yIYi33" title="Investment outstanding, measurement input"><ix:nonFraction name="ENVB:InvestmentOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PreModificationWarrantsMember" id="Fact001468" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.90</ix:nonFraction></span>%,
and expected dividend rate of <span id="xdx_90A_ecustom--InvestmentOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zmwuConmHkW8" title="Investment outstanding, measurement input"><ix:nonFraction name="ENVB:InvestmentOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PreModificationWarrantsMember" id="Fact001470" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%,
resulting in a fair value per share of $<span id="xdx_90A_ecustom--SharePriceOption_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zrnS9PJeicn5" title="Investment outstanding, per share"><ix:nonFraction name="ENVB:SharePriceOption" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember" id="Fact001472" decimals="INF" unitRef="USDPShares">.62</ix:nonFraction></span>). The total fair value of the <span id="xdx_907_eus-gaap--SharesOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_z0BA93tLj2hc" title="Shares outstanding"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_ExistingWarrantsMember" id="Fact001474" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">122,000</ix:nonFraction></span> Existing Warrants and <span id="xdx_909_eus-gaap--SharesOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_ztD05TA6sohg" title="Shares outstanding"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_InvestmentOptionsMember" id="Fact001476" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> Investment Options
was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zVhEgu2qiBfh" title="Intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_ExistingWarrantsMember" id="Fact001478" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">65,349</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_z5MR6FWFETJg" title="Intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_InvestmentOptionsMember" id="Fact001480" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">618,648</ix:nonFraction></span>, respectively. The post-modification fair value was determined using the intrinsic value of $<span id="xdx_909_ecustom--InvestmentIntrinsicValue_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember_zMYFJxOt02R5" title="Intrinsic value"><ix:nonFraction name="ENVB:InvestmentIntrinsicValue" contextRef="From2023-01-012023-12-31_custom_PostModificationWarrantsMember" id="Fact001482" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.19</ix:nonFraction></span>
due to the inducement and totaled $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zo6q6Crb4fEc" title="Intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_ExistingWarrantsMember" id="Fact001484" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">23,180</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_zUN1EbSFyMVk" title="Intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_InvestmentOptionsMember" id="Fact001486" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">190,000</ix:nonFraction></span> for the Existing Warrants and Investment Options, respectively. The change in fair value from the date of the modification prior to modification and the fair value on the
date of the modification after the modification, but prior to exercise was $<span id="xdx_903_ecustom--InvestmentInducementGain_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember_zYGxYB7iir1f" title="Inducement gain"><ix:nonFraction name="ENVB:InvestmentInducementGain" contextRef="From2023-01-012023-12-31_custom_PostModificationWarrantsMember" id="Fact001488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">470,817</ix:nonFraction></span>,
which was reflected as an inducement gain, within other expenses on the Company&#8217;s consolidated statement of operations and
comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant date fair value of these Inducement Warrants was estimated to be $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20231228__20231228_z2x1EoMCFBJl"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-12-282023-12-28" id="Fact001489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,599,552</ix:nonFraction></span> on December 28, 2023 and the proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231228__20231228_zJIFuTKtruIl"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-12-282023-12-28" id="Fact001490" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,500</ix:nonFraction></span>,
which were received on January 2, 2024, for the issuance of the Inducement Warrants is reflected as inducement expense, within other
expenses on the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001492" name="ENVB:ScheduleOfValuationOfWarrantsTextBlock"><p id="xdx_893_ecustom--ScheduleOfValuationOfWarrantsTextBlock_zjlfMoR7FOl7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its equity classified Inducement Warrants at the date of issuance on December 28, 2023.
The Company used a Black Scholes valuation model in order to determine their value. The key inputs into the Black Scholes valuation model
for the valuation of the warrants are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zy2L3wh6IEsj" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Roth and Inducement Warrants</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 28, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z52K9qwfKrY6" title="Term (years)"><ix:nonNumeric contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember" format="ixt-sec:duryear" id="Fact001494" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zvpHkwU31FQ6" title="Stock price"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001496" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.56</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zm3vVfJEgZJb" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001498" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.37</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zdaTE0h352rg" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001500" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zZ8qJnxEV6V3" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001502" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">92.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z72dh5NNsTw" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001504" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.80</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zMzy9I7TxUTl" title="Warrants, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001506" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,311,320</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zBRgEViXl0za" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001508" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.16</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zXHJwPy7aNrd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
C Preferred Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2022, the Board of Directors (the &#8220;Board&#8221;) declared a dividend of one one-thousandth of a share of the Company&#8217;s
Series C Preferred Stock (&#8220;Series C Preferred Stock&#8221;) for each outstanding share of the Company&#8217;s common stock held of record as of 5:00 p.m. Eastern Time on May 13, 2022 (the &#8220;Record Date&#8221;). This dividend
was based on the number of outstanding shares of common stock prior to the Reverse Stock Split. The outstanding shares of Series C Preferred
Stock were entitled to vote together with the outstanding shares of the Company&#8217;s common stock, as a single class, exclusively
with respect to a proposal giving the Board the authority, as it determines appropriate, to implement a reverse stock split within twelve
months following the approval of such proposal by the Company&#8217;s stockholders (the &#8220;Reverse Stock Split Proposal&#8221;),
as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split Proposal (the
&#8220;Adjournment Proposal&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company held a special meeting of stockholders on July 14, 2022 (the &#8220;Special Meeting&#8221;) for the purpose of voting on, among
other proposals, a Reverse Stock Split Proposal and an Adjournment Proposal. All shares of Series C Preferred Stock that were not present
in person or by proxy at the Special Meeting were automatically redeemed by the Company immediately prior to the opening of the polls
at Special Meeting (the &#8220;Initial Redemption&#8221;). All shares that were not redeemed pursuant to the Initial Redemption were
redeemed automatically upon the approval by the Company&#8217;s stockholders of the Reverse Stock Split Proposal at the Special Meeting
(the &#8220;Subsequent Redemption&#8221; and, together with the Initial Redemption, the &#8220;Redemption&#8221;). <span id="xdx_904_eus-gaap--PreferredStockVotingRights_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z5dqYDZjASmi" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2022-07-132022-07-14_us-gaap_SeriesCPreferredStockMember" id="Fact001510" name="us-gaap:PreferredStockVotingRights">Each share of Series
C Preferred Stock was entitled to receive $0.10 in cash for each 10 whole shares of Series C Preferred Stock immediately prior to the
Redemption. As of June 30, 2022, there were</ix:nonNumeric></span> <span id="xdx_904_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zdUuJvhOW6s9" title="Redeemable preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2022-07-14_us-gaap_SeriesCPreferredStockMember" id="Fact001512" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,684.548</ix:nonFraction></span> shares of Series C Preferred Stock issued and outstanding. As of December 31,
2022, both the Initial Redemption and the Subsequent Redemption had occurred. As a result, no shares of Series C Preferred Stock remain
outstanding. As of December 31, 2023 and 2022, there are <span id="xdx_90E_eus-gaap--PreferredStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zjdiSzO1vp5b" title="Preferred Stock authorized for future issuances"><ix:nonFraction name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001514" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of Series C Preferred Stock authorized for future issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001516" name="ENVB:RedeemableNonControllingInterestTextBlock"><p id="xdx_80C_ecustom--RedeemableNonControllingInterestTextBlock_zi5Q4GzDPrpf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. <span id="xdx_820_zpC01KA801s3">REDEEMABLE NON-CONTROLLING INTEREST</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Spin-Off
and Related Private Placement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Spin-Off, on May 5, 2022, Akos and the Company entered into into a Securities Purchase Agreement (the &#8220;Akos
Purchase Agreement&#8221;) with an accredited investor (the &#8220;Akos Investor&#8221;), pursuant to which Akos agreed to sell up to
an aggregate of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zb3OhmPCrJOj" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact001518" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span> shares of Akos Series A Preferred Stock, at price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zkAv4iFGwlvc" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact001520" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span> per share, and warrants (the &#8220;Akos Warrants&#8221;)
to purchase shares of Akos&#8217; common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_ziqdyNm1proh" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember" id="Fact001522" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share (the &#8220;Akos Common Stock&#8221;), for an aggregate purchase
price of up to $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zewKu8BntBy9" title="Sale of stock, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_srt_MaximumMember" id="Fact001524" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> (the &#8220;Akos Private Placement&#8221;). The Akos Purchase Agreement was guaranteed by the Company. Pursuant
to the Akos Purchase Agreement, Akos issued <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zG8bfr259E7" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember" id="Fact001526" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></span> shares of the Akos Series A Preferred Stock to the Akos Investor in exchange for $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7nhFd17DNtk" title="Sale of stock, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember" id="Fact001528" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></span>
on May 5, 2022. The additional $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zxgML5QugCI7" title="Sale of stock, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember" id="Fact001530" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000,000</ix:nonFraction></span> was to be received on or immediately prior to the Spin-Off. The issuance of the Akos Series
A Preferred Stock results in RNCI (see Note 2). Palladium Capital Advisors, LLC (&#8220;Palladium&#8221;) acted as placement agent for
the Akos Private Placement. <span id="xdx_90F_ecustom--SpinoffAndRelatedPrivatePlacementDescription_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zdbaTOlv0Foh" title="Spin-off and related private placement, description"><ix:nonNumeric contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember" id="Fact001532" name="ENVB:SpinoffAndRelatedPrivatePlacementDescription">Pursuant to the Akos Purchase Agreement, Akos had agreed to pay Palladium a fee equal to 9% of the aggregate
gross proceeds raised from the sale of the shares of the Akos Series A Preferred Stock and a non-accountable expense allowance of 1%
of the aggregate gross proceeds raised the sale of the Akos Series A Preferred Stock in the Akos Private Placement. The fee due in connection
with the Akos Private Placement to be paid to Palladium in the form of convertible preferred stock and warrants was on similar terms
to the securities issued in the Akos Private Placement.</ix:nonNumeric></span> Palladium was also entitled to warrants to purchase Akos Common Stock in an amount
up to <span id="xdx_908_ecustom--WarrantsToPurchaseCommonStockPercentage_pid_dp_uPure_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_z1kHLnr5gR2h" title="Warrants to purchase common stock, percentage"><ix:nonFraction name="ENVB:WarrantsToPurchaseCommonStockPercentage" contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember" id="Fact001534" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% of the number of shares of Akos Common Stock underlying the shares issuable upon conversion of the Akos Series A Preferred Stock.
As of December 31, 2023, no accruals are required to be recorded for the fees or warrants since the Akos Series A Preferred Stock has
been redeemed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Terms
of Akos Series A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Certificate of the Designations, Preferences, and Rights of Series A Convertible Preferred Stock of Akos (the &#8220;Akos Series
A Preferred Certificate of Designations&#8221;), on or immediately prior to the completion of the spin-off of Akos into an independent,
separately traded public company listed on the Nasdaq Stock Market, the outstanding Akos Series A Preferred Stock automatically converted
into a number of shares of Akos Common Stock equal to <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AkosMember_zptxw7wnlvwj" title="Percentage of stock issued and outstanding"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember" id="Fact001536" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% of the then issued and outstanding Akos Common Stock, subject to the Beneficial
Ownership Limitation (as defined in the Akos Purchase Agreement). Cumulative dividends on each share of Akos Series A Preferred Stock
accrue at the rate of <span id="xdx_900_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AkosMember_zqfJDBLNLuU3" title="Dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2022-05-042022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember" id="Fact001538" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Akos Series A Preferred Certificate of Designations provided that upon the earlier of (i) the one-year anniversary of May 5, 2022, and
only in the event that the Spin-Off has not occurred; or (ii) such time that Akos and the Company have abandoned the Spin-Off or the
Company is no longer pursuing the Spin-Off in good faith, the holders of the Akos Series A Preferred Stock shall have the right (the
&#8220;Put Right&#8221;), but not the obligation, to cause Akos to purchase all or a portion of the Akos Series A Preferred Stock for
a purchase price equal to $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znidGcp5SmHb" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember" id="Fact001540" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span> per share, subject to certain adjustments as set forth in the Akos Series A Preferred Certificate of
Designations (the &#8220;Stated Value&#8221;), plus all the accrued but unpaid dividends per share. In addition, after the one-year anniversary
of May 5, 2022, and only in the event that the Spin-Off has not occurred and Akos is not in material default of any of the transaction
documents, Akos may, at its option, at any time and from time to time, redeem the outstanding shares of Akos Series A Preferred Stock,
in whole or in part, for a purchase price equal to the aggregate Stated Value of the shares of Akos Series A Preferred Stock being redeemed
and the accrued and unpaid dividends on such shares. Pursuant to the Akos Purchase Agreement, the Company has guaranteed the payment
of the purchase price for the shares purchased under the Put Right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Akos Series A Preferred Certificate of Designations contains limitations that prevent the holder thereof from acquiring shares of Akos
Common Stock upon conversion of the Akos Series A Preferred Stock that would result in the number of shares of Akos Common Stock beneficially
owned by such holder and its affiliates exceeding 9.99% of the total number of shares of Akos Common Stock outstanding immediately after
giving effect to the conversion (the &#8220;Beneficial Ownership Limitation&#8221;), except that upon notice from the holder to Akos,
the holder may increase or decrease the limit of the amount of ownership of outstanding shares of Akos Common Stock after converting
the holder&#8217;s shares of Akos Series A Preferred Stock, provided that any change in the Beneficial Ownership Limitation shall not
be effective until 61 days following notice to Akos.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Redemption
of Akos Series A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right requiring Akos to force redemption of all of the Akos Series A Preferred Stock for $<span id="xdx_900_eus-gaap--DividendsPayableAmountPerShare_iI_pid_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztQh1TbMgLA2" title="Dividends, per share"><ix:nonFraction name="us-gaap:DividendsPayableAmountPerShare" contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember" id="Fact001542" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span>&#8239;per share, plus accrued
but unpaid dividends of approximately $<span id="xdx_905_ecustom--UnpaidDividends_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbljvP6uynA2" title="Unpaid dividends"><ix:nonFraction name="ENVB:UnpaidDividends" contextRef="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember" id="Fact001544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,000</ix:nonFraction></span>&#8239;for a total of approximately $<span id="xdx_901_eus-gaap--DividendsPreferredStock_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdtM4nK5oH7j" title="Dividends"><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember" id="Fact001546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,000</ix:nonFraction></span>. The Company had 20 days following the receipt
of the Put Exercise Notice to make the payment and made payment on May 19, 2023. Upon redemption in May 2023, the Company revalued the
derivative liability and the Company recognized a change in fair value of the derivative liability on the Company&#8217;s consolidated
statement of operations during the second quarter of 2023 of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20230630_zmKTPInuh3Li" title="Change in fair value of derivative liability"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-06-30" id="Fact001548" format="ixt:numdotdecimal" decimals="0" unitRef="USD">714,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, Akos, and the Akos Investor have terminated the Akos Purchase Agreement in connection with the planned Spin-Off and certain
registration rights agreement in connection with the Akos Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
for Akos Series A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the shares of Akos Series A Preferred Stock were redeemable at the option of the holder and the redemption is not solely in the control
of the Company, the shares of Akos Series A Preferred Stock were accounted for as a redeemable non-controlling interest and classified
within mezzanine equity in the Company&#8217;s consolidated balance sheets. The redeemable non-controlling interest was initially measured
at fair value. Dividends on the shares of Akos Series A Preferred Stock were recognized as preferred dividends attributable to redeemable
non-controlling interest in the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001550" name="us-gaap:TemporaryEquityTableTextBlock"><p id="xdx_897_eus-gaap--TemporaryEquityTableTextBlock_zpIqAAdWohPh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the reconciliation of changes in redeemable non-controlling interest:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zjoodKpMYtk6" style="display: none">SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_c20230101__20231231_z2KtOijK4HZ5" title="Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="AsOf2022-12-31" id="Fact001552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred dividends attributable to redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zjwjD9FtrCoi" title="Issuance of redeemable noncontrolling Series C preferred stock" style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-01to2023-12-31" id="Fact001554" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accretion of embedded derivative and transaction costs associated with Akos Series A Preferred Stock to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zVgFPFbJN1yh" title="Accretion of embedded derivative to redemption value" style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="From2023-01-01to2023-12-31" id="Fact001556" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,988</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Redemption of Akos Series A Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_iN_di_c20230101__20231231_z61deouwmhW3" title="Redemption of Akos Series A Preferred Stock" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock" contextRef="From2023-01-01to2023-12-31" id="Fact001558" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,057</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_c20230101__20231231_z2cCqG7L0c62" title="Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1560">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z5hvmzlTgjq6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Akos Series A Preferred Stock was redeemed for a total of <span id="xdx_90B_ecustom--RedeemableNoncontrollingInterest_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfzod7fCUkea" title="Redeemable noncontrolling interest"><ix:nonFraction name="ENVB:RedeemableNoncontrollingInterest" contextRef="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember" id="Fact001562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,057</ix:nonFraction></span>, and the balance of the redeemable non-controlling
interest is $<span id="xdx_902_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iI_dxL_c20231231_zAeOWuDFnGDk" title="Redeemable non-controlling interest::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1564">0</span></span> as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001566" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zzc4DQdOVCk6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_82E_zsrUTbzuipf3">FAIR VALUE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001568" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z7nYIEKnfDSb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides the financial liabilities measured on a recurring basis and reported at fair value on the balance sheet as of
December 31, 2023 and 2022, and indicates the fair value of the valuation inputs the Company utilized to determine such fair value of
warrant liabilities, derivative liability, and investment options:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_zv5Cq3TrTwbh" style="display: none">SCHEDULE
OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zwa6pMcie7mj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_ztyBGagJWl2d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zluQ4KiXC6C8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Warrant liabilities - January 2021 Warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001571" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zbxFjRea6mu7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrant liabilities - February 2021 Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001574" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdwlc80Umupj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrant liabilities - February 2022 Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zsQK5dRZG5R2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of warrant liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001579" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001580" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,215</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zBIbM8e99NVb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_z7y8UeEVWOR7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zqJ0MJeu0Ymi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; padding-bottom: 1.5pt">Derivative liability - May 2022</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 10%; text-align: center">3</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1582">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember" id="Fact001583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zR1tqPhaDMu9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of derivative liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1585">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231_z7T84h3p4yAc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zY86vTWnoNeh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_znMNJ66bvtl9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Wainwright investment options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember" id="Fact001588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,608</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember" id="Fact001589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,904</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zeZJIMkg8nk6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">RD investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1591">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember" id="Fact001592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">302,289</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zOFVpVS8Jrzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">PIPE investment options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1594">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember" id="Fact001595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">503,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdfcDlytmmXj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of investment option liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,608</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">851,008</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zlaHAKR4Y6A2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liabilities, derivative liability, and investment options are all classified as Level 3, for which there is no current market
for these securities such as the determination of fair value requires significant judgment or estimation. Changes in fair value measurement
categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded
within other income (expense) on the consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Initial
measurement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_InitialMeasurementMember" escape="true" id="Fact001600" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--InitialMeasurementMember_z1QM2DVjkmSk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the warrant liabilities are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BA_zyGP5uMpiwf9" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 2022 Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 2022 Post-Modification Warrants (See Note 7)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February 15, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zkRE5qfbxQV" title="Warrants term"><ix:nonNumeric contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember" format="ixt-sec:duryear" id="Fact001602" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.0</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_ztVxTxKwnXvb" title="Warrants term"><ix:nonNumeric contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" format="ixt-sec:duryear" id="Fact001604" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zg4vc6tNjoU6" title="Warrants, stock price" style="text-align: right"><ix:nonFraction name="ENVB:WarrantsAndRightsOutstandingStockPrice" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001606" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zUD00iEXtF7c" title="Warrants, stock price" style="text-align: right"><ix:nonFraction name="ENVB:WarrantsAndRightsOutstandingStockPrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001608" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMKqRGglU068" title="Warrants, exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001610" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKSgY0wy0iyh" title="Warrants, exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001612" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.78</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVyprhikOUP2" title="Warrants, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1614">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zFsXu3HGkuPe" title="Warrants, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1616">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zcJF7D6miHg7" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact001618" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">74.1</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zXulwjEnomb2" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact001620" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">80.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zDHnLKF0SByk" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001622" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.9</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_znzQkLQw96rk" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001624" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.9</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z4cDZMXOyqyk" title="Warrants, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember" id="Fact001626" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">460,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zw9U56dyLJU3" title="Warrants, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" id="Fact001628" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">122,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zSrYFRvG1GD9" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember" id="Fact001630" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zc94NSTnQNmh" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" id="Fact001632" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its derivative liability at the respective date of issuance. The Company used a Weighted
Expected Return valuation model in order to determine their value. The key inputs into the Weighted Expected Return valuation model for
the initial valuations of the warrant liabilities are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">May 2022 Derivative Liability</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">May 5, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%">Principal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ConvertiblePreferredStockPrincipalValue_iI_pid_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zA97NpTGuk22" title="Principal" style="width: 23%; text-align: right"><ix:nonFraction name="ENVB:ConvertiblePreferredStockPrincipalValue" contextRef="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember" id="Fact001634" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMajfNXiCdV7" title="Dividend rate" style="text-align: right"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001636" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Market rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketRateMember_zwinaaQECZ11" title="Market rate" style="text-align: right"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_custom_MeasurementInputMarketRateMember" id="Fact001638" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.4</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its investment options at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the investment options are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Wainwright Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">RD Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">PIPE Options</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zRRpPgv5agTj" title="Investment option term"><ix:nonNumeric contextRef="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001640" name="ENVB:InvestmentOptionTerm">5.0</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zdhDz6mJGNJ" title="Investment option term"><ix:nonNumeric contextRef="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001642" name="ENVB:InvestmentOptionTerm">5.5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zfSptC7W7KEg" title="Investment option term"><ix:nonNumeric contextRef="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001644" name="ENVB:InvestmentOptionTerm">5.5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zPlSJf5eL0A6" title="Investment, stock price" style="text-align: right"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_WainwrightInvestmentOptionsMember" id="Fact001646" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zqYpSozvjjQ8" title="Investment, stock price" style="text-align: right"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_RDInvestmentOptionsMember" id="Fact001648" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zDLPZtQBQ3f2" title="Investment, stock price" style="text-align: right"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_PIPEInvestmentOptionsMember" id="Fact001650" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYWvEhjRG27a" title="Investment, exercise price" style="text-align: right"><ix:nonFraction name="ENVB:StockOptionExercisePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_WainwrightInvestmentOptionsMember" id="Fact001652" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zidSfPnMN3kc" title="Investment, exercise price" style="text-align: right"><ix:nonFraction name="ENVB:StockOptionExercisePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_RDInvestmentOptionsMember" id="Fact001654" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z4ui6DjkSRej" title="Investment, exercise price" style="text-align: right"><ix:nonFraction name="ENVB:StockOptionExercisePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_PIPEInvestmentOptionsMember" id="Fact001656" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.78</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zQ8wA9rqzTjb" title="Investment, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1658">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zO3qrym8KSpa" title="Investment, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1660">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvzToWtaoU02" title="Investment, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1662">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_ziabNgPIphZ3" title="Investment, measurement input"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_WainwrightInvestmentOptionsMember" id="Fact001664" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">80.0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zofjONCNkiQb" title="Investment, measurement input"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_RDInvestmentOptionsMember" id="Fact001666" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">80.0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvIEEezFwTO9" title="Investment, measurement input"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_PIPEInvestmentOptionsMember" id="Fact001668" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">80.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z0rmtJQWmDCi" title="Investment, measurement input"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WainwrightInvestmentOptionsMember" id="Fact001670" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.9</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zKeYY8MkDdMi" title="Investment, measurement input"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_RDInvestmentOptionsMember" id="Fact001672" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.9</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z9Fo5tlv9cUh" title="Investment, measurement input"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PIPEInvestmentOptionsMember" id="Fact001674" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.9</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Number of investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYbQQoJTqgg2" title="Number of investment options" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember" id="Fact001676" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zwzPQkiN0jy2" title="Number of investment options" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember" id="Fact001678" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">375,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFk1flldufk" title="Number of investment options" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember" id="Fact001680" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">625,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zwdNPoSCez9h" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember" id="Fact001682" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zCIxDRegUmw8" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember" id="Fact001684" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFdwm4V6zmKk" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember" id="Fact001686" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zqJvQKCnT5l7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subsequent
measurement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_SubsequentMeasurementMember" escape="true" id="Fact001688" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zyPosEMl6298" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of the warrant liabilities, derivative liability, and investment options that are
classified as Level 3:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zf0YvucZm167" style="display: none">SCHEDULE
OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Warrant Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%">Fair value as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfWR0eRZvVP5" title="Total beginning balance" style="width: 23%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">653,674</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of February 2022 warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXGaIgmvYyJi" title="Issuance of equity" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,595,420</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value due to modification of February 2022 warrants as part of July 2022 raise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFIntmBPaxCj" title="Change in fair value, modification" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001694" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,357</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE0CYMPIHUj4" title="Change in fair value" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,315,236</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfghil2mtthe" title="Total beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001698" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkAmp56BB0z3" title="Change in fair value" style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001700" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,396</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercise of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDN8OycYqdhb" title="Exercise of warrants" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ENVB:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001702" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,349</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zme9nFXE8ezh" title="Total beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Derivative Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Fair value as of December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFGDcN74hZH" title="Total beginning balance" style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1706">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 73%; text-align: left; padding-bottom: 1.5pt">Issuance of May 2022 convertible preferred stock</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPpeS4e84xo4" title="Issuance of equity" style="padding-bottom: 1.5pt; width: 23%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="Fact001708" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSM8F2xaqSZb" title="Change in fair value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="Fact001710" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">325,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaWdjbixGpx4" title="Total beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="Fact001712" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value arising from redemption of Akos Series A Preferred Stock - See Note 8</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEhyNzluaeM9" title="Change in fair value" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="Fact001714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of derivative liability as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqz7o8NCcsD6" title="Total ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1716">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Investment Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkafZlF2mmd8" title="Total beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1718">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 73%">Issuance of July 2022 investment options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJCC3dQ45BP1" title="Issuance of equity" style="width: 23%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="From2022-01-012022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact001720" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,323,734</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAP0ZMaOKtx2" title="Change in fair value" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2022-01-012022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact001722" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,472,726</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsspxHsvJgQ5" title="Total beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact001724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">851,008</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2wRFtIor8lj" title="Change in fair value" style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact001726" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">208,752</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise of investment options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmmwHeZhV8Fi" title="Exercise of investment options" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ENVB:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" contextRef="From2023-01-012023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact001728" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">618,648</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair value of investment option liability as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwfYpkEyGifd" title="Total ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact001730" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,608</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zTDiFxmrLd74" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_SubsequentMeasurementMember" escape="true" id="Fact001732" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zVmNi2ZEtwR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the warrant liabilities as of December 31, 2023 are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B0_zGwJ3NUryGMb" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 2021 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February 2021 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February 2022 Warrants Unmodified</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_z6UybGHOxEm9" title="Warrants term"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember" format="ixt-sec:duryear" id="Fact001734" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.0</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z8aHZ5nk0zCe" title="Warrants term"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember" format="ixt-sec:duryear" id="Fact001736" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.1</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zUoJTl1pinb3" title="Warrants term"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember" format="ixt-sec:duryear" id="Fact001738" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.1</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z5f7OPJrG5A" title="Warrant measurement input" style="text-align: right"><ix:nonFraction name="ENVB:WarrantsAndRightsOutstandingStockPrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001740" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z43IGWEMy7mi" title="Warrant measurement input" style="text-align: right"><ix:nonFraction name="ENVB:WarrantsAndRightsOutstandingStockPrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001742" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPFDp0gpvu1f" title="Warrant measurement input" style="text-align: right"><ix:nonFraction name="ENVB:WarrantsAndRightsOutstandingStockPrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001744" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zzQ4UuJKdZN" title="Warrant measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001746" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">247.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zh3valY73Qz2" title="Warrant measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001748" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">245.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zI70P4KFepEe" title="Warrant measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001750" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zXom3SuDcJeh" title="Warrants, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1752">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmrl5hHMBCm2" title="Warrants, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1754">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zrAdZu39f75a" title="Warrants, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1756">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zGbl4bmvxqsh" title="Warrants, measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact001758" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">89.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUtVZGZgnQkc" title="Warrants, measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact001760" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">88.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUdeTyuL8oac" title="Warrants, measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact001762" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">87.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVAXZdk6d31h" title="Warrants, measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001764" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.20</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zXrUSp9jZPD9" title="Warrants, measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001766" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.20</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMV40M3mGbVf" title="Warrants, measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001768" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zn6PP51bQ6m" title="Warrants, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember" id="Fact001770" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z5JR5WBgvpN8" title="Warrants, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember" id="Fact001772" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z7TkfR5O3yy9" title="Warrants, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember" id="Fact001774" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">338,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zOg7y7IDF7R5" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember" id="Fact001776" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_zAR75z9wv3J9" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember" id="Fact001778" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zeqE92vGMb9d" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember" id="Fact001780" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.08</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the investment options as of December 31, 2023 are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">H.C. Wainwright &amp; Co., LLC Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zoMuNWVyzAm" title="Investment option term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001782" name="ENVB:InvestmentOptionTerm">3.6</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zUboA7OQUpLa" title="Investment, stock price" style="text-align: right"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="Fact001784" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--StockOptionExercisePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zgo6KhIG3Ijf" title="Investment, exercise price" style="text-align: right"><ix:nonFraction name="ENVB:StockOptionExercisePrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="Fact001786" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zN9N15RArLo6" title="Investment, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1788">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zA3LphOX94wg" title="Investment, measurement input"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="Fact001790" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">94.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zOhw3RzTphsk" title="Investment, measurement input"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="Fact001792" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Number of investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2nEB216o2a" title="Number of investment options" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="Fact001794" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zucFVItplnkl" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="Fact001796" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.34</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zrbMv2JczZWj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the date of the redemption of the of Akos Series A Preferred Stock in May 2023, the derivative liability fair value was $<span id="xdx_905_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBe0f08cNDD6" title="Derivative liability fair value"><ix:nonFraction name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember" id="Fact001798" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> due to the
probability of a spin-off occurring was zero. See Note 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001800" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJzHQhc2S99e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_824_zLAtIowfPq7c">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is periodically involved in legal proceedings, legal actions and claims arising in the normal course of business. Management
believes that the outcome of such legal proceedings, legal actions and claims will not have a significant adverse effect on the Company&#8217;s
financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Australian
Subsidiary Research and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2023, the Company issued a press release announcing the selection of Australian CRO, Avance Clinical, in preparation for Phase
1 Study of EB-373, the Company&#8217;s lead candidate targeting the treatment of anxiety disorders. Under the agreement, Avance Clinical
will manage the Phase 1 clinical trial of EB-373 in coordination with the Company&#8217;s newly established Australian subsidiary, Enveric
Therapeutics Pty, Ltd. The Phase 1 clinical trial is designed as a multi-cohort, dose-ascending study to measure the safety and tolerability
of EB-373. EB-373, a next-generation proprietary psilocin prodrug, has been recognized as a New Chemical Entity (NCE) by Australia&#8217;s
Therapeutic Goods Administration (TGA) and is currently in preclinical development targeting the treatment of anxiety disorder. The total
cost of the Avance Clinical contract is approximately <span id="xdx_902_eus-gaap--CapitalizedContractCostNet_iI_uAUD_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zP5GfH9I9BH2" title="Contract cost"><ix:nonFraction name="us-gaap:CapitalizedContractCostNet" contextRef="AsOf2023-12-31_custom_AvanceClinicalMember" id="Fact001802" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,000,000</ix:nonFraction></span> AUD, which translates to approximately $<span id="xdx_905_eus-gaap--CapitalizedContractCostNet_iI_uUSD_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zh1rCXdtro0i" title="Contract cost"><ix:nonFraction name="us-gaap:CapitalizedContractCostNet" contextRef="AsOf2023-12-31_custom_AvanceClinicalMember" id="Fact001804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span> USD as of December
31, 2023. As of December 31, 2023, the Company has paid approximately $<span id="xdx_904_eus-gaap--ConstructionContractCostProgressPaymentOffset_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zBWqr4Io24Ge" title="Payment of contract cost"><ix:nonFraction name="us-gaap:ConstructionContractCostProgressPaymentOffset" contextRef="AsOf2023-12-31_custom_AvanceClinicalMember" id="Fact001806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,036,940</ix:nonFraction></span> of the Avance Clinical contract costs and has accrued
$<span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_z3EcyGn4t8s5" title="Accrued liabilities"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2023-12-31_custom_AvanceClinicalMember" id="Fact001808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">523,284</ix:nonFraction></span> recorded as accrued liabilities and $<span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zYKiKTtPTDXc" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2023-12-31_custom_AvanceClinicalMember" id="Fact001810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239,320</ix:nonFraction></span> as accounts payable on the accompanying consolidated balance sheet. For the year
ended December 31, 2023, the Company has expensed $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_ztSbfQPHmw17" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_AvanceClinicalMember" id="Fact001812" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,751,444</ix:nonFraction></span> in research and development expenses within the accompanying consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Development
and Clinical Supply Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 22, 2021, the Company entered into a Development and Clinical Supply Agreement (the &#8220;PureForm Agreement&#8221;) with PureForm
Global, Inc. (&#8220;PureForm&#8221;), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&#8220;API&#8221;)
for the Company&#8217;s development plans for cancer treatment and supportive care. Under the terms of the PureForm Agreement, PureForm
has granted the Company the exclusive right to purchase API and related product for cancer treatment and supportive care during the term
of the Agreement (contingent upon an initial minimum order of 1 kilogram during the first thirty (30) days from the effective date) and
has agreed to manufacture, package and test the API and related product in accordance with specifications established by the parties.
All inventions that are developed jointly by the parties in the course of performing activities under the PureForm Agreement will be
owned jointly by the parties in accordance with applicable law; however, if the Company funds additional research and development efforts
by PureForm, the parties may enter into a further agreement whereby PureForm would assign any resulting inventions or technical information
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial term of the PureForm Agreement is three (3) years commencing on the effective date of the PureForm Agreement, subject to extension
by mutual agreement of the parties. The Company has met the minimum purchase requirement of 1 kilogram during the first thirty days of
the PureForm Agreement&#8217;s effectiveness. The Company did not pursue an extension of the PureForm Agreement beyond the initial term
and the agreement terminated in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purchase
agreement with Prof. Zvi Vogel and Dr. Ilana Nathan </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 26, 2017, Jay Pharma entered into a purchase agreement with Prof. Zvi Vogel and Dr. Ilana Nathan (the &#8220;Vogel-Nathan Purchase
Agreement&#8221;), pursuant to which Jay Pharma was assigned ownership rights to certain patents, which were filed and unissued as of
the date of the Vogel-Nathan Purchase Agreement. The Vogel-Nathan Purchase Agreement includes a commitment to pay a one-time milestone
totaling $<span id="xdx_909_eus-gaap--LongTermPurchaseCommitmentAmount_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember__srt--StatementScenarioAxis__custom--OneTimeMilestoneMember_zowhwjN3UqGl" title="Long-term purchase commitment, amount"><ix:nonFraction name="us-gaap:LongTermPurchaseCommitmentAmount" contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_OneTimeMilestoneMember" id="Fact001814" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> upon the issuance of a utility patent in the United States or by the European Patent Office, as defined in the agreement.
The Company has accrued such amount as of December 31, 2021, as a result of the milestone criteria being achieved. Payment was made during
January 2022. In addition, a milestone payment totaling $<span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember__srt--StatementScenarioAxis__custom--AdditionalMilestoneMember_zj2RHyb06Cu7" title="Long-term purchase commitment, amount"><ix:nonFraction name="us-gaap:LongTermPurchaseCommitmentAmount" contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_AdditionalMilestoneMember" id="Fact001816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span> is due upon initiation of a Phase II(b) study. Research activities related
to the relevant patents are still in pre-clinical stage, and accordingly, this milestone has not been achieved. The Vogel-Nathan Purchase
Agreement contains a commitment for payment of royalties equaling <span id="xdx_90E_ecustom--RoyaltiesPercentage_pid_dp_uPure_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember_zeaJzpkABMv3" title="Royalties percentage"><ix:nonFraction name="ENVB:RoyaltiesPercentage" contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember" id="Fact001818" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></span>% of the first $<span id="xdx_90D_eus-gaap--PaymentsForRoyalties_pn6n6_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember_zoZY67IeTyk6" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember" id="Fact001820" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million in net sales derived from the commercialization
of products utilizing the relevant patent. As these products are still in the preclinical phase of development, no royalties have been
earned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Consulting and Vendor Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into a number of agreements and work orders for future consulting, clinical trial support, and testing services,
with terms ranging between 1 and 18 months. These agreements, in aggregate, commit the Company to approximately $<span id="xdx_906_eus-gaap--Cash_iI_pn5n6_c20231231__us-gaap--TypeOfArrangementAxis__custom--OtherConsultingAndVendorAgreementsMember_zXfWx4ycr8Rc" title="Future cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31_custom_OtherConsultingAndVendorAgreementsMember" id="Fact001822" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million in future
cash payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Right-of-use
lease</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2021, MagicMed entered into a lease agreement (the &#8220;LSIH Lease&#8221;) with the University of Calgary for the use and
occupation of lab and office space at the University of Calgary&#8217;s Life Science Innovation Hub building located in Calgary, Alberta,
Canada (the &#8220;LSIH Facility&#8221;). The lease expired in July 2023, and was extended on a month-to-month basis through December
31, 2023. Accordingly, no operating lease liability or right-of-use asset is recorded as of December 31, 2023. The Company terminated
this lease effective in March 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense is recorded on the straight-line basis. Rent expense under the LSIH Lease for the years ended December 31, 2023 and 2022 was
$<span id="xdx_902_eus-gaap--PaymentsForRent_c20230101__20231231_zBINyAlGGitl" title="Rent expenses"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-01to2023-12-31" id="Fact001824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,241</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--PaymentsForRent_c20220101__20221231_zTe2yrPNRkw2" title="Rent expenses"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-01-012022-12-31" id="Fact001826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,667</ix:nonFraction></span>, respectively. Rent expense is recorded in research and development costs on the consolidated statements of operations
and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001828" name="ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_zcSidS9fkSDb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average remaining lease term and the weighted-average discount rate of the lease was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zQfu0TOu6lia" style="display: none">SCHEDULE OF WEIGHTED
AVERAGE REMAINING LEASE TERM</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Remaining lease term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; text-align: left">Operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231_zuiWJW2cO47k" title="Operating leases remaining lease term"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" id="Fact001830" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">0.6</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20221231_zk4ki5oTON06" title="Operating lease discount rate"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2022-12-31" id="Fact001832" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zFSM6H6fbVub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001834" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zYdOWhZhqi8i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11. <span id="xdx_82E_zmpByKrEU5va">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001836" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYpFlmqCGSD2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s U.S. and foreign loss before income taxes are set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zeA4xpukjyji" style="display: none">SCHEDULE OF EARNING (LOSS) BEFORE INCOME
TAX</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zxZNk46ZRzng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231_zijVKXfD02T1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzlef_z9MaFVvNgvr6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2023-01-01to2023-12-31" id="Fact001838" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,205,116</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2022-01-012022-12-31" id="Fact001839" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,251,228</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzlef_zE8rf8karcM4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2023-01-01to2023-12-31" id="Fact001841" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,057,703</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-01-012022-12-31" id="Fact001842" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,706,165</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_mtILFCOzlef_z2B2dgbOYfy4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact001844" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,262,819</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact001845" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,957,393</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zhNKqIFZq044" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recorded income tax expense of $<span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20231231_z3Bd8okIz0A9" title="Income tax expenses and benefits"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact001847" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,913</ix:nonFraction></span> and an income tax benefit of $<span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zTxFvfZupNSk" title="Income tax expenses and benefits"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact001849" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,486,060</ix:nonFraction></span>,
respectively. The income tax benefit (expense) is as follows:</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001851" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zBdQk1cD3aIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_z4LFMffO1bGa" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE BENEFITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231_zXpnWXEk0Qnd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zktAaySoCScj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Current:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_iN_di_maCITEBzYcv_zswZcV5nkVg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1853">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1854">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maCITEBzYcv_zAEkzY61kyi6" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact001856" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,913</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1857">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maCITEBzYcv_zBO2f4fpNnae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1859">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1860">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iNT_di_mtCITEBzYcv_maITEBzKnh_zBI0YA4EbLMh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total
    current income tax (expense) benefit</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact001862" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,913</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1863">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zO46stlDOwwa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1865">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1866">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_z7PzV6xiY5vd" style="vertical-align: bottom; background-color: White">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1868">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1869">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zXxtOtSLhIsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1871">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact001872" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,486,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDFITEzdpW_maITEBzKnh_zXY6vb4G9k2j" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred income tax (expense) benefit</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact001875" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,486,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzKnh_z5f9VHGVH2Ya" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total income tax (expense) benefit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact001877" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,913</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact001878" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,486,060</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zEMeV37Jgcl8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001880" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFSERvZE8hD1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s deferred tax assets and deferred tax liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B9_zVn0082ZSHDi" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zXa1FmWtibt5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zwvxf2F8NBJ1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNdz_maDTANzxkL_zMNkEZsyD8Wf" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001882" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,889,863</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" id="Fact001883" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,927,330</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzxkL_zg5Rc6Cqe1F8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001885" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,185,399</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" id="Fact001886" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,348,928</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ResearchAndDevelopmentCapitalizedExpenses_iI_maDTANzxkL_z756cbDpyv1k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development capitalized expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:ResearchAndDevelopmentCapitalizedExpenses" contextRef="AsOf2023-12-31" id="Fact001888" format="ixt:numdotdecimal" decimals="0" unitRef="USD">611,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:ResearchAndDevelopmentCapitalizedExpenses" contextRef="AsOf2022-12-31" id="Fact001889" format="ixt:numdotdecimal" decimals="0" unitRef="USD">614,041</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsAndIntangibleAmortization_iI_maDTANzxkL_zrt11foR7jeg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:DeferredTaxAssetsAndIntangibleAmortization" contextRef="AsOf2023-12-31" id="Fact001891" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:DeferredTaxAssetsAndIntangibleAmortization" contextRef="AsOf2022-12-31" id="Fact001892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,141</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOther_iI_maDTANzxkL_zLfR2vCU52Pd" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact001894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,730</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2022-12-31" id="Fact001895" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,453</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzXjO_msDTANzxkL_zMfzrABlkFk8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001897" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,837,755</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" id="Fact001898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,977,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzxkL_zeNN2eU460z" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1900">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1901">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zv3ekvcOLIcc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001903" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock"><p id="xdx_897_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zs9bhRynYJsl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially utilizable net operating loss tax carryforwards:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zt3NjQUFsfF" style="display: none">SCHEDULE
OF OPERATING LOSS CARRY FORWARDS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zulmzGTSNdN8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zZqWm1R4dBi8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zQU8ncu82Cef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,268,692</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember" id="Fact001906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,349,753</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zI0OIVbJPSr6" style="vertical-align: bottom; background-color: White">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001908" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,220,065</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001909" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,892,754</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zzjfJ55ZT1Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Foreign</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="Fact001911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,672,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_ForeignCountryMember" id="Fact001912" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,377,435</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zSAitNKZZYjl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net operating loss tax carryforwards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="Fact001914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,672,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_ForeignCountryMember" id="Fact001915" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,377,435</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_z7S3r24z5eD4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act of 2017 (the &#8220;Act&#8221;) limits the net operating loss deduction to 80% of taxable income for losses
arising in tax years beginning after December 31, 2017. As of December 31, 2023, the Company had federal net operating loss
carryforwards and state net operating loss carryforwards of $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zMyXJ1gm3FJ8"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,268,692</ix:nonFraction></span>
and $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zH57liFWfGbk" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,220,065</ix:nonFraction></span>,
respectively, both of which can be carried forward indefinitely and Canadian net operating loss carryforwards of $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zr2nJ9Kzy0j6" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="Fact001920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,672,420</ix:nonFraction></span>,
which will begin to expire in 2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001922" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzVMVNGeNJec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s effective tax rate varied from the statutory rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_z6qq60Xq2gJ2" style="display: none">SCHEDULE
OF EFFECTIVE STATUTORY INCOME TAX RATE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zcnUsjwkXjAj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_z6WLN5u7FCy" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maALCzr1A_zmTBblmRYrR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Federal income tax at the statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" id="Fact001924" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 3%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" id="Fact001925" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 3%; text-align: left">)%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maALCzr1A_zYGRPLUj28i3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax rate (net of federal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-01to2023-12-31" id="Fact001927" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.2</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" id="Fact001928" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.6</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maALCzr1A_z9kt9Ydnzk1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign tax rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-01-01to2023-12-31" id="Fact001930" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3.0</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-01-012022-12-31" id="Fact001931" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3.1</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_pid_dp_uPure_maALCzr1A_zTghWy4U2b78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" contextRef="From2023-01-01to2023-12-31" id="Fact001933" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.4</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" contextRef="From2022-01-012022-12-31" id="Fact001934" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">4.0</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueup_pid_dp_uPure_maALCzr1A_zw7LHgBY8Yg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:EffectiveIncomeTaxRateReconciliationDeferredTrueup" contextRef="From2023-01-01to2023-12-31" id="Fact001936" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13.2</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1937">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maALCzr1A_ztmgY4wYYHoh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-01to2023-12-31" id="Fact001939" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" id="Fact001940" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23.3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtALCzr1A_zWrMtwwBJC36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effective income tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-01to2023-12-31" id="Fact001942" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31" id="Fact001943" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">7.4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zsa35ks9ndR2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those temporary differences become deductible. The valuation allowance increased by
$<span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_znu1AgEoYdYj" title="Valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-01-01to2023-12-31" id="Fact001945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,859,862</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zQeSg7kdYWS3" title="Valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-012022-12-31" id="Fact001947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,429,869</ix:nonFraction></span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files U.S. federal and state returns. The Company&#8217;s foreign subsidiary also files a local tax return in their local jurisdiction.
From a U.S. federal, state and Canadian perspective the years that remain open to examination are consistent with each jurisdiction&#8217;s
statute of limitations. As of December 31, 2023, the Company has not filed tax returns for the fiscal year 2023 and Canadian corporate
tax returns for fiscal year 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Section
382</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
utilization of the Company&#8217;s net operating losses may be subject to a substantial limitation in the event of any significant future
changes in its ownership structure under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result
in the expiration of the net operating loss carryforwards before their utilization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Section
174</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in 2022, the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) eliminated the option to deduct research and development expenditures
in the current year and requires taxpayers to amortize US expenses over five years and foreign expense over fifteen years pursuant to
IRC Section 174. During the years ended December 31, 2023 and 2022, the Company has estimated and capitalized gross $<span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20230101__20231231_z0NaECqIR2Wg" title="Research and development expense gross"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2023-01-01to2023-12-31" id="Fact001949" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,696</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20220101__20221231_zOGeQR7Krns5" title="Research and development expense gross"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2022-01-012022-12-31" id="Fact001951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,684,319</ix:nonFraction></span>,
respectively, of research and development expenditures that will be amortized primarily over five years. This did not have a material
impact on the Company&#8217;s tax liability for the years ended December 31, 2023 and 2022. The Company will continue to evaluate the
impact of these tax law changes on the current and future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
Reduction Act</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2022, President Joe Biden signed the Inflation Reduction Act of 2022 (the &#8220;Act&#8221;) into law. The Act includes a
new 15% corporate minimum tax and a 1% excise tax on the value of corporate stock repurchases, net of new share issuances, after December
31, 2022. These provisions did not have a material impact on the Company&#8217;s consolidated financial position as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001953" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z18CjkrOmpN9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12. <span id="xdx_820_zNqnVHMzgyjl">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
February 29, 2024, the Company issued all <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztZQSzRfQhgf" title="Number of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-292024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact001955" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">704,000</ix:nonFraction></span> shares of common stock of the <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVMa1cegYz64" title="Existing Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact001957" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">704,000</ix:nonFraction></span> shares of Existing Warrants and Investment Options
exercised that were held in abeyance due to the beneficial ownership limitation provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 29, 2024, one investor exercised the Inducement Warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKrULxjy5eIa" title="Warrants to purchase shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact001959" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,954,000</ix:nonFraction></span> shares of common stock for cash proceeds of approximately
$<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl177HQBwHH" title="Cash proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-02-292024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact001961" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct offering
of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zxqKyTLmS3hh"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact001962" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">228,690</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock, par
value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z4fZ2TTDwlU6"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact001963" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to the Holders of the Inducement Warrants.
The issuance was made in exchange for the permanent and irrevocable waiver of the variable rate transaction limitation solely with respect
to the entry into and/or issuance of shares of common stock in an at the market offering contained in the Inducement Letters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2023, the Company sold an aggregate of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zZl25kVUlsV1" title="Number of shares sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember" id="Fact001965" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,668,000</ix:nonFraction></span> shares of common stock for aggregate gross proceeds of $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zP6ktUIcIwx3" title="Gross proceeds from sale of shares"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember" id="Fact001967" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,392,502</ix:nonFraction></span> and
net proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zBs01OrWOijg" title="Net Proceeds from sale of shares"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember" id="Fact001969" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,320,707</ix:nonFraction></span> under the Distribution Agreement with Canaccord.&#8221;</span></p>

</ix:nonNumeric><p id="xdx_81A_zTeRXMFLHAZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 103; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14
<SEQUENCE>2
<FILENAME>ex14.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
14</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ENVERIC
BIOSCIENCES, INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CORPORATE
CODE OF CONDUCT AND ETHICS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>AND</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>WHISTLEBLOWER
POLICY</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effective
December 31, 2020</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INTRODUCTION</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. (&ldquo;<B>we</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;) has adopted this Corporate Code of Conduct and Ethics
and Whistleblower Policy (the &ldquo;<B>Code</B>&rdquo;) to provide our associates, as defined below, with a clear understanding of the
principles of business conduct and ethics that are expected of them and to aid them in making decisions when conducting the Company&rsquo;s
business and performing day-to-day duties. The standards set forth in the Code apply to us all. Each associate of the Company must acknowledge
his or her review of, and agree to comply with, the Code as a condition of his or her relationship with the Company (see <U>Appendix
A</U> attached hereto). The term &ldquo;<B>us</B>&rdquo; or &ldquo;<B>associate</B>&rdquo; as used throughout the Code means (i) every
full and part-time employee of the Company and its subsidiaries, (ii) all members of the Company&rsquo;s senior management, including
the Chief Executive Officer and Chief Financial Officer, and (iii) every member of the Company&rsquo;s Board of Directors (the &ldquo;<B>Board</B>&rdquo;),
even if such member is not employed by the Company. The term &ldquo;<B>you</B>&rdquo; means any associate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPORTING
VIOLATIONS UNDER THE CODE; ANTI-RETALIATION PLEDGE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the responsibility of each of us to conduct ourselves in an ethical business manner and also to ensure that others do the same. If
any one of us violates these standards, he or she can expect a disciplinary response, up to and including termination of employment or
other relationship with the Company or, potentially, legal action. If you are aware of any breach of the Code, you are obligated to report
violations to the Corporate Compliance Officer, to the chairperson of the Audit Committee of the Board (the &ldquo;<B>Audit Committee</B>&rdquo;)
or to the anonymous Whistleblower Compliance Website that the Company utilizes to receive such reports, as described in more detail below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Code contains a clear anti-retaliation pledge, meaning that if you in good faith report a violation of the Code by any associate, or
by the Company or agents acting on its behalf, on the Whistleblower Compliance Website, or to the Corporate Compliance Officer or the
chairperson of the Audit Committee, you will not be fired, demoted, reprimanded or otherwise harmed for reporting the violation. Note
however that, although you will not be disciplined for <U>reporting</U> a violation, you may be subject to discipline if you are involved
in the underlying conduct or violation. You are entitled to make the report on a confidential and anonymous basis. To the extent an investigation
must be initiated, the Company will endeavor to keep confidential any report you make, except to the extent disclosure is required by
applicable law, regulation or court order or is necessary to permit a complete investigation of such report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPLYING
WITH THE CODE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate responsibility for maintaining the Code rests with each of us. As individuals of personal integrity, we can do no less than
to behave in a way that will continue to bring credit to ourselves and our company. Applying these standards to our business lives is
an extension of the values by which we are known as individuals and by which we want to be known as a company. To that end, the Company
has made the Code publicly available on its website. It is our responsibility to conduct ourselves in an ethical business manner and
also to ensure that others do the same. If any one of us violates these standards, he or she can expect a disciplinary response, up to
and including termination of employment or other relationship with the Company or, potentially, legal action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
it is impossible for this Code to address specifically every situation that may arise, the principles embodied in the Code should govern
our conduct at all times. If you are confronted with a situation not covered by the Code, or have questions regarding any matter that
is specifically addressed in the Code, you are urged to consult with the Corporate Compliance Officer or another member of senior management
of the Company. Furthermore, the policies set forth in this Code are in addition to other policies of the Company that associates must
comply with, including those set forth in any Employee Handbook in effect from time to time or in any other policy referenced in the
Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of the Code regarding the actions the Company will take are guidelines which the Company intends to follow. There may be circumstances,
however, that in the Company&rsquo;s judgment require different measures or actions and, in such cases, the Company may act accordingly
while still seeking to remain consistent with the principles embodied in the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of any inconsistency between the provisions set out in this Code and the rules contained in any mandatory text, laws or interpretive
case law applicable to the Company or associates, such mandatory text, laws or interpretive case law controls. In no instance should
this Code be interpreted as modifying, amending or otherwise changing any legal text or precedent that applies to the Company or associates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 200.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Table
of Contents</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHISTLEBLOWER
    POLICY</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligation
    to Report Violations or Suspected Violations</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in">4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whistleblower
    Compliance Website for Confidential and Anonymous Reporting</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Retaliation
    Pledge</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMPLEMENTATION
    OF THE CODE</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">III.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GENERAL
    REQUIREMENTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IV.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFLICTS
    OF INTEREST</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">V.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTECTION
    AND PROPER USE OF COMPANY ASSETS</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proper
    Use of Company Property</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
    Information</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Interference and Immunity</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">9</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accurate
    Records and Reporting</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">10</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Document
    Retention</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    Advances</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VI.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FAIR
    DEALING WITH CUSTOMERS, SUPPLIERS, COMPETITORS AND ASSOCIATES</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Giving
    Gifts</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receiving
    Gifts</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">12</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unfair
    Competition</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">12</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Antitrust
    Concerns</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">12</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unfair
    Practices in International Business</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">14</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VII.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GOVERNMENT RELATIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">14</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
    Procurement and Funding</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
    to Officials</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Political
    Contributions</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIII.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPLIANCE
    WITH LAWS, RULES AND REGULATIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider
    Trading Policy</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equal
    Employment Opportunity</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sexual
    Harassment Policy</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health,
    Safety &amp; Environment Laws</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IX.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUESTIONS
    UNDER THE CODE AND WAIVER PROCEDURES</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">17</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FREQUENTLY
    ASKED QUESTIONS AND ANSWERS (FAQ&rsquo;s) REGARDING REPORTING VIOLATIONS UNDER THE CODE, WHISTLEBLOWER POLICY AND WHISTLEBLOWER COMPLIANCE
    WEBSITE</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">17</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDIX
    A ASSOCIATE&rsquo;S AGREEMENT TO COMPLY</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">20</TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 41.95pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHISTLEBLOWER POLICY</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligation to Report Violations or Suspected Violations</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
associate having any information or knowledge regarding the existence of any violation or suspected violation of the Code has a duty
to report the violation or suspected violation on the Whistleblower Compliance Website (the contact details for which are below), the
Corporate Compliance Officer or the chairperson of the Audit Committee. Associates are also encouraged to raise any issues or concerns
regarding the Company&rsquo;s business or operations. Failure to report a suspected or actual violation is itself a violation of the
Code and may subject the associate to disciplinary action, up to and including termination of employment or other relationship with the
Company or, potentially, legal action. Reports may be made on a completely confidential and anonymous basis. To the extent any investigation
is necessitated by a report, the Company will endeavor to keep the proceedings and the identity of the reporting associate confidential,
except to the extent disclosure is required by law, regulation or court order or is necessary to permit a complete investigation of such
report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individuals
should consider leaving, but are not required to leave, their name or a contact number when submitting a report. Such information may
facilitate a more thorough and efficient investigation. The Corporate Compliance Officer will strive to maintain the integrity and confidentiality
of all compliance-related communications. However, in certain circumstances, the identity of the person reporting the issue may become
known or may need to be revealed, particularly if federal or state enforcement authorities become involved in the investigation. The
Company cannot guarantee confidentiality, particularly when material evidence of a violation of the law is disclosed or if the person
is identified during the normal course of an investigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whistleblower Compliance Website for Confidential and Anonymous
Reporting</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are aware of any breach of the Code, you are obligated to report violations on the Whistleblower Compliance Website, or to the Corporate
Compliance Officer or to the chairperson of the Audit Committee. The Whistleblower Compliance Website is operated by a third party service
provider, which the Company has engaged to receive such reports, the contact details for which are below. You may make such reports on
a completely anonymous and confidential basis by reporting complaints on the Whistleblower Compliance Website. Associates may report
on the Whistleblower Compliance Website any concerns he or she may have with respect to the Company, including, but not limited to, concerns
with the Company&rsquo;s business or operations, suspected violations of the Code, securities or antifraud laws, accounting issues, any
law relating to fraud against stockholders, or any other issue concerning the Company or such associate&rsquo;s employment or other relationship
with the Company. Reports made on the Whistleblower Compliance Website will, in turn, be provided directly to the Corporate Compliance
Officer and the Audit Committee on an anonymous (to the extent the report was made anonymously) and confidential basis. The confidential
third party Whistleblower Compliance Website may be reached 24 hours a day, 7 days a week at https://investors.drop.car/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Retaliation Pledge</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
associate who in good faith (a) reports a suspected violation under the Code by any associate,or by the Company or its agents acting
on its behalf, or (b) raises issues or concerns regarding the Company&rsquo;s business or operations, in either case on the Whistleblower
Compliance Website, or to the Corporate Compliance Officer, to any other member of the Compliance Committee or to the chairperson of
the Audit Committee, may not be fired, demoted, reprimanded or otherwise harmed for, or because of, the reporting of the suspected violation,
issue or concern, regardless of whether the suspected violation, issue or concern involves the associate, his or her supervisor or senior
management of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any associate who in good faith reports a suspected violation under the Code that he or she reasonably believes constitutes
a violation of a federal statute by the Company, or its agents acting on its behalf, to a federal regulatory or law enforcement agency
may not be reprimanded, discharged, demoted, suspended, threatened, harassed or in any manner discriminated against in the terms and
conditions of his or her employment for, or because of, the reporting of the suspected violation, regardless of whether the suspected
violation involves the associate, his or her manager or senior management of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMPLEMENTATION OF THE CODE</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following questions and answers address the Company&rsquo;s implementation of the Code. The Company has attempted to design procedures
that promote confidentiality, anonymity and, most importantly, freedom from the fear of retaliation for complying with and reporting
violations under the Code. In addition, each associate shall be required from time to time to sign the Associate&rsquo;s Agreement to
Comply with the Code in substantially the form attached as <U>Appendix A</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Who is responsible for administering, updating and enforcing
the Code?</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A:
</B>The Board has appointed a Corporate Compliance Officer to administer, update and enforce the Code. Ultimately, the Board of Directors
of the company must ensure that the Corporate Compliance Officer and the Compliance Committee fulfill their responsibilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporate Compliance Officer has overall responsibility for overseeing the implementation of the Code. Specific responsibilities of the
position are to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop the Code based on legal requirements, regulations and
ethical considerations that are raised in the company&rsquo;s operations;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensure that the Code is distributed to all associates and that
all associates acknowledge the principles of the Code;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work with the Audit Committee to provide a reporting mechanism
so that associates have a confidential and anonymous method of reporting not only suspected violations of the Code but concerns regarding
federal securities or antifraud laws, accounting issues, or any federal law relating to fraud against stockholders;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implement a training program to ensure that associates are
aware of and understand the Code;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit and assess compliance with the Code;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serve as a point person for reporting violations and asking
questions under the Code; and</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revise and update the Code as necessary to respond to detected
violations and changes in the law.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: justify; text-indent: 34.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporate Compliance Officer will provide a summary of all matters considered under the Code to the Board of Directors or a committee
thereof at each regular meeting thereof, or sooner if warranted by the severity of the matter. All proceedings and the identity of the
person reporting will be kept confidential to the extent required by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">How can I contact the Corporate Compliance Officer?</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A:
</B>The name, phone number and email address of the initial Corporate Compliance Officer is listed below. The Corporate Compliance Officer
can assist you in answering questions or reporting violations or suspected violations under the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carter
                                            Ward</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">239-302-1707</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CWard@Enveric.com</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporate Compliance Officer may change from time to time. You are encouraged to consult the copy of the Code that is included on the
Company&rsquo;s website to obtain the most current information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">III.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GENERAL REQUIREMENTS</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of us is expected to be honest, fair, and accountable in all business dealings and obligations, and to ensure:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ethical handling of conflicts of interest between personal and professional relationships;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">full,
    fair, accurate, timely and understandable disclosure in the reports required to be filed by the Company with the Securities and Exchange
    Commission (the &ldquo;<B>SEC</B>&rdquo;) and in other public communications made by the Company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with applicable governmental laws, rules and regulations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IV.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFLICTS OF INTEREST</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associates
should avoid any situation that may involve, or even appear to involve, a conflict between their personal interests and the interests
of the Company. In dealings with current or potential customers, suppliers, contractors, and competitors, each associate should act in
the best interests of the Company to the exclusion of personal advantage. Immediate family members of associates, executive officers
and directors are also covered in certain circumstances. For purposes of this section, an &ldquo;immediate family member&rdquo; in respect
of any person means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law of such person, and any person (other than a tenant or employee) sharing the household of such person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associates
and, in certain circumstances, their immediate family members, are prohibited from any of the following activities which could represent
an actual or perceived conflict of interest:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 74.35pt; text-align: justify; text-indent: -31.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    associate or immediate family member of an associate shall have a financial interest in, or significant obligation to, any outside
    enterprise which does or seeks to do business with the Company or which is an actual or potential competitor of the Company, without
    prior approval of the Corporate Compliance Officer and the Company&rsquo;s Chief Executive Officer or, in the case of executive officers
    or members of the Board, without prior approval of the Board or a committee thereof; provided however, that this provision shall
    not prevent any associate from investing in any mutual fund or owning up to 1% of the outstanding stock of any publicly traded company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    associate shall conduct business on the Company&rsquo;s behalf with an outside enterprise which does or seeks to do business with
    the Company if an immediate family member of such associate is a principal or officer of such enterprise, or an employee of such
    enterprise who will play a significant role in the business done or to be done between the Company and such enterprise, without prior
    approval of the Corporate Compliance Officer and the Company&rsquo;s Chief Executive Officer or, in the case of executive officers
    or members of the Board, without prior approval of the Board or a committee thereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    executive officer or employee of the Company, or immediate family member of an executive officer or employee of the Company, shall
    serve as a director, officer or in any other management or consulting capacity of any actual competitor of the Company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    director or immediate family member of a director shall serve as a director, officer or in any other management or consulting capacity
    of any actual competitor of the Company, without prior approval of the Board or a committee thereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    associate shall use any Company property or information or his or her position at the Company for his or her personal gain.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    associate shall engage in activities that are directly competitive with those in which the Company is engaged.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    associate shall divert a business opportunity from the Company to his or her own benefit. If an associate becomes aware of an opportunity
    to acquire or profit from a business opportunity or investment in which the Company is or may become involved or has or may have
    an existing interest, the associate should disclose the relevant facts to the Corporate Compliance Officer. The associate may proceed
    to take advantage of such opportunity only if the Company is unwilling or unable to take advantage of such opportunity as notified
    in writing by the Corporate Compliance Officer.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    associate or immediate family member of an associate shall receive any loan or advance from the Company or be the beneficiary of
    a guarantee by the Company of a loan or advance from a third party, except for customary advances or corporate credit in the ordinary
    course of business or approved by the Corporate Compliance Officer and the Company&rsquo;s Chief Executive Officer. Please see Section
    V.E. below, &ldquo;Corporate Advances,&rdquo; for more information on permitted corporate advances.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 74.35pt; text-align: justify; text-indent: -31.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Audit Committee will review and approve, in advance, all related-person transactions, as required by the SEC, The Nasdaq
Stock Market or any other regulatory body to which the Company is subject from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
associate should make prompt and full disclosure in writing to the Corporate Compliance Officer of any situation that may involve a conflict
of interest. Failure to disclose any actual or perceived conflict of interest is a violation of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">V.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTECTION AND PROPER USE OF COMPANY ASSETS</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proper
protection and use of Company assets and assets entrusted to it by others, including proprietary information, is a fundamental responsibility
of each associate of the Company. Associates must comply with security programs to safeguard such assets against unauthorized use or
removal, as well as against loss by criminal act or breach of trust. The provisions hereof relating to protection of the Company&rsquo;s
property also apply to property of others entrusted to it (including proprietary and confidential information).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proper Use of Company Property</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
removal from the Company&rsquo;s facilities of the Company&rsquo;s property is prohibited, unless authorized by the Company. This applies
to furnishings, equipment, and supplies, as well as property created or obtained by the Company for its exclusive use &ndash; such as
vendor lists, files, personnel information, reference materials and reports, computer software, data processing programs and data bases.
Neither originals nor copies of these materials may be removed from the Company&rsquo;s premises or used for purposes other than the
Company&rsquo;s business without prior written authorization from the Corporate Compliance Officer and the Company&rsquo;s Chief Executive
Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s products and services are its property; contributions made by any associate to their development and implementation are
the Company&rsquo;s property and remain the Company&rsquo;s property even if the associate&rsquo;s employment or other relationship with
the Company terminates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
associate has an obligation to use the time for which he or she receives compensation from the Company productively. Work hours should
be devoted to activities directly related to the Company&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential Information</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides its associates with confidential information relating to the Company and its business with the understanding that
such information is to be held in confidence and not communicated to anyone who is not authorized to see it, except as may be
required by law. The types of information that each associate must safeguard include, by way of example only, to the extent
unannounced or otherwise nonpublic, the Company&rsquo;s plans and business strategy; inventions, discoveries, results, protocols or
other similar information; products; product candidates; intellectual property, regulatory, corporate partnering or M&amp;A
information, developments, prospects or communications; contracts; sales data; significant projects; customer and supplier lists;
trade secrets; manufacturing techniques and sensitive financial information, in each case whether in electronic or paper format
(&ldquo;Confidential Information&rdquo;). These are costly, valuable resources developed for the exclusive benefit of the Company.
Without the prior written consent of the appropriate authority, an employee shall not, directly or indirectly, use for his or her
own account, use for any other purpose, acquire, access, copy, disclose to anyone, publish, exploit, destroy, modify or remove from
the offices of the Company, nor solicit, allow or assist another person or entity to use, acquire, access, copy, disclose, publish,
exploit, destroy, modify or remove from the offices of the Company, any Confidential Information or part thereof, except: (1) as
permitted in the proper performance of his or her duties for the Company; (2) as permitted in the ordinary course of the
Company&rsquo;s business for the benefit of the Company; (3) as permitted by applicable law or regulation where such employee
believes a violation of applicable law or regulation has occurred (as set forth in more detail in the No Interference and Immunity
Policy below); or (4) as otherwise required by applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Interference and Immunity</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
any other provision of the Confidential Information policy discussed above or any other policy or written agreement of the Company (including,
without limitation, any confidentiality/non- disclosure provision of an employment agreement between an employee and the Company), an
employee may disclose Confidential Information of the Company when required to do so by a court of competent jurisdiction, by any governmental
agency having authority over the employee or the business of the company or by any administrative body or legislative body (including
a committee thereof) with jurisdiction to order the employee to divulge, disclose, or make accessible such information. In addition,
nothing in this handbook, including, without limitation, the Confidentiality Policy, or any other policy or written agreement of the
Company (including, without limitation, any employment agreement between an employee and the company), is intended to interfere with
an employee&rsquo;s right to (i) report possible violations of federal, state or local law or regulation to any governmental agency or
entity charged with the enforcement of any such laws; (ii) make other disclosures that are protected under the whistleblower provisions
of federal, state, or local law or regulation; (iii) file a claim or charge with the Equal Employment Opportunity Commission (&ldquo;EEOC&rdquo;),
any state human rights commission, or any other governmental agency or entity; or (iv) testify, assist, or participate in an investigation,
hearing, or proceeding conducted by the EEOC, any state human rights commission, any other governmental or law enforcement agency or
entity, or any court. In making or initiating any such reports or disclosures, or engaging in any of the conduct set forth in the preceding
sentence, an employee may disclose Confidential Information to the extent necessary to such governmental or law enforcement agency or
entity or such court, need not seek prior authorization from the Company, and is not required to notify the company of any such reports,
disclosures or conduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
employees of the Company are hereby notified in accordance with the Defend Trade Secrets Act of 2016 that no employee will be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in confidence to a federal,
state, or local government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or investigating
a suspected violation of law, or is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding.
If an employee files a lawsuit for retaliation against the Company for reporting a suspected violation of law, the employee may disclose
the Company&rsquo;s trade secrets to the employee&rsquo;s attorney and use the trade secret information in the court proceeding if the
employee files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court
order.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42pt; text-align: justify; text-indent: -36.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accurate Records and Reporting</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
law, the Company is required to keep books, records and accounts that accurately and fairly reflect all Company transactions, dispositions
of assets and other events that are the subject of specific regulatory record keeping requirements, including generally accepted accounting
principles and other applicable rules, regulations and criteria for preparing financial statements and for preparing periodic reports
filed with the SEC. All Company reports, accounting records, sales reports, expense accounts, invoices, purchase orders, and other documents
must accurately and clearly represent the relevant facts and the true nature of transactions. Reports and other documents should state
all material facts of a transaction and not omit any information that would be important in interpreting such report or document. Under
no circumstance shall there be any unrecorded liability or fund of the Company, regardless of the purposes for which the liability or
fund may have been intended, or any improper or inaccurate entry knowingly made on the books or records of the Company. No payment on
behalf of the Company may be approved or made with the intention, understanding or awareness that any part of the payment is to be used
for any purpose other than that described by the documentation supporting the payment. In addition, intentional accounting misclassifications
(e.g., expense versus capital) and intentional improper acceleration or deferral of expenses or revenues are unacceptable reporting practices
that are expressly prohibited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has developed or will develop and maintain (a) a system of internal controls to provide reasonable assurance that transactions
are executed in accordance with management&rsquo;s authorization, are properly recorded and posted and are in compliance with regulatory
requirements and (b) disclosure controls and procedures to ensure that all of the information required to be disclosed by the Company
in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and
reported within the time periods specified by the SEC&rsquo;s rules and forms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associates
are expected to be familiar with, and to adhere strictly to, these internal controls and disclosure controls and procedures, in each
case to the extent applicable to their roles at the Company. For clarity, responsibility for compliance with these internal controls
and disclosure controls and procedures rests not solely with the Company&rsquo;s accounting personnel, but with all associates involved
in approving transactions, supplying documentation for transactions, and recording, processing, summarizing and reporting of transactions
and other information required by periodic reports filed with the SEC. <B>Because the integrity of the Company&rsquo;s external reports
to stockholders and the SEC depends on the integrity of the Company&rsquo;s internal reports and recordkeeping, all associates must adhere
to the highest standards of care with respect to our internal records and reporting. The Company is committed to full, fair, accurate,
timely, and understandable disclosure in its periodic reports required to be filed with the SEC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
associate who believes the Company&rsquo;s books and records are not in accord with these requirements should immediately report the
matter on the Whistleblower Compliance Website, or to the Corporate Compliance Officer or the chairperson of the Audit Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Document Retention</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
federal and state statutes require the proper retention of many categories of records and documents that are commonly maintained by companies.
In consideration of those legal requirements and the Company&rsquo;s business needs, all associates must maintain records in accordance
with these laws and any records retention policy that the Company may adopt from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
record, in paper or electronic format, relevant to a threatened, anticipated or actual internal or external inquiry, investigation, matter
or lawsuit may not be discarded, concealed, falsified, altered or otherwise made unavailable after the associate in possession of such
record has become aware of the existence of such threatened, anticipated or actual internal or external inquiry, investigation, matter
or lawsuit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
in doubt regarding retention of any record, do not discard or alter the record in question and seek guidance from the Corporate Compliance
Officer. Associates should also direct all questions regarding document retention and related procedures to the Corporate Compliance
Officer. <B>In addition, from time to time, the company may adopt additional specific written policies and procedures with respect to
document retention or amend existing policies and procedures. All associates will be notified if such policies and procedures are adopted
or if existing policies and procedures are amended.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Advances</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
law, the Company may not loan money to associates except in limited circumstances. It shall be a violation of the Code for any associate
to advance Company funds to any other associate or to himself or herself except for usual and customary business advances for legitimate
corporate purposes that are approved by a manager or pursuant to any corporate credit card for usual and customary, legitimate business
purposes. It is the Company&rsquo;s policy that any advance to an associate over $5,000 be approved in advance by the Corporate Compliance
Officer and the Company&rsquo;s Chief Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Company credit cards are to be used only for authorized, legitimate business purposes. An associate will be responsible for any unauthorized
charges to a Company credit card.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VI.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FAIR DEALING WITH CUSTOMERS, SUPPLIERS, COMPETITORS AND ASSOCIATES</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not seek to gain any advantage through the improper use of favors or other inducements. Good judgment and moderation must
be exercised to avoid misinterpretation and adverse effect on the reputation of the Company or associates. Offering, giving, soliciting
or receiving any form of bribe to or from a vendor, service provider, supplier or regulatory official to influence its conduct is strictly
prohibited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Giving Gifts</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
or cash-equivalent gifts must not be given by any associate to any person or enterprise. Gifts, favors and entertainment may be given
to non-governmental employees if what is given:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
    consistent with customary business practice;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
    not excessive in value and cannot be construed as a bribe or pay-off;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
    not in violation of applicable law or ethical standards; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
    not embarrass the Company or any associate if publicly disclosed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
also subsection E below for considerations relating to gifts to foreign officials and Section </FONT>VII.B below for considerations
relating to gifts to government employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receiving Gifts</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gifts,
favors, entertainment or other inducements may not be accepted by associates or members of their immediate families from any person or
organization that does or seeks to do business with, or is a competitor of, the Company, except as common courtesies usually associated
with customary business practices. If the gift is of more than token value, the Corporate Compliance Officer and the Company&rsquo;s
Chief Executive Officer must approve its acceptance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>An
especially strict standard applies when suppliers are involved. If a gift unduly influences or makes an associate feel obligated to &ldquo;pay
back&rdquo; the other party with business, receipt of the gift is unacceptable.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>It
is never acceptable to accept a gift in cash or cash equivalent. Even cash gifts of token value must be declined and returned to the
sender.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unfair Competition</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the free enterprise system is based upon competition, rules have been imposed providing what can and what cannot be done in a competitive
environment. The following practices can lead to liability for &ldquo;unfair competition&rdquo; and should be avoided. They are violations
of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Disparagement
of Competitors.</I> It is not illegal to point out weaknesses in a competitor&rsquo;s product, service or operation; however, associates
may not spread false rumors about competitors or make misrepresentations about their businesses. For example, an associate may not pass
on anecdotal or unverified stories about a competitor&rsquo;s product, service or operation as the absolute truth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Disrupting
a Competitor&rsquo;s Business.</I> This includes bribing a competitor&rsquo;s employees, posing as prospective customers or using deceptive
practices such as enticing away employees in order to obtain secrets or destroy a competitor&rsquo;s organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Misrepresentations
of Price and Product</I>. Lies or misrepresentations about the nature, quality or character of any Company product or service are both
illegal and contrary to Company policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Antitrust Concerns</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state antitrust laws are intended to preserve the free enterprise system by ensuring that competition is the primary regulator
of the economy. Every corporate decision that involves customers, competitors, and business planning with respect to output, sales
and pricing raises antitrust issues. Compliance with the antitrust laws is in the public interest, in the interest of the business
community at large, and in the Company&rsquo;s interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failing
to recognize antitrust risk is costly. Antitrust litigation can be very expensive and time consuming. Moreover, violations of the antitrust
laws can, among other things, subject you and the Company to the imposition of injunctions, treble damages and heavy fines. Criminal
penalties may also be imposed, and individual associates can receive heavy fines or even be imprisoned. For this reason, antitrust compliance
should be taken seriously at all levels within the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
primary focus of antitrust laws is on dealings between competitors. In all interactions with actual or potential competitors, associates
must follow these rules:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Never
    agree with a competitor or a group of competitors to charge the same prices or to use the same pricing methods, to allocate services,
    customers, private or governmental payor contracts, territories or on any other improper basis, to boycott or refuse to do business
    with a provider, vendor, payor or any other third party, or to refrain from the sale or marketing of, or limit the supply of, particular
    products or services.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Never
    discuss past, present, or future prices, pricing policies, bundling, discounts or allowances, royalties, terms or conditions of sale,
    costs, choice of customers, territorial markets, production quotas, allocation of customers or territories, or bidding on a job with
    a competitor.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Be
    careful of your conduct. An &ldquo;agreement&rdquo; that violates the antitrust laws may be not only a written or oral agreement,
    but also a &ldquo;gentlemen&rsquo;s agreement&rdquo; or a tacit understanding. Such an &ldquo;agreement&rdquo; need not be in writing.
    It can be inferred from conduct, discussions or communications of any sort with a representative of a competitor.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Make
    every output- and sales-related decision (pricing, volume, etc.) independently, in light of costs and market conditions and competitive
    prices.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carefully
    monitor trade association activity. These forums frequently create an opportunity for competitors to engage in antitrust violations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Another
focus of antitrust law is how a company deals with customers, suppliers, contractors and other third parties. The following practices
could raise issues, and associates should always consult with the Corporate Compliance Officer before doing any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
    to sell to any customer or prospective customer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditioning
    a sale on the customer&rsquo;s purchasing another product or service, or on not purchasing the product of a competitor;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreeing
    with a customer on a minimum or maximum resale price of our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposing
    restrictions on the geographic area to which our customers may resell our products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
    a supplier to purchase products from the Company as a condition of purchasing products from that supplier;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entering
    into an exclusive dealing arrangement with a supplier or customer; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">offering
    different prices, terms, services or allowances to different customers who compete or whose customers compete in the distribution
    of commodities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company has a dominant or potentially dominant position with respect to a particular product or market, especially rigorous standards
of conduct must be followed. In these circumstances, associates should:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consult
    with the Corporate Compliance Officer before selling at unreasonably low prices or engaging in any bundling practices; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keep
    the Corporate Compliance Officer fully informed of competitive strategies and conditions in any areas where the Company may have
    a significant market position.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
always immediately inform the Corporate Compliance Officer if local, state or federal law enforcement officials request information from
the Company concerning its operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unfair Practices in International Business</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Foreign Corrupt Practices Act (&ldquo;<B>FCPA</B>&rdquo;), associates are prohibited from making certain gifts to foreign officials.
&ldquo;Foreign officials&rdquo; include not only persons acting in an official capacity on behalf of a foreign government, agency, department
or instrumentality, but also representatives of international organizations, foreign political parties and candidates for foreign public
office. The gift is &ldquo;corrupt&rdquo; under the FCPA if it is made for the purpose of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">influencing
    any act or decision of a foreign official in his official capacity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inducing
    a foreign official to do or omit to do any act in violation of his lawful duty;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inducing
    a foreign official to use his position to affect any decision of the government; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inducing
    a foreign official to secure any &ldquo;improper advantage.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
gift is still &ldquo;corrupt&rdquo; even when paid through an intermediary. Any associate who has any questions whatsoever as to whether
a particular gift might be &ldquo;corrupt&rdquo; under the FCPA, please contact the Corporate Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VII.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GOVERNMENT RELATIONS</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associates
must adhere to the highest standards of ethical conduct in all relationships with government employees and must not improperly attempt
to influence the actions of any public official.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government Procurement and Funding</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. government, governments of other countries and many state, regional and local governments have adopted comprehensive laws and regulations
governing the purchase of products from private contractors or the provision of funds to the private sector for research and development.
These laws and regulations are intended to assure that governmental entities receive pricing, terms, and conditions equivalent to those
granted to the Company&rsquo;s most favored commercial counterparties and that there is full and open competition in contracting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
selling products or services to, or seeking funding from, government agencies, the Company is accountable for complying with all applicable
laws, regulations and other requirements. Certifications to, and contracts with, government agencies are to be signed by an associate
authorized by the Board to sign such documents, based upon knowledge that all requirements have been fully satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments to Officials</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
or gifts shall not be made directly or indirectly to any government official or other government associate if the gift or payment is
illegal under the laws of the country having jurisdiction over the transaction, or if it is for the purpose of influencing or inducing
the recipient to do, or omit to do, any act in violation of his or her lawful duty. Under no circumstances should gifts be given to any
government employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Political Contributions</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
funds, property or services may not be contributed to any political party or committee, or to any candidate for or holder of any office
of any government. This policy does not preclude, where lawful, company expenditures to support or oppose public referendum or separate
ballot issues, or, where lawful and when reviewed and approved in advance by the Corporate Compliance Officer and the Company&rsquo;s
Chief Executive Officer, the formation and operation of a political action committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIII.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPLIANCE WITH LAWS, RULES AND REGULATIONS</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expressly forbids any associate from trading on material nonpublic information or communicating material nonpublic information
to others in violation of the law. This conduct is frequently referred to as &ldquo;insider trading.&rdquo; This policy applies to every
associate and extends to activities both within and outside their duties to the Company, including trading for a personal account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
concept of who is an &ldquo;insider&rdquo; is broad. It includes officers, directors and employees of a company. In addition, a person
can be a &ldquo;temporary insider&rdquo; if he or she enters into a special confidential relationship in the conduct of a company&rsquo;s
affairs and as a result is given access to information solely for the company&rsquo;s purpose. A temporary insider can include, among
others, a company&rsquo;s investment advisors, agents, attorneys, accountants and lending institutions, as well as the employees of such
organizations. One may also become a temporary insider of <I>another company </I>with which the Company has a contractual or other relationship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
while aware of inside information is not a basis for liability unless the information is material. Generally, this is information that
a reasonable investor would consider important in making his or her investment decisions or information that is likely to have a significant
effect on the price of a company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
is nonpublic until it has been effectively communicated to the marketplace. Tangible evidence of such dissemination is the best indication
that the information is public. For example, information found in a report filed with the SEC or appearing in a national newspaper would
be considered public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
associate should be familiar with and abide by the Company&rsquo;s Insider Trading Policy. A copy of this policy is given to all new
associates and is available from the Human Resources Department or the Corporate Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equal Employment Opportunity</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company makes employment-related decisions without regard to a person&rsquo;s race, color, religious creed, age, sex, sexual orientation,
marital status, national origin, ancestry or any other legally protected status. &ldquo;Employment decisions&rdquo; generally mean decisions
relating to hiring, recruiting, training, promotions and compensation, but the term may encompass other employment actions as well.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company encourages its associates to bring any problem, complaint or concern regarding any alleged employment discrimination to the attention
of the Human Resources Department or the Corporate Compliance Officer. Associates who have concerns regarding conduct they believe is
discriminatory should also feel free to make a report on the Whistleblower Compliance Website, or to the Corporate Compliance Officer
or to the chairperson of the Audit Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sexual Harassment Policy</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is committed to maintaining a collegial work environment in which all individuals are treated with respect and dignity and which
is free of sexual harassment. In keeping with this commitment, the Company will not tolerate sexual harassment of associates by anyone,
including any manager, coworker, director, consultant, vendor, supplier or customer, whether in the workplace, at assignments outside
the workplace, at Company-sponsored social functions or elsewhere.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
associate should be familiar with and abide by the Company&rsquo;s Sexual Harassment Policy. A copy of this policy is given to all associates
and is available from the Human Resources Department or the Corporate Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health, Safety &amp; Environment Laws</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health,
safety, and environmental responsibilities are fundamental to the Company&rsquo;s values. Associates are responsible for ensuring that
the Company complies with all provisions of the health, safety, and environmental laws of each country in which the Company has operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
penalties that can be imposed against the Company and associates for failure to comply with health, safety, and environmental laws can
be substantial and include imprisonment and fines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IX.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUESTIONS UNDER THE CODE AND WAIVER PROCEDURES</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
associate is encouraged to consult with the Corporate Compliance Officer about any uncertainty or questions he or she may have about
the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any situation should arise where a course of action would likely result in a violation of the Code but for which you think a valid reason
for the course of action exists, you should contact the Corporate Compliance Officer to obtain a waiver prior to the time the action
is taken. You should never pursue a course of action that is unclear under the Code without first consulting the Corporate Compliance
Officer, and, if necessary, obtaining a waiver from the Code. Except as noted below, the Corporate Compliance Officer will review all
the facts surrounding the proposed course of action, consult with the Company&rsquo;s Chief Executive Officer and determine whether a
waiver from any policy in the Code should be granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Waiver
Procedures for Executive Officers and Directors. </I>Waiver requests by an executive officer or member of the Board shall be referred
by the Corporate Compliance Officer to the Board or a committee thereof for consideration. If either (i) a majority of the independent
directors on the Board or (ii) a committee comprised solely of independent directors agrees that the waiver should be granted, it will
be granted and, to the extent required by the rules of the SEC or The Nasdaq Stock Market, disclosed publicly. If the Board denies the
request for a waiver, the waiver will not be granted and the associate shall not pursue the intended course of action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Waivers
from the Code will be granted only in limited and extraordinary circumstances.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FREQUENTLY ASKED QUESTIONS AND ANSWERS (FAQ&rsquo;S) REGARDING
REPORTING VIOLATIONS UNDER THE CODE, WHISTLEBLOWER POLICY AND WHISTLEBLOWER COMPLIANCE WEBSITE</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following questions and answers address each associate&rsquo;s obligation to comply with the Code. The Company has attempted to design
procedures that promote confidentiality and, most importantly, freedom from the fear of retaliation for complying with and reporting
violations under the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Do I have a duty to report violations under the Code?</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A:
</B>Yes, participation in the Code is mandatory. You must immediately report any violation or suspected violation of the Code on the
Whistleblower Compliance Website, or to the Corporate Compliance Officer or to the chairperson of the Audit Committee. The Company will
endeavor to keep reports confidential, except to the extent disclosure is required by law, regulation or court order or is necessary
to permit a complete investigation of such report. Failure to report violations or suspected violations is itself a violation of the
Code and may subject you to disciplinary action, up to and including termination of employment or other relationship with the Company
or, potentially, legal action.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I&rsquo;m afraid of being fired for raising questions or reporting
violations under the Code. </FONT>Will I be risking my job if I do?</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A:
</B>The Code contains a clear anti-retaliation pledge, meaning that if you in good faith report a violation of the Code by any associate,
or by the Company or its agents acting on its behalf, on the Whistleblower Compliance Website, or to the Corporate Compliance Officer
or to the chairperson of the Audit Committee, you will not be fired, demoted, reprimanded or otherwise harmed for reporting the violation,
even if the violation involves you, your manager, or senior management of the Company. Note however that, although you will not be disciplined
for <U>reporting</U> a violation, you may be subject to discipline if you are involved in the underlying conduct or violation. You are
entitled to make the report on a confidential and anonymous basis. To the extent an investigation must be initiated, the Company will
endeavor to keep confidential any report you make, except to the extent disclosure is required by law, regulation or court order or is
necessary to permit a complete investigation of such report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if you in good faith report a suspected violation under the Code that you reasonably believe constitutes a violation of a federal
statute by any associate, or by the Company or its agents acting on its behalf, to a federal regulatory or law enforcement agency, you
may not be reprimanded, discharged, demoted, suspended, threatened, harassed or in any manner discriminated against in the terms and
conditions of your employment for reporting the suspected violation, regardless of whether the suspected violation involves you, your
manager or senior management of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individuals
should consider leaving, but are not required to leave, their name or a contact number when submitting a report. Such information may
facilitate a more thorough and efficient investigation. The Corporate Compliance Officer will strive to maintain the integrity and confidentiality
of all compliance-related communications. However, in certain circumstances, the identity of the person reporting the issue may become
known or may need to be revealed, particularly if federal or state enforcement authorities become involved in the investigation. The
Company cannot guarantee confidentiality when material evidence of a violation of the law is disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
in the Code prohibits you from reporting possible violations of federal law or regulation to any governmental agency or entity, including
but not limited to the Department of Justice, the SEC, the Congress, and any agency Inspector General, or making other disclosures that
are protected under the whistleblower provisions of federal law or regulation. You do not need the prior authorization of the Corporate
Compliance Officer or any other party to make any such reports or disclosures and you are not required to notify the Company that you
have made such reports or disclosures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">How are suspected violations investigated under the Code?</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A:
</B>When a suspected violation is reported on the Whistleblower Compliance Website, or to the Corporate Compliance Officer, the Corporate
Compliance Officer (or his or her delegate) will gather information about the allegation by interviewing the associate reporting the
suspected violation, the associate who is accused of the violation or any co-workers or associates of the accused associates to determine
if a factual basis for the allegation exists. The reporting associate&rsquo;s immediate manager will not be involved in the investigation
if the reported violation involved that manager. The Company will endeavor to keep the identity of the reporting associate confidential,
except to the extent disclosure is required by law, regulation or court order or is necessary to permit a complete investigation of such
report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the report is not substantiated, the reporting associate will be informed and at that time will be asked for any additional information
not previously communicated. If there is no additional information, the Corporate Compliance Officer will close the matter as unsubstantiated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the allegation is substantiated, the Corporate Compliance Officer and the Company&rsquo;s Chief Executive Officer will make a judgment
as to the degree of severity of the violation and the appropriate disciplinary response. In more severe cases, the Corporate Compliance
Officer will refer the matter to the Board. The Board&rsquo;s decision as to disciplinary and corrective action will be final. In the
case of less severe violations, the Corporate Compliance Officer may refer the violation to the individual&rsquo;s manager for appropriate
disciplinary action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporate Compliance Officer shall provide a summary of all matters considered under the Code to the Board or a committee thereof at
each regular meeting thereof, or sooner if warranted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Do I have to participate in any investigation under the Code?</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A:
</B>Your full cooperation with any pending investigation under the Code is a condition of your continued employment or other relationship
with the Company. The refusal to cooperate fully with any investigation is a violation of the Code and grounds for discipline, up to
and including termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What are the consequences of violating the Code?</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A:
</B>As explained above, associates who violate the Code may be subject to discipline, up to and including termination of employment or
other relationship with the Company or, potentially, legal action. Associates who violate the Code may simultaneously violate federal,
state, local or foreign laws, regulations or policies. Such associates may be subject to prosecution, imprisonment and fines, and may
be required to make reimbursement to the Company, the government or any other person for losses resulting from the violation. They may
be subject to punitive or treble damages depending on the severity of the violation and applicable law.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">What if I have questions under the Code or want to obtain a
waiver under any provision of the Code?</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A:
</B>The Corporate Compliance Officer can help answer questions you may have under the Code. In addition, Section IX of the Code provides
information on how you may obtain a waiver from the Code. Waivers will be granted only in very limited circumstances. You should never
pursue a course of action that is unclear under the Code without first consulting the Corporate Compliance Officer and, if necessary,
obtaining a waiver from the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDIX
A</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 130.7pt; text-align: justify; text-indent: 75.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE&rsquo;S
AGREEMENT TO COMPLY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have read the Enveric Biosciences, Inc. Corporate Code of Conduct and Ethics and Whistleblower Policy (the &ldquo;Code&rdquo;). I have
obtained an interpretation of any provision about which I had a question. I agree to abide by the provisions of the Code. Based on my
review, I acknowledge that</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 0.5in">_______</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    the best of my knowledge, I am not in violation of, or aware of any violation by others of, any provision contained in the Code;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>_______</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have made a full disclosure on the reverse side of this acknowledgement of the facts regarding any possible violation of the provisions
    set forth in the Code.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, I understand that I am required to report any violation or suspected violation of the Code and that I may make such reports
on a fully anonymous basis through the mechanisms described in this Code. I understand that I am required to cooperate fully with the
Company in connection with the investigation of any suspected violation. I understand that my failure to comply with the Code or its
procedures may result in disciplinary action, up to and including termination of employment or other relationship with the Company or,
potentially, legal action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    (Please print):</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Department/Location:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>3
<FILENAME>ex19.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
19</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><IMG SRC="ex19_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INSIDER
TRADING POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Insider Trading Policy (the &ldquo;<B><I>Policy</I></B>&rdquo;) provides guidelines to all employees and officers of Enveric Biosciences,
Inc. and its affiliates (the &ldquo;<B><I>Company</I></B>&rdquo;) as well as members of the Company&rsquo;s Board of Directors (the &ldquo;<B><I>Directors</I></B>&rdquo;)
with respect to transactions in the Company&rsquo;s securities, and codifies the Company&rsquo;s standards on trading and enabling the
trading of securities of the Company or other publicly-traded companies while in possession of material non-public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Scope of Policy </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Policy applies to Directors, officers and employees of the Company (&ldquo;<B><I>Insiders</I></B>&rdquo;), and is divided into two parts:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Part
                                            I</B> applies to all Insiders, and prohibits trading in the Company&rsquo;s and other companies
                                            securities in certain circumstances; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Part
                                            II</B> applies to Directors and certain officers and employees of the Company who typically
                                            have access to financial and other highly sensitive information regarding the Company&rsquo;s
                                            business, and imposes additional restrictions on those individuals with respect to trading
                                            in the Company&rsquo;s securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Exceptions for certain Transactions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy does not apply to all transactions involving the Company&rsquo;s securities. The following exceptions are intended to facilitate
several common types of transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
                                            Option Exercises. This Policy does not apply to the mere exercise of a stock option for cash
                                            under the Company&rsquo;s stock option plans. This Policy does apply, however, to:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#9675;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Any sale of stock as part of a broker assisted &ldquo;cashless&rdquo; exercise of an option (<I>i.e.</I>, any market sale for the purpose
of generating the cash needed to pay the exercise price of an option); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#9675;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Any sale of shares of Company stock received upon exercise of an option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
                                            Settlement upon Vesting of Restricted Stock. This Policy does not apply to a surrender of
                                            shares to the Company or the retention and withholding from delivery to the applicable officer,
                                            director or employee of shares by the Company (<I>i.e.</I>, a so-called &ldquo;net settlement&rdquo;)
                                            upon vesting of restricted stock in satisfaction of any tax withholding obligations in a
                                            manner permitted by the applicable equity award agreement or the Company plan pursuant to
                                            which the restricted stock was granted.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
                                            Stock Purchase Plan. This Policy does not apply to (i) an employee&rsquo;s election to participate
                                            in, or increase his or her participation in, the Company&rsquo;s employee stock purchase
                                            plan, (ii) purchases of Company stock in the plan resulting from periodic contributions of
                                            money to the plan pursuant to the elections made at the time of enrollment in the plan, or
                                            (iii) purchases of Company stock resulting from lump sum contributions to the plan, provided
                                            that the participant elected to participate by lump-sum payment at the beginning of the applicable
                                            enrollment period. However, this Policy does apply to a participant&rsquo;s sale of Company
                                            stock purchased under the plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">pg. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --><IMG SRC="ex19_002.jpg" ALT=""></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex19_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insider
Trading Prohibition (applies to all Directors, Officers and Employees of the Company)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider
trading occurs when a person in possession of material and non-public information obtained through involvement with the Company (1) uses
that information to make decisions to purchase, sell, or otherwise trade in securities of the Company or another company, or (2) provides
that information to others outside the Company to enable such trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S
federal law, and the laws of all countries in which the Company operates, prohibit insider trading, and a violation of these laws may
cause reputational and financial damage to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Scope </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
I of this Policy applies to all Insiders, and all transactions in the Company&rsquo;s securities, including common or preferred stock,
options and warrants to purchase common stock, notes, bonds, convertible securities and any other debt or equity securities that the
Company may issue, as well as to derivative securities relating to any of the Company&rsquo;s securities, whether or not issued by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
General Policy: No Trading or Causing Trading While in Possession of Material Non-public Information </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
No Insider may purchase or sell any Company security while in possession of material non- public information about the Company, its customers,
suppliers, consultants or other companies with which the Company has contractual relationships or may be negotiating transactions (the
terms &ldquo;material&rdquo; and &ldquo;non-public information&rdquo; are defined in Part I, Section 4(a) and (b) below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
No Insider who knows of any material non-public information about the Company may communicate that information to any other person, including
family and friends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
In addition, no Insider may purchase or sell any security of any other company, whether or not issued by the Company, while in possession
of material non-public information about that company that was obtained in the course of his or her involvement with the Company. No
Insider who knows of any such material non-public information may communicate that information to any other person, including family
and friends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
For compliance purposes, no Insider should ever trade, tip or recommend securities (or otherwise cause the purchase or sale of securities)
while in possession of information that the Insider has reason to believe is material and non-public unless the Insider first consults
with, and obtains the advance approval of, the Compliance Officer (which is defined in Part I, Section 4(c) below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">pg. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --><IMG SRC="ex19_002.jpg" ALT=""></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT><B><IMG SRC="ex19_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Other Prohibited Transactions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers it improper and inappropriate for Insiders to engage in short-term or speculative transactions in the Company&rsquo;s
securities or in other transactions that may lead to inadvertent violations of the insider trading laws. Accordingly, trading in the
Company&rsquo;s securities by Insiders is subject to the following additional restrictions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Short sales. No Insider may sell the Company&rsquo;s securities short (sale of stock that the seller does not own or a sale that is completed
by delivery of borrowed stock). Note that in addition to this Policy, Section 16(c) of the Exchange Act prohibits Section 16 Officers
and Directors of the Company from engaging in short sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Options trading. No Insider may buy or sell puts or calls or other derivative securities on the Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Trading on margin; Pledging. No Insider may hold Company securities in a margin account or pledge Company securities as collateral for
a loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Hedging. No Insider may enter into hedging, monetization transactions, or similar arrangements with respect to Company securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Definitions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B><I>Materiality</I></B><I>. </I>Insider trading restrictions come into play only if the information that a director, officer or employee
of the Company possess is &ldquo;material.&rdquo; Information is generally regarded as &ldquo;material&rdquo; if it has market significance,
that is, if its public dissemination is likely to affect the market price of securities, or if it otherwise is information that a reasonable
investor would want to know before making an investment decision. Information dealing with the following subjects is reasonably likely
to be found material in particular situations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            changes in the company&rsquo;s prospects;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
                                            results, projections of future earnings or losses;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            write-downs in assets;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timelines or the results of preclinical studies or clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">scientific,
                                            medical or financial data relating to the Company&rsquo;s products or products under development;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
                                            regarding significant litigation or government agency investigations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impending
                                            bankruptcy or liquidity problems;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in earnings estimates or unusual gains or losses in major operations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">major
                                            changes in management;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            determination to declare a dividend;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extraordinary
                                            borrowings;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entry
                                            into or modification or termination of a significant contract;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proposals,
                                            plans or agreements, even if preliminary in nature, involving mergers, acquisitions or tender
                                            offer, divestitures, recapitalizations, strategic alliances, licensing arrangements, or purchases
                                            or sales of substantial assets; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">public
                                            offerings; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">pg. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<IMG SRC="ex19_002.jpg" ALT=""><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex19_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
                                            of regulatory and health agencies, particularly the U.S. Food and Drug Administration. Material
                                            information is not limited to historical facts, but may also include projections and forecasts.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to a future event, such as a merger or acquisition or development of a new product, the point at which negotiations or new product
development plans are determined to be material is determined by balancing the probability that the event will occur against the magnitude
of the effect the event would have on a company&rsquo;s operations or stock price should it occur. Thus, information concerning an event
that would have a large effect on stock price, such as a merger, may be material even if the possibility that the event will occur is
relatively small. When in doubt about whether particular non-public information is material, presume it is material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keep
in mind that materiality is judged in hindsight, and while a development may not seem material at the time, if following its announcement
to the public, the Company&rsquo;s stock price increases or decreases, a plaintiff&rsquo;s lawyer or the United States Securities and
Exchange Commission (&ldquo;<B><I>SEC</I></B>&rdquo;) will use this fact to demonstrate materiality. If you are unsure whether information
is material, you should consult with the Compliance Officer before making any decision to disclose such information (other than to persons
who need to know it) or to trade in or recommend securities to which that information relates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B><I>Non-public Information</I></B><I>. </I>Insider trading prohibitions come into play only when you possess information that is material
and &ldquo;non-public.&rdquo; The fact that information has been disclosed to a few members of the public does not make it public for
insider trading purposes. To be &ldquo;public&rdquo; the information must have been disseminated in a manner designed to reach investors
generally, and the investors must be given the opportunity to absorb the information. Even after public disclosure of information about
the Company, <I>you must wait until the close of business on the second trading day after the information was publicly disclosed before
you can treat the information as public</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
with questions of materiality, if you are not sure whether information is considered public, you should either consult with the Compliance
Officer or assume that the information is &ldquo;non-public&rdquo; and treat it as confidential.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B><I>Compliance Officer</I></B><I>. </I>The Company has appointed its Chief Financial Officer as the Compliance Officer for this Policy.
The duties of the Compliance Officer include, but are not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
                                            assisting with implementation of this Policy;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
                                            circulating this Policy to all Directors, officers and employees of the Company and ensuring
                                            that this Policy is amended as necessary to remain up-to-date with insider trading laws;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
                                            notifying Covered Persons (as defined in Part II below) and, if appropriate, other employees
                                            of the Company of the Company&rsquo;s imposition of a trading &ldquo;blackout&rdquo; period
                                            as described in Part II, Section 3 below;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
                                            reviewing and approving Approved 10b5-1 Plans (as defined below) or revisions or amendments
                                            to such Plans, and referring such plans or revisions to such Plans to the Board or a duly
                                            appointed committee thereof for approval if required or otherwise appropriate, as described
                                            in Part II, Section 3(d) below; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
                                            pre-clearing all trading in securities of the Company by all Covered Persons in accordance
                                            with the procedures set forth in Part II, Section 4 below.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">pg. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --><IMG SRC="ex19_002.jpg" ALT=""></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex19_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the Compliance Officer is not available or desires to effect a transaction in Company securities for which pre-clearance
or approval is required under this Policy, the CEO of the Company shall serve as the Compliance Officer. In the event that the Compliance
Officer is unavailable and such information is cleared by the CEO, the Compliance Officer must be informed of such clearance as soon
as possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Violations of Insider Trading Laws </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalties
for trading on or communicating material non-public information can be severe, both for individuals involved in such unlawful conduct
and their employers and supervisors. Penalties may include jail terms, criminal fines, civil penalties and civil enforcement injunctions.
Given the severity of the potential penalties, compliance with this Policy is absolutely mandatory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person who tips others may also be liable for transactions by the tippees to whom he or she has disclosed material non-public information.
Tippers can be subject to the same penalties and sanctions as the tippees. The SEC has imposed large penalties even when the tipper did
not profit from the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individuals
who violate this Policy may be subject to disciplinary action by the Company, up to and including dismissal for cause. Any exceptions
to the Policy, if permitted, may only be granted by the Compliance Officer or the Chief Financial Officer in writing and must be provided
before any activity contrary to the above requirements takes place.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II<BR>
Additional Trading Restrictions for Covered Persons</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Covered Persons </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covered
Persons are the individuals described below (collectively, &ldquo;<B><I>Covered Persons</I></B>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
                                            Directors of the Company and its affiliates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Executive
                                            officers&rdquo; of the Company as described in Rule 3b-7<SUP>i</SUP> under the Securities
                                            Exchange Act of 1934, as amended (&ldquo;<B><I>Exchange Act</I></B>&rdquo;), and all individuals
                                            designated as &ldquo;officers&rdquo; of the Company for purposes of Section 16 under the
                                            Exchange Act<SUP>ii</SUP> (&ldquo;<B><I>Section 16 Officers</I></B>&rdquo;);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            employees in the accounting, finance, investor relations, and law departments of the Company
                                            and its affiliates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediate
                                            family members (parents, siblings, spouses, children) and household members of each of the
                                            foregoing groups.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Compliance Officer or Chief Financial Officer may designate additional &ldquo;Covered Persons&rdquo; from time to time
as described in Part II, Section 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Scope </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
Covered Persons are exposed to a wider range of material non-public information than their colleagues (<I>e.g.</I>, information regarding
quarterly results, strategic transactions, or the like), this Policy includes additional restrictions on transactions by such persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><SUP>&nbsp;</SUP></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>i
</SUP>17 CFR &sect; 240.3b-7 Definition of &ldquo;executive officer&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term <I>executive officer,</I> when used with reference to a registrant, means its president, any vice president of the registrant in
charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs
a policy making function or any other person who performs similar policy making functions for the registrant. Executive officers of subsidiaries
may be deemed executive officers of the registrant if they perform such policy making functions for the registrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>ii
</SUP>Refer to Section 16 under the Exchange Act, 17 CFR Section 240.16a-1 for a complete definition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
illustration, t<FONT STYLE="background-color: white">he SEC defines an &ldquo;officer&rdquo; in Rule 16a-1(f) and an &ldquo;executive
officer&rdquo; in Rule 3b-7, both under the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;).&nbsp; Rule 16a-1(f) defines
the term &ldquo;officer&rdquo; as the president, principal financial officer, principal accounting officer, any vice-president of the
issuer in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who
performs a policy-making function, or any other person who performs similar policy-making functions for the issuer.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">pg. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --><IMG SRC="ex19_002.jpg" ALT=""></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex19_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Blackout Periods </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Persons Covered. All Covered Persons are prohibited from trading in the Company&rsquo;s securities during blackout periods. In addition,
the Compliance Officer may notify other employees of the Company that they are prohibited from trading in the Company&rsquo;s securities
during blackout periods, in which event such notified persons shall also be considered &ldquo;Covered Persons.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Quarterly Blackout Periods<I>. </I>Announcement of quarterly financial results almost always has the potential to have a material effect
on the market for its securities. Therefore, to avoid even the appearance of trading on the basis of material, non-public information,
and to assist compliance with insider trading laws, the Company has created the following blackout periods during which Covered Persons
may not trade in the securities of the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
                                            From December 16 until the end of the second trading day following public announcement of
                                            fourth quarter and year-end financial results;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
                                            From March 16 until the end of the second trading day following public announcement of first
                                            quarter financial results;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
                                            From June 16 until the end of the second trading day following public announcement of second
                                            quarter financial results; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
                                            From September 16 until the end of the second trading day following public announcement of
                                            third quarter financial results.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Other Blackout Periods. From time to time, other types of material non-public information regarding the Company (such as negotiation
of mergers, acquisitions or dispositions, new product developments, clinical trials, or other material events) may be pending and not
be publicly disclosed. While such material non-public information is pending, the Company may impose special blackout periods during
which Covered Persons are prohibited from trading in the Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Approved Rule 10b5-1 Plan. These trading restrictions do not apply to transactions by Covered Persons under a pre-existing written plan,
contract, instruction or arrangement under Exchange Act Rule 10b5-1 (&ldquo;<B><I>Approved 10b5-1 Plan</I></B>&rdquo;) that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
has been reviewed and approved by the Compliance Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
was entered into in good faith by the Covered Person outside a Blackout Period and at a time when he or she was not in possession of
material non-public information about the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
gives a third party the authority to execute such purchases and sales, outside the control of the applicable officer, Director or employee,
providing such third party does not possess any material non-public information about the Company, or explicitly specifies the security
or securities to be purchased or sold, the number of shares, the prices and/or dates of transactions, or other formula(s) describing
such transactions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">pg. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --><IMG SRC="ex19_002.jpg" ALT=""></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex19_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Approved 10b5-1 Plans adopted or modified after February 27, 2023 , the Approved 10b5-1 Plans must additionally: (A) be subjected to
continuing good faith requirements throughout the duration of the Approved 10b5-1 Plan; (B) if entered into by a Director or Officer,
such Director or Officer must have included written certification in the plan that they (i) were not aware of material nonpublic information
about the Company or its securities and (ii) were adopting or modifying the plan in good faith and not as part of a plan or scheme to
evade the prohibitions of Rule 10b-5; and (C) must comply with the limitations of Rule 10b5-1 with regard to concurrent or successive
plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
Approved 10b5-1 Plans adopted or modified after February 27, 2023 are subjected to the following cooling-off periods:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Trades under an Approved 10b5-1 Plan by an Officer or Director cannot begin until expiration of a cooling-off period consisting of the
later of: (a) 90 days after the adoption or modification of such Approved 10b5-1 Plan, or (b) two business days after the company files
a quarterly or annual financial report with the SEC covering the quarter in which the plan was adopted or modified. In the case of (a)
or (b), the cooling period is subject to a maximum of 120 days after adoption of the Approved 10b5-1 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The cooling-off period is 30 days for Covered Persons who are not the Company, not a Director, and not an Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Pre-clearance of Securities Transactions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Because Covered Persons are likely to obtain material non-public information on a regular basis, the Company requires all Covered Persons
to obtain a pre-clearance, even outside a Blackout Period, from the Compliance Officer for all transactions in the Company&rsquo;s securities.
In addition, transactions made by a Section 16 Officer or Director require a supplemental pre-clearance by the Company&rsquo;s Chief
Financial Officer (or, for trades by the CFO, by the Company&rsquo;s EVP, Human Resources).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
These procedures also apply to transactions by such person&rsquo;s spouse, other persons living in such person&rsquo;s household and
minor children and to transactions by entities over which such person exercises control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Unless revoked, a grant of permission will normally remain valid until the close of trading <I>five days following the day on which it
was granted</I>. If the transaction does not occur during the five-day period, pre-clearance of the transaction must be re-requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Pre-clearance is not required for purchases and sales of securities under an Approved 10b5-1 Plan. With respect to any purchase or sale
under an Approved 10b5-1 Plan, the third party effecting transactions on behalf of the applicable Covered Person should be instructed
to send duplicate confirmations of all such transactions to the Compliance Officer or the Chief Financial Officer. In addition, pre-clearance
is not required for stock option exercises and net issuances of restricted stock under the limited circumstances described in the introduction
to this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Short Term Trading by Covered Persons </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
16</B> - Officers and Directors who purchase Company securities may not sell any Company securities of the same class for at least six
months after the purchase. This prohibition does not apply to stock option exercises (whether regular or cashless) and Employee Stock
Purchase Plan purchases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
that in addition to this Policy, under Section 16(b) of the Exchange Act, any &ldquo;short-swing profits&rdquo; realized by a Section
16 - Officer or director of the Company from a &ldquo;matching&rdquo; purchase and sale or &ldquo;matching&rdquo; sale and purchase of
Company stock occurring within a six-month period would be subject to disgorgement to the Company. Note that under Section 16(b), the
highest sale price is matched with the lowest purchase price in determining profit, and purchases and sales that result in a loss are
ignored&mdash; meaning that under these rules, you could be deemed to have a profit to be disgorged even though you actually lose money
on your trades in the aggregate. There is an active group of lawyers that track purchases and sales by Section 16 - Officers and Directors
for violation of these rules. There is no defense to a violation of these rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">pg. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --><IMG SRC="ex19_002.jpg" ALT=""></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex19_001.jpg" ALT="" STYLE="width: 169px; height: 48px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATTACHMENT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTIFICATION
OF COMPLIANCE RETURN BY AUGUST 30, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO:
C. Michael Gegenheimer, Vice President, Associate General Counsel and Chief IP Counsel<BR>
FROM: __________________________<BR>
RE: INSIDER TRADING COMPLIANCE POLICY OF ENVERIC BIOSCIENCES INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have received, reviewed and understand the above-referenced Insider Trading Compliance Policy and undertake, as a condition to my present
and continued employment with (or, if I am not an employee, affiliation with) Enveric Biosciences Inc., to comply fully with the policies
and procedures contained therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hereby certify, to the best of my knowledge, that during the calendar year ending August 30, 202___, I have complied fully with all policies
and procedures set forth in the above-referenced Insider Trading Compliance Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:
____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">pg. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --><IMG SRC="ex19_002.jpg" ALT=""></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 23.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements of Enveric Biosciences, Inc. on Form S-3 (File No.&rsquo;s 333-276473,
333-233260, 333-253196, 333-257690 and 333-266579) and Form S-8 (File No. 333-269330) of our report dated March 25, 2024, which includes
an explanatory paragraph as to the Company&rsquo;s ability to continue as a going concern with respect to our audits of the consolidated
financial statements of Enveric Biosciences, Inc. as of and for the years ended December 31, 2023 and 2022, which report is included
in this Annual Report on Form 10-K of Enveric Biosciences, Inc. for the year ended December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">East
Hanover, New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SARBANES&ndash;OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Dr. Joseph Tucker, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this annual report on Form 10&ndash;K of Enveric Biosciences, Inc;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a&ndash;15(f) and 15d&ndash;15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Dr. Joseph Tucker</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Joseph Tucker</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SARBANES&ndash;OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Kevin Coveney, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this annual report on Form 10&ndash;K of Enveric Biosciences, Inc;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a&ndash;15(f) and 15d&ndash;15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Kevin Coveney</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin
    Coveney</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>ex32.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SECTION 906</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
THE SARBANES&ndash;OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Enveric Biosciences, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31,
2023 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), each of the undersigned, in
the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Dr. Joseph Tucker</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Joseph Tucker</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Kevin Coveney</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin
    Coveney</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>ex97.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">Exhibit 97<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex97.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLAWBACK
POLICY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Introduction</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of Enveric Biosciences, Inc. (the &ldquo;<B>Company</B>&rdquo;) believes that it
is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability.
The Board has therefore adopted this Clawback Policy (the &ldquo;<B>Policy</B>&rdquo;), which provides for the recovery of certain incentive
compensation in the event of an accounting restatement. This Policy is designed to comply with, and shall be interpreted to be consistent
with, Section 10D of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), Rule 10D-1 promulgated
under the Exchange Act (&ldquo;<B>Rule 10D-1</B>&rdquo;) and Nasdaq Listing Rule 5608 (the &ldquo;<B>Listing Standards</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B><U>Administration</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be administered by the Compensation Committee of the Board (the &ldquo;<B>Administrator</B>&rdquo;). The Administrator is
authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration
of this Policy. Any determinations made by the Administrator shall be final and binding on all affected individuals and need not be uniform
with respect to each individual covered by this Policy. Subject to any limitations under applicable law, the Administrator may empower
any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this
Policy (other than with respect to any recovery under this Policy involving such officer or employee.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B><U>Covered Executives</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to the Company&rsquo;s current and former executive officers, as determined by the Board in accordance with Section 10D
of the Exchange Act and the Listing Standards (&ldquo;<B>Covered Executives</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B><U>Recoupment; Accounting Restatement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will reasonably promptly require reimbursement or forfeiture of any excess Incentive Compensation received by any Covered Executive
during the three completed fiscal years immediately preceding the date on which the Company is required to prepare an accounting restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&ldquo;accounting restatement&rdquo; means an accounting restatement of the Company&rsquo;s financial statements due to the Company&rsquo;s
material noncompliance with any financing reporting requirements under the securities laws, including any required accounting restatement
to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that
would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<B><U>Incentive Compensation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Policy, &ldquo;Incentive Compensation&rdquo; means compensation that is granted, earned, or vested based wholly or in
part on the attainment of a financial reporting measure, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual bonuses and other short- and long-term cash incentives</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock appreciation rights</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock units</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance shares</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
units</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;financial reporting measure&rdquo; is any measure that is determined and presented in accordance with the accounting principles
used in preparing the Company financial statements, and any measure that is derived wholly or in part from such measure. Financial reporting
measures include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
stock price</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total shareholder return</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
income</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
ratios</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
before interest, taxes, depreciation, and amortization (EBITDA)</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funds
from operations and adjusted funds from operations</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
measures such as working capital or operating cash flow</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
measures such as return on invested capital or return on assets</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
measures such as earnings per share</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial reporting measure need not be presented within the Company&rsquo;s financial statements or included in a filing with the Securities
and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<B><U>Application of Policy</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to Incentive Compensation received by a Covered Executive (a) after beginning services as a Covered Executive; (b) if
that person served as a Covered Executive at any time during the performance period for such incentive compensation; and (c) while the
Company had a listed class of securities on a national securities exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
Compensation is deemed &ldquo;received&rdquo; in the fiscal period in which the financial reporting measure specified in the Incentive
Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B><U>Excess Incentive Compensation: Amount Subject to Recovery</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount to be recovered will be the excess of the Incentive Compensation paid to the Covered Executive based on the erroneous data over
the Incentive Compensation that would have been paid to the Covered Executive had it been based on the restated results, as determined
by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excess
Incentive Compensation will be computed by the Administrator without regard to any taxes paid by the Covered Executive in respect of
the excess Incentive Compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Incentive Compensation based on stock price or total shareholder return, (a) the Administrator will determine the amount of excess Incentive
Compensation based on a reasonable estimate of the effect of the accounting restatement on the stock price or total shareholder return
upon which the Incentive Compensation was received; and (b) in the event of an accounting restatement, the Company shall maintain documentation
of the determination of that reasonable estimate and provide such documentation to The Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may retain legal counsel or compensation consultants to assist it in determining the amount of excess Incentive Compensation
that is subject to recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B><U>Method of Recoupment</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator will determine, in its sole discretion, the timing and method for recouping Incentive Compensation which may include, without
limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
requiring reimbursement of cash Incentive Compensation previously paid;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based
awards;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered Executive;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
cancelling outstanding vested or unvested equity awards; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
taking any other remedial and recovery action permitted by law, as determined by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may, but is not required to, discuss the method of recovery with the affected Covered Executive in order to structure a
satisfactory and reasonably prompt method of recovery under this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized and directed pursuant to this Policy to recoup excess Incentive Compensation in compliance with this Policy unless
the Administrator has determined that recovery would be impracticable solely for the following limited reasons, and subject to the following
procedural and disclosure requirements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before concluding that it would be impracticable to recover any amount of excess Incentive Compensation based on the expense of enforcement, the Administrator must make a reasonable attempt to recover such excess Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to Nasdaq; or</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recovery
    would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company,
    to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<B><U>No Indemnification of Covered Executives</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall not indemnify any Covered Executive against the loss of any incorrectly awarded Incentive Compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<B><U>Indemnification of Administrator</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
members of the Board who assist in the administration of this Policy shall not be personally liable for any action, determination or
interpretation made with respect to this Policy and shall be fully indemnified by the Company to the fullest extent under applicable
law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other
rights to indemnification of the members of the Board under applicable law or Company policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<B><U>Effective Date</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be effective as of October 2, 2023 (the &ldquo;<B>Effective Date</B>&rdquo;), and shall apply to Incentive Compensation
that is received by a Covered Executive on or after the Effective Date, even if such Incentive Compensation was approved, awarded or
granted to Covered Executives on or before that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<B><U>Amendment</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to reflect final regulations
adopted by the Securities and Exchange Commission under Section 10D of the Exchange Act and to comply with any rules or standards adopted
by a national securities exchange on which the Company&rsquo;s securities are listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<B><U>Other Recoupment Rights</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board intends that this Policy will be applied to the fullest extent of the law. The Board may require that any employment agreement,
equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit
thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in
addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms
of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available
to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
contained in this Policy, and no recoupment or recovery as contemplated by this Policy, shall limit any claims, damages, or other legal
remedies the Company or any of its affiliates may have against a Covered Executive arising out of or resulting from any actions or omissions
by the Covered Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<B><U>Successors</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other
legal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<B><U>Disclosure Requirements</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall file all disclosures with respect to this Policy required by applicable Securities and Exchange Commission rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clawback
Policy Acknowledgment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
my signature below, I agree and acknowledge that I am fully bound by, and subject to, all of the terms and conditions of the Enveric
Biosciences, Inc. Clawback Policy (as may be amended from time to time, the &ldquo;<B>Policy</B>&rdquo;). In the event of any inconsistency
between the Policy and the terms of any employment agreement to which I am a party, or the terms of any compensation plan, program or
agreement under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern. In the
event the Administrator determines that any amounts granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company,
I will promptly take any action necessary to effectuate such forfeiture or reimbursement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: __________________________ </FONT></TD>
  <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: ____________________</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex97.jpg
<TEXT>
begin 644 ex97.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !^ *,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex19_001.jpg
<TEXT>
begin 644 ex19_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P *D# 2(  A$! Q$!_\0
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M$D\]!Q79-K6FH[(U["&4X(W=#0U8=T]B_14-O=P7:EK>59%!P2M34@"BBB@
MHHHH **P_$&KMISV=NMU%:?:2^ZXE7=L"@=!W)R.O'6LS^V(/^AQ'_@-'_\
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9@LX[>>257E+2=0SD@?0=JL445+=RK6/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex19_002.jpg
<TEXT>
begin 644 ex19_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  S #$# 2(  A$! Q$!_\0
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M3YIRDN7W>:3:44DO=N]%ILDC]^C"$)5E",8_O%>RLV[.[?6]WN]6-\E?5_\
MOMO\:*EHH*"JTRJ7AR/O.4/)Y5@6(Z]R <]1V(!-%%'1_P"%_DR)[1_QP?S4
MKI_)ZGY ?LT_ #X.:W_P48_;5^.FM> =&U?XK^'/%'@;3_#WC'5'OM0O= MK
MSP?:071T2RN[R;2=)NIX;.WCDO[#3[>_9(]OVG#R;OU\=%5"%&,1X&">FW/7
M.3D]2>3WHHKU\\KU\14P?MZU6O[+)L#1I>VJ3J^SHPHRY:5/GE+DI1^S3CRP
M72)Y>3T*-%XOV-&E2]IFV)JU/9TX4^>K*?O5)\D8\U27VIRO)]6R:)0$0 <
M\<G^[G^=/C'R#ZM_Z$W>BBO%6U-=%!V7R1ZS^.H^KE%M]WKJ^X^BBBK&?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>envb-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa+ASbP9z5Z8mekhvWB1bcl6DyIhQw6MqiTyBm2mIeYB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ENVB="http://enveric.com/20231231" elementFormDefault="qualified" targetNamespace="http://enveric.com/20231231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://enveric.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" id="StatementsOfChangesInMezzanineEquityAndShareholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" id="StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical">
          <link:definition>00000006 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" id="BusinessAndLiquidityAndOtherUncertainties">
          <link:definition>00000008 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
          <link:definition>00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/IntangibleAssetsAndGoodwill" id="IntangibleAssetsAndGoodwill">
          <link:definition>00000011 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>00000012 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/AccruedLiabilities" id="AccruedLiabilities">
          <link:definition>00000013 - Disclosure - ACCRUED LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" id="ShareCapitalAndOtherEquityInstruments">
          <link:definition>00000014 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/RedeemableNon-controllingInterest" id="RedeemableNon-controllingInterest">
          <link:definition>00000015 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/FairValue" id="FairValue">
          <link:definition>00000016 - Disclosure - FAIR VALUE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000018 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000019 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" id="BusinessAndLiquidityAndOtherUncertaintiesTables">
          <link:definition>00000021 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
          <link:definition>00000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/IntangibleAssetsAndGoodwillTables" id="IntangibleAssetsAndGoodwillTables">
          <link:definition>00000024 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>00000025 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
          <link:definition>00000026 - Disclosure - ACCRUED LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" id="ShareCapitalAndOtherEquityInstrumentsTables">
          <link:definition>00000027 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/RedeemableNon-controllingInterestTables" id="RedeemableNon-controllingInterestTables">
          <link:definition>00000028 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/FairValueTables" id="FairValueTables">
          <link:definition>00000029 - Disclosure - FAIR VALUE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>00000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000031 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" id="ScheduleOfRestructuringCostsPayableDetails">
          <link:definition>00000032 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" id="BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative">
          <link:definition>00000033 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" id="ScheduleOfPotentiallyDilutiveSecuritiesDetails">
          <link:definition>00000034 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:definition>00000036 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfGoodwillDetails" id="ScheduleOfGoodwillDetails">
          <link:definition>00000037 - Disclosure - SCHEDULE OF GOODWILL (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" id="ScheduleOfIntangibleAssetsDetails">
          <link:definition>00000038 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" id="ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails">
          <link:definition>00000039 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" id="IntangibleAssetsAndGoodwillDetailsNarrative">
          <link:definition>00000040 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" id="ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails">
          <link:definition>00000041 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>00000042 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" id="ScheduleOfAccruedLiabilitiesDetails">
          <link:definition>00000043 - Disclosure - SCHEDULE OF ACCRUED LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfStockOptionDetails" id="ScheduleOfStockOptionDetails">
          <link:definition>00000044 - Disclosure - SCHEDULE OF STOCK OPTION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" id="ScheduleOfStockOptionAssumptionDetails">
          <link:definition>00000045 - Disclosure - SCHEDULE OF STOCK OPTION ASSUMPTION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" id="ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails">
          <link:definition>00000046 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" id="ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails">
          <link:definition>00000047 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" id="ScheduleOfWarrantsOutstandingDetails">
          <link:definition>00000048 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" id="ScheduleOfWarrantsAndInvestmentOptionsDetails">
          <link:definition>00000049 - Disclosure - SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" id="ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails">
          <link:definition>00000050 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" id="ShareCapitalAndOtherEquityInstrumentsDetailsNarrative">
          <link:definition>00000051 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" id="ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails">
          <link:definition>00000052 - Disclosure - SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" id="RedeemableNon-controllingInterestDetailsNarrative">
          <link:definition>00000053 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" id="ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails">
          <link:definition>00000054 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" id="ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails">
          <link:definition>00000055 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" id="ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails">
          <link:definition>00000056 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/FairValueDetailsNarrative" id="FairValueDetailsNarrative">
          <link:definition>00000057 - Disclosure - FAIR VALUE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" id="ScheduleOfWeightedAverageRemainingLeaseTermDetails">
          <link:definition>00000058 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" id="ScheduleOfEarningLossBeforeIncomeTaxDetails">
          <link:definition>00000060 - Disclosure - SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" id="ScheduleOfIncomeTaxExpenseBenefitsDetails">
          <link:definition>00000061 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>00000062 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" id="ScheduleOfOperatingLossCarryForwardsDetails">
          <link:definition>00000063 - Disclosure - SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" id="ScheduleOfEffectiveStatutoryIncomeTaxRateDetails">
          <link:definition>00000064 - Disclosure - SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000065 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000066 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="ENVB_SeriesCRedeemablePreferredStockMember" name="SeriesCRedeemablePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterestMember" name="RedeemableNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_MezzanineEquityMember" name="MezzanineEquityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SubscriptionReceivableMember" name="SubscriptionReceivableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_EquityDistributionAgreementMember" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_KanubaddiSeparationAgreementMember" name="KanubaddiSeparationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_MrKanubaddiEmploymentAgreementMember" name="MrKanubaddiEmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PrefundedCommonStockWarrantsMember" name="PrefundedCommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantsToPurchaseSharesOfCommonStockMember" name="WarrantsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" name="RestrictedStockUnitsVestedAndUnIssuedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RestrictedStockUnitsUnvestedMember" name="RestrictedStockUnitsUnvestedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" name="RestrictedStockAwardsVestedAndUnIssuedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_CommonStockInAbeyanceMember" name="CommonStockInAbeyanceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" name="InvstmentOptionsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_OptionsToPurchaseSharesOfCommonStockMember" name="OptionsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_LabEquipmentMember" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" name="ComputerEquipmentAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_DistributionAgreementMember" name="DistributionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_CanaccordGenuityLLCMember" name="CanaccordGenuityLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RegistrationRightsAgreementMember" name="RegistrationRightsAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_UnderwritersMember" name="UnderwritersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" name="RegisteredDirectSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PIPESecuritiesPurchaseAgreementMember" name="PIPESecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RDOfferingAndPIPEInvestmentOptionsMember" name="RDOfferingAndPIPEInvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_TwoThousandTwentyLongTermIncentivePlanMember" name="TwoThousandTwentyLongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantAmendmentAgreementsMember" name="WarrantAmendmentAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PlacementAgentPreferredInvestmentOptionsMember" name="PlacementAgentPreferredInvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FebruaryWarrantsMember" name="FebruaryWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PreModificationWarrantsMember" name="PreModificationWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ExistingWarrantsMember" name="ExistingWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOptionsMember" name="InvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PostModificationWarrantsMember" name="PostModificationWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RothAndInducementWarrantsMember" name="RothAndInducementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AkosSecuritiesPurchaseAgreementMember" name="AkosSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AkosMember" name="AkosMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InitialMeasurementMember" name="InitialMeasurementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SubsequentMeasurementMember" name="SubsequentMeasurementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" name="WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" name="WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" name="WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" name="DerivativeLiabilityMayTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WainwrightInvestmentOptionsMember" name="WainwrightInvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RDInvestmentOptionsMember" name="RDInvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PIPEInvestmentOptionsMember" name="PIPEInvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FebruaryTwentyTwentyTwoWarrantsMember" name="FebruaryTwentyTwentyTwoWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" name="FebruaryTwentyTwentyTwoPostModificationWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_MeasurementInputMarketRateMember" name="MeasurementInputMarketRateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_JanuaryTwentyTwentyOneWarrantsMember" name="JanuaryTwentyTwentyOneWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FebruaryTwentyTwentyOneWarrantsMember" name="FebruaryTwentyTwentyOneWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" name="HCWainwrightAndCoLLCInvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AvanceClinicalMember" name="AvanceClinicalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_VogalNathanPurchaseAgreementMember" name="VogalNathanPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_OneTimeMilestoneMember" name="OneTimeMilestoneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AdditionalMilestoneMember" name="AdditionalMilestoneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_OtherConsultingAndVendorAgreementsMember" name="OtherConsultingAndVendorAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantLiabilitiesCurrent" name="WarrantLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InducementExpense" name="InducementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_TemporaryEquityShares" name="TemporaryEquityShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" name="PreferredDividendsAttributableToRedeemableNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" name="AccretionOfEmbeddedDerivativeToRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" name="AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" name="StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" name="StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterestValue" name="RedeemableNoncontrollingInterestValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterestShares" name="RedeemableNoncontrollingInterestShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" name="IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" name="StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" name="StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" name="RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" name="RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" name="IssuanceOfRoundedSharesAsResultOfReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_NetOfferingCosts" name="NetOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" name="RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterestIssuanceCosts" name="RedeemableNoncontrollingInterestIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_NoncashIncomeTaxExpense" name="NoncashIncomeTaxExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" name="IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance" name="WarrantsIssuedInConjunctionWithCommonStockIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_IssuanceOfEmbeddedDerivative" name="IssuanceOfEmbeddedDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockSubscriptionReceivable" name="StockSubscriptionReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_OfferingCostsAccruedNotPaid" name="OfferingCostsAccruedNotPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantsIssuedForOfferingCosts" name="WarrantsIssuedForOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" name="IssuanceOfCommonSharesForDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" name="InducedConversionOfWarrantsAndPreferredInvestmentOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" name="InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise" name="ModificationOfWarrantsAsPartOfShareCapitalRaise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" name="DisclosureRedeemableNoncontrollingInterestAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNonControllingInterestTextBlock" name="RedeemableNonControllingInterestTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" name="ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" name="RedeemableNoncontrollingInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock" name="ScheduleOfWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ScheduleOfValuationOfWarrantsTextBlock" name="ScheduleOfValuationOfWarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" name="ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RestructuringCostsIncurred" name="RestructuringCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ExpenseRelatedToAccelerationOfVesting" name="ExpenseRelatedToAccelerationOfVesting" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_MarketPerformanceBasedShares" name="MarketPerformanceBasedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" name="MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PrepaidResearchAndDevelopment" name="PrepaidResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PrepaidFranchiseTaxReceivable" name="PrepaidFranchiseTaxReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" name="PrepaidResearchAndDevelopmentTaxIncentiveReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillCurrencyTranslation" name="GoodwillCurrencyTranslation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillImpairmentLossGross" name="GoodwillImpairmentLossGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillAccumulatedImpairmentLoss" name="GoodwillAccumulatedImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillCurrencyTranslationImpairmentLoss" name="GoodwillCurrencyTranslationImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillForeignCurrencyTranslationGainLossGross" name="GoodwillForeignCurrencyTranslationGainLossGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" name="GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillCurrencyTranslationLoss" name="GoodwillCurrencyTranslationLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AccruedProductDevelopmentCost" name="AccruedProductDevelopmentCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AccruedRestructuringCosts" name="AccruedRestructuringCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" name="SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_CommissionPercentage" name="CommissionPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantLiability" name="WarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PaymentsOfStockIssuanceCost" name="PaymentsOfStockIssuanceCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PaymentsOfAllocatedEquity" name="PaymentsOfAllocatedEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PaymentsOfInvestmentOptionLiability" name="PaymentsOfInvestmentOptionLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" name="PaymentsOfStockIssuanceCostsRecordedExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_NumberOfVestedAndUnissuedShares" name="NumberOfVestedAndUnissuedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" name="ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ClassOfWarrantOrRightReasonForIssuing" name="ClassOfWarrantOrRightReasonForIssuing" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOptionSharePrice" name="InvestmentOptionSharePrice" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOptionExercisePrice" name="InvestmentOptionExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOptionTerm" name="InvestmentOptionTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOutstandingMeasurementInput" name="InvestmentOutstandingMeasurementInput" nillable="true" xbrli:periodType="instant" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SharePriceOption" name="SharePriceOption" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentIntrinsicValue" name="InvestmentIntrinsicValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentInducementGain" name="InvestmentInducementGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SpinoffAndRelatedPrivatePlacementDescription" name="SpinoffAndRelatedPrivatePlacementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantsToPurchaseCommonStockPercentage" name="WarrantsToPurchaseCommonStockPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_UnpaidDividends" name="UnpaidDividends" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterest" name="RedeemableNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantsAndRightsOutstandingStockPrice" name="WarrantsAndRightsOutstandingStockPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ConvertiblePreferredStockPrincipalValue" name="ConvertiblePreferredStockPrincipalValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockOptionExercisePrice" name="StockOptionExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RoyaltiesPercentage" name="RoyaltiesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ResearchAndDevelopmentCapitalizedExpenses" name="ResearchAndDevelopmentCapitalizedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_DeferredTaxAssetsAndIntangibleAmortization" name="DeferredTaxAssetsAndIntangibleAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" name="EffectiveIncomeTaxRateReconciliationDeferredTrueup" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_JulyWarrantsMember" name="JulyWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermIssued" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermIssued" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_EffectiveIncomeTaxRateReconciliationReturnToProvision" name="EffectiveIncomeTaxRateReconciliationReturnToProvision" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>envb-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://enveric.com/role/Cover" xlink:href="envb-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BalanceSheets" xlink:href="envb-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BalanceSheetsParenthetical" xlink:href="envb-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="envb-20231231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:href="envb-20231231.xsd#StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:href="envb-20231231.xsd#StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfCashFlows" xlink:href="envb-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" xlink:href="envb-20231231.xsd#BusinessAndLiquidityAndOtherUncertainties" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="envb-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="envb-20231231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsAndGoodwill" xlink:href="envb-20231231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipment" xlink:href="envb-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/AccruedLiabilities" xlink:href="envb-20231231.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" xlink:href="envb-20231231.xsd#ShareCapitalAndOtherEquityInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterest" xlink:href="envb-20231231.xsd#RedeemableNon-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValue" xlink:href="envb-20231231.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingencies" xlink:href="envb-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxes" xlink:href="envb-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SubsequentEvents" xlink:href="envb-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="envb-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:href="envb-20231231.xsd#BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="envb-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="envb-20231231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="envb-20231231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipmentTables" xlink:href="envb-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/AccruedLiabilitiesTables" xlink:href="envb-20231231.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:href="envb-20231231.xsd#ShareCapitalAndOtherEquityInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterestTables" xlink:href="envb-20231231.xsd#RedeemableNon-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValueTables" xlink:href="envb-20231231.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingenciesTables" xlink:href="envb-20231231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxesTables" xlink:href="envb-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" xlink:href="envb-20231231.xsd#ScheduleOfRestructuringCostsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:href="envb-20231231.xsd#BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="envb-20231231.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="envb-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="envb-20231231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfGoodwillDetails" xlink:href="envb-20231231.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="envb-20231231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:href="envb-20231231.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:href="envb-20231231.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:href="envb-20231231.xsd#ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="envb-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:href="envb-20231231.xsd#ScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStockOptionDetails" xlink:href="envb-20231231.xsd#ScheduleOfStockOptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" xlink:href="envb-20231231.xsd#ScheduleOfStockOptionAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:href="envb-20231231.xsd#ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:href="envb-20231231.xsd#ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="envb-20231231.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:href="envb-20231231.xsd#ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:href="envb-20231231.xsd#ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:href="envb-20231231.xsd#ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:href="envb-20231231.xsd#ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" xlink:href="envb-20231231.xsd#RedeemableNon-controllingInterestDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:href="envb-20231231.xsd#ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:href="envb-20231231.xsd#ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:href="envb-20231231.xsd#ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValueDetailsNarrative" xlink:href="envb-20231231.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:href="envb-20231231.xsd#ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="envb-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:href="envb-20231231.xsd#ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:href="envb-20231231.xsd#ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="envb-20231231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" xlink:href="envb-20231231.xsd#ScheduleOfOperatingLossCarryForwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:href="envb-20231231.xsd#ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxesDetailsNarrative" xlink:href="envb-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SubsequentEventsDetailsNarrative" xlink:href="envb-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilitiesCurrent" xlink:label="loc_ENVBWarrantLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_ENVBWarrantLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" weight="1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InducementExpense" xlink:label="loc_ENVBInducementExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_ENVBInducementExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaapTemporaryEquityAccretionToRedemptionValueAdjustment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapTemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders&apos; Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InducementExpense" xlink:label="loc_ENVBInducementExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ENVBInducementExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_NoncashIncomeTaxExpense" xlink:label="loc_ENVBNoncashIncomeTaxExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ENVBNoncashIncomeTaxExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:label="loc_ENVBIncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ENVBIncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfRedeemablePreferredStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfRedeemablePreferredStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" xlink:title="00000008 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000011 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/AccruedLiabilities" xlink:title="00000013 - Disclosure - ACCRUED LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" xlink:title="00000014 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterest" xlink:title="00000015 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValue" xlink:title="00000016 - Disclosure - FAIR VALUE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxes" xlink:title="00000018 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:title="00000021 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000024 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/AccruedLiabilitiesTables" xlink:title="00000026 - Disclosure - ACCRUED LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:title="00000027 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterestTables" xlink:title="00000028 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValueTables" xlink:title="00000029 - Disclosure - FAIR VALUE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingenciesTables" xlink:title="00000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="00000033 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PrepaidResearchAndDevelopment" xlink:label="loc_ENVBPrepaidResearchAndDevelopment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_ENVBPrepaidResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PrepaidFranchiseTaxReceivable" xlink:label="loc_ENVBPrepaidFranchiseTaxReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_ENVBPrepaidFranchiseTaxReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:label="loc_ENVBPrepaidResearchAndDevelopmentTaxIncentiveReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_ENVBPrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfGoodwillDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF GOODWILL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="00000040 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000042 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF ACCRUED LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AccruedProductDevelopmentCost" xlink:label="loc_ENVBAccruedProductDevelopmentCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_ENVBAccruedProductDevelopmentCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AccruedRestructuringCosts" xlink:label="loc_ENVBAccruedRestructuringCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_ENVBAccruedRestructuringCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStockOptionDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF STOCK OPTION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF STOCK OPTION ASSUMPTION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:title="00000051 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" xlink:title="00000053 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValueDetailsNarrative" xlink:title="00000057 - Disclosure - FAIR VALUE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000062 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ResearchAndDevelopmentCapitalizedExpenses" xlink:label="loc_ENVBResearchAndDevelopmentCapitalizedExpenses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_ENVBResearchAndDevelopmentCapitalizedExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DeferredTaxAssetsAndIntangibleAmortization" xlink:label="loc_ENVBDeferredTaxAssetsAndIntangibleAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_ENVBDeferredTaxAssetsAndIntangibleAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:label="loc_ENVBEffectiveIncomeTaxRateReconciliationDeferredTrueup" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_ENVBEffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000065 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000066 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>envb-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://enveric.com/role/Cover" xlink:href="envb-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BalanceSheets" xlink:href="envb-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BalanceSheetsParenthetical" xlink:href="envb-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="envb-20231231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:href="envb-20231231.xsd#StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:href="envb-20231231.xsd#StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfCashFlows" xlink:href="envb-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" xlink:href="envb-20231231.xsd#BusinessAndLiquidityAndOtherUncertainties" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="envb-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="envb-20231231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsAndGoodwill" xlink:href="envb-20231231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipment" xlink:href="envb-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/AccruedLiabilities" xlink:href="envb-20231231.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" xlink:href="envb-20231231.xsd#ShareCapitalAndOtherEquityInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterest" xlink:href="envb-20231231.xsd#RedeemableNon-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValue" xlink:href="envb-20231231.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingencies" xlink:href="envb-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxes" xlink:href="envb-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SubsequentEvents" xlink:href="envb-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="envb-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:href="envb-20231231.xsd#BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="envb-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="envb-20231231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="envb-20231231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipmentTables" xlink:href="envb-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/AccruedLiabilitiesTables" xlink:href="envb-20231231.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:href="envb-20231231.xsd#ShareCapitalAndOtherEquityInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterestTables" xlink:href="envb-20231231.xsd#RedeemableNon-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValueTables" xlink:href="envb-20231231.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingenciesTables" xlink:href="envb-20231231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxesTables" xlink:href="envb-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" xlink:href="envb-20231231.xsd#ScheduleOfRestructuringCostsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:href="envb-20231231.xsd#BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="envb-20231231.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="envb-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="envb-20231231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfGoodwillDetails" xlink:href="envb-20231231.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="envb-20231231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:href="envb-20231231.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:href="envb-20231231.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:href="envb-20231231.xsd#ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="envb-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:href="envb-20231231.xsd#ScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStockOptionDetails" xlink:href="envb-20231231.xsd#ScheduleOfStockOptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" xlink:href="envb-20231231.xsd#ScheduleOfStockOptionAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:href="envb-20231231.xsd#ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:href="envb-20231231.xsd#ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="envb-20231231.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:href="envb-20231231.xsd#ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:href="envb-20231231.xsd#ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:href="envb-20231231.xsd#ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:href="envb-20231231.xsd#ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" xlink:href="envb-20231231.xsd#RedeemableNon-controllingInterestDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:href="envb-20231231.xsd#ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:href="envb-20231231.xsd#ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:href="envb-20231231.xsd#ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValueDetailsNarrative" xlink:href="envb-20231231.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:href="envb-20231231.xsd#ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="envb-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:href="envb-20231231.xsd#ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:href="envb-20231231.xsd#ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="envb-20231231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" xlink:href="envb-20231231.xsd#ScheduleOfOperatingLossCarryForwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:href="envb-20231231.xsd#ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxesDetailsNarrative" xlink:href="envb-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SubsequentEventsDetailsNarrative" xlink:href="envb-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SeriesCRedeemablePreferredStockMember" xlink:label="loc_ENVBSeriesCRedeemablePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBSeriesCRedeemablePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SeriesCRedeemablePreferredStockMember" xlink:label="loc_ENVBSeriesCRedeemablePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBSeriesCRedeemablePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestMember" xlink:label="loc_ENVBRedeemableNoncontrollingInterestMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBRedeemableNoncontrollingInterestMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MezzanineEquityMember" xlink:label="loc_ENVBMezzanineEquityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBMezzanineEquityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SubscriptionReceivableMember" xlink:label="loc_ENVBSubscriptionReceivableMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBSubscriptionReceivableMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_TemporaryEquityShares" xlink:label="loc_ENVBTemporaryEquityShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBTemporaryEquityShares_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_ENVBPreferredDividendsAttributableToRedeemableNoncontrollingInterest_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBPreferredDividendsAttributableToRedeemableNoncontrollingInterest_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:label="loc_ENVBAccretionOfEmbeddedDerivativeToRedemptionValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBAccretionOfEmbeddedDerivativeToRedemptionValue_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:label="loc_ENVBAdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBAdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" xlink:label="loc_ENVBStockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_100" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_100" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_100" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestValue" xlink:label="loc_ENVBRedeemableNoncontrollingInterestValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRedeemableNoncontrollingInterestValue_100" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestShares" xlink:label="loc_ENVBRedeemableNoncontrollingInterestShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRedeemableNoncontrollingInterestShares_100" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" xlink:label="loc_ENVBIssuanceOfRedeemableNoncontrollingSeriesPreferredStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBIssuanceOfRedeemableNoncontrollingSeriesPreferredStock_100" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_ENVBTemporaryEquityStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBTemporaryEquityStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" xlink:label="loc_ENVBStockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_100" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_100" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" xlink:label="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_100" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" xlink:label="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_100" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" xlink:label="loc_ENVBIssuanceOfRoundedSharesAsResultOfReverseStockSplit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBIssuanceOfRoundedSharesAsResultOfReverseStockSplit_100" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_100" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders&apos; Equity (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" xlink:title="00000008 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000011 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/AccruedLiabilities" xlink:title="00000013 - Disclosure - ACCRUED LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" xlink:title="00000014 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterest" xlink:title="00000015 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValue" xlink:title="00000016 - Disclosure - FAIR VALUE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxes" xlink:title="00000018 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:title="00000021 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000024 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/AccruedLiabilitiesTables" xlink:title="00000026 - Disclosure - ACCRUED LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:title="00000027 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterestTables" xlink:title="00000028 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValueTables" xlink:title="00000029 - Disclosure - FAIR VALUE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InitialMeasurementMember" xlink:label="loc_ENVBInitialMeasurementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBInitialMeasurementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SubsequentMeasurementMember" xlink:label="loc_ENVBSubsequentMeasurementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBSubsequentMeasurementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingenciesTables" xlink:title="00000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="00000033 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_EquityDistributionAgreementMember" xlink:label="loc_ENVBEquityDistributionAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBEquityDistributionAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_KanubaddiSeparationAgreementMember" xlink:label="loc_ENVBKanubaddiSeparationAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBKanubaddiSeparationAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MrKanubaddiEmploymentAgreementMember" xlink:label="loc_ENVBMrKanubaddiEmploymentAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBMrKanubaddiEmploymentAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WorkingCapital" xlink:label="loc_ENVBWorkingCapital_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBWorkingCapital_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromShortTermDebt_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSeveranceCosts1_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSalariesAndWages_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccruedBonusesCurrent_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaapRestructuringReserve_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRestructuringReserve_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ExpenseRelatedToAccelerationOfVesting" xlink:label="loc_ENVBExpenseRelatedToAccelerationOfVesting_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBExpenseRelatedToAccelerationOfVesting_130" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MarketPerformanceBasedShares" xlink:label="loc_ENVBMarketPerformanceBasedShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBMarketPerformanceBasedShares_130" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" xlink:label="loc_ENVBMinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBMinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_130" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBWarrantsToPurchaseSharesOfCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBWarrantsToPurchaseSharesOfCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" xlink:label="loc_ENVBRestrictedStockUnitsVestedAndUnIssuedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBRestrictedStockUnitsVestedAndUnIssuedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RestrictedStockUnitsUnvestedMember" xlink:label="loc_ENVBRestrictedStockUnitsUnvestedMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBRestrictedStockUnitsUnvestedMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" xlink:label="loc_ENVBRestrictedStockAwardsVestedAndUnIssuedMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBRestrictedStockAwardsVestedAndUnIssuedMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_CommonStockInAbeyanceMember" xlink:label="loc_ENVBCommonStockInAbeyanceMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBCommonStockInAbeyanceMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBInvstmentOptionsToPurchaseSharesOfCommonStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBInvstmentOptionsToPurchaseSharesOfCommonStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_OptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBOptionsToPurchaseSharesOfCommonStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBOptionsToPurchaseSharesOfCommonStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_countryCA_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCA_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="loc_countryAU_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryAU_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PrefundedCommonStockWarrantsMember" xlink:label="loc_ENVBPrefundedCommonStockWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENVBPrefundedCommonStockWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockIssued1_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease_80" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfGoodwillDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF GOODWILL (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="00000040 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_LabEquipmentMember" xlink:label="loc_ENVBLabEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ENVBLabEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" xlink:label="loc_ENVBComputerEquipmentAndLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ENVBComputerEquipmentAndLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000042 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF ACCRUED LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStockOptionDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF STOCK OPTION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF STOCK OPTION ASSUMPTION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_70" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionsMember" xlink:label="loc_ENVBInvestmentOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBInvestmentOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RothAndInducementWarrantsMember" xlink:label="loc_ENVBRothAndInducementWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBRothAndInducementWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice_30" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:title="00000051 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DistributionAgreementMember" xlink:label="loc_ENVBDistributionAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBDistributionAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RegistrationRightsAgreementMember" xlink:label="loc_ENVBRegistrationRightsAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBRegistrationRightsAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBRegisteredDirectSecuritiesPurchaseAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBRegisteredDirectSecuritiesPurchaseAgreementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PIPESecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBPIPESecuritiesPurchaseAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPIPESecuritiesPurchaseAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantAmendmentAgreementsMember" xlink:label="loc_ENVBWarrantAmendmentAgreementsMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBWarrantAmendmentAgreementsMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_CanaccordGenuityLLCMember" xlink:label="loc_ENVBCanaccordGenuityLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ENVBCanaccordGenuityLLCMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PlacementAgentPreferredInvestmentOptionsMember" xlink:label="loc_ENVBPlacementAgentPreferredInvestmentOptionsMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBPlacementAgentPreferredInvestmentOptionsMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_UnderwritersMember" xlink:label="loc_ENVBUnderwritersMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ENVBUnderwritersMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RDOfferingAndPIPEInvestmentOptionsMember" xlink:label="loc_ENVBRDOfferingAndPIPEInvestmentOptionsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBRDOfferingAndPIPEInvestmentOptionsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_620" xlink:type="arc" order="621" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_TwoThousandTwentyLongTermIncentivePlanMember" xlink:label="loc_ENVBTwoThousandTwentyLongTermIncentivePlanMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ENVBTwoThousandTwentyLongTermIncentivePlanMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ExistingWarrantsMember" xlink:label="loc_ENVBExistingWarrantsMember_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENVBExistingWarrantsMember_560" xlink:type="arc" order="562" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionsMember" xlink:label="loc_ENVBInvestmentOptionsMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENVBInvestmentOptionsMember_570" xlink:type="arc" order="572" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_460" xlink:type="arc" order="462" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FebruaryWarrantsMember" xlink:label="loc_ENVBFebruaryWarrantsMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryWarrantsMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PreModificationWarrantsMember" xlink:label="loc_ENVBPreModificationWarrantsMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBPreModificationWarrantsMember_510" xlink:type="arc" order="511" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PostModificationWarrantsMember" xlink:label="loc_ENVBPostModificationWarrantsMember_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBPostModificationWarrantsMember_580" xlink:type="arc" order="581" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_490" xlink:type="arc" order="491" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember_520" xlink:type="arc" order="521" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_530" xlink:type="arc" order="531" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_540" xlink:type="arc" order="541" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockVotingRights_660" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_660" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_660" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_660" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_660" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" xlink:label="loc_ENVBSaleOfStockConsiderationExpectedMaximumPriceOnLimitation_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSaleOfStockConsiderationExpectedMaximumPriceOnLimitation_660" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_CommissionPercentage" xlink:label="loc_ENVBCommissionPercentage_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBCommissionPercentage_660" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_660" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_660" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_660" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_660" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_660" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_660" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_660" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_660" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_660" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesWarrantsExercised_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesWarrantsExercised_660" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_660" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiability" xlink:label="loc_ENVBWarrantLiability_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBWarrantLiability_660" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_660" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_660" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_660" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromOtherEquity_660" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PaymentsOfStockIssuanceCost" xlink:label="loc_ENVBPaymentsOfStockIssuanceCost_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfStockIssuanceCost_660" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PaymentsOfAllocatedEquity" xlink:label="loc_ENVBPaymentsOfAllocatedEquity_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfAllocatedEquity_660" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PaymentsOfInvestmentOptionLiability" xlink:label="loc_ENVBPaymentsOfInvestmentOptionLiability_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfInvestmentOptionLiability_660" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" xlink:label="loc_ENVBPaymentsOfStockIssuanceCostsRecordedExpense_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfStockIssuanceCostsRecordedExpense_660" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_660" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_660" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_660" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_660" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_660" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_660" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_660" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_660" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_NumberOfVestedAndUnissuedShares" xlink:label="loc_ENVBNumberOfVestedAndUnissuedShares_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBNumberOfVestedAndUnissuedShares_660" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_660" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_660" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" xlink:label="loc_ENVBClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_660" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_660" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_660" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease_660" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_660" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_660" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_660" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ClassOfWarrantOrRightReasonForIssuing" xlink:label="loc_ENVBClassOfWarrantOrRightReasonForIssuing_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBClassOfWarrantOrRightReasonForIssuing_660" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_660" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_660" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_660" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionSharePrice" xlink:label="loc_ENVBInvestmentOptionSharePrice_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOptionSharePrice_660" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionExercisePrice" xlink:label="loc_ENVBInvestmentOptionExercisePrice_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOptionExercisePrice_660" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionTerm" xlink:label="loc_ENVBInvestmentOptionTerm_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOptionTerm_660" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOutstandingMeasurementInput" xlink:label="loc_ENVBInvestmentOutstandingMeasurementInput_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOutstandingMeasurementInput_660" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharePriceOption" xlink:label="loc_ENVBSharePriceOption_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharePriceOption_660" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesOutstanding_660" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_660" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentIntrinsicValue" xlink:label="loc_ENVBInvestmentIntrinsicValue_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentIntrinsicValue_660" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentInducementGain" xlink:label="loc_ENVBInvestmentInducementGain_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentInducementGain_660" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_660" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights_660" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_660" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapPreferredStockCapitalSharesReservedForFutureIssuance_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockCapitalSharesReservedForFutureIssuance_660" xlink:type="arc" order="61" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" xlink:title="00000053 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AkosSecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBAkosSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBAkosSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBSecuritiesPurchaseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBSecuritiesPurchaseAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SeriesAConvertiblePreferredStockMember" xlink:label="loc_ENVBSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AkosMember" xlink:label="loc_ENVBAkosMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_ENVBAkosMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SpinoffAndRelatedPrivatePlacementDescription" xlink:label="loc_ENVBSpinoffAndRelatedPrivatePlacementDescription_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBSpinoffAndRelatedPrivatePlacementDescription_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsToPurchaseCommonStockPercentage" xlink:label="loc_ENVBWarrantsToPurchaseCommonStockPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBWarrantsToPurchaseCommonStockPercentage_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="loc_us-gaapDividendsPayableAmountPerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPayableAmountPerShare_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_UnpaidDividends" xlink:label="loc_ENVBUnpaidDividends_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBUnpaidDividends_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterest" xlink:label="loc_ENVBRedeemableNoncontrollingInterest_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRedeemableNoncontrollingInterest_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount_140" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBWarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBWarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" xlink:label="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:label="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WainwrightInvestmentOptionsMember" xlink:label="loc_ENVBWainwrightInvestmentOptionsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBWainwrightInvestmentOptionsMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RDInvestmentOptionsMember" xlink:label="loc_ENVBRDInvestmentOptionsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBRDInvestmentOptionsMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PIPEInvestmentOptionsMember" xlink:label="loc_ENVBPIPEInvestmentOptionsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBPIPEInvestmentOptionsMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesRelatedToInvestmentContractsFairValueDisclosure_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesRelatedToInvestmentContractsFairValueDisclosure_170" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InitialMeasurementMember" xlink:label="loc_ENVBInitialMeasurementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBInitialMeasurementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SubsequentMeasurementMember" xlink:label="loc_ENVBSubsequentMeasurementMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBSubsequentMeasurementMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FebruaryTwentyTwentyTwoWarrantsMember" xlink:label="loc_ENVBFebruaryTwentyTwentyTwoWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryTwentyTwentyTwoWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" xlink:label="loc_ENVBFebruaryTwentyTwentyTwoPostModificationWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryTwentyTwentyTwoPostModificationWarrantsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_JanuaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBJanuaryTwentyTwentyOneWarrantsMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBJanuaryTwentyTwentyOneWarrantsMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FebruaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBFebruaryTwentyTwentyOneWarrantsMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryTwentyTwentyOneWarrantsMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MeasurementInputMarketRateMember" xlink:label="loc_ENVBMeasurementInputMarketRateMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_ENVBMeasurementInputMarketRateMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:label="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WainwrightInvestmentOptionsMember" xlink:label="loc_ENVBWainwrightInvestmentOptionsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBWainwrightInvestmentOptionsMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RDInvestmentOptionsMember" xlink:label="loc_ENVBRDInvestmentOptionsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBRDInvestmentOptionsMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PIPEInvestmentOptionsMember" xlink:label="loc_ENVBPIPEInvestmentOptionsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBPIPEInvestmentOptionsMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" xlink:label="loc_ENVBHCWainwrightAndCoLLCInvestmentOptionsMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBHCWainwrightAndCoLLCInvestmentOptionsMember_510" xlink:type="arc" order="512" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_580" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsAndRightsOutstandingStockPrice" xlink:label="loc_ENVBWarrantsAndRightsOutstandingStockPrice_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBWarrantsAndRightsOutstandingStockPrice_580" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_580" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_580" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_580" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_580" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ConvertiblePreferredStockPrincipalValue" xlink:label="loc_ENVBConvertiblePreferredStockPrincipalValue_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBConvertiblePreferredStockPrincipalValue_580" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaapAlternativeInvestmentMeasurementInput_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapAlternativeInvestmentMeasurementInput_580" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionTerm" xlink:label="loc_ENVBInvestmentOptionTerm_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBInvestmentOptionTerm_580" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_580" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockOptionExercisePrice" xlink:label="loc_ENVBStockOptionExercisePrice_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBStockOptionExercisePrice_580" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" xlink:label="loc_us-gaapRetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapRetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_580" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_580" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeMember" xlink:label="loc_us-gaapDerivativeMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDerivativeMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:label="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:label="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_160" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValueDetailsNarrative" xlink:title="00000057 - Disclosure - FAIR VALUE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AvanceClinicalMember" xlink:label="loc_ENVBAvanceClinicalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ENVBAvanceClinicalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_VogalNathanPurchaseAgreementMember" xlink:label="loc_ENVBVogalNathanPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBVogalNathanPurchaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_OtherConsultingAndVendorAgreementsMember" xlink:label="loc_ENVBOtherConsultingAndVendorAgreementsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBOtherConsultingAndVendorAgreementsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_OneTimeMilestoneMember" xlink:label="loc_ENVBOneTimeMilestoneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBOneTimeMilestoneMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AdditionalMilestoneMember" xlink:label="loc_ENVBAdditionalMilestoneMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBAdditionalMilestoneMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="loc_us-gaapCapitalizedContractCostNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCapitalizedContractCostNet_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:label="loc_us-gaapConstructionContractCostProgressPaymentOffset_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapConstructionContractCostProgressPaymentOffset_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaapLongTermPurchaseCommitmentAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLongTermPurchaseCommitmentAmount_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RoyaltiesPercentage" xlink:label="loc_ENVBRoyaltiesPercentage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_ENVBRoyaltiesPercentage_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCash_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForRent_90" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000062 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000065 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000066 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PurchaseAgreementMember" xlink:label="loc_ENVBPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPurchaseAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DistributionAgreementMember" xlink:label="loc_ENVBDistributionAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBDistributionAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_60" xlink:type="arc" order="6" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>envb-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SeriesCRedeemablePreferredStockMember" xlink:label="ENVB_SeriesCRedeemablePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SeriesCRedeemablePreferredStockMember" xlink:to="ENVB_SeriesCRedeemablePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SeriesCRedeemablePreferredStockMember_lbl" xml:lang="en-US">Series C Redeemable Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestMember" xlink:label="ENVB_RedeemableNoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestMember" xlink:to="ENVB_RedeemableNoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterestMember_lbl" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MezzanineEquityMember" xlink:label="ENVB_MezzanineEquityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MezzanineEquityMember" xlink:to="ENVB_MezzanineEquityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_MezzanineEquityMember_lbl" xml:lang="en-US">Mezzanine Equity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SubscriptionReceivableMember" xlink:label="ENVB_SubscriptionReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SubscriptionReceivableMember" xlink:to="ENVB_SubscriptionReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SubscriptionReceivableMember_lbl" xml:lang="en-US">Subscription Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_EquityDistributionAgreementMember" xlink:label="ENVB_EquityDistributionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_EquityDistributionAgreementMember" xlink:to="ENVB_EquityDistributionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_EquityDistributionAgreementMember_lbl" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_KanubaddiSeparationAgreementMember" xlink:label="ENVB_KanubaddiSeparationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_KanubaddiSeparationAgreementMember" xlink:to="ENVB_KanubaddiSeparationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_KanubaddiSeparationAgreementMember_lbl" xml:lang="en-US">Kanubaddi Separation Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MrKanubaddiEmploymentAgreementMember" xlink:label="ENVB_MrKanubaddiEmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MrKanubaddiEmploymentAgreementMember" xlink:to="ENVB_MrKanubaddiEmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_MrKanubaddiEmploymentAgreementMember_lbl" xml:lang="en-US">Mr Kanubaddi Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="country_CA" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CA_lbl" xml:lang="en-US">CANADA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="country_AU" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl" xml:lang="en-US">AUSTRALIA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PrefundedCommonStockWarrantsMember" xlink:label="ENVB_PrefundedCommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrefundedCommonStockWarrantsMember" xlink:to="ENVB_PrefundedCommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PrefundedCommonStockWarrantsMember_lbl" xml:lang="en-US">Prefunded Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="ENVB_WarrantsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Warrants to Purchase Shares of Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" xlink:label="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" xlink:to="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember_lbl" xml:lang="en-US">Restricted Stock Units Vested and Unissued [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RestrictedStockUnitsUnvestedMember" xlink:label="ENVB_RestrictedStockUnitsUnvestedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestrictedStockUnitsUnvestedMember" xlink:to="ENVB_RestrictedStockUnitsUnvestedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RestrictedStockUnitsUnvestedMember_lbl" xml:lang="en-US">Restricted Stock Units Unvested [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" xlink:label="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" xlink:to="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember_lbl" xml:lang="en-US">Restricted Stock Awards Vested and Unissued [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_CommonStockInAbeyanceMember" xlink:label="ENVB_CommonStockInAbeyanceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CommonStockInAbeyanceMember" xlink:to="ENVB_CommonStockInAbeyanceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_CommonStockInAbeyanceMember_lbl" xml:lang="en-US">Common stock in abeyance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" xlink:label="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Investment Options to Purchase Shares of Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_OptionsToPurchaseSharesOfCommonStockMember" xlink:label="ENVB_OptionsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OptionsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_OptionsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_OptionsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Options to Purchase Shares of Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_LabEquipmentMember" xlink:label="ENVB_LabEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_LabEquipmentMember" xlink:to="ENVB_LabEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_LabEquipmentMember_lbl" xml:lang="en-US">Lab Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" xlink:label="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" xlink:to="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember_lbl" xml:lang="en-US">Computer Equipment and Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DistributionAgreementMember" xlink:label="ENVB_DistributionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DistributionAgreementMember" xlink:to="ENVB_DistributionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_DistributionAgreementMember_lbl" xml:lang="en-US">Distribution Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_CanaccordGenuityLLCMember" xlink:label="ENVB_CanaccordGenuityLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CanaccordGenuityLLCMember" xlink:to="ENVB_CanaccordGenuityLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_CanaccordGenuityLLCMember_lbl" xml:lang="en-US">Canaccord Genuity LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RegistrationRightsAgreementMember" xlink:label="ENVB_RegistrationRightsAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegistrationRightsAgreementMember" xlink:to="ENVB_RegistrationRightsAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RegistrationRightsAgreementMember_lbl" xml:lang="en-US">Registration Rights Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_UnderwritersMember" xlink:label="ENVB_UnderwritersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_UnderwritersMember" xlink:to="ENVB_UnderwritersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_UnderwritersMember_lbl" xml:lang="en-US">Underwriters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" xlink:label="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" xlink:to="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Registered Direct Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PIPESecuritiesPurchaseAgreementMember" xlink:label="ENVB_PIPESecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PIPESecuritiesPurchaseAgreementMember" xlink:to="ENVB_PIPESecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PIPESecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">PIPE Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RDOfferingAndPIPEInvestmentOptionsMember" xlink:label="ENVB_RDOfferingAndPIPEInvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RDOfferingAndPIPEInvestmentOptionsMember" xlink:to="ENVB_RDOfferingAndPIPEInvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RDOfferingAndPIPEInvestmentOptionsMember_lbl" xml:lang="en-US">RD Offering and Pipe Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_TwoThousandTwentyLongTermIncentivePlanMember" xlink:label="ENVB_TwoThousandTwentyLongTermIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TwoThousandTwentyLongTermIncentivePlanMember" xlink:to="ENVB_TwoThousandTwentyLongTermIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_TwoThousandTwentyLongTermIncentivePlanMember_lbl" xml:lang="en-US">2020 Long Term Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantAmendmentAgreementsMember" xlink:label="ENVB_WarrantAmendmentAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantAmendmentAgreementsMember" xlink:to="ENVB_WarrantAmendmentAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantAmendmentAgreementsMember_lbl" xml:lang="en-US">Wainwright Amendment Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PlacementAgentPreferredInvestmentOptionsMember" xlink:label="ENVB_PlacementAgentPreferredInvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PlacementAgentPreferredInvestmentOptionsMember" xlink:to="ENVB_PlacementAgentPreferredInvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PlacementAgentPreferredInvestmentOptionsMember_lbl" xml:lang="en-US">Placement Agent Preferred Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FebruaryWarrantsMember" xlink:label="ENVB_FebruaryWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryWarrantsMember" xlink:to="ENVB_FebruaryWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FebruaryWarrantsMember_lbl" xml:lang="en-US">February Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PreModificationWarrantsMember" xlink:label="ENVB_PreModificationWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PreModificationWarrantsMember" xlink:to="ENVB_PreModificationWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PreModificationWarrantsMember_lbl" xml:lang="en-US">Pre-Modification Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ExistingWarrantsMember" xlink:label="ENVB_ExistingWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ExistingWarrantsMember" xlink:to="ENVB_ExistingWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ExistingWarrantsMember_lbl" xml:lang="en-US">Existing Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionsMember" xlink:label="ENVB_InvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionsMember" xlink:to="ENVB_InvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOptionsMember_lbl" xml:lang="en-US">Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PostModificationWarrantsMember" xlink:label="ENVB_PostModificationWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PostModificationWarrantsMember" xlink:to="ENVB_PostModificationWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PostModificationWarrantsMember_lbl" xml:lang="en-US">Post-Modification Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RothAndInducementWarrantsMember" xlink:label="ENVB_RothAndInducementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RothAndInducementWarrantsMember" xlink:to="ENVB_RothAndInducementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RothAndInducementWarrantsMember_lbl" xml:lang="en-US">Roth And Inducement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AkosSecuritiesPurchaseAgreementMember" xlink:label="ENVB_AkosSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AkosSecuritiesPurchaseAgreementMember" xlink:to="ENVB_AkosSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AkosSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Akos Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SeriesAConvertiblePreferredStockMember" xlink:label="ENVB_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SeriesAConvertiblePreferredStockMember" xlink:to="ENVB_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SecuritiesPurchaseAgreementMember" xlink:label="ENVB_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SecuritiesPurchaseAgreementMember" xlink:to="ENVB_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities purchase agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AkosMember" xlink:label="ENVB_AkosMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AkosMember" xlink:to="ENVB_AkosMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AkosMember_lbl" xml:lang="en-US">Akos [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InitialMeasurementMember" xlink:label="ENVB_InitialMeasurementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InitialMeasurementMember" xlink:to="ENVB_InitialMeasurementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InitialMeasurementMember_lbl" xml:lang="en-US">Initial Measurement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SubsequentMeasurementMember" xlink:label="ENVB_SubsequentMeasurementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SubsequentMeasurementMember" xlink:to="ENVB_SubsequentMeasurementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SubsequentMeasurementMember_lbl" xml:lang="en-US">Subsequent Measurement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" xlink:label="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_lbl" xml:lang="en-US">Warrant liabilities - January 2021 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" xlink:label="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_lbl" xml:lang="en-US">Warrant liabilities - February 2021 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" xlink:label="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" xlink:to="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_lbl" xml:lang="en-US">Warrant liabilities - February 2022 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:label="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:to="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember_lbl" xml:lang="en-US">Derivative Liability May 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WainwrightInvestmentOptionsMember" xlink:label="ENVB_WainwrightInvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WainwrightInvestmentOptionsMember" xlink:to="ENVB_WainwrightInvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WainwrightInvestmentOptionsMember_lbl" xml:lang="en-US">Wainwright Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RDInvestmentOptionsMember" xlink:label="ENVB_RDInvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RDInvestmentOptionsMember" xlink:to="ENVB_RDInvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RDInvestmentOptionsMember_lbl" xml:lang="en-US">RD Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PIPEInvestmentOptionsMember" xlink:label="ENVB_PIPEInvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PIPEInvestmentOptionsMember" xlink:to="ENVB_PIPEInvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PIPEInvestmentOptionsMember_lbl" xml:lang="en-US">Pipe Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FebruaryTwentyTwentyTwoWarrantsMember" xlink:label="ENVB_FebruaryTwentyTwentyTwoWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryTwentyTwentyTwoWarrantsMember" xlink:to="ENVB_FebruaryTwentyTwentyTwoWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FebruaryTwentyTwentyTwoWarrantsMember_lbl" xml:lang="en-US">February 2022 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" xlink:label="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" xlink:to="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_lbl" xml:lang="en-US">February 2022 Post-Modification Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MeasurementInputMarketRateMember" xlink:label="ENVB_MeasurementInputMarketRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MeasurementInputMarketRateMember" xlink:to="ENVB_MeasurementInputMarketRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_MeasurementInputMarketRateMember_lbl" xml:lang="en-US">Measurement Input Market Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_JanuaryTwentyTwentyOneWarrantsMember" xlink:label="ENVB_JanuaryTwentyTwentyOneWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_JanuaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_JanuaryTwentyTwentyOneWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_JanuaryTwentyTwentyOneWarrantsMember_lbl" xml:lang="en-US">January 2021 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FebruaryTwentyTwentyOneWarrantsMember" xlink:label="ENVB_FebruaryTwentyTwentyOneWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_FebruaryTwentyTwentyOneWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FebruaryTwentyTwentyOneWarrantsMember_lbl" xml:lang="en-US">February 2021 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" xlink:label="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" xlink:to="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember_lbl" xml:lang="en-US">HC Wainwright and Co LLC Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeMember" xlink:label="us-gaap_DerivativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeMember" xlink:to="us-gaap_DerivativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeMember_lbl" xml:lang="en-US">Derivative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options Held [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AvanceClinicalMember" xlink:label="ENVB_AvanceClinicalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AvanceClinicalMember" xlink:to="ENVB_AvanceClinicalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AvanceClinicalMember_lbl" xml:lang="en-US">Avance Clinical [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_VogalNathanPurchaseAgreementMember" xlink:label="ENVB_VogalNathanPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_VogalNathanPurchaseAgreementMember" xlink:to="ENVB_VogalNathanPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_VogalNathanPurchaseAgreementMember_lbl" xml:lang="en-US">Vogal Nathan Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_OneTimeMilestoneMember" xlink:label="ENVB_OneTimeMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OneTimeMilestoneMember" xlink:to="ENVB_OneTimeMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_OneTimeMilestoneMember_lbl" xml:lang="en-US">One Time Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AdditionalMilestoneMember" xlink:label="ENVB_AdditionalMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AdditionalMilestoneMember" xlink:to="ENVB_AdditionalMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AdditionalMilestoneMember_lbl" xml:lang="en-US">Additional Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_OtherConsultingAndVendorAgreementsMember" xlink:label="ENVB_OtherConsultingAndVendorAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OtherConsultingAndVendorAgreementsMember" xlink:to="ENVB_OtherConsultingAndVendorAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_OtherConsultingAndVendorAgreementsMember_lbl" xml:lang="en-US">Other Consulting and Vendor Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PurchaseAgreementMember" xlink:label="ENVB_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PurchaseAgreementMember" xlink:to="ENVB_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated By Reference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Other assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use operating lease asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of right-of-use operating lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Investment option liability</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilitiesCurrent" xlink:label="ENVB_WarrantLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesCurrent" xlink:to="ENVB_WarrantLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantLiabilitiesCurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US">Mezzanine equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl" xml:lang="en-US">Redeemable non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Total mezzanine equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value, 100,000,000 shares authorized, 2,739,315 and 2,078,271 shares issued and outstanding as of December 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xml:lang="en-US">Stock subscription receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities, mezzanine equity, and shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Temporary equity, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Temporary equity, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Temporary equity, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Temporary equity, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US">Impairment of intangible assets and goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (expense) income</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InducementExpense" xlink:label="ENVB_InducementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InducementExpense" xlink:to="ENVB_InducementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_InducementExpense_lbl" xml:lang="en-US">Inducement expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Change in fair value of investment option liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (expense) income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax (expense) benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Less preferred dividends attributable to non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US">Less deemed dividends attributable to accretion of embedded derivative at redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_TemporaryEquityShares" xlink:label="ENVB_TemporaryEquityShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TemporaryEquityShares" xlink:to="ENVB_TemporaryEquityShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ENVB_TemporaryEquityShares_lbl" xml:lang="en-US">Mezzanine equity balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:label="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:to="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest_lbl" xml:lang="en-US">Preferred dividends attributable to redeemable non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:label="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:to="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue_lbl" xml:lang="en-US">Accretion of embedded derivative to redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xml:lang="en-US">Redemption of Series C preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xml:lang="en-US">Redemption of Series C preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Issuance of common shares in exchange for RSU conversions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Issuance of common shares in exchange for RSU conversions, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common shares for deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common shares for deferred offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of Inducement Warrants, net of offering costs of $239,302</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:label="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:to="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_lbl" xml:lang="en-US">Induced conversion of warrants and preferred investment options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Exercise of warrants and preferred investment options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Exercise of warrants and preferred investment options, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xml:lang="en-US">Foreign exchange translation loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" xlink:label="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" xlink:to="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_lbl" xml:lang="en-US">February 2022 registered direct offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" xlink:label="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" xlink:to="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_lbl" xml:lang="en-US">February 2022 registered direct offering, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Conversion of RSUs into common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Conversion of RSUs into common shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestValue" xlink:label="ENVB_RedeemableNoncontrollingInterestValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestValue" xlink:to="ENVB_RedeemableNoncontrollingInterestValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterestValue_lbl" xml:lang="en-US">Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestShares" xlink:label="ENVB_RedeemableNoncontrollingInterestShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestShares" xlink:to="ENVB_RedeemableNoncontrollingInterestShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterestShares_lbl" xml:lang="en-US">Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" xlink:label="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" xlink:to="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock_lbl" xml:lang="en-US">Issuance of redeemable Series C preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of redeemable Series C preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" xlink:label="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" xlink:to="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_lbl" xml:lang="en-US">Conversion of RSAs into common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:label="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:to="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_lbl" xml:lang="en-US">Conversion of RSAs into common shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" xlink:label="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" xlink:to="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_lbl" xml:lang="en-US">July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" xlink:label="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" xlink:to="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_lbl" xml:lang="en-US">July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" xlink:label="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" xlink:to="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit_lbl" xml:lang="en-US">Issuance of rounded shares as a result of the reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Issuance of rounded shares as a result of the reverse stock split, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TemporaryEquityShares" xlink:to="ENVB_TemporaryEquityShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_TemporaryEquityShares_2_lbl" xml:lang="en-US">Mezzanine equity balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_NetOfferingCosts" xlink:label="ENVB_NetOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NetOfferingCosts" xlink:to="ENVB_NetOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_NetOfferingCosts_lbl" xml:lang="en-US">Net offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" xlink:label="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" xlink:to="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative_lbl" xml:lang="en-US">Issuance of embedded derivative</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestIssuanceCosts" xlink:label="ENVB_RedeemableNoncontrollingInterestIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestIssuanceCosts" xlink:to="ENVB_RedeemableNoncontrollingInterestIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterestIssuanceCosts_lbl" xml:lang="en-US">Redeemable noncontrolling interest issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnInvestments_2_lbl" xml:lang="en-US">Change in fair value of investment option liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InducementExpense" xlink:to="ENVB_InducementExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InducementExpense_2_lbl" xml:lang="en-US">Inducement expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_2_lbl" xml:lang="en-US">Impairment of intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_NoncashIncomeTaxExpense" xlink:label="ENVB_NoncashIncomeTaxExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NoncashIncomeTaxExpense" xlink:to="ENVB_NoncashIncomeTaxExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_NoncashIncomeTaxExpense_lbl" xml:lang="en-US">Non-cash income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of ROU asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on disposal of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:label="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:to="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_lbl" xml:lang="en-US">Right-of-use operating lease asset and obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, warrants, and investment options, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment for equity distribution offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock_lbl" xml:lang="en-US">Redemption of Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:label="us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:to="us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_lbl" xml:lang="en-US">Proceeds from the sale of redeemable non-controlling interest, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Foreign Exchange Rate on Changes on Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash and non-cash transactions:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance" xlink:label="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance" xlink:to="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance_lbl" xml:lang="en-US">Warrants issued in conjunction with common stock issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IssuanceOfEmbeddedDerivative" xlink:label="ENVB_IssuanceOfEmbeddedDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfEmbeddedDerivative" xlink:to="ENVB_IssuanceOfEmbeddedDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_IssuanceOfEmbeddedDerivative_lbl" xml:lang="en-US">Issuance of embedded derivative</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockSubscriptionReceivable" xlink:label="ENVB_StockSubscriptionReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockSubscriptionReceivable" xlink:to="ENVB_StockSubscriptionReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockSubscriptionReceivable_lbl" xml:lang="en-US">Stock subscription receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_OfferingCostsAccruedNotPaid" xlink:label="ENVB_OfferingCostsAccruedNotPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OfferingCostsAccruedNotPaid" xlink:to="ENVB_OfferingCostsAccruedNotPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_OfferingCostsAccruedNotPaid_lbl" xml:lang="en-US">Offering costs accrued not paid</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsIssuedForOfferingCosts" xlink:label="ENVB_WarrantsIssuedForOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsIssuedForOfferingCosts" xlink:to="ENVB_WarrantsIssuedForOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantsIssuedForOfferingCosts_lbl" xml:lang="en-US">Warrants issued for offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:label="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:to="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts_lbl" xml:lang="en-US">Issuance of common shares for deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:label="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:to="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions_lbl" xml:lang="en-US">Induced conversion of warrants and preferred investment options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:to="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest_2_lbl" xml:lang="en-US">Preferred dividends attributable to redeemable non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" xlink:label="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" xlink:to="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance_lbl" xml:lang="en-US">Investment options issued in conjunction with common stock issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise" xlink:label="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise" xlink:to="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise_lbl" xml:lang="en-US">Modification of warrants as part of share capital raise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:to="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue_2_lbl" xml:lang="en-US">Accretion of embedded derivative to redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:label="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Redeemable Non-controlling Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNonControllingInterestTextBlock" xlink:label="ENVB_RedeemableNonControllingInterestTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNonControllingInterestTextBlock" xlink:to="ENVB_RedeemableNonControllingInterestTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNonControllingInterestTextBlock_lbl" xml:lang="en-US">REDEEMABLE NON-CONTROLLING INTEREST</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Principal of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property &amp; Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DeferredOfferingCostsPolicyTextBlock" xlink:label="ENVB_DeferredOfferingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DeferredOfferingCostsPolicyTextBlock" xlink:to="ENVB_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilityPolicyTextBlock" xlink:label="ENVB_WarrantLiabilityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilityPolicyTextBlock" xlink:to="ENVB_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liability and Investment Options</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" xlink:label="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" xlink:to="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_lbl" xml:lang="en-US">Modification and Inducement of Warrants and Investment Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:label="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:to="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock_lbl" xml:lang="en-US">Redeemable Non-controlling Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRUCTURING COSTS PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US">SCHEDULE OF GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ASSUMPTION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:to="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ScheduleOfValuationOfWarrantsTextBlock" xlink:label="ENVB_ScheduleOfValuationOfWarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ScheduleOfValuationOfWarrantsTextBlock" xlink:to="ENVB_ScheduleOfValuationOfWarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ScheduleOfValuationOfWarrantsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" xlink:label="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" xlink:to="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INCOME TAX EXPENSE BENEFITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPERATING LOSS CARRY FORWARDS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_lbl" xml:lang="en-US">Restructuring cost payable, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RestructuringCostsIncurred" xlink:label="ENVB_RestructuringCostsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestructuringCostsIncurred" xlink:to="ENVB_RestructuringCostsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RestructuringCostsIncurred_lbl" xml:lang="en-US">Restructuring costs incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCosts" xlink:to="us-gaap_RestructuringCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCosts_lbl" xml:lang="en-US">Restructuring costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringCosts" xlink:label="us-gaap_OtherRestructuringCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestructuringCosts" xlink:to="us-gaap_OtherRestructuringCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherRestructuringCosts_lbl" xml:lang="en-US">Restructuring costs reversed</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_2_lbl" xml:lang="en-US">Restructuring cost payable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WorkingCapital" xlink:label="ENVB_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WorkingCapital" xlink:to="ENVB_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Additional working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Warrants for cash proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Exercise of warrants to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Cash proceeds of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Salaries and benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Performance bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US">Reversed amount</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ExpenseRelatedToAccelerationOfVesting" xlink:label="ENVB_ExpenseRelatedToAccelerationOfVesting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ExpenseRelatedToAccelerationOfVesting" xlink:to="ENVB_ExpenseRelatedToAccelerationOfVesting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ExpenseRelatedToAccelerationOfVesting_lbl" xml:lang="en-US">Expense related to acceleration of vesting</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MarketPerformanceBasedShares" xlink:label="ENVB_MarketPerformanceBasedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MarketPerformanceBasedShares" xlink:to="ENVB_MarketPerformanceBasedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_MarketPerformanceBasedShares_lbl" xml:lang="en-US">Market performance based shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" xlink:label="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" xlink:to="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_lbl" xml:lang="en-US">Minimum of stockholders equity required for continued listing pursuant to exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total potentially dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Stock and warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PrepaidResearchAndDevelopment" xlink:label="ENVB_PrepaidResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidResearchAndDevelopment" xlink:to="ENVB_PrepaidResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PrepaidResearchAndDevelopment_lbl" xml:lang="en-US">Prepaid research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidTaxes_lbl" xml:lang="en-US">Prepaid value-added taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid other</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PrepaidFranchiseTaxReceivable" xlink:label="ENVB_PrepaidFranchiseTaxReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidFranchiseTaxReceivable" xlink:to="ENVB_PrepaidFranchiseTaxReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PrepaidFranchiseTaxReceivable_lbl" xml:lang="en-US">Franchise tax receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:label="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:to="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable_lbl" xml:lang="en-US">R&amp;D tax incentive receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross" xlink:label="us-gaap_GoodwillGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillGross" xlink:to="us-gaap_GoodwillGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_GoodwillGross_lbl" xml:lang="en-US">Goodwill Gross, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_lbl" xml:lang="en-US">Accumulated Impairment Losses, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillCurrencyTranslation" xlink:label="ENVB_GoodwillCurrencyTranslation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslation" xlink:to="ENVB_GoodwillCurrencyTranslation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ENVB_GoodwillCurrencyTranslation_lbl" xml:lang="en-US">Currency Translation, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillImpairmentLossGross" xlink:label="ENVB_GoodwillImpairmentLossGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillImpairmentLossGross" xlink:to="ENVB_GoodwillImpairmentLossGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_GoodwillImpairmentLossGross_lbl" xml:lang="en-US">Goodwill Gross, Impairment losses</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillAccumulatedImpairmentLoss" xlink:label="ENVB_GoodwillAccumulatedImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillAccumulatedImpairmentLoss" xlink:to="ENVB_GoodwillAccumulatedImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_GoodwillAccumulatedImpairmentLoss_lbl" xml:lang="en-US">Accumulated Impairment Losses, Impairment losses</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillCurrencyTranslationImpairmentLoss" xlink:label="ENVB_GoodwillCurrencyTranslationImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslationImpairmentLoss" xlink:to="ENVB_GoodwillCurrencyTranslationImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_GoodwillCurrencyTranslationImpairmentLoss_lbl" xml:lang="en-US">Currency Translation, Impairment losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill, Impairment losses</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillForeignCurrencyTranslationGainLossGross" xlink:label="ENVB_GoodwillForeignCurrencyTranslationGainLossGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillForeignCurrencyTranslationGainLossGross" xlink:to="ENVB_GoodwillForeignCurrencyTranslationGainLossGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillForeignCurrencyTranslationGainLossGross_lbl" xml:lang="en-US">Goodwill Gross, Loss on currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" xlink:label="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" xlink:to="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Accumulated Impairment Losses, Loss on currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillCurrencyTranslationLoss" xlink:label="ENVB_GoodwillCurrencyTranslationLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslationLoss" xlink:to="ENVB_GoodwillCurrencyTranslationLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillCurrencyTranslationLoss_lbl" xml:lang="en-US">Currency Translation, Loss on currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Goodwill, Loss on currency translation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillGross" xlink:to="us-gaap_GoodwillGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_GoodwillGross_2_lbl" xml:lang="en-US">Goodwill Gross, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2_lbl" xml:lang="en-US">Accumulated Impairment Losses, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslation" xlink:to="ENVB_GoodwillCurrencyTranslation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_GoodwillCurrencyTranslation_2_lbl" xml:lang="en-US">Currency Translation, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_2_lbl" xml:lang="en-US">Goodwill, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Balance, Indefinite lived intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Loss on currency translation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xml:lang="en-US">Balance, Indefinite lived intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Balance, Definite lived intangible assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Balance, Definite lived intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xml:lang="en-US">Finite lived assets amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_3_lbl" xml:lang="en-US">Intangible assets, amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Computer equipment and leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AccruedProductDevelopmentCost" xlink:label="ENVB_AccruedProductDevelopmentCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccruedProductDevelopmentCost" xlink:to="ENVB_AccruedProductDevelopmentCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AccruedProductDevelopmentCost_lbl" xml:lang="en-US">Product development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued salaries, wages, and bonuses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AccruedRestructuringCosts" xlink:label="ENVB_AccruedRestructuringCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccruedRestructuringCosts" xlink:to="ENVB_AccruedRestructuringCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AccruedRestructuringCosts_lbl" xml:lang="en-US">Accrued restructuring costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Accrued franchise taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term, outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Outstanding at end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable shares at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable weighted average price at end</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_lbl" xml:lang="en-US">Stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, Non-vested beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value, Non-vested beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value, Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of shares, non-vested ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average fair value, Non-vested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense for RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrant shares outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise Price, Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining life, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_lbl" xml:lang="en-US">Intrinsic Value, Outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_lbl" xml:lang="en-US">Warrant shares outstanding, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_lbl" xml:lang="en-US">Weighted average exercise price, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrant shares outstanding, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_lbl" xml:lang="en-US">Exchanged for common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Warrant shares outstanding, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrant shares outstanding at end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise Price, Outstanding at end</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_lbl" xml:lang="en-US">Warrant shares outstanding, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_lbl" xml:lang="en-US">Weighted average remaining life, Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2_lbl" xml:lang="en-US">Intrinsic Value, Outstanding end</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_2_lbl" xml:lang="en-US">Investment options outstanding, Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Investment options outstanding, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding end</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants, number of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Value (per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Common stock voting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Common stock, offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" xlink:label="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" xlink:to="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_lbl" xml:lang="en-US">Aggregate gross sales price</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_CommissionPercentage" xlink:label="ENVB_CommissionPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CommissionPercentage" xlink:to="ENVB_CommissionPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_CommissionPercentage_lbl" xml:lang="en-US">Commission percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Purchase committment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_2_lbl" xml:lang="en-US">Offering expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issued shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:to="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_2_lbl" xml:lang="en-US">Stock issued during period conversion of restricted stock award</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Purchase of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Exercised of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds from offering</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiability" xlink:label="ENVB_WarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiability" xlink:to="ENVB_WarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_WarrantLiability_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xml:lang="en-US">Proceeds from inducement warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Proceeds from RD offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PaymentsOfStockIssuanceCost" xlink:label="ENVB_PaymentsOfStockIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfStockIssuanceCost" xlink:to="ENVB_PaymentsOfStockIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PaymentsOfStockIssuanceCost_lbl" xml:lang="en-US">Offerings costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PaymentsOfAllocatedEquity" xlink:label="ENVB_PaymentsOfAllocatedEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfAllocatedEquity" xlink:to="ENVB_PaymentsOfAllocatedEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PaymentsOfAllocatedEquity_lbl" xml:lang="en-US">Payments of allocated equity</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PaymentsOfInvestmentOptionLiability" xlink:label="ENVB_PaymentsOfInvestmentOptionLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfInvestmentOptionLiability" xlink:to="ENVB_PaymentsOfInvestmentOptionLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PaymentsOfInvestmentOptionLiability_lbl" xml:lang="en-US">Payments of investment option liability</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" xlink:label="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" xlink:to="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense_lbl" xml:lang="en-US">Payments of stock issuance costs recorded expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Incentive plan description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Authorized shares reserved</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available ofr grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Stock based compensation, expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Stock-based compensation, unamortized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Common stock vested restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_lbl" xml:lang="en-US">Unissued shares for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_NumberOfVestedAndUnissuedShares" xlink:label="ENVB_NumberOfVestedAndUnissuedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NumberOfVestedAndUnissuedShares" xlink:to="ENVB_NumberOfVestedAndUnissuedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_NumberOfVestedAndUnissuedShares_lbl" xml:lang="en-US">Number of vested and unissued shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Issued shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" xlink:label="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" xlink:to="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Purchase of additional warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrant expiration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Offerings costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ClassOfWarrantOrRightReasonForIssuing" xlink:label="ENVB_ClassOfWarrantOrRightReasonForIssuing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ClassOfWarrantOrRightReasonForIssuing" xlink:to="ENVB_ClassOfWarrantOrRightReasonForIssuing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ClassOfWarrantOrRightReasonForIssuing_lbl" xml:lang="en-US">Warrant issued description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants outstanding, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Term (years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Warrants outstanding, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionSharePrice" xlink:label="ENVB_InvestmentOptionSharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionSharePrice" xlink:to="ENVB_InvestmentOptionSharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_InvestmentOptionSharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionExercisePrice" xlink:label="ENVB_InvestmentOptionExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionExercisePrice" xlink:to="ENVB_InvestmentOptionExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_InvestmentOptionExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionTerm" xlink:label="ENVB_InvestmentOptionTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionTerm" xlink:to="ENVB_InvestmentOptionTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_InvestmentOptionTerm_lbl" xml:lang="en-US">Term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOutstandingMeasurementInput" xlink:label="ENVB_InvestmentOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOutstandingMeasurementInput" xlink:to="ENVB_InvestmentOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOutstandingMeasurementInput_lbl" xml:lang="en-US">Investment outstanding, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharePriceOption" xlink:label="ENVB_SharePriceOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharePriceOption" xlink:to="ENVB_SharePriceOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SharePriceOption_lbl" xml:lang="en-US">Investment outstanding, per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentIntrinsicValue" xlink:label="ENVB_InvestmentIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentIntrinsicValue" xlink:to="ENVB_InvestmentIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_InvestmentIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentInducementGain" xlink:label="ENVB_InvestmentInducementGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentInducementGain" xlink:to="ENVB_InvestmentInducementGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentInducementGain_lbl" xml:lang="en-US">Inducement gain</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xml:lang="en-US">Preferred stock voting rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_2_lbl" xml:lang="en-US">Redeemable preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Preferred Stock authorized for future issuances</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract_2_lbl" xml:lang="en-US">Schedule Of Reconciliation Change In Redeemable Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of redeemable noncontrolling Series C preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xml:lang="en-US">Accretion of embedded derivative to redemption value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock_2_lbl" xml:lang="en-US">Redemption of Akos Series A Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Sale of stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SpinoffAndRelatedPrivatePlacementDescription" xlink:label="ENVB_SpinoffAndRelatedPrivatePlacementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SpinoffAndRelatedPrivatePlacementDescription" xlink:to="ENVB_SpinoffAndRelatedPrivatePlacementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SpinoffAndRelatedPrivatePlacementDescription_lbl" xml:lang="en-US">Spin-off and related private placement, description</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsToPurchaseCommonStockPercentage" xlink:label="ENVB_WarrantsToPurchaseCommonStockPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsToPurchaseCommonStockPercentage" xlink:to="ENVB_WarrantsToPurchaseCommonStockPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantsToPurchaseCommonStockPercentage_lbl" xml:lang="en-US">Warrants to purchase common stock, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Percentage of stock issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xml:lang="en-US">Dividends, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_UnpaidDividends" xlink:label="ENVB_UnpaidDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_UnpaidDividends" xlink:to="ENVB_UnpaidDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_UnpaidDividends_lbl" xml:lang="en-US">Unpaid dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividends</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterest" xlink:label="ENVB_RedeemableNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterest" xlink:to="ENVB_RedeemableNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterest_lbl" xml:lang="en-US">Redeemable noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" xlink:label="us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" xlink:to="us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_lbl" xml:lang="en-US">Fair value of investment option liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsAndRightsOutstandingStockPrice" xlink:label="ENVB_WarrantsAndRightsOutstandingStockPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsAndRightsOutstandingStockPrice" xlink:to="ENVB_WarrantsAndRightsOutstandingStockPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantsAndRightsOutstandingStockPrice_lbl" xml:lang="en-US">Warrant measurement input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant measurement input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2_lbl" xml:lang="en-US">Warrants, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ConvertiblePreferredStockPrincipalValue" xlink:label="ENVB_ConvertiblePreferredStockPrincipalValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ConvertiblePreferredStockPrincipalValue" xlink:to="ENVB_ConvertiblePreferredStockPrincipalValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ConvertiblePreferredStockPrincipalValue_lbl" xml:lang="en-US">Principal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xml:lang="en-US">Market rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionTerm" xlink:to="ENVB_InvestmentOptionTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOptionTerm_2_lbl" xml:lang="en-US">Investment option term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Investment, stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockOptionExercisePrice" xlink:label="ENVB_StockOptionExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockOptionExercisePrice" xlink:to="ENVB_StockOptionExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockOptionExercisePrice_lbl" xml:lang="en-US">Investment, exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" xlink:label="us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" xlink:to="us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_lbl" xml:lang="en-US">Investment, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xml:lang="en-US">Number of investment options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US">Schedule of Fair Value, off-Balance-Sheet Risks [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Total beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US">Issuance of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US">Change in fair value, modification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:to="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Total ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:to="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_lbl" xml:lang="en-US">Exercise of investment options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_lbl" xml:lang="en-US">Derivative liability fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Operating leases remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Operating lease discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US">Contract cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:to="us-gaap_ConstructionContractCostProgressPaymentOffset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset_lbl" xml:lang="en-US">Payment of contract cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US">Long-term purchase commitment, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RoyaltiesPercentage" xlink:label="ENVB_RoyaltiesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RoyaltiesPercentage" xlink:to="ENVB_RoyaltiesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RoyaltiesPercentage_lbl" xml:lang="en-US">Royalties percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Payments for royalties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Future cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">United States</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current income tax (expense) benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred income tax (expense) benefit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Total income tax (expense) benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ResearchAndDevelopmentCapitalizedExpenses" xlink:label="ENVB_ResearchAndDevelopmentCapitalizedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ResearchAndDevelopmentCapitalizedExpenses" xlink:to="ENVB_ResearchAndDevelopmentCapitalizedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ResearchAndDevelopmentCapitalizedExpenses_lbl" xml:lang="en-US">Research and development capitalized expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DeferredTaxAssetsAndIntangibleAmortization" xlink:label="ENVB_DeferredTaxAssetsAndIntangibleAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DeferredTaxAssetsAndIntangibleAmortization" xlink:to="ENVB_DeferredTaxAssetsAndIntangibleAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_DeferredTaxAssetsAndIntangibleAmortization_lbl" xml:lang="en-US">Intangible amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss tax carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal income tax at the statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax rate (net of federal)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign tax rate differential</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_lbl" xml:lang="en-US">Non-deductible expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:label="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:to="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup_lbl" xml:lang="en-US">Deferred true-up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income tax expenses and benefits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_4_lbl" xml:lang="en-US">Income tax expenses and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and development expense gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Number of common stock issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Existing Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants to purchase shares of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Net Proceeds from sale of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_3_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Number of shares sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3_lbl" xml:lang="en-US">Gross proceeds from sale of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SeriesCRedeemablePreferredStockMember" xlink:to="ENVB_SeriesCRedeemablePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SeriesCRedeemablePreferredStockMember_doc" xml:lang="en-US">Series C Redeemable Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InducementExpense" xlink:to="ENVB_InducementExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InducementExpense_doc" xml:lang="en-US">Inducement expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccruedProductDevelopmentCost" xlink:to="ENVB_AccruedProductDevelopmentCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AccruedProductDevelopmentCost_doc" xml:lang="en-US">Accrued product and development cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccruedRestructuringCosts" xlink:to="ENVB_AccruedRestructuringCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AccruedRestructuringCosts_doc" xml:lang="en-US">Accrued restructuring costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DistributionAgreementMember" xlink:to="ENVB_DistributionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_DistributionAgreementMember_doc" xml:lang="en-US">Distribution Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CanaccordGenuityLLCMember" xlink:to="ENVB_CanaccordGenuityLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_CanaccordGenuityLLCMember_doc" xml:lang="en-US">Canaccord Genuity LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" xlink:to="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_doc" xml:lang="en-US">Sale of stock consideration expected maximum price on limitation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CommissionPercentage" xlink:to="ENVB_CommissionPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_CommissionPercentage_doc" xml:lang="en-US">Commission percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegistrationRightsAgreementMember" xlink:to="ENVB_RegistrationRightsAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RegistrationRightsAgreementMember_doc" xml:lang="en-US">Registration Rights Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_UnderwritersMember" xlink:to="ENVB_UnderwritersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_UnderwritersMember_doc" xml:lang="en-US">Underwriters [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Number of share warrants (or share units) exercised during the current period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" xlink:to="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Registered Direct Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NoncashIncomeTaxExpense" xlink:to="ENVB_NoncashIncomeTaxExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_NoncashIncomeTaxExpense_doc" xml:lang="en-US">Noncash income tax expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PIPESecuritiesPurchaseAgreementMember" xlink:to="ENVB_PIPESecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PIPESecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">PIPE Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:to="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_doc" xml:lang="en-US">Right-of-use operating lease asset and obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RDOfferingAndPIPEInvestmentOptionsMember" xlink:to="ENVB_RDOfferingAndPIPEInvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RDOfferingAndPIPEInvestmentOptionsMember_doc" xml:lang="en-US">RD Offering and Pipe Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfAllocatedEquity" xlink:to="ENVB_PaymentsOfAllocatedEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PaymentsOfAllocatedEquity_doc" xml:lang="en-US">Payments of allocated equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfInvestmentOptionLiability" xlink:to="ENVB_PaymentsOfInvestmentOptionLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PaymentsOfInvestmentOptionLiability_doc" xml:lang="en-US">Payments of investment option liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" xlink:to="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense_doc" xml:lang="en-US">Payments of stock issuance costs recorded expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TwoThousandTwentyLongTermIncentivePlanMember" xlink:to="ENVB_TwoThousandTwentyLongTermIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_TwoThousandTwentyLongTermIncentivePlanMember_doc" xml:lang="en-US">2020 Long Term Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfEmbeddedDerivative" xlink:to="ENVB_IssuanceOfEmbeddedDerivative_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_IssuanceOfEmbeddedDerivative_doc" xml:lang="en-US">Issuance of embedded derivative.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:to="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue_doc" xml:lang="en-US">Accretion of embedded derivative to redemption value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise" xlink:to="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise_doc" xml:lang="en-US">Modification of warrants as part of share capital raise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" xlink:to="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance_doc" xml:lang="en-US">Investment options issued in conjunction with common stock issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:to="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest_doc" xml:lang="en-US">Preferred dividends attributable to redeemable noncontrolling interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockSubscriptionReceivable" xlink:to="ENVB_StockSubscriptionReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockSubscriptionReceivable_doc" xml:lang="en-US">Stock subscription receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OfferingCostsAccruedNotPaid" xlink:to="ENVB_OfferingCostsAccruedNotPaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_OfferingCostsAccruedNotPaid_doc" xml:lang="en-US">Offering costs accrued not paid.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsIssuedForOfferingCosts" xlink:to="ENVB_WarrantsIssuedForOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantsIssuedForOfferingCosts_doc" xml:lang="en-US">Warrants issued for offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:to="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts_doc" xml:lang="en-US">Issuance of common shares for deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted average grant date fair value, outstanding at beginning of the year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted average grant date fair value, expired, forfeited, or cancelled.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted average grant date fair value, exercisable.</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Options outstanding weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TemporaryEquityShares" xlink:to="ENVB_TemporaryEquityShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_TemporaryEquityShares_doc" xml:lang="en-US">Temporary Equity Shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestMember" xlink:to="ENVB_RedeemableNoncontrollingInterestMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterestMember_doc" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions stock price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SubscriptionReceivableMember" xlink:to="ENVB_SubscriptionReceivableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SubscriptionReceivableMember_doc" xml:lang="en-US">Subscription Receivable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NumberOfVestedAndUnissuedShares" xlink:to="ENVB_NumberOfVestedAndUnissuedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_NumberOfVestedAndUnissuedShares_doc" xml:lang="en-US">Number of vested and unissued shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:to="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_doc" xml:lang="en-US">Induced conversion of warrants and preferred investment options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" xlink:to="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_doc" xml:lang="en-US">February 2022 registered direct offering, net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" xlink:to="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock_doc" xml:lang="en-US">Issuance of redeemable noncontrolling series preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_doc" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestIssuanceCosts" xlink:to="ENVB_RedeemableNoncontrollingInterestIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterestIssuanceCosts_doc" xml:lang="en-US">Redeemable noncontrolling interest issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:to="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock_doc" xml:lang="en-US">Schedule of warrants outstanding [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestShares" xlink:to="ENVB_RedeemableNoncontrollingInterestShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterestShares_doc" xml:lang="en-US">Redeemable noncontrolling interest shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" xlink:to="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_doc" xml:lang="en-US">Stock issued during period shares issued direct offering net of offering cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:to="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_doc" xml:lang="en-US">Stock issued during period shares conversion of restricted stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" xlink:to="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_doc" xml:lang="en-US">Registered direct offering pipe offering modification of warrants and exercise of pre funded warrants net of offering costs shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_doc" xml:lang="en-US">Warrant shares outstanding, issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exchanged.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_doc" xml:lang="en-US">Weighted average exercise price, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Warrants, weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which option holders acquired shares when converting their warrants into shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_doc" xml:lang="en-US">Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_doc" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Non Option.</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_doc" xml:lang="en-US">Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WorkingCapital" xlink:to="ENVB_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_EquityDistributionAgreementMember" xlink:to="ENVB_EquityDistributionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_EquityDistributionAgreementMember_doc" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantAmendmentAgreementsMember" xlink:to="ENVB_WarrantAmendmentAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantAmendmentAgreementsMember_doc" xml:lang="en-US">Wainwright Amendment Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionsMember" xlink:to="ENVB_InvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOptionsMember_doc" xml:lang="en-US">Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_doc" xml:lang="en-US">Stock options, outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_doc" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Non Options Exercisable Intrinsic Value1,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_KanubaddiSeparationAgreementMember" xlink:to="ENVB_KanubaddiSeparationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_KanubaddiSeparationAgreementMember_doc" xml:lang="en-US">Kanubaddi Separation Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PlacementAgentPreferredInvestmentOptionsMember" xlink:to="ENVB_PlacementAgentPreferredInvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PlacementAgentPreferredInvestmentOptionsMember_doc" xml:lang="en-US">Placement Agent Preferred Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNonControllingInterestTextBlock" xlink:to="ENVB_RedeemableNonControllingInterestTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNonControllingInterestTextBlock_doc" xml:lang="en-US">Redeemable non controlling interest [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AkosSecuritiesPurchaseAgreementMember" xlink:to="ENVB_AkosSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AkosSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Akos Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SeriesAConvertiblePreferredStockMember" xlink:to="ENVB_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SpinoffAndRelatedPrivatePlacementDescription" xlink:to="ENVB_SpinoffAndRelatedPrivatePlacementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SpinoffAndRelatedPrivatePlacementDescription_doc" xml:lang="en-US">Spinoff and related private placement, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsToPurchaseCommonStockPercentage" xlink:to="ENVB_WarrantsToPurchaseCommonStockPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantsToPurchaseCommonStockPercentage_doc" xml:lang="en-US">Warrants to purchase common stock percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SecuritiesPurchaseAgreementMember" xlink:to="ENVB_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities purchase agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AkosMember" xlink:to="ENVB_AkosMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AkosMember_doc" xml:lang="en-US">Akos [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_UnpaidDividends" xlink:to="ENVB_UnpaidDividends_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_UnpaidDividends_doc" xml:lang="en-US">Unpaid dividends.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterest" xlink:to="ENVB_RedeemableNoncontrollingInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterest_doc" xml:lang="en-US">Redeemable non controlling interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InitialMeasurementMember" xlink:to="ENVB_InitialMeasurementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InitialMeasurementMember_doc" xml:lang="en-US">Initial Measurement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryWarrantsMember" xlink:to="ENVB_FebruaryWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_FebruaryWarrantsMember_doc" xml:lang="en-US">February Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsAndRightsOutstandingStockPrice" xlink:to="ENVB_WarrantsAndRightsOutstandingStockPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantsAndRightsOutstandingStockPrice_doc" xml:lang="en-US">Warrants, stock price.</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_JulyWarrantsMember" xlink:label="ENVB_JulyWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_JulyWarrantsMember" xlink:to="ENVB_JulyWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_JulyWarrantsMember_doc" xml:lang="en-US">July Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ConvertiblePreferredStockPrincipalValue" xlink:to="ENVB_ConvertiblePreferredStockPrincipalValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ConvertiblePreferredStockPrincipalValue_doc" xml:lang="en-US">Convertible Preferred Stock Principal Value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:to="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember_doc" xml:lang="en-US">Derivative Liability May 2022 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MeasurementInputMarketRateMember" xlink:to="ENVB_MeasurementInputMarketRateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_MeasurementInputMarketRateMember_doc" xml:lang="en-US">Measurement Input Market Rate [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionTerm" xlink:to="ENVB_InvestmentOptionTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOptionTerm_doc" xml:lang="en-US">Investment option term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WainwrightInvestmentOptionsMember" xlink:to="ENVB_WainwrightInvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WainwrightInvestmentOptionsMember_doc" xml:lang="en-US">Wainwright Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockOptionExercisePrice" xlink:to="ENVB_StockOptionExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockOptionExercisePrice_doc" xml:lang="en-US">Stock option exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RDInvestmentOptionsMember" xlink:to="ENVB_RDInvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RDInvestmentOptionsMember_doc" xml:lang="en-US">RD Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PIPEInvestmentOptionsMember" xlink:to="ENVB_PIPEInvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PIPEInvestmentOptionsMember_doc" xml:lang="en-US">Pipe Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" xlink:to="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_doc" xml:lang="en-US">Minimum of stockholders equity required for continued listing pursuant to exchange.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DeferredOfferingCostsPolicyTextBlock" xlink:to="ENVB_DeferredOfferingCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_DeferredOfferingCostsPolicyTextBlock_doc" xml:lang="en-US">Deferred Offering Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilityPolicyTextBlock" xlink:to="ENVB_WarrantLiabilityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantLiabilityPolicyTextBlock_doc" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" xlink:to="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_doc" xml:lang="en-US">Modification and Inducement of Warrants and Investment Options [Policy text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SubsequentMeasurementMember" xlink:to="ENVB_SubsequentMeasurementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SubsequentMeasurementMember_doc" xml:lang="en-US">Subsequent Measurement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_JanuaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_JanuaryTwentyTwentyOneWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_JanuaryTwentyTwentyOneWarrantsMember_doc" xml:lang="en-US">January 2021 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_FebruaryTwentyTwentyOneWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_FebruaryTwentyTwentyOneWarrantsMember_doc" xml:lang="en-US">February 2021 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryTwentyTwentyTwoWarrantsMember" xlink:to="ENVB_FebruaryTwentyTwentyTwoWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_FebruaryTwentyTwentyTwoWarrantsMember_doc" xml:lang="en-US">February 2022 warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" xlink:to="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember_doc" xml:lang="en-US">HC Wainwright and Co LLC Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:to="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock_doc" xml:lang="en-US">Redeemable non controlling interest policy [Text block].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AvanceClinicalMember" xlink:to="ENVB_AvanceClinicalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AvanceClinicalMember_doc" xml:lang="en-US">Avance Clinical [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_VogalNathanPurchaseAgreementMember" xlink:to="ENVB_VogalNathanPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_VogalNathanPurchaseAgreementMember_doc" xml:lang="en-US">Vogal Nathan Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OneTimeMilestoneMember" xlink:to="ENVB_OneTimeMilestoneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_OneTimeMilestoneMember_doc" xml:lang="en-US">One Time Milestone [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AdditionalMilestoneMember" xlink:to="ENVB_AdditionalMilestoneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AdditionalMilestoneMember_doc" xml:lang="en-US">Additional Milestone [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RoyaltiesPercentage" xlink:to="ENVB_RoyaltiesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RoyaltiesPercentage_doc" xml:lang="en-US">Royalties percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OtherConsultingAndVendorAgreementsMember" xlink:to="ENVB_OtherConsultingAndVendorAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_OtherConsultingAndVendorAgreementsMember_doc" xml:lang="en-US">Other Consulting and Vendor Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" xlink:to="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_doc" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Term [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ResearchAndDevelopmentCapitalizedExpenses" xlink:to="ENVB_ResearchAndDevelopmentCapitalizedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ResearchAndDevelopmentCapitalizedExpenses_doc" xml:lang="en-US">Research and development capitalized expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DeferredTaxAssetsAndIntangibleAmortization" xlink:to="ENVB_DeferredTaxAssetsAndIntangibleAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_DeferredTaxAssetsAndIntangibleAmortization_doc" xml:lang="en-US">Deferred tax assets and intangible amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrefundedCommonStockWarrantsMember" xlink:to="ENVB_PrefundedCommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PrefundedCommonStockWarrantsMember_doc" xml:lang="en-US">Prefunded Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CommonStockInAbeyanceMember" xlink:to="ENVB_CommonStockInAbeyanceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_CommonStockInAbeyanceMember_doc" xml:lang="en-US">Common stock in abeyance [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidResearchAndDevelopment" xlink:to="ENVB_PrepaidResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PrepaidResearchAndDevelopment_doc" xml:lang="en-US">Prepaid research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NetOfferingCosts" xlink:to="ENVB_NetOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_NetOfferingCosts_doc" xml:lang="en-US">Net offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" xlink:to="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative_doc" xml:lang="en-US">Issuance of embedded derivative.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesCurrent" xlink:to="ENVB_WarrantLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantLiabilitiesCurrent_doc" xml:lang="en-US">Warrant liabilities current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiability" xlink:to="ENVB_WarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantLiability_doc" xml:lang="en-US">Warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MezzanineEquityMember" xlink:to="ENVB_MezzanineEquityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_MezzanineEquityMember_doc" xml:lang="en-US">Mezzanine Equity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestValue" xlink:to="ENVB_RedeemableNoncontrollingInterestValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterestValue_doc" xml:lang="en-US">Redeemable noncontrolling interest value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" xlink:to="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_doc" xml:lang="en-US">Stock issued during period value conversion of restricted stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" xlink:to="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_doc" xml:lang="en-US">Registered direct offering pipe offering modification of warrants and exercise of prefunded warrants net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" xlink:to="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit_doc" xml:lang="en-US">Issuance of rounded shares as result of reverse stock split.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options forfeited in eriod weighted average exercise price.</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermIssued" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermIssued" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermIssued_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments issued in period weighted average exercise price exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:to="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability period exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:to="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability period exercise of investment options.</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:label="ENVB_EffectiveIncomeTaxRateReconciliationReturnToProvision" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:to="ENVB_EffectiveIncomeTaxRateReconciliationReturnToProvision_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_EffectiveIncomeTaxRateReconciliationReturnToProvision_doc" xml:lang="en-US">Effective income taxRrateRreconciliation return to provision.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidFranchiseTaxReceivable" xlink:to="ENVB_PrepaidFranchiseTaxReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PrepaidFranchiseTaxReceivable_doc" xml:lang="en-US">Prepaid franchise tax receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RothAndInducementWarrantsMember" xlink:to="ENVB_RothAndInducementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RothAndInducementWarrantsMember_doc" xml:lang="en-US">Roth And Inducement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ScheduleOfValuationOfWarrantsTextBlock" xlink:to="ENVB_ScheduleOfValuationOfWarrantsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ScheduleOfValuationOfWarrantsTextBlock_doc" xml:lang="en-US">Schedule Of Valuation Of Warrants [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ExpenseRelatedToAccelerationOfVesting" xlink:to="ENVB_ExpenseRelatedToAccelerationOfVesting_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ExpenseRelatedToAccelerationOfVesting_doc" xml:lang="en-US">Expense related to acceleration of vesting.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MrKanubaddiEmploymentAgreementMember" xlink:to="ENVB_MrKanubaddiEmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_MrKanubaddiEmploymentAgreementMember_doc" xml:lang="en-US">Mr Kanubaddi Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MarketPerformanceBasedShares" xlink:to="ENVB_MarketPerformanceBasedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_MarketPerformanceBasedShares_doc" xml:lang="en-US">Market performance based shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionExercisePrice" xlink:to="ENVB_InvestmentOptionExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOptionExercisePrice_doc" xml:lang="en-US">Investment option exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionSharePrice" xlink:to="ENVB_InvestmentOptionSharePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOptionSharePrice_doc" xml:lang="en-US">Investment option share price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOutstandingMeasurementInput" xlink:to="ENVB_InvestmentOutstandingMeasurementInput_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOutstandingMeasurementInput_doc" xml:lang="en-US">Investment outstanding measurement input.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentIntrinsicValue" xlink:to="ENVB_InvestmentIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentIntrinsicValue_doc" xml:lang="en-US">Investment intrinsic value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentInducementGain" xlink:to="ENVB_InvestmentInducementGain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentInducementGain_doc" xml:lang="en-US">Investment inducement gain.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ClassOfWarrantOrRightReasonForIssuing" xlink:to="ENVB_ClassOfWarrantOrRightReasonForIssuing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ClassOfWarrantOrRightReasonForIssuing_doc" xml:lang="en-US">Warrant issued description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance" xlink:to="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance_doc" xml:lang="en-US">Warrants issued in conjunction with common stock issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" xlink:to="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember_doc" xml:lang="en-US">Restricted Stock Awards Vested and Unissued [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OptionsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_OptionsToPurchaseSharesOfCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_OptionsToPurchaseSharesOfCommonStockMember_doc" xml:lang="en-US">Options to Purchase Shares of Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_WarrantsToPurchaseSharesOfCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantsToPurchaseSharesOfCommonStockMember_doc" xml:lang="en-US">Warrants to Purchase Shares of Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" xlink:to="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember_doc" xml:lang="en-US">Restricted Stock Units Vested and Unissued [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestrictedStockUnitsUnvestedMember" xlink:to="ENVB_RestrictedStockUnitsUnvestedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RestrictedStockUnitsUnvestedMember_doc" xml:lang="en-US">Restricted Stock Units Unvested [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember_doc" xml:lang="en-US">Investment Options to Purchase Shares of Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:to="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable_doc" xml:lang="en-US">Prepaid research and development tax incentive receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillImpairmentLossGross" xlink:to="ENVB_GoodwillImpairmentLossGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillImpairmentLossGross_doc" xml:lang="en-US">Goodwill impairment loss gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillForeignCurrencyTranslationGainLossGross" xlink:to="ENVB_GoodwillForeignCurrencyTranslationGainLossGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillForeignCurrencyTranslationGainLossGross_doc" xml:lang="en-US">Goodwill foreign currency translation gain loss gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillAccumulatedImpairmentLoss" xlink:to="ENVB_GoodwillAccumulatedImpairmentLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillAccumulatedImpairmentLoss_doc" xml:lang="en-US">Goodwill accumulated impairment loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" xlink:to="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_doc" xml:lang="en-US">Goodwill accumulated impairment loss foreign currency translation gain loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslation" xlink:to="ENVB_GoodwillCurrencyTranslation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillCurrencyTranslation_doc" xml:lang="en-US">Goodwill currency translation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslationImpairmentLoss" xlink:to="ENVB_GoodwillCurrencyTranslationImpairmentLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillCurrencyTranslationImpairmentLoss_doc" xml:lang="en-US">Goodwill currency translation impairment loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslationLoss" xlink:to="ENVB_GoodwillCurrencyTranslationLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillCurrencyTranslationLoss_doc" xml:lang="en-US">Goodwill currency translation loss.</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Weighted average remaining contractual term for option granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_doc" xml:lang="en-US">Warrant liabilities - January 2021 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_doc" xml:lang="en-US">Warrant liabilities - February 2021 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" xlink:to="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_doc" xml:lang="en-US">Warrant liabilities - February 2022 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Share based Compensation Arrangement By share based Payment Award Options Forfeited Weighted Average Remaining Contractual Term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PurchaseAgreementMember" xlink:to="ENVB_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_LabEquipmentMember" xlink:to="ENVB_LabEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_LabEquipmentMember_doc" xml:lang="en-US">Lab Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" xlink:to="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember_doc" xml:lang="en-US">Computer Equipment and Leasehold Improvements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestructuringCostsIncurred" xlink:to="ENVB_RestructuringCostsIncurred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RestructuringCostsIncurred_doc" xml:lang="en-US">Restructuring costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" xlink:to="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_doc" xml:lang="en-US">February 2022 Post-Modification Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:to="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions_doc" xml:lang="en-US">Induced conversion of warrants and preferred investment options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" xlink:to="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_doc" xml:lang="en-US">Class of warrant or right number of additional securities called by warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PreModificationWarrantsMember" xlink:to="ENVB_PreModificationWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PreModificationWarrantsMember_doc" xml:lang="en-US">Pre Modification Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PostModificationWarrantsMember" xlink:to="ENVB_PostModificationWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PostModificationWarrantsMember_doc" xml:lang="en-US">Post Modification Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:to="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup_doc" xml:lang="en-US">Effective income tax rate reconciliation deferred trueup.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ExistingWarrantsMember" xlink:to="ENVB_ExistingWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ExistingWarrantsMember_doc" xml:lang="en-US">Existing Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharePriceOption" xlink:to="ENVB_SharePriceOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SharePriceOption_doc" xml:lang="en-US">Share price option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfStockIssuanceCost" xlink:to="ENVB_PaymentsOfStockIssuanceCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PaymentsOfStockIssuanceCost_doc" xml:lang="en-US">Payments of stock issuance cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2_lbl" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_2_lbl" xml:lang="en-US">Stockholders' Equity Note, Subscriptions Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_2_lbl" xml:lang="en-US">Operating Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_3_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TemporaryEquityShares" xlink:to="ENVB_TemporaryEquityShares_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_TemporaryEquityShares_4_lbl" xml:lang="en-US">TemporaryEquityShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:to="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_3_lbl" xml:lang="en-US">IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_3_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock_3_lbl" xml:lang="en-US">Payments for Repurchase of Redeemable Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfEmbeddedDerivative" xlink:to="ENVB_IssuanceOfEmbeddedDerivative_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_IssuanceOfEmbeddedDerivative_3_lbl" xml:lang="en-US">IssuanceOfEmbeddedDerivative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:to="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts_3_lbl" xml:lang="en-US">IssuanceOfCommonSharesForDeferredOfferingCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:to="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions_3_lbl" xml:lang="en-US">InducedConversionOfWarrantsAndPreferredInvestmentOptions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:to="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock_3_lbl" xml:lang="en-US">Redeemable non controlling interest policy</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3_lbl" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillGross" xlink:to="us-gaap_GoodwillGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillGross_3_lbl" xml:lang="en-US">Goodwill, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3_lbl" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslation" xlink:to="ENVB_GoodwillCurrencyTranslation_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillCurrencyTranslation_4_lbl" xml:lang="en-US">GoodwillCurrencyTranslation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_3_lbl" xml:lang="en-US">Goodwill [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillImpairmentLossGross" xlink:to="ENVB_GoodwillImpairmentLossGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillImpairmentLossGross_3_lbl" xml:lang="en-US">GoodwillImpairmentLossGross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillAccumulatedImpairmentLoss" xlink:to="ENVB_GoodwillAccumulatedImpairmentLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillAccumulatedImpairmentLoss_3_lbl" xml:lang="en-US">GoodwillAccumulatedImpairmentLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslationImpairmentLoss" xlink:to="ENVB_GoodwillCurrencyTranslationImpairmentLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillCurrencyTranslationImpairmentLoss_3_lbl" xml:lang="en-US">GoodwillCurrencyTranslationImpairmentLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_2_lbl" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_2_lbl" xml:lang="en-US">Asset Impairment Charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_4_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_4_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiability" xlink:to="ENVB_WarrantLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantLiability_3_lbl" xml:lang="en-US">WarrantLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionSharePrice" xlink:to="ENVB_InvestmentOptionSharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOptionSharePrice_3_lbl" xml:lang="en-US">InvestmentOptionSharePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionExercisePrice" xlink:to="ENVB_InvestmentOptionExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOptionExercisePrice_3_lbl" xml:lang="en-US">InvestmentOptionExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentIntrinsicValue" xlink:to="ENVB_InvestmentIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentIntrinsicValue_3_lbl" xml:lang="en-US">InvestmentIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_2_lbl" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:to="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_3_lbl" xml:lang="en-US">FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:to="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_3_lbl" xml:lang="en-US">FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>envb-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://enveric.com/role/Cover" xlink:href="envb-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BalanceSheets" xlink:href="envb-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BalanceSheetsParenthetical" xlink:href="envb-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="envb-20231231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:href="envb-20231231.xsd#StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:href="envb-20231231.xsd#StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfCashFlows" xlink:href="envb-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" xlink:href="envb-20231231.xsd#BusinessAndLiquidityAndOtherUncertainties" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="envb-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="envb-20231231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsAndGoodwill" xlink:href="envb-20231231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipment" xlink:href="envb-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/AccruedLiabilities" xlink:href="envb-20231231.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" xlink:href="envb-20231231.xsd#ShareCapitalAndOtherEquityInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterest" xlink:href="envb-20231231.xsd#RedeemableNon-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValue" xlink:href="envb-20231231.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingencies" xlink:href="envb-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxes" xlink:href="envb-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SubsequentEvents" xlink:href="envb-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="envb-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:href="envb-20231231.xsd#BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="envb-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="envb-20231231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="envb-20231231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipmentTables" xlink:href="envb-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/AccruedLiabilitiesTables" xlink:href="envb-20231231.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:href="envb-20231231.xsd#ShareCapitalAndOtherEquityInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterestTables" xlink:href="envb-20231231.xsd#RedeemableNon-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValueTables" xlink:href="envb-20231231.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingenciesTables" xlink:href="envb-20231231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxesTables" xlink:href="envb-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" xlink:href="envb-20231231.xsd#ScheduleOfRestructuringCostsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:href="envb-20231231.xsd#BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="envb-20231231.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="envb-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="envb-20231231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfGoodwillDetails" xlink:href="envb-20231231.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="envb-20231231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:href="envb-20231231.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:href="envb-20231231.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:href="envb-20231231.xsd#ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="envb-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:href="envb-20231231.xsd#ScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStockOptionDetails" xlink:href="envb-20231231.xsd#ScheduleOfStockOptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" xlink:href="envb-20231231.xsd#ScheduleOfStockOptionAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:href="envb-20231231.xsd#ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:href="envb-20231231.xsd#ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="envb-20231231.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:href="envb-20231231.xsd#ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:href="envb-20231231.xsd#ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:href="envb-20231231.xsd#ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:href="envb-20231231.xsd#ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" xlink:href="envb-20231231.xsd#RedeemableNon-controllingInterestDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:href="envb-20231231.xsd#ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:href="envb-20231231.xsd#ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:href="envb-20231231.xsd#ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValueDetailsNarrative" xlink:href="envb-20231231.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:href="envb-20231231.xsd#ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="envb-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:href="envb-20231231.xsd#ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:href="envb-20231231.xsd#ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="envb-20231231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" xlink:href="envb-20231231.xsd#ScheduleOfOperatingLossCarryForwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:href="envb-20231231.xsd#ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxesDetailsNarrative" xlink:href="envb-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SubsequentEventsDetailsNarrative" xlink:href="envb-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilitiesCurrent" xlink:label="loc_ENVBWarrantLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_ENVBWarrantLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaapTemporaryEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityAbstract" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SeriesCRedeemablePreferredStockMember" xlink:label="loc_ENVBSeriesCRedeemablePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBSeriesCRedeemablePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaapOperatingCostsAndExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InducementExpense" xlink:label="loc_ENVBInducementExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_ENVBInducementExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaapTemporaryEquityAccretionToRedemptionValueAdjustment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapTemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SeriesCRedeemablePreferredStockMember" xlink:label="loc_ENVBSeriesCRedeemablePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ENVBSeriesCRedeemablePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestMember" xlink:label="loc_ENVBRedeemableNoncontrollingInterestMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ENVBRedeemableNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MezzanineEquityMember" xlink:label="loc_ENVBMezzanineEquityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ENVBMezzanineEquityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SubscriptionReceivableMember" xlink:label="loc_ENVBSubscriptionReceivableMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ENVBSubscriptionReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_TemporaryEquityShares" xlink:label="loc_ENVBTemporaryEquityShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBTemporaryEquityShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_ENVBPreferredDividendsAttributableToRedeemableNoncontrollingInterest" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBPreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:label="loc_ENVBAccretionOfEmbeddedDerivativeToRedemptionValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBAccretionOfEmbeddedDerivativeToRedemptionValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:label="loc_ENVBAdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBAdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" xlink:label="loc_ENVBStockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestValue" xlink:label="loc_ENVBRedeemableNoncontrollingInterestValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRedeemableNoncontrollingInterestValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestShares" xlink:label="loc_ENVBRedeemableNoncontrollingInterestShares" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRedeemableNoncontrollingInterestShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" xlink:label="loc_ENVBIssuanceOfRedeemableNoncontrollingSeriesPreferredStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBIssuanceOfRedeemableNoncontrollingSeriesPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_ENVBTemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBTemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" xlink:label="loc_ENVBStockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" xlink:label="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" xlink:label="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" xlink:label="loc_ENVBIssuanceOfRoundedSharesAsResultOfReverseStockSplit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBIssuanceOfRoundedSharesAsResultOfReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_TemporaryEquityShares" xlink:label="loc_ENVBTemporaryEquityShares_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBTemporaryEquityShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_NetOfferingCosts" xlink:label="loc_ENVBNetOfferingCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_ENVBNetOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" xlink:label="loc_ENVBRedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_ENVBRedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestIssuanceCosts" xlink:label="loc_ENVBRedeemableNoncontrollingInterestIssuanceCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_ENVBRedeemableNoncontrollingInterestIssuanceCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InducementExpense" xlink:label="loc_ENVBInducementExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ENVBInducementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_NoncashIncomeTaxExpense" xlink:label="loc_ENVBNoncashIncomeTaxExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ENVBNoncashIncomeTaxExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:label="loc_ENVBIncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_ENVBIncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfRedeemablePreferredStock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfRedeemablePreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance" xlink:label="loc_ENVBWarrantsIssuedInConjunctionWithCommonStockIssuance" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBWarrantsIssuedInConjunctionWithCommonStockIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IssuanceOfEmbeddedDerivative" xlink:label="loc_ENVBIssuanceOfEmbeddedDerivative" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBIssuanceOfEmbeddedDerivative" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockSubscriptionReceivable" xlink:label="loc_ENVBStockSubscriptionReceivable" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBStockSubscriptionReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_OfferingCostsAccruedNotPaid" xlink:label="loc_ENVBOfferingCostsAccruedNotPaid" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBOfferingCostsAccruedNotPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsIssuedForOfferingCosts" xlink:label="loc_ENVBWarrantsIssuedForOfferingCosts" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBWarrantsIssuedForOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:label="loc_ENVBIssuanceOfCommonSharesForDeferredOfferingCosts" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBIssuanceOfCommonSharesForDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:label="loc_ENVBInducedConversionOfWarrantsAndPreferredInvestmentOptions" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_ENVBPreferredDividendsAttributableToRedeemableNoncontrollingInterest" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBPreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" xlink:label="loc_ENVBInvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBInvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise" xlink:label="loc_ENVBModificationOfWarrantsAsPartOfShareCapitalRaise" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBModificationOfWarrantsAsPartOfShareCapitalRaise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:label="loc_ENVBAccretionOfEmbeddedDerivativeToRedemptionValue" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBAccretionOfEmbeddedDerivativeToRedemptionValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" xlink:title="00000008 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000011 - Disclosure - INTANGIBLE ASSETS AND GOODWILL">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/AccruedLiabilities" xlink:title="00000013 - Disclosure - ACCRUED LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" xlink:title="00000014 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterest" xlink:title="00000015 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST">
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:label="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNonControllingInterestTextBlock" xlink:label="loc_ENVBRedeemableNonControllingInterestTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_ENVBRedeemableNonControllingInterestTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValue" xlink:title="00000016 - Disclosure - FAIR VALUE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxes" xlink:title="00000018 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_ENVBDeferredOfferingCostsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ENVBDeferredOfferingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilityPolicyTextBlock" xlink:label="loc_ENVBWarrantLiabilityPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ENVBWarrantLiabilityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" xlink:label="loc_ENVBModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ENVBModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:label="loc_ENVBRedeemableNoncontrollingInterestPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ENVBRedeemableNoncontrollingInterestPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:title="00000021 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000024 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaapScheduleOfGoodwillTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfGoodwillTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/AccruedLiabilitiesTables" xlink:title="00000026 - Disclosure - ACCRUED LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:title="00000027 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="loc_ENVBScheduleOfWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBScheduleOfWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ScheduleOfValuationOfWarrantsTextBlock" xlink:label="loc_ENVBScheduleOfValuationOfWarrantsTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBScheduleOfValuationOfWarrantsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterestTables" xlink:title="00000028 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Tables)">
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:label="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaapTemporaryEquityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapTemporaryEquityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValueTables" xlink:title="00000029 - Disclosure - FAIR VALUE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InitialMeasurementMember" xlink:label="loc_ENVBInitialMeasurementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBInitialMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SubsequentMeasurementMember" xlink:label="loc_ENVBSubsequentMeasurementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBSubsequentMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingenciesTables" xlink:title="00000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" xlink:label="loc_ENVBScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_ENVBScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaapRestructuringAndRelatedCostCostIncurredToDate1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RestructuringCostsIncurred" xlink:label="loc_ENVBRestructuringCostsIncurred" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_ENVBRestructuringCostsIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaapRestructuringCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRestructuringCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringCosts" xlink:label="loc_us-gaapOtherRestructuringCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOtherRestructuringCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaapRestructuringAndRelatedCostCostIncurredToDate1_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRestructuringAndRelatedCostCostIncurredToDate1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="00000033 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_EquityDistributionAgreementMember" xlink:label="loc_ENVBEquityDistributionAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBEquityDistributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_KanubaddiSeparationAgreementMember" xlink:label="loc_ENVBKanubaddiSeparationAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBKanubaddiSeparationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MrKanubaddiEmploymentAgreementMember" xlink:label="loc_ENVBMrKanubaddiEmploymentAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBMrKanubaddiEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WorkingCapital" xlink:label="loc_ENVBWorkingCapital" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaapRestructuringReserve" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRestructuringReserve" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ExpenseRelatedToAccelerationOfVesting" xlink:label="loc_ENVBExpenseRelatedToAccelerationOfVesting" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBExpenseRelatedToAccelerationOfVesting" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MarketPerformanceBasedShares" xlink:label="loc_ENVBMarketPerformanceBasedShares" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBMarketPerformanceBasedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" xlink:label="loc_ENVBMinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBMinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" xlink:label="loc_ENVBRestrictedStockUnitsVestedAndUnIssuedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBRestrictedStockUnitsVestedAndUnIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RestrictedStockUnitsUnvestedMember" xlink:label="loc_ENVBRestrictedStockUnitsUnvestedMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBRestrictedStockUnitsUnvestedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" xlink:label="loc_ENVBRestrictedStockAwardsVestedAndUnIssuedMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBRestrictedStockAwardsVestedAndUnIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_CommonStockInAbeyanceMember" xlink:label="loc_ENVBCommonStockInAbeyanceMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBCommonStockInAbeyanceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBInvstmentOptionsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBInvstmentOptionsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_OptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBOptionsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBOptionsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_countryCA" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="loc_countryAU" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryAU" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PrefundedCommonStockWarrantsMember" xlink:label="loc_ENVBPrefundedCommonStockWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENVBPrefundedCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PrepaidResearchAndDevelopment" xlink:label="loc_ENVBPrepaidResearchAndDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_ENVBPrepaidResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PrepaidFranchiseTaxReceivable" xlink:label="loc_ENVBPrepaidFranchiseTaxReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_ENVBPrepaidFranchiseTaxReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:label="loc_ENVBPrepaidResearchAndDevelopmentTaxIncentiveReceivable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_ENVBPrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfGoodwillDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaapGoodwillGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairedAccumulatedImpairmentLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillCurrencyTranslation" xlink:label="loc_ENVBGoodwillCurrencyTranslation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillCurrencyTranslation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillImpairmentLossGross" xlink:label="loc_ENVBGoodwillImpairmentLossGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillImpairmentLossGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillAccumulatedImpairmentLoss" xlink:label="loc_ENVBGoodwillAccumulatedImpairmentLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillAccumulatedImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillCurrencyTranslationImpairmentLoss" xlink:label="loc_ENVBGoodwillCurrencyTranslationImpairmentLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillCurrencyTranslationImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillForeignCurrencyTranslationGainLossGross" xlink:label="loc_ENVBGoodwillForeignCurrencyTranslationGainLossGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillForeignCurrencyTranslationGainLossGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" xlink:label="loc_ENVBGoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillCurrencyTranslationLoss" xlink:label="loc_ENVBGoodwillCurrencyTranslationLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillCurrencyTranslationLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaapGoodwillForeignCurrencyTranslationGainLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaapGoodwillGross_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillGross_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairedAccumulatedImpairmentLoss_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillImpairedAccumulatedImpairmentLoss_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_GoodwillCurrencyTranslation" xlink:label="loc_ENVBGoodwillCurrencyTranslation_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillCurrencyTranslation_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="00000040 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_LabEquipmentMember" xlink:label="loc_ENVBLabEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ENVBLabEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" xlink:label="loc_ENVBComputerEquipmentAndLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ENVBComputerEquipmentAndLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000042 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF ACCRUED LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AccruedProductDevelopmentCost" xlink:label="loc_ENVBAccruedProductDevelopmentCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_ENVBAccruedProductDevelopmentCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AccruedRestructuringCosts" xlink:label="loc_ENVBAccruedRestructuringCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_ENVBAccruedRestructuringCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStockOptionDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF STOCK OPTION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF STOCK OPTION ASSUMPTION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionsMember" xlink:label="loc_ENVBInvestmentOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RothAndInducementWarrantsMember" xlink:label="loc_ENVBRothAndInducementWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBRothAndInducementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:title="00000051 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DistributionAgreementMember" xlink:label="loc_ENVBDistributionAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBDistributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RegistrationRightsAgreementMember" xlink:label="loc_ENVBRegistrationRightsAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBRegistrationRightsAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBRegisteredDirectSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBRegisteredDirectSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PIPESecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBPIPESecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPIPESecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantAmendmentAgreementsMember" xlink:label="loc_ENVBWarrantAmendmentAgreementsMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBWarrantAmendmentAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_CanaccordGenuityLLCMember" xlink:label="loc_ENVBCanaccordGenuityLLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ENVBCanaccordGenuityLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PlacementAgentPreferredInvestmentOptionsMember" xlink:label="loc_ENVBPlacementAgentPreferredInvestmentOptionsMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBPlacementAgentPreferredInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_UnderwritersMember" xlink:label="loc_ENVBUnderwritersMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ENVBUnderwritersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RDOfferingAndPIPEInvestmentOptionsMember" xlink:label="loc_ENVBRDOfferingAndPIPEInvestmentOptionsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBRDOfferingAndPIPEInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_TwoThousandTwentyLongTermIncentivePlanMember" xlink:label="loc_ENVBTwoThousandTwentyLongTermIncentivePlanMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ENVBTwoThousandTwentyLongTermIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ExistingWarrantsMember" xlink:label="loc_ENVBExistingWarrantsMember" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENVBExistingWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionsMember" xlink:label="loc_ENVBInvestmentOptionsMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENVBInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FebruaryWarrantsMember" xlink:label="loc_ENVBFebruaryWarrantsMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PreModificationWarrantsMember" xlink:label="loc_ENVBPreModificationWarrantsMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBPreModificationWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PostModificationWarrantsMember" xlink:label="loc_ENVBPostModificationWarrantsMember" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBPostModificationWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="110" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="120" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" xlink:label="loc_ENVBSaleOfStockConsiderationExpectedMaximumPriceOnLimitation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSaleOfStockConsiderationExpectedMaximumPriceOnLimitation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_CommissionPercentage" xlink:label="loc_ENVBCommissionPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBCommissionPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiability" xlink:label="loc_ENVBWarrantLiability" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromOtherEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PaymentsOfStockIssuanceCost" xlink:label="loc_ENVBPaymentsOfStockIssuanceCost" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfStockIssuanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PaymentsOfAllocatedEquity" xlink:label="loc_ENVBPaymentsOfAllocatedEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfAllocatedEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PaymentsOfInvestmentOptionLiability" xlink:label="loc_ENVBPaymentsOfInvestmentOptionLiability" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfInvestmentOptionLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" xlink:label="loc_ENVBPaymentsOfStockIssuanceCostsRecordedExpense" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfStockIssuanceCostsRecordedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_NumberOfVestedAndUnissuedShares" xlink:label="loc_ENVBNumberOfVestedAndUnissuedShares" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBNumberOfVestedAndUnissuedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" xlink:label="loc_ENVBClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ClassOfWarrantOrRightReasonForIssuing" xlink:label="loc_ENVBClassOfWarrantOrRightReasonForIssuing" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBClassOfWarrantOrRightReasonForIssuing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionSharePrice" xlink:label="loc_ENVBInvestmentOptionSharePrice" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOptionSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionExercisePrice" xlink:label="loc_ENVBInvestmentOptionExercisePrice" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOptionExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionTerm" xlink:label="loc_ENVBInvestmentOptionTerm" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOptionTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOutstandingMeasurementInput" xlink:label="loc_ENVBInvestmentOutstandingMeasurementInput" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SharePriceOption" xlink:label="loc_ENVBSharePriceOption" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharePriceOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentIntrinsicValue" xlink:label="loc_ENVBInvestmentIntrinsicValue" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentInducementGain" xlink:label="loc_ENVBInvestmentInducementGain" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentInducementGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapPreferredStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)">
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:label="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapTemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapTemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaapTemporaryEquityAccretionToRedemptionValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapTemporaryEquityAccretionToRedemptionValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfRedeemablePreferredStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfRedeemablePreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" xlink:title="00000053 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:label="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AkosSecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBAkosSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBAkosSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SeriesAConvertiblePreferredStockMember" xlink:label="loc_ENVBSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AkosMember" xlink:label="loc_ENVBAkosMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_ENVBAkosMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SpinoffAndRelatedPrivatePlacementDescription" xlink:label="loc_ENVBSpinoffAndRelatedPrivatePlacementDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBSpinoffAndRelatedPrivatePlacementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsToPurchaseCommonStockPercentage" xlink:label="loc_ENVBWarrantsToPurchaseCommonStockPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBWarrantsToPurchaseCommonStockPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="loc_us-gaapDividendsPayableAmountPerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPayableAmountPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_UnpaidDividends" xlink:label="loc_ENVBUnpaidDividends" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBUnpaidDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RedeemableNoncontrollingInterest" xlink:label="loc_ENVBRedeemableNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRedeemableNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBWarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBWarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" xlink:label="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:label="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WainwrightInvestmentOptionsMember" xlink:label="loc_ENVBWainwrightInvestmentOptionsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBWainwrightInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RDInvestmentOptionsMember" xlink:label="loc_ENVBRDInvestmentOptionsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBRDInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PIPEInvestmentOptionsMember" xlink:label="loc_ENVBPIPEInvestmentOptionsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBPIPEInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesRelatedToInvestmentContractsFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesRelatedToInvestmentContractsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InitialMeasurementMember" xlink:label="loc_ENVBInitialMeasurementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBInitialMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_SubsequentMeasurementMember" xlink:label="loc_ENVBSubsequentMeasurementMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBSubsequentMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FebruaryTwentyTwentyTwoWarrantsMember" xlink:label="loc_ENVBFebruaryTwentyTwentyTwoWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryTwentyTwentyTwoWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" xlink:label="loc_ENVBFebruaryTwentyTwentyTwoPostModificationWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryTwentyTwentyTwoPostModificationWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_JanuaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBJanuaryTwentyTwentyOneWarrantsMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBJanuaryTwentyTwentyOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FebruaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBFebruaryTwentyTwentyOneWarrantsMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryTwentyTwentyOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_MeasurementInputMarketRateMember" xlink:label="loc_ENVBMeasurementInputMarketRateMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_ENVBMeasurementInputMarketRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:label="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WainwrightInvestmentOptionsMember" xlink:label="loc_ENVBWainwrightInvestmentOptionsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBWainwrightInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RDInvestmentOptionsMember" xlink:label="loc_ENVBRDInvestmentOptionsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBRDInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PIPEInvestmentOptionsMember" xlink:label="loc_ENVBPIPEInvestmentOptionsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBPIPEInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" xlink:label="loc_ENVBHCWainwrightAndCoLLCInvestmentOptionsMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBHCWainwrightAndCoLLCInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_WarrantsAndRightsOutstandingStockPrice" xlink:label="loc_ENVBWarrantsAndRightsOutstandingStockPrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBWarrantsAndRightsOutstandingStockPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ConvertiblePreferredStockPrincipalValue" xlink:label="loc_ENVBConvertiblePreferredStockPrincipalValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBConvertiblePreferredStockPrincipalValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaapAlternativeInvestmentMeasurementInput" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapAlternativeInvestmentMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_InvestmentOptionTerm" xlink:label="loc_ENVBInvestmentOptionTerm" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBInvestmentOptionTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_StockOptionExercisePrice" xlink:label="loc_ENVBStockOptionExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBStockOptionExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" xlink:label="loc_us-gaapRetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapRetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeMember" xlink:label="loc_us-gaapDerivativeMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDerivativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:label="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:label="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValueDetailsNarrative" xlink:title="00000057 - Disclosure - FAIR VALUE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AvanceClinicalMember" xlink:label="loc_ENVBAvanceClinicalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ENVBAvanceClinicalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_VogalNathanPurchaseAgreementMember" xlink:label="loc_ENVBVogalNathanPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBVogalNathanPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_OtherConsultingAndVendorAgreementsMember" xlink:label="loc_ENVBOtherConsultingAndVendorAgreementsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBOtherConsultingAndVendorAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_OneTimeMilestoneMember" xlink:label="loc_ENVBOneTimeMilestoneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBOneTimeMilestoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_AdditionalMilestoneMember" xlink:label="loc_ENVBAdditionalMilestoneMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBAdditionalMilestoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="loc_us-gaapCapitalizedContractCostNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCapitalizedContractCostNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:label="loc_us-gaapConstructionContractCostProgressPaymentOffset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapConstructionContractCostProgressPaymentOffset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaapLongTermPurchaseCommitmentAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLongTermPurchaseCommitmentAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_RoyaltiesPercentage" xlink:label="loc_ENVBRoyaltiesPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_ENVBRoyaltiesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000062 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_ResearchAndDevelopmentCapitalizedExpenses" xlink:label="loc_ENVBResearchAndDevelopmentCapitalizedExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ENVBResearchAndDevelopmentCapitalizedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DeferredTaxAssetsAndIntangibleAmortization" xlink:label="loc_ENVBDeferredTaxAssetsAndIntangibleAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ENVBDeferredTaxAssetsAndIntangibleAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:label="loc_ENVBEffectiveIncomeTaxRateReconciliationDeferredTrueup" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ENVBEffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000065 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000066 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_PurchaseAgreementMember" xlink:label="loc_ENVBPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20231231.xsd#ENVB_DistributionAgreementMember" xlink:label="loc_ENVBDistributionAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBDistributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861200114848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ENVERIC
BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000890821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4484725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4851
                                            Tamiami Trail N<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Naples<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">302-1707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENVB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,294,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated By Reference</a></td>
<td class="text">Portions
of the Company&#8217;s proxy statement for the Annual Meeting of Stockholders to be held May 28, 2024 are incorporated by reference into
Part III of this report. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s
fiscal year ended December 31, 2023. Additionally, portions of the Annual Report are incorporated by reference in this Form 10-K in response
to Items within Part II.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">East
Hanover, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861201811168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 2,287,977<span></span>
</td>
<td class="nump">$ 17,723,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,293,554<span></span>
</td>
<td class="nump">708,053<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,581,531<span></span>
</td>
<td class="nump">18,431,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">507,377<span></span>
</td>
<td class="nump">677,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use operating lease asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">63,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">210,932<span></span>
</td>
<td class="nump">379,686<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">718,309<span></span>
</td>
<td class="nump">1,120,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,299,840<span></span>
</td>
<td class="nump">19,552,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,218,783<span></span>
</td>
<td class="nump">463,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">1,075,643<span></span>
</td>
<td class="nump">1,705,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of right-of-use operating lease obligation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">63,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Investment option liability</a></td>
<td class="nump">23,608<span></span>
</td>
<td class="nump">851,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantLiabilitiesCurrent', window );">Warrant liability</a></td>
<td class="nump">25,470<span></span>
</td>
<td class="nump">185,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">727,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,343,504<span></span>
</td>
<td class="nump">3,995,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">885,028<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Total mezzanine equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">885,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 100,000,000 shares authorized, 2,739,315 and 2,078,271 shares issued and outstanding as of December 31, 2023 and 2022, respectively</a></td>
<td class="nump">27,392<span></span>
</td>
<td class="nump">20,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">100,815,851<span></span>
</td>
<td class="nump">94,395,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Stock subscription receivable</a></td>
<td class="num">(1,817,640)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(96,499,518)<span></span>
</td>
<td class="num">(79,207,786)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(569,749)<span></span>
</td>
<td class="num">(536,734)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">1,956,336<span></span>
</td>
<td class="nump">14,671,924<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and shareholders&#8217; equity</a></td>
<td class="nump">$ 4,299,840<span></span>
</td>
<td class="nump">$ 19,552,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 14<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 15<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861110506544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,739,315<span></span>
</td>
<td class="nump">2,078,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,739,315<span></span>
</td>
<td class="nump">2,078,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ENVB_SeriesCRedeemablePreferredStockMember', window );">Series C Redeemable Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENVB_SeriesCRedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENVB_SeriesCRedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861201851136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 8,852,021<span></span>
</td>
<td class="nump">$ 11,605,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,252,437<span></span>
</td>
<td class="nump">8,027,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of intangible assets and goodwill</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,453,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">343,982<span></span>
</td>
<td class="nump">327,910<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">16,448,440<span></span>
</td>
<td class="nump">27,415,106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(16,448,440)<span></span>
</td>
<td class="num">(27,415,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InducementExpense', window );">Inducement expense, net</a></td>
<td class="num">(1,848,235)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">94,396<span></span>
</td>
<td class="nump">4,315,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Change in fair value of investment option liability</a></td>
<td class="nump">208,752<span></span>
</td>
<td class="nump">3,472,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">727,000<span></span>
</td>
<td class="num">(325,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="nump">3,708<span></span>
</td>
<td class="num">(5,249)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="num">(814,379)<span></span>
</td>
<td class="nump">7,457,713<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(17,262,819)<span></span>
</td>
<td class="num">(19,957,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(28,913)<span></span>
</td>
<td class="nump">1,486,060<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,291,732)<span></span>
</td>
<td class="num">(18,471,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Less preferred dividends attributable to non-controlling interest</a></td>
<td class="nump">19,041<span></span>
</td>
<td class="nump">33,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Less deemed dividends attributable to accretion of embedded derivative at redemption value</a></td>
<td class="nump">147,988<span></span>
</td>
<td class="nump">295,976<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to shareholders</a></td>
<td class="num">(17,458,761)<span></span>
</td>
<td class="num">(18,800,323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(33,015)<span></span>
</td>
<td class="num">(505,932)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (17,491,776)<span></span>
</td>
<td class="num">$ (19,306,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (8.09)<span></span>
</td>
<td class="num">$ (13.00)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (8.09)<span></span>
</td>
<td class="num">$ (13.00)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">2,159,063<span></span>
</td>
<td class="nump">1,446,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">2,159,063<span></span>
</td>
<td class="nump">1,446,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InducementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inducement expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InducementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861105815456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Series C Redeemable Preferred Stock [Member]</div></th>
<th class="th"><div>Redeemable Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Mezzanine Equity [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Subscription Receivable [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,519<span></span>
</td>
<td class="nump">$ 83,066,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (60,736,453)<span></span>
</td>
<td class="num">$ (30,802)<span></span>
</td>
<td class="nump">$ 22,305,920<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest', window );">Preferred dividends attributable to redeemable non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 33,014<span></span>
</td>
<td class="nump">33,014<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33,014)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue', window );">Accretion of embedded derivative to redemption value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">295,976<span></span>
</td>
<td class="nump">295,976<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(295,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(295,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Redemption of Series C preferred stock</a></td>
<td class="num">$ (527)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(527)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Redemption of Series C preferred stock, shares</a></td>
<td class="num">(52,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,620,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,620,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(505,932)<span></span>
</td>
<td class="num">(505,932)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,471,333)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,471,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost', window );">February 2022 registered direct offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">5,798,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,802,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost', window );">February 2022 registered direct offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Conversion of RSUs into common shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Conversion of RSUs into common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNoncontrollingInterestValue', window );">Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 556,038<span></span>
</td>
<td class="nump">556,038<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNoncontrollingInterestShares', window );">Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock', window );">Issuance of redeemable Series C preferred stock</a></td>
<td class="nump">$ 527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of redeemable Series C preferred stock, shares</a></td>
<td class="nump">52,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards', window );">Conversion of RSAs into common shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards', window );">Conversion of RSAs into common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts', window );">July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">3,239,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,249,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares', window );">July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit', window );">Issuance of rounded shares as a result of the reverse stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
<td class="num">(242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Issuance of rounded shares as a result of the reverse stock split, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 885,028<span></span>
</td>
<td class="nump">885,028<span></span>
</td>
<td class="nump">$ 20,782<span></span>
</td>
<td class="nump">94,395,662<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(79,207,786)<span></span>
</td>
<td class="num">(536,734)<span></span>
</td>
<td class="nump">14,671,924<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,078,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest', window );">Preferred dividends attributable to redeemable non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,041<span></span>
</td>
<td class="nump">19,041<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,041)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,041)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue', window );">Accretion of embedded derivative to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,988<span></span>
</td>
<td class="nump">147,988<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(147,988)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(147,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Redemption of Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,052,057)<span></span>
</td>
<td class="num">(1,052,057)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Redemption of Series C preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,150,160<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,150,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of common shares in exchange for RSU conversions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,036<span></span>
</td>
<td class="num">(1,036)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Issuance of common shares in exchange for RSU conversions, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares for deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,394<span></span>
</td>
<td class="nump">253,713<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">255,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for deferred offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Inducement Warrants, net of offering costs of $239,302</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,967,424<span></span>
</td>
<td class="num">(280,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,686,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions', window );">Induced conversion of warrants and preferred investment options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">683,997<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">683,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Exercise of warrants and preferred investment options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,180<span></span>
</td>
<td class="nump">1,532,960<span></span>
</td>
<td class="num">(1,537,140)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Exercise of warrants and preferred investment options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33,015)<span></span>
</td>
<td class="num">(33,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,291,732)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,291,732)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 27,392<span></span>
</td>
<td class="nump">$ 100,815,851<span></span>
</td>
<td class="num">$ (1,817,640)<span></span>
</td>
<td class="num">$ (96,499,518)<span></span>
</td>
<td class="num">$ (569,749)<span></span>
</td>
<td class="nump">$ 1,956,336<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,739,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of embedded derivative to redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Induced conversion of warrants and preferred investment options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of redeemable noncontrolling series preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of rounded shares as result of reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred dividends attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNoncontrollingInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable noncontrolling interest shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNoncontrollingInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNoncontrollingInterestValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable noncontrolling interest value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNoncontrollingInterestValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registered direct offering pipe offering modification of warrants and exercise of prefunded warrants net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registered direct offering pipe offering modification of warrants and exercise of pre funded warrants net of offering costs shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issued direct offering net of offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>February 2022 registered direct offering, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_TemporaryEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_TemporaryEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Stock Issued During Period Shares New Issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861105564064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_NetOfferingCosts', window );">Net offering costs</a></td>
<td class="nump">$ 239,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative', window );">Issuance of embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNoncontrollingInterestIssuanceCosts', window );">Redeemable noncontrolling interest issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_NetOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_NetOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNoncontrollingInterestIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable noncontrolling interest issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNoncontrollingInterestIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of embedded derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861199889936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,291,732)<span></span>
</td>
<td class="num">$ (18,471,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(94,396)<span></span>
</td>
<td class="num">(4,315,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Change in fair value of investment option liability</a></td>
<td class="num">(208,752)<span></span>
</td>
<td class="num">(3,472,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(727,000)<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,150,160<span></span>
</td>
<td class="nump">2,620,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InducementExpense', window );">Inducement expense</a></td>
<td class="nump">1,848,235<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of intangibles</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,453,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_NoncashIncomeTaxExpense', window );">Non-cash income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,504,302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of ROU asset</a></td>
<td class="nump">64,048<span></span>
</td>
<td class="nump">107,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">168,754<span></span>
</td>
<td class="nump">168,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">175,228<span></span>
</td>
<td class="nump">159,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of property and equipment</a></td>
<td class="num">(4,206)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(6,857)<span></span>
</td>
<td class="num">(374,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(103,848)<span></span>
</td>
<td class="nump">263,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation', window );">Right-of-use operating lease asset and obligation</a></td>
<td class="num">(64,045)<span></span>
</td>
<td class="num">(107,288)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,094,411)<span></span>
</td>
<td class="num">(17,146,723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(5,180)<span></span>
</td>
<td class="num">(584,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">16,847<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">11,667<span></span>
</td>
<td class="num">(584,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, warrants, and investment options, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,222,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment for equity distribution offering costs</a></td>
<td class="num">(291,084)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock', window );">Redemption of Series A Preferred Stock</a></td>
<td class="num">(1,052,057)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock', window );">Proceeds from the sale of redeemable non-controlling interest, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">958,038<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,343,141)<span></span>
</td>
<td class="nump">18,180,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of Foreign Exchange Rate on Changes on Cash</a></td>
<td class="num">(10,022)<span></span>
</td>
<td class="num">(81,364)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash</a></td>
<td class="num">(15,435,907)<span></span>
</td>
<td class="nump">367,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash at beginning of year</a></td>
<td class="nump">17,723,884<span></span>
</td>
<td class="nump">17,355,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash at end of year</a></td>
<td class="nump">2,287,977<span></span>
</td>
<td class="nump">17,723,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash and non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">9,507<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance', window );">Warrants issued in conjunction with common stock issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,595,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_IssuanceOfEmbeddedDerivative', window );">Issuance of embedded derivative</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">402,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockSubscriptionReceivable', window );">Stock subscription receivable</a></td>
<td class="nump">1,817,640<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_OfferingCostsAccruedNotPaid', window );">Offering costs accrued not paid</a></td>
<td class="nump">182,724<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsIssuedForOfferingCosts', window );">Warrants issued for offering costs</a></td>
<td class="nump">77,991<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts', window );">Issuance of common shares for deferred offering costs</a></td>
<td class="nump">255,107<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions', window );">Induced conversion of warrants and preferred investment options</a></td>
<td class="nump">683,997<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest', window );">Preferred dividends attributable to redeemable non-controlling interest</a></td>
<td class="nump">19,041<span></span>
</td>
<td class="nump">33,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance', window );">Investment options issued in conjunction with common stock issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,323,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise', window );">Modification of warrants as part of share capital raise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">251,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue', window );">Accretion of embedded derivative to redemption value</a></td>
<td class="nump">$ 147,988<span></span>
</td>
<td class="nump">$ 295,976<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of embedded derivative to redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use operating lease asset and obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Induced conversion of warrants and preferred investment options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InducementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inducement expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InducementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment options issued in conjunction with common stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_IssuanceOfEmbeddedDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of embedded derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_IssuanceOfEmbeddedDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification of warrants as part of share capital raise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_NoncashIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_NoncashIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_OfferingCostsAccruedNotPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering costs accrued not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_OfferingCostsAccruedNotPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred dividends attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantsIssuedForOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued for offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantsIssuedForOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued in conjunction with common stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for reacquisition of callable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash inflows (outflows) from issuing and redeeming redeemable preferred stock; includes convertible and nonconvertible redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861106338992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--NatureOfOperations_zcYw7bouB0pi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_827_zeGb70wjgan">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature
of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. (&#8220;Enveric&#8221; or the &#8220;Company&#8221;) is a biotechnology company developing novel neuroplastogenic small-molecule
therapeutics for the treatment of depression, anxiety, and addiction disorders. The head office of the Company is located in Naples,
Florida. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (&#8220;Jay Pharma&#8221;), 1306432 B.C. Ltd. (&#8220;HoldCo&#8221;),
MagicMed Industries, Inc. (&#8220;MagicMed&#8221;), Enveric Canada Inc., and Enveric Therapeutics, Pty. Ltd. (&#8220;Enveric Therapeutics&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging
its unique discovery and development platform, The Psybrary&#8482;, Enveric has created a robust Intellectual Property portfolio of New
Chemical Entities for specific mental health indications. Enveric&#8217;s lead program, the EVM201 Series, comprises next generation
synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series &#8211; EB-373
&#8211; for the treatment of psychiatric disorders. Enveric is also advancing its second program, the EVM301 Series, expected to offer
a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity
without also inducing hallucinations in the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Company&#8217;s amalgamation with MagicMed completed in September 2021 (the &#8220;Amalgamation&#8221;), the Company has continued
to pursue the development of MagicMed&#8217;s proprietary Psychedelic Derivatives library, the Psybrary&#8482; which the Company believes
will help to identify and develop the right drug candidates needed to address mental health challenges, including cancer-related distress.
The Company synthesizes novel versions of classic psychedelics, such as psilocybin, DMT, mescaline and MDMA, using a mixture of chemistry
and synthetic biology, resulting in the expansion of the Psybrary&#8482;, which includes 15 patent families with over a million potential
variations and hundreds of synthesized molecules. Within the Psybrary&#8482; the Company has three different types of molecules, Generation
1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). The Company is working to add novel psychedelic
molecular compounds and derivatives (&#8220;Psychedelic Derivatives&#8221;) on a regular basis through its work at the Company&#8217;s
labs in Calgary, Alberta, Canada, where the Company has a team of PhD scientists with expertise in synthetic biology and chemistry. To
date the Company has created over 500 molecules that are housed in the Psybrary&#8482;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company screens newly synthesized molecules in the Psybrary&#8482; through PsyAI&#8482;, a proprietary artificial intelligence (&#8220;AI&#8221;)
tool. Leveraging AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. The Company
believes it streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological
effects to help determine ideal drug candidates, tailored to each indication. Each of these molecules that the Company believes are patentable
can then be further screened to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New
compounds of sufficient purity are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal),
and ultimately clinical (human) evaluations. The Company intends to utilize the Psybrary&#8482; and the AI tool to categorize and characterize
the Psybrary&#8482; substituents to focus on bringing more psychedelics-inspired molecules from discovery to the clinical phase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Australian
Subsidiary</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2023, the Company established Enveric Therapeutics, an Australia-based subsidiary, to support the Company&#8217;s plans to
advance its lead program, the EVM201 Series, comprised of the next generation synthetic prodrugs of the active metabolite, psilocin (&#8220;EVM201
Series&#8221;), towards the clinic. Enveric Therapeutics will oversee the Company&#8217;s preclinical, clinical, and regulatory activities
in Australia, including ongoing interactions with the local Human Research Ethics Committees (HREC) and the Therapeutic Goods Administration
(TGA), Australia&#8217;s regulatory authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern, Liquidity and Other Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred a loss since inception resulting in an accumulated deficit of $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_zeXL2JVUG7I7" title="Accumulated deficit">96,499,518</span> as of December 31, 2023 and further losses
are anticipated in the development of its business. Further, the Company has operating cash outflows of $<span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20231231_zC9IEOtZAr8a" title="Net cash used in operating activities">14,094,411</span> for the year ended
December 31, 2023. For the year ended December 31, 2023, the Company had a loss from operations of $<span id="xdx_906_eus-gaap--OperatingIncomeLoss_iN_di_c20230101__20231231_zptySDPGyAxb" title="Loss from operations">16,448,440</span>. Since inception, being
a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its
operations. The Company&#8217;s operations have been funded principally through the issuance of equity. These factors raise substantial
doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the Company&#8217;s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate
sufficient cash flow in the future to support its operating and capital expenditure commitments. At December 31, 2023, the Company had
cash of $<span id="xdx_906_eus-gaap--Cash_iI_c20231231_zvJyRYCpQVAi" title="Cash">2,287,977</span> and working capital of $<span id="xdx_900_ecustom--WorkingCapital_iI_c20231231_znZyDndGCB39" title="Working capital">1,238,027</span>. The Company&#8217;s current cash on hand is not sufficient enough to satisfy its
operating cash needs for the 12 months from the filing of this Annual Report on Form 10-K. These conditions raise substantial doubt regarding
the Company&#8217;s ability to continue as a going concern for a period of one year after the date the financial statements are issued.
Management&#8217;s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public
or private equity or debt financings or other sources, which has included the Equity Distribution Agreement with Canaccord for proceeds
of up to $<span id="xdx_901_eus-gaap--ProceedsFromShortTermDebt_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z37fhioYnxFk" title="Additional working capital">2.4</span> million (see Note 7), the Purchase Agreement with Lincoln Park (see Note 7), subject to registration, the Inducement Letters
and resulting sales of common stock under the Existing Warrants for cash proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zz97PuFdcZcd" title="Warrants for cash proceeds">1.8</span> million received in January 2024 (see Note
7), and the exercise of warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBnxG2jQtVMb" title="Exercise of warrants to purchase">1,954,000</span> shares of common stock for cash proceeds of approximately $<span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240201__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zck6XEqy8KS5" title="Cash proceeds of warrants">2.7</span> million in February
2024 (see Note 12), and may include additional collaborations with third parties as well as disciplined cash spending. Adequate additional
financing may not be available to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital,
the Company may be required to undertake cost-cutting measures including delaying or discontinuing certain operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as
a going concern for a period of one year after the date of the financial statements are issued. The Company&#8217;s consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reduction
in Force/Restructuring</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Company entered into a cost reduction plan, including a reduction in force (&#8220;RIF&#8221;) of approximately 35% of
its full-time employees to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that
were focused on the Akos cannabinoid spin-out were terminated. The Company recognized severance charges of approximately $<span id="xdx_909_eus-gaap--SeveranceCosts1_c20230501__20230531_z8D58hHBUYA" title="Severance costs">453,059</span> through
December 31, 2023. The plan included a focus on progressing the Company&#8217;s existing non-cannabinoid pipeline while reducing the
rate of spend and managing cash flow. In June 2023, the Company completed the reduction in force, with such severance expenses recorded
in general and administrative accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 16, 2023, the Company entered into a separation agreement with Avani Kanubaddi, the Company&#8217;s President and Chief Operating
Officer (the &#8220;Kanubaddi Separation Agreement&#8221;). In accordance with the Kanubaddi Separation Agreement, Mr. Kanubaddi&#8217;s
outstanding restricted stock units (&#8220;RSUs&#8221;) will retain their vesting conditions. Mr. Kanubaddi&#8217;s 2023 salary and benefits
of $<span id="xdx_907_eus-gaap--SalariesAndWages_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_zMaUHcTYjBF4" title="Salaries and benefit">550,974</span>, inclusive of the 2023 performance bonus in the amount of $<span id="xdx_90A_eus-gaap--AccruedBonusesCurrent_iI_c20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_ztd6F7MB8w7c" title="Performance bonus">129,760</span> were accrued and the salary and benefits, excluding the
2023 performance bonus will be paid out in twelve equal monthly installments beginning in July 2023. As of December 31, 2023, the performance
metrics for the 2023 performance bonus were not achieved and the accrued amount of amount of $<span id="xdx_906_eus-gaap--RestructuringReserve_iI_c20231231_zRuin27dgPvk" title="Reversed amount">129,760</span> was reversed. Upon termination,
any unvested time-based RSUs became fully vested. The Company accelerated expense recognized related to these shares that vested was
$<span id="xdx_907_ecustom--ExpenseRelatedToAccelerationOfVesting_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--MrKanubaddiEmploymentAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLAvMlfADMU2" title="Expense related to acceleration of vesting">231,273</span>. All of the <span id="xdx_906_ecustom--MarketPerformanceBasedShares_iI_c20230616__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmfQq6R0AFH7" title="Market performance based shares">11,278</span> market performance-based RSUs previously granted that were subject to the original terms and conditions of
Mr. Kanubaddi&#8217;s employment agreement were forfeited during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z5glKSFld41e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_ztulwBwkUNX1" style="display: none">SCHEDULE
OF RESTRUCTURING COSTS PAYABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued<br/>
Restructuring Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>January 1, 2023 Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20230101__20231231_zAlZ6w4mtdef" style="text-align: right" title="Restructuring cost payable, beginning"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Restructuring costs incurred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_ecustom--RestructuringCostsIncurred_c20230101__20231231_zWEiabbndsUi" style="width: 16%; text-align: right" title="Restructuring costs incurred">1,004,033</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restructuring costs paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RestructuringCosts_c20230101__20231231_zH5WzRsnJSdh" style="text-align: right" title="Restructuring costs">(572,628</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restructuring costs reversed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OtherRestructuringCosts_c20230101__20231231_zY0iQ8QQEIX6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Restructuring costs reversed">(129,760</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">December 31, 2023 ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20230101__20231231_z5ABeYZz2MK4" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending">301,645</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zbWxkJfj9qfh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers the current inflationary trend existing in the North American economic environment reasonably likely to have a material
unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price
inflation, have caused a general increase in the cost of labor and materials. In addition, there is an increased risk of the Company
experiencing labor shortages due to a potential inability to attract and retain human resources due to increased labor costs resulting
from the current inflationary environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Notice</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that as
of September 30, 2023, the Company did not meet the minimum of $<span id="xdx_90A_ecustom--MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_iI_c20231121_zRjXM8zUUidi" title="Minimum of stockholders equity required for continued listing pursuant to exchange">2,500,000</span> in stockholders&#8217; equity required for continued listing
pursuant to Nasdaq Listing Rule 5550(b)(1). On February 6, 2024, the Company received a letter from Nasdaq, granting the Company an extension
to regain compliance with the minimum stockholders&#8217; equity requirement by May 20, 2024. If the Company fails to evidence compliance
upon filing its periodic report for June 30, 2024 with the SEC and Nasdaq, the Company may be subject to delisting. The Company plans
to regain and evidence compliance with the Stockholders&#8217; Equity Requirement by the required deadlines, but it is not assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861102921760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_z1Usp4Epnijl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_827_z29VOpGCLrQb">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6VcoZZsSz29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zbIKrsz2JJMb">Basis
of Presentation and Principal of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance and in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and the applicable rules
and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) regarding consolidated financial information. All intercompany
transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--UseOfEstimates_zLE80GiwQAK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zMMySFR20SIc">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported.
By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such
estimates in future periods could be significant. Significant areas requiring management&#8217;s estimates and assumptions include determining
the fair value of transactions involving common stock, the valuation of warrants and preferred investment options, and the valuation
of stock-based compensation and accruals associated with third party providers supporting research and development efforts. Actual results
could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z5nptn10VcWl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zFKLsC1vhXHf">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through December 31, 2023, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#8217;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended December
31, 2023 and 2022, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the consolidated statements of operations and comprehensive loss as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6AeRnFPvu0k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zNjHpvv4Gia">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The
Company did not have any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zIej6k2jp2B1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z0Oa78Uy6iHe">Concentration
of Credit Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zB4bQGBLtGA6" title="Cash FDIC insured amount">250,000</span> in the United States and Australia and $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zGy542i4yAyf" title="Cash insured amount">100,000</span> in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of December 31, 2023, the Company had greater than $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zQv2tJGpW28l" title="Cash FDIC insured amount">250,000</span> at United States financial institutions, less than $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--AU_zPZgCdbAQVk7" title="Cash FDIC insured amount">250,000</span>
at Australian financial institutions, and greater than $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zkz71lJ5798l" title="Cash FDIC insured amount">100,000</span> at Canadian financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zuPlfgRbEyZd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztBjC43QkT38">Comprehensive
Loss</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss consists of two components, net loss and other comprehensive income (loss). Other comprehensive loss refers to revenue, expenses,
gains, and losses that under GAAP are recorded as an element of shareholders&#8217; equity but are excluded from net loss. Other comprehensive
loss consists of foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziQD2CBAghZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zPkCB4Owiyud">Intangible
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the Psybrary&#8482; and Patent Applications, In Process Research and Development (&#8220;IPR&amp;D&#8221;) and license
agreements. Psybrary&#8482; and Patent Applications intangible assets are valued using the relief from royalty method. The cost of license
agreements is amortized over the economic life of the license. The Company assesses the carrying value of its intangible assets for impairment
each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IPR&amp;D
intangible assets are acquired in conjunction with the acquisition of a business and are assigned a fair value, using the multi-period
excess earnings method, related to incomplete research projects which, at the time of acquisition, have not reached technological feasibility.
The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion
or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then-useful
life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to
be generated, and begin amortization. The Company tests its intangible assets for impairment at least annually and whenever events or
circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator
of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company&#8217;s
expected future cash flows; a sustained, significant decline in the Company&#8217;s stock price and market capitalization; a significant
adverse change in legal factors or in the business climate of the Company&#8217;s segments; unanticipated competition; and slower growth
rates. If the fair value determined is less than the carrying amount, an impairment loss is recognized in operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z32t25Ny06rb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zdX7mG65WS1b">Goodwill</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company tests goodwill for potential impairment at least annually, or more frequently if an event or other circumstance indicates that
the Company may not be able to recover the carrying amount of the net assets of the reporting unit. The Company has determined that the
reporting unit is the entire company, due to the integration of all of the Company&#8217;s activities. In evaluating goodwill for impairment,
the Company may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that
the fair value of a reporting unit is less than its carrying amount. If the Company bypasses the qualitative assessment, or if the Company
concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company performs
a quantitative impairment test by comparing the fair value of a reporting unit with its carrying amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zNmGyuL93vpj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z622SrpvFB74">Property
&amp; Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Major property additions, replacements, and betterments are capitalized, while maintenance and repairs
that do not extend the useful lives of an asset or add new functionality are expensed as incurred. Depreciation and amortization are
recorded using the straight-line method over the respective estimated useful lives of the Company&#8217;s long-lived assets. The estimated
useful lives are typically <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDXlWGeWzm" title="Estimated useful lives">3</span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zuaBlK6Ilio2" title="Estimated useful lives">5</span> years for office furniture and equipment and are depreciated on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_ecustom--DeferredOfferingCostsPolicyTextBlock_zI13qPYdFR16" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zmmelDy6vXh3">Deferred
Offering Costs</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocates offering costs to the different components of the capital raise on a pro rata basis. Any offering costs allocated to
common stock are charged directly to additional paid-in capital. Any offering costs allocated to warrant liabilities are charged to general
and administrative expenses on the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirements of ASC Topic 340, <i>Other Assets and Deferred Costs</i> (&#8220;ASC 340&#8221;) and SAB 5A <i>-
Expenses of Offering</i>. Offering costs, which consist mainly of legal, accounting and consulting fees directly attributable to the
issuance of an equity contract to be classified in equity are recorded as a reduction in equity. For the year ended December 31, 2023,
the Company incurred $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zOw3Bao897qf" title="Deferred offering costs">567,603</span> in deferred offering costs in connection with the Equity Distribution Agreement (the &#8220;Distribution
Agreement&#8221;), with Canaccord Genuity LLC (&#8220;Canaccord&#8221;) and the Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). These deferred offering costs will be proportionately offset against
the total proceeds from the issuance of common stock available under the agreements and the Company will expense any remaining balance
of deferred offering costs if the agreements are terminated. For the year ended December 31, 2023, there were no issuances of common
stock under the agreements resulting in the deferral of offering costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84C_ecustom--WarrantLiabilityPolicyTextBlock_zanLVGGwng9c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zH6VWLIKl02j">Warrant
Liability and Investment Options</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its financial instruments, including issued stock purchase warrants and investment options, to determine if
such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 &#8220;Distinguishing
Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;) and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;).
The Company accounts for warrants and investment options for shares of the Company&#8217;s common stock that are not indexed to its own
stock as derivative liabilities at fair value on the consolidated balance sheets. The Company accounts for common stock warrants and
investment options with put options as liabilities under ASC 480. Such warrants and investment options are subject to remeasurement at
each consolidated balance sheet date and any change in fair value is recognized as a component of other expense on the consolidated statements
of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration
of such common stock warrants and investment options. At that time, the portion of the warrant liability and investment options related
to such common stock warrants will be reclassified to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_ecustom--ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_zOLylevrf7oj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zHBF6D1y83y9">Modification
and Inducement of Warrants and Investment Options</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in any of the terms or conditions of warrants is accounted for as a modification. For a warrant modification accounted for under
ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over the fair
value of the original warrant immediately before its terms are modified, measured based on the fair value of the shares and other pertinent
factors at the modification date. The accounting for incremental fair value of warrants is based on the specific facts and circumstances
related to the modification. When a modification is directly attributable to equity offerings, the incremental change in fair value of
the warrants are accounted for as equity issuance costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the inducement to exercise warrants in accordance with ASC Subtopic 470-20-40 &#8220;Debt with Conversion and Other
Options&#8221; (&#8220;ASC 470-20-40&#8221;). ASC 470-20-40 requires the recognition through earnings of an inducement charge equal to
the fair value of the consideration delivered in excess of the consideration issuable under the original conversion terms. Therefore,
the Company recognized a loss on the warrant inducement for the incremental change of the warrants related to the reduced exercise price
and the issuance of new warrants as these components induced the holders to exercise the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_ze8NOutWO18c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zBwpH1gx3ZNb">Derivative
Liability</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as assets or liabilities, the derivative
instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the
fair value reported in the consolidated statements of operations. The classification of derivative instruments, including whether such
instruments should be recorded as assets or liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion
of the instrument could be required within 12 months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zL6shVmPF5Cf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zsORoSsW5NTg">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#8217;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liabilities. In management&#8217;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The
amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that
do not meet these recognition and measurement standards. As of December 31, 2023 and 2022, no liability for unrecognized tax benefits
was required to be recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy for recording interest and penalties associated with tax audits is to record such items as a component of operating
expenses. There were no amounts accrued for penalties and interest for the years ended December 31, 2023 and 2022. The Company does not
expect its uncertain tax positions to change during the next twelve months. Management is currently unaware of any issues under review
that could result in significant payments, accruals or material deviations from its position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified its United States, Canadian and Australian federal tax returns, and its state and provincial tax returns in Florida,
Massachusetts, New Jersey, Pennsylvania, and Ontario, CA as its &#8220;major&#8221; tax jurisdictions. The Company is in the process
of filing its United States federal and state and Australian federal corporate tax returns for the year ended December 31, 2023. The
Company is in the process of filing its Canadian corporate tax returns for the years ended December 31, 2023 and 2022. Net operating
losses for these periods will not be available to reduce future taxable income until the returns are filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zEsxkwpAfIyl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zVtfgEZ2LSf1">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows ASC 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions, requiring
such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded at the more
readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The Company uses the Black-Scholes
option-pricing model to determine the grant date fair value of certain stock-based awards under ASC 718. The assumptions used in calculating
the fair value of stock-based awards represent management&#8217;s reasonable estimates and involve inherent uncertainties and the application
of management&#8217;s judgment. Fair value of restricted stock units or restricted stock awards is determined by the closing price per
share of the Company&#8217;s common stock on the date of award grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value is amortized as a charge to earnings on a straight-line basis, for awards or portions of awards that do not require
specified milestones or performance criteria as a vesting condition and also depending on the terms and conditions of the award, and
the nature of the relationship of the recipient of the award to the Company. The Company records the grant date fair value in line with
the period over which it was earned. For employees and consultants, this is typically considered to be the vesting period of the award.
The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of awards that require specified milestones or recipient performance are charged to expense when such milestones
or performance criteria are probable to be met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
stock units, restricted stock awards, and stock options are granted at the discretion of the Compensation Committee of the Company&#8217;s
board of directors (the &#8220;Board of Directors&#8221;). These awards are restricted as to the transfer of ownership and generally
vest over the requisite service periods, typically over a 12 to 48-month period. A significant portion of these awards may include vesting
terms that include, without limitation, defined volume weighted average price levels being achieved by the Company&#8217;s common stock,
specific performance milestones, employment, or engagement by the Company, with no assurances of achievement of any such vesting conditions,
if applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RSU&#8217;s is equal to the product of the number of units awarded, multiplied by the closing price per share of the Company&#8217;s
common stock on the date of the award. The terms and conditions of each RSU is defined in the RSU agreement and includes vesting terms
that consist of any or all of the following: immediate vesting, vesting over a defined period of time, vesting based on achievement of
a defined volume weighted average price levels at specified times, vesting based on achievement of specific performance milestones within
a specific time frame, change of control, termination of the employee without cause by the Company, resignation of the employee with
good cause. The value assigned to each RSU is charged to expense based on the vesting terms, as follows: value of RSU&#8217;s that vest
immediately are charged to expense on the date awarded, value of RSU&#8217;s that vest based upon time, or achievement of stock price
levels over a period of time are charged to expense on a straight line basis over the time frame specified in the RSU and the value of
RSU&#8217;s that vest based upon achievement of specific performance milestones are charged to expense during the period that such milestone
is achieved. Vested RSU&#8217;s may be converted to shares of common stock of an equivalent number upon either the termination of the
recipient&#8217;s employment with the Company, or in the event of a change in control. If the recipient is not an employee, such person&#8217;s
engagement with the Company must either be terminated prior to such conversion of RSU&#8217;s to shares of common stock, or in the event
of a change in control. Furthermore, as required by Section 409A of the Internal Revenue Code, if the recipient is a &#8220;specified
employee&#8221; (generally, certain officers and highly compensated employees of publicly traded companies), such recipient may only
convert vested RSU&#8217;s into shares of common stock no earlier than the first day of the seventh month following such recipients termination
of employment with the Company, or the event of change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RSA&#8217;s is equal to the product of the number of restricted shares awarded, multiplied by the closing price per share of
the Company&#8217;s common stock on the date of the award. The terms and conditions of each RSA is defined in the RSA agreement and includes
vesting terms that consist of any or all of the following: immediate vesting, vesting over a defined period of time, or vesting based
on achievement of a defined volume weighted average price levels at specified times. Upon vesting, the recipient may receive restricted
stock which includes a legend prohibiting sale of the shares during a restriction period that is defined in the RSA agreement. Termination
of employment by or engagement with the Company is not required for the recipient to receive restricted shares of common stock. The value
assigned to each RSA is charged to expense based on the vesting terms, as follows: value of RSA&#8217;s that vest immediately are charged
to expense on the date awarded, value of RSA&#8217;s that vest based upon time, or achievement of stock price levels over a period of
time are charged to expense on a straight-line basis over the time frame specified in the RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z2bNPdQ0lNxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zX4N0aihbZJi">Net
Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the years ended December 31, 2023 and 2022 excludes
potentially dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully
diluted. In accordance with ASC 260 &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;), penny warrants were included in the calculation
of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022 the Company issued <span id="xdx_908_eus-gaap--StockIssued1_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zrEmdvuW4kc3" title="Stock and warrants issued">767,500</span> pre-funded common stock warrants, which were exercised on various dates during
the year ended December 31, 2022. The pre-funded common stock warrants became exercisable on July 26, 2022 based on the terms and conditions
of the agreements. As the pre-funded common stock warrants are exercisable for $<span id="xdx_90D_eus-gaap--WarrantExercisePriceDecrease_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zklaTLhZDQRk" title="Warrant exercise price">0.0001</span>, these shares are considered outstanding common
shares and are included in the computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants
is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions
were met on July 26, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3HM0uaIm6yl" style="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,799,213</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">655,463</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,848</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,492</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock units - unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,491</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,053</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_z5qaULxH0YR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock awards - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0893">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">708</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_zqhcUe1s59cj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock in abeyance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">704,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zq1067Obsksb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment options to purchase shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,070,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zhYSctrl3dxd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase shares of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,764,881</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,901,045</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zJID65LmxDb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqetmarc655b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztG9Z6EAI5m2">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value
Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), approximates the carrying amounts in the balance sheets, excluding the derivative,
warrants, and preferred investment option liabilities, primarily due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zWzfZ1GdSou9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zKPLQOyArmx4">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and
liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by
other market participants. These valuations require significant judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, including cash and accounts payable, the carrying amounts approximate their fair values as of December
31, 2023 and 2022 because of their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ziSLQKNyYoCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zuz1Rz8vQhr9">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_zQ7ioewi5Gc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease assets are included within right-of-use operating lease asset and operating lease liabilities are included in current portion of
right-of-use operating lease obligation and non-current portion of right-of-use operating lease obligation on the consolidated balance
sheets as of December 31, 2023 and 2022. The Company has elected not to present short-term leases as these leases have a lease term of
12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise.
Lease payments for short-term leases are recognized on a straight-line basis over the term of the lease. All other lease assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the
Company&#8217;s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information
available at adoption date in determining the present value of lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain
a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset
and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company
has elected to account for non-lease components associated with its leases and lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes a right-of-use asset, which represents the Company&#8217;s right to use the underlying asset for the lease term, and
a lease liability, which represents the present value of the Company&#8217;s obligation to make payments arising over the lease term.
The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing
rate<b><i>.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of
ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset
that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset,
(iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v)
the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of
the lease term. All other leases are recorded as operating leases. Finance lease payments are bifurcated into (i) a portion that is recorded
as interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did not have any finance
leases as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_846_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zxsDQhAmPSMf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_za6xEu8hPKl1">Redeemable
Non-controlling Interest</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of Akos Series A Preferred Stock, the Akos Purchase Agreement (as defined below in Note 8) and certificate
of designation contain a put right guaranteed by the Company as defined in Note 8. Applicable accounting guidance requires an equity
instrument that is redeemable for cash or other assets to be classified outside of permanent equity if it is redeemable (a) at a fixed
or determinable price on a fixed or determinable date, (b) at the option of the holder, or (c) upon the occurrence of an event that is
not solely within the control of the issuer. As a result of this feature, the Company recorded the non-controlling interests as Redeemable
Non-Controlling Interests (&#8220;RNCI&#8221;) and classified them in mezzanine equity within its consolidated balance sheet initially
at its acquisition-date estimated redemption value or fair value. In addition, the Company has elected to recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument by accreting the embedded derivative at each reporting
period over 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right (as defined below) requiring Akos to force redemption of all of the Akos Series A Preferred Stock. See Note 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQ4s5yz0SOx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zww0mCbaLZc1">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines its reporting units in accordance with FASB ASC 280, &#8220;Segment Reporting&#8221; (&#8220;ASC 280&#8221;). The
Company evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated. The Company has multiple operations related
to psychedelics and cannabinoids. Both of these operations exist under one reporting unit: Enveric. The Company has one operating segment
and reporting unit. The Company is organized and operated as one business. Management reviews its business as a single operating segment,
using financial and other information rendered meaningful only by the fact that such information is presented and reviewed in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6VQKIWjEQ2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zwwObdI2aaB5">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>Debt&#8212;Debt with Conversion and Other Options</i> (Subtopic 470-20) and <i>Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</i> (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;) to simplify certain financial
instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features
from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2023, and should be applied on a full or modified retrospective basis. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06
effective January 1, 2023, and has determined that the adoption of this guidance had no impact on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently evaluating ASU 2023-07 to determine its impact on the Company&#8217;s
disclosures, however, as the Company currently has one reportable segment, the Company does not expect ASU 2023-07 to have a material
impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its consolidated financial statements
and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861104009008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--OtherCurrentAssetsTextBlock_zaAAsItDs3Mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3.<span> <span id="xdx_82D_z7UD1gS7KARl">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3Gs4LNqtEXh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, the prepaid expenses and other current assets of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zTydFvT6Kuv4" style="display: none">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_z62twSxO8pL7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_z3hHr38UO7Tf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zIwSnFeaEsv8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">46,320</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">268,686</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_znbflNJJ4xcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid value-added taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,782</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_z3HJkewuOo16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,406</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zRR1RvRhJGo5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,179</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_zv88yG4YKVt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">567,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0939">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zujCa29AAHXe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Franchise tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,258</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zaRKpTVrRgM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">R&amp;D tax incentive receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,349</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0945">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zieXSbV2rhJ5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,293,554</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">708,053</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zesRhFyyZGE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861106018672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text"><p id="xdx_804_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_z9SCaXsACTk5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span id="xdx_824_zU9uwK220FDb">INTANGIBLE ASSETS AND GOODWILL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performs an annual impairment test at the reporting unit level as of December 31 of each fiscal year. As of December 31, 2022,
the Company&#8217;s goodwill and intangible assets were fully impaired, and thus no annual impairment test was necessary as of December
31, 2023. The following table provides the Company&#8217;s goodwill, indefinite and definite lives intangible assets as of December 31,
2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zNA8zJSGKUU" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s goodwill consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_zywzBm3sR0Xd" style="display: none">SCHEDULE
OF GOODWILL</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Impairment Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Currency Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--GoodwillGross_iS_c20220101__20221231_zrL5hyJCBTck" style="width: 11%; text-align: right" title="Goodwill Gross, Beginning balance">9,834,855</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNS_di_c20220101__20221231_zoA3HbV75zY9" style="width: 11%; text-align: right" title="Accumulated Impairment Losses, Beginning balance">(8,225,862</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--GoodwillCurrencyTranslation_iS_c20220101__20221231_zsv05uR0T8P7" style="width: 11%; text-align: right" title="Currency Translation, Beginning balance">(21,359</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Goodwill_iS_c20220101__20221231_zcXRwm58qzs1" style="width: 11%; text-align: right" title="Goodwill, Beginning balance">1,587,634</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--GoodwillImpairmentLossGross_iN_di_c20220101__20221231_zkf3VkHhApy6" style="text-align: right" title="Goodwill Gross, Impairment losses"><span style="-sec-ix-hidden: xdx2ixbrl0962">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--GoodwillAccumulatedImpairmentLoss_iN_di_c20220101__20221231_zUssTZVnGsp9" style="text-align: right" title="Accumulated Impairment Losses, Impairment losses">(1,486,060</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--GoodwillCurrencyTranslationImpairmentLoss_iN_di_c20220101__20221231_zl7mHTPCTDti" style="text-align: right" title="Currency Translation, Impairment losses"><span style="-sec-ix-hidden: xdx2ixbrl0966">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zsSlcGVeDune" style="text-align: right" title="Goodwill, Impairment losses">(1,486,060</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--GoodwillForeignCurrencyTranslationGainLossGross_c20220101__20221231_zyhq88vbkWy9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill Gross, Loss on currency translation"><span style="-sec-ix-hidden: xdx2ixbrl0970">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_c20220101__20221231_zyyjjekFt9Bh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Impairment Losses, Loss on currency translation"><span style="-sec-ix-hidden: xdx2ixbrl0972">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--GoodwillCurrencyTranslationLoss_c20220101__20221231_zapkiDJnziL9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Currency Translation, Loss on currency translation">(101,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20220101__20221231_zMG8RIR4uUE4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill, Loss on currency translation">(101,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GoodwillGross_iE_c20220101__20221231_zs3uh3Cgc7W3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill Gross, Ending balance">9,834,855</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNE_di_c20220101__20221231_zIXJIohBvg8a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Impairment Losses, Ending balance">(9,711,922</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--GoodwillCurrencyTranslation_iE_c20220101__20221231_zW9O3fTzJnD2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Currency Translation, Ending balance">(122,933</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zvobPkbyOarl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zxEPfyg8txe4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zUeFBNUXA8mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s indefinite lived intangible assets consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B7_zWEh1BmzLMM6" style="display: none">SCHEDULE
OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Indefinite lived intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iS_d0_c20220101__20221231_zYcj6o314Pg" style="width: 16%; text-align: right" title="Balance, Indefinite lived intangible assets">6,375,492</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetImpairmentCharges_iN_di_c20220101__20221231_z8wLJAfYqT8g" style="text-align: right" title="Impairment losses">(5,967,602</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Loss on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20220101__20221231_z1veDDOEjT78" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loss on currency translation">(407,890</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iE_c20220101__20221231_z7LKtTyUhh1h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Balance, Indefinite lived intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl0994">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023 and 2022, the definite lived intangible assets consisted of: &#160; &#160; &#160; &#160;</p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; width: 80%">Definite lived intangible assets</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 16%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold">Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20220101__20221231_ziSpokWclQNl" style="text-align: right" title="Balance, Definite lived intangible assets">548,436</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20220101__20221231_zSxeeR1NJHi1" style="border-bottom: Black 1.5pt solid; text-align: right">(168,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold">Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20230101__20231231_zoS9i0Nplzqe" style="text-align: right">379,686</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20231231_zNNExnK3q2ec" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">(168,754</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20230101__20231231_zIT0j5Uxijbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, Definite lived intangible assets">210,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zXWcVfQneWi8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
identified definite lived intangible assets, amortization expense amounted to $<span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zk2p8bhGkqR9" title="Intangible assets, amortization expense">168,754</span> and $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zyBCbH7OAWC" title="Intangible assets, amortization expense">168,750</span> during the years ended December 31,
2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zqb59wU0hIE9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company amortizes definite lived intangible assets on a&#8239;straight-line basis over their estimated useful lives. Amortization expense
of identified intangible assets based on the carrying amount as of December 31, 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B8_zzVXkKpEcQPl" style="display: none">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231_zkDZQgKYy2ck">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzC0U_zTyAhx8Iihm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">168,750</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzC0U_zWOFDxfsxxFe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,182</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzC0U_zC9XwcaOuro6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Finite lived assets amortization
    expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">210,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zPK37hZCJdad" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861105914784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXXYZu4HU6c9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_825_zaytaYVEUUm6">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVVGahhpzvNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following assets which are located in Calgary, Canada and placed in service by Enveric Biosciences Canada,
Inc. (&#8220;EBCI&#8221;), with all amounts translated into U.S. dollars:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BF_zxF5quYUvBz1" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zzCZHNQZFxvd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zvLPGndd0db5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zp4aNQNMWWri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Lab equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">836,709</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">831,123</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_z9JhYXtwNtFl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment and leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,379</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,137</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zPgLn2Oc6tvg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(357,711</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(178,775</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zXt2mt3bMunh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net of accumulated depreciation</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">507,377</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">677,485</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z2MshGQnoZt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_90D_eus-gaap--Depreciation_c20230101__20231231_zaY42joe7YG7" title="Depreciation">175,228</span> and $<span id="xdx_905_eus-gaap--Depreciation_c20220101__20221231_z0vGnuRplH4c" title="Depreciation">159,160</span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861107226544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED LIABILITIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zBePLueQV7ve" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_828_zbdmk1JonaWe">ACCRUED LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zEC0nxuwQfD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and December 31, 2022, the accrued liabilities of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B6_z2CYiR69qip9" style="display: none">SCHEDULE
OF ACCRUED LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zIdUdedJs0bc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_ztfCG22lB8m6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_zzTIaLc6TzX6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Product development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">139,981</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">195,104</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zxArVFIfjro7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued salaries, wages, and bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,889</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,175,963</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zmvujpsSA58g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">584,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,255</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zGJabHMfEVH5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued restructuring costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,645</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_z6PA2plzHgPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued franchise taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zTXa5jxvaF64" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Patent costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zHLlMDwwvI65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,075,643</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,705,655</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zfLwpnfUgaDl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861102822288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</a></td>
<td class="text"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zDwGAQBPdjdj" style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_821_zPkNv6EA0ckj">SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Authorized
Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--CommonStockVotingRights_c20230101__20231231_zyP7HBT2y9O4" title="Common stock voting rights">The
holders of the Company&#8217;s common stock are entitled to one vote per share</span>. Holders of common stock are entitled to receive ratably
such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Upon the liquidation, dissolution,
or winding up of the Company, holders of common stock are entitled to share ratably in all assets of the Company that are legally available
for distribution. As of December 31, 2023, <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_z3kEFDBFbKC" title="Common stock, shares authorized">100,000,000</span> shares of common stock and <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zBU2P1eYPMuf" title="Preferred stock, shares authorized">20,000,000</span> shares of Preferred Stock were authorized
under the Company&#8217;s articles of incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Distribution Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2023, the Company entered into the Distribution Agreement, with Canaccord, pursuant to which the Company may offer and sell
from time to time, through Canaccord as sales agent and/or principal, shares of common stock of the Company, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zzPld5phABZh" title="Common stock, par value">0.01</span> per share
having an aggregate offering price of up to $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zV61LRnnxsQj" title="Common stock, offering price">10.0</span> million. Due to the offering limitations applicable to the Company and in accordance
with the terms of the Distribution Agreement, the Company may offer common stock having an aggregate gross sales price of up to $<span id="xdx_900_ecustom--SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zFsQ1hTkiWgf" title="Aggregate gross sales price">2,392,514</span>
pursuant to the prospectus supplement dated September 1, 2023 (the &#8220;Prospectus Supplement&#8221;). Subject to the terms and conditions
of the Distribution Agreement, Canaccord may sell the common stock by any method permitted by law deemed to be an &#8220;at-the-market
offering&#8221;. The Company will pay Canaccord a commission equal to <span id="xdx_909_ecustom--CommissionPercentage_pid_dp_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zXJHXmkSZzdf" title="Commission percentage">3.0</span>% of the gross sales price of the common stock sold through
Canaccord under the Distribution Agreement and has also agreed to reimburse Canaccord for certain expenses. The Company may also sell
common stock to Canaccord as principal for Canaccord&#8217;s own account at a price agreed upon at the time of sale. Any sale of common stock to Canaccord as principal would be pursuant to the terms of a separate terms agreement between the Company and Canaccord.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inducement Letters (as defined below within this Note 7) prohibits the Company from entering into any variable rate transaction as defined
in the Inducement Letters, including the issuance of (1) any variable priced debt or equity securities or (2) transactions whereby the
Company may issue securities at a future determined price, such as through an at-the-market offering or an equity line of credit. The
variable rate transaction restriction expires after six-month from the closing date of December 28, 2023 for the Inducement Letters for
an issuance through an at-the-market offering, and one-year for the remaining variable rate transactions. Subsequent to December 31, 2023, the limitation on the at-the-market offering was waived. See Note 12.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lincoln
Park Equity Line</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, the Company entered into a Purchase Agreement and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;),
with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $<span id="xdx_904_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zOOeNanEtQna" title="Purchase committment">10.0</span> million of the Company&#8217;s common stock,
par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zHrjprwA7De7" title="Common stock, par value">0.01</span> per share subject to certain limitations and satisfaction of the conditions set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln
Park, and Lincoln Park is obligated to purchase up to $<span id="xdx_90A_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zs6V54OtPzKd" title="Purchase committment">10.0</span> million of the Company&#8217;s common stock (the &#8220;Purchase Shares&#8221;).
However, such sales of common stock by the Company, if any, will be subject to important limitations set forth in the Purchase Agreement,
including limitations on number of shares that may be sold. Sales may occur from time to time, at the Company&#8217;s sole discretion,
over the 24-month period commencing on the date that the conditions to Lincoln Park&#8217;s purchase obligation set forth in the Purchase
Agreement are satisfied, including that a registration statement on Form S-1 covering the resale of the shares of our common stock that
have been and may be issued to Lincoln Park under the Purchase Agreement, which the Company has filed with the SEC pursuant to the Registration
Rights Agreement, is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the purchase price per share to be paid by Lincoln Park for the shares of common stock that we may elect to sell to Lincoln Park under
the Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock at the time we elect to sell shares to
Lincoln Park pursuant to the Purchase Agreement, if any, it is not possible for us to predict the number of shares of Common Stock that
we will sell to Lincoln Park under the Purchase Agreement, the purchase price per share that Lincoln Park will pay for shares purchased
from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by Lincoln Park under
the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company has issued no shares of common stock through the Equity Line or the Distribution Agreement.
The Company had capitalized deferred offering costs of $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zKz2gddhOKWe" title="Deferred offering costs">567,603</span> related to establishing the Distribution Agreement with Canaccord and
the Purchase Agreement with Lincoln Park and no reductions to additional paid in capital. Of this amount, $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zPkUqxA8u6Vg">255,107</span> represents the fair
value of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDJ8hpMn6Hwc">139,403</span> shares of common stock issued to Lincoln Park as consideration for its commitment under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Activity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023 a total of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znp99CIqxNdk" title="Issuance of common shares in exchange for RSU conversions, shares">103,641</span> shares of common stock were issued pursuant to the conversion of restricted stock
units. During the year ended December 31, 2022, a total of <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVVRjjZ5Exei" title="Stock issued during period conversion of restricted stock award">1,223</span> and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9r9oyNeumEg">899</span> shares of common stock were issued pursuant to the conversion
of restricted stock awards and restricted stock units, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, the Company completed a public offering of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220213__20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zntTgZMDrl9k" title="Public offering">400,000</span> shares of common stock and warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTUe4kaUETye" title="Warrants to purchase">400,000</span> shares
of common stock for gross proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220213__20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6jFxLXor71f" title="Proceeds from common stock">10.0</span> million, before deducting underwriting discounts and commissions and other
offering expenses. A.G.P./Alliance Global Partners acted as sole book-running manager for the offering. In addition, Enveric granted
the underwriter a 45-day option to purchase up to an additional <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zq0ZVhdNZHnc" title="Additional shares of common stock purchase">60,000</span> shares of common stock and/or warrants to purchase up to an additional
<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zxA8e1kW3047" title="Additional warrants purchase">60,000</span> shares of common stock at the public offering price, which the underwriter has partially exercised for warrants to purchase up
to <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zX7UOxhPkFLc" title="Exercised of warrants">60,000</span> shares of common stock. At closing, Enveric received net proceeds from the offering of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zcX0o9TCANtj" title="Net proceeds from offering">9.1</span> million, after deducting
underwriting discounts and commissions and estimated offering expenses with $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zwY93X07Ejgd" title="Offering expenses">5.8</span> million allocated to equity, $<span id="xdx_905_ecustom--WarrantLiability_iI_pn5n6_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zlHQkuaWT4Ck" title="Warrant liability">3.6</span> million to warrant
liability and the remaining $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zNb2KWCaTJi7" title="Warrant expenses">0.3</span> million recorded as an expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, the Company entered into a securities purchase agreement (the &#8220;Registered Direct Securities Purchase Agreement&#8221;)
with an institutional investor for the purchase and sale of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zq67jFtpMDv2" title="Sale of stock">116,500</span> shares of the Company&#8217;s common stock, pre-funded warrants to
purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zjWAalEsmIM2" title="Purchase of common stock">258,500</span> shares of common stock (the &#8220;RD Pre-Funded Warrants&#8221;), and unregistered preferred investment options
(the &#8220;RD Preferred Investment Options&#8221;) to purchase up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_z19ToUBw98Gi" title="Issued shares">375,000</span> shares of common stock (the &#8220;RD Offering&#8221;).
The gross proceeds from the RD Offering were approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zmk1U6vmH2Ck" title="Proceeds from issuance of warrants">3,000,000</span>. Subject to certain ownership limitations, the RD Pre-Funded Warrants
became immediately exercisable at an exercise price equal to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zsYLFes8tIh5" title="Share price">0.0001</span> per share of common stock. On August 3, 2022, all of the issued
RD Pre-Funded Warrants were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with the RD Offering, the Company entered into a securities purchase agreement (the &#8220;PIPE Securities Purchase Agreement&#8221;)
with institutional investors for the purchase and sale of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zo2AVAUxuI0k" title="Sale of stock">116,000</span> shares of common stock, pre-funded warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zjS5ykHZolGe" title="Purchase of common stock">509,000</span>
shares of common stock (the &#8220;PIPE Pre-Funded Warrants&#8221;), and preferred investment options (the &#8220;PIPE Preferred Investment
Options&#8221;) to purchase up to <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zdO9qNgWdtvg" title="Issued shares">625,000</span> shares of the common stock in a private placement (the &#8220;PIPE Offering&#8221;). The gross
proceeds from the PIPE Offering were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zcihzISSJtPf" title="Proceeds from issuance of warrants">5,000,000</span>. Subject to certain ownership limitations, the PIPE Pre-Funded Warrants
became immediately exercisable at an exercise price equal to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zaSq53mrSBkh" title="Share price">0.0001</span> per share of common stock. All of the issued PIPE Pre-Funded Warrants
were exercised on various dates prior to August 18, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RD Offering and PIPE Offering closed on July 26, 2022, with aggregate gross proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromOtherEquity_pn6n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zFQmF58p6Dzl" title="Proceeds from RD offerings">8</span> million. The aggregate net proceeds
from the offerings, after deducting the placement agent fees and other estimated offering expenses, were approximately $<span id="xdx_90D_ecustom--PaymentsOfStockIssuanceCost_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zUK66EqEgCdh" title="Offerings costs">7.1</span> million,
with $<span id="xdx_90F_ecustom--PaymentsOfAllocatedEquity_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_z7bhCebODrmj" title="Payments of allocated equity">3.2</span> million allocated to equity, $<span id="xdx_90E_ecustom--PaymentsOfInvestmentOptionLiability_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zSkUFLNUdin9" title="Payments of investment option liability">4.3</span> million to investment option liability, and the remaining $<span id="xdx_901_ecustom--PaymentsOfStockIssuanceCostsRecordedExpense_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zmXneHwiVHlh" title="Payments of stock issuance costs recorded expense">0.4</span> million recorded as an expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment
to 2020 Long-Term Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2022, our board of directors (&#8220;Board&#8221;) adopted the First Amendment (the &#8220;Plan Amendment&#8221;) to the Enveric
Biosciences, Inc. 2020 Long-Term Incentive Plan (the &#8220;Incentive Plan&#8221;) to <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220502__20220503_zZJBKbAFKI05" title="Incentive plan description">(i) increase the aggregate number of shares available
for the grant of awards by 146,083 shares to a total of 200,000 shares, and (ii) add an &#8220;evergreen&#8221; provision whereby the
number of shares authorized for issuance pursuant to awards under the Incentive Plan will be automatically increased on the first trading
date immediately following the date the Company issues any share of common stock (defined below) to any person or entity, to the extent
necessary so that the number of shares of the Company&#8217;s common stock authorized for issuance under the Incentive Plan will equal
the greater of (x) 200,000 shares, and (y) 15% of the total number of shares of the Company&#8217;s common stock outstanding as of such
issuance date (the &#8220;Evergreen Provision&#8221;). The Plan Amendment was approved by the Company&#8217;s shareholders at a special
meeting of the Company&#8217;s shareholders held on July 14, 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 2, 2023, the shareholders approved the amendments to the 2020 Long-Term Incentive Plan, which was approved by the Board on August
8, 2023 (the &#8220;Amended Incentive Plan&#8221;). The Amended Incentive Plan (i) increased the number of authorized shares reserved
for issuance under the Amended Incentive Plan to a maximum of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231102__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zlmk1poNjGA3" title="Authorized shares reserved">350,000</span>, subject to adjustment, and (ii) removed the Evergreen Provision
implemented in the Plan Amendment. As of December 31, 2023, the total number of shares available for grant under the Incentive Plan was
<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zwU3zwqNsFga" title="Shares available ofr grant">107,453</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8YtSqYx16Ag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity under the Company&#8217;s incentive plan for the years ended December 31, 2023 and 2022 is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zu3hZq6igFI4" style="display: none">SCHEDULE OF STOCK OPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Outstanding at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zlfachWgXyo4" style="width: 9%; text-align: right" title="Number of Shares, Outstanding at beginning">23,829</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zBHipcjjafJb" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning">79.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_z3KUiEblBS32" style="width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning">103.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zc6QHY3pugra" title="Weighted Average Remaining Contractual Term (years)">5.3</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zWsvXq7xXltk" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Outstanding">34,333</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zUwzel36BOnk" style="text-align: right" title="Number of Shares, Granted">25,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z5kJ7HfnP6pf" style="text-align: right" title="Weighted Average Exercise Price, Granted">3.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znh44xkmKi5a" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin-top: 0; margin-bottom: 0"><span></span></p>
                                                                          <p style="margin-top: 0; margin-bottom: 0"><span>&#160;</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zMwQE9ty7cd5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, forfeited">(1,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zODjjvTnFKVd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, forfeited">175.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znQpNtug7kVc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited">140.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span>&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_z8a4TyNt1Z85" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Outstanding at beginning">48,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zg98NijbXZh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning">37.05</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zIZUyOqQArtj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning">44.82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5ShG7pIcpf5" title="Weighted Average Remaining Contractual Term (years)">4.1</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zfbN7fLAAKpi" style="text-align: right" title="Number of Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1180">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zvXECFVHHTLj" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1182">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231_z4H5Vu8Biz83" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, forfeited">(18,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zV15MinWPaA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, forfeited">3.07</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zMCYL5FZJYyj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited">2.58</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_z0vJtB0G1Poe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Outstanding at end">30,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zTWGbA0Nvv66" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at end">57.17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zUfoA887Azb9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at end">77.22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_za3lss46TUsl" title="Weighted average remaining contractual term, outstanding balance">3.4</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231_zN4jPjsgp21g" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable shares at end">25,677</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_ziRZaH57gja8" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable weighted average price at end">64.45</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zx8Su3tDvHy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, exercisable">88.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z4vf0GnUomE9" title="Weighted average remaining contractual term, exercisable">2.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zXYm0PO3CNlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEutDXJS5oV9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted during the years ended December 31, 2022 were valued using the Black Scholes model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zR9P2uQxAng7" style="display: none">SCHEDULE OF STOCK OPTION ASSUMPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zj6iPtU5AHta" title="Term (years)">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20221231_zlKRFdSy2ve2" title="Stock price">3.07</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231_zX3WUGe0AYX2" title="Exercise price">3.07</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z5lvwkDplOW2" title="Dividend yield">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_zXidb2KriXN1" title="Expected volatility">112.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_za8yif42LrIb" title="Risk free interest rate">3.9</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A1_zSkXtPvxBb04" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above assumptions are determined by the Company as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    price &#8211; Based on closing price of the Company&#8217;s common stock on the date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average risk-free interest rate &#8212; Based on the daily yield curve rates for U.S. Treasury obligations with maturities, which
    correspond to the expected term of the Company&#8217;s stock options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield &#8212; The Company has not paid any dividends on common stock since its inception and does not anticipate paying dividends
    on its common stock in the foreseeable future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility &#8212; Based on the historical volatility of comparable companies in a similar industry.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term &#8212; The Company has had no stock options exercised since inception. The expected option term represents the period that
    stock-based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin (&#8220;SAB&#8221;)
    No. 107, Share-Based Payment, which averages an award&#8217;s weighted-average vesting period and expected term for &#8220;plain
    vanilla&#8221; share options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock based compensation expense, recorded within general and administrative expense, related to stock options for the
years ended December 31, 2023 and 2022 was $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zt08RojEH0Xh" title="General and administrative expense">156,075</span> and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXVmi6fVuBdb" title="General and administrative expense">180,042</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za7OVdVnQO29" title="Unamortized stock option expense">84,774</span> in unamortized stock option expense, which will be recognized over a weighted average period
of <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zN1HXhFc7nl6">1.00</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recorded $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoynQV9JMUSl" title="Stock-based compensation expense">0</span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWmTrUjkTZp7" title="Stock-based compensation expense">24,363</span>, respectively, in stock-based compensation expense within
general and administrative expense, related to restricted stock awards. There were no RSA grants during the years ended December 31,
2023 and 2022. As of December 31, 2022, there were no unvested RSA shares. As of December 31, 2023, there were no unamortized stock-based
compensation costs related to restricted share awards. During the year ended December 31, 2023 the Company settled the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1bnkYOkliK7" title="Common stock , shares issued restricted stock awards">708</span> vested and
unissued shares (as of December 31, 2022) for cash of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLFTi9qtv6r6" title="Unissued shares for cash">14,250</span>. There are <span id="xdx_900_ecustom--NumberOfVestedAndUnissuedShares_iI_do_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2mtX7G3wVJd" title="Number of vested and unissued shares">no</span> restricted stock awards as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuance
of Restricted Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zeKrkjRh7dje" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activity in restricted stock units was as follows for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zOnUfbNkVcx6" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average<br/>
 fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Non-vested at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEDhw9y1hxZb" style="width: 16%; text-align: right" title="Number of shares, Non-vested beginning">62,013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaILPTwaljuj" style="width: 16%; text-align: right" title="Weighted average fair value, Non-vested beginning">126.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zirQtPdDJsZi" style="text-align: right" title="Number of shares, Granted">37,445</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUYL7MfjSel" style="text-align: right" title="Weighted average fair value, Granted">33.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxzxsA9U3MM5" style="text-align: right" title="Number of shares, Forfeited">(26,772</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoUqJoFo0SPa" style="text-align: right" title="Weighted average fair value, Forfeited">79.64</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCGHiACcoei3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Vested">(8,633</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmbvrrJRPdT2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average fair value, Vested">130.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Non-vested at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3a70kwxF3V2" style="text-align: right" title="Number of shares, Non-vested beginning">64,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLrYNbURiDu7" style="text-align: right" title="Weighted average fair value, Non-vested beginning">92.57</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znLFWlg2TGh1" style="text-align: right" title="Number of shares, Granted">182,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfBGTV22anXd" style="text-align: right" title="Weighted average fair value, Granted">2.73</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2mJgukWkvO9" style="text-align: right" title="Number of shares, Forfeited">(43,426</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxHfzIDptRA4" style="text-align: right" title="Weighted average fair value, Forfeited">25.72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNyxeKRhEEJ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested">(62,636</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrqPsZk6qtR7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average fair value, Vested">19.80</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIJwWAqEmkx2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, non-vested ending">140,491</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJYYLsJCm9Q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average fair value, Non-vested ending">28.97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zBLyP5ujOgX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recorded $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaktYeVWKPm1" title="Stock based compensation, expenses">1,994,085</span> and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJPvzY0F5oTg" title="Stock based compensation, expenses">2,416,266</span>, respectively, in stock-based compensation
expense related to restricted stock units, which is a component of both general and administrative and research and development expenses
in the consolidated statement of operations and comprehensive loss. As of December 31, 2023, the Company had unamortized stock-based
compensation costs related to restricted stock units of $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRBdOX0w06He" title="Stock-based compensation, unamortized">2,021,021</span> which will be recognized over a weighted average period of <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyktIo5qhnf1" title="Weighted average period">1.9</span> years
and unamortized stock-based costs related to restricted stock units which will be recognized upon achievement of specified milestones.
As of December 31, 2023, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxLDWxSkxrQi" title="Common stock vested restricted stock units">20,848</span> restricted stock units are vested without shares of common stock being issued, with all of these shares
due as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z3ex9jdX7Hgd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s recognition of stock-based compensation for restricted stock units for the following periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zwVhDWsRp68h" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zPQew5K1VjCh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zCbffNV9umPf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense for RSUs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zSOwB6VgYaZd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,085,791</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,389,359</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfdu3M9qPMBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">908,294</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,026,907</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zcduJChWGdHc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,994,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,416,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_zgOmbiRFAoQe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock-based compensation expense for RSUs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,994,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,416,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A3_zs23cTYn7Nd8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants
and Preferred Investment Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zCwAZnLGDADf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about shares issuable under warrants outstanding at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_z8ZFdYdYVEvf" style="display: none">SCHEDULE
OF WARRANTS OUTSTANDING</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrant shares outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTfdpCfJmiBi" style="width: 11%; text-align: right" title="Warrant shares outstanding at beginning">195,463</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3fi1daRxsLi" style="width: 11%; text-align: right" title="Weighted average exercise Price, Outstanding at beginning">131.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z54Yv7nvu7W9" title="Weighted average remaining life, Outstanding">3.4</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVKnQZX3WT3" style="width: 11%; text-align: right" title="Intrinsic Value, Outstanding beginning">801,024</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoHdcQoSVWS2" style="text-align: right" title="Warrant shares outstanding, Issued">1,227,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq4CkgY3nmbb" style="text-align: right" title="Weighted average exercise price, Issued">10.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoCiirvRQcd1" style="text-align: right" title="Warrant shares outstanding, Exercised">(767,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchanged for common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPYXssDy289d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchanged for common stock"><span style="-sec-ix-hidden: xdx2ixbrl1315">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziP88dUalGL3" style="text-align: right" title="Warrant shares outstanding at beginning">655,463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgN4PA0LOL52" style="text-align: right" title="Weighted average exercise Price, Outstanding at beginning">58.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNat7GYdCief" title="Weighted average remaining life, Outstanding">3.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zif7UujrkK8h" style="text-align: right" title="Intrinsic Value, Outstanding beginning">5,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF9wfK13hB3a" style="text-align: right" title="Warrant shares outstanding, Issued">2,311,320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzzaBhPs6fcj" style="text-align: right" title="Weighted average exercise price, Issued">1.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFg4HAtR0Uo3" style="text-align: right" title="Warrant shares outstanding, Exercised">(122,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjBdEmkvsgQ3" style="text-align: right" title="Weighted average exercise price, Exercised">1.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWsO7MCiRq3g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant shares outstanding, Forfeited">(45,570</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0n5xO3Jttvj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Forfeited">111.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG0zfcvh1EB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant shares outstanding at end">2,799,213</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVykSWQShf2c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise Price, Outstanding at end">11.79</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo234JlDnvN9" title="Weighted average remaining life, Outstanding">4.6</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TQKNs9s47l" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant shares outstanding, Exercisable">2,799,213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxF5xDyqxuv9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">11.79</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziBL756oG0Sj" title="Weighted average remaining life, Exercisable">4.6</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znZZJLvwpd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding end"><span style="-sec-ix-hidden: xdx2ixbrl1349">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A4_zPsrElVeMZDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 11, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;)
with A.G.P./Alliance Global Partners (the &#8220;Underwriter&#8221;). Pursuant to the Underwriting Agreement, the Company agreed to sell,
in a firm commitment offering, <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220210__20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBeMIQlREhB9" title="Sale of stock">400,000</span> shares of the Company&#8217;s common stock and accompanying warrants to purchase up to an aggregate
of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwRjsuVzK6ll" title="Warrant exercises, shares">400,000</span> shares of its common stock (&#8220;February 2022 Warrants&#8221;), as well as up to <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220210__20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4yI7NRdWlc6" title="Additional shares of common stock">60,000</span> additional shares of common stock
and/or warrants to purchase an aggregate of up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zCnVO8Hipssf" title="Warrant exercises, shares">60,000</span> shares of its common stock that may be purchased by the Underwriter pursuant
to a 45-day option granted to the Underwriter by the Company (the &#8220;Offering&#8221;). Each share of common stock was sold together
with a common warrant to purchase one share of common stock, at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt7SQbdnlyZ9" title="Warrant, exercise price">27.50</span> per share. Such common warrants were immediately
exercisable and will expire five years from the date of issuance. There is not expected to be any trading market for the common warrants
issued in the Offering. The combined public offering price of each share of common stock and accompanying common warrant sold in the Offering
was $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUsxAEI45Quk" title="Sale of stock, price per share">25.00</span>. On February 14, 2022, the Underwriter exercised its option to purchase an additional <span id="xdx_905_ecustom--ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_iI_c20220214__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5i9uo6XMQy" title="Purchase of additional warrants">60,000</span> warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Registered Direct (&#8220;RD&#8221;) Offering and the Private Investment in Public Entity (&#8220;PIPE&#8221;) Offering
entered into on July 22, 2022, the Company entered into Warrant Amendment (the &#8220;Warrant Amendments&#8221;) with the investors in
both offerings to amend certain existing warrants to purchase up to an aggregate of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220722__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zBOpNG8waIyk" title="Purchase of common stock">122,000</span> shares of common stock that were previously
issued to the investors, with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220714__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zphVdaVhW65b" title="Exercise price">27.50</span> per share (subsequent to the 1-for-50 reverse stock split that occurred on
July 14, 2022) and expiration date of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220714__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zgyCnvlpoemb" title="Warrant expiration">February 15, 2027</span>. Pursuant to the Warrant Amendments, the previously issued warrants were amended,
effective upon the closing of the offerings, so that the amended warrants have a reduced exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220722__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_znAWYBaoUBq9" title="Exercise price">7.78</span> per share and expire
five and one-half years following the closing of the offerings. In connection with this transaction, the Company determined the fair
value of the February 2022 Warrants immediately prior to the Warrant Amendment and the fair value of the amended warrants immediately
after the Warrant Amendment. For the year ended December 31, 2022, the incremental change in fair value was deemed to be $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zSNM3dV6YnM1" title="Offerings costs">251,357</span>, which was included as equity issuance costs
related to the RD and PIPE financing transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants assumed pursuant to the acquisition of MagicMed contain certain down round features, which were not triggered by the February
2022 and July 2022 public offerings, that would require adjustment to the exercise price upon certain events when the offering price
is less than the stated exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z00XmdXvzoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about investment options outstanding at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B7_zXmcUZK6ggX1" style="display: none">SCHEDULE
OF WARRANTS  AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Investment options outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zEwvcLEoJfDe" style="text-align: right" title="Investment options Outstanding, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1377">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zxaDKk1asuL5" style="text-align: right" title="Weighted average exercise price, Outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1379">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zlJw8znfo0I4" style="text-align: right" title="Intrinsic value, Outstanding beginning">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1381">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; padding-bottom: 1.5pt">Issued</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zDF48VFSv1A7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Investment options outstanding, Issued">1,070,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVx10hGW7qx2" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Weighted average exercise price, Issued">7.93</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zqwHo3jONiyh" style="text-align: right" title="Investment options outstanding, beginning">1,070,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVu0eC11XHn7" style="text-align: right" title="Weighted average exercise price, Outstanding beginning">7.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7cYhlQli82i" title="Weighted average remaining life, Outstanding">5.1</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zW78kJ5dKbha" style="text-align: right" title="Intrinsic value, Outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1393">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLWd0NriqTJ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Investment options outstanding, Exercised">(1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zJbc1b45aUy4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Exercised">1.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z1lexvtMAU48" style="border-bottom: Black 1.5pt solid; text-align: right" title="Investment options outstanding, end">70,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z64Vkjb4vBD2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Outstanding end">10.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zo3u42JYc9hg" title="Weighted average remaining life, Outstanding">4.1</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLfLYOEFU04b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic value, Outstanding end"><span style="-sec-ix-hidden: xdx2ixbrl1405">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zSZT9LEs53K1" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment options outstanding, Exercisable">70,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zaDEqPn9Z6kf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding end">10.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zyrHBnlcTyT6" title="Weighted average remaining life, Exercisable">4.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zhirJurCktSd" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1413">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zN7RQXnULVth" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Registered Direct Securities Purchase Agreement the Company issued unregistered preferred investment options to purchase
up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zZV69Zq59PW2" title="Issued shares">375,000</span> shares of common stock. Subject to certain ownership limitations, the RD Preferred Investment Options became immediately
exercisable at an exercise price equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zntitPn12CAh" title="Exercise price">7.78</span> per share of common stock. The RD Preferred Investment Options are exercisable for five
and one-half years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the PIPE Securities Purchase Agreement the Company issued unregistered preferred investment options to purchase up to
<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zLjlPihd61Y1" title="Issued shares">625,000</span> shares of the common stock. Subject to certain ownership limitations, PIPE Preferred Investment Options became immediately exercisable
at an exercise price equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zOI44kWNylt2" title="Exercise price">7.78</span> per share of common stock. The PIPE Preferred Investment Options are exercisable for five and one-half
years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2022, in connection with the RD Offering and PIPE Offering, the Company issued preferred investment options (the &#8220;Placement
Agent Preferred Investment Options&#8221;) to an entity to purchase up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220725__20220726__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_z4HuoSUpk0bk" title="Purchase of common stock">70,000</span> shares of the common stock for acting as a placement
agent. The Placement Agent Preferred Investment Options have substantially the same terms as the RD Preferred Investment Options and
the PIPE Preferred Investments Options, except the Placement Agent Preferred Investment Options have an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220726__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_zZKCojjEaSb2" title="Exercise price">10.00</span> per
share. The Placement Agent Preferred Investment Options are exercisable for five years from the date of the commencement of the RD Offering
and PIPE Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#8220;Inducement Letters&#8221;) with
certain holders (the &#8220;Holders&#8221;) of the February 2022 Post-Modification Warrants and RD and PIPE preferred investment
options to purchase shares of the Company&#8217;s common stock (the &#8220;Existing Warrants and Investment Options&#8221;) pursuant
to which the Holders agreed to exercise for cash their Existing Warrants and Investment Options to purchase <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_z8kGZoMo5WF2" title="Issued shares">1,122,000</span>
shares of the Company&#8217;s common stock, in the aggregate, at a reduced exercised price of $<span id="xdx_90B_eus-gaap--WarrantExercisePriceDecrease_pid_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MinimumMember_zmre4xpOatuj" title="Share price">1.37</span>
per share (from an original exercise price of $<span id="xdx_903_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MaximumMember_zHGTrhQQ6C24" title="Share price">7.78</span>
per share), in exchange for the Company&#8217;s agreement to issue new warrants (the &#8220;Inducement Warrants&#8221;) to purchase
up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zZZklwjzMRFc" title="Issued shares">2,244,000</span>
shares of the Company&#8217;s common stock (the &#8220;Inducement Warrant Shares&#8221;), and the Holders to make a cash payment of
$<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zLm5mALpc9N2" title="Cash payment">0.125</span>
per Inducement Warrant share for total proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zD00dqXJGv56" title="Proceeds from inducement warrant">280,500</span>. In January 2024, the Company received aggregate gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGk6Yg4XAvBi" title="Gross proceeds">1,817,640</span>
from the exercise of the Existing Warrants and Investment Options by the Holders and the sale of the Inducement Warrants. Because
the Existing Warrants and Investment Options by the Holders and the sale of the Inducement Warrants that exercised on December 28,
2023 and unsettled until January 2024, the proceeds are included in the consolidated balance sheet as a subscription receivable as
of December 31, 2023. As of December 31, 2023, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOGsXVkNBqP9">418,000</span>
shares of the Existing Warrants and Investment Options exercised were considered issued as the Company had the enforceable right to
the obtain the cash proceeds, which were in-transit, and the Holders were no longer able to rescind the exercise election. Due to
the beneficial ownership limitation provisions, <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zhAJrEorEKnf" title="Issued shares">704,000</span>
shares of the Existing Warrants and Investment Options exercised were initially unissued and held in abeyance for the benefit of the
Holder until notice is received from the Holder that the shares may be issued in compliance with such limitation. <span id="xdx_903_ecustom--ClassOfWarrantOrRightReasonForIssuing_c20230101__20231231_zwnPNtnbyEcl" title="Warrant issued description">The
Company engaged Roth Capital Partners, LLC (&#8220;Roth&#8221;) to act as its financial advisor in connection with the transactions
summarized above and will pay Roth approximately $144,000 for its services, in addition to reimbursement for certain expenses. Roth
was also issued warrants to purchase up to 67,320 shares of common stock. The Roth Warrants have the same terms as the Inducement
Warrants. The grant date fair value of these Roth Warrants was estimated to be $77,991 on December 28, 2023 and were charged to
additional paid in capital as issuance costs. The Company also incurred legal fees of $17,254 related to the transactions above that
were charged to additional paid in capital as issuance costs.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also agreed to file a registration statement on Form S-3 covering the resale of the Inducement Warrant Shares issued or issuable
upon the exercise of the Inducement Warrants (the &#8220;Resale Registration Statement&#8221;) by January 8, 2024 (filed January 11,
2024). In the Inducement Letters, the Company agreed not to issue any shares of common stock or common stock equivalents or to file any
other registration statement with the SEC (in each case, subject to certain exceptions) for a period ending on February 26, 2024. The
Company also agreed not to effect or agree to effect any variable rate transaction (as defined in the Inducement Letters) until December
28, 2024. See the <i>Equity Distribution Agreement</i> section of this Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company determined the fair value of the Existing Warrants and Investment Options immediately
prior to the Inducement Letters and the fair value of the amended warrants and investment options immediately after the Inducement
Letters. The pre-modification measurement of fair value of the Existing Warrants and Investment Options were determined utilizing a
Black-Scholes model considering all relevant assumptions current at the date of modification (i.e. for the Existing Warrants share
price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_z4IjDXLBbkR3" title="Warrants share price">1.56</span>,
exercise price of $<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zXyDya2udmf7" title="Exercise price">7.78</span>,
term of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_z18G9NhjUGR9" title="Term (years)">3.6</span>
years, volatility of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zAwHYm59mTXh" title="Warrants outstanding, measurement input">94</span>%,
risk-free rate of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zm3bbvuCJqC7" title="Warrants outstanding, measurement input">3.96</span>%,
and expected dividend rate of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zl0yVDmgmajc" title="Warrants outstanding, measurement input">0</span>%,
resulting in a fair value per share of $<span id="xdx_904_eus-gaap--SharePrice_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zhUcl0TXRUT1" title="Warrants outstanding, per share">.54</span> and for the Investment Options share price of $<span id="xdx_90D_ecustom--InvestmentOptionSharePrice_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zGpacZ3BNDs9" title="Share price">1.56</span>,
exercise price of $<span id="xdx_907_ecustom--InvestmentOptionExercisePrice_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zKnYAoUxhJdj" title="Exercise price">7.78</span>,
term of <span id="xdx_903_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zhEXHdObGO13" title="Term (years)">4.1</span> years,
volatility of <span id="xdx_907_ecustom--InvestmentOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zYBQ1dLbufLc" title="Investment outstanding, measurement input">95</span>%,
risk-free rate of <span id="xdx_90F_ecustom--InvestmentOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zntwM6yIYi33" title="Investment outstanding, measurement input">3.90</span>%,
and expected dividend rate of <span id="xdx_90A_ecustom--InvestmentOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zmwuConmHkW8" title="Investment outstanding, measurement input">0</span>%,
resulting in a fair value per share of $<span id="xdx_90A_ecustom--SharePriceOption_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zrnS9PJeicn5" title="Investment outstanding, per share">.62</span>). The total fair value of the <span id="xdx_907_eus-gaap--SharesOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_z0BA93tLj2hc" title="Shares outstanding">122,000</span> Existing Warrants and <span id="xdx_909_eus-gaap--SharesOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_ztD05TA6sohg" title="Shares outstanding">1,000,000</span> Investment Options
was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zVhEgu2qiBfh" title="Intrinsic value">65,349</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_z5MR6FWFETJg" title="Intrinsic value">618,648</span>, respectively. The post-modification fair value was determined using the intrinsic value of $<span id="xdx_909_ecustom--InvestmentIntrinsicValue_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember_zMYFJxOt02R5" title="Intrinsic value">0.19</span>
due to the inducement and totaled $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zo6q6Crb4fEc" title="Intrinsic value">23,180</span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_zUN1EbSFyMVk" title="Intrinsic value">190,000</span> for the Existing Warrants and Investment Options, respectively. The change in fair value from the date of the modification prior to modification and the fair value on the
date of the modification after the modification, but prior to exercise was $<span id="xdx_903_ecustom--InvestmentInducementGain_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember_zYGxYB7iir1f" title="Inducement gain">470,817</span>,
which was reflected as an inducement gain, within other expenses on the Company&#8217;s consolidated statement of operations and
comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant date fair value of these Inducement Warrants was estimated to be $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20231228__20231228_z2x1EoMCFBJl">2,599,552</span> on December 28, 2023 and the proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231228__20231228_zJIFuTKtruIl">280,500</span>,
which were received on January 2, 2024, for the issuance of the Inducement Warrants is reflected as inducement expense, within other
expenses on the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfValuationOfWarrantsTextBlock_zjlfMoR7FOl7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its equity classified Inducement Warrants at the date of issuance on December 28, 2023.
The Company used a Black Scholes valuation model in order to determine their value. The key inputs into the Black Scholes valuation model
for the valuation of the warrants are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zy2L3wh6IEsj" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Roth and Inducement Warrants</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 28, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z52K9qwfKrY6" title="Term (years)">5.0</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zvpHkwU31FQ6" title="Stock price">1.56</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zm3vVfJEgZJb" title="Exercise price">1.37</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zdaTE0h352rg" title="Dividend yield">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zZ8qJnxEV6V3" title="Expected volatility">92.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z72dh5NNsTw" title="Risk free interest rate">3.80</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zMzy9I7TxUTl" style="text-align: right" title="Warrants, number of warrants">2,311,320</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zBRgEViXl0za" style="text-align: right" title="Value (per share)">1.16</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zXHJwPy7aNrd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
C Preferred Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2022, the Board of Directors (the &#8220;Board&#8221;) declared a dividend of one one-thousandth of a share of the Company&#8217;s
Series C Preferred Stock (&#8220;Series C Preferred Stock&#8221;) for each outstanding share of the Company&#8217;s common stock held of record as of 5:00 p.m. Eastern Time on May 13, 2022 (the &#8220;Record Date&#8221;). This dividend
was based on the number of outstanding shares of common stock prior to the Reverse Stock Split. The outstanding shares of Series C Preferred
Stock were entitled to vote together with the outstanding shares of the Company&#8217;s common stock, as a single class, exclusively
with respect to a proposal giving the Board the authority, as it determines appropriate, to implement a reverse stock split within twelve
months following the approval of such proposal by the Company&#8217;s stockholders (the &#8220;Reverse Stock Split Proposal&#8221;),
as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split Proposal (the
&#8220;Adjournment Proposal&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company held a special meeting of stockholders on July 14, 2022 (the &#8220;Special Meeting&#8221;) for the purpose of voting on, among
other proposals, a Reverse Stock Split Proposal and an Adjournment Proposal. All shares of Series C Preferred Stock that were not present
in person or by proxy at the Special Meeting were automatically redeemed by the Company immediately prior to the opening of the polls
at Special Meeting (the &#8220;Initial Redemption&#8221;). All shares that were not redeemed pursuant to the Initial Redemption were
redeemed automatically upon the approval by the Company&#8217;s stockholders of the Reverse Stock Split Proposal at the Special Meeting
(the &#8220;Subsequent Redemption&#8221; and, together with the Initial Redemption, the &#8220;Redemption&#8221;). <span id="xdx_904_eus-gaap--PreferredStockVotingRights_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z5dqYDZjASmi" title="Preferred stock voting rights">Each share of Series
C Preferred Stock was entitled to receive $0.10 in cash for each 10 whole shares of Series C Preferred Stock immediately prior to the
Redemption. As of June 30, 2022, there were</span> <span id="xdx_904_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zdUuJvhOW6s9" title="Redeemable preferred stock, shares outstanding">52,684.548</span> shares of Series C Preferred Stock issued and outstanding. As of December 31,
2022, both the Initial Redemption and the Subsequent Redemption had occurred. As a result, no shares of Series C Preferred Stock remain
outstanding. As of December 31, 2023 and 2022, there are <span id="xdx_90E_eus-gaap--PreferredStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zjdiSzO1vp5b" title="Preferred Stock authorized for future issuances">100,000</span> shares of Series C Preferred Stock authorized for future issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861105888912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEEMABLE NON-CONTROLLING INTEREST<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DisclosureRedeemableNoncontrollingInterestAbstract', window );"><strong>Redeemable Non-controlling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNonControllingInterestTextBlock', window );">REDEEMABLE NON-CONTROLLING INTEREST</a></td>
<td class="text"><p id="xdx_80C_ecustom--RedeemableNonControllingInterestTextBlock_zi5Q4GzDPrpf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. <span id="xdx_820_zpC01KA801s3">REDEEMABLE NON-CONTROLLING INTEREST</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Spin-Off
and Related Private Placement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Spin-Off, on May 5, 2022, Akos and the Company entered into into a Securities Purchase Agreement (the &#8220;Akos
Purchase Agreement&#8221;) with an accredited investor (the &#8220;Akos Investor&#8221;), pursuant to which Akos agreed to sell up to
an aggregate of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zb3OhmPCrJOj" title="Sale of stock">5,000</span> shares of Akos Series A Preferred Stock, at price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zkAv4iFGwlvc" title="Sale of stock price per share">1,000</span> per share, and warrants (the &#8220;Akos Warrants&#8221;)
to purchase shares of Akos&#8217; common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_ziqdyNm1proh" title="Common stock par value">0.01</span> per share (the &#8220;Akos Common Stock&#8221;), for an aggregate purchase
price of up to $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zewKu8BntBy9" title="Sale of stock, value">5,000,000</span> (the &#8220;Akos Private Placement&#8221;). The Akos Purchase Agreement was guaranteed by the Company. Pursuant
to the Akos Purchase Agreement, Akos issued <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zG8bfr259E7" title="Sale of stock">1,000</span> shares of the Akos Series A Preferred Stock to the Akos Investor in exchange for $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7nhFd17DNtk" title="Sale of stock, value">1,000,000</span>
on May 5, 2022. The additional $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zxgML5QugCI7" title="Sale of stock, value">4,000,000</span> was to be received on or immediately prior to the Spin-Off. The issuance of the Akos Series
A Preferred Stock results in RNCI (see Note 2). Palladium Capital Advisors, LLC (&#8220;Palladium&#8221;) acted as placement agent for
the Akos Private Placement. <span id="xdx_90F_ecustom--SpinoffAndRelatedPrivatePlacementDescription_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zdbaTOlv0Foh" title="Spin-off and related private placement, description">Pursuant to the Akos Purchase Agreement, Akos had agreed to pay Palladium a fee equal to 9% of the aggregate
gross proceeds raised from the sale of the shares of the Akos Series A Preferred Stock and a non-accountable expense allowance of 1%
of the aggregate gross proceeds raised the sale of the Akos Series A Preferred Stock in the Akos Private Placement. The fee due in connection
with the Akos Private Placement to be paid to Palladium in the form of convertible preferred stock and warrants was on similar terms
to the securities issued in the Akos Private Placement.</span> Palladium was also entitled to warrants to purchase Akos Common Stock in an amount
up to <span id="xdx_908_ecustom--WarrantsToPurchaseCommonStockPercentage_pid_dp_uPure_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_z1kHLnr5gR2h" title="Warrants to purchase common stock, percentage">8</span>% of the number of shares of Akos Common Stock underlying the shares issuable upon conversion of the Akos Series A Preferred Stock.
As of December 31, 2023, no accruals are required to be recorded for the fees or warrants since the Akos Series A Preferred Stock has
been redeemed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Terms
of Akos Series A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Certificate of the Designations, Preferences, and Rights of Series A Convertible Preferred Stock of Akos (the &#8220;Akos Series
A Preferred Certificate of Designations&#8221;), on or immediately prior to the completion of the spin-off of Akos into an independent,
separately traded public company listed on the Nasdaq Stock Market, the outstanding Akos Series A Preferred Stock automatically converted
into a number of shares of Akos Common Stock equal to <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AkosMember_zptxw7wnlvwj" title="Percentage of stock issued and outstanding">25</span>% of the then issued and outstanding Akos Common Stock, subject to the Beneficial
Ownership Limitation (as defined in the Akos Purchase Agreement). Cumulative dividends on each share of Akos Series A Preferred Stock
accrue at the rate of <span id="xdx_900_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AkosMember_zqfJDBLNLuU3" title="Dividend rate">5</span>% annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Akos Series A Preferred Certificate of Designations provided that upon the earlier of (i) the one-year anniversary of May 5, 2022, and
only in the event that the Spin-Off has not occurred; or (ii) such time that Akos and the Company have abandoned the Spin-Off or the
Company is no longer pursuing the Spin-Off in good faith, the holders of the Akos Series A Preferred Stock shall have the right (the
&#8220;Put Right&#8221;), but not the obligation, to cause Akos to purchase all or a portion of the Akos Series A Preferred Stock for
a purchase price equal to $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znidGcp5SmHb" title="Sale of stock, price per share">1,000</span> per share, subject to certain adjustments as set forth in the Akos Series A Preferred Certificate of
Designations (the &#8220;Stated Value&#8221;), plus all the accrued but unpaid dividends per share. In addition, after the one-year anniversary
of May 5, 2022, and only in the event that the Spin-Off has not occurred and Akos is not in material default of any of the transaction
documents, Akos may, at its option, at any time and from time to time, redeem the outstanding shares of Akos Series A Preferred Stock,
in whole or in part, for a purchase price equal to the aggregate Stated Value of the shares of Akos Series A Preferred Stock being redeemed
and the accrued and unpaid dividends on such shares. Pursuant to the Akos Purchase Agreement, the Company has guaranteed the payment
of the purchase price for the shares purchased under the Put Right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Akos Series A Preferred Certificate of Designations contains limitations that prevent the holder thereof from acquiring shares of Akos
Common Stock upon conversion of the Akos Series A Preferred Stock that would result in the number of shares of Akos Common Stock beneficially
owned by such holder and its affiliates exceeding 9.99% of the total number of shares of Akos Common Stock outstanding immediately after
giving effect to the conversion (the &#8220;Beneficial Ownership Limitation&#8221;), except that upon notice from the holder to Akos,
the holder may increase or decrease the limit of the amount of ownership of outstanding shares of Akos Common Stock after converting
the holder&#8217;s shares of Akos Series A Preferred Stock, provided that any change in the Beneficial Ownership Limitation shall not
be effective until 61 days following notice to Akos.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Redemption
of Akos Series A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right requiring Akos to force redemption of all of the Akos Series A Preferred Stock for $<span id="xdx_900_eus-gaap--DividendsPayableAmountPerShare_iI_pid_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztQh1TbMgLA2" title="Dividends, per share">1,000</span>&#8239;per share, plus accrued
but unpaid dividends of approximately $<span id="xdx_905_ecustom--UnpaidDividends_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbljvP6uynA2" title="Unpaid dividends">52,000</span>&#8239;for a total of approximately $<span id="xdx_901_eus-gaap--DividendsPreferredStock_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdtM4nK5oH7j" title="Dividends">1,052,000</span>. The Company had 20 days following the receipt
of the Put Exercise Notice to make the payment and made payment on May 19, 2023. Upon redemption in May 2023, the Company revalued the
derivative liability and the Company recognized a change in fair value of the derivative liability on the Company&#8217;s consolidated
statement of operations during the second quarter of 2023 of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20230630_zmKTPInuh3Li" title="Change in fair value of derivative liability">714,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, Akos, and the Akos Investor have terminated the Akos Purchase Agreement in connection with the planned Spin-Off and certain
registration rights agreement in connection with the Akos Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
for Akos Series A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the shares of Akos Series A Preferred Stock were redeemable at the option of the holder and the redemption is not solely in the control
of the Company, the shares of Akos Series A Preferred Stock were accounted for as a redeemable non-controlling interest and classified
within mezzanine equity in the Company&#8217;s consolidated balance sheets. The redeemable non-controlling interest was initially measured
at fair value. Dividends on the shares of Akos Series A Preferred Stock were recognized as preferred dividends attributable to redeemable
non-controlling interest in the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--TemporaryEquityTableTextBlock_zpIqAAdWohPh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the reconciliation of changes in redeemable non-controlling interest:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zjoodKpMYtk6" style="display: none">SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_c20230101__20231231_z2KtOijK4HZ5" style="width: 16%; text-align: right" title="Beginning balance">885,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred dividends attributable to redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zjwjD9FtrCoi" style="text-align: right" title="Issuance of redeemable noncontrolling Series C preferred stock">19,041</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accretion of embedded derivative and transaction costs associated with Akos Series A Preferred Stock to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zVgFPFbJN1yh" style="text-align: right" title="Accretion of embedded derivative to redemption value">147,988</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Redemption of Akos Series A Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_iN_di_c20230101__20231231_z61deouwmhW3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Redemption of Akos Series A Preferred Stock">(1,052,057</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_c20230101__20231231_z2cCqG7L0c62" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1560">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_z5hvmzlTgjq6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Akos Series A Preferred Stock was redeemed for a total of <span id="xdx_90B_ecustom--RedeemableNoncontrollingInterest_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfzod7fCUkea" title="Redeemable noncontrolling interest">1,052,057</span>, and the balance of the redeemable non-controlling
interest is $<span id="xdx_902_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iI_dxL_c20231231_zAeOWuDFnGDk" title="Redeemable non-controlling interest::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1564">0</span></span> as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DisclosureRedeemableNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DisclosureRedeemableNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNonControllingInterestTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable non controlling interest [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNonControllingInterestTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861103758944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE</a></td>
<td class="text"><p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zzc4DQdOVCk6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_82E_zsrUTbzuipf3">FAIR VALUE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z7nYIEKnfDSb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides the financial liabilities measured on a recurring basis and reported at fair value on the balance sheet as of
December 31, 2023 and 2022, and indicates the fair value of the valuation inputs the Company utilized to determine such fair value of
warrant liabilities, derivative liability, and investment options:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_zv5Cq3TrTwbh" style="display: none">SCHEDULE
OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zwa6pMcie7mj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_ztyBGagJWl2d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zluQ4KiXC6C8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Warrant liabilities - January 2021 Warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">81</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zbxFjRea6mu7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrant liabilities - February 2021 Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdwlc80Umupj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrant liabilities - February 2022 Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">185,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zsQK5dRZG5R2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of warrant liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">185,215</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zBIbM8e99NVb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_z7y8UeEVWOR7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zqJ0MJeu0Ymi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; padding-bottom: 1.5pt">Derivative liability - May 2022</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 10%; text-align: center">3</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1582">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">727,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zR1tqPhaDMu9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of derivative liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1585">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">727,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231_z7T84h3p4yAc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zY86vTWnoNeh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_znMNJ66bvtl9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Wainwright investment options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">23,608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">44,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zeZJIMkg8nk6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">RD investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1591">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">302,289</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zOFVpVS8Jrzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">PIPE investment options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1594">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">503,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdfcDlytmmXj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of investment option liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,608</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">851,008</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zlaHAKR4Y6A2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liabilities, derivative liability, and investment options are all classified as Level 3, for which there is no current market
for these securities such as the determination of fair value requires significant judgment or estimation. Changes in fair value measurement
categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded
within other income (expense) on the consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Initial
measurement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--InitialMeasurementMember_z1QM2DVjkmSk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the warrant liabilities are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BA_zyGP5uMpiwf9" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 2022 Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 2022 Post-Modification Warrants (See Note 7)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February 15, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zkRE5qfbxQV" title="Warrants term">5.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_ztVxTxKwnXvb" title="Warrants term">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zg4vc6tNjoU6" style="text-align: right" title="Warrants, stock price">15.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zUD00iEXtF7c" style="text-align: right" title="Warrants, stock price">6.33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMKqRGglU068" style="text-align: right" title="Warrants, exercise price">27.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKSgY0wy0iyh" style="text-align: right" title="Warrants, exercise price">7.78</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVyprhikOUP2" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1614">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zFsXu3HGkuPe" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1616">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zcJF7D6miHg7" title="Warrants, measurement input">74.1</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zXulwjEnomb2" title="Warrants, measurement input">80.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zDHnLKF0SByk" title="Warrants, measurement input">1.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_znzQkLQw96rk" title="Warrants, measurement input">2.9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z4cDZMXOyqyk" style="text-align: right" title="Warrants, number of warrants">460,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zw9U56dyLJU3" style="text-align: right" title="Warrants, number of warrants">122,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zSrYFRvG1GD9" style="text-align: right" title="Value (per share)">8.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zc94NSTnQNmh" style="text-align: right" title="Value (per share)">4.07</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its derivative liability at the respective date of issuance. The Company used a Weighted
Expected Return valuation model in order to determine their value. The key inputs into the Weighted Expected Return valuation model for
the initial valuations of the warrant liabilities are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">May 2022 Derivative Liability</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">May 5, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%">Principal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ConvertiblePreferredStockPrincipalValue_iI_pid_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zA97NpTGuk22" style="width: 23%; text-align: right" title="Principal">1,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMajfNXiCdV7" style="text-align: right" title="Dividend rate">5.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Market rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketRateMember_zwinaaQECZ11" style="text-align: right" title="Market rate">4.4</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its investment options at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the investment options are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Wainwright Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">RD Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">PIPE Options</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zRRpPgv5agTj" title="Investment option term">5.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zdhDz6mJGNJ" title="Investment option term">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zfSptC7W7KEg" title="Investment option term">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zPlSJf5eL0A6" style="text-align: right" title="Investment, stock price">6.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zqYpSozvjjQ8" style="text-align: right" title="Investment, stock price">6.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zDLPZtQBQ3f2" style="text-align: right" title="Investment, stock price">6.33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYWvEhjRG27a" style="text-align: right" title="Investment, exercise price">10.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zidSfPnMN3kc" style="text-align: right" title="Investment, exercise price">7.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z4ui6DjkSRej" style="text-align: right" title="Investment, exercise price">7.78</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zQ8wA9rqzTjb" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1658">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zO3qrym8KSpa" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1660">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvzToWtaoU02" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1662">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_ziabNgPIphZ3" title="Investment, measurement input">80.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zofjONCNkiQb" title="Investment, measurement input">80.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvIEEezFwTO9" title="Investment, measurement input">80.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z0rmtJQWmDCi" title="Investment, measurement input">2.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zKeYY8MkDdMi" title="Investment, measurement input">2.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z9Fo5tlv9cUh" title="Investment, measurement input">2.9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Number of investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYbQQoJTqgg2" style="text-align: right" title="Number of investment options">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zwzPQkiN0jy2" style="text-align: right" title="Number of investment options">375,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFk1flldufk" style="text-align: right" title="Number of investment options">625,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zwdNPoSCez9h" style="text-align: right" title="Value (per share)">3.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zCIxDRegUmw8" style="text-align: right" title="Value (per share)">4.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFdwm4V6zmKk" style="text-align: right" title="Value (per share)">4.07</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zqJvQKCnT5l7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subsequent
measurement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zyPosEMl6298" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of the warrant liabilities, derivative liability, and investment options that are
classified as Level 3:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zf0YvucZm167" style="display: none">SCHEDULE
OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Warrant Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%">Fair value as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfWR0eRZvVP5" style="width: 23%; text-align: right" title="Total beginning balance">653,674</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of February 2022 warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXGaIgmvYyJi" style="text-align: right" title="Issuance of equity">3,595,420</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value due to modification of February 2022 warrants as part of July 2022 raise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFIntmBPaxCj" style="text-align: right" title="Change in fair value, modification">251,357</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE0CYMPIHUj4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(4,315,236</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfghil2mtthe" style="text-align: right" title="Total beginning balance">185,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkAmp56BB0z3" style="text-align: right" title="Change in fair value">(94,396</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercise of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDN8OycYqdhb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise of warrants">(65,349</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zme9nFXE8ezh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total beginning balance">25,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Derivative Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Fair value as of December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFGDcN74hZH" style="padding-bottom: 1.5pt; text-align: right" title="Total beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1706">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 73%; text-align: left; padding-bottom: 1.5pt">Issuance of May 2022 convertible preferred stock</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPpeS4e84xo4" style="padding-bottom: 1.5pt; width: 23%; text-align: right" title="Issuance of equity">402,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSM8F2xaqSZb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">325,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaWdjbixGpx4" style="text-align: right" title="Total beginning balance">727,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value arising from redemption of Akos Series A Preferred Stock - See Note 8</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEhyNzluaeM9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(727,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of derivative liability as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqz7o8NCcsD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1716">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Investment Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkafZlF2mmd8" style="text-align: right" title="Total beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1718">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 73%">Issuance of July 2022 investment options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJCC3dQ45BP1" style="width: 23%; text-align: right" title="Issuance of equity">4,323,734</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAP0ZMaOKtx2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(3,472,726</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsspxHsvJgQ5" style="text-align: right" title="Total beginning balance">851,008</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2wRFtIor8lj" style="text-align: right" title="Change in fair value">(208,752</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise of investment options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmmwHeZhV8Fi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise of investment options">(618,648</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair value of investment option liability as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwfYpkEyGifd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance">23,608</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zTDiFxmrLd74" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zVmNi2ZEtwR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the warrant liabilities as of December 31, 2023 are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B0_zGwJ3NUryGMb" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 2021 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February 2021 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February 2022 Warrants Unmodified</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_z6UybGHOxEm9" title="Warrants term">2.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z8aHZ5nk0zCe" title="Warrants term">2.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zUoJTl1pinb3" title="Warrants term">3.1</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z5f7OPJrG5A" style="text-align: right" title="Warrant measurement input">1.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z43IGWEMy7mi" style="text-align: right" title="Warrant measurement input">1.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPFDp0gpvu1f" style="text-align: right" title="Warrant measurement input">1.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zzQ4UuJKdZN" style="text-align: right" title="Warrant measurement input">247.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zh3valY73Qz2" style="text-align: right" title="Warrant measurement input">245.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zI70P4KFepEe" style="text-align: right" title="Warrant measurement input">27.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zXom3SuDcJeh" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1752">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmrl5hHMBCm2" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1754">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zrAdZu39f75a" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1756">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zGbl4bmvxqsh" style="text-align: right" title="Warrants, measurement input">89.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUtVZGZgnQkc" style="text-align: right" title="Warrants, measurement input">88.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUdeTyuL8oac" style="text-align: right" title="Warrants, measurement input">87.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVAXZdk6d31h" style="text-align: right" title="Warrants, measurement input">4.20</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zXrUSp9jZPD9" style="text-align: right" title="Warrants, measurement input">4.20</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMV40M3mGbVf" style="text-align: right" title="Warrants, measurement input">4.00</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zn6PP51bQ6m" style="text-align: right" title="Warrants, number of warrants">36,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z5JR5WBgvpN8" style="text-align: right" title="Warrants, number of warrants">34,281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z7TkfR5O3yy9" style="text-align: right" title="Warrants, number of warrants">338,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zOg7y7IDF7R5" style="text-align: right" title="Value (per share)">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_zAR75z9wv3J9" style="text-align: right" title="Value (per share)">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zeqE92vGMb9d" style="text-align: right" title="Value (per share)">0.08</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the investment options as of December 31, 2023 are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">H.C. Wainwright &amp; Co., LLC Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zoMuNWVyzAm" title="Investment option term">3.6</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zUboA7OQUpLa" style="text-align: right" title="Investment, stock price">1.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--StockOptionExercisePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zgo6KhIG3Ijf" style="text-align: right" title="Investment, exercise price">10.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zN9N15RArLo6" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1788">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zA3LphOX94wg" title="Investment, measurement input">94.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zOhw3RzTphsk" title="Investment, measurement input">4.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Number of investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2nEB216o2a" style="text-align: right" title="Number of investment options">70,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zucFVItplnkl" style="text-align: right" title="Value (per share)">0.34</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zrbMv2JczZWj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the date of the redemption of the of Akos Series A Preferred Stock in May 2023, the derivative liability fair value was $<span id="xdx_905_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBe0f08cNDD6" title="Derivative liability fair value">0</span> due to the
probability of a spin-off occurring was zero. See Note 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861105297664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJzHQhc2S99e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_824_zLAtIowfPq7c">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is periodically involved in legal proceedings, legal actions and claims arising in the normal course of business. Management
believes that the outcome of such legal proceedings, legal actions and claims will not have a significant adverse effect on the Company&#8217;s
financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Australian
Subsidiary Research and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2023, the Company issued a press release announcing the selection of Australian CRO, Avance Clinical, in preparation for Phase
1 Study of EB-373, the Company&#8217;s lead candidate targeting the treatment of anxiety disorders. Under the agreement, Avance Clinical
will manage the Phase 1 clinical trial of EB-373 in coordination with the Company&#8217;s newly established Australian subsidiary, Enveric
Therapeutics Pty, Ltd. The Phase 1 clinical trial is designed as a multi-cohort, dose-ascending study to measure the safety and tolerability
of EB-373. EB-373, a next-generation proprietary psilocin prodrug, has been recognized as a New Chemical Entity (NCE) by Australia&#8217;s
Therapeutic Goods Administration (TGA) and is currently in preclinical development targeting the treatment of anxiety disorder. The total
cost of the Avance Clinical contract is approximately <span id="xdx_902_eus-gaap--CapitalizedContractCostNet_iI_uAUD_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zP5GfH9I9BH2" title="Contract cost">3,000,000</span> AUD, which translates to approximately $<span id="xdx_905_eus-gaap--CapitalizedContractCostNet_iI_uUSD_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zh1rCXdtro0i" title="Contract cost">2,000,000</span> USD as of December
31, 2023. As of December 31, 2023, the Company has paid approximately $<span id="xdx_904_eus-gaap--ConstructionContractCostProgressPaymentOffset_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zBWqr4Io24Ge" title="Payment of contract cost">1,036,940</span> of the Avance Clinical contract costs and has accrued
$<span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_z3EcyGn4t8s5" title="Accrued liabilities">523,284</span> recorded as accrued liabilities and $<span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zYKiKTtPTDXc" title="Accounts payable">239,320</span> as accounts payable on the accompanying consolidated balance sheet. For the year
ended December 31, 2023, the Company has expensed $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_ztSbfQPHmw17" title="Research and development expenses">1,751,444</span> in research and development expenses within the accompanying consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Development
and Clinical Supply Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 22, 2021, the Company entered into a Development and Clinical Supply Agreement (the &#8220;PureForm Agreement&#8221;) with PureForm
Global, Inc. (&#8220;PureForm&#8221;), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&#8220;API&#8221;)
for the Company&#8217;s development plans for cancer treatment and supportive care. Under the terms of the PureForm Agreement, PureForm
has granted the Company the exclusive right to purchase API and related product for cancer treatment and supportive care during the term
of the Agreement (contingent upon an initial minimum order of 1 kilogram during the first thirty (30) days from the effective date) and
has agreed to manufacture, package and test the API and related product in accordance with specifications established by the parties.
All inventions that are developed jointly by the parties in the course of performing activities under the PureForm Agreement will be
owned jointly by the parties in accordance with applicable law; however, if the Company funds additional research and development efforts
by PureForm, the parties may enter into a further agreement whereby PureForm would assign any resulting inventions or technical information
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial term of the PureForm Agreement is three (3) years commencing on the effective date of the PureForm Agreement, subject to extension
by mutual agreement of the parties. The Company has met the minimum purchase requirement of 1 kilogram during the first thirty days of
the PureForm Agreement&#8217;s effectiveness. The Company did not pursue an extension of the PureForm Agreement beyond the initial term
and the agreement terminated in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purchase
agreement with Prof. Zvi Vogel and Dr. Ilana Nathan </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 26, 2017, Jay Pharma entered into a purchase agreement with Prof. Zvi Vogel and Dr. Ilana Nathan (the &#8220;Vogel-Nathan Purchase
Agreement&#8221;), pursuant to which Jay Pharma was assigned ownership rights to certain patents, which were filed and unissued as of
the date of the Vogel-Nathan Purchase Agreement. The Vogel-Nathan Purchase Agreement includes a commitment to pay a one-time milestone
totaling $<span id="xdx_909_eus-gaap--LongTermPurchaseCommitmentAmount_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember__srt--StatementScenarioAxis__custom--OneTimeMilestoneMember_zowhwjN3UqGl" title="Long-term purchase commitment, amount">200,000</span> upon the issuance of a utility patent in the United States or by the European Patent Office, as defined in the agreement.
The Company has accrued such amount as of December 31, 2021, as a result of the milestone criteria being achieved. Payment was made during
January 2022. In addition, a milestone payment totaling $<span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember__srt--StatementScenarioAxis__custom--AdditionalMilestoneMember_zj2RHyb06Cu7" title="Long-term purchase commitment, amount">300,000</span> is due upon initiation of a Phase II(b) study. Research activities related
to the relevant patents are still in pre-clinical stage, and accordingly, this milestone has not been achieved. The Vogel-Nathan Purchase
Agreement contains a commitment for payment of royalties equaling <span id="xdx_90E_ecustom--RoyaltiesPercentage_pid_dp_uPure_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember_zeaJzpkABMv3" title="Royalties percentage">2</span>% of the first $<span id="xdx_90D_eus-gaap--PaymentsForRoyalties_pn6n6_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember_zoZY67IeTyk6" title="Payments for royalties">20</span> million in net sales derived from the commercialization
of products utilizing the relevant patent. As these products are still in the preclinical phase of development, no royalties have been
earned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Consulting and Vendor Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into a number of agreements and work orders for future consulting, clinical trial support, and testing services,
with terms ranging between 1 and 18 months. These agreements, in aggregate, commit the Company to approximately $<span id="xdx_906_eus-gaap--Cash_iI_pn5n6_c20231231__us-gaap--TypeOfArrangementAxis__custom--OtherConsultingAndVendorAgreementsMember_zXfWx4ycr8Rc" title="Future cash">1.3</span> million in future
cash payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Right-of-use
lease</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2021, MagicMed entered into a lease agreement (the &#8220;LSIH Lease&#8221;) with the University of Calgary for the use and
occupation of lab and office space at the University of Calgary&#8217;s Life Science Innovation Hub building located in Calgary, Alberta,
Canada (the &#8220;LSIH Facility&#8221;). The lease expired in July 2023, and was extended on a month-to-month basis through December
31, 2023. Accordingly, no operating lease liability or right-of-use asset is recorded as of December 31, 2023. The Company terminated
this lease effective in March 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense is recorded on the straight-line basis. Rent expense under the LSIH Lease for the years ended December 31, 2023 and 2022 was
$<span id="xdx_902_eus-gaap--PaymentsForRent_c20230101__20231231_zBINyAlGGitl" title="Rent expenses">114,241</span> and $<span id="xdx_900_eus-gaap--PaymentsForRent_c20220101__20221231_zTe2yrPNRkw2" title="Rent expenses">120,667</span>, respectively. Rent expense is recorded in research and development costs on the consolidated statements of operations
and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_zcSidS9fkSDb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average remaining lease term and the weighted-average discount rate of the lease was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zQfu0TOu6lia" style="display: none">SCHEDULE OF WEIGHTED
AVERAGE REMAINING LEASE TERM</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Remaining lease term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; text-align: left">Operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231_zuiWJW2cO47k" title="Operating leases remaining lease term">0.6</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20221231_zk4ki5oTON06" title="Operating lease discount rate">12.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A4_zFSM6H6fbVub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861106345488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zYdOWhZhqi8i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11. <span id="xdx_82E_zmpByKrEU5va">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYpFlmqCGSD2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s U.S. and foreign loss before income taxes are set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zeA4xpukjyji" style="display: none">SCHEDULE OF EARNING (LOSS) BEFORE INCOME
TAX</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zxZNk46ZRzng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231_zijVKXfD02T1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzlef_z9MaFVvNgvr6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(10,205,116</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,251,228</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzlef_zE8rf8karcM4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,057,703</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,706,165</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_mtILFCOzlef_z2B2dgbOYfy4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,262,819</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(19,957,393</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AF_zhNKqIFZq044" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recorded income tax expense of $<span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20231231_z3Bd8okIz0A9" title="Income tax expenses and benefits">28,913</span> and an income tax benefit of $<span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zTxFvfZupNSk" title="Income tax expenses and benefits">1,486,060</span>,
respectively. The income tax benefit (expense) is as follows:</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zBdQk1cD3aIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_z4LFMffO1bGa" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE BENEFITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231_zXpnWXEk0Qnd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zktAaySoCScj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Current:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_iN_di_maCITEBzYcv_zswZcV5nkVg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1853">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1854">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maCITEBzYcv_zAEkzY61kyi6" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(28,913</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1857">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maCITEBzYcv_zBO2f4fpNnae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1859">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1860">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iNT_di_mtCITEBzYcv_maITEBzKnh_zBI0YA4EbLMh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total
    current income tax (expense) benefit</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,913</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1863">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zO46stlDOwwa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1865">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1866">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_z7PzV6xiY5vd" style="vertical-align: bottom; background-color: White">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1868">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1869">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zXxtOtSLhIsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1871">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,486,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDFITEzdpW_maITEBzKnh_zXY6vb4G9k2j" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred income tax (expense) benefit</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,486,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzKnh_z5f9VHGVH2Ya" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total income tax (expense) benefit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(28,913</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,486,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zEMeV37Jgcl8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFSERvZE8hD1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s deferred tax assets and deferred tax liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B9_zVn0082ZSHDi" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zXa1FmWtibt5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zwvxf2F8NBJ1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNdz_maDTANzxkL_zMNkEZsyD8Wf" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">10,889,863</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,927,330</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzxkL_zg5Rc6Cqe1F8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,185,399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,348,928</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ResearchAndDevelopmentCapitalizedExpenses_iI_maDTANzxkL_z756cbDpyv1k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development capitalized expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">611,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">614,041</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsAndIntangibleAmortization_iI_maDTANzxkL_zrt11foR7jeg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,141</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOther_iI_maDTANzxkL_zLfR2vCU52Pd" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,453</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzXjO_msDTANzxkL_zMfzrABlkFk8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,837,755</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,977,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzxkL_zeNN2eU460z" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1900">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1901">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zv3ekvcOLIcc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zs9bhRynYJsl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially utilizable net operating loss tax carryforwards:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zt3NjQUFsfF" style="display: none">SCHEDULE
OF OPERATING LOSS CARRY FORWARDS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zulmzGTSNdN8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zZqWm1R4dBi8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zQU8ncu82Cef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">24,268,692</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18,349,753</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zI0OIVbJPSr6" style="vertical-align: bottom; background-color: White">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,220,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,892,754</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zzjfJ55ZT1Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Foreign</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,672,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,377,435</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zSAitNKZZYjl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net operating loss tax carryforwards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,672,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,377,435</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A8_z7S3r24z5eD4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act of 2017 (the &#8220;Act&#8221;) limits the net operating loss deduction to 80% of taxable income for losses
arising in tax years beginning after December 31, 2017. As of December 31, 2023, the Company had federal net operating loss
carryforwards and state net operating loss carryforwards of $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zMyXJ1gm3FJ8">24,268,692</span>
and $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zH57liFWfGbk" title="Net operating loss carryforwards">11,220,065</span>,
respectively, both of which can be carried forward indefinitely and Canadian net operating loss carryforwards of $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zr2nJ9Kzy0j6" title="Net operating loss carryforwards">17,672,420</span>,
which will begin to expire in 2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzVMVNGeNJec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s effective tax rate varied from the statutory rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_z6qq60Xq2gJ2" style="display: none">SCHEDULE
OF EFFECTIVE STATUTORY INCOME TAX RATE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zcnUsjwkXjAj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_z6WLN5u7FCy" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maALCzr1A_zmTBblmRYrR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Federal income tax at the statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 3%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 3%; text-align: left">)%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maALCzr1A_zYGRPLUj28i3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax rate (net of federal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.6</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maALCzr1A_z9kt9Ydnzk1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign tax rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.1</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_pid_dp_uPure_maALCzr1A_zTghWy4U2b78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4.0</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueup_pid_dp_uPure_maALCzr1A_zw7LHgBY8Yg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1937">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maALCzr1A_ztmgY4wYYHoh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtALCzr1A_zWrMtwwBJC36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effective income tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table>

<p id="xdx_8A9_zsa35ks9ndR2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those temporary differences become deductible. The valuation allowance increased by
$<span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_znu1AgEoYdYj" title="Valuation allowance">1,859,862</span> and $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zQeSg7kdYWS3" title="Valuation allowance">4,429,869</span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files U.S. federal and state returns. The Company&#8217;s foreign subsidiary also files a local tax return in their local jurisdiction.
From a U.S. federal, state and Canadian perspective the years that remain open to examination are consistent with each jurisdiction&#8217;s
statute of limitations. As of December 31, 2023, the Company has not filed tax returns for the fiscal year 2023 and Canadian corporate
tax returns for fiscal year 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Section
382</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
utilization of the Company&#8217;s net operating losses may be subject to a substantial limitation in the event of any significant future
changes in its ownership structure under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result
in the expiration of the net operating loss carryforwards before their utilization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Section
174</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in 2022, the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) eliminated the option to deduct research and development expenditures
in the current year and requires taxpayers to amortize US expenses over five years and foreign expense over fifteen years pursuant to
IRC Section 174. During the years ended December 31, 2023 and 2022, the Company has estimated and capitalized gross $<span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20230101__20231231_z0NaECqIR2Wg" title="Research and development expense gross">463,696</span> and $<span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20220101__20221231_zOGeQR7Krns5" title="Research and development expense gross">2,684,319</span>,
respectively, of research and development expenditures that will be amortized primarily over five years. This did not have a material
impact on the Company&#8217;s tax liability for the years ended December 31, 2023 and 2022. The Company will continue to evaluate the
impact of these tax law changes on the current and future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
Reduction Act</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2022, President Joe Biden signed the Inflation Reduction Act of 2022 (the &#8220;Act&#8221;) into law. The Act includes a
new 15% corporate minimum tax and a 1% excise tax on the value of corporate stock repurchases, net of new share issuances, after December
31, 2022. These provisions did not have a material impact on the Company&#8217;s consolidated financial position as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861206763408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z18CjkrOmpN9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12. <span id="xdx_820_zNqnVHMzgyjl">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
February 29, 2024, the Company issued all <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztZQSzRfQhgf" title="Number of common stock issued">704,000</span> shares of common stock of the <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVMa1cegYz64" title="Existing Warrants">704,000</span> shares of Existing Warrants and Investment Options
exercised that were held in abeyance due to the beneficial ownership limitation provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 29, 2024, one investor exercised the Inducement Warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKrULxjy5eIa" title="Warrants to purchase shares of common stock">1,954,000</span> shares of common stock for cash proceeds of approximately
$<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl177HQBwHH" title="Cash proceeds">2.7</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct offering
of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zxqKyTLmS3hh">228,690
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock, par
value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z4fZ2TTDwlU6">0.01
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to the Holders of the Inducement Warrants.
The issuance was made in exchange for the permanent and irrevocable waiver of the variable rate transaction limitation solely with respect
to the entry into and/or issuance of shares of common stock in an at the market offering contained in the Inducement Letters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2023, the Company sold an aggregate of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zZl25kVUlsV1" title="Number of shares sold">1,668,000</span> shares of common stock for aggregate gross proceeds of $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zP6ktUIcIwx3" title="Gross proceeds from sale of shares">2,392,502</span> and
net proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zBs01OrWOijg" title="Net Proceeds from sale of shares">2,320,707</span> under the Distribution Agreement with Canaccord.&#8221;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861201581248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principal of Consolidation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6VcoZZsSz29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zbIKrsz2JJMb">Basis
of Presentation and Principal of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance and in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and the applicable rules
and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) regarding consolidated financial information. All intercompany
transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_846_eus-gaap--UseOfEstimates_zLE80GiwQAK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zMMySFR20SIc">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported.
By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such
estimates in future periods could be significant. Significant areas requiring management&#8217;s estimates and assumptions include determining
the fair value of transactions involving common stock, the valuation of warrants and preferred investment options, and the valuation
of stock-based compensation and accruals associated with third party providers supporting research and development efforts. Actual results
could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z5nptn10VcWl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zFKLsC1vhXHf">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through December 31, 2023, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#8217;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended December
31, 2023 and 2022, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the consolidated statements of operations and comprehensive loss as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6AeRnFPvu0k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zNjHpvv4Gia">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The
Company did not have any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zIej6k2jp2B1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z0Oa78Uy6iHe">Concentration
of Credit Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zB4bQGBLtGA6" title="Cash FDIC insured amount">250,000</span> in the United States and Australia and $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zGy542i4yAyf" title="Cash insured amount">100,000</span> in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of December 31, 2023, the Company had greater than $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zQv2tJGpW28l" title="Cash FDIC insured amount">250,000</span> at United States financial institutions, less than $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--AU_zPZgCdbAQVk7" title="Cash FDIC insured amount">250,000</span>
at Australian financial institutions, and greater than $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zkz71lJ5798l" title="Cash FDIC insured amount">100,000</span> at Canadian financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zuPlfgRbEyZd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztBjC43QkT38">Comprehensive
Loss</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss consists of two components, net loss and other comprehensive income (loss). Other comprehensive loss refers to revenue, expenses,
gains, and losses that under GAAP are recorded as an element of shareholders&#8217; equity but are excluded from net loss. Other comprehensive
loss consists of foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziQD2CBAghZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zPkCB4Owiyud">Intangible
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the Psybrary&#8482; and Patent Applications, In Process Research and Development (&#8220;IPR&amp;D&#8221;) and license
agreements. Psybrary&#8482; and Patent Applications intangible assets are valued using the relief from royalty method. The cost of license
agreements is amortized over the economic life of the license. The Company assesses the carrying value of its intangible assets for impairment
each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IPR&amp;D
intangible assets are acquired in conjunction with the acquisition of a business and are assigned a fair value, using the multi-period
excess earnings method, related to incomplete research projects which, at the time of acquisition, have not reached technological feasibility.
The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion
or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then-useful
life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to
be generated, and begin amortization. The Company tests its intangible assets for impairment at least annually and whenever events or
circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator
of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company&#8217;s
expected future cash flows; a sustained, significant decline in the Company&#8217;s stock price and market capitalization; a significant
adverse change in legal factors or in the business climate of the Company&#8217;s segments; unanticipated competition; and slower growth
rates. If the fair value determined is less than the carrying amount, an impairment loss is recognized in operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z32t25Ny06rb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zdX7mG65WS1b">Goodwill</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company tests goodwill for potential impairment at least annually, or more frequently if an event or other circumstance indicates that
the Company may not be able to recover the carrying amount of the net assets of the reporting unit. The Company has determined that the
reporting unit is the entire company, due to the integration of all of the Company&#8217;s activities. In evaluating goodwill for impairment,
the Company may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that
the fair value of a reporting unit is less than its carrying amount. If the Company bypasses the qualitative assessment, or if the Company
concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company performs
a quantitative impairment test by comparing the fair value of a reporting unit with its carrying amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property &amp; Equipment</a></td>
<td class="text"><p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zNmGyuL93vpj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z622SrpvFB74">Property
&amp; Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Major property additions, replacements, and betterments are capitalized, while maintenance and repairs
that do not extend the useful lives of an asset or add new functionality are expensed as incurred. Depreciation and amortization are
recorded using the straight-line method over the respective estimated useful lives of the Company&#8217;s long-lived assets. The estimated
useful lives are typically <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDXlWGeWzm" title="Estimated useful lives">3</span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zuaBlK6Ilio2" title="Estimated useful lives">5</span> years for office furniture and equipment and are depreciated on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p id="xdx_844_ecustom--DeferredOfferingCostsPolicyTextBlock_zI13qPYdFR16" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zmmelDy6vXh3">Deferred
Offering Costs</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocates offering costs to the different components of the capital raise on a pro rata basis. Any offering costs allocated to
common stock are charged directly to additional paid-in capital. Any offering costs allocated to warrant liabilities are charged to general
and administrative expenses on the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirements of ASC Topic 340, <i>Other Assets and Deferred Costs</i> (&#8220;ASC 340&#8221;) and SAB 5A <i>-
Expenses of Offering</i>. Offering costs, which consist mainly of legal, accounting and consulting fees directly attributable to the
issuance of an equity contract to be classified in equity are recorded as a reduction in equity. For the year ended December 31, 2023,
the Company incurred $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zOw3Bao897qf" title="Deferred offering costs">567,603</span> in deferred offering costs in connection with the Equity Distribution Agreement (the &#8220;Distribution
Agreement&#8221;), with Canaccord Genuity LLC (&#8220;Canaccord&#8221;) and the Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). These deferred offering costs will be proportionately offset against
the total proceeds from the issuance of common stock available under the agreements and the Company will expense any remaining balance
of deferred offering costs if the agreements are terminated. For the year ended December 31, 2023, there were no issuances of common
stock under the agreements resulting in the deferral of offering costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability and Investment Options</a></td>
<td class="text"><p id="xdx_84C_ecustom--WarrantLiabilityPolicyTextBlock_zanLVGGwng9c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zH6VWLIKl02j">Warrant
Liability and Investment Options</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its financial instruments, including issued stock purchase warrants and investment options, to determine if
such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 &#8220;Distinguishing
Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;) and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;).
The Company accounts for warrants and investment options for shares of the Company&#8217;s common stock that are not indexed to its own
stock as derivative liabilities at fair value on the consolidated balance sheets. The Company accounts for common stock warrants and
investment options with put options as liabilities under ASC 480. Such warrants and investment options are subject to remeasurement at
each consolidated balance sheet date and any change in fair value is recognized as a component of other expense on the consolidated statements
of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration
of such common stock warrants and investment options. At that time, the portion of the warrant liability and investment options related
to such common stock warrants will be reclassified to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock', window );">Modification and Inducement of Warrants and Investment Options</a></td>
<td class="text"><p id="xdx_846_ecustom--ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_zOLylevrf7oj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zHBF6D1y83y9">Modification
and Inducement of Warrants and Investment Options</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in any of the terms or conditions of warrants is accounted for as a modification. For a warrant modification accounted for under
ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over the fair
value of the original warrant immediately before its terms are modified, measured based on the fair value of the shares and other pertinent
factors at the modification date. The accounting for incremental fair value of warrants is based on the specific facts and circumstances
related to the modification. When a modification is directly attributable to equity offerings, the incremental change in fair value of
the warrants are accounted for as equity issuance costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the inducement to exercise warrants in accordance with ASC Subtopic 470-20-40 &#8220;Debt with Conversion and Other
Options&#8221; (&#8220;ASC 470-20-40&#8221;). ASC 470-20-40 requires the recognition through earnings of an inducement charge equal to
the fair value of the consideration delivered in excess of the consideration issuable under the original conversion terms. Therefore,
the Company recognized a loss on the warrant inducement for the incremental change of the warrants related to the reduced exercise price
and the issuance of new warrants as these components induced the holders to exercise the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liability</a></td>
<td class="text"><p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_ze8NOutWO18c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zBwpH1gx3ZNb">Derivative
Liability</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as assets or liabilities, the derivative
instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the
fair value reported in the consolidated statements of operations. The classification of derivative instruments, including whether such
instruments should be recorded as assets or liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion
of the instrument could be required within 12 months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zL6shVmPF5Cf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zsORoSsW5NTg">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#8217;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liabilities. In management&#8217;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The
amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that
do not meet these recognition and measurement standards. As of December 31, 2023 and 2022, no liability for unrecognized tax benefits
was required to be recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy for recording interest and penalties associated with tax audits is to record such items as a component of operating
expenses. There were no amounts accrued for penalties and interest for the years ended December 31, 2023 and 2022. The Company does not
expect its uncertain tax positions to change during the next twelve months. Management is currently unaware of any issues under review
that could result in significant payments, accruals or material deviations from its position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified its United States, Canadian and Australian federal tax returns, and its state and provincial tax returns in Florida,
Massachusetts, New Jersey, Pennsylvania, and Ontario, CA as its &#8220;major&#8221; tax jurisdictions. The Company is in the process
of filing its United States federal and state and Australian federal corporate tax returns for the year ended December 31, 2023. The
Company is in the process of filing its Canadian corporate tax returns for the years ended December 31, 2023 and 2022. Net operating
losses for these periods will not be available to reduce future taxable income until the returns are filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zEsxkwpAfIyl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zVtfgEZ2LSf1">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows ASC 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions, requiring
such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded at the more
readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The Company uses the Black-Scholes
option-pricing model to determine the grant date fair value of certain stock-based awards under ASC 718. The assumptions used in calculating
the fair value of stock-based awards represent management&#8217;s reasonable estimates and involve inherent uncertainties and the application
of management&#8217;s judgment. Fair value of restricted stock units or restricted stock awards is determined by the closing price per
share of the Company&#8217;s common stock on the date of award grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value is amortized as a charge to earnings on a straight-line basis, for awards or portions of awards that do not require
specified milestones or performance criteria as a vesting condition and also depending on the terms and conditions of the award, and
the nature of the relationship of the recipient of the award to the Company. The Company records the grant date fair value in line with
the period over which it was earned. For employees and consultants, this is typically considered to be the vesting period of the award.
The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of awards that require specified milestones or recipient performance are charged to expense when such milestones
or performance criteria are probable to be met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
stock units, restricted stock awards, and stock options are granted at the discretion of the Compensation Committee of the Company&#8217;s
board of directors (the &#8220;Board of Directors&#8221;). These awards are restricted as to the transfer of ownership and generally
vest over the requisite service periods, typically over a 12 to 48-month period. A significant portion of these awards may include vesting
terms that include, without limitation, defined volume weighted average price levels being achieved by the Company&#8217;s common stock,
specific performance milestones, employment, or engagement by the Company, with no assurances of achievement of any such vesting conditions,
if applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RSU&#8217;s is equal to the product of the number of units awarded, multiplied by the closing price per share of the Company&#8217;s
common stock on the date of the award. The terms and conditions of each RSU is defined in the RSU agreement and includes vesting terms
that consist of any or all of the following: immediate vesting, vesting over a defined period of time, vesting based on achievement of
a defined volume weighted average price levels at specified times, vesting based on achievement of specific performance milestones within
a specific time frame, change of control, termination of the employee without cause by the Company, resignation of the employee with
good cause. The value assigned to each RSU is charged to expense based on the vesting terms, as follows: value of RSU&#8217;s that vest
immediately are charged to expense on the date awarded, value of RSU&#8217;s that vest based upon time, or achievement of stock price
levels over a period of time are charged to expense on a straight line basis over the time frame specified in the RSU and the value of
RSU&#8217;s that vest based upon achievement of specific performance milestones are charged to expense during the period that such milestone
is achieved. Vested RSU&#8217;s may be converted to shares of common stock of an equivalent number upon either the termination of the
recipient&#8217;s employment with the Company, or in the event of a change in control. If the recipient is not an employee, such person&#8217;s
engagement with the Company must either be terminated prior to such conversion of RSU&#8217;s to shares of common stock, or in the event
of a change in control. Furthermore, as required by Section 409A of the Internal Revenue Code, if the recipient is a &#8220;specified
employee&#8221; (generally, certain officers and highly compensated employees of publicly traded companies), such recipient may only
convert vested RSU&#8217;s into shares of common stock no earlier than the first day of the seventh month following such recipients termination
of employment with the Company, or the event of change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RSA&#8217;s is equal to the product of the number of restricted shares awarded, multiplied by the closing price per share of
the Company&#8217;s common stock on the date of the award. The terms and conditions of each RSA is defined in the RSA agreement and includes
vesting terms that consist of any or all of the following: immediate vesting, vesting over a defined period of time, or vesting based
on achievement of a defined volume weighted average price levels at specified times. Upon vesting, the recipient may receive restricted
stock which includes a legend prohibiting sale of the shares during a restriction period that is defined in the RSA agreement. Termination
of employment by or engagement with the Company is not required for the recipient to receive restricted shares of common stock. The value
assigned to each RSA is charged to expense based on the vesting terms, as follows: value of RSA&#8217;s that vest immediately are charged
to expense on the date awarded, value of RSA&#8217;s that vest based upon time, or achievement of stock price levels over a period of
time are charged to expense on a straight-line basis over the time frame specified in the RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z2bNPdQ0lNxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zX4N0aihbZJi">Net
Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the years ended December 31, 2023 and 2022 excludes
potentially dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully
diluted. In accordance with ASC 260 &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;), penny warrants were included in the calculation
of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022 the Company issued <span id="xdx_908_eus-gaap--StockIssued1_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zrEmdvuW4kc3" title="Stock and warrants issued">767,500</span> pre-funded common stock warrants, which were exercised on various dates during
the year ended December 31, 2022. The pre-funded common stock warrants became exercisable on July 26, 2022 based on the terms and conditions
of the agreements. As the pre-funded common stock warrants are exercisable for $<span id="xdx_90D_eus-gaap--WarrantExercisePriceDecrease_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zklaTLhZDQRk" title="Warrant exercise price">0.0001</span>, these shares are considered outstanding common
shares and are included in the computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants
is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions
were met on July 26, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3HM0uaIm6yl" style="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,799,213</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">655,463</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,848</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,492</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock units - unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,491</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,053</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_z5qaULxH0YR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock awards - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0893">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">708</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_zqhcUe1s59cj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock in abeyance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">704,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zq1067Obsksb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment options to purchase shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,070,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zhYSctrl3dxd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase shares of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,764,881</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,901,045</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zJID65LmxDb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqetmarc655b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztG9Z6EAI5m2">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value
Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), approximates the carrying amounts in the balance sheets, excluding the derivative,
warrants, and preferred investment option liabilities, primarily due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zWzfZ1GdSou9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zKPLQOyArmx4">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and
liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by
other market participants. These valuations require significant judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, including cash and accounts payable, the carrying amounts approximate their fair values as of December
31, 2023 and 2022 because of their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ziSLQKNyYoCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zuz1Rz8vQhr9">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_zQ7ioewi5Gc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease assets are included within right-of-use operating lease asset and operating lease liabilities are included in current portion of
right-of-use operating lease obligation and non-current portion of right-of-use operating lease obligation on the consolidated balance
sheets as of December 31, 2023 and 2022. The Company has elected not to present short-term leases as these leases have a lease term of
12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise.
Lease payments for short-term leases are recognized on a straight-line basis over the term of the lease. All other lease assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the
Company&#8217;s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information
available at adoption date in determining the present value of lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain
a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset
and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company
has elected to account for non-lease components associated with its leases and lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes a right-of-use asset, which represents the Company&#8217;s right to use the underlying asset for the lease term, and
a lease liability, which represents the present value of the Company&#8217;s obligation to make payments arising over the lease term.
The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing
rate<b><i>.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of
ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset
that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset,
(iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v)
the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of
the lease term. All other leases are recorded as operating leases. Finance lease payments are bifurcated into (i) a portion that is recorded
as interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did not have any finance
leases as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNoncontrollingInterestPolicyTextBlock', window );">Redeemable Non-controlling Interest</a></td>
<td class="text"><p id="xdx_846_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zxsDQhAmPSMf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_za6xEu8hPKl1">Redeemable
Non-controlling Interest</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of Akos Series A Preferred Stock, the Akos Purchase Agreement (as defined below in Note 8) and certificate
of designation contain a put right guaranteed by the Company as defined in Note 8. Applicable accounting guidance requires an equity
instrument that is redeemable for cash or other assets to be classified outside of permanent equity if it is redeemable (a) at a fixed
or determinable price on a fixed or determinable date, (b) at the option of the holder, or (c) upon the occurrence of an event that is
not solely within the control of the issuer. As a result of this feature, the Company recorded the non-controlling interests as Redeemable
Non-Controlling Interests (&#8220;RNCI&#8221;) and classified them in mezzanine equity within its consolidated balance sheet initially
at its acquisition-date estimated redemption value or fair value. In addition, the Company has elected to recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument by accreting the embedded derivative at each reporting
period over 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right (as defined below) requiring Akos to force redemption of all of the Akos Series A Preferred Stock. See Note 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQ4s5yz0SOx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zww0mCbaLZc1">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines its reporting units in accordance with FASB ASC 280, &#8220;Segment Reporting&#8221; (&#8220;ASC 280&#8221;). The
Company evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated. The Company has multiple operations related
to psychedelics and cannabinoids. Both of these operations exist under one reporting unit: Enveric. The Company has one operating segment
and reporting unit. The Company is organized and operated as one business. Management reviews its business as a single operating segment,
using financial and other information rendered meaningful only by the fact that such information is presented and reviewed in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6VQKIWjEQ2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zwwObdI2aaB5">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>Debt&#8212;Debt with Conversion and Other Options</i> (Subtopic 470-20) and <i>Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</i> (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;) to simplify certain financial
instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features
from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2023, and should be applied on a full or modified retrospective basis. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06
effective January 1, 2023, and has determined that the adoption of this guidance had no impact on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently evaluating ASU 2023-07 to determine its impact on the Company&#8217;s
disclosures, however, as the Company currently has one reportable segment, the Company does not expect ASU 2023-07 to have a material
impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its consolidated financial statements
and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification and Inducement of Warrants and Investment Options [Policy text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNoncontrollingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable non controlling interest policy [Text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNoncontrollingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861103682064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">SCHEDULE OF RESTRUCTURING COSTS PAYABLE</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z5glKSFld41e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_ztulwBwkUNX1" style="display: none">SCHEDULE
OF RESTRUCTURING COSTS PAYABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued<br/>
Restructuring Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>January 1, 2023 Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20230101__20231231_zAlZ6w4mtdef" style="text-align: right" title="Restructuring cost payable, beginning"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Restructuring costs incurred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_ecustom--RestructuringCostsIncurred_c20230101__20231231_zWEiabbndsUi" style="width: 16%; text-align: right" title="Restructuring costs incurred">1,004,033</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restructuring costs paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RestructuringCosts_c20230101__20231231_zH5WzRsnJSdh" style="text-align: right" title="Restructuring costs">(572,628</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restructuring costs reversed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OtherRestructuringCosts_c20230101__20231231_zY0iQ8QQEIX6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Restructuring costs reversed">(129,760</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">December 31, 2023 ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20230101__20231231_z5ABeYZz2MK4" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending">301,645</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861103067696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3HM0uaIm6yl" style="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,799,213</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">655,463</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,848</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,492</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock units - unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,491</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,053</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_z5qaULxH0YR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock awards - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0893">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">708</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_zqhcUe1s59cj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock in abeyance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">704,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zq1067Obsksb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment options to purchase shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,070,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zhYSctrl3dxd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase shares of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,764,881</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,901,045</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861201579168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3Gs4LNqtEXh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, the prepaid expenses and other current assets of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zTydFvT6Kuv4" style="display: none">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_z62twSxO8pL7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_z3hHr38UO7Tf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zIwSnFeaEsv8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">46,320</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">268,686</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_znbflNJJ4xcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid value-added taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,782</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_z3HJkewuOo16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,406</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zRR1RvRhJGo5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,179</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_zv88yG4YKVt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">567,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0939">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zujCa29AAHXe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Franchise tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,258</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zaRKpTVrRgM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">R&amp;D tax incentive receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,349</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0945">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zieXSbV2rhJ5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,293,554</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">708,053</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861105398704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">SCHEDULE OF GOODWILL</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zNA8zJSGKUU" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s goodwill consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_zywzBm3sR0Xd" style="display: none">SCHEDULE
OF GOODWILL</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Impairment Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Currency Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--GoodwillGross_iS_c20220101__20221231_zrL5hyJCBTck" style="width: 11%; text-align: right" title="Goodwill Gross, Beginning balance">9,834,855</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNS_di_c20220101__20221231_zoA3HbV75zY9" style="width: 11%; text-align: right" title="Accumulated Impairment Losses, Beginning balance">(8,225,862</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--GoodwillCurrencyTranslation_iS_c20220101__20221231_zsv05uR0T8P7" style="width: 11%; text-align: right" title="Currency Translation, Beginning balance">(21,359</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Goodwill_iS_c20220101__20221231_zcXRwm58qzs1" style="width: 11%; text-align: right" title="Goodwill, Beginning balance">1,587,634</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--GoodwillImpairmentLossGross_iN_di_c20220101__20221231_zkf3VkHhApy6" style="text-align: right" title="Goodwill Gross, Impairment losses"><span style="-sec-ix-hidden: xdx2ixbrl0962">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--GoodwillAccumulatedImpairmentLoss_iN_di_c20220101__20221231_zUssTZVnGsp9" style="text-align: right" title="Accumulated Impairment Losses, Impairment losses">(1,486,060</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--GoodwillCurrencyTranslationImpairmentLoss_iN_di_c20220101__20221231_zl7mHTPCTDti" style="text-align: right" title="Currency Translation, Impairment losses"><span style="-sec-ix-hidden: xdx2ixbrl0966">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zsSlcGVeDune" style="text-align: right" title="Goodwill, Impairment losses">(1,486,060</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--GoodwillForeignCurrencyTranslationGainLossGross_c20220101__20221231_zyhq88vbkWy9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill Gross, Loss on currency translation"><span style="-sec-ix-hidden: xdx2ixbrl0970">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_c20220101__20221231_zyyjjekFt9Bh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Impairment Losses, Loss on currency translation"><span style="-sec-ix-hidden: xdx2ixbrl0972">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--GoodwillCurrencyTranslationLoss_c20220101__20221231_zapkiDJnziL9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Currency Translation, Loss on currency translation">(101,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20220101__20221231_zMG8RIR4uUE4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill, Loss on currency translation">(101,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GoodwillGross_iE_c20220101__20221231_zs3uh3Cgc7W3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill Gross, Ending balance">9,834,855</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNE_di_c20220101__20221231_zIXJIohBvg8a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Impairment Losses, Ending balance">(9,711,922</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--GoodwillCurrencyTranslation_iE_c20220101__20221231_zW9O3fTzJnD2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Currency Translation, Ending balance">(122,933</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zvobPkbyOarl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">SCHEDULE OF INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zUeFBNUXA8mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s indefinite lived intangible assets consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B7_zWEh1BmzLMM6" style="display: none">SCHEDULE
OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Indefinite lived intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iS_d0_c20220101__20221231_zYcj6o314Pg" style="width: 16%; text-align: right" title="Balance, Indefinite lived intangible assets">6,375,492</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetImpairmentCharges_iN_di_c20220101__20221231_z8wLJAfYqT8g" style="text-align: right" title="Impairment losses">(5,967,602</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Loss on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20220101__20221231_z1veDDOEjT78" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loss on currency translation">(407,890</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iE_c20220101__20221231_z7LKtTyUhh1h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Balance, Indefinite lived intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl0994">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023 and 2022, the definite lived intangible assets consisted of: &#160; &#160; &#160; &#160;</p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; width: 80%">Definite lived intangible assets</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 16%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold">Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20220101__20221231_ziSpokWclQNl" style="text-align: right" title="Balance, Definite lived intangible assets">548,436</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20220101__20221231_zSxeeR1NJHi1" style="border-bottom: Black 1.5pt solid; text-align: right">(168,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold">Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20230101__20231231_zoS9i0Nplzqe" style="text-align: right">379,686</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20231231_zNNExnK3q2ec" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">(168,754</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20230101__20231231_zIT0j5Uxijbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, Definite lived intangible assets">210,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zqb59wU0hIE9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company amortizes definite lived intangible assets on a&#8239;straight-line basis over their estimated useful lives. Amortization expense
of identified intangible assets based on the carrying amount as of December 31, 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B8_zzVXkKpEcQPl" style="display: none">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231_zkDZQgKYy2ck">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzC0U_zTyAhx8Iihm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">168,750</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzC0U_zWOFDxfsxxFe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,182</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzC0U_zC9XwcaOuro6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Finite lived assets amortization
    expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">210,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861103769248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</a></td>
<td class="text"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVVGahhpzvNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following assets which are located in Calgary, Canada and placed in service by Enveric Biosciences Canada,
Inc. (&#8220;EBCI&#8221;), with all amounts translated into U.S. dollars:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BF_zxF5quYUvBz1" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zzCZHNQZFxvd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zvLPGndd0db5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zp4aNQNMWWri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Lab equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">836,709</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">831,123</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_z9JhYXtwNtFl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment and leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,379</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,137</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zPgLn2Oc6tvg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(357,711</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(178,775</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zXt2mt3bMunh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net of accumulated depreciation</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">507,377</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">677,485</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861105903104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED LIABILITIES</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zEC0nxuwQfD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and December 31, 2022, the accrued liabilities of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B6_z2CYiR69qip9" style="display: none">SCHEDULE
OF ACCRUED LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zIdUdedJs0bc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_ztfCG22lB8m6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_zzTIaLc6TzX6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Product development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">139,981</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">195,104</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zxArVFIfjro7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued salaries, wages, and bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,889</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,175,963</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zmvujpsSA58g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">584,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,255</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zGJabHMfEVH5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued restructuring costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,645</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_z6PA2plzHgPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued franchise taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zTXa5jxvaF64" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Patent costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zHLlMDwwvI65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,075,643</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,705,655</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861107438608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8YtSqYx16Ag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity under the Company&#8217;s incentive plan for the years ended December 31, 2023 and 2022 is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zu3hZq6igFI4" style="display: none">SCHEDULE OF STOCK OPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Outstanding at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zlfachWgXyo4" style="width: 9%; text-align: right" title="Number of Shares, Outstanding at beginning">23,829</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zBHipcjjafJb" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning">79.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_z3KUiEblBS32" style="width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning">103.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zc6QHY3pugra" title="Weighted Average Remaining Contractual Term (years)">5.3</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zWsvXq7xXltk" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Outstanding">34,333</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zUwzel36BOnk" style="text-align: right" title="Number of Shares, Granted">25,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z5kJ7HfnP6pf" style="text-align: right" title="Weighted Average Exercise Price, Granted">3.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znh44xkmKi5a" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin-top: 0; margin-bottom: 0"><span></span></p>
                                                                          <p style="margin-top: 0; margin-bottom: 0"><span>&#160;</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zMwQE9ty7cd5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, forfeited">(1,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zODjjvTnFKVd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, forfeited">175.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znQpNtug7kVc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited">140.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span>&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_z8a4TyNt1Z85" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Outstanding at beginning">48,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zg98NijbXZh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning">37.05</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zIZUyOqQArtj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning">44.82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5ShG7pIcpf5" title="Weighted Average Remaining Contractual Term (years)">4.1</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zfbN7fLAAKpi" style="text-align: right" title="Number of Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1180">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zvXECFVHHTLj" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1182">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231_z4H5Vu8Biz83" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, forfeited">(18,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zV15MinWPaA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, forfeited">3.07</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zMCYL5FZJYyj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited">2.58</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_z0vJtB0G1Poe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Outstanding at end">30,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zTWGbA0Nvv66" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at end">57.17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zUfoA887Azb9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at end">77.22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_za3lss46TUsl" title="Weighted average remaining contractual term, outstanding balance">3.4</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231_zN4jPjsgp21g" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable shares at end">25,677</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_ziRZaH57gja8" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable weighted average price at end">64.45</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zx8Su3tDvHy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, exercisable">88.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z4vf0GnUomE9" title="Weighted average remaining contractual term, exercisable">2.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF STOCK OPTION ASSUMPTION</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEutDXJS5oV9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted during the years ended December 31, 2022 were valued using the Black Scholes model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zR9P2uQxAng7" style="display: none">SCHEDULE OF STOCK OPTION ASSUMPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zj6iPtU5AHta" title="Term (years)">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20221231_zlKRFdSy2ve2" title="Stock price">3.07</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231_zX3WUGe0AYX2" title="Exercise price">3.07</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z5lvwkDplOW2" title="Dividend yield">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_zXidb2KriXN1" title="Expected volatility">112.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_za8yif42LrIb" title="Risk free interest rate">3.9</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zeKrkjRh7dje" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activity in restricted stock units was as follows for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zOnUfbNkVcx6" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average<br/>
 fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Non-vested at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEDhw9y1hxZb" style="width: 16%; text-align: right" title="Number of shares, Non-vested beginning">62,013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaILPTwaljuj" style="width: 16%; text-align: right" title="Weighted average fair value, Non-vested beginning">126.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zirQtPdDJsZi" style="text-align: right" title="Number of shares, Granted">37,445</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUYL7MfjSel" style="text-align: right" title="Weighted average fair value, Granted">33.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxzxsA9U3MM5" style="text-align: right" title="Number of shares, Forfeited">(26,772</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoUqJoFo0SPa" style="text-align: right" title="Weighted average fair value, Forfeited">79.64</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCGHiACcoei3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Vested">(8,633</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmbvrrJRPdT2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average fair value, Vested">130.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Non-vested at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3a70kwxF3V2" style="text-align: right" title="Number of shares, Non-vested beginning">64,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLrYNbURiDu7" style="text-align: right" title="Weighted average fair value, Non-vested beginning">92.57</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znLFWlg2TGh1" style="text-align: right" title="Number of shares, Granted">182,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfBGTV22anXd" style="text-align: right" title="Weighted average fair value, Granted">2.73</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2mJgukWkvO9" style="text-align: right" title="Number of shares, Forfeited">(43,426</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxHfzIDptRA4" style="text-align: right" title="Weighted average fair value, Forfeited">25.72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNyxeKRhEEJ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested">(62,636</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrqPsZk6qtR7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average fair value, Vested">19.80</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIJwWAqEmkx2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, non-vested ending">140,491</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJYYLsJCm9Q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average fair value, Non-vested ending">28.97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z3ex9jdX7Hgd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s recognition of stock-based compensation for restricted stock units for the following periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zwVhDWsRp68h" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zPQew5K1VjCh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zCbffNV9umPf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense for RSUs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zSOwB6VgYaZd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,085,791</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,389,359</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfdu3M9qPMBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">908,294</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,026,907</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zcduJChWGdHc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,994,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,416,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_zgOmbiRFAoQe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock-based compensation expense for RSUs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,994,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,416,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ScheduleOfWarrantsOutstandingTableTextBlock', window );">SCHEDULE OF WARRANTS OUTSTANDING</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zCwAZnLGDADf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about shares issuable under warrants outstanding at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_z8ZFdYdYVEvf" style="display: none">SCHEDULE
OF WARRANTS OUTSTANDING</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrant shares outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTfdpCfJmiBi" style="width: 11%; text-align: right" title="Warrant shares outstanding at beginning">195,463</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3fi1daRxsLi" style="width: 11%; text-align: right" title="Weighted average exercise Price, Outstanding at beginning">131.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z54Yv7nvu7W9" title="Weighted average remaining life, Outstanding">3.4</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVKnQZX3WT3" style="width: 11%; text-align: right" title="Intrinsic Value, Outstanding beginning">801,024</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoHdcQoSVWS2" style="text-align: right" title="Warrant shares outstanding, Issued">1,227,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq4CkgY3nmbb" style="text-align: right" title="Weighted average exercise price, Issued">10.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoCiirvRQcd1" style="text-align: right" title="Warrant shares outstanding, Exercised">(767,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchanged for common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPYXssDy289d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchanged for common stock"><span style="-sec-ix-hidden: xdx2ixbrl1315">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziP88dUalGL3" style="text-align: right" title="Warrant shares outstanding at beginning">655,463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgN4PA0LOL52" style="text-align: right" title="Weighted average exercise Price, Outstanding at beginning">58.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNat7GYdCief" title="Weighted average remaining life, Outstanding">3.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zif7UujrkK8h" style="text-align: right" title="Intrinsic Value, Outstanding beginning">5,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF9wfK13hB3a" style="text-align: right" title="Warrant shares outstanding, Issued">2,311,320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzzaBhPs6fcj" style="text-align: right" title="Weighted average exercise price, Issued">1.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFg4HAtR0Uo3" style="text-align: right" title="Warrant shares outstanding, Exercised">(122,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjBdEmkvsgQ3" style="text-align: right" title="Weighted average exercise price, Exercised">1.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWsO7MCiRq3g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant shares outstanding, Forfeited">(45,570</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0n5xO3Jttvj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Forfeited">111.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG0zfcvh1EB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant shares outstanding at end">2,799,213</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVykSWQShf2c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise Price, Outstanding at end">11.79</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo234JlDnvN9" title="Weighted average remaining life, Outstanding">4.6</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TQKNs9s47l" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant shares outstanding, Exercisable">2,799,213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxF5xDyqxuv9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">11.79</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziBL756oG0Sj" title="Weighted average remaining life, Exercisable">4.6</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znZZJLvwpd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding end"><span style="-sec-ix-hidden: xdx2ixbrl1349">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z00XmdXvzoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about investment options outstanding at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B7_zXmcUZK6ggX1" style="display: none">SCHEDULE
OF WARRANTS  AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Investment options outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zEwvcLEoJfDe" style="text-align: right" title="Investment options Outstanding, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1377">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zxaDKk1asuL5" style="text-align: right" title="Weighted average exercise price, Outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1379">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zlJw8znfo0I4" style="text-align: right" title="Intrinsic value, Outstanding beginning">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1381">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; padding-bottom: 1.5pt">Issued</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zDF48VFSv1A7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Investment options outstanding, Issued">1,070,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVx10hGW7qx2" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Weighted average exercise price, Issued">7.93</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zqwHo3jONiyh" style="text-align: right" title="Investment options outstanding, beginning">1,070,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVu0eC11XHn7" style="text-align: right" title="Weighted average exercise price, Outstanding beginning">7.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7cYhlQli82i" title="Weighted average remaining life, Outstanding">5.1</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zW78kJ5dKbha" style="text-align: right" title="Intrinsic value, Outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1393">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLWd0NriqTJ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Investment options outstanding, Exercised">(1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zJbc1b45aUy4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Exercised">1.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z1lexvtMAU48" style="border-bottom: Black 1.5pt solid; text-align: right" title="Investment options outstanding, end">70,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z64Vkjb4vBD2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Outstanding end">10.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zo3u42JYc9hg" title="Weighted average remaining life, Outstanding">4.1</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLfLYOEFU04b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic value, Outstanding end"><span style="-sec-ix-hidden: xdx2ixbrl1405">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zSZT9LEs53K1" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment options outstanding, Exercisable">70,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zaDEqPn9Z6kf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding end">10.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zyrHBnlcTyT6" title="Weighted average remaining life, Exercisable">4.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zhirJurCktSd" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1413">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ScheduleOfValuationOfWarrantsTextBlock', window );">SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfValuationOfWarrantsTextBlock_zjlfMoR7FOl7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its equity classified Inducement Warrants at the date of issuance on December 28, 2023.
The Company used a Black Scholes valuation model in order to determine their value. The key inputs into the Black Scholes valuation model
for the valuation of the warrants are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zy2L3wh6IEsj" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Roth and Inducement Warrants</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 28, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z52K9qwfKrY6" title="Term (years)">5.0</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zvpHkwU31FQ6" title="Stock price">1.56</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zm3vVfJEgZJb" title="Exercise price">1.37</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zdaTE0h352rg" title="Dividend yield">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zZ8qJnxEV6V3" title="Expected volatility">92.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z72dh5NNsTw" title="Risk free interest rate">3.80</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zMzy9I7TxUTl" style="text-align: right" title="Warrants, number of warrants">2,311,320</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zBRgEViXl0za" style="text-align: right" title="Value (per share)">1.16</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ScheduleOfValuationOfWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Valuation Of Warrants [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ScheduleOfValuationOfWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ScheduleOfWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrants outstanding [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ScheduleOfWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861202113248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEEMABLE NON-CONTROLLING INTEREST (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DisclosureRedeemableNoncontrollingInterestAbstract', window );"><strong>Redeemable Non-controlling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST</a></td>
<td class="text"><p id="xdx_897_eus-gaap--TemporaryEquityTableTextBlock_zpIqAAdWohPh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the reconciliation of changes in redeemable non-controlling interest:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zjoodKpMYtk6" style="display: none">SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_c20230101__20231231_z2KtOijK4HZ5" style="width: 16%; text-align: right" title="Beginning balance">885,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred dividends attributable to redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zjwjD9FtrCoi" style="text-align: right" title="Issuance of redeemable noncontrolling Series C preferred stock">19,041</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accretion of embedded derivative and transaction costs associated with Akos Series A Preferred Stock to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zVgFPFbJN1yh" style="text-align: right" title="Accretion of embedded derivative to redemption value">147,988</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Redemption of Akos Series A Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_iN_di_c20230101__20231231_z61deouwmhW3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Redemption of Akos Series A Preferred Stock">(1,052,057</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_c20230101__20231231_z2cCqG7L0c62" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1560">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DisclosureRedeemableNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DisclosureRedeemableNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861200216144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS</a></td>
<td class="text"><p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z7nYIEKnfDSb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides the financial liabilities measured on a recurring basis and reported at fair value on the balance sheet as of
December 31, 2023 and 2022, and indicates the fair value of the valuation inputs the Company utilized to determine such fair value of
warrant liabilities, derivative liability, and investment options:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_zv5Cq3TrTwbh" style="display: none">SCHEDULE
OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zwa6pMcie7mj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_ztyBGagJWl2d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zluQ4KiXC6C8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Warrant liabilities - January 2021 Warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">81</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zbxFjRea6mu7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrant liabilities - February 2021 Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdwlc80Umupj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrant liabilities - February 2022 Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">185,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zsQK5dRZG5R2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of warrant liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">185,215</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zBIbM8e99NVb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_z7y8UeEVWOR7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zqJ0MJeu0Ymi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; padding-bottom: 1.5pt">Derivative liability - May 2022</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 10%; text-align: center">3</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1582">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">727,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zR1tqPhaDMu9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of derivative liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1585">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">727,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231_z7T84h3p4yAc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zY86vTWnoNeh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_znMNJ66bvtl9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Wainwright investment options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">23,608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">44,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zeZJIMkg8nk6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">RD investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1591">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">302,289</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zOFVpVS8Jrzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">PIPE investment options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1594">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">503,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdfcDlytmmXj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of investment option liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,608</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">851,008</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--InitialMeasurementMember_z1QM2DVjkmSk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the warrant liabilities are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BA_zyGP5uMpiwf9" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 2022 Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 2022 Post-Modification Warrants (See Note 7)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February 15, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zkRE5qfbxQV" title="Warrants term">5.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_ztVxTxKwnXvb" title="Warrants term">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zg4vc6tNjoU6" style="text-align: right" title="Warrants, stock price">15.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zUD00iEXtF7c" style="text-align: right" title="Warrants, stock price">6.33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMKqRGglU068" style="text-align: right" title="Warrants, exercise price">27.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKSgY0wy0iyh" style="text-align: right" title="Warrants, exercise price">7.78</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVyprhikOUP2" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1614">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zFsXu3HGkuPe" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1616">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zcJF7D6miHg7" title="Warrants, measurement input">74.1</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zXulwjEnomb2" title="Warrants, measurement input">80.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zDHnLKF0SByk" title="Warrants, measurement input">1.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_znzQkLQw96rk" title="Warrants, measurement input">2.9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z4cDZMXOyqyk" style="text-align: right" title="Warrants, number of warrants">460,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zw9U56dyLJU3" style="text-align: right" title="Warrants, number of warrants">122,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zSrYFRvG1GD9" style="text-align: right" title="Value (per share)">8.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zc94NSTnQNmh" style="text-align: right" title="Value (per share)">4.07</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its derivative liability at the respective date of issuance. The Company used a Weighted
Expected Return valuation model in order to determine their value. The key inputs into the Weighted Expected Return valuation model for
the initial valuations of the warrant liabilities are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">May 2022 Derivative Liability</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">May 5, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%">Principal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ConvertiblePreferredStockPrincipalValue_iI_pid_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zA97NpTGuk22" style="width: 23%; text-align: right" title="Principal">1,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMajfNXiCdV7" style="text-align: right" title="Dividend rate">5.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Market rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketRateMember_zwinaaQECZ11" style="text-align: right" title="Market rate">4.4</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its investment options at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the investment options are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Wainwright Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">RD Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">PIPE Options</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zRRpPgv5agTj" title="Investment option term">5.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zdhDz6mJGNJ" title="Investment option term">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zfSptC7W7KEg" title="Investment option term">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zPlSJf5eL0A6" style="text-align: right" title="Investment, stock price">6.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zqYpSozvjjQ8" style="text-align: right" title="Investment, stock price">6.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zDLPZtQBQ3f2" style="text-align: right" title="Investment, stock price">6.33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYWvEhjRG27a" style="text-align: right" title="Investment, exercise price">10.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zidSfPnMN3kc" style="text-align: right" title="Investment, exercise price">7.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z4ui6DjkSRej" style="text-align: right" title="Investment, exercise price">7.78</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zQ8wA9rqzTjb" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1658">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zO3qrym8KSpa" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1660">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvzToWtaoU02" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1662">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_ziabNgPIphZ3" title="Investment, measurement input">80.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zofjONCNkiQb" title="Investment, measurement input">80.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvIEEezFwTO9" title="Investment, measurement input">80.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z0rmtJQWmDCi" title="Investment, measurement input">2.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zKeYY8MkDdMi" title="Investment, measurement input">2.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z9Fo5tlv9cUh" title="Investment, measurement input">2.9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Number of investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYbQQoJTqgg2" style="text-align: right" title="Number of investment options">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zwzPQkiN0jy2" style="text-align: right" title="Number of investment options">375,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFk1flldufk" style="text-align: right" title="Number of investment options">625,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zwdNPoSCez9h" style="text-align: right" title="Value (per share)">3.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zCIxDRegUmw8" style="text-align: right" title="Value (per share)">4.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFdwm4V6zmKk" style="text-align: right" title="Value (per share)">4.07</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zVmNi2ZEtwR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the warrant liabilities as of December 31, 2023 are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B0_zGwJ3NUryGMb" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 2021 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February 2021 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February 2022 Warrants Unmodified</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_z6UybGHOxEm9" title="Warrants term">2.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z8aHZ5nk0zCe" title="Warrants term">2.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zUoJTl1pinb3" title="Warrants term">3.1</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z5f7OPJrG5A" style="text-align: right" title="Warrant measurement input">1.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z43IGWEMy7mi" style="text-align: right" title="Warrant measurement input">1.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPFDp0gpvu1f" style="text-align: right" title="Warrant measurement input">1.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zzQ4UuJKdZN" style="text-align: right" title="Warrant measurement input">247.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zh3valY73Qz2" style="text-align: right" title="Warrant measurement input">245.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zI70P4KFepEe" style="text-align: right" title="Warrant measurement input">27.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zXom3SuDcJeh" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1752">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmrl5hHMBCm2" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1754">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zrAdZu39f75a" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1756">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zGbl4bmvxqsh" style="text-align: right" title="Warrants, measurement input">89.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUtVZGZgnQkc" style="text-align: right" title="Warrants, measurement input">88.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUdeTyuL8oac" style="text-align: right" title="Warrants, measurement input">87.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVAXZdk6d31h" style="text-align: right" title="Warrants, measurement input">4.20</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zXrUSp9jZPD9" style="text-align: right" title="Warrants, measurement input">4.20</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMV40M3mGbVf" style="text-align: right" title="Warrants, measurement input">4.00</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zn6PP51bQ6m" style="text-align: right" title="Warrants, number of warrants">36,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z5JR5WBgvpN8" style="text-align: right" title="Warrants, number of warrants">34,281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z7TkfR5O3yy9" style="text-align: right" title="Warrants, number of warrants">338,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zOg7y7IDF7R5" style="text-align: right" title="Value (per share)">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_zAR75z9wv3J9" style="text-align: right" title="Value (per share)">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zeqE92vGMb9d" style="text-align: right" title="Value (per share)">0.08</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the investment options as of December 31, 2023 are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">H.C. Wainwright &amp; Co., LLC Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zoMuNWVyzAm" title="Investment option term">3.6</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zUboA7OQUpLa" style="text-align: right" title="Investment, stock price">1.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--StockOptionExercisePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zgo6KhIG3Ijf" style="text-align: right" title="Investment, exercise price">10.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zN9N15RArLo6" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1788">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zA3LphOX94wg" title="Investment, measurement input">94.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zOhw3RzTphsk" title="Investment, measurement input">4.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Number of investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2nEB216o2a" style="text-align: right" title="Number of investment options">70,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zucFVItplnkl" style="text-align: right" title="Value (per share)">0.34</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zyPosEMl6298" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of the warrant liabilities, derivative liability, and investment options that are
classified as Level 3:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zf0YvucZm167" style="display: none">SCHEDULE
OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Warrant Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%">Fair value as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfWR0eRZvVP5" style="width: 23%; text-align: right" title="Total beginning balance">653,674</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of February 2022 warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXGaIgmvYyJi" style="text-align: right" title="Issuance of equity">3,595,420</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value due to modification of February 2022 warrants as part of July 2022 raise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFIntmBPaxCj" style="text-align: right" title="Change in fair value, modification">251,357</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE0CYMPIHUj4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(4,315,236</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfghil2mtthe" style="text-align: right" title="Total beginning balance">185,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkAmp56BB0z3" style="text-align: right" title="Change in fair value">(94,396</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercise of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDN8OycYqdhb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise of warrants">(65,349</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zme9nFXE8ezh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total beginning balance">25,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Derivative Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Fair value as of December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFGDcN74hZH" style="padding-bottom: 1.5pt; text-align: right" title="Total beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1706">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 73%; text-align: left; padding-bottom: 1.5pt">Issuance of May 2022 convertible preferred stock</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPpeS4e84xo4" style="padding-bottom: 1.5pt; width: 23%; text-align: right" title="Issuance of equity">402,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSM8F2xaqSZb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">325,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaWdjbixGpx4" style="text-align: right" title="Total beginning balance">727,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value arising from redemption of Akos Series A Preferred Stock - See Note 8</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEhyNzluaeM9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(727,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of derivative liability as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqz7o8NCcsD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1716">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Investment Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkafZlF2mmd8" style="text-align: right" title="Total beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1718">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 73%">Issuance of July 2022 investment options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJCC3dQ45BP1" style="width: 23%; text-align: right" title="Issuance of equity">4,323,734</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAP0ZMaOKtx2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(3,472,726</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsspxHsvJgQ5" style="text-align: right" title="Total beginning balance">851,008</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2wRFtIor8lj" style="text-align: right" title="Change in fair value">(208,752</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise of investment options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmmwHeZhV8Fi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise of investment options">(618,648</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair value of investment option liability as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwfYpkEyGifd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance">23,608</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ENVB_InitialMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861103684880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock', window );">SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_zcSidS9fkSDb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average remaining lease term and the weighted-average discount rate of the lease was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zQfu0TOu6lia" style="display: none">SCHEDULE OF WEIGHTED
AVERAGE REMAINING LEASE TERM</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Remaining lease term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; text-align: left">Operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231_zuiWJW2cO47k" title="Operating leases remaining lease term">0.6</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20221231_zk4ki5oTON06" title="Operating lease discount rate">12.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Weighted Average Remaining Lease Term [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861106159584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYpFlmqCGSD2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s U.S. and foreign loss before income taxes are set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zeA4xpukjyji" style="display: none">SCHEDULE OF EARNING (LOSS) BEFORE INCOME
TAX</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zxZNk46ZRzng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231_zijVKXfD02T1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzlef_z9MaFVvNgvr6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(10,205,116</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,251,228</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzlef_zE8rf8karcM4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,057,703</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,706,165</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_mtILFCOzlef_z2B2dgbOYfy4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,262,819</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(19,957,393</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF INCOME TAX EXPENSE BENEFITS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zBdQk1cD3aIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_z4LFMffO1bGa" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE BENEFITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231_zXpnWXEk0Qnd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zktAaySoCScj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Current:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_iN_di_maCITEBzYcv_zswZcV5nkVg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1853">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1854">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maCITEBzYcv_zAEkzY61kyi6" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(28,913</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1857">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maCITEBzYcv_zBO2f4fpNnae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1859">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1860">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iNT_di_mtCITEBzYcv_maITEBzKnh_zBI0YA4EbLMh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total
    current income tax (expense) benefit</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,913</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1863">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zO46stlDOwwa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1865">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1866">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_z7PzV6xiY5vd" style="vertical-align: bottom; background-color: White">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1868">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1869">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zXxtOtSLhIsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1871">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,486,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDFITEzdpW_maITEBzKnh_zXY6vb4G9k2j" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred income tax (expense) benefit</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,486,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzKnh_z5f9VHGVH2Ya" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total income tax (expense) benefit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(28,913</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,486,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFSERvZE8hD1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s deferred tax assets and deferred tax liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B9_zVn0082ZSHDi" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zXa1FmWtibt5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zwvxf2F8NBJ1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNdz_maDTANzxkL_zMNkEZsyD8Wf" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">10,889,863</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,927,330</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzxkL_zg5Rc6Cqe1F8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,185,399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,348,928</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ResearchAndDevelopmentCapitalizedExpenses_iI_maDTANzxkL_z756cbDpyv1k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development capitalized expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">611,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">614,041</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsAndIntangibleAmortization_iI_maDTANzxkL_zrt11foR7jeg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,141</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOther_iI_maDTANzxkL_zLfR2vCU52Pd" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,453</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzXjO_msDTANzxkL_zMfzrABlkFk8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,837,755</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,977,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzxkL_zeNN2eU460z" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1900">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1901">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">SCHEDULE OF OPERATING LOSS CARRY FORWARDS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zs9bhRynYJsl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially utilizable net operating loss tax carryforwards:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zt3NjQUFsfF" style="display: none">SCHEDULE
OF OPERATING LOSS CARRY FORWARDS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zulmzGTSNdN8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zZqWm1R4dBi8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zQU8ncu82Cef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">24,268,692</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18,349,753</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zI0OIVbJPSr6" style="vertical-align: bottom; background-color: White">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,220,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,892,754</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zzjfJ55ZT1Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Foreign</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,672,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,377,435</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zSAitNKZZYjl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net operating loss tax carryforwards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,672,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,377,435</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzVMVNGeNJec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s effective tax rate varied from the statutory rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_z6qq60Xq2gJ2" style="display: none">SCHEDULE
OF EFFECTIVE STATUTORY INCOME TAX RATE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zcnUsjwkXjAj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_z6WLN5u7FCy" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maALCzr1A_zmTBblmRYrR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Federal income tax at the statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 3%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 3%; text-align: left">)%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maALCzr1A_zYGRPLUj28i3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax rate (net of federal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.6</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maALCzr1A_z9kt9Ydnzk1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign tax rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.1</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_pid_dp_uPure_maALCzr1A_zTghWy4U2b78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4.0</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueup_pid_dp_uPure_maALCzr1A_zw7LHgBY8Yg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1937">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maALCzr1A_ztmgY4wYYHoh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtALCzr1A_zWrMtwwBJC36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effective income tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861104503744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring cost payable, beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RestructuringCostsIncurred', window );">Restructuring costs incurred</a></td>
<td class="nump">1,004,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="num">(572,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Restructuring costs reversed</a></td>
<td class="num">(129,760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring cost payable, ending</a></td>
<td class="nump">$ 301,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RestructuringCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RestructuringCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861106234480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2023</div></th>
<th class="th"><div>Jun. 16, 2023</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,499,518<span></span>
</td>
<td class="nump">$ 79,207,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,094,411<span></span>
</td>
<td class="nump">17,146,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,448,440<span></span>
</td>
<td class="nump">27,415,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,287,977<span></span>
</td>
<td class="nump">$ 17,723,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants for cash proceeds</a></td>
<td class="nump">$ 280,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 453,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reversed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange', window );">Minimum of stockholders equity required for continued listing pursuant to exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_MarketPerformanceBasedShares', window );">Market performance based shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants for cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,817,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Exercise of warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,954,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_EquityDistributionAgreementMember', window );">Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Additional working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_KanubaddiSeparationAgreementMember', window );">Kanubaddi Separation Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Performance bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_MrKanubaddiEmploymentAgreementMember', window );">Mr Kanubaddi Employment Agreement [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ExpenseRelatedToAccelerationOfVesting', window );">Expense related to acceleration of vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ExpenseRelatedToAccelerationOfVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense related to acceleration of vesting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ExpenseRelatedToAccelerationOfVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_MarketPerformanceBasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market performance based shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_MarketPerformanceBasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum of stockholders equity required for continued listing pursuant to exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_KanubaddiSeparationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_KanubaddiSeparationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_MrKanubaddiEmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_MrKanubaddiEmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861106136816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">3,764,881<span></span>
</td>
<td class="nump">1,901,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants to Purchase Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">2,799,213<span></span>
</td>
<td class="nump">655,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockUnitsVestedAndUnIssuedMember', window );">Restricted Stock Units Vested and Unissued [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">20,848<span></span>
</td>
<td class="nump">62,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockUnitsUnvestedMember', window );">Restricted Stock Units Unvested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">140,491<span></span>
</td>
<td class="nump">64,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockAwardsVestedAndUnIssuedMember', window );">Restricted Stock Awards Vested and Unissued [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_CommonStockInAbeyanceMember', window );">Common stock in abeyance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">704,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember', window );">Investment Options to Purchase Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">1,070,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_OptionsToPurchaseSharesOfCommonStockMember', window );">Options to Purchase Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">30,329<span></span>
</td>
<td class="nump">48,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockUnitsVestedAndUnIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockUnitsVestedAndUnIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockUnitsUnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockUnitsUnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockAwardsVestedAndUnIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockAwardsVestedAndUnIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_CommonStockInAbeyanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_CommonStockInAbeyanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_OptionsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_OptionsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861201758896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 567,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENVB_PrefundedCommonStockWarrantsMember', window );">Prefunded Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Stock and warrants issued</a></td>
<td class="nump">$ 767,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">AUSTRALIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ENVB_PrefundedCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ENVB_PrefundedCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861105588480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">$ 46,320<span></span>
</td>
<td class="nump">$ 268,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid value-added taxes</a></td>
<td class="nump">243,429<span></span>
</td>
<td class="nump">159,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">149,559<span></span>
</td>
<td class="nump">174,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">62,036<span></span>
</td>
<td class="nump">105,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">567,603<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PrepaidFranchiseTaxReceivable', window );">Franchise tax receivable</a></td>
<td class="nump">79,258<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable', window );">R&amp;D tax incentive receivable</a></td>
<td class="nump">145,349<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,293,554<span></span>
</td>
<td class="nump">$ 708,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PrepaidFranchiseTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid franchise tax receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PrepaidFranchiseTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development tax incentive receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861105770608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF GOODWILL (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill Gross, Beginning balance</a></td>
<td class="nump">$ 9,834,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated Impairment Losses, Beginning balance</a></td>
<td class="num">(8,225,862)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillCurrencyTranslation', window );">Currency Translation, Beginning balance</a></td>
<td class="num">(21,359)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning balance</a></td>
<td class="nump">1,587,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillImpairmentLossGross', window );">Goodwill Gross, Impairment losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillAccumulatedImpairmentLoss', window );">Accumulated Impairment Losses, Impairment losses</a></td>
<td class="num">(1,486,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillCurrencyTranslationImpairmentLoss', window );">Currency Translation, Impairment losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment losses</a></td>
<td class="num">(1,486,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillForeignCurrencyTranslationGainLossGross', window );">Goodwill Gross, Loss on currency translation</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss', window );">Accumulated Impairment Losses, Loss on currency translation</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillCurrencyTranslationLoss', window );">Currency Translation, Loss on currency translation</a></td>
<td class="num">(101,574)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Goodwill, Loss on currency translation</a></td>
<td class="num">(101,574)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill Gross, Ending balance</a></td>
<td class="nump">9,834,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated Impairment Losses, Ending balance</a></td>
<td class="num">(9,711,922)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillCurrencyTranslation', window );">Currency Translation, Ending balance</a></td>
<td class="num">(122,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill accumulated impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill accumulated impairment loss foreign currency translation gain loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillCurrencyTranslationImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill currency translation impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillCurrencyTranslationImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillCurrencyTranslationLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill currency translation loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillCurrencyTranslationLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillForeignCurrencyTranslationGainLossGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill foreign currency translation gain loss gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillForeignCurrencyTranslationGainLossGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillImpairmentLossGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill impairment loss gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillImpairmentLossGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861106973792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Balance, Indefinite lived intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,375,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,967,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Loss on currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(407,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Balance, Indefinite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Balance, Definite lived intangible assets</a></td>
<td class="nump">379,686<span></span>
</td>
<td class="nump">548,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(168,754)<span></span>
</td>
<td class="num">(168,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Balance, Definite lived intangible assets</a></td>
<td class="nump">$ 210,932<span></span>
</td>
<td class="nump">$ 379,686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861104754688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 168,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">42,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived assets amortization expense</a></td>
<td class="nump">$ 210,932<span></span>
</td>
<td class="nump">$ 379,686<span></span>
</td>
<td class="nump">$ 548,436<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861106297936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets, amortization expense</a></td>
<td class="nump">$ 168,754<span></span>
</td>
<td class="nump">$ 168,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861107170368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">$ (357,711)<span></span>
</td>
<td class="num">$ (178,775)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">507,377<span></span>
</td>
<td class="nump">677,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Computer equipment and leasehold improvements</a></td>
<td class="nump">836,709<span></span>
</td>
<td class="nump">831,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_ComputerEquipmentAndLeaseholdImprovementsMember', window );">Computer Equipment and Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Computer equipment and leasehold improvements</a></td>
<td class="nump">$ 28,379<span></span>
</td>
<td class="nump">$ 25,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_ComputerEquipmentAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_ComputerEquipmentAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861105928608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 175,228<span></span>
</td>
<td class="nump">$ 159,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861105804784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccruedProductDevelopmentCost', window );">Product development</a></td>
<td class="nump">$ 139,981<span></span>
</td>
<td class="nump">$ 195,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries, wages, and bonuses</a></td>
<td class="nump">8,889<span></span>
</td>
<td class="nump">1,175,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">584,810<span></span>
</td>
<td class="nump">83,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccruedRestructuringCosts', window );">Accrued restructuring costs</a></td>
<td class="nump">301,645<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued franchise taxes</a></td>
<td class="nump">22,318<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Patent costs</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">251,333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 1,075,643<span></span>
</td>
<td class="nump">$ 1,705,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_AccruedProductDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued product and development cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_AccruedProductDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_AccruedRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_AccruedRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861206602256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding at beginning</a></td>
<td class="nump">48,329<span></span>
</td>
<td class="nump">23,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning</a></td>
<td class="nump">$ 37.05<span></span>
</td>
<td class="nump">$ 79.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding at beginning</a></td>
<td class="nump">$ 44.82<span></span>
</td>
<td class="nump">$ 103.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding balance</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, forfeited</a></td>
<td class="num">(18,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited</a></td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 175.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited</a></td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="nump">$ 140.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding at end</a></td>
<td class="nump">30,329<span></span>
</td>
<td class="nump">48,329<span></span>
</td>
<td class="nump">23,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at end</a></td>
<td class="nump">$ 57.17<span></span>
</td>
<td class="nump">$ 37.05<span></span>
</td>
<td class="nump">$ 79.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding at end</a></td>
<td class="nump">$ 77.22<span></span>
</td>
<td class="nump">$ 44.82<span></span>
</td>
<td class="nump">$ 103.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable shares at end</a></td>
<td class="nump">25,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable weighted average price at end</a></td>
<td class="nump">$ 64.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, exercisable</a></td>
<td class="nump">$ 88.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value, exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value, expired, forfeited, or cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value, outstanding at beginning of the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861104754688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ASSUMPTION (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice', window );">Stock price</a></td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">112.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions stock price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861110545088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Non-vested beginning</a></td>
<td class="nump">64,053<span></span>
</td>
<td class="nump">62,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Non-vested beginning</a></td>
<td class="nump">$ 92.57<span></span>
</td>
<td class="nump">$ 126.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="nump">182,500<span></span>
</td>
<td class="nump">37,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Granted</a></td>
<td class="nump">$ 2.73<span></span>
</td>
<td class="nump">$ 33.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Forfeited</a></td>
<td class="num">(43,426)<span></span>
</td>
<td class="num">(26,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Forfeited</a></td>
<td class="nump">$ 25.72<span></span>
</td>
<td class="nump">$ 79.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, vested</a></td>
<td class="num">(62,636)<span></span>
</td>
<td class="num">(8,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Vested</a></td>
<td class="nump">$ 19.80<span></span>
</td>
<td class="nump">$ 130.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, non-vested ending</a></td>
<td class="nump">140,491<span></span>
</td>
<td class="nump">64,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Non-vested ending</a></td>
<td class="nump">$ 28.97<span></span>
</td>
<td class="nump">$ 92.57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861107339392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense for RSUs</a></td>
<td class="nump">$ 1,994,085<span></span>
</td>
<td class="nump">$ 2,416,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense for RSUs</a></td>
<td class="nump">1,085,791<span></span>
</td>
<td class="nump">1,389,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense for RSUs</a></td>
<td class="nump">$ 908,294<span></span>
</td>
<td class="nump">$ 1,026,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861200023008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS OUTSTANDING (Details) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at beginning</a></td>
<td class="nump">655,463<span></span>
</td>
<td class="nump">195,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise Price, Outstanding at beginning</a></td>
<td class="nump">$ 58.36<span></span>
</td>
<td class="nump">$ 131.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average remaining life, Outstanding</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic Value, Outstanding beginning</a></td>
<td class="nump">$ 5,514<span></span>
</td>
<td class="nump">$ 801,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued', window );">Warrant shares outstanding, Issued</a></td>
<td class="nump">2,311,320<span></span>
</td>
<td class="nump">1,227,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice', window );">Weighted average exercise price, Issued</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="nump">$ 10.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrant shares outstanding, Exercised</a></td>
<td class="num">(122,000)<span></span>
</td>
<td class="num">(767,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged', window );">Exchanged for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Warrant shares outstanding, Forfeited</a></td>
<td class="num">(45,570)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">$ 111.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at end</a></td>
<td class="nump">2,799,213<span></span>
</td>
<td class="nump">655,463<span></span>
</td>
<td class="nump">195,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise Price, Outstanding at end</a></td>
<td class="nump">$ 11.79<span></span>
</td>
<td class="nump">$ 58.36<span></span>
</td>
<td class="nump">$ 131.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber', window );">Warrant shares outstanding, Exercisable</a></td>
<td class="nump">2,799,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 11.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption', window );">Weighted average remaining life, Exercisable</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic Value, Outstanding end</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,514<span></span>
</td>
<td class="nump">$ 801,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exchanged.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant shares outstanding, issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their warrants into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options forfeited in eriod weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Non Option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861199972992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details) - Investment Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at beginning</a></td>
<td class="nump">1,070,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1', window );">Weighted average exercise price, Outstanding beginning</a></td>
<td class="nump">$ 7.93<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic Value, Outstanding beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued', window );">Investment options outstanding, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,070,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice', window );">Weighted average exercise price, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average remaining life, Outstanding</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Investment options outstanding, Exercised</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at end</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">1,070,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1', window );">Weighted average exercise price, Outstanding end</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 7.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic Value, Outstanding end</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber', window );">Warrant shares outstanding, Exercisable</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption', window );">Weighted average remaining life, Exercisable</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1', window );">Intrinsic value, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant shares outstanding, issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments issued in period weighted average exercise price exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock options, outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Non Options Exercisable Intrinsic Value1,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Non Option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENVB_InvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENVB_InvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861106985888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_RothAndInducementWarrantsMember', window );">Roth And Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice', window );">Stock price</a></td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, number of warrants</a></td>
<td class="nump">2,311,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions stock price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_RothAndInducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_RothAndInducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861082340528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 28, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 03, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 01, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 26, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 22, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 14, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 03, 2022</div></th>
<th class="th">
<div>Feb. 15, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 21, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 02, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 14, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
holders of the Company&#8217;s common stock are entitled to one vote per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 567,603<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,222,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from inducement warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Incentive plan description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) increase the aggregate number of shares available
for the grant of awards by 146,083 shares to a total of 200,000 shares, and (ii) add an &#8220;evergreen&#8221; provision whereby the
number of shares authorized for issuance pursuant to awards under the Incentive Plan will be automatically increased on the first trading
date immediately following the date the Company issues any share of common stock (defined below) to any person or entity, to the extent
necessary so that the number of shares of the Company&#8217;s common stock authorized for issuance under the Incentive Plan will equal
the greater of (x) 200,000 shares, and (y) 15% of the total number of shares of the Company&#8217;s common stock outstanding as of such
issuance date (the &#8220;Evergreen Provision&#8221;). The Plan Amendment was approved by the Company&#8217;s shareholders at a special
meeting of the Company&#8217;s shareholders held on July 14, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation, expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,994,085<span></span>
</td>
<td class="nump">2,416,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offerings costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 291,084<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ClassOfWarrantOrRightReasonForIssuing', window );">Warrant issued description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Company engaged Roth Capital Partners, LLC (&#8220;Roth&#8221;) to act as its financial advisor in connection with the transactions
summarized above and will pay Roth approximately $144,000 for its services, in addition to reimbursement for certain expenses. Roth
was also issued warrants to purchase up to 67,320 shares of common stock. The Roth Warrants have the same terms as the Inducement
Warrants. The grant date fair value of these Roth Warrants was estimated to be $77,991 on December 28, 2023 and were charged to
additional paid in capital as issuance costs. The Company also incurred legal fees of $17,254 related to the transactions above that
were charged to additional paid in capital as issuance costs.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,599,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 714,000<span></span>
</td>
<td class="num">$ (94,396)<span></span>
</td>
<td class="num">(4,315,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from inducement warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,817,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryWarrantsMember', window );">February Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from inducement warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PreModificationWarrantsMember', window );">Pre-Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Warrants outstanding, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionSharePrice', window );">Share price | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionTerm', window );">Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharePriceOption', window );">Investment outstanding, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PreModificationWarrantsMember', window );">Pre-Modification Warrants [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOutstandingMeasurementInput', window );">Investment outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PreModificationWarrantsMember', window );">Pre-Modification Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOutstandingMeasurementInput', window );">Investment outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PreModificationWarrantsMember', window );">Pre-Modification Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOutstandingMeasurementInput', window );">Investment outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PostModificationWarrantsMember', window );">Post-Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentIntrinsicValue', window );">Intrinsic value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentInducementGain', window );">Inducement gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | February Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | February Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation, expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,075<span></span>
</td>
<td class="nump">180,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock-based compensation, unamortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation, expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">24,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Common stock vested restricted stock units | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid', window );">Unissued shares for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_NumberOfVestedAndUnissuedShares', window );">Number of vested and unissued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation, expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,994,085<span></span>
</td>
<td class="nump">$ 2,416,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock-based compensation, unamortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,021,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Common stock vested restricted stock units | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,636<span></span>
</td>
<td class="nump">8,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENVB_ExistingWarrantsMember', window );">Existing Warrants [Member] | Pre-Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENVB_ExistingWarrantsMember', window );">Existing Warrants [Member] | Post-Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENVB_InvestmentOptionsMember', window );">Investment Options [Member] | Pre-Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 618,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENVB_InvestmentOptionsMember', window );">Investment Options [Member] | Post-Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ENVB_TwoThousandTwentyLongTermIncentivePlanMember', window );">2020 Long Term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares reserved | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available ofr grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ENVB_RDOfferingAndPIPEInvestmentOptionsMember', window );">RD Offering and Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from RD offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PaymentsOfStockIssuanceCost', window );">Offerings costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PaymentsOfAllocatedEquity', window );">Payments of allocated equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PaymentsOfInvestmentOptionLiability', window );">Payments of investment option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PaymentsOfStockIssuanceCostsRecordedExpense', window );">Payments of stock issuance costs recorded expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offerings costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 251,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series
C Preferred Stock was entitled to receive $0.10 in cash for each 10 whole shares of Series C Preferred Stock immediately prior to the
Redemption. As of June 30, 2022, there were<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable preferred stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,684.548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance', window );">Preferred Stock authorized for future issuances | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ENVB_UnderwritersMember', window );">Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercised of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantLiability', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from inducement warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Issuance of common shares in exchange for RSU conversions, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards', window );">Stock issued during period conversion of restricted stock award | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,739,315<span></span>
</td>
<td class="nump">2,078,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="nump">704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock | shares</a></td>
<td class="nump">1,954,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,954,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Common stock vested restricted stock units | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights', window );">Purchase of additional warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ENVB_PlacementAgentPreferredInvestmentOptionsMember', window );">Placement Agent Preferred Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember', window );">Distribution Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Common stock, offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,392,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,320,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,668,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember', window );">Distribution Agreement [Member] | Canaccord Genuity LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Common stock, offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation', window );">Aggregate gross sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,392,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_CommissionPercentage', window );">Commission percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_RegistrationRightsAgreementMember', window );">Registration Rights Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase committment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember', window );">Registered Direct Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from inducement warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_PIPESecuritiesPurchaseAgreementMember', window );">PIPE Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">509,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from inducement warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_WarrantAmendmentAgreementsMember', window );">Wainwright Amendment Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="nump">$ 27.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of additional securities called by warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ClassOfWarrantOrRightReasonForIssuing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant issued description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ClassOfWarrantOrRightReasonForIssuing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_CommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_CommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentInducementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment inducement gain.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentInducementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment option exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentOptionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment option share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentOptionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment option term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment outstanding measurement input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_NumberOfVestedAndUnissuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vested and unissued shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_NumberOfVestedAndUnissuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PaymentsOfAllocatedEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of allocated equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PaymentsOfAllocatedEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PaymentsOfInvestmentOptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of investment option liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PaymentsOfInvestmentOptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PaymentsOfStockIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of stock issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PaymentsOfStockIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PaymentsOfStockIssuanceCostsRecordedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of stock issuance costs recorded expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PaymentsOfStockIssuanceCostsRecordedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration expected maximum price on limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharePriceOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharePriceOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share warrants (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of nonredeemable preferred shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid to settle liability for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PreModificationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_PreModificationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PostModificationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_PostModificationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ENVB_ExistingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ENVB_ExistingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ENVB_InvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ENVB_InvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ENVB_TwoThousandTwentyLongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ENVB_TwoThousandTwentyLongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_RDOfferingAndPIPEInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_RDOfferingAndPIPEInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ENVB_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ENVB_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENVB_PlacementAgentPreferredInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENVB_PlacementAgentPreferredInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ENVB_CanaccordGenuityLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ENVB_CanaccordGenuityLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_RegistrationRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_RegistrationRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_PIPESecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_PIPESecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_WarrantAmendmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_WarrantAmendmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861102793360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DisclosureRedeemableNoncontrollingInterestAbstract', window );"><strong>Redeemable Non-controlling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance</a></td>
<td class="nump">$ 885,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of redeemable noncontrolling Series C preferred stock</a></td>
<td class="nump">19,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of embedded derivative to redemption value</a></td>
<td class="nump">147,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock', window );">Redemption of Akos Series A Preferred Stock</a></td>
<td class="num">(1,052,057)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 885,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DisclosureRedeemableNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DisclosureRedeemableNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for reacquisition of callable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 14<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 15<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861104281648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2023</div></th>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liability</a></td>
<td class="nump">$ 2,599,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 714,000<span></span>
</td>
<td class="num">$ (94,396)<span></span>
</td>
<td class="num">$ (4,315,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 885,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_UnpaidDividends', window );">Unpaid dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNoncontrollingInterest', window );">Redeemable noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,052,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_AkosSecuritiesPurchaseAgreementMember', window );">Akos Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SpinoffAndRelatedPrivatePlacementDescription', window );">Spin-off and related private placement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the Akos Purchase Agreement, Akos had agreed to pay Palladium a fee equal to 9% of the aggregate
gross proceeds raised from the sale of the shares of the Akos Series A Preferred Stock and a non-accountable expense allowance of 1%
of the aggregate gross proceeds raised the sale of the Akos Series A Preferred Stock in the Akos Private Placement. The fee due in connection
with the Akos Private Placement to be paid to Palladium in the form of convertible preferred stock and warrants was on similar terms
to the securities issued in the Akos Private Placement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsToPurchaseCommonStockPercentage', window );">Warrants to purchase common stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_AkosSecuritiesPurchaseAgreementMember', window );">Akos Securities Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_AkosSecuritiesPurchaseAgreementMember', window );">Akos Securities Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_AkosSecuritiesPurchaseAgreementMember', window );">Akos Securities Purchase Agreement [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_SecuritiesPurchaseAgreementMember', window );">Securities purchase agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_SecuritiesPurchaseAgreementMember', window );">Securities purchase agreement [Member] | Series A Preferred Stock [Member] | Akos [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable non controlling interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SpinoffAndRelatedPrivatePlacementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Spinoff and related private placement, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SpinoffAndRelatedPrivatePlacementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_UnpaidDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_UnpaidDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantsToPurchaseCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase common stock percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantsToPurchaseCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 14<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 15<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_AkosSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_AkosSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ENVB_AkosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ENVB_AkosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861105220224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details) - Fair Value, Inputs, Level 3 [Member] - Fair Value, Recurring [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of warrant liability</a></td>
<td class="nump">$ 25,470<span></span>
</td>
<td class="nump">$ 185,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">727,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure', window );">Fair value of investment option liability</a></td>
<td class="nump">23,608<span></span>
</td>
<td class="nump">851,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Derivative Liability May 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">727,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Wainwright Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure', window );">Fair value of investment option liability</a></td>
<td class="nump">23,608<span></span>
</td>
<td class="nump">44,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">RD Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure', window );">Fair value of investment option liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">302,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure', window );">Fair value of investment option liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">503,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember', window );">Warrant liabilities - January 2021 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of warrant liability</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember', window );">Warrant liabilities - February 2021 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of warrant liability</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember', window );">Warrant liabilities - February 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of warrant liability</a></td>
<td class="nump">$ 25,462<span></span>
</td>
<td class="nump">$ 185,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability related to investment contracts for example, but not limited to, guaranteed investment contract or annuities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479436/944-825-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_WainwrightInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_WainwrightInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_RDInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_RDInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_PIPEInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_PIPEInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861081017712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 26, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 05, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 15, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Derivative Liability May 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ConvertiblePreferredStockPrincipalValue', window );">Principal | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Wainwright Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionTerm', window );">Investment option term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of investment options | shares</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | RD Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionTerm', window );">Investment option term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of investment options | shares</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionTerm', window );">Investment option term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of investment options | shares</a></td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Share Price [Member] | Wainwright Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Investment, stock price</a></td>
<td class="nump">$ 6.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockOptionExercisePrice', window );">Investment, exercise price</a></td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Share Price [Member] | RD Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Investment, stock price</a></td>
<td class="nump">6.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockOptionExercisePrice', window );">Investment, exercise price</a></td>
<td class="nump">7.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Share Price [Member] | Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Investment, stock price</a></td>
<td class="nump">6.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockOptionExercisePrice', window );">Investment, exercise price</a></td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Expected Dividend Rate [Member] | Derivative Liability May 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Market rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Expected Dividend Rate [Member] | Wainwright Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Expected Dividend Rate [Member] | RD Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Expected Dividend Rate [Member] | Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Option Volatility [Member] | Wainwright Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Option Volatility [Member] | RD Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Option Volatility [Member] | Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Risk Free Interest Rate [Member] | Wainwright Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Risk Free Interest Rate [Member] | RD Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Risk Free Interest Rate [Member] | Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input Market Rate [Member] | Derivative Liability May 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Market rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, number of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsAndRightsOutstandingStockPrice', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Warrants [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Post-Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, number of warrants | shares</a></td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Post-Modification Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsAndRightsOutstandingStockPrice', window );">Warrant measurement input</a></td>
<td class="nump">6.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Post-Modification Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant measurement input</a></td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Post-Modification Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Post-Modification Warrants [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Post-Modification Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | HC Wainwright and Co LLC Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionTerm', window );">Investment option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of investment options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | Measurement Input, Share Price [Member] | HC Wainwright and Co LLC Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Investment, stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockOptionExercisePrice', window );">Investment, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | Measurement Input, Expected Dividend Rate [Member] | HC Wainwright and Co LLC Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | Measurement Input, Option Volatility [Member] | HC Wainwright and Co LLC Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | Measurement Input, Risk Free Interest Rate [Member] | HC Wainwright and Co LLC Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, number of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February 2022 Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsAndRightsOutstandingStockPrice', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February 2022 Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February 2022 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February 2022 Warrants [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February 2022 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January 2021 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, number of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January 2021 Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsAndRightsOutstandingStockPrice', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January 2021 Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January 2021 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January 2021 Warrants [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January 2021 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February 2021 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, number of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February 2021 Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsAndRightsOutstandingStockPrice', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February 2021 Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February 2021 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February 2021 Warrants [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February 2021 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ConvertiblePreferredStockPrincipalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock Principal Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ConvertiblePreferredStockPrincipalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment option term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantsAndRightsOutstandingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, stock price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantsAndRightsOutstandingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure direct or indirect retained investment in deconsolidated subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ENVB_InitialMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_WainwrightInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_WainwrightInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_RDInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_RDInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_PIPEInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_PIPEInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ENVB_MeasurementInputMarketRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ENVB_MeasurementInputMarketRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryTwentyTwentyTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryTwentyTwentyTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_JanuaryTwentyTwentyOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_JanuaryTwentyTwentyOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryTwentyTwentyOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryTwentyTwentyOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861199925760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Total beginning balance</a></td>
<td class="nump">$ 185,215<span></span>
</td>
<td class="nump">$ 653,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,595,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Change in fair value, modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(94,396)<span></span>
</td>
<td class="num">(4,315,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="num">(65,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Total ending balance</a></td>
<td class="nump">25,470<span></span>
</td>
<td class="nump">185,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Total beginning balance</a></td>
<td class="nump">727,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(727,000)<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Total ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">727,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Options Held [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Total beginning balance</a></td>
<td class="nump">851,008<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,323,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(208,752)<span></span>
</td>
<td class="num">(3,472,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Total ending balance</a></td>
<td class="nump">23,608<span></span>
</td>
<td class="nump">$ 851,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions', window );">Exercise of investment options</a></td>
<td class="num">$ (618,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability period exercise of investment options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability period exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861107111056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE (Details Narrative)<br></strong></div></th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Derivative liability fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480463/815-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861102983536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating leases remaining lease term</a></td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease discount rate</a></td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861107050928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 26, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>AUD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,252,437<span></span>
</td>
<td class="nump">$ 8,027,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Future cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,287,977<span></span>
</td>
<td class="nump">17,723,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,241<span></span>
</td>
<td class="nump">$ 120,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_VogalNathanPurchaseAgreementMember', window );">Vogal Nathan Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RoyaltiesPercentage', window );">Royalties percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for royalties</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_VogalNathanPurchaseAgreementMember', window );">Vogal Nathan Purchase Agreement [Member] | One Time Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term purchase commitment, amount</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_VogalNathanPurchaseAgreementMember', window );">Vogal Nathan Purchase Agreement [Member] | Additional Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term purchase commitment, amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_OtherConsultingAndVendorAgreementsMember', window );">Other Consulting and Vendor Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Future cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_AvanceClinicalMember', window );">Avance Clinical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionContractCostProgressPaymentOffset', window );">Payment of contract cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,036,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">523,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,751,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RoyaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RoyaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionContractCostProgressPaymentOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of progress payment netted against construction contract cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 20<br> -Topic 910<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482332/910-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionContractCostProgressPaymentOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_VogalNathanPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_VogalNathanPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ENVB_OneTimeMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ENVB_OneTimeMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ENVB_AdditionalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ENVB_AdditionalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_OtherConsultingAndVendorAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_OtherConsultingAndVendorAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_AvanceClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_AvanceClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861107263904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (10,205,116)<span></span>
</td>
<td class="num">$ (7,251,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(7,057,703)<span></span>
</td>
<td class="num">(12,706,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="num">$ (17,262,819)<span></span>
</td>
<td class="num">$ (19,957,393)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861107331824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(28,913)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax (expense) benefit</a></td>
<td class="num">(28,913)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,486,060<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax (expense) benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,486,060<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (expense) benefit</a></td>
<td class="num">$ (28,913)<span></span>
</td>
<td class="nump">$ 1,486,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861110626288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 10,889,863<span></span>
</td>
<td class="nump">$ 8,927,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,185,399<span></span>
</td>
<td class="nump">1,348,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ResearchAndDevelopmentCapitalizedExpenses', window );">Research and development capitalized expenses</a></td>
<td class="nump">611,245<span></span>
</td>
<td class="nump">614,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DeferredTaxAssetsAndIntangibleAmortization', window );">Intangible amortization</a></td>
<td class="nump">80,518<span></span>
</td>
<td class="nump">54,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">70,730<span></span>
</td>
<td class="nump">33,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowances</a></td>
<td class="num">(12,837,755)<span></span>
</td>
<td class="num">(10,977,893)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DeferredTaxAssetsAndIntangibleAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets and intangible amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DeferredTaxAssetsAndIntangibleAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ResearchAndDevelopmentCapitalizedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development capitalized expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ResearchAndDevelopmentCapitalizedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861106483136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss tax carryforwards</a></td>
<td class="nump">$ 24,268,692<span></span>
</td>
<td class="nump">$ 18,349,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss tax carryforwards</a></td>
<td class="nump">11,220,065<span></span>
</td>
<td class="nump">16,892,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss tax carryforwards</a></td>
<td class="nump">$ 17,672,420<span></span>
</td>
<td class="nump">$ 16,377,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861106504896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax at the statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax rate (net of federal)</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(2.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(3.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation', window );">Non-deductible expenses</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup', window );">Deferred true-up</a></td>
<td class="nump">13.20%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">10.80%<span></span>
</td>
<td class="nump">23.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(7.40%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation deferred trueup.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861107465088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses and benefits</a></td>
<td class="nump">$ 28,913<span></span>
</td>
<td class="num">$ (1,486,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses and benefits</a></td>
<td class="num">(28,913)<span></span>
</td>
<td class="nump">1,486,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">10,889,863<span></span>
</td>
<td class="nump">8,927,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="nump">1,859,862<span></span>
</td>
<td class="nump">4,429,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development expense gross</a></td>
<td class="nump">463,696<span></span>
</td>
<td class="nump">$ 2,684,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">24,268,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,220,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 17,672,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139861107066384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Feb. 11, 2022</div></th>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net Proceeds from sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 17,222,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="nump">228,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net Proceeds from sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,320,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,668,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,392,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Existing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,954,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net Proceeds from sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M8[;)BA73LD;SV>I[C1H?-*(30Y8G2E)[QORA?LI6[.,%/R76K'IA%]>:+"-
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M#FA8'7P[4&O]R5LCV\F]1EV*1SG.\)BCPC.? &K0"C2L%<:[S:3 EV4I=35
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M]5:"XQ[[M7U>>Z\GAN/!J^/Q2)SWIWWQR2?MZ(\F3::F&1E=RHV.+['9/$_
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M!7QAJ[G=Y*6&7R_JJ@6$%_SS[<JH'(YBO<FK+1[&W/]L"KVP50Y/PH,M3&=
M(G2M7N5W1L^,J32 N\D;&&>1Q^=U4\!H0TO"-S 32B[;;8&QNI7^<GQSK)>F
M,DU>EEM\P&QPD3Q0PH8!+8$6'O_U+^>GIY/7OTRGG^C/D]=/:.9N!2ML-D R
M^:PTNNEAM,(?&K/L2]I5B_O$<3=FWC>V0]K"$9=?YZN\6AK P7IM6Y)NCW&<
MK'5S>>&7@MGRICB $5NQ7(9)CO6TQ"\ZTP@F%9!QU>9SAB9@S)06) G-Q!@*
M1W&LO[0&C^^R[2S,"S#CX3".^;!D5P\?T0CV$8^PJ3]Z"]0!8JP"N8^#=5?#
MI]^--GY91%7>@J[8$/BJ6^6=SA<+D.:T/D!4-W1R:SPX! N&FXZ?+&T^LZ4@
MG1] 2!WPH_#B<^8K:+L6'BK@R #M.'AC&EL7K5_Q6+W9X@^VT8#$OC$9?FH3
MX!L#:F[V&P$+6S-Y"^-HIST09].!M@2<.$HRM"T@F&H_=  YTPTAMNWG*Q76
M@V\6/8+B@05J+@LX;MW:96470*=5!XP</B",>2N'@5L-IX'D=_+R=;O_-&#!
M>=D7@%0#Y ;$!!,H CT'K-SE9<^HCNG/5G=U><>TO%[#5D&WS7\GW-$3GKKN
M\P:>DP,!REN8AMG[#N A'-8,1>81Z)]'TJ5YCU!5%[@4'FB00L#G39^7+>ZF
M!APC!1%I=BO;P')Y ^>R:>H[6YBF!3QO\- 1:I1G>3-?T32%N0-[9D/0P.G!
MD!;X;][!U#@03()6\1$4%@ZWT8NF7L,:=4PFQQH,"S ;*G71PQ:K^5;?(L98
M?NAW\(@"1!O:+3S<U/URI4$'FO4,IG1Z,(OX@=#K)A-BOV!I 'AMZ?.7RN*N
M;SHZV:(NR[S1]RL+<HR.$"@4%X2=N)D0JT*U@TD]J0"UM[:P>8,<YU:Z )*"
M[RJW"&)NVJ-V+<.WA(7!%AP5&[0;_(Z5VS%-!'^<9LD&3;4$"F9%H*N>D#2D
MPL)4=23\!A"VXR#BV<)/<K*9BA>U;<SI(#]J9'4^[XAAB<V=Y&\(\PZ3WX(D
MG2\!^6T7':!*#O"8Y+0#JA,R,GP.>P0C &#A:P] <H8#,/QO6U0Q]7Y"RCNU
MLU=$ ,LX)^)F>4E:FAT/%,W'^C/P5-6;@2!&4>JW4SAA#KJL@;/>NPR+;V5R
MX-<UVJ"@ZYFH0,-5(/E*^P^8K8O8C1#,.*I;MW)CT*# =5N]8&8-_#5\6C_&
M)Y]DR$RPKO5BLE!" 8G23(5[NX+U5G6)8D>X2J-L1C6!M(>2K*Z,:+KYO%_W
MC)$:)F[H9W@>O250\PA'2A$KF*2J05BA?4"T#X>(/P1E RO;NQR=)(VDUO0,
M&RE>HFOX7C0US(%/@!OW.QQ?8UN0X[Q7Y%YBBVB&PJ 2 BS LRM3+%G.6 !L
M3KO90:SC(MZ#9[5UOLWTJKX'.FDRF0D58> Z6&!D,B&11=FC@&9S0@Z$M2:P
M=_%;S\K%61JP*>'BE,8<3R,A'Q L>22&Z8!@5EZRK.>1:"4J<V2"#XX<I\+C
MU ^3$'CJC9B>2,:[)(&4!&OATL '%WF[(IL5_]"70&N@1FFNF'!P/=:%8##K
M%3BYP$JEA=&Q2F[UI@?=2#J7U"ELMF[LTE9$)AT:P**0&F.8)0'F1H/=W.*Q
M@:4R1S!, ",EX +60P(F,Y8 &PS'S<$".^K1*XMC]#KF,+3QIL(%( )H^C,0
ML'[G&$'M4/^F[N"#)8_!"_N(, '^>3PU6VL\-S('([$E8B>PQ=MHF5)B<QYL
M@Z['.3+%4@0%GET;,': _)$6C6&;9V$*=&* \(#X;5>39 8N(+DZKT5 PHK_
MH4^?3[+)9*)/)ORO^SS\_B*ANO=(,1>[A"B;805V7P?)!#!6( Z8TJIQR03D
M5Z^-2,IC_7&/\-)D]A%E-*P6,J\2,D6B.HME-1U3#]9"PS[&4';GZ/6P 7Y8
MULYZLHP1T<R2) +<MD8!WL7*04V1!U$36X6)\D5"[UOG@)#/ZM1K*Z['B)EV
MK"^O?[W\?'6AWEQ]O %W_/KB\B;35]<7(."NWX(;_^;FZNW5]#,ZZNC;W^C;
MC_KBX_4->.]OI[>7;_6[J^OI]<75]+V^N84O/EQ>W][H*W#CJZ4%1U=-V9*(
MOA';(J)P!/E3NYTU8"P =L_.3U]S "!'+M)3=IO%@K^J]*>FGJ,4^!P;V&\C
M ]MYX5>?/O\U7V]>OTU<<9@,R4+E2Y L:Q8<W[@\:D'9A[>1&O8FX.3# 33@
M,9L%GU93;_,2"&5MX-P*5E#SFG>^"PH: >"@@E6+Y@8R)5N"@"[0%G-X8N&=
M4GDZU7D(EE X2LBFH?B(][!L-[8)H#]2K[9!(-@*VAHT$CT*U?C6\SGYYBXP
M\)L0F7.19 "(&_'5<F 80),1CJ<I6M;V*-B\-YA%V 3#I;-';(TI%&CP, "'
M/F0K:,T0Y:3A0 "0R-B4X&D&'PP\M-_(928AF3FS$"4EVT<>RHPU!G)4@XC
M.<U\5=5EO;2HB1?@!ENRB;?'"E'/ 07&QSS?V$Z,1;]!%MXH&^J&56IA0(:#
M,7Q4@CPH=D\DBWV$<#( 24O^#D:>2BW;)-T$$\]@P;IR,HLB$;)KL&$W-04!
M$'F+/GX4Q]*!R^#41;JW9<F1EMS[[B*62-@2$D&N'?6M@7E53)_#7651',W-
M!9N?;:.H"=(1ZS'\#F4<S-&Q[?A;'8P"T?Z+LKYO1?YN '@B  6V :\$GUGJ
MS\P2-2<SE@2N8JY!O+;?Q!Q(.250 /Q153W'!&&!>\ !FID:E0\*]4;-;0-&
M-\(/2!<SD/4.G#]*%!-/B\J:"*^>.WMK&L=BHK#5;WVQI&>L"Y(P_T6Q%6T7
MJ,)D(0 &63\LAL9]6.<&36(_M"50Q,+,<%F8CC0SLRQR=@U*#V."'*U]!;01
M0UJ8.4:+G0$Z\/R5/RF)0(6#?(T3@:[+D2ZR[YB30S@8B)5 KC@:GAL)SM<I
MG"HOX,!:9Z'CU*59(H.#B8YXP',7[]/)+ !B'84%=\ P=#"PD;Y"LL7P=>>B
M2IT5( "^%K8+Q+)LZOMNI1H.[EQ)K#&$Q"(N@;-FT]>Y!5ZV,V%D=-[AB-D%
M:,FH@2W_0YP%MO@Y.H5!IV/]2UT7Q.5)/(#X8>E^0A;P-NU!9L@0:\!FZ J!
MA01C@$&8&(DS\&<Q\R+V\!S!AED2+T%J1&$,3$VA<[+PYEXS#M#@3@8-,.%?
M^28$BWJ0O"G[(S]$N"8FA6=4^@RBDY0QH 'IEA_.=-$;)PHQFKX,<6_T@/:0
M"F47*:QRC#:-D8@D+)5@/> ZV\$*JWK]!R">./'.>-(%</Q^4#81QGD'=#BE
M_=V46R8F1.YCEDMH(_-O=@50(.PTG,8]G_SGDW \:> VU[NH"N2*<G5P3I[:
MW89FVTWN[99X2[Q+P@!Q9/*80C<*!958] >VZ [UGX=<#!-4=PGHP%.8M&A5
MCH #<0CD [V-BHYHQB<*'H"$;*A1W($%#(MV6T6V&;GB;/GZ'R@DYK].O9N.
M[,]C_0$U*JI]>@3\C,**D0V E/F<+5*G0#LD)S-BYV02"\:,/H@(GTS#%)!M
M)#Q2U!Q-^@HCV!UE@T&C 40\FE?,L'C(  IP\'WDLU!82]1\U;*/%B(3;PUX
M5QB<]U'[2-/C<\KO/IB5&*K$%/P1*1:V(X/%#?(1U12>HXN_%SLPCS%V"?I2
MS#H60"QJ_"0JF82BE=L-&I9 K,_T<]@+YR_41\P#(+ 7=3N(L<#@>BXQ81DT
MIT$BACB'@"<??.U@-]'):=@\Z#Y$#Y( QJIR+%>P&+NNML.)W8ID7\7Y&*8&
M\(\QD%Z 7)RCQ,=8H9 3+ 5T4!RA@\!+/[B R^BD6;EH'1@BIB01>EZ@U=-2
M,.7.A%!P/6XLC$?$OBD@=CP(=8$13?D+Y^U(JM)'V*8W%_JVAN/5S\XFF00#
MIB&Z[@Y;SOA(77K8%]H3P/,7+[,7DV=_DK?^=T:V>B_(9H/V*F3//DH.+]ZZ
MZ"O3.AV'<BJ-2TE$+ [TVK;M">=DK4D ,,W?C67M$FUF%ZIE@S4$W9 V0C2:
M+#<X9$H_@;>&5J;H!U(L"XJ08]"O0(D0/9@A4"W*<%P3#^_L?.+R[&\M^5[@
M)ZXP5? ^HDUR]"\I("2A!A^#D$F2",2[Z<V;B#3.3YYG?I%H%SCT;Z8 SV4Y
M-BL\YF9E/]1+!Q<L1 /B >32& IO[15H";=+K)O]8_1COXK/C?1^7RF1"6V<
M'!CDUF.M-Q*B3C(]@X!^LK,$KGB;:F2;Q*&;/GP!(,9P<2A0#DM<HH=0-TC:
M(]N'M'TN893]>^," Y)?*$N\$Q+A)[7?=],Z;$F+O!O%9@CXJT2^I7@E<Q,Y
MQE9LRW+,4:),3BP0TD.&,H*3PQ%D&^<-2,3&T1*01S,G/4-@VA!))Q[>>X0C
MZ 8AYXPXNV8S3).Y%$I,AFICN^_D)%B$^:4#<!!69F0YE1BD6EBF]4.:[4-=
MD'M)VV0Y6O1SKV#^'N]Q1,1.5:"#O/*Q#I1]3JJ)D984/F#0<!ADRL$,#K!P
MTCSW*(I_&SQ+K*!$PF11O0D;J<F3(#D81T+ZA<2;O04RQQ*B[MZ(R3PH]\#@
M'DV'62"!S%M@.%8E8WV"R(VUZ[4IL"8#3(Z9P2@Z"2)&%[*GFST+ '*=1[T/
M'I&%(1V!QK%%AE/.N1(_(D$$9Z0I&A@*P\B!J^8L$2BP$*\6GUX"%!J>.#-Y
M<V*)Q+$D%<4ZAX <Z[^C>S(X)EC!FV9YUS5VUG?.F98\AC/'VDP<V0#VJ&BJ
M%RIBN78\T"ESH]J7+%,[3-,E(IU7]@Q#]1$B0 *VDJH]DNM(JS?]K"-M>O9R
M<G0Z.3H+>MO,Q)>ZJ"N,^#@G@:PQ):PWJK?=5%[/ZN3K4)G&MA])ZJ3VQH>I
M:Q>/<WMC4Q8Q!!@&FWJ<&ETR58C,H-,@T78)A(\.)(3C^;):2WAG'I! ?$+'
MT1#SI"&&6/-P.$GHTW-?V$TXO!VR265SJP?$"[N!28IPT!3$4ZY0RY,.3(,>
M8: W0GIK8@^' >(')5N7T% ,!SJ-SD*)3-]Q&W>O<3LT3?6_U315\8-[Z!YD
M-,OVR.#: ZHSW795A03*FM@D8CD09HVRW!QXMI+@C@,+A*@=^VY)Y.+-'0ZC
M88G^D63.L& $C:40 ,'!&>\R+8I2T?2^I/-[2ATD R<:?>YC=>/5++'WXN)H
M5$L98[9=N>+))(4\AE4="\8,4>&HS)<J88#$Y62&%6XQU<;3*O*.@Y4RAI#4
ML$8H. ],$9>JKH[<1Z^,W(;I]PYCJD<4K(=]=2XYWD0"1?G$CZ>4><",) KQ
M3 &\DU-?U+'86^%U1<E_=9M_-:G[V8.]"9*I#5&CN%9MBZ7638T(1 H/[!#I
M9HE0"79%4V.E08>+,9%062=)RN'ORNOL'A-K\A,>-=4R+$ B1'E[$8^8M8=C
M7.=DOEN@SH@I$<%.B(<#3%-NB*G\*PEV7O%8O0W5K@$ZW!A7T[/UF'\-%<.+
MR#1K4]O,HRG@A<0P/$Z!H;VA;")TM:>,VE0YY^5@FL85'XM!Z=0&YIK;-/47
M0SG([U&%1R.)[Q%I[90Q5K0(/1!_"Z80D*C $4QPP"@X];A05%B, :E[EK4H
MK!Z(+*L6L>_]D8;"(GR"N\N28R$Y#5=:B.%87]V."=?6Y_G:*-=*Y?IPN%U2
M6X]SE_F]Q%K7&-6D BFTSDVU=&2*S-)CC1&9E'G?ANHTF!YFO;-U'U=Q,\'%
MITK)BI'*;S"]*DJ>YP6:-!U> 1#F:7>X)[I:L(;QE O(N18ZI6_*#0, O_6-
M;0O+I05W7/+"I78.U"SVROS1M9@79VK!$F[8CEQ5X23G#/-$:$7ES1:(*?^J
M9J8R"]N%6DXQ@.JJ9/\7H:'R*=J8Y]YQNJ J-9_0Y#,P7W//S[*[O ?9T AZ
MD:0EE16G[MH=#ZM$^[&-\\("O&1"6E"[!@LO7?8&9<^<4H,"9QW3'T,7)/NQ
MF@Y<?S&,^RJ"BV2#X,Q9T!*T(#5(!D:U3<:AG@(/WLNXH3@A06' ,A($*\D=
MK%$OL,T7F]J4[HT"+^@D%7E3< WVP0*_#.8=;'+O[M2]O_S 0BC2]G]6'54D
MWCQV-GCMC&'EY2FN2D6Z+3/V!B1NR1)X>&6!B*VP['-*(K4IQ&@E?3028W(I
M8^7BZN(QZ'M#>BO4O^!5"3GT" @*P0A\J<!/J_7'"C#C(%51<Z&;%!"0K>DO
MQPP9LW;N1W0OIS)?@8#N37GG"DH3H6N]003,T5?Y/3(V^6WLP?HH(<I)<\^R
MENT;3J;3/9NH9F&3;UT&S5TBP>2X*X8N8!I)-I LP_VX'>S68H-= (8+&W<P
M,"FEST))_J *W]5\1CS%^3R<@RQDN30#LIIU?\Q]L)]W)4BF(L_4!R F,*AZ
ME! PQS7X8O^%2AB,V$^FJMIM>9=7-N?9/X*# ^8JP#6E1!TL)M*#JGB<I!B*
M]D%4TOH:Y@U7_*%]N0!>18H?XL!OE<HK_,Y&< $D#WH:!\1[C2ES'V&FI[(#
MGD[!\V?R\(+?P@K7F!KUO"AEK#))&^YQQ;9%?I?;,A1-H'/LBFX&>C8$<!UX
M2/RP&:H/HOM1;]#<I<W[^U$Q-A9U2;58Z).^/#G/=#+RB"=)OG37'D!Q-Z%D
M<1 ^B^]F"3\E9?19N)#&::&DQI[%]""\V8ZDWUUQYO0>-8<O^64$^PPYP@/6
M@W4V:>SY<B".,LUPZN56=!(AV07#?1YY).S(>1-</MSR.S2>X4@9IG=(?%/F
M@+6;^:K&:Z8<]3["P K=VZL+4Z:!BX&3GB[G)&Q\%#GC*61-X,@E_!E=^NM;
M*0S-RSE=<AV]]#<R;_!?1DQ-O(8(9AXB-KUO*+5P\.^*D]_AZJ131$1AH: 7
M!<K("L[P/M;O$DA1A0$2.Y_"Q#(-$NH[O\A&;#M2Z3@'YI5[PW-B7$7$]DWY
M-XFHN+NI3#!T="R<1FDFJ2EF#<_11PR.^0@E1HW3F@CR^C(VXH0Q&N?CM'YY
M,8/%2A,324D0&Q9<@Q0!X"L.?DBQ#(>#P>A%7<@PW4EMJ\]Q<&ZL;)%206J0
MI2/[EP@_Y>CCC B=+P)%>HB(C:_<ABHPN6R]LIOPW=QN;%0VRU@5CTN.(^4T
MYOSV .-@-2$57X'A17!(?2NE-^2^5T<7'_$$4,QB$,^L-V6]-<;O#>V*G&R(
M;F79;//5(E&X@ 4=+N.PZ):+=G0@2PS_+8SE:"3[%ULN$#U 58/SEX/7^PX^
M8#DF@4%5ATMEDLM-\CQ,HO923T,J>.8T':6C.KP?Z)A21>R:[6/63$P'8K,H
MQ4OG&X1\8=MY8V+O.]%T=$F_Z\P^=E:S&HF+XC"8D<&$4GR;_XW[^:W[.20?
M;DG3"])9 ?F=1.78J $7G(.M[RLPTI#6<6^^_%HAE<2U3ES][M6*LR:RB-IH
M=(YQ.UCG[/R(+&@?EDQKE=.\;( YJBQVA*J8E:4N6HJ.=VN,,TTE\[!1D/']
M&IT/E%.X<;FXQ-*TQ&L@&->BZ-5\9<U=$+R')&NF?-HM)K) ?IDPIZ]$Y-O#
M9)&D\TO<&CVC5NY7L;1D<%PN&)F02'Q'\+69PI)9WRZ"F=!SW>>;+WX+MO4I
M)&>*@ID7RF#]I696570.E [%.Q58O+1?*^E#6DD=TDI!XI#0W">L*<(-FV$M
MR:<K%C5^ZR_%B'*7.D^'+9K5.6'^+A$ES9NX\)8-4WCB54@7NTDR/YM0MP,C
MDIY4;."&^=!X>I8J_S[R!)B#F)3;>@\LH1\@3XFK R1^(%UN630Y;B DXS#[
MU-1EIH>19;0X1?UX!N0@X9"\&[J?N_])A27,_"Q3 ).NO^A#9D<X^Q'YG^3#
MDQ//^&8U.1NO]"A/$$W@0RJN#]BC:6+2]=QQ>-HX\L_D@10W.*UP(4')H0N)
MI:1U *Q@C>E@C06A'4XWHJ68?:)6%Y2N?W OWTEP>R#?:83"BZ7*7%'%"DOG
M8_TK? F3Q !*>)9S2Q+V#V5JJ?#AVP7^8J\3>AQNM=W*(6R'WI6W24('$R_C
M0U&GI_MP(43N,BS8E);J".$L7]H>+![+-S013.&3C!$"& )?)ER-"2IEN#I(
M;#@MV<XL[ :%%6"YT:&6R>?WAP2\#X4[.U/[=O:N;Q  ='2)$7U %$3$C?1-
M.YO\,'5BX0H#?QB2EUX-L!O4[W8$0;FS@#PU*X<L7YOA#9@L:B\").KN)LEM
M<]_$!>L*O$4-(&WZ&:C4DN[7%G(O)Z_ .7PBYQ$@0@+$J+\2$B1N&1 I]438
M0Y55[6OA_)6=A6U:]!1\75=+V):.$T%3#6!I8]+%HWF(2!,*'3G%/R]:'0G.
MZ??;*+%A+F58_XR]$E>Q?),7_7WVRG347IGNL5=4HKWT_Y.] E,F]H3:%>__
MLLDBETH]:"E'(__ )X.%"LW0$1/_UYET.5Z\,QR'7MF9);C;/$3.A!I$M>1^
M0A0WL9)YX&#@>/<RTFP[L.EW!+ (<2_R7  W[)DS*H,M[Q$0D6&D1@RCZ;_/
M,)J.:/T]AI'Z#L-H;-KO,XST'L-(?;-A=/1/&$842>=>%2@T;DAH8!?"N?+-
M*((TL20Y-GW'@J>P=Y;B4'ZH2*,=Y@E2;9_9TG>4JJ1JIZ'-=*S>VI(6]?&Y
M<9A"-/L !&Y=7]I*&KC %8!6L^AJ9SHR E'M@J@_[7ELT-HAJ0E,!H8RQ4WM
M.EZY>O'%,!)3^1+A5CT.V^X:BK-O93@'\I^X-@N()6_Q(9W,]<@A?U\JQK7Z
M:%7<YL5A$W2ZZ]ZX T3+58RCZ_,5?&8!"7X;5RH'LG#-HV8U""7>!X*SZ#&8
M4S"I4&G&6(G@Z0M?"WL94Q.1_EC=*SS@@DX99G*I%YPKBC>#_D.DBUV G\7J
M#BGNTI/'^:9OL%,4\T?($T2;+/9RPK%^RVV['DC<G0[D.%U">OGB9?9\,M&3
MX\ED<A*(V2$T/4LM_8G]EKE^>H9-BN-.F4D7F&Z7!MUF1JA@0('J  7.##OF
MQ#*^-K^C/B]T-F3^WU-N.@"'5U./W-Z.]<W%WR[??GE_J3Z^TY_ S+N^!8/N
M_7_KMU?OO]Q>_7JI;RXOOGR^N@4S4+U[@$,4P8>P*7_% 4N*W!6O/3+P-'OY
MPP_9Z<DS_>+Y\^SLQ3/U>1B;Y;C5D3._$07P%1_AZ20[/SO7+TZSLQ].]S_:
M5_+PR=D$1I[H%V?9Y/G(6A*E'%^,U-WI:_UR<HY)S[ )+,R=F2WQW,O)&35&
MDL'J:O?NR3>@Y:5T6<HF_)>K4?^69Y]-LF>G/^BS<_Q'W=8H=1^04_I9]A)0
M<GY^ DO^,(%ESYY3YDO]ZM2][W4%,B;4O=ZFY;@'RP.'S01=]C<J>QXO6PXY
M1KDM!Z?NQ!FEYPA(]2&4 ,G52MNBBX IC=';<Z>1C*-RT:^22F2!EMRX]IG^
MM(8V$WYWNBB4$&?*"<SLH:ZD*5+ ,%KG#>:/0U<!BQ*B;KHCM/,DG_5G.7'1
ML2<8?1<NXT1&MI2BL35'9N!]5 EMZ!(TNLBF+)/[W7AMBC;G4A5Y5(9%5Y\T
M)M:;<AOG\UVUJI+N'MA[E5ILT)%+"CZJ!),[.35;(+G(2[Z"'Q6&)F4 ]+34
MO@=_'"S8!ML(;3G68C&3VBHV;D"Z$V.&RE&V0:A?D)$D>.CI&RWW2K]' UB=
M@,3YU3T=W07ZHZ\EO#.72@0N L(F1'LZ=%K7MEXZH( -PFN<[EFCGF'*1TI!
M:"M1]\$4@%CITZ0@+3A2D;<CL+9V;;D!F8-4'80T.[C?T0F'6Y>9=%)4S:MD
MOO&(<D?F!D4HP&KVO.+ 8]/4,ZK:(<,_&B34!]25.^P^VX/=OMK%+T@">L,
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M-PE!1YP*"M(N@!KD)0H (5)IL/B="G'3*W+BA.5<1A'E(I'=X#F^,--*Y89
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M2W%A2E*UJ;>=C0$F"C7OW*^Z!0 PU)/FQ]<DS>ZP:P<]\E8^Q2.9]@TZJ-+
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M2BC??=KRO6HIZ=8 8IRNZV!D3>?@&B7]%;;)O=6D6.)Y[[\)>%K4=W':[+L
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MP'[=W8$ # _P_',<4)G"5=?6VT#4,V#_7[493Y[(4C#T#3@<HI) 9#/2UOM
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MK:B24%NV.2]\WCUORF38%!G7)&.FE;$P8> ;>U?=4;27]'$A[)H:VK[;TO_
M<G>!X3S:!IEQDP]?XGV)P(0;%^Y6??6L3?R9];L#-IE]G]Q-Q\'Y]&:.L1E=
M\1Q]U&S<=1/U_-OY?'HQ'=W10$US-\;J&YJSYS=7TXO1_>2"?9G.1ABX1U=L
M?H\?_#3N+M .57I8 ;5^KD,JC:HEFFW6KQO&:[Z4\35\_<SGFT%P;T]X-9]^
M95>T8+<7I"7?"DGS+[7WB->89TMJ4.MVK'+#91*H.*Y*7H^4&5\XYZH4U1OC
M"5TVL,V8OE=>PW-7,A5L'DM!17**J?7!"_U:+=BBDIF;@3"BU'2TV8^1,%M0
MVH7!&,F?\)?F?>&Q&XIJ"WT&>:^(QU)Z5['?*D31S]4.D 1>HM.$DKV@Z8S0
M<FC5H7N@&T)?I52U7+&:UX+Z @L1=T4?:F?0LE#U30"9X<[&D.2G-:J@NA5B
M(AGA:B"-7CJIJ:(YA&T/:=>#+5^#5*2I36RJ)(S<W" X*K^CR00.0,40.X=M
MRBL-:$XKND;RYOI-K-ZT[8VV.&H XJNV]]\+Q9V+\1"1GP/D3G\81L,^ZT>]
M\/CXQ-'(VMVSBN20 S;43:*\@EVW#G0]1%VV7JS&!(C>#MKJ%KGZC9[(H6E&
M-S$?V7S\=7+Q[6K";KZPWR?3RZ_(Q&"$3!Y=3MC=Y'HTG4UGE^QJ,II/V/WD
M[CIX;E 4W.U3[IUSPD%PLQMZPWK=X^"BK>#+)?VHVV/_8/MN$8]:M\"YP"Q,
M=]W4(4&:OQ!N?FVNTT?^%GF[W-_% Q#@1L)*BJV][LG[CL=B_6)5Z>Z4%\I:
ME;O'E>"(.RW ]U0I6[_0 <U_,IS]%U!+ P04    "  PIWE8\CT$=\$)  !E
M%P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RU6-MNVT@2?>=7-#23
M@0TP,B^ZV7$,R!*]H\"1#$G.S&*Q#RVR9?6$%TTW:=GY^CW5I"C)EI/L OMB
MDZVNZJI35:>J>;G)U%>]$B)G3TF<ZH^-59ZO+\[.=+@2"=?-;"U2_++,5,)S
MO*J',[U6@D=&*(G//,?IG"5<IHVK2[-VIZXNLR*/92KN%--%DG#U?"WB;/.Q
MX3:V"U/YL,IIX>SJ<LT?Q$SD]^L[A;>S6DLD$Y%JF:5,B>7'1M^]N&[1?K/A
MBQ0;O??,R)-%EGVEEU'TL>&002(684X:./X]BH&(8U($,_ZN=#;J(TEP_WFK
M_<;X#E\67(M!%O\AHWSUL=%KL$@L>1'GTVSSNZC\:9.^,(NU^<LVY5[?;["P
MT'F65,*P()%I^9\_53CL"?2<-P2\2L S=I<'&2N'/.=7ERK;,$6[H8T>C*M&
M&L;)E((RRQ5^E9#+KT;CP>1SP.;]/X/9Y5D.C;1^%E;2UZ6T]X:TZ['/69JO
M- O22$2'"LY@2FV/M[7GVONNQJ$(F\QW;>8YGO\=?7[MGV_T^6_YEX99(MB<
M/[&AU&&<Z4()]J_^0N<*&?'O8SZ7&EO'-5*57.@U#\7'!LI "_4H&E>__>)V
MG _?L;=5V]OZGO8?QN.[TL=M&T_F@>6Z3;:OF\U7PAIDR9JGS[_]TO/<[@?-
M[INS)N-IQ%#L2.>4 2[-%H)>F2R1S/F3T(QC08,R\$N^P@[4]@6;#7X/AO>W
M 9O<L* _'8_&_V GMY/9[)1=!S>3:5!98,$"B^)+0?8LA%PD"Z$H['O+]ZG,
M1<1F.<]QX*_LQ'5LSVG;KMMAI_3>M;VV:WM>CYU:-Y7!6'3:7;OK^-ASXGIX
MZMANIXTM\RSGL=$#P8YG]]SS4H][;I]#QC\G&2BR\I5@SX(KS01E-=LWT.2E
MP8B,M!GMK6 $1X69(H$=5$P\@3ZU8-D21WD]^]SUF6NW>AW;Z3@U8A80VT6'
M!7_>!>-9 -3&P<UH/CN$:% H)=+\@NVPNA&14,8[$TOOP^[),@"RD^KLTWI]
M"]EK"8.4%9;'[#MS4GESBHBG8BES@J]6O%,P%$L!X>CB)PS;KK]E5@U69594
MZ?Z17;OS7FCX;QS:12H8?PFFHX%U/9K,!J-@/ AF-H6LR?KC(9O=7\]&PU%_
M.D)E4;VAOB9L,!G/)K>C87\>#-G-:-P?#T;]6S:;8^%S,)X?+\+:03*0:U29
M-OEVL!Y+OI"QS"5*(\S0(G5.*4;9N,QB5*-,'RX.TFL8W 33*0RA!.O/9@&.
M)]-O1_WKT>UH#LM_7)/#U[9=6&/P (8$Q7,<6E)&R)5Z!C=LN(JH=E&ZO=ZY
MW>OX> &\'LK-=Y !6?CU/375"%XD% IN>K5KN[TV*O(<3WZ+!'K6%'S&5;BJ
MP'@$YZP32M"0KR7B*K]!2Q5/S3HNJ*'5QO^6[;1<:Y3F/'V0BU@PGH"TY+?R
MI)YCM]T>:[=L%[LF %"QKF-W?8?YOMUJ^]:M@$.//"Y* 4[H\C3$&<0O/1]L
MTVX;MG'L\V[7[A&/&%".1?)((>QG 5OQZ#"*;)WE\%+BW&=6Y CZ-TY>I*]1
MIV,.D#_,@,E=,.W/B92)D]F@/YW^DX&6_^A/AS\1^UTI>RT0:,_NG'L4VAXB
M= X,_*J@L42L[*!LVO32 2+@X7:K+FTL=NU.U[-;GE/N\(%;RV\?2Z573KTM
M;H"D3C\HJIKYE"TTZX>F-CS'[;(3PI9P]YP/6#=/[H=3U%,B(4._'@$6G%Z4
M0V2>(6/>F5+C3R8.%9O .K-7:(LKJ4E4IL;XLI,LQ(-,4UKFRQS8ON@I;A=$
MHDGOJV9SV&,H/Y95)%Y;:ATB11!H$Y0C3AUN+?O3+K![,=Q#^QA?B>52F-':
M>*OHM$= @+1?JBPQQI,-19ZIY_)GKJOT?I&@P<U-,)B/O@2&(N_G$^3G7E=$
M\@8_GZ9[+,_S8U:<>&[38:?OZH<J?_<$RWT&N^46=2KTIE?*-3LDMDWK6B*2
M@$251<M._.H4O^G2[G&6OJ_RB=*G)BRWV6+8U2I-V1&M*L3[8LU<'X>^JRGC
MG358@<_(VF/<!,)M]K#=\YL^]@9UB%XZYQBM)UT<#AM'J44TI4WZ$F2XYAF^
MH5;S3" <H30;UY$4][>2BZD7 2?--BMAR!0]56J6T 09RZ\"));#<I9F%!1$
M1I,]:V)D.( B@@]6U<F.\>=&QK$17FRM$U&3\I+A&B83\JDRNE1XU&2R*!)K
MFNY@<[&FPH:&!\P :BMG+8N<K@HOZCPJU!8<E)/,4#H(P68ET9CR589)+Q<)
MW,$%M\X#ZA4+48K7D2^-/A8[G 07J"<NGBV:07IM:IT>:Z$&Z>G\H&,L92RJ
MT7U+#+NZ5P).I+H\[&7E;J=\72P0-$DF\UAGE48.F@BAS.2*46,8;26DJG[Y
M"UCH2!IF;%HW5.W\P!"[LH+L&2!)<$9*L.GUEC'J2=OD@A+T&8&(RC"M>.*X
M\5;P(!35H$,QVTA<.P0'Z/M&;#VSRE(W4[=A=J-#_S3%:I-A!$.TY[X!K&S.
MN$G"?[)\=Q^H'<0E@!(@%]9+V1=R7I/-RH\3EM_S3%"K!K_-W?Q(U%Y3.8*5
M\&>J"$3R+V@D\+@)*X8>PT([%*H@,@Q0J>$U<EDC#>12AMC-RKRW0L,O)KNI
M,V8;U(9>R35"JI#"5!H%ZD=M76#D0F4RABVA4AP[I5,*\B$JLT##CAC>EWFQ
M5MFCU&5H9@6"N6<F>80K+*K:VEK\M);J )H?=K7JZEHF[1ZV.^#=;NO_--M?
M;SL^V;^[+/Y@/JEFD_G@4[\>3@3!@CH0Y6B8K;>C2,DF!-/QR=@TETA2L/06
MQ>VUSB0A"2CQ=R&Q@3)]S9^)NRE]RB%9L/O9KD=ECX*2^'%;M/N?"NJ+;KD'
M0PZ*N-RV+I0N*+7RS!I-!W7& /LF&^X(]7^Y<U.Q"ETR?V3V[%\''A3EQ*^L
MU?$QU7289W=Z+=O'S7^4+F.3"KA7;(<["L0DM?K%0X'K%.;*ZKP[H"--J_B4
M"79-CZ9BJGC4JMBA*A-3SWMSYI0I<([YIB1GD@#SQT5$W&NE8L/<]KL=F=#'
M/YD42=G&X"=G[CN@'DI=]O.JB5%',<2WD]1TS4*<$0=4-0)ILVJFH5/TBKA5
M:@I12+\=#JA6%0#/F*GWBQ8-+C),N>)("<XH!HK81B(V!$!ZE,"(QK-81B9B
M2R1V&I+0.M.RI/KC)-UDQSZOG>U]^DR$>C ?>.F,(LW+KZ#U:OT-N5]^.MUM
M+S] ?^8*%:M9+)80=9K==H.I\J-N^9)G:_,A=9'E>9:8QY7@X$#:@-^7&:YJ
MU0L=4']9O_H/4$L#!!0    ( #"G>5@LXR8/C@,  +<'   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;(V5VV[;.!"&[_T4A+KHE6!)M.-#:AM(4A<M
MT$.V3MJ+Q5[0TE@BPH-*4G;R]CND;,5I'6,!0^9IOOEG2 YG.VT>; 7@R*,4
MRLZCRKGZ,DEL7H%DMJ]K4#BST48RAUU3)K8VP(I@)$5"TW242,95M)B%L5NS
MF.G&":[@UA#;2,G,TS4(O9M'6708^,[+ROF!9#&K60DK</?UK<%>TE$*+D%9
MKA4QL)E'5]GE]="O#PM^<-C9HS;QD:RU?O"=3\4\2KT@$) [3V#XMX4;$,*#
M4,:O/3/J7'K#X_:!_B'$CK&LF84;+7[RPE7S:!*1 C:L$>Z[WGV$?3P7GI=K
M8<.7[-JU=!J1O+%.R[TQ*I!<M?_L<9^'(X-)^HH!W1O0H+MU%%2^9XXM9D;O
MB/&KD>8;(=1@C>*X\INR<@9G.=JYQ>K^>K7\^W[Y]8XL?^!W-4L<8OUDDN\1
MURV"OH+(*/FBE:LL6:H"BI> !/5THNA!U#4]2WP/>9\,LIC0E [.\ 9=D(/
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M4E.ZC&@'I%8L*6Z(<88<66WP8HI -2C!<4[$N-.SB<W>NC#D#NA,L\8 ZH>
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MS+O6>H4DAFG5X285CXP'>Y#+5DL5<(]F.(P@8Z,&(]'OII_D$$DGGMD1#"7
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M3U?4?OS6512*<)=\=+M;-*JU%%TA)N5$U&&! "NF\,9KGPU@!TG=:(+=%HR
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MBVL5AVDC3J,&D+;='$1J0:T3<BEJS$KLP2KGX2%"!,30A!(4)&KI(2GU-#J
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M0UI5UU*XEU+9^BK=L;HP!4WJW(?#,'EG^P@$=EZ76$T*0HXS "FE085\_&0
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MB@]N@#9LK/C.0^CB\T&<-DATP6Y_XE)]L.'$PG;A=CD$VVR'0*;#W#Z0!\*
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M5J)IFR2^0V&PF9MKP#P]\S'E/>@',WK.@@Z*M\,-L?NW.,QWDD\M[1MVMCF
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M#4</WB':1X$/T]Y'.SD>[60812+'^.0S8;E>"E ])XQP0QFC;*-G+M%E1O@
M9Z?7;M.]/0E0ESB/5"[,?<2EKCME42X$QAK <=H-I]4Z:)81&L-YY\IM=-UK
MN#AH(_ 9A=10YTWW8^.JZV@[W6N8KE#4_0;(XK?L6DZST6UWX-!3V:\&-$6Q
M*=:0U/%RILI9K;7UIAN6 _[/O%R3CT3HRDA(<*U=G<NKC@6B7#VEH'A6C/N*
M*[T\BN-6;VL4QD#?KSE7>\$$J/?_X"]02P,$%     @ ,*=Y6/;L1"ZF P
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MAH9I+>;T>J&R"G2^E=*<%M9!^QZ.?@-02P,$%     @ ,*=Y6*XL4K$8 P
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MV03:SZ4TQXD]H/\+S7X"4$L#!!0    ( #"G>5BC(<^\-0@   09   9
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MS1 1BPUC@@%X)4T1CI;0EL2, P7F:(4I0X\XV!!!+[C>X0"X$I1%.TY1O%)
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M::DMW1-VL=6V;BO3?CGE5@I+-U73:RL3?S*HIW1T2_6,EWI_->30 EMI/,>
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MH%%T\DPP2T^1H^GP<Y09CT%S":.PIP)T.IKK0-G2+$L9?"5L05-2])JNY@B
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MOBV(O5THLTU=+7F9E666U!_7+%BQ7&S O[_/LO)U032P*TL^_Q]02P,$%
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MV"<L-9#?+ZEDJ;A)-RB/Q@;_ 5!+ P04    "  PIWE82^8VV64$  #'%P
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M( ;O1>/LH#.MP'9=YT3D@*%O3 S7/FD4_6@ 4-/75\RV\A!!!6RDHW'MR].
MM0--NQ&T;F:"-15RPFB6N1P"@2D#^7Y#J7C9J#&C'RO#[U!+ P04    "  P
MIWE81A*!=90#   2#@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6RE
MEV%OFS@8Q[^*Q9U.F[05; *!7A(I:;JN4J=6ZWI[<;H7#CQ)T(R=LTVS??L9
M2""W$)?TWB08[+]_C_W8?WNT%?*;6@-H]#UG7(V=M=:;2]=5R1IRJB[$!KCY
MLA0RI]H4Y<I5&PDTK1KES"6>%[HYS;@S&57O'N1D) K-,@X/$JDBSZG\,0,F
MMF,'._L7G[/56I<OW,EH0U?P"/II\R!-R6U4TBP'KC+!D83EV)GBRQF.RP95
MC;\RV*J#9U2&LA#B6UFX3<>.5Q(!@T27$M3\/<,5,%8J&8Y_=Z).TV?9\/!Y
MK_ZA"MX$LZ *K@3[FJ5Z/78B!Z6PI 73G\7V(^P""DJ]1#!5_:)M73?T')04
M2HM\U]@0Y!FO_^GWW4 <-"#D1 .R:T J[KJCBG).-9V,I-@B6=8V:N5#%6K5
MVL!EO)R51RW-U\RTTY/'JX_7\Z>[:W3_ =W<W\^_WM[=H3=ST#1CZNW(U::/
MLJ:;[/1FM1XYH8<)^B2X7BMTS5-(_RO@&KB&D.P)9\2J.(?D OGX'2(>(>CI
M<8[>_/[6HNLWD?N5KG]"]T:(=)LQABA/T2W7E*^R!0,T50JT0O-,)4RH0@+Z
M>[I06IK\^:=K/.I>!MV]E(OJ4FUH F/'K!H%\AF<R1^_X=#[TQ+#H(EA8%-O
M8[B10JEW: :KC/.,KTRF,LH3Z *N)8>59+EHGR=QY ^B(!BYSQTL0<,26%FF
M25+D!:,:S'#F&YI)LW@UNC-@T!>M[B$\0'L?$1)$(>EF"QNVT,IV54@)//F!
MODC*E6$T&T)/I/ 8B6 _B+N!A@W0L-?$]808'D'@(!J&_J";(FHHHK/2YV#:
M6#5M72Q6R>Y\1Y94CQO6^/^D5R_T^'@N\2 *O=#K'D?LM;NH]XH$ZP5E5SY_
M0/'!UH][)F$_4'SN\)&6A)R5B.6L(N/9R7Y8=3NLG6A6^5>,86LBV+J_OY26
M9P?R"C>Q!M(Z";9;27<&G\T_Z,@1#P?#$SL5;MT%V^VE3=:SF3I<Q<K4N@JV
MV\JO:6N./"]LY/C83JSFBUM#P79'>2$1>Z =F\S[>(AQ3$Z8+VYM!MM]ICNW
M>B!%'3-'2.S[)XA:,\%V-VFSJ0>%5>J,->D>'--SD*OJ,J)0(@JNZQ-[\[:Y
M\$SK8WY;O;XM?:+2'!L48K T3;V+H<EQ65] ZH(6F^K0OQ#:7"&JQ[6YM($L
M*YCO2R'TOE!VT%P#)S\!4$L#!!0    ( #"G>5C+Y(:A/@,  *L*   9
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MW;$PFQ>E#3#W<R'TQK )VEV>_ %02P,$%     @ ,*=Y6"B'%R _ P  G L
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M7;MB@=#Z?*X[G!35$;<D7!R857,MKC1 98#X'Q/"WSKRU&PO2<$?4$L#!!0
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MD@;H1D?Z44$?7*#W WC@F4HD3+,8X]\)7.VU-!R<#(^"6L8)1@UH^A\@\((
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MXF!I"YQ.!-TE7>22"MF3)L.M_-L 3!G(YVM*Q<M$;9#_$>G_!E!+ P04
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MN&C1U8H))[EJ#'/"19M1PY7X$0 J#<3^@A"^F\@/5+\6[;]02P,$%     @
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MUCE; ->UE9I^2/LFM58T8:*'<2"Y^AHJ.]D<M']V.T\W7>C_@)?6PT/K[G$
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MI#K.IX\3I %R74%]'S$FEP7=0'&'T_P?4$L#!!0    ( #"G>5BWD$E5&P0
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M[-N3GVFO+[GKU>:ND-35/)N?>;PG?OS@TN-]\>/'EQX?7#A^60"\+U_\;^^
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M344U#=5T5#-0S40U"]5L5'-0S44U#]5\5 L.6OW;_[EY C2<C&HQJB64UJP
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M7CM8%YL+\QCGRH!8[5H&4$U!-175-%334<U -1/5+%2S4<U!-1?5/%3S42U
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M[S?K]>;XEZJ!S^O\S]W3^?7_ 5!+ P04    "  PIWE8>C 3R3$#  !S"0
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M?G2X('A&F#*0U^=A*%Y.U/>HY/MC^W]02P,$%     @ ,*=Y6.8A^2JC%
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M&1SM\,\[^'Q##0N4)A3-?@=HPV+02[1C@$8[4)I":4+1;/VTXS% HQU^6J?
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M<9C2](XQ'7"R3J[IW@CG)$P>5QC-,8T-Q/<%(?QS$$^0W_1V_@-02P,$%
M  @ ,*=Y6$8%VBH% @  %P0  !D   !X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL?91O;]HP$,:_RLF;IDZ:ZI#TS\222%!6K5*9$(CNQ;07)KD0"R?.;).4
M;S_;"0A-+6^(S[[G\>_L,W$GU4Z7B 9>*U'KA)3&-&-*=59BQ?2U;+"V*X54
M%3,V5%NJ&X4L]Z)*T# ([FC%>$W2V,\M5!K+O1&\QH4"O:\JI@Y3%+)+R(@<
M)Y9\6QHW0=.X85M<H5DW"V4C>G+)>86UYK(&A45")J/Q-'+Y/N&%8Z?/QN J
MV4BY<\%3GI#  :' S#@'9C\M/J 0SLAB_!T\R6E+)SP?']T??>VVE@W3^"#%
M+YZ;,B%?">18L+TP2]G]P*&>6^>72:']+W1];G1#(-MK(ZM!; DJ7O=?]CJ<
MPYD@'+TC" =!Z+G[C3SEC!F6QDIVH%RV=7,#7ZI76SA>NTM9&657N=69]''R
MM(27R?/Z.US-T# N-/QD2C%W6)]C:NP>+I-F@]^T]PO?\9NS T2C+Q &803K
MU0RN/O[G0BWA"3,\88;>]N8=VQ4JCAHFL+"7ADIA#BLCLQW\GF.U0?7G+=*+
MEJ[;Q[IA&2;$MK-&U2))/WT8W07?+@!')^#H(O#, K?^$$%PMN&"FP,4C"MH
MF=CC6[B]X;TW=&^I38.8MN<,].R>W9.9,[7EM0:!A=4$U_>W!%3?AGU@9..O
M?B.-;20_+.W+1>42['HAI3D&KIM._P7I/U!+ P04    "  PIWE8SM\!BU "
M  #J!   &0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6R55&UOVC 0_BNG
M3)HV:2(O4#IU$(E"VB+U3="7#],^F.0@5F,[LPVT_[YGAT9,HDC[$OO.]SSW
MG'/GP5;I%U,B6G@5E33#H+2V/@M#DY<HF.FH&B6=+)46S)*I5Z&I-;+"@T05
M)E'4#P7C,D@'WG>OTX%:VXI+O-=@UD(P_7:.E=H.@SCX<,SXJK3.$::#FJUP
MCO:QOM=DA2U+P05*PY4$C<MA,(K/SGLNW@<\<=R:O3VX2A9*O3AC6@R#R G"
M"G/K&!@M&QQC53DBDO%WQQFT*1UP?__!?N%KIUH6S.!85<^\L.4P^!E @4NV
MKNQ,;:]P5\^)X\M59?P7MDUL/PH@7QNKQ Y,"@27S<I>=_>P!XC[GP"2'2#Q
MNIM$7N6$698.M-J"=M'$YC:^5(\F<5RZGS*WFDXYX6PZ'U]ED\?K#.XNX#F;
M7EX]9!,8/66ST64&L^QF-+V=WE["=3::9_"0S6[@VP0MXY7Y/@@M"7 T8;Y+
M=MXD2SY)-L&\ ]WX!R11DOP+#TEW*SYIQ2>>K_L)WU@)P2VUB#7 9 %C)2V7
M*Y0Y1P,3;O)*F;5&^#U:&*NI _X<$MTDZ1U.XJ;BS-0LQV% ;6]0;S!(OWZ)
M^]&O(R5TVQ*ZQ]C3NQHU<Z*A0FHN0XWN1JEU@$4M#HD^3GL*@NZB--"'@KV9
M(T)[K=#>_PB%@FY7K:4%\N(A@0U=''D^]S9LTJ@3TV_?[*L(]UK7O0(W3*^X
M-)1D2;"H<WH2@&XFJS&LJGTW+Y2EV?#;DAXCU"Z SI=*V0_##4C[O*7O4$L#
M!!0    ( #"G>5C;81&]P04  #$I   9    >&PO=V]R:W-H965T<R]S:&5E
M=#4Y+GAM;+6:76_;-A2&_PKA#4,'=)%$R9:3.09<B]T"U(G1I-W%L M&8FQA
M^G!).FF _?A1'Y%,2V&BXJ07C27S/*3>0Q_QE3A[R/F_8LN81-_3)!/GHZV4
MNS/+$N&6I52<Y#N6J6_N<IY2J0[YQA([SFA4!J6)A6U[8J4TSD;S67ENS>>S
M?"^3.&-KCL0^32E__,"2_.%\Y(R>3GR.-UM9G+#FLQW=L&LFO^S67!U9#26*
M4Y:).,\09W?GHX5S1O"D""A;?(W9@SCXC(I+N<WS?XN#B^A\9!<C8@D+98&@
MZL\]6[(D*4AJ'-]JZ*CILP@\_/Q$_UA>O+J86RK8,D_^BB.Y/1]-1RAB=W2?
MR,_YPY^LOJ!QP0OS1)3_HX>JK>^.4+@7,D_K8#6"-,ZJO_1[+<1! ,;/!. Z
M +\VP*T#W-<&>'6 ]]J <1U07KI577LI7$ EG<]X_H!XT5K1B@^E^F6TTBO.
MBHER+;GZ-E9Q<KZ\6JTN;E;D\N8:+2X#M+RZO+FX_(-<+B_(-7H7,$GC1*!+
MRCDM4OKKS)*JVR+8"NLNEE47^)DN'(Q6>2:W I$L8I$.L-1XFT'CIT%_P$9B
MP,(3A"?O$;8='WVY#M"[GWL']@J,ZQ08[!HPP>LQV( A0T:S^-*#T<1RFPR[
M)==]AKOFJJIP^?@>K1.:242S")%O^WBG?NX2_?U)-4<7DJ7BGYXQ?ZC87C^[
MJ&)G8D=#=CY294HP?L]&\U]^<B;V[WWI@(0%D# "!-,2Y#4)\DST^6=%I#S<
MEIF)V+TJWE5NV'=U.Q!,].7%B!R:EPKFE[#BSG(_]_$8>ZX_L^X/)>^VF]K8
M]WU7;T> !J>I.6[4'!O5_+B7>\Y02,6V3S=C\%#=*MCD0 ^,I_ZI?ZQ;MYWC
M^]B=3KTCX8!&IPDW:82;O# -7YARQO"ATDVZDC@>]IPCY2:=&>=@>S(Y$I@
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M5\?L7 =4N444Q<630=7^E74.U.&"T@)0&H&BZ4EL_;(S?LLZ!VJH06D!*(U
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M_?O9#F2  MK#7A)_W'/N.3?Q=6O#^*M8 DCTGF=4M*VEE,6M;8MX"3D1UZP
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M86DKFPX$7>IN<$J%["WUX4*V_\#4!?+\C%*Q&Z@%\G\HO+]02P,$%     @
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M':HAS@^0-C&CACUJ>!%UAAM&1;DFM%E@>=EAV=Q@$52XR!NF:,6^H0=XT1;
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M%2#OSR@5+QLUJ963N?\74$L#!!0    ( #"G>5B+-RWO7P,  '\*   9
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M#UCXE(A,9F6P9IZ =)ALQIIM(Q,OC)GJ+W3&72XXBR :IIBQ9L=$*QHRXM"
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M>#ZW7"]_67[MG-SC%YS3;45]_@M02P,$%     @ ,*=Y6*5_#G'N 0  D"8
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MJ_E/6>^=6_]Q_/@L.]OT;_EL_"/:X@502P$"% ,4    "  PIWE8!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( #"G>5B6QPK<[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #"G>5B97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M,*=Y6%2/@&3+"   7#8  !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #"G>5B='7.AGP8   @>   8
M          " @0\1  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    "  PIWE8<PTBRV<#  #^#@  &               @('D%P  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ,*=Y6#H0IRPS!@  ?1@
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M965T."YX;6Q02P$"% ,4    "  PIWE8\E"U;+HG  #Z?@  &
M    @('F2@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M,*=Y6+V;1W)? P  ;0<  !D              ("!UG(  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    "  PIWE811\E&R$%  #T#   &0
M            @(%L=@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( #"G>5C0B6EP=P,  "H'   9              " @<1[  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ,*=Y6'7:_\T6 P
MF 8  !D              ("!<G\  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    "  PIWE8IU([84\8  #P2@  &0              @(&_
M@@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #"G>5C[
M<YYVT@@  "T8   9              " @46;  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ ,*=Y6$,S7<8J"0  1QT  !D
M     ("!3J0  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #"G>5@W2>Y1W (   L&   9              "
M@?+O  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ ,*=Y
M6/;L1"ZF P  \ <  !D              ("!!?,  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    "  PIWE8C[2XYV,#  !0!P  &0
M        @('B]@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( #"G>5A8MD 78 0  -@+   9              " @7SZ  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ ,*=Y6+50/;5@ P  &P<
M !D              ("!$_\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    "  PIWE8KBQ2L1@#  "1!@  &0              @(&J @$
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #"G>5BC(<^\
M-0@   09   9              " @?D% 0!X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ ,*=Y6/M]/2P6 P  ^ 8  !D
M ("!90X! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  P
MIWE8O!O\L%H(  #,'0  &0              @(&R$0$ >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( #"G>5B7P\K;N0(  .(%   9
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M970S-"YX;6Q02P$"% ,4    "  PIWE82^8VV64$  #'%P  &0
M    @($X- $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M #"G>5CG4DT^?P,  &(*   9              " @=0X 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ ,*=Y6$82@764 P  $@X  !D
M             ("!BCP! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    "  PIWE8R^2&H3X#  "K"@  &0              @(%50 $ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( #"G>5A-EP:?Q0(
M #T(   9              " @<I# 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ ,*=Y6.^:#UF! @  UP4  !D              ("!
MQD8! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  PIWE8
M*(<7(#\#  "<"P  &0              @(%^20$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( #"G>5APCKFF:0(  *@%   9
M      " @?1, 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ ,*=Y6.UN7F07 P  , D  !D              ("!E$\! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  PIWE8%$.,4Q4%  ":&0
M&0              @('B4@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( #"G>5C!%\#YM (   X'   9              " @2Y8 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ ,*=Y6/(FJ7[>
M P  E P  !D              ("!&5L! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    "  PIWE8QC[TWO$"  !F"   &0
M@($N7P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( #"G
M>5C,SBA9ZP0  +@8   9              " @59B 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ ,*=Y6&>&G0H:!   SQ$  !D
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M=#4S+GAM;%!+ 0(4 Q0    ( #"G>5@?C;J&K@0  (L<   9
M  " @0NW 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
M,*=Y6.8A^2JC%   938! !D              ("!\+L! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    "  PIWE8P\?VWM4$  #U%0  &0
M            @('*T $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( #"G>5A&!=HJ!0(  !<$   9              " @=;5 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ ,*=Y6,[? 8M0 @
MZ@0  !D              ("!$M@! 'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    "  PIWE8VV$1O<$%   Q*0  &0              @(&9
MV@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( #"G>5AG
MH*ZCNP(  .L&   9              " @9'@ 0!X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ ,*=Y6!RJZFLF P  7 P  !D
M     ("!@^,! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #"G>5AR7E06XP4  (\T   9              "
M@6+U 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ ,*=Y
M6+3K<^Q= P  L!8   T              ( !?/L! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  PIWE8EXJ[',     3 @  "P              @ $$_P$
M7W)E;',O+G)E;'-02P$"% ,4    "  PIWE8C*C_^9P%   ,+   #P
M        @ 'M_P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ,*=Y6![?
MF5X< @  /2<  !H              ( !M@4" 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ ,*=Y6*5_#G'N 0  D"8  !,
M     ( !"@@" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $H 2@ ]%
&*0H"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>279</ContextCount>
  <ElementCount>430</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>94</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties</Role>
      <ShortName>BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/AccruedLiabilities</Role>
      <ShortName>ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ShareCapitalAndOtherEquityInstruments</Role>
      <ShortName>SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/RedeemableNon-controllingInterest</Role>
      <ShortName>REDEEMABLE NON-CONTROLLING INTEREST</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - FAIR VALUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/FairValue</Role>
      <ShortName>FAIR VALUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables</Role>
      <ShortName>BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/PropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/AccruedLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables</Role>
      <ShortName>SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/ShareCapitalAndOtherEquityInstruments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/RedeemableNon-controllingInterestTables</Role>
      <ShortName>REDEEMABLE NON-CONTROLLING INTEREST (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/RedeemableNon-controllingInterest</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - FAIR VALUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/FairValueTables</Role>
      <ShortName>FAIR VALUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/FairValue</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails</Role>
      <ShortName>SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative</Role>
      <ShortName>BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - SCHEDULE OF GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfGoodwillDetails</Role>
      <ShortName>SCHEDULE OF GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/IntangibleAssetsAndGoodwillDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - SCHEDULE OF ACCRUED LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - SCHEDULE OF STOCK OPTION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfStockOptionDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - SCHEDULE OF STOCK OPTION ASSUMPTION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ASSUMPTION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails</Role>
      <ShortName>SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails</Role>
      <ShortName>SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS OUTSTANDING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails</Role>
      <ShortName>SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative</Role>
      <ShortName>SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative</Role>
      <ShortName>REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/RedeemableNon-controllingInterestTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails</Role>
      <ShortName>SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - FAIR VALUE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/FairValueDetailsNarrative</Role>
      <ShortName>FAIR VALUE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/FairValueTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails</Role>
      <ShortName>SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails</Role>
      <ShortName>SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails</Role>
      <ShortName>SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails</Role>
      <ShortName>SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails</Role>
      <ShortName>SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/IncomeTaxesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/SubsequentEvents</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[EXG.rendering.tooManyDimensions] Presentation group http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative with 12 axes could have more than 6 billion cells.  Split up this presentation group and see EXG, Rendering, to see how to reduce the number of combinations by selecting fewer members for each axis. - form10-k.htm  - form10-k.htm </Log>
  </Logs>
  <InputFiles>
    <File>envb-20231231.xsd</File>
    <File>envb-20231231_cal.xml</File>
    <File>envb-20231231_def.xml</File>
    <File>envb-20231231_lab.xml</File>
    <File>envb-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="862">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "ENVB",
   "nsuri": "http://enveric.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "envb-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "envb-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "envb-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "envb-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "envb-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    }
   },
   "keyStandard": 324,
   "keyCustom": 106,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 34,
   "memberCustom": 58,
   "hidden": {
    "total": 244,
    "http://enveric.com/20231231": 90,
    "http://fasb.org/us-gaap/2023": 151,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 279,
   "entityCount": 1,
   "segmentCount": 94,
   "elementCount": 647,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 862,
    "http://xbrl.sec.gov/dei/2023": 39
   },
   "report": {
    "R1": {
     "role": "http://enveric.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://enveric.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://enveric.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity",
     "shortName": "Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical",
     "longName": "00000006 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "ENVB:NetOfferingCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "ENVB:NetOfferingCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://enveric.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties",
     "longName": "00000008 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES",
     "shortName": "BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://enveric.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://enveric.com/role/IntangibleAssetsAndGoodwill",
     "longName": "00000011 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://enveric.com/role/PropertyAndEquipment",
     "longName": "00000012 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://enveric.com/role/AccruedLiabilities",
     "longName": "00000013 - Disclosure - ACCRUED LIABILITIES",
     "shortName": "ACCRUED LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://enveric.com/role/ShareCapitalAndOtherEquityInstruments",
     "longName": "00000014 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS",
     "shortName": "SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://enveric.com/role/RedeemableNon-controllingInterest",
     "longName": "00000015 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST",
     "shortName": "REDEEMABLE NON-CONTROLLING INTEREST",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "ENVB:RedeemableNonControllingInterestTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "ENVB:RedeemableNonControllingInterestTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://enveric.com/role/FairValue",
     "longName": "00000016 - Disclosure - FAIR VALUE",
     "shortName": "FAIR VALUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://enveric.com/role/CommitmentsAndContingencies",
     "longName": "00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://enveric.com/role/IncomeTaxes",
     "longName": "00000018 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://enveric.com/role/SubsequentEvents",
     "longName": "00000019 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables",
     "longName": "00000021 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)",
     "shortName": "BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "00000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://enveric.com/role/IntangibleAssetsAndGoodwillTables",
     "longName": "00000024 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://enveric.com/role/PropertyAndEquipmentTables",
     "longName": "00000025 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://enveric.com/role/AccruedLiabilitiesTables",
     "longName": "00000026 - Disclosure - ACCRUED LIABILITIES (Tables)",
     "shortName": "ACCRUED LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables",
     "longName": "00000027 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)",
     "shortName": "SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://enveric.com/role/RedeemableNon-controllingInterestTables",
     "longName": "00000028 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Tables)",
     "shortName": "REDEEMABLE NON-CONTROLLING INTEREST (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ENVB:RedeemableNonControllingInterestTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ENVB:RedeemableNonControllingInterestTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://enveric.com/role/FairValueTables",
     "longName": "00000029 - Disclosure - FAIR VALUE (Tables)",
     "shortName": "FAIR VALUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://enveric.com/role/CommitmentsAndContingenciesTables",
     "longName": "00000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://enveric.com/role/IncomeTaxesTables",
     "longName": "00000031 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails",
     "longName": "00000032 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)",
     "shortName": "SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "ENVB:RestructuringCostsIncurred",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "ENVB:RestructuringCostsIncurred",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
     "longName": "00000033 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)",
     "shortName": "BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "ENVB:WorkingCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails",
     "longName": "00000034 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)",
     "shortName": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredOfferingCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ENVB:DeferredOfferingCostsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember",
      "name": "us-gaap:StockIssued1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "00000036 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "ENVB:PrepaidResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "ENVB:PrepaidResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://enveric.com/role/ScheduleOfGoodwillDetails",
     "longName": "00000037 - Disclosure - SCHEDULE OF GOODWILL (Details)",
     "shortName": "SCHEDULE OF GOODWILL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31",
      "name": "us-gaap:GoodwillGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31",
      "name": "us-gaap:GoodwillGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://enveric.com/role/ScheduleOfIntangibleAssetsDetails",
     "longName": "00000038 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "shortName": "SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails",
     "longName": "00000039 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)",
     "shortName": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://enveric.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
     "longName": "00000040 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails",
     "longName": "00000041 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)",
     "shortName": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://enveric.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "00000042 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails",
     "longName": "00000043 - Disclosure - SCHEDULE OF ACCRUED LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ACCRUED LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "ENVB:AccruedProductDevelopmentCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "ENVB:AccruedProductDevelopmentCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://enveric.com/role/ScheduleOfStockOptionDetails",
     "longName": "00000044 - Disclosure - SCHEDULE OF STOCK OPTION (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails",
     "longName": "00000045 - Disclosure - SCHEDULE OF STOCK OPTION ASSUMPTION (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION ASSUMPTION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails",
     "longName": "00000046 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)",
     "shortName": "SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails",
     "longName": "00000047 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)",
     "shortName": "SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails",
     "longName": "00000048 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)",
     "shortName": "SCHEDULE OF WARRANTS OUTSTANDING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ENVB:ScheduleOfWarrantsOutstandingTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_WarrantMember",
      "name": "ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENVB:ScheduleOfWarrantsOutstandingTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
     "longName": "00000049 - Disclosure - SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)",
     "shortName": "SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_custom_InvestmentOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31_custom_InvestmentOptionsMember",
      "name": "ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
     "longName": "00000050 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)",
     "shortName": "SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENVB:ScheduleOfValuationOfWarrantsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
     "longName": "00000051 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)",
     "shortName": "SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails",
     "longName": "00000052 - Disclosure - SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ENVB:RedeemableNonControllingInterestTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
     "longName": "00000053 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)",
     "shortName": "REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember",
      "name": "us-gaap:DividendsPayableAmountPerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "ENVB:RedeemableNonControllingInterestTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
     "longName": "00000054 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
     "longName": "00000055 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)",
     "shortName": "SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember",
      "name": "ENVB:ConvertiblePreferredStockPrincipalValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember",
      "name": "ENVB:ConvertiblePreferredStockPrincipalValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails",
     "longName": "00000056 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://enveric.com/role/FairValueDetailsNarrative",
     "longName": "00000057 - Disclosure - FAIR VALUE (Details Narrative)",
     "shortName": "FAIR VALUE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember",
      "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember",
      "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails",
     "longName": "00000058 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)",
     "shortName": "SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails",
     "longName": "00000060 - Disclosure - SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)",
     "shortName": "SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails",
     "longName": "00000061 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)",
     "shortName": "SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "00000062 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails",
     "longName": "00000063 - Disclosure - SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)",
     "shortName": "SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_DomesticCountryMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_DomesticCountryMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails",
     "longName": "00000064 - Disclosure - SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)",
     "shortName": "SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://enveric.com/role/IncomeTaxesDetailsNarrative",
     "longName": "00000065 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://enveric.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000066 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-03-082024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "AU",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/AccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED LIABILITIES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r660"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r801"
     ]
    },
    "ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "AccretionOfEmbeddedDerivativeToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of embedded derivative to redemption value",
        "label": "Accretion of embedded derivative to redemption value",
        "documentation": "Accretion of embedded derivative to redemption value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance bonus",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued franchise taxes",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r135"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ENVB_AccruedProductDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "AccruedProductDevelopmentCost",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product development",
        "documentation": "Accrued product and development cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ENVB_AccruedRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "AccruedRestructuringCosts",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued restructuring costs",
        "documentation": "Accrued restructuring costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent costs",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r640"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued salaries, wages, and bonuses",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r640"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r161",
      "r503"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r103",
      "r167",
      "r499",
      "r516",
      "r517"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r14",
      "r36",
      "r418",
      "r421",
      "r448",
      "r512",
      "r513",
      "r711",
      "r712",
      "r713",
      "r720",
      "r721",
      "r722"
     ]
    },
    "ENVB_AdditionalMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "AdditionalMilestoneMember",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Milestone [Member]",
        "documentation": "Additional Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r660",
      "r804"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r526",
      "r720",
      "r721",
      "r722",
      "r785",
      "r805"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r342"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Inducement Warrants, net of offering costs of $239,302",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r64",
      "r125"
     ]
    },
    "ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Induced conversion of warrants and preferred investment options",
        "documentation": "Induced conversion of warrants and preferred investment options."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_AkosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "AkosMember",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Akos [Member]",
        "documentation": "Akos [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_AkosSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "AkosSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Akos Securities Purchase Agreement [Member]",
        "documentation": "Akos Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense for RSUs",
        "verboseLabel": "Stock based compensation, expenses",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r383"
     ]
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AlternativeInvestmentMeasurementInput",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market rate",
        "documentation": "Value of input used to measure alternative investment."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://enveric.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://enveric.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of intangibles",
        "negatedLabel": "Amortization",
        "verboseLabel": "Intangible assets, amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54",
      "r57"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total potentially dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment losses",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r163",
      "r188",
      "r221",
      "r230",
      "r232",
      "r269",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r412",
      "r415",
      "r436",
      "r493",
      "r566",
      "r660",
      "r672",
      "r747",
      "r748",
      "r792"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r168",
      "r188",
      "r269",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r412",
      "r415",
      "r436",
      "r660",
      "r747",
      "r748",
      "r792"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r269",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r412",
      "r415",
      "r436",
      "r747",
      "r748",
      "r792"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r686",
      "r687"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r686",
      "r687"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r686",
      "r687"
     ]
    },
    "ENVB_AvanceClinicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "AvanceClinicalMember",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Avance Clinical [Member]",
        "documentation": "Avance Clinical [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Principal of Consolidation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CA",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_CanaccordGenuityLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "CanaccordGenuityLLCMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canaccord Genuity LLC [Member]",
        "documentation": "Canaccord Genuity LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostNet",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract cost",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "verboseLabel": "Future cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r495",
      "r537",
      "r561",
      "r660",
      "r672",
      "r706"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash at beginning of year",
        "periodEndLabel": "Cash at end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r112",
      "r185"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r112"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/FairValueDetailsNarrative",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r164",
      "r165",
      "r166",
      "r188",
      "r209",
      "r210",
      "r213",
      "r215",
      "r219",
      "r220",
      "r269",
      "r303",
      "r305",
      "r306",
      "r307",
      "r310",
      "r311",
      "r315",
      "r316",
      "r318",
      "r321",
      "r328",
      "r436",
      "r520",
      "r521",
      "r522",
      "r523",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r538",
      "r553",
      "r575",
      "r593",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r695",
      "r717",
      "r724"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants share price",
        "verboseLabel": "Warrant measurement input",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of additional warrants",
        "documentation": "Class of warrant or right number of additional securities called by warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued shares",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants to purchase",
        "verboseLabel": "Purchase of common stock",
        "terseLabel": "Warrants to purchase shares of common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, number of warrants",
        "verboseLabel": "Existing Warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ClassOfWarrantOrRightReasonForIssuing": {
     "xbrltype": "stringItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ClassOfWarrantOrRightReasonForIssuing",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issued description",
        "documentation": "Warrant issued description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "ENVB_CommissionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "CommissionPercentage",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commission percentage",
        "documentation": "Commission percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 10)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r90",
      "r494",
      "r552"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r297",
      "r298",
      "r625",
      "r746"
     ]
    },
    "ENVB_CommonStockInAbeyanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "CommonStockInAbeyanceMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock in abeyance [Member]",
        "documentation": "Common stock in abeyance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r663",
      "r664",
      "r666",
      "r667",
      "r668",
      "r669",
      "r720",
      "r721",
      "r785",
      "r803",
      "r805"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock par value",
        "terseLabel": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r553"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r97",
      "r553",
      "r572",
      "r805",
      "r806"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.01 par value, 100,000,000 shares authorized, 2,739,315 and 2,078,271 shares issued and outstanding as of December 31, 2023 and 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r497",
      "r660"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r171",
      "r173",
      "r178",
      "r489",
      "r508"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ComputerEquipmentAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ComputerEquipmentAndLeaseholdImprovementsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment and Leasehold Improvements [Member]",
        "documentation": "Computer Equipment and Leasehold Improvements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r146"
     ]
    },
    "us-gaap_ConstructionContractCostProgressPaymentOffset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionContractCostProgressPaymentOffset",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of contract cost",
        "documentation": "Amount of progress payment netted against construction contract cost."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ENVB_ConvertiblePreferredStockPrincipalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ConvertiblePreferredStockPrincipalValue",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal",
        "documentation": "Convertible Preferred Stock Principal Value."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r719",
      "r782"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r719"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total current income tax (expense) benefit",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r399",
      "r405",
      "r719"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r719",
      "r782"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r781",
      "r782"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r719",
      "r781"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred income tax (expense) benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r131",
      "r152",
      "r404",
      "r405",
      "r719"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "verboseLabel": "Offering expenses",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ENVB_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "documentation": "Deferred Offering Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r781",
      "r782"
     ]
    },
    "ENVB_DeferredTaxAssetsAndIntangibleAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "DeferredTaxAssetsAndIntangibleAmortization",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible amortization",
        "documentation": "Deferred tax assets and intangible amortization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r780"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r780"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r780"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowances",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://enveric.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59"
     ]
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/FairValueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability fair value",
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivative liability",
        "negatedLabel": "Change in fair value of derivative liability",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "DerivativeLiabilityMayTwoThousandTwentyTwoMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability May 2022 [Member]",
        "documentation": "Derivative Liability May 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative [Member]",
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender)."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r82",
      "r83",
      "r84",
      "r85",
      "r191"
     ]
    },
    "ENVB_DisclosureRedeemableNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "DisclosureRedeemableNoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Non-controlling Interest",
        "verboseLabel": "Schedule Of Reconciliation Change In Redeemable Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_DistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "DistributionAgreementMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution Agreement [Member]",
        "documentation": "Distribution Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableAmountPerShare",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, per share",
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r125"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r686",
      "r687"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r686",
      "r687",
      "r689"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated By Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r206",
      "r209",
      "r213",
      "r214",
      "r215",
      "r217",
      "r426",
      "r427",
      "r490",
      "r509",
      "r642"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r209",
      "r213",
      "r214",
      "r215",
      "r217",
      "r426",
      "r427",
      "r490",
      "r509",
      "r642"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Foreign Exchange Rate on Changes on Cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal income tax at the statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r390",
      "r407"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r783"
     ]
    },
    "ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup": {
     "xbrltype": "percentItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTrueup",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred true-up",
        "documentation": "Effective income tax rate reconciliation deferred trueup."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign tax rate differential",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r783"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible expenses",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r783"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax rate (net of federal)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r783"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, unamortized",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r156",
      "r175",
      "r176",
      "r177",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r204",
      "r218",
      "r270",
      "r271",
      "r330",
      "r375",
      "r376",
      "r377",
      "r400",
      "r401",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r448",
      "r512",
      "r513",
      "r514",
      "r526",
      "r593"
     ]
    },
    "ENVB_EquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "EquityDistributionAgreementMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Distribution Agreement [Member]",
        "documentation": "Equity Distribution Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "auth_ref": [
      "r266",
      "r267",
      "r268"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of stock issued and outstanding",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "ENVB_ExistingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ExistingWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Warrants [Member]",
        "documentation": "Existing Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ExpenseRelatedToAccelerationOfVesting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ExpenseRelatedToAccelerationOfVesting",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense related to acceleration of vesting",
        "documentation": "Expense related to acceleration of vesting."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      },
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liabilities",
        "label": "Change in fair value of warrant liability",
        "verboseLabel": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of derivative liability",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r434"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r434"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://enveric.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r430",
      "r455",
      "r456",
      "r457",
      "r650",
      "r651",
      "r654",
      "r655",
      "r656"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r432",
      "r433",
      "r435"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://enveric.com/role/FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r430",
      "r457",
      "r650",
      "r651",
      "r654",
      "r655",
      "r656"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://enveric.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r87"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of equity",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercise of investment options",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability period exercise of investment options.",
        "label": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercise of warrants",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability period exercise of warrants.",
        "label": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value, modification",
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of derivative liability",
        "periodStartLabel": "Total beginning balance",
        "periodEndLabel": "Total ending balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r455",
      "r456",
      "r457",
      "r650",
      "r651",
      "r654",
      "r655",
      "r656"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r435"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r25"
     ]
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_FebruaryTwentyTwentyOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "FebruaryTwentyTwentyOneWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2021 Warrants [Member]",
        "documentation": "February 2021 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "FebruaryTwentyTwentyTwoPostModificationWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2022 Post-Modification Warrants [Member]",
        "documentation": "February 2022 Post-Modification Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_FebruaryTwentyTwentyTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "FebruaryTwentyTwentyTwoWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2022 Warrants [Member]",
        "documentation": "February 2022 warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_FebruaryWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "FebruaryWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February Warrants [Member]",
        "documentation": "February Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r313",
      "r326",
      "r423",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r507",
      "r646",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r727",
      "r728",
      "r729",
      "r730"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant liability",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails",
      "http://enveric.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, Definite lived intangible assets",
        "periodEndLabel": "Balance, Definite lived intangible assets",
        "totalLabel": "Finite lived assets amortization expense",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r487"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of investment option liability",
        "negatedLabel": "Change in fair value of investment option liability",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r694"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r577"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Goodwill, Beginning balance",
        "periodEndLabel": "Goodwill, Ending balance",
        "label": "Goodwill [Default Label]",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r282",
      "r488",
      "r649",
      "r660",
      "r735",
      "r742"
     ]
    },
    "ENVB_GoodwillAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "GoodwillAccumulatedImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Impairment Losses, Impairment losses",
        "documentation": "Goodwill accumulated impairment loss.",
        "label": "GoodwillAccumulatedImpairmentLoss"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Impairment Losses, Loss on currency translation",
        "documentation": "Goodwill accumulated impairment loss foreign currency translation gain loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of intangible assets and goodwill",
        "verboseLabel": "Impairment of intangibles",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/IntangibleAssetsAndGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS AND GOODWILL",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r288",
      "r649"
     ]
    },
    "ENVB_GoodwillCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "GoodwillCurrencyTranslation",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Currency Translation, Beginning balance",
        "periodEndLabel": "Currency Translation, Ending balance",
        "documentation": "Goodwill currency translation.",
        "label": "GoodwillCurrencyTranslation"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_GoodwillCurrencyTranslationImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "GoodwillCurrencyTranslationImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Currency Translation, Impairment losses",
        "documentation": "Goodwill currency translation impairment loss.",
        "label": "GoodwillCurrencyTranslationImpairmentLoss"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_GoodwillCurrencyTranslationLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "GoodwillCurrencyTranslationLoss",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency Translation, Loss on currency translation",
        "documentation": "Goodwill currency translation loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Loss on currency translation",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ENVB_GoodwillForeignCurrencyTranslationGainLossGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "GoodwillForeignCurrencyTranslationGainLossGross",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill Gross, Loss on currency translation",
        "documentation": "Goodwill foreign currency translation gain loss gross."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillGross",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Goodwill Gross, Beginning balance",
        "periodEndLabel": "Goodwill Gross, Ending balance",
        "label": "Goodwill, Gross",
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r287",
      "r649"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Accumulated Impairment Losses, Beginning balance",
        "negatedPeriodEndLabel": "Accumulated Impairment Losses, Ending balance",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r287",
      "r649"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Goodwill, Impairment losses",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r283",
      "r285",
      "r288",
      "r649"
     ]
    },
    "ENVB_GoodwillImpairmentLossGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "GoodwillImpairmentLossGross",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Goodwill Gross, Impairment losses",
        "documentation": "Goodwill impairment loss gross",
        "label": "GoodwillImpairmentLossGross"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "HCWainwrightAndCoLLCInvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "HC Wainwright and Co LLC Investment Options [Member]",
        "documentation": "HC Wainwright and Co LLC Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r686",
      "r687"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r406"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income taxes",
        "label": "Total",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r104",
      "r137",
      "r221",
      "r229",
      "r231",
      "r233",
      "r491",
      "r505",
      "r643"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r406"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r292",
      "r578"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r578"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r386",
      "r391",
      "r392",
      "r397",
      "r402",
      "r408",
      "r409",
      "r410",
      "r525"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax (expense) benefit",
        "negatedTotalLabel": "Total income tax (expense) benefit",
        "label": "Income tax expenses and benefits",
        "negatedTerseLabel": "Income tax expenses and benefits",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r153",
      "r203",
      "r204",
      "r222",
      "r389",
      "r403",
      "r510"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r387",
      "r388",
      "r392",
      "r393",
      "r396",
      "r398",
      "r519"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense gross",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use operating lease asset and obligation",
        "documentation": "Right-of-use operating lease asset and obligation.",
        "label": "IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, Indefinite lived intangible assets",
        "periodEndLabel": "Balance, Indefinite lived intangible assets",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on currency translation",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "InducedConversionOfWarrantsAndPreferredInvestmentOptions",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Induced conversion of warrants and preferred investment options",
        "documentation": "Induced conversion of warrants and preferred investment options.",
        "label": "InducedConversionOfWarrantsAndPreferredInvestmentOptions"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InducementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "InducementExpense",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      },
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inducement expense, net",
        "label": "Inducement expense",
        "documentation": "Inducement expense."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InitialMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "InitialMeasurementMember",
     "presentation": [
      "http://enveric.com/role/FairValueTables",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Measurement [Member]",
        "documentation": "Initial Measurement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r483",
      "r484",
      "r485",
      "r487",
      "r641"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income (expense), net",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r183",
      "r184"
     ]
    },
    "ENVB_InvestmentInducementGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "InvestmentInducementGain",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inducement gain",
        "documentation": "Investment inducement gain."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "InvestmentIntrinsicValue",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intrinsic value",
        "documentation": "Investment intrinsic value.",
        "label": "InvestmentIntrinsicValue"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOptionExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "InvestmentOptionExercisePrice",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price",
        "documentation": "Investment option exercise price.",
        "label": "InvestmentOptionExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOptionSharePrice": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "InvestmentOptionSharePrice",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share price",
        "documentation": "Investment option share price.",
        "label": "InvestmentOptionSharePrice"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOptionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "InvestmentOptionTerm",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Term (years)",
        "label": "Investment option term",
        "documentation": "Investment option term."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment options issued in conjunction with common stock issuance",
        "documentation": "Investment options issued in conjunction with common stock issuance."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "InvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Options [Member]",
        "documentation": "Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "InvestmentOutstandingMeasurementInput",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment outstanding, measurement input",
        "documentation": "Investment outstanding measurement input."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of investment options",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r543",
      "r601",
      "r609",
      "r616",
      "r664"
     ]
    },
    "ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "InvstmentOptionsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Options to Purchase Shares of Common Stock [Member]",
        "documentation": "Investment Options to Purchase Shares of Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "IssuanceOfCommonSharesForDeferredOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common shares for deferred offering costs",
        "documentation": "Issuance of common shares for deferred offering costs.",
        "label": "IssuanceOfCommonSharesForDeferredOfferingCosts"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_IssuanceOfEmbeddedDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "IssuanceOfEmbeddedDerivative",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of embedded derivative",
        "documentation": "Issuance of embedded derivative.",
        "label": "IssuanceOfEmbeddedDerivative"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "IssuanceOfRedeemableNoncontrollingSeriesPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of redeemable Series C preferred stock",
        "documentation": "Issuance of redeemable noncontrolling series preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "IssuanceOfRoundedSharesAsResultOfReverseStockSplit",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of rounded shares as a result of the reverse stock split",
        "documentation": "Issuance of rounded shares as result of reverse stock split."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_JanuaryTwentyTwentyOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "JanuaryTwentyTwentyOneWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2021 Warrants [Member]",
        "documentation": "January 2021 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_KanubaddiSeparationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "KanubaddiSeparationAgreementMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kanubaddi Separation Agreement [Member]",
        "documentation": "Kanubaddi Separation Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab Equipment [Member]",
        "documentation": "Lab Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, mezzanine equity, and shareholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r136",
      "r501",
      "r660",
      "r718",
      "r731",
      "r788"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r159",
      "r188",
      "r269",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r413",
      "r415",
      "r416",
      "r436",
      "r660",
      "r747",
      "r792",
      "r793"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesRelatedToInvestmentContractsFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of investment option liability",
        "documentation": "Fair value portion of liability related to investment contracts for example, but not limited to, guaranteed investment contract or annuities."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term purchase commitment, amount",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_MarketPerformanceBasedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "MarketPerformanceBasedShares",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market performance based shares",
        "documentation": "Market performance based shares."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r338",
      "r482",
      "r511",
      "r544",
      "r545",
      "r599",
      "r603",
      "r607",
      "r608",
      "r614",
      "r635",
      "r636",
      "r645",
      "r652",
      "r657",
      "r661",
      "r749",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ENVB_MeasurementInputMarketRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "MeasurementInputMarketRateMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Market Rate [Member]",
        "documentation": "Measurement Input Market Rate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_MezzanineEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "MezzanineEquityMember",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine Equity [Member]",
        "documentation": "Mezzanine Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r338",
      "r482",
      "r511",
      "r544",
      "r545",
      "r599",
      "r603",
      "r607",
      "r608",
      "r614",
      "r635",
      "r636",
      "r645",
      "r652",
      "r657",
      "r661",
      "r749",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799"
     ]
    },
    "ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum of stockholders equity required for continued listing pursuant to exchange",
        "documentation": "Minimum of stockholders equity required for continued listing pursuant to exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification and Inducement of Warrants and Investment Options",
        "documentation": "Modification and Inducement of Warrants and Investment Options [Policy text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ModificationOfWarrantsAsPartOfShareCapitalRaise",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of warrants as part of share capital raise",
        "documentation": "Modification of warrants as part of share capital raise."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_MrKanubaddiEmploymentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "MrKanubaddiEmploymentAgreementMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Kanubaddi Employment Agreement [Member]",
        "documentation": "Mr Kanubaddi Employment Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r154"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r114",
      "r138",
      "r157",
      "r170",
      "r172",
      "r177",
      "r188",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r211",
      "r221",
      "r229",
      "r231",
      "r233",
      "r269",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r427",
      "r436",
      "r506",
      "r574",
      "r591",
      "r592",
      "r643",
      "r670",
      "r747"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to shareholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r197",
      "r198",
      "r199",
      "r200",
      "r206",
      "r207",
      "r212",
      "r215",
      "r221",
      "r229",
      "r231",
      "r233",
      "r643"
     ]
    },
    "ENVB_NetOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "NetOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net offering costs",
        "documentation": "Net offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_NoncashIncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "NoncashIncomeTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash income tax benefit",
        "documentation": "Noncash income tax expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense) income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (expense) income"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_NumberOfVestedAndUnissuedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "NumberOfVestedAndUnissuedShares",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of vested and unissued shares",
        "documentation": "Number of vested and unissued shares."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_OfferingCostsAccruedNotPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "OfferingCostsAccruedNotPaid",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering costs accrued not paid",
        "documentation": "Offering costs accrued not paid."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_OneTimeMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "OneTimeMilestoneMember",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Time Milestone [Member]",
        "documentation": "One Time Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Costs and Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "negatedLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r229",
      "r231",
      "r233",
      "r643"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of right-of-use operating lease obligation",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use operating lease asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of ROU asset",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss tax carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_OptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Held [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r562",
      "r567",
      "r581",
      "r587",
      "r611",
      "r612",
      "r613",
      "r662",
      "r663"
     ]
    },
    "ENVB_OptionsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "OptionsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options to Purchase Shares of Common Stock [Member]",
        "documentation": "Options to Purchase Shares of Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation",
        "verboseLabel": "Foreign exchange translation loss",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_OtherConsultingAndVendorAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "OtherConsultingAndVendorAgreementsMember",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Consulting and Vendor Agreements [Member]",
        "documentation": "Other Consulting and Vendor Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment option liability",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r660"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r732"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_OtherRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherRestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring costs reversed",
        "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ENVB_PIPEInvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PIPEInvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pipe Investment Options [Member]",
        "documentation": "Pipe Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PIPESecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PIPESecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PIPE Securities Purchase Agreement [Member]",
        "documentation": "PIPE Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expenses",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase committment",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfRedeemablePreferredStock",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails",
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Redemption of Series A Preferred Stock",
        "negatedTerseLabel": "Redemption of Akos Series A Preferred Stock",
        "label": "Payments for Repurchase of Redeemable Preferred Stock",
        "documentation": "The cash outflow for reacquisition of callable preferred stock."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ENVB_PaymentsOfAllocatedEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PaymentsOfAllocatedEquity",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of allocated equity",
        "documentation": "Payments of allocated equity."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PaymentsOfInvestmentOptionLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PaymentsOfInvestmentOptionLiability",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of investment option liability",
        "documentation": "Payments of investment option liability."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PaymentsOfStockIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PaymentsOfStockIssuanceCost",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offerings costs",
        "documentation": "Payments of stock issuance cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment for equity distribution offering costs",
        "verboseLabel": "Offerings costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ENVB_PaymentsOfStockIssuanceCostsRecordedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PaymentsOfStockIssuanceCostsRecordedExpense",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of stock issuance costs recorded expense",
        "documentation": "Payments of stock issuance costs recorded expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "ENVB_PlacementAgentPreferredInvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PlacementAgentPreferredInvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Preferred Investment Options [Member]",
        "documentation": "Placement Agent Preferred Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "ENVB_PostModificationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PostModificationWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Modification Warrants [Member]",
        "documentation": "Post Modification Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ENVB_PreModificationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PreModificationWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Modification Warrants [Member]",
        "documentation": "Pre Modification Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PreferredDividendsAttributableToRedeemableNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Preferred dividends attributable to redeemable non-controlling interest",
        "label": "Preferred dividends attributable to redeemable non-controlling interest",
        "documentation": "Preferred dividends attributable to redeemable noncontrolling interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock authorized for future issuances",
        "documentation": "Aggregate number of nonredeemable preferred shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend rate",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r600",
      "r604",
      "r606",
      "r615"
     ]
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less preferred dividends attributable to non-controlling interest",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r315"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r553"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r315"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r553",
      "r572",
      "r805",
      "r806"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r496",
      "r660"
     ]
    },
    "us-gaap_PreferredStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockVotingRights",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock voting rights",
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r96"
     ]
    },
    "ENVB_PrefundedCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PrefundedCommonStockWarrantsMember",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Common Stock Warrants [Member]",
        "documentation": "Prefunded Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ENVB_PrepaidFranchiseTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PrepaidFranchiseTaxReceivable",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Franchise tax receivable",
        "documentation": "Prepaid franchise tax receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r647",
      "r732"
     ]
    },
    "ENVB_PrepaidResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PrepaidResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid research and development",
        "documentation": "Prepaid research and development."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PrepaidResearchAndDevelopmentTaxIncentiveReceivable",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D tax incentive receivable",
        "documentation": "Prepaid research and development tax incentive receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid value-added taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r648",
      "r732"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock, warrants, and investment options, net of offering costs",
        "verboseLabel": "Proceeds from common stock",
        "terseLabel": "Net Proceeds from sale of shares",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants for cash proceeds",
        "verboseLabel": "Proceeds from inducement warrant",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from RD offerings",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepurchaseOfRedeemablePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of redeemable non-controlling interest, net of offering costs",
        "documentation": "Cash inflows (outflows) from issuing and redeeming redeemable preferred stock; includes convertible and nonconvertible redeemable preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from disposal of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional working capital",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash proceeds of warrants",
        "verboseLabel": "Gross proceeds",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r147",
      "r150",
      "r151"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer equipment and leasehold improvements",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r160",
      "r504"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net of accumulated depreciation",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r492",
      "r504",
      "r660"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property &amp; Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r147",
      "r150",
      "r502"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://enveric.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RDInvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RDInvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RD Investment Options [Member]",
        "documentation": "RD Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RDOfferingAndPIPEInvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RDOfferingAndPIPEInvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RD Offering and Pipe Investment Options [Member]",
        "documentation": "RD Offering and Pipe Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r331",
      "r338",
      "r369",
      "r370",
      "r371",
      "r458",
      "r482",
      "r511",
      "r544",
      "r545",
      "r599",
      "r603",
      "r607",
      "r608",
      "r614",
      "r635",
      "r636",
      "r645",
      "r652",
      "r657",
      "r661",
      "r664",
      "r745",
      "r749",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r331",
      "r338",
      "r369",
      "r370",
      "r371",
      "r458",
      "r482",
      "r511",
      "r544",
      "r545",
      "r599",
      "r603",
      "r607",
      "r608",
      "r614",
      "r635",
      "r636",
      "r645",
      "r652",
      "r657",
      "r661",
      "r664",
      "r745",
      "r749",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799"
     ]
    },
    "ENVB_RedeemableNonControllingInterestTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RedeemableNonControllingInterestTextBlock",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REDEEMABLE NON-CONTROLLING INTEREST",
        "documentation": "Redeemable non controlling interest [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RedeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RedeemableNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable noncontrolling interest",
        "documentation": "Redeemable non controlling interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable non-controlling interest",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r69"
     ]
    },
    "ENVB_RedeemableNoncontrollingInterestIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RedeemableNoncontrollingInterestIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable noncontrolling interest issuance costs",
        "documentation": "Redeemable noncontrolling interest issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of embedded derivative",
        "documentation": "Issuance of embedded derivative."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RedeemableNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RedeemableNoncontrollingInterestMember",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Noncontrolling Interest [Member]",
        "documentation": "Redeemable Noncontrolling Interest [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RedeemableNoncontrollingInterestPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RedeemableNoncontrollingInterestPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Redeemable Non-controlling Interest",
        "documentation": "Redeemable non controlling interest policy [Text block].",
        "label": "Redeemable non controlling interest policy"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RedeemableNoncontrollingInterestShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RedeemableNoncontrollingInterestShares",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962, shares",
        "documentation": "Redeemable noncontrolling interest shares."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RedeemableNoncontrollingInterestValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RedeemableNoncontrollingInterestValue",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962",
        "documentation": "Redeemable noncontrolling interest value."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs",
        "documentation": "Registered direct offering pipe offering modification of warrants and exercise of prefunded warrants net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs, shares",
        "documentation": "Registered direct offering pipe offering modification of warrants and exercise of pre funded warrants net of offering costs shares."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RegisteredDirectSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Direct Securities Purchase Agreement [Member]",
        "documentation": "Registered Direct Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RegistrationRightsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RegistrationRightsAgreementMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Rights Agreement [Member]",
        "documentation": "Registration Rights Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ResearchAndDevelopmentCapitalizedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ResearchAndDevelopmentCapitalizedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development capitalized expenses",
        "documentation": "Research and development capitalized expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expenses",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r385",
      "r800"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ENVB_RestrictedStockAwardsVestedAndUnIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RestrictedStockAwardsVestedAndUnIssuedMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards Vested and Unissued [Member]",
        "documentation": "Restricted Stock Awards Vested and Unissued [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RestrictedStockUnitsUnvestedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RestrictedStockUnitsUnvestedMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units Unvested [Member]",
        "documentation": "Restricted Stock Units Unvested [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RestrictedStockUnitsVestedAndUnIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RestrictedStockUnitsVestedAndUnIssuedMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units Vested and Unissued [Member]",
        "documentation": "Restricted Stock Units Vested and Unissued [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restructuring cost payable, beginning",
        "periodEndLabel": "Restructuring cost payable, ending",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "documentation": "Amount of costs incurred to date for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r293",
      "r295",
      "r296"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring costs",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ENVB_RestructuringCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RestructuringCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring costs incurred",
        "documentation": "Restructuring costs incurred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reversed amount",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r294"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r125",
      "r500",
      "r515",
      "r517",
      "r524",
      "r554",
      "r660"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r204",
      "r270",
      "r271",
      "r375",
      "r376",
      "r377",
      "r400",
      "r401",
      "r417",
      "r419",
      "r420",
      "r422",
      "r425",
      "r512",
      "r514",
      "r526",
      "r805"
     ]
    },
    "us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, measurement input",
        "documentation": "Value of input used to measure direct or indirect retained investment in deconsolidated subsidiary."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ENVB_RothAndInducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RothAndInducementWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roth And Inducement Warrants [Member]",
        "documentation": "Roth And Inducement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RoyaltiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "RoyaltiesPercentage",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalties percentage",
        "documentation": "Royalties percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries and benefit",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "SaleOfStockConsiderationExpectedMaximumPriceOnLimitation",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate gross sales price",
        "documentation": "Sale of stock consideration expected maximum price on limitation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, offering price",
        "verboseLabel": "Sale of stock, value",
        "terseLabel": "Gross proceeds from sale of shares",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock",
        "verboseLabel": "Number of shares sold",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, price per share",
        "verboseLabel": "Investment, stock price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/FairValueTables",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "auth_ref": [
      "r205",
      "r339",
      "r696",
      "r723"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://enveric.com/role/AccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCRUED LIABILITIES",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INCOME TAX EXPENSE BENEFITS",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://enveric.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268"
     ]
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, off-Balance-Sheet Risks [Table]",
        "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r133"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://enveric.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF GOODWILL",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://enveric.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INTANGIBLE ASSETS",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESTRUCTURING COSTS PAYABLE",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r76"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r75"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION ASSUMPTION",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ENVB_ScheduleOfValuationOfWarrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ScheduleOfValuationOfWarrantsTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS",
        "documentation": "Schedule Of Valuation Of Warrants [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ScheduleOfWarrantsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ScheduleOfWarrantsOutstandingTableTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANTS OUTSTANDING",
        "documentation": "Schedule of warrants outstanding [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM",
        "documentation": "Schedule of Weighted Average Remaining Lease Term [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://enveric.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ENVB_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities purchase agreement [Member]",
        "documentation": "Securities purchase agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r234",
      "r235",
      "r540",
      "r541",
      "r542",
      "r602",
      "r605",
      "r610",
      "r617",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r637",
      "r653",
      "r664",
      "r751",
      "r802"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r234",
      "r644"
     ]
    },
    "ENVB_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://enveric.com/role/FairValueDetailsNarrative",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r708",
      "r750"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r708",
      "r750"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r708",
      "r750"
     ]
    },
    "ENVB_SeriesCRedeemablePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "SeriesCRedeemablePreferredStockMember",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Redeemable Preferred Stock [Member]",
        "documentation": "Series C Redeemable Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive plan description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r74"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, Non-vested beginning",
        "periodEndLabel": "Number of shares, non-vested ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average fair value, Non-vested beginning",
        "periodEndLabel": "Weighted average fair value, Non-vested ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unissued shares for cash",
        "documentation": "Amount of cash paid to settle liability for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, vested",
        "label": "Common stock vested restricted stock units",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock price",
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions stock price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchanged for common stock",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exchanged."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrant shares outstanding, Exercised",
        "label": "Investment options outstanding, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrant shares outstanding, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant shares outstanding, Issued",
        "verboseLabel": "Investment options outstanding, Issued",
        "documentation": "Warrant shares outstanding, issued."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Issued",
        "documentation": "Weighted average exercise price, issued"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average exercise price, Exercised",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments issued in period weighted average exercise price exercised.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrant shares outstanding at beginning",
        "periodEndLabel": "Warrant shares outstanding at end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise Price, Outstanding at beginning",
        "periodEndLabel": "Weighted average exercise Price, Outstanding at end",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding beginning",
        "periodEndLabel": "Weighted average exercise price, Outstanding end",
        "documentation": "Stock options, outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining life, Outstanding",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Warrant shares outstanding, Exercisable",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Number.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, Exercisable",
        "documentation": "Warrants, weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorized shares reserved",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available ofr grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable shares at end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable weighted average price at end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average grant date fair value, exercisable",
        "documentation": "Weighted average grant date fair value, exercisable.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, forfeited",
        "documentation": "Weighted average grant date fair value, expired, forfeited, or cancelled."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Grant Date Fair Value",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Outstanding at beginning",
        "periodEndLabel": "Number of Shares, Outstanding at end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding at beginning",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding at beginning",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding at end",
        "documentation": "Weighted average grant date fair value, outstanding at beginning of the year.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their warrants into shares."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Forfeited",
        "documentation": "Share based compensation arrangements by share based payment award non options forfeited in eriod weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r347",
      "r366",
      "r367",
      "r368",
      "r369",
      "r372",
      "r378",
      "r379",
      "r380",
      "r381"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value (per share)",
        "verboseLabel": "Warrants outstanding, per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_SharePriceOption": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "SharePriceOption",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment outstanding, per share",
        "documentation": "Share price option."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Intrinsic Value, Outstanding beginning",
        "periodEndLabel": "Intrinsic Value, Outstanding end",
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value, Exercisable",
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Non Options Exercisable Intrinsic Value1,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term, exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption": {
     "xbrltype": "durationItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining life, Exercisable",
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Non Option."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term, outstanding balance",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r186"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ENVB_SpinoffAndRelatedPrivatePlacementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "SpinoffAndRelatedPrivatePlacementDescription",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spin-off and related private placement, description",
        "documentation": "Spinoff and related private placement, description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/FairValueDetailsNarrative",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r164",
      "r165",
      "r166",
      "r188",
      "r209",
      "r210",
      "r213",
      "r215",
      "r219",
      "r220",
      "r269",
      "r303",
      "r305",
      "r306",
      "r307",
      "r310",
      "r311",
      "r315",
      "r316",
      "r318",
      "r321",
      "r328",
      "r436",
      "r520",
      "r521",
      "r522",
      "r523",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r538",
      "r553",
      "r575",
      "r593",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r695",
      "r717",
      "r724"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r34",
      "r156",
      "r175",
      "r176",
      "r177",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r204",
      "r218",
      "r270",
      "r271",
      "r330",
      "r375",
      "r376",
      "r377",
      "r400",
      "r401",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r448",
      "r512",
      "r513",
      "r514",
      "r526",
      "r593"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r540",
      "r541",
      "r542",
      "r602",
      "r605",
      "r610",
      "r617",
      "r624",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r637",
      "r653",
      "r664",
      "r751",
      "r802"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/FairValueDetailsNarrative",
      "http://enveric.com/role/FairValueTables",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r218",
      "r486",
      "r518",
      "r538",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r593",
      "r665"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/FairValueTables",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r339",
      "r696",
      "r697",
      "r723"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/FairValueDetailsNarrative",
      "http://enveric.com/role/FairValueTables",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r218",
      "r486",
      "r518",
      "r538",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r593",
      "r665"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock and warrants issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of RSAs into common shares, shares",
        "verboseLabel": "Stock issued during period conversion of restricted stock award",
        "documentation": "Stock issued during period shares conversion of restricted stock awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares in exchange for RSU conversions, shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r71",
      "r96",
      "r97",
      "r125"
     ]
    },
    "ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2022 registered direct offering, net of offering costs, shares",
        "documentation": "Stock issued during period shares issued direct offering net of offering cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares for deferred offering costs, shares",
        "verboseLabel": "Issued shares",
        "terseLabel": "Number of common stock issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r96",
      "r97",
      "r125",
      "r520",
      "r593",
      "r619"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants and preferred investment options, shares",
        "verboseLabel": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of RSUs into common shares, shares",
        "verboseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r125"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of rounded shares as a result of the reverse stock split, shares",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ENVB_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised of warrants",
        "documentation": "Number of share warrants (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of RSAs into common shares",
        "documentation": "Stock issued during period value conversion of restricted stock awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares in exchange for RSU conversions",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r34",
      "r125"
     ]
    },
    "ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2022 registered direct offering, net of offering costs",
        "documentation": "February 2022 registered direct offering, net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares for deferred offering costs",
        "verboseLabel": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r96",
      "r97",
      "r125",
      "r526",
      "r593",
      "r619",
      "r671"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants and preferred investment options",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of RSUs into common shares",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r96",
      "r97",
      "r125"
     ]
    },
    "ENVB_StockOptionExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "StockOptionExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, exercise price",
        "documentation": "Stock option exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption of Series C preferred stock, shares",
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption of Series C preferred stock",
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ENVB_StockSubscriptionReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "StockSubscriptionReceivable",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock subscription receivable",
        "documentation": "Stock subscription receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r100",
      "r101",
      "r116",
      "r555",
      "r572",
      "r594",
      "r595",
      "r660",
      "r672",
      "r718",
      "r731",
      "r788",
      "r805"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r187",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r330",
      "r424",
      "r596",
      "r597",
      "r623"
     ]
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Stock subscription receivable",
        "label": "Stockholders' Equity Note, Subscriptions Receivable",
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r96",
      "r97",
      "r100",
      "r598"
     ]
    },
    "ENVB_SubscriptionReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "SubscriptionReceivableMember",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Receivable [Member]",
        "documentation": "Subscription Receivable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r450"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r450"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r450"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r450"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r450"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://enveric.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r451"
     ]
    },
    "ENVB_SubsequentMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "SubsequentMeasurementMember",
     "presentation": [
      "http://enveric.com/role/FairValueTables",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Measurement [Member]",
        "documentation": "Subsequent Measurement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OPERATING LOSS CARRY FORWARDS",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash and non-cash transactions:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accretion of embedded derivative to redemption value",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "documentation": "Value of accretion of temporary equity to its redemption value during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less deemed dividends attributable to accretion of embedded derivative at redemption value",
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r305",
      "r306",
      "r307",
      "r310",
      "r311",
      "r382",
      "r498"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total mezzanine equity",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r188",
      "r269",
      "r436"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, par value",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r65"
     ]
    },
    "ENVB_TemporaryEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "TemporaryEquityShares",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Mezzanine equity balance, shares",
        "periodEndLabel": "Mezzanine equity balance, shares",
        "documentation": "Temporary Equity Shares.",
        "label": "TemporaryEquityShares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, shares outstanding",
        "verboseLabel": "Redeemable preferred stock, shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of redeemable Series C preferred stock, shares",
        "documentation": "Temporary Equity Stock Issued During Period Shares New Issues."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of redeemable noncontrolling Series C preferred stock",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r65"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r791"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r313",
      "r326",
      "r423",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r507",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r727",
      "r728",
      "r729",
      "r730"
     ]
    },
    "ENVB_TwoThousandTwentyLongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "TwoThousandTwentyLongTermIncentivePlanMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2020 Long Term Incentive Plan [Member]",
        "documentation": "2020 Long Term Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_UnderwritersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "UnderwritersMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters [Member]",
        "documentation": "Underwriters [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_UnpaidDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "UnpaidDividends",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unpaid dividends",
        "documentation": "Unpaid dividends."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r143",
      "r145",
      "r148",
      "r149"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "ENVB_VogalNathanPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "VogalNathanPurchaseAgreementMember",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vogal Nathan Purchase Agreement [Member]",
        "documentation": "Vogal Nathan Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WainwrightInvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WainwrightInvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wainwright Investment Options [Member]",
        "documentation": "Wainwright Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantAmendmentAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WarrantAmendmentAgreementsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wainwright Amendment Agreements [Member]",
        "documentation": "Wainwright Amendment Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price",
        "verboseLabel": "Share price",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ENVB_WarrantLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WarrantLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability",
        "documentation": "Warrant liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities - February 2021 Warrants [Member]",
        "documentation": "Warrant liabilities - February 2021 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities - February 2022 Warrants [Member]",
        "documentation": "Warrant liabilities - February 2022 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities - January 2021 Warrants [Member]",
        "documentation": "Warrant liabilities - January 2021 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant liability",
        "documentation": "Warrant liability.",
        "label": "WarrantLiability"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability and Investment Options",
        "documentation": "Warrant Liability [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r663",
      "r666",
      "r667",
      "r668",
      "r669"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expiration",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding, measurement input",
        "verboseLabel": "Warrants, measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "ENVB_WarrantsAndRightsOutstandingStockPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WarrantsAndRightsOutstandingStockPrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant measurement input",
        "documentation": "Warrants, stock price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Term (years)",
        "label": "Warrants term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ENVB_WarrantsIssuedForOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WarrantsIssuedForOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued for offering costs",
        "documentation": "Warrants issued for offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WarrantsIssuedInConjunctionWithCommonStockIssuance",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued in conjunction with common stock issuance",
        "documentation": "Warrants issued in conjunction with common stock issuance."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantsToPurchaseCommonStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WarrantsToPurchaseCommonStockPercentage",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common stock, percentage",
        "documentation": "Warrants to purchase common stock percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WarrantsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Shares of Common Stock [Member]",
        "documentation": "Warrants to Purchase Shares of Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r215"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r215"
     ]
    },
    "ENVB_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20231231",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital",
        "documentation": "Working capital."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480463/815-10-45-5"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.28)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "825",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479436/944-825-25-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "910",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482332/910-20-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001493152-24-011210-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-011210-xbrl.zip
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M@>W8ZN"GYP*OZ"_I?U$&"YB=ID.)3D;:HJ\#!S ]]:=S4+:9_(U-7C]%U73
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MQ%/3F<O:'+9,)J"3@>U3W:1JBIABSG<V]DLF0OZ<PHH<@ZA$(4N^B[JB:3+
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MPRB]SK]RAE@4Y\WKJC@;7=G(ZD)2?M\HZZVR+: SW^NZ@D7;;I7=B-)4DU%
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MR.O/"BBB4C_17#XQOC%TUH30&4(MD$=5'<+' O*2D2\V\O&)_HMVR,>^ZC[
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M^YZS_X,V>\Z>F8=TXGQV^D[O/;1$)[PC2QI])-/[HD.3D,T;BG"3E!/W7[\
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M#V7,TD*[MQDT@FE<]Y?-UYQF) "IG+;P1C9ALCBRH]6NBVDL3<)V.%:_7;"
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MBO2 OPI3NO+211AE)>/NPP#R@98?R'#<JS($(F>JP^N B^J>KL.!# ;X%(9
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M[&BKE[#QZF=I:^SQ2#^R!'8FWX["\XL-Y:D^O]C0X(L-29SFP"$_[8 A/^Q
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MJQBA30G=*G,4'D-;QL3)H(IX CTPJK,H#@F[=N/OB \3[2?JIBV^7QX9>39
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MR0$"^I/B/&[Z^4S)]@Z"P,R$FC\;[,1" #TMVJZRQ[06581RQ;)ZM-I<@L/
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M<"5Y@M#-58Z$HKC6OZ?_N2&G5O*;_P]02P,$%     @ ,Z=Y6!T^?@^ F@
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M'RJ*U13_NXBQ?GF[;TNNSTWW-+5[FMJR&1BL/ F[[+3^]M@:>H?*!A&AVGN
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MNRU7=U$NR#MR#:['K8::'_$V'+V<U MQ3'A*!*,U/9THBW/$<NY.?BM@'L^
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M -@)C!L2(#@BA24+BYMW!?BIG7=XW$;KZVT2R%=96C*.*^;Q\#K%\HX"@!C
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MWKXA6&P^S0AQP7E:W;]JKW%)2U$X:U]G+/-'1'Q<!%#;>!71Q+PXS"9Y<6"
MQI_TCB+UK8P<+TYM$,HU X/9(:BG5C(@K%I&0:/IXK(F;1+P:.ZP0_73%LY.
M:LZA4SS9Z(9?[-T6#.*?;@#O%KN>#LHRVZ<DC#;1NBRR7;O^["Y(Z27N-"8I
MRX,N@TA\*X1U$\Y8W=.XFLF6^C#8VP]TE['-5MI#.-VL2%ER*8M8T;IH#*6T
M-1\#.%T\P(6U_.ID,4P5!Z?8K7/<1[93AS(X]T0MJ/18-"-9IJV&XO+D&;L,
MS/MFYB)]"N*RQC]QR5FRC<)B:Y]%K!G=NR]>37E2(]C6]Q/KRBH,U+;3^TF&
M?!VM2TN&:-A[=QG#&FYILM'V!6JUSN8\S?996G[U!'1\!*B[LH/\D.+%1ILO
M*Q)T>BY-"K1U_HR3 L-**;0NQ2X?[N>WL_M[-+F]0C?S_WR87\U7/[._+58_
MSI;HX78Z6ZXF\]O5?';OG4%E"6$R7[LC76%M<)VT0L'I=3I:X*VK=*328!BF
MA2BI_DRGVI4&)-]T'SW%+#2-<]ZT%?Z:7V[EY\I-E9VF9EH9U,K,--($PT0K
MN-PN\<.G3Y/ESVAQC>[G'V_GU_/IY':%)M/IXH&XO-N/Z&YQ,Y]"\'W51@#;
M "CG6M&O."SO$6C?.7!5IYAJ'.3)K;J]36J05]"^@.JD)L'T@F'LX*^Y*I=4
M6;,D!CTV?('*IHO"3*QU5#2/CNU#<O$,XK2X6J, JO/K2@VGDS$]]-842RX.
MAK!ZC-P"_W)V-YE?H=E_W<UN[V?WC2AU^K!<SJC?OK^?K?R[:OE-O>:.V;(-
MI]>R]3'/[/YER"ZV#VKNDK:R#>8SCZW =IQ&ANM\J6TCX BM]+AV+9P7I75^
M>7Z[FMQ^G%_>S$K_RQSSQ\7BZJ?YS8UW]DH+6&L<L(&>X^I@9F9TRH&IE< P
MT12IH. 7TR/A*-5D?K76A>1$I0::NU"[)D"0T]!]VNC#IZRYZ[Q;+NYFRW+!
M=?:?#_.[3R2,]<_5XH*VK+K=+=CJUEF5&HX+@^J@=XJ RL3A\$R+45"OEFDP
M;UCI0'*&)K<(FOO%WJUYV 'H:[)@>\"V*3"$/@T_M[$PG2X?9G3W:G(YOYF#
MV*>:L2+1&I_9%7):!5 (L%61KR4!ACM"6%RENJ)&-R"'Q]+YGI-MB-.L0'>;
MY-C<Q5GH.]UDLC6KM<]DJ@R&?+:(N=VF'R?+&9I.[N:KR4UC^9)&?B0(G-_>
MKY8/- (\V8-)\C*/4'5IUA+?U;L59]F9_4VL<_?LF_#.T--PBZK"EVGRMYTT
M^?FX:?(MX%,>N,Q/VBH[HZ.U034+C35AD,\6+L>YV=5L]FE"5Q%O%[?OIHO;
MU7)Q<T.WX.>WJ]ER=N]_7GP=1"G+?#WV--W$6*WB<JPV =\<GE7RWBEG ;)+
M-*J"F$YCNP74[%ADE"Y U.CX)IHR$%0J@*::SJE=3^9+]'ER\S#S3BIZK"C*
MB[3CF)[,I&E2.%ZWYMH:9V;9AM-"M'W,:Y7MM&D #"G[H.:*RQW;8 N&K5:
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MSHOJ&,LH^V6:XC#*Z9^D"Y,*#;=+PUKH[75@J3@<CFDQ\IL6#0T6[3$-1%4
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M8/&^$1\V][1'FL8,.)$_%O-KO-9)7K]UR\54V^;\3./[&2V>Q=NU!:9;G6B
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M:S5;(F"H(L;%7Y592@'9=KX/MD%*#QS&X4_!D]3-\&).62$!V:)%1P8.+\3
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M)N+E0VB7;#X&'9^#J@<56_V-1U&EZF&(/ VQQX')3#SQM=UHLA*':][IJL'
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MX3F;B'N(USY8%'X*&.\. <H;T'J&)[:+'=+%[0W=Q7XIUK6-' 3@T--3UB/
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M42_WO5Y%V7J;T.6P8\>\)3H)B:Z3[;:8H&%Z^GWRF.5IL.97$^V;@./.3C6
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MN[2LU="62F8HK32+?QCD>-XHY*3;GK2>,RT9;O%FVFJ^"2DR0D?%I@YH$@J
M:NB'PE(%1FGW\A)H>G%S53IDFF2Y?*A6*;BDFAYXZXBA5!H,O;00^0O#"BFT
M3@!4:Z779.7I@5V(U<1_ER9/Y%5EY96&B\TFDW/+K@VG=.MC7OL^.XL&X)"R
M!VKN4%HA0Z<N:U"4I3>C'G"SNL.4S-D(U**BP[KXB^3-F"H[/:5F95#KF)J1
M)K0C.E:H1??BTGM^MD=M"(RDH4%UFX<='?6:CKEH:DJ'B#HU@"PTA"R@(--$
M^T+5VQV\&2;BSP3R%7[!VV1/_?7LZQ['XJU;I0*\DWQF</D*^846*[T3'O40
M+A3]>XN;I"A T[RL+V(+@^U[DKOS&*V:TRFCH1&M*:-&!TSX9 BT2SVJ]HZN
M2K3O48S*,U4!TQWKEH_D-=C2P5!]0Z=0S-U='G*0Q^L[>!GOO-  XUQ0)0GI
MXLSFW?05/@G]Q:).[QE4@&W=*RB0\\X6 W"2N5:&-DF*TDK85X&H('L6+\9D
MS_"BA!8J[I3*(:>'3]9$!E0'E$\(."E?W4X2Z'=$0'8V>>2^!!4(SF,2'N";
M),NNR6>@ZS11?(CBIW+I.8FS2TP< B[D5L%7G%V1/V1YM):\A9-:='L@^F33
MV^>E>S<'AL&GV\#?)AG16^3O\R _3[:3SHRCIWBX%U8W")SK'<-/I'K9VCDS
MO6T"-\P7OWJ*EWJ8,_N:IT&2AE$<I*_L(*S^<D,'CP-04\NEE<+D2^]^LER(
MO,8AL71++"M7O"YQC#>1= ].I^5TU\W,A-;D0JT");G0#B[GIPIQ*!1C@0&M
MDTX>8DLTG:X'NIF9(R"=6A$H]8Q <]5,<A#)*V7G*49M6P\GU?+AX30FB#R<
M1 4HS31P>T1B+BE61P<V#),J>2"8Q@ !OR0:/NC%XBD#CJDABX_(E#NT*&*Z
M* ^^HF_+A9W?H<>B >\LO"HK09?COAT;397=9M;;&-1.JS?1A.8$K5!#C?:N
MZGKDC8BA'Q?-FO#!2!OC1+PTT8?*3@OL, /"NIL5T4-//ZE1]N(GC0P2^DFE
M)E0F&J&&&C-61O2C'RC>]2 <(*9IXT8SS.+ ,2QU>T>.HZ\D&WTVF>F.5G M
M/Y@.K?A3G45L3XPJCET>3Q@E638-TO1UDZ1?@C24I=E8M>##BUB8)O(H!NI@
MMAOL,7.EK3$]UUV?&2-::-U4@T=8\H?JW\IN.4UV]+]L?X7$DV4OS5A)[\L@
MHR><C@+T/(GIVQSD45Z[P( O2]E7!G@.M RM$6WDIS/)^I=WCU2#IM[6*F,E
MW0HSU!LG DOSA+5/+)3=)>C:&G1,VS75].[R>\$U/F6P/C8Q6**9A'U<OR+&
MS..<P*37T$UV29I'OS+ZB]Z C;8S_MF;5!/07!4& ZWQ\M>U5,+T9$$M#2_.
M6.3/.#6.NPIAO^%N$[ ZLJ62WOED!(^K;T!_@T>6^K+TR7:;?*'ESTR-%6EZ
MI9'<%"6G>#6HJWUZR-P)*4RF12^5- HJ<8"S(U75*Y&H5ZI):UGQ<DZ]56ZZ
MDB= *)I@UXMW=$TH8 K>F2-?*5#=%*75<LDG0Q.:U-*H@!D3S7#*B_]0-=32
M W/%D]RT&\U53D::, C(F6)&PAMP5S"98[4CXXW974J>&6G]4J#PSXYV9\ V
M\^5K.L;"6L*>;39X7=QR7NXGT0)N[0JNDRHIFZ8V' B&UY:PY'T-TK)+Q@[X
M*IK4'J!9:+.5X4R2)'@U]RF#')%Y-<JJ9F!4"S1Y!>(D(FF-@-.:A-93=,;;
M=A%9>V#&AP&,$*:2-?L"I3[Z-L:LA-RFZ"N_.XN^T$UCHA)7$5&D*<=1<,I+
MU3<-K6^8O@S;/J)K]ZSZBJ$QDM2W8W<)&SIGT55NDSC$(:TT2>;$Y:;9%=ZG
M>!V)MIZ&;1I:5S%]&;9=1=?N67450V.X"4H2OSOJC;VW:F)(O7:9'O!A+]KC
MZ].*L[W6_B;6>Z[V37AGZFFX^:L3JO5H(O7NL#\+EUU<*#>/^^^]#?X4:(Z\
MQRNR]>D6C_#>:<:U2W[AH6"G$&@/$Q6HL'J)X@;\]PN587K*B[1A;4!:X^:N
M>*H:Z$Y]S_<,@=M;^%0.1X>0SXFJ/T$5(+(,O?+0@*^*B@-\DW_T<JX#I^K4
M7AW:(;^/$^_.#U+=<:P:WY2UFNV;<>GI^QK9Y*EM&V!<2D_@729_!AB:'(<P
M[81;G/^LZ^7]VW5?;V^ UR#TRWT;!=,!AK+$MO ^>DJ3S+^'OS\\9OAO!WJ3
MP OY'U6.EEC4)9558)OL%,F!(9P"'+>'5(LB)@LFUZICPXTFP4HN[I$]'&@%
M@V[ Y4]I .J9=&.6*#7F]Z"GT^99=L#AU8%>,EQ<*\Q.N66W^ O[2?QUC#0=
M3]QRW>S $C6WXG_8/>*TN']LMR.15D;;0Q%KT%=M_&V098O-3T&:!G&^2)?1
MTW.^..19'K [VT4?3Z<#L*:^*6+^ONLH8PEDI:JW*PQ$!A1\6FSNZ1W?Q;5C
M)';'X>5KA;84%';!$YN$UC>',J?+@$H0Y<GQ%IR,]?AN3_;$C;LT66,<LKK"
MU /1J=MB,V7 F,<2?7VM$K3O:PY8E E::2/ZZE 6;-D-]L5G]-6EC]#O@G21
MLG2CD%UM3H85-J8(NZU>#=JGLX',7R[+^A=3OD!$'25I<0% B%@+B#2!6!N^
M@B!")N)A*,#:W3!>%8'"/%X1_Y$%:UF^A(T^O)&U%WIY8%0ZUBS9^@J(&@;1
M2V>CL-PN6>(UCEYPN+#XGOH&H'75?N"[W_,C71A!>S@^ER5)W)-@G00 2QQB
MO*.S\+NTKC=([/V$*0FYE! CK;^&R=K91R3/.M!U*&DE!!O(W#23Z:(I.FJC
M6KUPP^C/10NN9YW,MGD<'M98<B^H6 +6QY'!XW>6*KEJO?'W/MYW>3LQB9_H
M4FJSM$BG )!>&M9W,($JNZIY7RCQM5(TMXF/_)&6N+@CG2U-4#/XJC9229 ?
M1PI3]F'2I@+[')F77G,5$1S1XX%MRSVEF/5CR0"CD(7U4?1 N6S"A@:J5;R.
M'],@#M;K) W_O_:NK;EM'%G_%;QEIDJI6F?/_@#%EXSW.+'+469J:A^F:!&2
MN2N1.B1E6_/K%XT;+P!(D+J@Y3D/DTEL=*/!KP$T&HWN+S3=)N7N[N[2@8NS
M)2Y4^L0T#E2J/9$$A%$$A<1E<\+^.&?GO*_16[+>KA_RA)WXT[MDG32_1F6J
MC62$"] ]1V$8=,KNYJ;;O,Z1&Q; DJP%3[:Q,::$_6:EV099/^'4GQ0%Z[ZC
ML+*M$2XH.R2T^3E$TUJ-Y2#?_I$N8=D6QS[N&^W;P7HI<*'B*ZX9#U#1$4&(
M9%/[D;(I_9HG<+QW8&0VP06*4SZS!FC5,.RVU749J&X-KM_89$X*&IN;U2!R
M7&"-DKW'Z4=>U47+3UDN?[1-D[+XF6U3DA.)A6$/+])5O9P-[SK@2DES]A62
MG&VDU2W3@[PH\ELY!W# I0=CQ;>OK,"'"$:DXD04*R1K+93@C(KG=J"P :VC
M'2X NX6TO%B$UO5W 2%=4P^W#]?#IYP7%2Z4AHC<Q@QH$<\FIGDYC>"]K/C_
MK;#(LL6VH%7*'_@-CV2>IO']TRI9VL]_^S##A?@!1F*LL<#@8[;XR%C4$R,!
M$Y%YD+LS,\TGS)9Z=0_Y IAD;$R@N[?I"RU*^%CW&_YJR;63>A+BPGF@U :F
M5T31<_ >D@TE%0LB>02=X0_1#F0I[A?P/F$.%_?7_P=^)W-E=K7$A5F?F,8*
M+-N#I1LI"D(Y29A]4P^@K6UW2?24K+JQ<=)@1:E/X"Z\DFHN99R8K!1U8.CT
M$0SBH/C5"+Q^R&.=Z+\#PEY:K%#Z"MX%:15S"TS$'1'))9N@]NSL-9L]9]N"
MK>2S5R;N[BY+ES.:KYDU  ET7N@#&Y5C_QM"C O>$9*W\?WTMT]_(T!&@(YH
M0@*48>U;':EXS62(F8I=L>WZ)0+I3/NUHS$NS#PD->(9U(QC<Y!*(A)KJF#!
M#13&:!O'+(,0F#5?]GFDH?4RW9\<%X*C9+==NW,F#E A9CK7G'CVBS! ?\WB
M9)',(S%@Y:&<%@]17LJ 15DJYS%*+'OG0'I<4(\3OHUUG0O K=VU44$VC%/E
MR)45@T@.W(+ ;9RB5##J99;^>YORX,7?DO*Y%IBLEB>+4V$T+UQJL/] S!"U
MEG5<R+=,D.IF7G$EKXRM^>8).(>QHE4\XU7RDL0TC8MI*>)4(-Q1+'XB]!$\
MGEE:,JZ,Q_(V!1^U)>QM7X:X%.5 HS&,<!U%&BN^)*HQ5IN%##I-&[R91@GF
M012&3P9X@#G/DTT5#MU^O-S7%A?,_8):BQ&2HD8"!R=)$P08Y?WB9T$9!/@M
M*Q^BQ+QP[6B+"YA^08V""LH)*$ZSD8R&3+.2;<U)F,M196>(7>8FRQO#,M#I
M;HX+("]9G>\(Y1:YR.#NNXY;&%.I_92.W^&S,:DD,MVP#2/'!>,HV;N.M<K"
M$6^8 &!=W@D!TO;:LU/0RB6_"/R\JYI(C]D4RF1(<['V7/HW"I=)-)Z^T#Q:
MTB^@V%=126^B)+<?E4_9.2XM"S!R8^F1="02A&0)E"2&_-P+1BL.YA.255U!
MW8<GNDS2%/[!=!M";G8TRL]2=?F7HO'IU=:WX_>EL@-';9B9W(O F9.Z *0F
M ?F\(_5V4@K"Q=#WGE(0HB> %$7\@H P!*01+XG/4;.OWS9)SFV0!4W8"._S
M2]B-(,?!Z;5]'V'>UPPXP)<8NXA3T?4$[ _1^02>S,]5_V>Y@,M84CAGAE!K
M_\[?FQH/'OEXM=5==6KH'B40^%"?^K_&TV!+[)&NHR3E)X6TS*-YN8U6<!/I
MQ.3$4IRL!$.X3]R<[2<5 >&<#S%^L\JG,,+JIXK7]FJ0*YYD7C$E)>,:)@2#
MKC=9'N4[$=$E/ )FK(6M%2XMZ!*Q#91N2T1C85B'<5+TW2TXWU'XD.&":)#,
MYHL)?5'2I":*/.S;J+&&AS8GID6Q%6$#A4@<!2]3#V?:=?>#2U&..TC[Z9OO
M#N#0K$[?4>WT_;23=_VBW4:>OB-^^J[,.H@K5QW+BU_^PCC,&<1ZU>7*^M/1
M&)EV]$MJ2R6K;_ JFK#/JF3RL%_9TL4LCC3^D8J+$L<>W-,>%T9^PKH?2+YP
M.A[BOY64\I8A3-A<_.^MB/LH9MDTCA,8=[2""\K;5.0M8DM5RDR\HAERE,8Z
M","(1C&CZX[1"RZ]..80[?FD8$U7_)I17"FD-5+754;<>Z K*_L[8[ZGR1_S
MYZ+JHNX;97^MW]K9HS/VX8A+@0XU'+,0^%.^A1/!I[]]^L0.:?IY;BR>YZKK
MS F1U9 1W&]6U[DNRUKDMFLFP^NXT1["!I=:[#6&KAMN=WQ6(?(&5DL(-_=0
M'.(')ZD?SP67&NPSA'XG 3?G!3LB^!'!4/H/"&,I?H_3E=!X1S38H]"@Q@7[
M&-$[_ N.0,S6$ZHP]L'\F<9;2)>ET[E7SD9>:&5&W\K/*]LZ/X 6%[S#!3?.
M?Y)#PP"LNVE%D1H"? AG%.1(V*?'CI.A'QDN3 ?)/&*N!CPL=NXZ!S7B![#$
MA?[!QF,/V)8. YD[2>1+4D&*ZG=-L]YJU>/3GOK1F*>*32"9(2?A_D]S;=B/
MW1EIC>]8AFM,TW^0:][2O\M=P*$,OF8V*C5!("N&^KOC+5P:JVQE]PLX%&VA
M=*#ZK3';"N?.<UH!<.ECH-%WY!)KKVH;2(^B_[5V/FA,8YUR#G[!SK1$B%2U
ML;H]@FZS8R^)F,$A'(?B7'>;0@9M[I(4:\OA[MSZ>L*ESL<>IN-]B"XM59GC
M$[D>OQ>]NGZ;\X+$)U$MW=F[UZ[V2 ]_L9O"0BEN#47Z(G; T-VS)5/V?Z9Z
M6H]V%%=O1]!/LY/WII?.$1X^S)_UJ4/]:[T2T>V9JJ$QK]T!><IH.G!LS-ZB
MO#>5WO,[G'HA[@RXU(9MP$"<8UE6MZDX CLP$8U.-EF&RO3N9\W(#]+[HJ"I
MTI,P]92/L'N>>+7W[?J]Z>G <;O>]4_.<ZTMO+\/+7JF[DC%/+0$9Z:?1QI^
M[ZHI2OU$)7E]3N;/RIQXSE8Q%-:(YFSUSG68(6M$4^GZ+64%AB2OW&%)6F8^
MWJ]]7V^=RHQS/77YK)[$!S<T/20\[:LO1 ,/>1#J%>_,EJ<0WZ9W[7*_&N-9
M5]CQZ&/S>"1NI5I.U91\>$A_3[^F5[/T%_:_[Q^ >AV5_.TTV[VC]6;%[,D/
M#Q>__^/KQ=^O/K".-PP&?LJ"A!CLGUD.@BVBN;@/2$66#,8!TE^NF73/S#*
M&X7R.6%-V2H:1[N 5P1[O QTVTDN8"^TEM@G92!A$$[!L%^BRT/1[YI[ZLC
M47?+&5DXM'RD)B!/X7Q1\^V]:X/BFC=&NS(K\?Y:ID03%%QVA) -X0J&ZL/\
MOP5QG)R.6?X?^/(BP;,Q09J_QJ6C5MD,-1&-5 ;K\[+2C#E4.1"FRV5.EU%)
M;YFN)VF1S/D+H6]9*EX6'LXZVT,(7/H2\ M8K;&/GO=%'RWW11/;+5%UAP3+
MBY(,/#E"M(#9^L4G["@W;^AK+P4NY?(5MZT)\NE-G1!)'3_I!9\R06(^%914
MKGIM?02X /.4UKP;2-+7'$P/HDDKP,+69?,MK'<6=?2&E<U#5B$O7(#"!:*@
MD0M<&A7^0]A#\_66?191'F,,*.O%;--B<NCML7I#J)E''NKA'8*N6#W=O\C!
M>S$)H:O_&Z7;IRB.D^]T$^61C\793X)+:[SE;4.O"4E%B<3H?%A%<RK,,?:'
M.R.*JQ+X(')<<(Z2W:C(HY@0SH54%7J064B-Y[&7YO-8]RMO;TI<\ X5N_M)
M,+&^"?Y7X.?=T_]D16]5>P-0+RI<8 X1V:BPR&A)14P4-9(56*21F5[*P""F
M;\V4,J[L>EYDN% <)+-A/XGL.%-2(Z\MM\*T#PKD)DFSQ6*:QH]T!07*'W@-
M3ZJWB"NJ4P::< X@1@;J<,D-: 4+?D.3"R9PZ@(N9*/83$A<,0I:CFN6J26D
M5N?Q@=GC\)F69OBF)QTN6(<)[:S4569DH];;1O7*C681YF@]>-<\LQUS[&Y9
MVR@U<!&*C1+V\0Z+!B,(AEQ6VR3D1_V10G5#7:74^+*MW^/ZO';AVM]8M*HJ
MIJ+,I-9]ZD)?[W9D/5N/,U:8>QVV $:KKS0JMGG7GN!JB N<'BG-JQW>G-3:
M!UVB5")595,XL+ WPX5$IXS.!++:F$)P.PV)9A[AIJ1^%=-17<"/#!=*@V1V
MOV7S3=:_1_SM/[<KQ[2HC\?6ZF31J&X1M8Z837#I@U.^-O;0$,=L=;I8F.JF
M\V03K>QUWCSI<.$S3.@V:%WN),U W*P%L1RO*/>$)"_T+HF>DE52[KY&N]EK
M-GO.M@5;E6:O[./ #QS3:R@#7.".E+Z-<L6&:#Z$,1+9V4-.U9J9=9MNMN77
M*/\/+1^CTE57I8\ %WZ>TK;QJAN?G(X(0@*4J(*^K!7T;(UPX=(A84>LEPSH
M#U9<KHH&]+VA[J7 !8NON!UADL@NGOE.*L.YNK,<.!KB JA'RJZ(,PPA98]7
MOA/'V1(7'GUB&BZG*VP3Y.'VX=H[WL;=%A<L_8(:D3206189-%^3-%EOU_<+
M/HUE8@\1E/I(17:/FRR'X)(DW=+X+BD@L\?#-H>R#N4L4_DD31ON0(QQ@7[@
M41DVH6 /3_R*6@?J94XNN^#O!N>J$[(2O<!M%N\&KB15GLU !SIQQFSD8W[(
M5LE\YP["\B'"I0P#)#8/:_(4KF@))R;_$N2ABVI(#X\^1_9AU],>%VQ^PKHR
M+U=G:R18U;.E3]-85/#C6U(]=;JQ4_5!>ABVN) _Z)B,M;N>*1[B?"KVL)YK
MIZGXE6D$2&TJ09N>@FD35'UENPR_0>N[&^QHBPOW?D%MQ6\%!9I+PG]&*=R5
M*6<@_'F?TKZ+!P\B7%@-D-BXG!"DX/"\P'%)H2XXAX'F184+M2$B=Y4118S;
M[#4;@9M!A1\WE\C=Y5]?,>#VRV7E)60[^65V=W?IZW@80(L+P^&"MY'\Y9+4
MO*M@H%QFA''!YJSHB\'JLVD'TN.">9SP8][\;(0E*I[^"%,T3 7Y%UZ E/V8
MF=4K5V"LI1$NX#HD-()E>5.BV@:=;+]FRVCU+2J?H]0W@+R?!!<RWO*V<>*$
M1%!B>VW%S*Y9LJ9?DQ6;RUGJNF.W-\.%3Z>,;4Q88P*MB6X>-I8_CA,8%YOQ
M/4@X6^("HT],8RW3[9$@\ICMHA5_+N)^R&1I@PL%MX#&3J]:AGZ(=%\^4[@2
M*;8KN*9@)NJO-(VSO#?[DR\A+H0&2FTL8T!.*GINC@L.6))"U6J+.[)NWE&V
M'T*\C7]Y]6&<<$&^[S"Z2J]WY$/F3'DF9#2UV O*VCXSG;^B+W25;>"SR6R:
MR9\TOGZ#I##6HKB>E+B 'RJV>1H3]'R2QQ4'E5L46! J>02]RIU%;].BH/*"
MI&2#@'#BZ3K+R^3/QO<Q+G3[27&!.EANY^5N&;V1B+/@ ">:"8EJ7(+@J@LH
MU]X\][@W^TEPX>@MKQ&GHPB)H)2A\B@\T[6QW*;3)[H#AX$#L(ZVN)#J%]1\
MTE![:)^D)))$8</<<@KO<.V;@FTZN5OCPL='5,LDXH^2<\<6%V35XU7B:\$Z
M!BCM!KAP<$C7_O3?:-FJ.8_R03@4<80Y>[^X9E,V9NMM]81EL.N^BQDN$ \P
M$N/Y@B2!\P*51&RN*:J0J614N%1"B\LM,XHL"Z&S)2[<^L1T!8RM*@(R%Q08
M -GUX;!#_?EWGE]]%^1;?Z5__AFQ,SH5H<'.9VZ65KB^>I>(YH,VV9;(#/28
MKXKMCX.]J' A-$3D[LM@ZUUPN/H.XCC JS1?;<&4$55-^7C$B^:"?9+[!;-*
MRSR9E_)%-$\D;!IV>W'#A?@AAF)_Q"5J8I.8<X5K \96:("LZ@J,P<C(-6MY
M!!.%CP*9F<ND &V-KY*<SK6%#*]MU-_KL;F-6%_UP.U^H0_]ZK?<V.X^+9RN
M:UP:>/)QFPN7$H#$7(+JO+.!1U;Z7^MZ4#93W-=Z%+9^K,A^L=$^']TDI:+6
M5OB35'4D>,RXD#R#>C$MV!3?KDJ8ZC Y*9_%WS?,[#%4=3@+7"HW6OZNLU(N
M6*GRU5$!"QOC)I8XSD^N;P5P/-O:[#=9OJ!)"9F_ ]5F'R0!+LT+-?RNZ@JN
M E^%KO!%+!6^ZM6\X FA$ G<IV*GWZ= R+F76!7VU"C\3RG>7ZO$:A,47"56
MA6QGME2=_,.,6<1\US!;O<+.>D<=Y5S%R0?G!C\<- &!SUZC_G&2239"K'<_
MO\9_DU-/+>D<8-;"QLM<T/\,,ZUNHB3G+I':^\W?DO+Y1YH]%31_$66M-FR]
M>*3 *UDE_',]0G9P..\Q$).B>B3.QUR=7=61U9@W)^H7U\0X[:"-AVBL=^FF
M6M<>Z[XR <BV)@'371"![0-U&>"?0@B8%$E171TH1:_["91WX#WJM/%H[-3*
M;0CPE])RU^A#JGO23HS7K?A[G *O%PLZA]OJVY3M7G06O4$>Q/:'++=Y.LL>
M\NPE*1PHC61TLI/57@.M:EF/X8)K.NTS!*/FM>+%-!:80>CE8P[L#.T'AKQH
MBV(9*OX2PJ-NV&8R?V:3#49/YS3A,]<5*V9OC0M5'U%=L6(+1<0C9W--%N9>
M*2N?&TEB>L)C>]KC0LE/6/-)$=MBILW4-BBB8JL'&+ _M^Z<?)Z?=)'A0FZ0
MS,Z')?<+HLGA'Q6*@9^0R <3LM#:+)O.YW1%<SG.7RG/=&?NACY4N' <(K*Q
MVPE:74F.[691C1P,MQ?!($ST4Z[+ 5^O-ZM,^$%ZWH[[$.%"<(#$1JA43JJ*
MR14QDA?D(@\Y.YXLLGP-=Z7<GR4N7$W<.AHCPZM?4@,GD9%]4]%(QYFX,0X3
M#- Z)G9?WG:VQH6/CZC]B=L19*!N#X2KF!\\55/<V!AR]@,C_,XH4*DNB=JU
M&[H <E.AQ:I7Y"[8:E=I=3\3]RH%1O V+?,D+9*Y/8S7U1 K3E8I.Z!)5/N
MX;EUZ=5A\$N4F)XJ5T.\8%BD[ 1#GX67C" (&)>KJ"CT,? ^YT7='MFDS=*;
M+(<[1MNIR8L*%TQ#1'8]#5%1SDAJ;:L;X,LL_?<VG8,\<*E0?Q,K0Q8- (>S
MP(7F:/F=Q;BK2^IYQ4M<C31J<R>27Z"(=4M@/ISX:3Q-XQ^I^!PN-^, 8EQH
MCY#<DB]#O3L0+Q8$$R*X\*#N'ZG4@: YV,1=65597IPR[Q<UE78E/?(FQ87N
M8+F-Q$<R,+7,JHQZ@@?XLQJ9&#!4B1V#[0!:7. .%]RY0B.'M[5(L=6D'+LT
M=]'B@G>XX+T+,^>!;EVV#?0'-^4'@=HDP8^E55Y/"!5MZ(J4C<B8,8OO"!ZX
MD!T_@([3ZYGLNIT9:&;1VVT*&2Z3%]H?1#&$!RX%&#^ H<EY>/Q%HMB%CL3X
MDF7Q:[):W:Z9T#G(=Y<5Q9><_6& W-$6%YC]@K9!4Q0DT21DQ9J3)1"%!.8F
MRVFR3$4^E/ENQBR]8L5'#BZT?K \Z7$".$QX)Z@+P4:FB(%"4!4C[EBL81UT
M%D[G[,-L>>!!4W>=\#HI< +:)ZX3PJ@B;,]1G(CUJ^YP3/MYGAGJW@,:HQ>>
MTSZH^EA&[E0+2UN<<+L%=<)H@P@;,)XK<B_EV8 V;(6VSC),2[5EA$.!/"OX
M1H/6B]2^"0F>^I]Y/K6?><K#]!?P=-+V8T[7>^E/MD]V<A%.FUC@]!^W^:[Y
M=/WCFHEA!F_<!0QXF ^5SF4 V5)T/H';W0\/Z>_IU_1JEO["_O?] ^'QF>6$
MMZ=OT7JSHA/6ZN+W?WR]^/O5!];%!IP=_ ;B&7K<9#F(L(CF(LM32LF.1CGC
M !Z/-9/CN9APOTCYG+"F-"5QM NS.YBI1T<5@QW'!I<&[S4&GQ2M'PF^,K+F
MH,<5EAW)![L&[%-\UJX""$O2^@V[OTCM2#[GJ .^A6S[=>#3,!T(:'OJ3&.>
M>_0QK(3A,IR-]3GV\Q[,_!PJ *YY&VCT7:ERZH*0FB3D<S-5CI1&1)SI:U,M
M4%>=KII0O%I7F ?GGC5<SZ)PZ[!JK<@*M-Y%3Y &:M,!@MD$U_=WRM?^]*PA
MT2U#%T[:;-F14DLS36->0.\Y6X''/\]>.HM1#J3'A=<XX2U%ESB7&J)P/M:,
M2)U3^#BO+5MQ=2+IVY2[$<T\=^ZFN"#LE=,:SZ4(1/)J".G@).\ET>'P[)1V
M@RRT5+A4#=,G.9,$HF'2P=G/O ]LJM>S[_<X!$9QP:6P^PS!R*[6./8#BX]U
M'CB<0>*-8ERO]E&KL !U%7@!TOZ$?F,9X<)_SU&8X;&<7:OF2:-TQ$;Q')HA
M[VCFK>UAY+<M:.C]8AK'"8@6K;Y#\C]1O"Q:K6C\>:<^E"0Q5>1@G''IS*&'
M91C+P+^F-R3+20X$).6=P*\BW0TI=#]DSCN"34RKG*(-HUML @W83SI;X](!
M'U$MH=,$WX8P<,\_I\U]U"X.1 AA\DEYJ<N/YUNZW1C0#6>!"\[1\OND_"20
M\K.=\#;6Y=@YNR!+Z/5;PO.Q]<Q+>S-D ';):&:J$XUQ3+\J:Y$P .W.@%H#
M7%_>(9W]B"QR\&?A\EM(QP"SL1H9',!U9>Y'[K:X(.@7U-B)) 78>\W<$]PG
M=VIHML7'911M_I@6!2UM)9FM#?[X],?J:74R&!IRR\_?+5?[JXM6$R+;!?W(
M4)>U[SM7;=!]:HMHKJ]=-0WZP=V?&=W'[?FD@3YC=]%V=RM$G[=#....LFH:
M>L&8T?4FRZ-\)QSHE\QHVC'K:;K.MI"8;+[:@F/Z(<NY0[XL\^1I6\*[W%EF
MK_YLG0N'[P41\$<<7%MQ=%>RX#G3'MD;$=U-B.Z0R!Y)O4MX==_LE.A> VD@
M-VO@,I?FA1C5MZRDW[=/.EE:87]B/XH!(KT9)[>UCK;D\D&J!0%&$])@12I>
M:(#V0_./_T$,F1;..(?*"=J>?0]1P-6^MO%,T]@/D#X:1#/*6]2.#9E?MHCF
M@4"ZW_"L^C+F@M<OY\GWK3NKLS$B6/IE-#.S20K"200FDB@T*L*+V'XCV='L
MC[_C0\(BG1L#T9C\!,U_#O3YF=&2-867^F #P=D8T:3HE[$-2)U"8R*)@L%"
MRTJ5IB]1LA*&;2TOE%R!H1+=W K6,!:8(!PIN0$L+9MSC&AF8#'44V))?A/"
M.08"'6*T<OK,]$Y?JK AW"]FT9L-X([FB,#TD=(6GJIIFA!."*":+0BC1V($
M<G=RZ[#J*+%B;87 #O<0SGEDKK<.=0*RACE:3T'6EHBF2X^ UANBCY^;[UJJ
M^$GAR(V*9V7E!0)(Y=>Y3[]'4/#L(8<=M]P]L,&4.@;=!I@?)2( !PILY,J
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M"F$'O"<,FD%+P0G3D!K0#?F5RE-_RTY]_3@.W8==S$Y^JV!NR75JA:'P7DH
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MGK0%HVIQ8NZ/5O1XZP5?HO+M[B\:VQT=J9<,A;U?'8C2VJ9*>J%%;+*YS,.
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MF4>U;86,H<HOG-B;:W)K4-S##"L!P1@4LP0]#+IL:BI34-;'#(Q54@O QY0
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M)!4()8H/TA$[C+*B/&95(IP_+=5EG,6/)*3GE&CGQ4F]HH_T%!^$AUG(G^"
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M&TKT0.V!L:^UFY 6?4:>L>J8AX%-B,/?&V7ZD-WRSM:9$Y986 !=L<TP37$
M,^., <]0,[?"6<@]( Z[ZB=T>^1[(\AQ(.Z,?;^MJP/@##ECV)<6*PS#J3SH
M-VX')?;1V,\8PQ([46L4;.-?UURLP**S-B,R! _H$<AUTA3$!;&)^TR<F;90
M0(;!SMVL+A5P)C6J*,21,>E?V/\\6!&AO_G_4$L#!!0    ( #.G>5BL=61$
M^5\  ),E P (    97@Q-"YH=&WMO6MS&T>R!?@=$?@/O;-[)Z2(%FW)ECVV
M?'V7HB ;>V620U+6^--& 5T RFITP_T@A?WUFR>SJKH: !^221&@>N)>BR0:
MU?7(RG>>_.G7L]_>_-SO_?3K8/\5_1OA?S^=#<_>#'[^Z2OYES[]RG[\T\NC
M5W]$IV=_O!G\]S\F>5;]&#W]>E%%9V:NR^A07T0G^5QEL?PACDYU82;_H"_2
M5X\_]GLOHKDJIB9[4N6+'R-ZW/]AE%=5/K=_J_2'ZHE*S33[,1KKK-+%/W[^
MZ?71X5GXOB<3-3?I\L?KWLC/EN;_TS)!&NGES__,1N7BQ4]?O:0=P;CTS_'?
M7!)/O?G_]B(*,YU5M[R&P8>9&9FJWWOZ[:TNY*&>S6>8^D]O?QX<_CXX&1[T
M>R^'1Z<'P\'AP> TCH:'!WL_??7VY^Z@MN:@#HY.CH].]L\&_=[!T:M!=/0Z
M.C@Z?/7VX"S:/WP5#<Y^'1Z<WOJ9?<8%TBIV>?KO?AV>DJAZ^>;HW>"DWSL^
M>C,\^.-N%G09U_ZS+BLS67;7QHN<R42/*W.N^[U7>JSG(UU$WSR-HV=?/_OZ
M!@L:Y6FR*_S-G=*.G=#P\.SD"$QL>'38G<A'GHB][_:/)DLTAOQZ[[G);G,A
M@^R</AF3BF#R<FQT-L;3PVR\%SWZ9YK\5><OZ"0O-,[OGP7_'N5%5,UTU'Q\
MD,\7*EL&SSR.9JJ,5)(O*IW0TZ:,#O)BD1>JTO13HJ-\0O]F23VN(I4ET8">
M&9?]'GY^1X]7J1ZE^07=Z>,\->-E]&CUE8ENO:_*HT61GQL,71>1*LM\;.AM
MM!J:2:(G)J.9C#0-&D<7III%*AJG6A5137M;E!6]V613S(O>U.\M"I.-S2*E
MW:0_C>J2OE^6T3B8L^8YT^.*?B]TI#\LB"/16V2,.3]$\U(FD=]-1N?]'F])
M]-B4)L_*Z&*F,S<J/L$R[7[^LRBQ-MH5_WJ,N-#%)"_F/(Q:TC5X0O]$25T9
M7>Y%9_1]7HPJDC(J=45G7M!JZ=TR-&V06BS2)696TXAINA<-U'C6;)F=OYM&
M-"=2C-3X?99?I#J9TN;@/(D*9G0\A3XW1&WY).;)J6FA-88>TY?I)=CI.'AS
MB6VGU9J*5H\7M89*%?Y<SLQ"CBB<Q:.2!H8JL5AH^OZ'?F\?$CA2546SIUVG
M(725/Y8MH/L^#\BE+E<(N/G(+SM\@N99ETRY15Y/9WE=-6N8:T7G]L@\CC3=
MG66_-ZG35$Y&%=63BBY<I&GQ^5*O;26>,A6=2STJ36)484"@CPP-1@=!0T.,
ME2O?<G1 IYD9FCO=:S75<V((,1WK.*U!N/T>?V-F]"0:?-#C&J(Q.II,S)BV
M%N^5SUZ;3!%AJ]1])N=&4W +LK.X;!(O<Z(L?/C*%$3N.4UWY6[R$^'EC/L]
M&CF+S(063I1F7T GG^65VRNZG,OPA1O/<9G7X3')4?#&NE/<VUEU[$8RY2.%
MY*7"<%6NW*Y4.1F0.7,V//REW_M]>/1F'QK :?3V\-7@)#K[=1#!R'E!ILW9
M\,G)X&S_S9"?B([?#%[],MC9 _QL^O1GT@V&5;]G2KZ3A2X7Q)C-R*2F6N+V
M:X@,^I=$"'-[$8LD>DN=GM-K2-ZH3$0D\1HOP.B]F>5'*BUS?%=G94W2D\5H
M3B\CAI+D_-92S?5>-)Q +:"79MJ^\-SD*40['BH#<1>3# !S+^F?,=[. IDD
M3F)*R')B?<3>[%IT'-4+%L_@R8Z-,L.AYYQX$N8$7DL#]WL\OVL$54XL=9%7
M]!7BLNDRCE(]I2U08WP%RXF(B['"H"[P7WH+OC8JW)8Z21/[!_,1';QB52JG
MMY,>14<CN\!*1)7;+S4J%LW;$*/7#9NW#XUGRA2D0Y2R0/QIGY9>X3MS4U6-
MT!).O\+<5YX-V3QM3^'>HK(\6\YS.JRV-A=,[)TF&5C9@P\WD$172F18RF+'
M&H*,Y8:LW&ETY;@P(YVP5I73)B6Z4B85%>^!2X%=X!YGT*)982+F0">3E5[C
M5G0UGI"R1A.2B[9@O3)F>2Y*,)&$D8M"QSO-\R2:*%PT(0$:R5-_>&.@0K2T
M@9AO;5NQ (<@_2DC-4R)SDV#0"D;Z9E*28_-156^CG#CJ"'WJVZ>M9?ZO>MO
MGMSX"T.J(#2CD8XFI&0E,='VG#@*_4#K+PQM?P(SHQ!^>6&("<Y4,:>_D;)O
M]\@9$WZC]J)#&H.4=UH/Z7F\R725TFH&%7?MS9YGVE%)]?8#B^+=#"WSGI,9
M,L)5'?T)MDM;TXSA3A/<S&3G.<F(A*2+[#1;8.D2,_:"I @G_H?])G@J'0FS
M0;*DM)5-3!*TJ6Q:3$PBK%>$C.=#(U4:V$=R8$3ZX.DD)&@VFB[$E%_5[[&Q
M,\(DR411O.<A[? .D?VAU;F<_GNM%ZNO7;HYR:Z\IW/5'\9Z43ERL6_']J0Y
M2S^2LX7^J\9I$Q&3P",3C23G*-51JBYP[M/:T7M![ZNQXB(1ZH(B37RR+"'>
M8 A#AE6\'42,NM+M18+X GYZ5[SRNWMB/!LY*"WK_WCRA*P?G28_1L=T_U_0
M '_5<'C0%Z,G3VQT\J=7P]_=-*YS-/$*1WP,_F\O4[*4HZ=[SVD'RCPU"2WM
M;/_E&U)Z!V_>'.^_>D5J\7__X^M_\.^GQ_L'[G?[4CO>.$]3M2AI<NZG%T1\
M237#,K_^KTWJY]F)&X.N=P6]R^T\K:!]%*F>\#=>N6\$0S<[>/8*0=H3_ <K
MH']I<S;L$U27]T]&FM@$S6;!FQONW7>;G70?NS.M.?Z$>37SWV3A?/R: A+Y
M"C0B9+%+ZL/'V""[84L>'/UV_.8/MB7?#<]^]?;CSFIX#\U,9$6O3BM22ZHU
M2W'"_BK#"F#CWDSX.5*YV'AJ3,F]:!^68V+.35*3?8B_BL)$<I4&T=."!HVC
M"['OR$S,<N)E)3MA27B3[(,2=Z[9_(PNU%)429;:4$--5K-W<E2PLD'2UK!0
M;NQ6* UP((^=%VH?SE([]=#8M%]K3-O4L-W+3FR1\&6@GIZKM*:/216]()-X
MAB5 HX%3-8,]$ZX:<P@?O""%F6<=/*^:&;)*0ZLDM:2EK)"JIV!Q)[K9]D5-
MIN0X)17YG(PEUB^L]GLA6BT9J!44"BQMY2P_S<ZG[;BQH1_=H9TOL86;&?K1
MW[?S=Y8]/1@#E.RWE#B387(V\T5>$B43O4_8'N.(5,+,0"5) 9HMB8K,!'1,
M]T-<X70C:B$1IEI8.*HPH"E00A CTO-1GACQ1OC+5I)E12)VFM-8Q)V$K=CX
M4<4.?P0+RI9/"*9$04NAH6R4JID#++,Q!@N=Y8D8HLSU2)\MQ2-$]@+=%- Y
M1W 469=B\;%+K[52N_SVW!O?4UU,Q>"BF97$YL.+<+712[877Z,FGK 6P*!-
M:449]J+79-G0E^#1L9N,^)_1:[$L=X!B46(5$E,"6^;7^B^NQ& D7N?C@QS>
M(N,\C%<%7&*6@_.$K\88 Q??^968RBC/W^,#S1D)$1W?G ^6K3W\"Q--OA?,
M# QJ0D=)F^9V7OPE'>NX=]9Q)A'@_-P&:4,74W.SV,\YMA[851]!!?<$:'-:
MFT3#!5):@1X^"ITF$UUB0F9>?L%1+_J6]:6,33&NYQ!\B,M[WTUL/619.)B/
MT/U9)U,69-:C0&)QPI16P<$&&<PA5S=U!;6!AF*7P%B5V)A6^!=,#RQK/,YY
MX2EI%A=@KB21L=12:PYJL[L6RAZS"E.RC\-SBVN894?U]T[UPTR"R* !%Y6@
M,W-G.09%5A=:9_8\_?4 >T2(O,V7LT3<<S6.W/J Y<R%JDB7JW(XK&A1,;Q<
MI3!*DE2+0DMF%T^%/HH"?YAWN3;>W"#90P+,-Q@\\F-C;D6>0@Y#QM)3<N&L
M_,:FN$6Q8]".06N!>DV4/(%]$$>DQ-H<DM Q.R;+9.H$L:B(F!0>6B"Z@<.T
M,@EKU.65"[RK:_+L:R*GYY<0WCU[YYZ]B(X6S*M^Q(M.-3.N%]'O,*GHXRN=
M=P_05W>MKRO<3+>-+Z*SY8+>OU^HD1F_B Z)6F6K#W-LX+.6\\M]"Y_<JA^0
M)G?</B'K"G1T<?S0/'*W+![N->WQ# R8=?8#F"A95=ZQU+XCG^+F,VFN?GC5
M5UG!1Z^OQ0DNY1C_8(H/^,+-7["!@_S#W9^&:]Q\O,^:.GOV*ICJP1&V_O"_
M__'L$_;Y\][CUKPO8>5R,Z\7._*V;3@<L-APB<SV;Y,P:3-H\=,BK[,$MR O
M?HR*Z>C1LZ^_C9]]\Z_XV?/GC_\&\=ZJ.KRW>T2Z4JB"*;MBE4^@V[]'E=]^
M/@IZ-S.5_EL\SS+INPY&;]K]OT4\=S?S_4O(?]M(_DARXSAY W,DZ^E$LB]^
M;Q+DR(8ZK4N;GM_\_;/?BM7C^HQW9$NY[%U?D-N<Z\L=N1*MS#69YH:\2\1!
M#E;SI?9]OM1)D^S5B8[N+JRE9>S(7=A'KNE)DVMJE2)..+T'RGZ^HPP_2)^Z
M[;.^IZ'OYGQ7T\R^)/8UW$6+:?C;\9O!;X/#,RY!DCD?O5[/,NM8Q">QB-L_
M^NY.?]X[O8N7^I?!X>!D_XU,]F3P[[?#$[[CI_=PG;_KKG-WG;?F.O^^@[?Y
MX.CP]9OAP=FIE\[#P[/!R>#TK+O.W77^DJ_S+M[FXY.CL\%!HVP#X(S^=CPX
MB=Z>6NBSWVCR?T3[IZ>#>Q'9_]K1._YE>J)V)5!Q7.0+YXY]6UH$)$GQDH^J
MY<.F]6WBG+M$X+L2=@B#"3++80:D*O:[/FS2[MCX%Q-0.,P=;1.1V0(.#IT-
MY_,Z,_?"Q'_HF/BVD\VK'2'O_?&X1DV7]9UIU'Q(1>I]!H2??MWQ\ATB]L&.
M$/NK?%Q+&:(0.Q?SWHNN\O1IQ\*WG5I>[PA5^[I<ZV!)SKE\\(%3=9?NT#E?
M/Z_S=1<CHZ_WAS8O_-5@_\WP\)>(074.WIZ>'?TV.#FE;[X]/GXSY!_AB!V<
M#<^.3D[93;M_>GIT,-P_&]R'4W9G><F7*2QWQ2O[BSEG]&S,[Q<SJ1ZZF-PF
M#KI+]+PK3M@3!LR]?Y)^UG'K':+N77&^OLTFR@0E#;HR]V6P?T8"[WCV _>Y
M M:X8!@J(6PRUXM[J$[KV/:.$?BN^%E#MGU< 'AJK!DZDH-HF0(/5VGTTJ)'
MW@?A[U3)6>>>VD[WU):RM-]W,XG_Z/?!R2'2]J.3@>TAU'&&3@[NLK.)D6";
MB.-QD8_K@I%0.<3^NF8 N?N@\EVM.OLR"7Y7O%''BB&U2YEAE0L\L%'IO>AX
MGY'&.T[^L!U1Z$K+=.!-]JHPH_I^4&5VF'UWELQV6C+;Q+]^W\TB9&Y<,]P_
M/!C(?#G0_F;_W6D<G;Q],Y"0^LG@E[?W:-OL*MOX,H7CKI@YPZPTB2MU.BL4
M@V)+'_<'3N3;Q#9WB;)WQ9X9_%4[E6_0- PZ6B S_KZ*/Y[N:DGZETGJNV+A
MG.H/GM9_584J2Z;U^V/CGY',.S;^L /NOVJT/8YE@J=JHJME]$\U)UH89.>F
MR-E%&[U1%_=BR^\J/^]L^<Z6O]8T^,\.6O+_?CLX91-=IOOV\-7@Q",$LAG_
M;G_X._WM^.3H8/#J[<G]),A__Y#X1@=-M-L7?1?O^6M !0X.S][\82OG3O]W
M\"KRMU]J8 Y/WPU.3J-'K_?_[3KN/88;;_\$+6+HI^.CDS/\]/OPR'KV5CA&
M'+7:--@.#<)'6A^L>1 '+T^'9_>!2;JSO.7+U,,?V%SOAJ;O<@GWP^X];_WF
MHWGKK;JICX\'AZ^&_[%,M"D;M/R2&.DO)P,&9(W.CH3+W4>#FF>KH!*VO=UZ
M&[-1GB8W>LVF7F;?/MW[X;+.BBMMSI[<=?^9F[1;_*;KK-A0R2UT5ORFZZQX
M-Y+CIY=^;2]_OKR9WU74]O+HA#2SD/!:U'6CEHL?Q2+ KJ\F4=<(<"-1WGG7
MI_5 ^]4SN;/F91OZEEE&W;#ICER_=')=CXA_/G)M&H]]<L^QATS1.]@ ?3];
M]GN^UW8T4^>N;[=I@"QQKN^S_((["$6%GJJ"\QO0LEM_D$[IOGWZN3MV?*OT
MU!#\>6)[?2=X7QFI**DKF@515"$4A8^O'T9ZLK<:?VWJ^?6(^[O3NM6XBA)=
M*9.6$1J!7<S,>!:I BW.Z=N/8XS7[WDHH7 PSN&E\>EK/-Q,F6*AB[)9SGZ=
MF I?F9NJTGHOVO<-S/D=*BWSB/8IKPO2/!+<GT*A63KO=5G6FJ_/V!9"]GOM
M;;:PN<[]$HULW1@W7J>9R$7;BU[3\NJ".\;;S53![J&O^KBJ51KLHRDC4Y4Z
MI=-;.R3LANUK/U=+&FCT)PW$$VIHAEZ5F')L:*\R52SQ!AHACNH%/L)W339.
M:UF*+N;TE'N%;A(*7 -YFK;E&C.S("9:S=Q$7&OX.%KDE4"NILO8]I>7E^Y9
MGE3R=$>:_J'IT[L4;2R]2U<Z76*/VQW@E.\ -U*EH5T\RRUM5U*F@-MPKNE"
MNJZ+M&F9'M/^FTIA8T>T;+OA<:N3_85)4SKV1*MST$X>O==ZP4\LBGRL-79%
ML ;Q-YE5M71$53C\P6"[P]G'_9[^,-;$9JK6C'$>:5Z"$&BF!>G?II!9INHB
MQ@VNF\L%DL3^)T+??FDX2QIV@2.K@AUL[P6F6M;C&0@6D]V[7::XNUW+[X^G
M#[/$G)N$KCFQD7*6UZ3W$-5P@AI=%V;Q,7&0BAE3EE<-A=!YXP'-1&R**"/#
MCKF&YZ!9/1]I,$^=@1^ VS%]6EK=(P6 N&HH/.@J]GL3-38I7Q9Z=)Z#0\WR
M(J^G,R9^S342(-T6<=%-Y+MT!4?F"U96A3EG3C17AN9I1#;0CWI:X#[A'>'%
M,1 X$%CTY;$?] GS'HU'&=AV[+CJKR1<2!&,4;]++^47C$TQKN=EQ4!S\<;K
M:R5$<XOY(?!ZRY_H/<3:(%KY)N*/F99C&.'VGVM%,I<8GH(22G>V(/9E)M%$
MTU$2\X)HY#W5V.^QK:JJL;6F,D0T\@IL:IZ>:W!BNS&KF]PPV+'*0!+36A6*
M]D^O[MO*;)@0Z*2)%FE"^AQ/6F5@7>83]P%_L>Q)!)()]XHYJ[QL8NCSI"[<
MOF4@J)2Y56F5C95U/##.T]E'MY17^1G-^>N4T:L;T/9[&P&'.Y-IN\3KI-];
MYK5H]1?XK[5\X+$DV1?8-W'D'LS%<K:*OVCFYX'A?#-C)HY$B:Q"J2BL>X.A
MDM_85CF[B2%%G%DL#:?O5C-3)"P-R#30Q3F]N-\CM18R@&2EV%>A,@QK3V=3
M;_\P;I=F]='NB16D-S#7]J(_:&LA,>?J?7N,"'*DI?$W"OZJ(B :/];32&G^
M(O2(&Y]+R]K#G&0P4C%N:*2RX+6F7S1CE:N<B99 )KD6.ZC0;,<U!,"[&C?F
ME2AUD-ZIH:/E78X#D])94S>T)N--=G?9IN]2CVNK:T!-A-PN5)U TM/WU9C$
M=<:;*B9NC)7V>] #Q,Z#<,\C^8Z:TJ:7%:DT^?C]C*01$6TLPRZM<2C*DUW1
MBFTLC@+0B#L+O[[K[,SUK0DM23$A;W2.T$992ZSJ@CC)B,T\W =294C!'E?I
M<NW^!N/T>^[^.HMPY:JR+9L%]/RH;?@U1F-TH>S<_</I\O$E]"\<8-QJ9A+>
M[FO7;<UM9H"TUF??1C/H:?#M**+0[_$/?KO0^GVDJFA658ORQZ^^$@4N+\J]
MI,@7>V-5?/7 U+BK X_?=H''6PT\?ML%'KM(SJY8*NME,9_/4@'^WI,34J^(
MD;.%?LS._<[LV%JS8R52<S'+H6=,\SR))@K:RR/UV&O :F/(I,[@ ?3!%RCQ
MI#;Y,6/2C>AO*RJ5P7!3()JPDQTHNX@:5' NS50Z80WMT>BQA#/*#;&,Z%-"
M&:Q%:<.JVEB5FU6PENESE8VTP7,82W3":99SS7Y-K]SZQP/=ZQ*;"KK2FJ86
MBS>/=''2BR9PKL9DSLSS"C_0,16&#CT1%QC/X +!H)DJYO2W":(<. T]5C5[
MN^*5>("=YX93CN%#@Y;<G$!L3R#E79[ 9\=KOFR$:'4 YT LVZ&?.)H9/C8,
M5M8+V(!ESL9GJ3.3T_G0(HEX1/.>M!3LAZ7F[2)'&<),3A(C9]YB!1O8RT>Q
MEFH&)=_;L:11T551HQ160FHT* D1B<I4-9G,L-9;OF+E/=QP;],C*WPIWLB8
MHA6^A/OM![(QK[Q@I@8#M.4SIW'&2Y"KO[/!'8W98TUW<]JZQ;P/\GDUHR62
M!8:?9UPY:IW;&>\K#9/1]F 4&A,!4-V8N]8GC] H^R?Z/=H:.16^K<$="^S8
MO\4B;L(/^KT@1GS]]9>+'MS]Z'-=_7NY.YW+_C89T7VFX U_.W[#B=E<N()F
MW*YHI5.&M_;Z<<1RDJ>D!8+5D9E?"K^4=(Z2=$/Z.4D*<+A-2J>!;QB\:2TG
MR<6<&Y>U(GUNOK"^^T27M%#)WDCJ L*+A1W] 6)A/5HJ[C<;A":M, ?+GX-)
MJZQ" LNDT#K)Y_0O_0>SF&C%BF@1F&<35L9HTDNLE[V56*KG]@&W+E>$\5XT
MS*)&SG.,HA'TY0PQ<)9W-@= YD'[S]JN_9<7S6KNFG-U?TH+8#9?Y58A7T:!
M/S5!O!FY HB52]:.+#,OYMA;<1G2/O_T]N?]!22J^1#M__35VY\A6'25/S15
ML9,2GU:2_.-]!G9SR:0J%TBD&:42RE4)*7/(?RPX^E(O$@EI<$H+JY=\-=T]
M^)].HGRR1+GEN>__B*U_"4$2O<Q)%Q9.OUCD2!HB=G1UUA%,"W_V]N!U<.PZ
MX+YO4V*B"G%(T=#E=<3?7W%$*"]*3D62N*=(G3FMF4;B!#Z6+M<Y,WR\:*/C
M8E*G$Z1)24Z7)V(D9!E=/C3VNJOJS)7G"^H$DC:$=>L E\R(\%&IM<\QNT*[
M.27SSM"@:W3@<WX7><FZ @?;J_S'!T8?GUO\WI[D;4F\MIA=07JXL8Q^=LN4
M_/0>+;E7^ERG^2)P<"MVPV0V1]QJN(S.'29!6Z^+KF;8=9\J:S]C_HN;P/YM
MGT(Y7C$H&L_UIJKHCSC?CSO*CSSY30 ==S:SVSO99_=(58,U,9QHF\0J^-=B
M%X(QJZ#D@^6QJOJ]U0_&326-E &8#+43NI58T]'0K9_C-_>9%YH7[QN3>#6G
M!T46DB7DT^@AR.=Z/%.D8<[[O3*W;*BA(TX+4U?5LLR)H>6).!+<F/!MYUFZ
MO#:SBS/)U@-X_9YWS']LXI?-XW+?OWD*6'<7;IT>O[U/?ZO339%!2C*5T_B(
M_J>%FH,00K-'M6KHB)<VZ;:)>+G@4THZMGEWQ_7\/I-4F%$R5RM+>'*;4IVV
M@[$[]UO?^^_N\=SI[Q!NB#6S/\854L'2;619(+B$1-ZS@&IB 6TW^ L\=8T#
M;C6KS]IWZ]9=F.DGGKNK\SR?=WF>MYKG^;S+\^Q<)@_$9?+]/7+:$WTN& 2)
M\V%[ T"MU(&+N]#&0*O5%!%;64,&RU27SD=".O[>9PMY/+\QY-@WW^X]X[O=
M.:(_WA'-]=:-N5K6\SD(Q-92SQ$K+TKO0]/)6F98?DD0Q)696ZN8HV:%QKB5
MQ*S%88=,3>V*J?$Y6Y9EGB/!RDPBLA"X;CEQ*6,E*K>#HFR9XEZT+^NX#H.A
MWUNKXN8M&.GH/8 76@9XNQ@GQ%U0"]K(L4+@L'4K.I=Z%]&^%\[_:WZ!4O]H
MZ(LMKXLQ=M'KK8Q> Z(CCA8S8H .G(/CT'-E4I\"97F?R0SSJ2LYO"FC%''M
MQ!7:7H?!T>^!D,A$IV]QP3-GO2('JYV;=9GUMAG@:2V-Z:YXYN=DCR$[7&67
M'[V:%O>\U+AS+.YV0'G_!C*UG_!SMOIVAE<<J*)RG=UN^K]WI-VTJ(#W;!LI
M]F!F]$3F]]ID=*W!'^S%#E;P=Q&U=_/HGWWSPY-OOG[VY.GW7W^_(\<)RON_
M!QETWO$>:=.K9W@#Z.?M/8_/9F=]7IL*52=B.J\GWPK.!<(>;?! 6%AU6ME<
MA,6R%;SCX F0E!@90G(@0A0]G[5P8>OW:<!\Y'&S.$=Y7!>% ')Y**_.;.G,
M%B[7N,]ZC5\&AX.3_3<1&I<,3[ARX[2S3+;6HS10P(8DYE2C-#C2'ZR>+Q!W
ML%K**D:)81%+&$<R!]A3 CL"KA97()QHFKOSU>0>B[B4;_K8\9TE+':6PF>V
M%.ZZ;.]6=-K;G^3_^<-WW_]P.[.\S7FQ!H%YN$Q)4EF2U)::P@^:FG'%O@;D
MT!=TL>F*5Q=:9S: :U.4%D4^ 70N_R&$8=J8ZK,5%'D[[1CO8)1MVJ1MZ)NT
M/7.]Q4M\YY.=U&EJ6\-:23PF]9]+O&&#I,N5A"N6SB'(=!;4G@> TR+D)R9M
MPC$-,+;-WSEM$@GQDL$'L81D-IPDR:Q"<-S_F28P7$A).AT<0$/Z9\%_>&QQ
MQBV8QZ(FY6"\ N,K:&CM:5R6%++-]VGG>\YNTQYO*7O:5DYTF_,:!["'F(X4
M-3=QTBF*FK@MM:0+HV:C3BV;"*HW-J48/"3W5N>E^#0OQ>_WZ*0X.#I\_69X
M<'8*/(GAX=G@9'!ZUGDIMM9+T<#W^HX)ZCPW"9<LE*:JE30]@E\5WEH+B,.Y
M)_J<#!SB6T!MJ/+F(^5M(F\&20&N-X:<F10DG[B_^))@CT<[S!K_![-*YZ"E
M*?B&*/3'DNXS ^>6-7@I_X@0?Z$XS2:V$+#SA:Z,_&$-$4+6/X;O5XK71YIQ
MBMQLVU-KLE[&:5W:>M/&X$O.%7'P*6 HYG.=\"ODF"SF&H_79/K3?#Z02E@!
M&3H7!SD HC*'H(M4(=]09PP9(45Y&_LR[$6OL3UUL<A+5V%E2A2O.- KIU*:
MS9.S^B5>8.&7I6\$+=OF!<VUXNPWN/!-"EBH2B_LCPN%$Y(_^9\7>5T".=F,
M4D8-F+/.2K3]A)NS3%3K5WJ%_SE1]716-1_V>Z.B_66$TKDFW?[%=6>QD[4N
MMF;RCW(+_(0 /MVQ3 E!"="4UH^!#^);,,PP<U3EK S[P.("5Z=R?]>E<M]J
M*O=W72KWC@=+/Z=P9@RE*[OPD("]A)=#]A6,R#XS(X;'YV@K8X!.+"210Y0"
MHN"Y>"6D\<"8A2)  75)R\1,7"^UG$4Z]S)(&ID?N$'O*B#Q_;=[W]RTS?(W
M3_>^_QQ)SUT$8STXL%N.T<\[\UURDQ[F,K=&5\XO93:V0]4JT)HMVY[X5"L?
M*C&95=^F&>!96!$+VZT*0FM>5TBLMW$8?'=1H()#F%222SEVJ?7[DBLU\B9Z
MNMKB(O)-54P9M;E98TYX.V%%Z8]Y.)J-S(0F@?3]!0H#,,;DVFSB%F)1F)+"
M"6G1P-L 34>;V&-O*.D MLE0P&SR(C0M?+F!G_,ET[4U":TR!%=E\*)IY#%S
MS> L) 3M'G_&I@^?LLP"M?8+]'"S+20;4F"Q8WN7H4+>@L36O/^3.A-0Z NN
MC)8NFD__RTT2!  7/#[C*GG7?4A\WL#6*U0B/>S:8*M;YGGMO-M=1*Z+R-U<
MU(C\ #1T#8^2!\W/-H/J,P:V PIU8N,3)(9,(Q0;1EHO7B[VVDV86+HXF!N1
M+[ECZ?;99E86)L3['YKNLFOR+K>E:*E"+[)0;!9YZD.23>X0ZB,$P7^DY;?
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M=2$6"N/NPE>R);F0<P>1?^ESC 9E [U^'OXQ*9QPJ<?.-]4@X-J2NU8 'W&
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M/Z'K9&+0:[A\P:&/--42('$Z5!R$Z^(@^P$9(YDN;+;<;_^D77FQW^^U;*E
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M%FK9[XW4^+UM3L#49G&D%;J!,[D[(H\E7V+AT<L<B8>070\X27\W26Y8]7O
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MP#'%%.=YQDZIJD!S(>=-YG1,I-^9:LG9RR7#9==S%/QQN!$-H,?<(0C*1;Y
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MPV"9UW#P9._Q/*TWL:F0_5Z3:+_R/OW!E,B$QU?M#&^*4@SBSD?<PTM%%\H
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M%T__JY='K_Y@C>W7L]_>_/S_ U!+ P04    "  SIWE8CK* ?$4I  ">3@$
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M@,$%RI(K4!P;G1?R7EJ.7<&++@_\!LDL!<Z6A2_83C9ES+IN]8#M3.J/J<]
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M?[5K"=X@.:K6<<E]YI(M"ZF&"I%R+@!"V=!!A/E]TG;3B\..7^XSO\#3,TE
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M0_0@B++?.^Y?>YHJY\9PG@E[GGYK]B\AL5_[ME9UK96$&U=X$.""=4?6)G.
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ML(NA9#WGC1R454N;675<KQK&WJQ1TX1 N'2_U5^CM]_;0/" 4-Z4WLCYA:3
M$6T:ZUW:R>),19>@42F(V1ZP<15S[RP;W?5=@(65_]>[V)L2RE>D/*K40$?.
M*[WRI6%A_?.P^(O$Y/!C*5>&\ESJ*5G8T8.[!Y1] "C+%FRMV#8_R#YQW0AR
M?Y7<2>DS&>DW W*8728ZY'090E*DJ<LUQ=U1)LOAEQ-I=*VZZV!#M&)@D]P2
M6X=O+7&LK319K1(\#1I+O5.AS&J1S+5MY>0#[ZS&[F!O%>;\^-KEMD!Q>TV/
M#NK;07UW@7^YAR4XW^&I^58%A%MA!Z(K'(Y= ^R^:RD57FYU*UED771NBWDI
M,JI.3>*6G%0K$'$'2,.:Y.W06UTIT"K[?I 9G"DWR+O <IG9$BKO6+?CUJZ8
MY]7L^M]%K&Z46_F>FV+7KN1>5SBSP;$7*LUWK"#D<YV%F[FVP\A^YX8/-88X
M)==.T_@>,I/ENH2QNDK%^2I5YDN =QY(5S-/??"MT@.1^@QRGSX,QY7-%;ES
MF3:N?#%\&RO?*K':70WQWY&.J5%GCE0Q)H])KO7\R\V^JX:0PFYQA0/ TL5:
M 2U-=;#%'W9S(\*O&S28^?:I=:N<:M%0R0V!G2;Q"1O,<:SAT&*/_S776@<B
MW-4>"V&/^8K&'%LORQJ33\DHOXXU7&B8<'6X-(U6MH=<#23:9!"& DBJ *<^
MNR8.&1;=B*F"\:#?X\(7"#[!;I]940*B,@+4TCG #ZJ!"*J$UY/0VJHUK_7^
M0P?Q?7,0W?KY=>,^"-__C2MOJ[!2>/NJ$BQW>^CW8O5P^;#E&P4Y*8DDQ^;3
M8H8-L:<2/<-^^:I20<#Y@@YC$ N-(Y[7GJI+XB%/T-"R2!6^"X4/O,+V)&2T
M+GJ%KSX N0%NY32J&R]W<?KO!P<A"V$/1,0LL>:.F9S,-++(YTEF^R$R_LSJ
M.VF1P3%@E"LM1H IQU34RA!/E"1R1@>>5J"$43%3!^=R%0N0N5P,$<XB+M'D
M:^Q7:?)])UU#3%:AMN0\T@#59R1(Y]BP&16O*75;+2,9*ZJ16N_$2FH@CYLJ
M[)LD"EF=BPLRN=# GX-"9D,OU&Z79N@AZJO4-)>#0/4,$=9&D>(BDGMFWV6%
MD=;'DU"YY4XSW%>@O9YW:*^;07L][]!>NT</?4N[I2LS_KVOT"U(6,*IM_?*
MD6&2YGQT+9*003+<1OB=FF0%%CY\_.- /'[T^(G@$ZS].51,L4Q;1"KWCO8K
M=20I)9.M2AT7E!Y?*J3U<HKS+"EF<W="AX4#6T\WOO^EV'NSCPDP-:476X?4
M- IKI SL"=KR5:7)M$W&#+U='*#4GE(=8RZN3N=Y).,*J F,)[%4M@>I7,IL
M+>]T71OI]];4$;$&*2&="I5[?CPM&Z%&[+JMG/.,"*JK^]9G1;V<,9V<<?!X
M'2HLP5R1YZ[?4Y?2:FJU-N1PN;/I#YYQX]Z]XWV>*<*<K,J6*M1V5:[=A^MD
M\\C0T8>*$S!"P#6MB(HBP%Y[E,E '90Z+]2.R+_@5(-H-;@)D8$;H"H &C"C
M($FP-,<!Z/_.M=GY?G;M^\%ZJ<K[".-6@4NR-:Z6QO#"-,! $1;6G6&[3(HV
M@6&E2R$N6Y:=(9C&YO9P_@X6)D;["4X2N2]^>H1A*5/I<<\RD'V2S(B!?P?)
M]S;"R;C:F^R+?)F4&4"-)P>N7I>.%&6'ECA"2M6)BUJJ4J;2)*MT2L?,K@!]
M*TXFN[B7AZ9Z08W.DY;]Y'MD!&!7XG@(!LR4#RR)-(5N^K2IUFM&R.)GO2@6
ME-'UN#9SY:QM/DYO3?AV/IAMO'CC<IVK6P76^HE=TI8JQI0XYKJ@USP<I +X
M?3HHU0*_C[MUWVWVQ=-AOW=6;<ICBP0Z'7!<#>MT61D[SLJP96A:HZ]8W(5#
M<<DDQ[[1UWDDT2F)VG&!:9Z$ :\'A:V%9-J:(5(-??L>6>_J-&#4^4;7_J#L
MS]"2UD')Y5%4#R=>'T#N]ZI)(_6[%VABD&&V7I*RID;8 <.%IDA=8_FH/KI&
M$X*R>!>6Z>KWUNMT[:'<<QUJE._ <?SN=+#I62>_G0W$+P5P!1:03XH,[)3]
MSCK992((!\(KW3LICV=C\+M2(:GD5JH$.*BE7!O8M9>N'VG+/6690(EPO86.
M4=NUE02%S<5HOAR323@%XE*YOFN5AV,$)0LT!DUL=*1CK5U"G'Z-([0',G69
M?,+^(Y*[CN Y3%U).+BYU!$*<I#=$17\6J#DO032P@J\CA!!U02?5Z/74RSA
M8C4W9P.3CXO:G%CVT#D'<&V_$T1(@#TP;3;1*2-?20"BUV7HD($-KSG 9Z96
MR*=-I:+Y+-<+!:Y#P:L,O+CCQ%T"@>IZH&W_Z'LRVDK2S7BKA1,[??%*$WXH
M_L4>.8QULMD(>H9[*#GEX)']WI4/826E&H_E'#GBQ*HHQ(Y!:BZC:4OTMX%#
M,"!HHY";-#+P"-M08!-U1*R&!=V74SAYJJW^1"-'564M-.J<3ENW"ZJGOC:;
M9;8MB,F3X).PYG4IV,G.4CD5Y\";B58'WX);^;:R.@OY4+&UN\Z"8F%ROJ=6
M%93[<.2,;207,HW25Q+LMNYNVU5>S-$A-,8:.*[[4 L*K[/@=KI0U@#I]PZ?
MXTJ( U\:G[9LV3R#2O$XN=C24==EOQJ%.>7QJNT:![3''GQ!) W[;F0N0*3
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M$';V2RK)R;: )SXGFSDK")2W2@K0GNQTV!*39;D#V[B3P6UNAGSY @S-TP-
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MFF$_B_1&/[W)[U_MI_\!\!]02P,$%     @ ,Z=Y6*.HYY&C!P  ;S    H
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ME<H$4J0!>>JGP?9.QY9'\P31['*#&")@R8P]IFH:BW D&CZH131#!:NILBR
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MSG":17V20Y_@2(]TZ),??P)02P,$%     @ ,Z=Y6 78D3 +%@  W]D   @
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MI<X"$04B"D2TL@'O7F1EL#D$H@E$LS)<EP+C[2.5!H4MD$T@FU7ANLH%IE!
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M_K4XY5BM+ATC[<Q:X]D&UK@$+YR/7!?U;)(#>!S8H;";L-(!4"#H2K.DZP)
MUA_A' <$T(X2T&T!QZ[H,S5M;DX!5$" \ %085WPLDF*P)"/S'8T5#/49%]D
M%*\!0(GX@X@X)&%<%[QL*E( 7EJ41$ 9&/M9]O L6SIJZ)V)W*S)O5L,_;J
M9S:R MA7(H+SS)$!T)AHC\$CZ!>@Q4FGEN3.P,C6 F_]T'-8.P,R*2')5V6H
MU<KZE1*AX!)PQ(Q/@4#>:G!D3^1!H?1YLN]."W6P/O>.?AY'ET@_")?S4KW\
M6=@4ED@_F4VGBQ6T:O5\(S[S10MR5UK1[T#; ]1G0/DG?1IDU=Z#VK.N)@H+
MG:#L^_5Z5*Y[=+>@"O&U"E]]QT):X%L#I#G NY<T4<,8E%3:4[6@:KV:V5F?
MWAUJ>JG=R:5.K3!<N]OJ]QW:!WX._ FX@,MT,6C6YA;4Y!9,]-9>;N'K^UDR
MD^?L,[[S/1<8,C+@6U^ G;+0B4:L4V;EC!6?95%XMX75L17/(^=T@VW=C;C8
M&(GG >_7W(6,LU-SL_S:>LM?/T<P7\NOK[7\1L9.3&LO/UJMI&\T!)/K3:?U
M-=>9/>JU*,]('&@;A,T8/4\I7HOD"B9!S%"3MSL0,]L=-V"5\=/]2HGK.QQ'
MT-?YS;*[+G6>!1J,0!I@!TE+9R;C*(5_@O(-8(-08>X71KKPDS=.2::>H0:$
M;Q:/_X)>B;K ENEK8M!%;Y872\R+XBDA,%_)^.G%?AK8O@NB[.D%[L8OTE&R
M.:EAOL7-G-Z4S)'S8#6,NM+W^V1'7**-5 'WN2%T5\S531L!W L:/5PMR<*:
MV3N;%FQK[COWUTMO3F;.% L8/: "&E=)8\#RM<U00"J@@S0CR00;C?F(X:W)
MU=W0KN,39QRP"<DL C F]FT2 DSR0:=^T)CG 4XS?6M.$X,#[_EA[F-OSLJU
MTXQ[<V^[7CP2M86].LV\5T&:=X2Y5\A\7=MD!I(<!L"9P6!U&]VYU1<?//)W
M /?%P6-=DMA.F^=O;Y>6YM.G"3WNC>S."JSZ-!$P66]_=J?X5"=D7*3US1)L
MT\)O<@?.LB>C[T_SV\@&9(^D[P\#!')G67SF_-K,XCAE#BG]R^>,8(9$_A>Q
M)@7RG44W+H"3*69[4E96WYTT?64[VY,#76XSV[,-53>9#Y@+T;O"9JTO?7]I
M1SH<'&O;_O*EO:0T/CO/KLO)J.@--:A#S*@"X3.U:&]&-X<E0G#GV2.GZT"V
M*.@/<&6V-25<CQX<)1S8%UO?('294^F#71-)$QL\S\RAMG4@6[QCV1VO$J[)
M$IR,8&5&_R K3>+_*N M<Y[K)^UN , E]B^SDGD5%F+$Z'3CNYA9'<P,YA)[
MF9ETPZ,6M+OI75R_O]<D@!N'++.T"" #F$1VUE3]R_RPS47V(3=+@S #@2XR
M3JZY[O5 !PJ+I3&[%7 ]:=J%,,(#_=%ZB'Z1:"0^4QWZ ) .F ':&/R)8/,*
M VKIU.6_F\SZ\='5!W1(X$':*_][X. SJ?7<+>-95>&?DU?7.)(_>^,1K-9E
MPY$9?TWBR>)5KNT[\DUP$<+-/LK%\N7,04YQ3W@79N)ZX^#+\&M4,SW68]31
M^"( KH'GC3Y^^/#R\G+B4OVD;S]_:'?^?719@?^=7U3.:]6?/DS>'+[L0]K;
MY+M&/(5K"@2P2!P/4_0OHY4$SXE^F[P+M./H'K[BZ-U&_([@Z_C;@^_D5L[<
MWI#8*J?E>J4X6\HL-/.\RPCV\/GRE\UM3J-<J9=K!<*WV.9(V+>W.84CQ@3F
M),AJ\YM3*_#FU+:].9/>A*7Z,NQE)R-&3OOHA(B^E[\8 ,GKR&0ZD_X/S6!#
M;(AB6_'F&L"S>?\'D;EB#T>VA1'CUBMSCRY%"M(RFR  G7IG#-H/J> 6A%H4
M0A0$(7;&(0)GHMB,SP>+!VV3N$$C"H$#X26S5W[HW$ =?OX.?WN4/].V+8P*
ME3#V:FL8>[5M&WOK]1P\!!J;(VB7VX6#H[=TE$AOZ7C@&)"ZZ$,_\-D-,@_W
MM,- U^2:W\IAS^\V>O@'/W?]AXX$L>2-Z=95!X\"PJB>L_9#/_X%#;P/]^0G
M<Z*2"W\KQ[Y\\^;#QX2E]^)0D:.J'*Z%<KA6=XP0RC.0>\_ KE%">0;V[!G8
MV8$KS\ ;8OC*,Y!?S\#.D4"9AGDP#7=/^\HT+(QIN"OD*$[8=2>;LZ@_M;*@
M\VA!YSC]>G'#<V6!Y]$"+S!**0M^'Q9\$1%&>0"4P%H9690'(2<>A"(BD<I-
MR$UN0A'11SFP]N[ *C+:* =8SAU@^4>NF4.\E&<H]YZA?-5J+$(HY1DJ@&>H
M6"BE/$-[]PP5!&&49T@)K)6117F&\N@9*A@2*=,^'Z9]P=!&F?9%,NWSA5SI
M[8J4_95/^VN7+4I49#T']M,^#ES9/_O/C=_Y82O[)2?VRQY9O(I,[S\RO4\>
MH,S//)1&[)[U*_,QW^;C3I!C4=J2V+<KYGH.Z_I\=G3?H;&I.$7&CJ?QB-[U
M8L.P8Y)AX<)5DD <@1HA O%/\1Z7X42EZ^>#P)J)!2$23?2V3%OQWM"EL0:Z
MR#/<GN.I@:-X:Q?SD>1 3=+MH,\!6\426;8G_?@+ N:E\%+AY0J\M;8&;XUC
M\U:209N!+@>?BE3P.JGG-%?7<_B*M[JYI^5J,_P4SFS^-['\+C$,]DA'Q"%O
M2%->O/)]JLIX6JNB$)[K-H-N"G%RB#B3TY<B%-B*N9W.1;XZX:9<#T>F/>9;
MEMR4F.,.C5.</,MEX3>+>>[#X[?#1IIE=FBC2DGKA3C&M#8T=_,5PTMC> >/
MMWE'E9VPN,C=7"WJ@#D)^PXB<+9O><[X^[?'(J*]ZWB1R?8SM?L.&0V83DR!
M_G)Q'[\]'IS7?,8QMEL'?(SMUELYQM:W S[&UK=#/T;8B.]?F<6&_G!"8;[K
M]9C.D[I&Q;:N\*P?4#D69XM_)E:\407XWK'A5+SQO0GGU;*,</\^CZ=UG=0M
M?A,81U[?&L;%5ZPP;B=Q^IEUCEAU[%L&-6+.\=\)6M#> 23T3!A6W!&P>,5[
ML\+SE>N_*,4CV+0G^]YW] %QZ>. .!18W$'%MUKP5(.9OL>>Z2/5?8=YC+K7
MK[KI Q+A)F&\R?>X'_*N%R2%W5.';\?G<?H#8ABYPD:JY)&EN)I"S3>$FL7B
MFFE.O=_@.VJ PO+-ZKBN3PV%FHM1<X6-5%QSR38J"C7?#&H6GVM^LY[YGBJ,
M7 \CD_NG>.3:/%(AXD$@8J$Y(O=T*&F] 92<NY.*2Z[#)15R'C9R%HMSQCP7
M':O5I6-BZ0=0LKA]7)RS<8HO+L47%>H=$.H5B^MUK&?7P_7?\:8%RC6>%277
MV%#%)9?BD@I5WS"J%HNK*@S=#(86 #&+Q4,58KX9Q,P7QTSO%?:%= \@F7&E
M/$../M/K/K@,0WG@-77@N3KPVK8/?-JK!HR6.N'J89N^4&"8 ]LT.L.18S_S
M"H,#R"I='AM6W)0WPAL4JA0657; 52H7H,P$J#*GCUJ(3<0BNFX[QL_4PNXO
M7[ZTBX\W\RK9L_266P8&@[*/7VB?F-=\P^(X.FNK]\:X.+)L 1LCN_\B;(FC
M\%+AY0K.@HO5G06)>[;AQ:J"H5B//D7A^CZ>';>2'UA_X+EOI)/,PH7O$8'X
M":WJ;8K?LQ6C7J%-WM!FLO]$A !;*2,$#; >?FJ&!:N=^[OBGSEV*F0&(\[X
MD9AP^B+E)E$U&JYSG^X^/(,5W7W\M+;'&10Z[,L>2QSL+BA>,O]OED&=%X>!
MR5I@.QWKT9^8AZ?;L0SVS P_:'S!.?WT*A7=I]&]0HI#I?ZS<JT:?JHE53_J
M4..*.53WHMA9$"=[4ZK@"ANQ3_YQ%FM.MBS_P%/?*O]0:%4TM$IRH#B"[) #
MW7?NK]\L>BRU>,5IYG :A3YY0I_=<Y1F^"GLH?QP==?KP7.M?LLR<(LZO"XQ
MEC=9?*P(&_VU3>*Z"9-6R)TE]V#/O&6U1L7RG+?G6*_QB0.U\%.].-UK)S<7
MU['JYC9WX'0.&??3B_TTL'V76,;3"ZQT_,6V^D_4&78L'1?^3#'67GQ*Q57<
MDF$\16"5I>_5 [T-[IV>=:2P(>?8L.OQ@X$#6O3XIY0+."&ZBH\%,_K$SUSK
M/L/?1<B55\B2!V3)=?ZZ0I$]H4@^Q,A;..[\<()<BHW9R#'1F^-@$21UG0I)
MEM,M%)(HG6*&3J%0XTWI$FI\64XFW158?"BD4>)D27&B4$6)EW [#G/T_%80
M8Q4 "C=X/J_2#YAE)?Q4/4QL+1RRR'-9-1R,)[@]J3>)(G)"R9M!C\1Z]R3E
M)@YY&PT#%O"!Z=%Y;^#H5^<,RP"1>4+?H>*8PJA#.^R&DAI[/^3&5@\YGN(K
MU]R")1@\ 3;(;SV /,YYV;V+UKV_X]]28F_\^('&U?'G]OBW0OT+AU&HO.Y"
MY'7GR,.Z>/B.JE/+?YU:CCU?Z=G,"JV*@%;[=?>K^K4<UJ\5CM,H],D3^NR2
MH\PL?[PWB2YVJ@__NG<HZ(O @ ]964[WF0@<66DW]JDVYZ@<,N&'48A5,,2:
M\M6<;E.O 397.X\^!<AR0[N.3YRQ]&(< %)(BUPNZ,[A#0-C")&^XCUJ+_P\
M5M=>HGNVTKET%701T4%F'49T<$L(M P(:;'!^+8J+%W*6)N'I8<2P\X9ENXK
M@ET02U )W'T*W$E[+V)*6V^8H(Y[_\>]PZD\8%]\M0W8=9TWJWX[ISYWX8=^
M^$&6RU=*7-_AUF;'&OG2M/S--F%/3%B!U$,.'5<FMV$Z8WRYC=J(LJ(0. ,"
M/S#WQXU#:<?"X)#K/8!JI)!XQA6S-TLA\KX1^?IU1+% Y0J[2X..KQ!Y#B+/
MWBR%R/L+0!\J?A8&#0KB:E@298*+KF&G/6;U%4)MGL--U$ORMZ?O]\&QLPP8
M>8"!RGRC9+YBH7L4L;;KO5$9.W?E2LC.8VESM^X-2]EL**7$[-9Q\BW*V?TB
MY9L3M!-9) 5MTY_+Y =1WU6/U>&%/53AH=1MAZENAU9B/5UR%5XR>^5[TV'D
M.:V$/!.U>UO*&%4HDQ^4V4GAY@Q?N3K\_!S^UF5R-31^J^)5!97)U35,P^JV
M3<.JZA"8NPZ!U6W;7JJ#:/X.O;9['V)P_#]3BSK$;%E&RQ@RB\'F$!P.A$%5
MRZ7%1X..I=M#&DK7+[8PI9-(L=0N*+_B<CV)%4KE'Z4*TD\C)J0H<?0![.85
M?::F/>)E=&\*H9;8 \6AENZ:KM IQ^B4+^XTPUI2/0(/R3J:Y6]0Q[U73I O
MO\E"P:*01(F+&7X6A1IORJ^BCEO9(3,"6 HU#BE0-6$='&ZRTC+=B_*5,;1U
M:V%F3V%U_'EI?Y9?Q5"A2GXXQ1X4177\>>(4N58<%:KDAU/L/@LY[/YM>^BL
M[UB&+SI$OIWBC 5+WR/7R%.F=7H#+X4V>4";G;3TBJR29KG2"#\U U1H_;#=
MA8VM@XM%LFFK;0/[=3S6->FA9=S.ZP&^U%8M1*"U1.&,$2W+G<<^32U$NA5-
M+8Z>VS2U%/XK_-]-$40<D[<RO&QE3%:X>4B(L!GA?E ]A?/!P'+;7CA?(GDS
M^)LL FLID;PGD9PL24L]!X7WF\-[A=,*D=(UP8VPS#@N'C;"'10#758[>82C
M,7P3-D6XV;]2;V#'1@I-?TOI+1G2"4)]HXJUHC!%80=+88<G[Q1='0IC#N-9
M\(*I_A\'9_H5Q]A*Q++XV6PU;Z89Y,TH-,@5&DSFSS17SY])(,]VZXDKI^5Z
MI:#-8]9+3N(KWLWF3J0I@90B9JQ+?W&IDNMV 44^ZM0BL%^)W*3TM:H\MJ50
MY='ONO0OGV_;&\"6.<M5"#,G\5&F[7QAI(OCED#X_8M8.+/MZ076+?]]9]&)
MOK&!IG!#F/,;,7W*IX6X7[#:O3[KFMC)N ^H<CO,ZA<7)9=-E5IOBS=JRH='
M\'D<?OP%-@*;%(SYH275H#G'NBVX8LAQXW!*UL<S@)J#1_O,.]M%9S%%M8IJ
M%=5NS+VRVU[LTR@5#$A59+L]LEUJCQ7=%HAN]R]M%=TJNE5T>QCR]NG%5G2[
M9;J=VF-%MP6BVWS*6T6WBFX5W>9"WBK"4TA]<,)((;5":L6I%^Q7H+)= 6C/
MO =_H%&,OQ)4'YX&MN\2RPCU"44,AT,,JT"WJ 9Y50Q2XD=1JJ)41:DS*;7P
M,O5WPJP7!^WV ^Q.IDAS&Z2Y$&64U%2TJ&CQ3=-BX>7BPY6B046#2]'@3%11
M<E#1GJ*]-T5[A9=[]YW[:T5]BOJ6HKXYR*)DGZ(_17]OCOZV+O]JY0J\H[FH
M5CGX?:E\HR(2UM8*FU?!ST7Y7YO)]MH6IG)$VBJFGI5KIQDQ]=YVO:^V 9@C
M9D KS-TGYLX_C?UA,B):L7ANJ!S%'L-E_>. ./3>87J!Y[@7&<6WF(H[>=38
M+2NI82U"!B4KUI<5BN)R2G$9A<I;H< #DG'7K]31F:N(3HFY6?B@)-T6))VB
MN[W37:Z%7:[H\*#DW8CJ'C6NV#/2@O$ N*O(3XF]F6BAI-]6I)^BPGQ08<Z%
M8/ZH\H!DH8C2_6:;</*\JD%1X%N7@^DHH63@%F2@HKX\4%^NY5_>J/& 9-\#
M<W_<.)1V  R'NI[20)7\FXL62@9N008J*LP+%>9:#N:1*K<N"^.3RA91Y5MH
M<I +ZCJ87@%;'K2V9?Q5CL4#1OFWYU,L-BW*^R8W^BMQ?E"ET;U9 N2P+4**
M@Z.Y: (T*(C-U>VK@VR\40@RRE7_BLE9RHA,X>.7G*4<MU V/XAO;0P_J)+Z
M0F!V+BK3#QBC#ZQ0MA XG9-ZTQQC]8K^W65+,I2BLFW4WT%EQ,'J33OVT6Z%
MLI2"],8I*A?ZVB%0DE+,WCPMY41/+!(US?:0*]TO?]25(9ZAM,!"4)O2!Q65
M*<UP6]2E=$1%7TI;7)_"TG/4E::8/QI;LYI :8FYIS*E(2KJ4MKAIJE*:8:*
MKI16N!YES:[84)IA_F@L0WV-T@X+06U*0U14IK3$;5&7TA05?2EM4=4X[)UH
ME(:U&0Q5ZI+22O*%D4K%4))\!U@9S'246/?H=UT^?\R;B9C_(M9D.Y$[BQ[^
M;* Y6[-1)%W4SV69_=\3MFY] N+JV)K6_4:AZP[1=:D#4/CZYH<&YAE?\S(W
M,(?XNHPT>M/3G_*"UQM1&[;KS\O)O*<<4ME20E2160[(;#/JCJ*S_-"9&A]:
M%#K+6V]A16=;T1K?R"2UO%!: 13'_,Q.RR&M9=,=%;'M7:PI:BLXM:GAO 6B
MMKPID8K:MJ='OJ76X7FAN4*HDSGK&)Y#RLNJ52K2RX>X4[1W&+2G!F(7C_;R
MIVHJVMNJQOEV)H#FA>P*H&WF:N9G#BDNFZ:I2"X/DD[17/%I3HV9+Q;-Y4V[
M5#2W1<WR;<W5S0O9%4"[S-TDW1Q27C8-4Y%>7B2>HKW#H+WE-4U%>WFAO;QI
MFV^(]N0TNWJY4H5_UJ+"7]I1HXB69;3M+U_:;ZCX?%>$M:C^?(5CV"46)V;>
M230+'[_,S+L)W-_\S+L5,'[5D4**-'9"&CO(KG\#E)I376_]80V*^G)*?1EB
MQ8H.\T:'\]MB*QK,*0WFH%.VHK]-T-_BAJ.*!G-*@SGI0:KH4'D]\DI4"G<7
MXFY5XFX@(*0K=4)LW!#F_$9,GW+.XWZAS]2L%Q<_ _RX81:Q=$;,#NRKX^.#
MDCPWL1L;1<UP1S^/PX^_P *)HP_&?'^3D,PY@3VA9G7;;N5:Z%:N*2152+JF
MU[BVAM>XMFVOL4)HA=#KMN7=>3!/(:E"TE6Y;JYC=0JA%4*OQG5W;H9=P:.>
MB<>>J<).?L'DAB@$S8LQIE!5H>I"5"V>2:;06J'U*AQXCX:90E6%JJMQX$*8
M9PJM%5JOPH%W;J2) *%"3GY!?#,48N;%.%,HJE#T@(PRA<X*G7-NC"D452AZ
M0$:80F>%SKDPOB:2;%O/<%2T;3*+Z3B\N>BX=^_8L#G>^-Z$;6M9QO5?/AOA
MXSZ/HU1PGK2:MO*#._1%E>7J^/=U_#D680)IJF?X@EHS_!0.OO_-[A/SEG@#
M8MW[P%F)2UM]AZ;DY]]9] D.Z2LS*?QM%;BS1X!@B$5WO1:F>/1I)-DX2BW>
MEXT(NT55 >F;OB_<#M!H%=P.$"[7N-TR#(9J## /A=X[1.^9^ZXP?$,8KA#X
MC:-0NJEPYPVHT[8MUS<]9O5!N_H-WFD[X1X6N-)N&?19=OT'9T3,BBO;0V"_
M3&_;ON4Y!>X1'!Q^Q])A24_DM>5[ ]L!N"?BQFD+?BNGS44RX/P7&\RE?_D.
M<PVF1VZ<0S[W!4M_*QAP8SN4]:TW0^YIZSW4LY[*VE2\_1"C;C-.6_'VG/'V
MG6. XNT'>-;2^=\H5\!.O(@^170?]@^Y?J93!7QM>SBT+=[KH_@(,;'4Z;9
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MY^ZVD,NKR>7]3MP!L_J>;1V7KD[:)UJMTFQ<[&I)?X*6S7KC3=)/0#P%.X\
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MZLGP]_V_/[=IR_N7WMR, $A)1TJ'Y^CRCYD)29H4!)C/JH4%X(JHBT?4B.R
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MTN)5@A;ON45T8]K$^\XZWT=6TSJ5]'A:KWS_^]>G3I?JSG^>?XV&(MWPP#E
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MR+.]JI_^K3WZPR%Q"E,PMQ=TFV1W\#7"\,^CVLK=:;8KLII@E79^OFT]?7O
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M&.=P$L3SO[#&I\?"NQ@.J_"8@ST,XBP*)TCP";"BMQF PHO9<$RY( RD<SZ
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M9P:?(^Z''3L,[-?!0,7ESR!=9F*:%:S:%0D _,T&[8+8[L)YDXB]PLIY4GU
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M8I X%1SS4KCHIF!QXFDEU\-.C-B06XX9&'%]T.'C6_"G.!'=(:@QLK.,*=K
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MS[]T>=1Y'ZJJ$H/S.55DM!+7I4/4QPB\E7"T&($%I+,1''1DVV#)KLA;"9"
MOHX0$SF'TAT;[,RA;WIL9$[:R]PS!M^ B064X#S;/EA[O$<'@!&9FP!+%Q-W
M<<R#RQ"B(-X :P+M"1]Z#%S.POIAC";P!^-"^@[SQH$Q%\(7V&$';B$5>T&
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MBHKL*9$0PHU<T$Q'W""+3/# F+/@.PQ0\_Y1,0L^D)\,27Z$T7E1@M+S/:1
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M+@]8O(HM1XU ^1AB"/HQ$7Q/+ZX/F=#(YTS#2\J"U80$1".VB9Y>\W>R-$D
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M1,MRO(9,E%2X6?OR(W)$T%'":6P71RL&D*K(?,(*<[D%O"G:=\19>.SL)S.
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M5N4RK&IZ&%*B1?M[X5KU84_HQ<C1M_IU=CE31)1:Y]AG./!<($?N9UL/=+X
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ML"8J#GCZ[&L&E#[_6O]K5^Z=5+%S_37_U^07)>ZSXK9T50"9!:\D@PVT=7O
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MAM65;\#%YK^]_BH/KXK'NSA(_YY*[>5;A$(V*!4/Y<ALZRRX9)N_T+1F(Z&
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MZ,<9_7C1#ML%305*'JHJ9/(6I$F&JN;@)@,&3,$\\3[-O29ZK%@L@C$N4!4
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M3]/O):W4-)H?"\7;PZKR/GKB\@?$(!=U:BLX]L^/SNJH!1)R4[@C==E(L0^
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MA[.F9=AC([NN[:I^^W6X.LM(/$C9[*6S\S[L"9T6YSWJ:&%'5-L=V+Q/"._
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MC,%ME:>&*?:,J.:(9O&";M:%"PXP/9=;4.T:\Z>&2+#9NL&J NQ:<,67R(3
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MVTL8C=U;!-P1M+;61.NN'%;AC(1S<Y6_#6>(K,QPTD3D6JB?20S4%E2@=HB
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M]+7%61M9+N:[R<?3A6"74SQ-</]L?FFR+:2$4<S^\#65&#0NW\*'! R6%&0
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MAL+ KX=#*2V-9D<)K?@Z.-&.W&L-4/PBJ.FPJ3M_;1Q]]!RQAA;@Y,R1H-5
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M$3?4!9FXB[/9[P]@NFAA+ F7\I+SM=%A"%N6P16\.,8TBB'<3F3\@N+%>:^
MSW_X!(DSG(7[CU"DU%PT=FQA#F]@..C?C,V=> _R*$*!66I7Q%S7V<B"7&7?
MW;VOXUXM)#9G;U6LN*C# <7ZD9 0@/J4787<=SA>Y$GN,DP9]NAT6Z(15 0(
M>0^*(X\'N\_.X8JQ7=+8'$WXIO!A2<!D2L..[,V=< >UG[A>W=0O351'C'%3
M@TE6Y<YAZRQDYB2E S9,1A2BUL=@2(K-7C<-6CSU?#QWQU@#N(V4V]HQ%VUR
M)JG]T6(U]-"X!X6);F,#IJI7 KQ86$,M@_,M?C_XO8=R>-?K&^7@U_#G\Y.%
MP/$J8[7V;5GMXS78+\+1L&T;7N1S\?*\[(=Z7<93\7'%O)O6Q#Z(3!:-Y*EF
MMI!90,E&:.Y?4(4N^Y@EH"5FN=0O_-RY&]?RJP77\EEQ+5\MN)8%UW+1GN 3
M+:9-Q,_W;E=U>TG'6A%:2I<.%0Z5>@'X/[;EA^21$0B!EV=R_L*^0NK"=[W5
M%*AM&U1[9$@!YT>B/"9LD]QL2'GZR!P1 OEHAG!/,<G<IT7IWS0-(M'(2!5I
MJGC]S9M7]-$_\[6Y'#'NNLNBORI]3&,!\H!75B5P>51_E'%G0*]1D8I!DSIS
M;#8HC\=]Q2%_:*=2C,[,9 0*AVD=8M2"P]37(R7R$M@74$YTW&F[[R74X&%W
MKKTA_>E=ZT1^D<)#)BVL?-2819[MJ-*#/F(\6I *^/&ZV@<:\0]U<[MWFYUC
M?%D4_9M$/YK)-D2MR/)038.7G7C=)/B(B5O347WODH2KRX% "NHF'Y]Z.$P:
M[8<@^B</$')O:5(E"U0C[%]3#@_Y0.;$4&VA-O9^:,]=FO=O'25G"8FWV:!I
MCQ[*](;?$1YE4;I!@>O[DVWX2UL;/PVMGNHL79"ENRSHS_=8:-GWL<7B^]@+
M_"V3 CSA![R 9DJJR@C=+!]/$VH@TPD;^?)L4HPPFM2+WE*@K1#?D5JIGM)Z
MVG!O&<X@&$FIZD4[:<YJ)JJ@XY4KC-+U TL@![ Y[:3,C*.\2TX?/^9J_?0Y
M32X<)_*CRQCLH3S'2D]B$I!COAK4Z?A];ZU"6V3*.0YM-SCVK)0]X:8JZ19_
M];^4VY KUJOP,1949M@2:,&>:O]W](=+,1]E%4(@^D/*=A_'A1C;^XO\K\5?
M7V[\\_?7IWW?GHY]"76E_ 5ZMK[Z\@]OOOV!_O7+/WP!8K+.KUK\&?",;]]\
M^ZH(6XNQ\;Q+QYB9'8J=),E\0:OBPA?]VQHD([64^X*4I+6RY*AS\Z:M]S%8
M\04RT<'K_&*.X\GT+SJVXY0<!DT)9*'I@)XL^F(<:F'A?2,&_)NFV>1O$#'A
M:J^;[D ;XY7_Y(MOWKQ^]04[K/@G _^Q&]D-('"YTU"):'4"#J=@IY3V<R8U
M7HHO:"C^%- S0!Y,&/^J-MYA4%E6K@GL$=J@95GJI<=R_8%%M_VP^G;HK[?#
MOHB-!3<R0:Q#1)VB-^XJ"P^CA^#?KMY?\2S@-S03KXQ,.=Z+MSA?),?:QFVQ
MI0F)X-I#+CL?3UO(WH\3L3KE@0E)XH',/B1%37*%T.X;/L"U@EC'JLI=W5!E
M:4T2W(<@@^:G')5;P2"1I#R8*04&NZDZH&=U=+!&XWN^T#":VAN:S1?IVXY>
M?E 45VG+P+0I$<RJV4BWC]'G+.OJ@$A9A_ #>2!^(BDXR 0T .B=X[1_9+&A
M912-\?U&,_^!BIC>)X'J5(1=G*%(Y6,'0B-9T"O-727@M[7CK>>T(JZ'CW^S
M.(RT"#HZA[@)G98C=_[*?!^:&E0RQVN="*+Y,755&DX661^AR6I1A'37T"#\
M'03@_:U?OF8QUOS%=S^\_H(7\O?4&4-U.-KS?G";QK$P*WAI-W-/I1'AS.%Y
MYDD+CDUC0\N=O=3_"C7I!9T6%Y?>FV*#ZY*-Q-:Z.F:;YK-$B (CG*%GE".L
MDQZN3SI=LQ<P'.9TI>$PP "[,P+:#=-5M_;G2B6:=$0#!H5B<C#_E9,^FSGI
MIYRI<Y';K;O[T(\?/A? :>#V.G"@9>\C!QH=^Z_?^^-.C\?XN=Q\[NV!>"'P
MH:\_TC_QS3GCRKDB/Z_-#G&CR5<VK?/+D^+&95\_X@>BGL*,B;MW0]F6?MD9
M.4'Q4L?1'!^IM B1N28%0#IA'"DD6D)@NHS%X$=%6Y,.E6, ;)5E9PB)8WJ7
M\(1@U/'GW,MP,QZ(8?\;][?>:Y"BQV%=C.P5NDAQ,<JXCS,?T8\PB639@[&3
M=NXYR<L6[=N1XPXW&YAU8C,?V&T2(C?.7-,5P;,69V6 !^*#85>SF$_IS=.&
M4SX-<[D0 8TBHTA;#--$3T5_#P]E6B,8J>)>KO<^"J!<,XU&3+UA51P]60I
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M@BA5 ,H*5$4,Z(9)"T<EJV4%/OE1+:;JT;V2YVJJ-E6W1J<T<P*B[=QQMP7
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M4Q_Z:N@6WLFG/ZK%/#VZ5_)<S9,ER*!!;LJ^5"Q$T_9)HY.PXBX+Z\F/:K%
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MG3:7\(3F:^%VVK7EH0O"BQ3S#-)(H(T\QL3FK^Q,_!0./SY8 HV?ML3F[RO
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M@;$R0V:1'P>"0E-N%>ROZW$E86%*?QH/]"<.!5!0B ",SWHP$+%U>2(] )?
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M5"XH0=8Y]T'&8*>'^E\T%\5</%F4T65B#X8\KJ_K9M_L3E?Y-^00T'OOB%I
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MUB2+28@;-=T:*(VL%47^7NZ1^3XJ^<G7OC7;S]'T.@N8+30NJXC^FJ;YC>;
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MRJAS].%1G HI+)]=E(0CXZ,F4@:/;]4%ESB1T;[U[3'?/@O["*)J%O\K+W2
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M!'<M^+/&AX;A4SJ%>VPI/(N8\\+[ZV'XM-.:>=;L"4;UA;&4>$D&T<'!@3X
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M:&Z3O%1[<3G64& E5I0!W85>0/9+$)\D4)@:%/&%F^"^W8"84[9[+F4;-+,
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ML>M3&:9=;S>OH'M>4H.69VJ/I8IY=*%F0M.]>EI]K&V3)V2K2^30'-T1:^/
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M984#=I,7C+2FH8&:G"]!,U+*B:$F*8S._.R'+]L#T2$(>8%)3S5R2O0)NOP
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MI"H9:C?+P('A]I/&(<>MX_32.;_4$G29;AC_Y+,P34I$!_A(=$# !-*9[,?
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MYK&PSU+]*\H?L0Z'49]D))AJ+55<.D4CP+>(6AW:<,//3?3-]Y[%4L,=EC(
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M[I\$6A5SML'AX):XYP/$GAE4P4=_X,-=EB;UTE%YW8#6,:E N:6?U,+Z_>U
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M+[@_XG;((D$'\,F 6.PF(K 3!GE?OMR"\,W)+RZI\ 3%DICU7;- 0Y:@,-3
ML("LP;P3Y27=K^S%PX;<$A$/[\TAR;/ T"*@)V\R*7",5BF$=O_+EDN,N\L&
M^^Q'G_UX0#_U$5Q2@]3F<Z^:1@:ZQG1AA7Q67_ 2R013%N6UW36S&-Q"<:LJ
M"&=*:6,;ICI&HIL;';(1V&4A1EPYHY0?LOIZ^^$M:;/!X;)Y@E]<"M3-JR*>
M*?C/?9"F'U4?N-N8U=\&@=B=-+#"\.8J=\ )W ULLL'X=UBJ<8T.*'*UZXF@
MH4?,%*(KT5Y_;$A#]O.UF$S)6^?4Q!@F>>2E)X#TE\[QVD\2@4-A9H$XA%1V
MDQ5?Y:3]^Y/=CZJ7=ANS^ILL[9C>#2)G288U#,)\6MW$!A=&AT9+?)Q^5!,C
MN2*)WU['J:$-Z\AN2/B(\PJ:E=:D N;QPH-O&"_&J>I/;3^J7I)MS.IOLB2[
MAR,+VPW2S%%N(];'=([(R7I]#G!D7:J%1.5T&OEY'S\WJIU8S48>N[ZH.T )
M(IU7D7$XH=HI/;L/_X/G0[]I9_MAW]G^H)WMP[ZS_;OM;.]+\ON@](X43WV!
M@I=PM5:LJX!K3#&4%$!)&;VK-?4KI*0SH*-*JJ7-;8E4TQIHUGQHW-'(\2:C
MK@*!)B;*\\P.\"&J\C\:)50\%%T4AL^ *3JO02"GQI]2FG3IH7FV@8)^N;AX
M)]P!+Y\WPNYZ"5#(U5J&;AN%1]%IIWRENJT^+>NE(OEA%LKZJ 5E_?-^^)99
MLE^[P.9VYUYW$@S^=1:\B1>Z4&->%Z!"M9!B%Y_RDK])C[P(WS&# ^! GT,U
M3AF%5WI^$9>.=;$EDZ?F*=BP3>G6JN=\8.I4]5D5XZ3DHC$5OJM!4H9:5)$4
M$ '\?6&888R!B1)^2E,%NM9K@*SQ9! ='!R@G?/P_$<29V%Y%2-L/D_K4ECM
M:12C&EC,S&5O>$8%I0W!IL],=IDNPB?'!]ZSA%2URBON &]_E-YZ/*3_G399
M=5">.SP()_&B])HV!5R$01X,TB?6Y*5>I?"WO&*J6; !?5(-ZGF!:YBX7] 2
M87<'YSWXY<9/R*MCC?@H&^ /?;!?9]<*O+:AU%@* K;YXSL=VPPO#&.'QO3+
M--Z&0T](XPPYI ]S<J;>3J<.742SO@6D71.0D ES#*XBW8V['BNC8!HK.J_D
M(MM/&_'2'[X-GE!##329]7S6,MIZD%(#+E'"42F>[?&/>7^CK1=YO20/#X__
MQA72@#NJTW2OHK&%)-+3?*%4B0)F.GXJGJ4HT\:G;)1>%VK0#TAMAN.XO/)J
M]\.+B4!8HG@YLM31FKNF1!\^?Y<,R]CRJW'Q\30?UQ[!-@YS,*9[$H^2+"<]
M4.*RP KGSOZ1\NY@4Z3# K_,&-$&[Q-0'+J9!5 V:<Y/SDZ/HN'IX6J&1WD>
M%M92,P6Q##"4 .!E(1' 3H0"]5E[(.B&\*<P3^:*%U38'WF?K+K1BKQ$3-*!
M_G"7!Y9X"F .$"'>7=^),DNV_Y613\LGPO=\W"HQEE&I'-L!/E_&J=!,,@(,
M^6-?M3)S6T3&XUKVQRW+ODD-\=XB/KW2_'__K(NDG"2Z48$OV3N-V_LZ8^A<
M_.'Q[.CM-/L?D>ZI,ASQY P_TO7YI@'\HSZ _Z !_,,^@/_=!O"_>IQ#%O5Q
M-=B)U6#O+MY_#%Z_?KW5L]L)-K7F#ITV;8S! 6P,C4(9+8/WB3WXW)",AK^@
MR(?;C[=[578RQ/B'\@EA&U2P2^1I!EGX6F,&&JK:VL)"CN.Y&)9P>88'/[Y,
M':*H.S+\Q\&/YD-=)X7_-J#/+)^N=;X>F*^_XF4A.S@5%_4JF2\]@/]('LT[
M[CH//[:A;#_H.0Q.GL;/PI]5QAAX@)N\R>@K]$C7]LBNEJ17S&N"I7$^SR?L
MT3W/,WA?_)*7M)SC^RT-O6J65)52-I3[LP&)M6MM/AQ<U.1]NZ_<ZT7D&"2@
M]J&585_B'<"K%NU'<"!78LM@69SGI2G]^RV?:0C!$DQV=G3F 60 J[C0Z20F
M*0*\=,*[3D_ZO' TU_"R/XROR&L%T/31!0>.\15R=H\,)?(;W4Y""^$-J@R?
MZI'R,P/[3#V,9Q&'4.:,&$U^./F_)J P99":+ ]Q4)A^@TZ#"0['4_RNYS+:
M8,G=TF=G+7TVV/?$S',+H]&GQ#;P*#ZRONJD5S/RJG$VK/"B#_P%:1UT2>O&
MB]PW5\K+EI#L1<\F1.;.6U)FN ]+HBX ;^LL!Y@!&IU_R;+@L_7&@_&@?QIC
MQ=>V;[C@I0_:[;!@^FLGIT-6W4/266/Z_V?OS[O31K8]8/A_?PK=W-O/VWV6
MG&A"@J1/UF)R3&*#8W"<Y%G/8@E4&,5"(I+PP*=_JTH# B0T((%$=%;WZ<0&
MJ6H/O]I[UQ[:OQ=H"6O@=(/N0CQ9)%$QZH0X?UK6$4-MX!;[UI6S-3=J#8ZV
MG"97DCIN-GWI_^=0>._!63JP1?C!5BS7^BRR:QW7]O(5QB"D.BNMJ=RJX 94
MT1M0Q;U%62[V5(^ZE32+,N8N '#D37^"AUV&IE()1'FRGP@WXA-%*DK_*L)]
M;J6\STWU/I<K[W/+^]Q"WWAN',K,QGWNMV+$)0H;:&+8#2NH@L+94WDDVZVS
M5MTY5]<HSAU*&30ZZNF+TLI7Q05.WS2K@;!UZ20:N+K-BAE#.V=K<N\%M(K@
MT\Z_G/KPJ,)8Z'_3_YSYZ-Q!IWN59<.1RH8M&Q2^"AJI#SIT#"3T.DU_3_QO
ML]EN7USDHP7(OR(QA=[0?]_\K_AK2%'0[;7T'U\E=3SM*FYQ=0BN":BO:D8O
M9'WV[SOQ(_'W3;/>:^"_$YW6>P*O\..UJ$/<(:ZN;FP>$_^[.F%>I)=AC1*&
M0 +R^3G.(M!T](".-!RC>VZ*INCA$/V)AO\,E]KCK*(]&M_F4W3-*K^\5S6U
M"V%-E\<XZ1_*ZBW:RH6NS="WSBD:_F-J^,\T<\[2;_"++\2Q2<'_<?P;0H5&
M\W_?P!6\7UO FX]\M?KON[5W.*?#/^E7,V]8I*F#WL4YG5DWFV!!?Y[*)LBE
MF$-#L@F]?.0TXB!B0U1P5*\_!< TD$!GQ>-TN<H<@:MIP-<Z-]@TB;+&U]4)
MB>"LMUY.A(*^.I@"*]ISI1F&2TTQ[XQG"ZG.ZVSG#L1V>\8 KDD$RZ6HHFHH
M^\(1Q^A0+;"=R&774]F_+HX\<"<!!/RA) (5MUU UZA &L\76^.[HF5=IEK?
M!'!W@#5&^WE'Q6&R<)AV)H4N>LS>R69\G>Q58.N4O.W,)YNEJ_(J>.OAS:K/
MH>'PAIB*3\">P0Y6I=3P;]9T+W,*7G$,3%TKCR31E/;-NT#96'W?;NPT]F"-
M_PQX^!S50B8TH=G4,KK1.PB]BZW&[#]G3K"ZU-B<1%_[ #A%*RBX](+.;X=)
MSAVYU5-' L98E]UV/^BN'-@?+%L!'/H>:*/)%\V_=2X'[#RH+T1_,8,+>RTO
M?=:E*<OR_K-"E?>?QHUTI]MJ?S\;](CV]\M.HS/H%T/@3_ZB9=M+#<\6VM]E
M=N/UPI8YEHGTV4<EWFH7F98>V=O+L;4Y[E(+T\FS/SK[[87WLTV3HYFSJK6R
M7S;9M$?T9I].Q%&3I@[(T;T67Z"E'MJTW#=$N!T*U!]&?S,41S)LE60JE7\.
M((C,6SH+H?$D^AV$QTX(=&J:<^/]NW?/S\]O#3!^^Z ]O:OKXZG\!(QW0'H0
M]7>2:(KOJC4*FM3O*(JB:8YB>9I!=]4\+[P#+\R0?CLU9^ZI? X?= [?BMK=
MO7?\(^AEH1L-G]Z0)&$%23^+Z@+:ZG"GN* <_O_(N@H9 ?,9A4WJU^W;#G&I
M*>A0@+ONJ..W^ -U=!,.CW;[1W][\JJEC<1JU[$C(".=SK*;;>N:"UVWL@O6
MDHZJYU](.TO)[32):U4-:UR&NMH":VWA'S>ZF[+@W^\7 X\L[5F)Y<$%?C.1
MMN 8Q)P 2_;!(*[&TA4&8A!=8:LLQ"":.H\$0@. :[=Z$X@(1'\QQPJ^:E.+
MT&1@=].T8SSUF:@\B';P=0NTZHL'N!^"9C8P2YQIJ%6T#V*1$"5>B1L(AC.1
MN ;Z U[(R.>7U@]HAN4KO$ TWC;?$G<J[KP/7WPEBR-9<<I34;-+]-J&J$/X
M^:*AKIM )U$V)6XAB@ 2-=U'[?;QG-HG$!$F:2H#G-R@6@F3>=')$X-)]@18
MD@I,,FRM4HT!DQ P5 DC(G3H"9H8:$3:R.DV$**K_MB),*L$2W6;4"5<YD4W
M3PPNN1-@20IP25,T(U08Y-E&1<M=0(=;V7-8=>D-C&NK3SA/O"%KQEA&:.(:
MB31+\1S+6$AV-6BY/^*]/[+:GCS(XVOXHHXJ02KHLO.0(SK"WCV7<)47W3@I
MN&+_^$"<"U<4Q;(\A"OVG(D"5QL#DU:V'D0!_!=[(/8MP!E$6Q.6.BZJV(9>
M((Q%1"#V+9-9*(XO02A?$G]2()3>70G[EBGOI YP)Y4RX+() -<[H0[W[ 5X
MJ$QC:TA<*M#*'@A:,[OD*Q&V1-AT$)8M$;9X",M%CE=NFJV-5T5\-M)!4:Y$
MT1)%2Q1%*,J5*%H4%&5J#,-B%(UYZ^.,7,X:5M.//':UI[7;DA)82V M"+!6
M2F M!K R%,U0 A\=6(,# ,YL##L&T/2+ 7CPT7NG9%VO,/MC[:UWQ/;:Y"$;
M<^M;F&NWYW=FX;9?QKB=A<\MD+U*DKA @WY1-@$DY#G#<SQ5(G.)S,5 9KY$
MYL(@,P=!+86[,'O:2.JH30LQ83OP:BP<MM_M ]S.0M>1FPA![M2[@ARU]S=?
M]OY6T^S]72E[?_^QO;]/J-CW"/;-CIK>],T=(4,;PEN\6QH_:1L_-9:C$[NE
M:\;/D1*!,JC)6RC0F+'=T-+E+%W.[+C"E2F)%A*A)MD<BY"(BX9$K?6^2AXO
M)1IP0,IO^%PN< 0/$$CL'$$:N&.OR\3"O,CM24%)>H8%5R86%L6 0VDO58:+
M#IL8RB#NW>C@_&*![;5[4=?1L+>_(6 MK!:18TU5[;F3&.J<S!-T.^J=H&!-
MC;0J_*#O]4\,[,VLD0)37N*68%LDL"US# L(MI&N"ARP/0;"9E<?4R)LB;#%
M0M@R_[ X",NR AO?G(V L!=@I.?=B'772-,EQI886R2,+5,1BX.Q@E 1,,96
MXF"L6W2X MMH.%D)PLG@0&M(,["Y+BM$"9$E1!8*(LN<P,) ),/4^ 115;>Q
MC@.1WNOOO>^E@LW*9-=2?3 W[<H7H<32$DN+A*79)1R56)IRBA'%\5PM/I8B
MK,)IRB@[VNT![K$]=WKX3,[\^4J9350";)$ MEH";%$ EJ%8GHD/L+<M_RP
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M9F()'"5P% $XFO6K$CCR 1Q-41DO%"OJ<"6KCR/1* V1$D^*A2>M]D6))_G
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M8SX$"OJ<=U3"#OO\0318!2.(%IC(8_E/$@#/YG$HAEB+Q1!745O/G 0UK.,
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M),6&CX#^(TCO.T=J@]*)7=NT*%W>O"8X#7-[\QIU T7W:.FB>[1T;N\AHVZ
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M-UVZ"\D3TKA"7IME3O 8GI(0HZ G*!,V$1?R<EFV_UCK8V\@KV4]D3>P9X?
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M<0HI0_(,A;*&LE"ZVJKFKJ-*B[%5&_""M@JVU4VK7<S4UQO=_"8>^@Q<K8X
MUO*.(AC6]/E-2B73*CYQ"S&:K'(0LM@DPX@/HU41"V#Y/0>=^<ITW>MS:9KT
M+"M*794ZJ@G-*'FD@+IA +,SFT-C"C%Q6\X_*:-?ZBW3>+Q.(N=)CA4HX.YZ
M+!?+66S6X;#(K"KF*-4H I (SY.;I"1782-5!"20_>H*SYUP,XXM#\270%2_
M?;G^O5 9F?UR<,\&KO$<QX-EO$K"%%^($5#!1#;S(O8%&T&&#Z@ UB>2\Q0:
M=I,5B(8LE?8HJJ9WBJISCW %H+5VBTC4F]P9EJ;79QJ4YB6VW0*U@/KY>".W
MGBLCY1#S4H,4PKM4= [<]NX($>WAJ" :E[K)["$A1AAW7<)XCJ2X\%KB7!Y0
MJ= V1(F%Y)8FA:^GLSBJO-7,WGWV)AL'M<^5U</LFNM]XB: JF9Y9&WKXP'M
MLIU2LYM@"?4O<=B6YE'(.[RD)9<*F("48>J6N$6D1<A,PFO-M1#X7(>+" BJ
M=5OC1_K'+Z[9.>;EDW>-1W7Y5R'9U8(2*ECB?BFT4"&9"-TR<JE@H80+4Z?D
M70$KM11BC[[J)/A>[/9%!?0F-SI*:S%?;Q31:K0Q=\(,V]=*7R?57@VT;KGG
M),JVE_.%EDU ;J&L<,T0%72^S>VE$Z(JX0Y7>.EYN9?<1=YD*EE-'):%"$?E
M,?DBJF-;#9V#LF=J*O0^=632MH#U7T\:F]UJP9/#QC2&R\$%SWVG#7%^+1\L
MARU:*K-[_^I)5\/6 583Y^ZU3&A.*#6-G5)SHX.Y*$LMN[NF[0;55:LTW_40
MV&UL?7EI*3K'"J/6^-#8:B_:,5PL0='0@HDQGB!NVA)T7&A-1NV$4)LX8LJ3
MU8J00Z@]''%#+*1J8L.2%3B2JB0Q+'=%YJB="ET?CZ&>F<:-^(H*.>'VX4_T
M!9"N5D"*%'K=*P'&YY_C*ZWRHYHD2S6U^)R]=F)N+1[KM6@MWWL0Y$WRHM \
MH5JG$""F6'2AF4,-/QB90Q2\ECQ[@&=)/D*SH60!O%7NP"8E<"!3FRP,L![@
MM,*:$/%&\%U. ,+G[+XUIP^_>N;-SQ\'OI0*K#/$.SK7)N=P3QY#4$&[L@YS
MZY!W-[9)XE,9!FOG0"3G>#*@J24.8N/K@?!<B3]H0/)!.1N&;<F;*:'+B6K\
M&6Q)Q@"OQ4^CU^6B\JS!<&:ND&TF-IOMV^;R67L:+J<MC>X\WM4KRL,!C!HV
M'N"A2L[(Q5JGI@J>FL6(K$Z(:BF4-$)XJW$D1\>?]?;G05Q*? W#M/T'2]$"
M27,\*3"9CCG?U[+*;Z0I5XL)S5,,$$>K$">XTT/M5KFOUMJ]JRF=GTX/[J++
M3@__?_:^M*EM95OTNWZ%7NJ=5TF5X'@>]KXW568,"0'"D.F+2[;:6(DL.9(,
MV+_^K;5Z4$N6!PPF3%5WWQ- :G6O7O-XC^YT,"FI(.L\:'7_C-R0I<(@H(7I
M@:9BRJ *+H/VY-P[^_#I3_.G<[:V0-.LLO"34=CMV^@%?:01IN5ANY*0KQ=6
MSFRJ6L7&8ZQ>6B] YTO7>F%E2[#:J%C%VBII\_-,@Y).IF'09<R)\"0YX<HL
MG2H?)]'H66GKVY:]\[-P4?YK71QFF@/R9&8/F?SR0>,GJT$N0/'E+WI%IG&'
M="RK45D<,%E:;<R'Z=.[S^4BX_7"PDJ'E2 WJ_YJ!1TP[55 UI'R*GR;_&Y<
M%8X//D6K!-+7X3M5KH2A.)S9&9MOA5_AG6@H\,P<"RO9GSF7O2+W6#W7K&C5
M:J_<XW[\"<O>YR*-YQ8I<+,F"RRI^CRD,V&VQO)X#;5'M9E5_0I[KF_[W=E^
MA:#XQPM&%^?5PJ_[DR K.1/43E^="7=$B[T95LI!%(UP>MMQ3YN'E;)-?GPI
MM2?=SF%P\/&Z=/[K(5HMS'0EI(P0L#^H$4J7-@XKP<XMV3PLLL@>F6I6!+_'
M=G3P6M#KL1!1JQM$:\_$6E;[+-ZQ)/HOY4(LQ*A5Q%YQ=1.H;I5*):O0;*ZI
M:\*47^ZX1\>49]]&E)KRQ!$E[7[Y&DV^%NL?6LZ#>^+X9A&H<GXQ&/)QZ'9&
MHL+I 2EB21]2'F!7TXF+*V<@8H?60F.5 J='DNY=+];7D.Y=S:&#O2 \94/A
M\3WN)7.%3T*1]J@$S#1I#)HWI=/H9/^R^3>%#.YY,)0E?SB^@45FRU0',.D$
MCX,ZE@3WB@2S<M\?()<JL-]'F;:[+,F4"FL@F>8,+6Q9FDDK9<WH3_VW\Z73
M^;:VUJUW\A+C> 6II(7J5#A^8D.;,8Y5M31D?(%F]F1]!TMC7&DMGL>G#+FE
ME<Z5N> "';2T<GI:L]JP"N5[3$^[52'-\I9_VIN,?"7E31Y>?1A^\UW[[,??
M:XRQV+&<.)-U%W-/>0^>D6-Y-4]DSL6OIA24[B%CS2I7RE:Q\IJP=M=XP;*W
MNHC)K6P9%1N8H6 5RVN*&+SFJCT*YZ&>_;P+REDW/N[MWG2I,/;4CMFQC]B)
M_V'4^PI4/K!-3AFZ%KHQ<_ /+=])_T)[\L#O>B-$CAV15K /%SF$-^!GQ&;7
M'S%'Y&8&?I064-VC;VSKLK!;LM>3!+>T,.* 0?T5K#(&SYL21";""&OM>2EQ
M1/\$$#QYIK5 %OU]5%E1QMT]WE8L6#0H[%7 /6U<620Y[U[^V !UJ+;8M_B:
MY?TD)6=-DYQW0N83%KJ!,UV=)5!<)QM.2FT7K3I-4'[ZN=?Z5:ZR1F.5FLK;
M"TINGKUUQ%8QSX?_"XN)NIKX^SLNU(>]C=4$4?GNHVV*5:M2KEK-PJ/TQ3[V
M&UK _LLKIR*7:W4+"'%-38#OA^7<5BUWS]J3S^RLN;==&X[">ZPS6%H%I_01
M.S8[[-+U?73\@#8^9G;XY+6G-5+*G=2D5G3<FTD==XG?UTME()![U(M>A$O\
MKR-",1<15N^(6;?*59!>2R1RW)\?_>\QT-WVI-/Y=;G]D6U?%M<SRG,Q+RVE
M>2G#KA;+<='2:L1#KYE.,.IXN6/II^;0WG*5IT$Y^0K@RGG<):O4J%O-^NT=
MLZ6[<=!7)+AW.;IZ!]35Y>A26/#J9'@43@9=8)V-AD./IA/9'B(H)E,?^!Q]
MX-Y3>=Z=8#?J]\K78V\]^59+I7SK&\9TQ*X71*.0)_:2" +YX\M!(;!W/^(8
M_)H'?F>'U(%(O#FQ78=/OBRV)]5!Z\_@B[W]87"/S?5OIW50[TQ,4I6904]<
MYBR9_U-9F/O]*JJU[GLIW%W%>U-9V3ZM6J7*[2V2VXK4F1TU^5@?%J7H]GI_
M//QY4SWNV:O0[3T:#@=JF!.+B)2?-QIF;V,U3V]EY12,IE5=PK?[LCC'L@QW
M85;\_9%P*VF7*8?=8TT#9O%L!_ZOD4_W]LV-^UK5C*QZX!0^.OJ\/6Y=?IV$
MM;\@F>6N39>V34&<9./F->P\58E%S^'F7P@N-5^%]T*N21TF;X_^JPCWZLH]
M<\M6M5FU*J7%C7?NQ!W^&V.&\GO#^)^A;B_QE'OSW!V ]#QBU^9I,+!]B__"
MHG*4WK_FP XO75@>'Y7_E39K4Y_O,E23,EA,9EG/'KC>^)]%'Z)G(W?"^+Y@
MI8XZ3>>]PO0AG,/XG_^SL6'NN<QS_C%/[$M C#/V9\3@ O\QZ[5_S:\XN1[6
M,3<V!*XZ[M7RSG!^9O5$C79#0(1C>IZX#+I0_!EVUI4_I[\!#-&SAQ%L1?[K
M7V!?3MS',Q;^DW?HV0Z..!CFW?@,#LOO(_6Y-^_W-G3(29C]:YZ/A["#5FAW
MW.Z_YA%0$(?K48 0K.DO_5>^A7])\$PBV?_\%R"= _.0V;\W.@SH!)8>TI4)
M*,.QGA"(4^#,$EL>$'30(4@))>^-$@OI[?X"N>_VQ@]#A4^.FX!,V#T]V#:V
M#H[/M@]VC[9WSRSSX&A[TVP=[9AG%UMG!SL'K=.#W;.G?];MXZ.SX\.#G=;Y
M[HYQ=@[_\WGWZ/S,/-XSMUMG'\R]P^-OZS[F?1Y)XJ"^V5NQB^4/M!QC>9-K
M.ZL^]:HR?7?08:#".3NP^)4=NU="Q?Y0JP7=/^/BCW ]U2YBJ[7&?Y:I<I$&
MM=@VND29V#@H,'+G6:U$?*/TGYD+WDUGE.#..<)JZJ-<L/2?.VG@U87E<]K.
M[ZB,/SL8SVD(/X=H5E+,5ZZHJQ1*%JRP4"V_ZS7/*G:7;(1LD[-1)^J&+M6)
MG[(N X@ H#D7:0R[D^Z'+_:7:O,O&.JT/3/2]F>&:H//UJJ<<RFK>>2JJR>M
M6(UBW:I5UF1 /MG+6Y:/UQ[.*[>74/6Q*#JG#B-B;L]10/$%3M7[E</)5O.<
MQ=%ZHJ5+$_AQJCQ>S9_R@_C9NMN)Q.?<T(HDOGIB1:-DU4MKRJIXLE>W+(&O
MQU6Z:$I5VN^X%X0I?.(T;N^5MF^NKN(_[!Z;,ZWL8L<0^.UZ83QR!%G6*9R]
MG-7(N[9RW_5ZW6HV;U^>_DK=0-VU6W<QN5-<?-JV%P&$OATR[(\DQVWF4'M\
M?OG=<3NUUO?U-%Q?R<*7,33:/[$ 1S:>>B&\X'97N2)O6#GW Z[:*KY&W%=D
M#K=NKKXZ<VCH RJ=49<YVX$/Y!W!;1WWI,!I^8[J$G2@FH4>#T5&/BG^PT88
M_W*C,[:*XG]7I4#L';%<;!ZYA.QR2NF10]6:;KK=Z1/'JWF#"E>[TQ7YQ<J)
M^+5&&92)5WZQ&K]H/!R_*";\0F'/CHO]=GPG:L6\32KZD\Z#I,/84>!KK>QD
M4B+G&\'X\\&?T=?+_6'E[ZH72>M*1Y['M+4#F7&P3'^^)XYRLUG)7:][-992
M7SE#I=BT"BMTSWK>'.6!KW=!E*.^LNU9+EN%XOKK=6;H21EA>=L4Q</R#KLZ
MJY^Q+>^OJ$I9[><U63%7K-9?*PV6UC)7IHB5V,;*9FG%*I?*5KW\D)Q#<[]\
M#ARW!U0>IQ7QZ,0.X^,>6?#;]M"-;>_4=B/!+4[BF\Y1JWKY<WN]\Z\S6*CO
M-6U+8;U"2"W<R/UB=OF6S1#W_,1Q?%G6L)[HVY,%VVS6<$N47XD=K%[^72U:
MY27ZKZ_%?,+8'.-@F<X9X?H6;[!/&<&<%XQ+#?;=9H>]O;\1>5$[GI%C)2TD
M,1?@"O?];!'[=M>WHO&S^FR!2MUJ-F[?5_NELJE[N,T%7*JQLB%;:E:M9KWV
MQ HMUI_>G9-7.[^ZHOY:77&_U17UU^J*>ZZN6)WZ.+AH,D &2_7?\0$"A<WR
M%&M0!"KW?K>D^@7;>9X%$W_[T'PQE#I'=KM0*+Z1!SLZ/M\],\^/3;VVPMP[
M.&H=;1^T#LVDRN+AH+$B1G(A>#0:P*>Z2VM5+ (K%1EAB-([)9=+;[)C!.QX
M%++CGM:%Z#U 02KQC50GF>F'VY/NC^MZ)QAM%8;N"C4<]PR\>T4PQ".CN&DF
MB$80*=7;$[;?J1>N?UW:_IOW6Q=G!T>[9V=$:X<'7RZ ULY_T$_'YQ]V3\T+
MH,?3\];!T3D1H$"WOX-Y#P&W_W$5$KO/_:"<(@PP$1.:>'3'%K]T?8?Y1$%5
MUU]WS=<S/NXNIA>X76/+#:*NBTH@/'S@=S?-M^@F*Q7^%4_03\5_S2"DN6?B
MC]O! '8R%G]\9[J1:9L=-XA9M^\'7G YQC@$/@)VTA7S@B%&7/T _FGZ;!0&
M0\^.XN"2^2 2(C"CO(U!X+'NR&,&?"8$UC\"=8XGBN%W8] Z10BD!TL.0Q9A
M<@1.P[UQ63SF8W%1U>26HN-&I%1&F^8YO-YG-N69N3P9#5<41\"M>T'7CGDX
MY<@>>@ *8\\+0M>Q^=ORT;X=T:L]4$^#:SS1=1_^.=X(KGUX'6M37,>U<;+B
M/^9'>VR>]&VP']-P37XOH6>9Q7*A5BF7S*U-4'<.8R=Y^D/@.=N!>M+X;%^Z
MW<_P,<P3P8Y]4_<FGTA6%S=I;MN^[?#=<'#)/YQK$+?,DWB<V43><W+YS1=#
M,B^,0QP"W8: 2_ZEX<81>CC 6*1.=D#%X9@02- VT250=(SN$HM(YB0:=T([
M1 Y1:93^39 0:0B;EB.]V688=. T)H:D/2#_>&1[Y@EP!S#FQN8P"&%%SPV0
M9&'CQG:?#=#&@\5BF@I%["$:LBYZK$W1; ]HW8O[0,R.\&(##]"86;'^+U \
M\H-A&%R&-FP8:7KWZ^=2H2CFHEK$O4(W@D_X &43&)60C$8T]N%Y( %\WPE'
MEY'D*#2-C<$VP'2$;<?,,H>1"\S%]=4.D-UH')&XB1L""'"Q43=.)DRF-D1\
MMPAL>'=KHUPO&_+'7/8XC,;=OFMC.T^=#VH[L+TH &9Y)<;(X?U&##3S:9B4
M-9BP&X TWEL<\)Q=P^:;!R3<Z )#IR'DUZ8]A%7L;A^?F^;=+G+AD1<#!6P
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M]-S?F(N&#<VQ!Y1M8G):B#G$([]G7P4A^:)<V%27BH!YDK"HG%%Y]WJKJ0_
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M*S8!^XO@N( LEV%P'?<-*M93?6ZUJGV-2N"ND[AL2CQSQ+#HOI,KYKGDD3X
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MTR@8N;!?.]00T)B+@-9<-,Y=,(O18B4N-[!##4U8ZO*NI+ "'<V0#%8^I($
MGNG:/I\R%88!&+*VZ-2J/21D!<@"^Y5HGNEQ.=&49Q#-R)\FFY#U/)QVA;W\
M1R$.2J7&9P.>66#)+K:J$SVJ#X$/*XQ-^\H&Q,:UM#< "@Z.V3,X/>8H*')^
MZU6R0S7V6)N=^FOD7%*S_!=S>2\,5_>"T)"CSW*]]I9@W=0KT([ZO$6@')H^
MM,>(>U:^JUUSQ@OO=Z)MTH!UG"PLFMP8L_M^J69?K[[SA_5C3/7I.P66@88'
MML]#)A<,$4=V^32&W#BL7NN[Q-OMB7MV^.73T?A'L&T_:]]%K3T938JGD\;5
MEW[8I'(W HY!$:\$/"_!>?&B0Z^IBW>2BY=#3J8&HP9#L/Y%(WI2K$<A=4B5
M"YDS%U(CS8%!HZHAE'5,[4$VST=KTC[@Q'S.9C>(8@K\!EV7U%G2/X8AZWJN
M3\JU]B6+6K%B,C*V? 4P3H0'PO9'/6 JO&V_W Z/IZIUXA#>B%*-7@V0,^%(
MJ/-\)_*XTM<C9L1S(/%!ZR!SKER':]YP3C<.U+2 * :Q$<GP-GV1C .YB'I5
M#KMU_:L _V(H_Q&UNL2Z>@4B-::>OQQ&U/R>"T0NO3)GM'"^36HHO8FS>P8$
M7SPFF![A@!(20^;Q2#:%CPWXQ"_658^1RXJA)0*"..:#3_WD: +"<,$1?]Y%
M):\;@'HW0?#H#:63 0UB)6Q"%P:>I_4 Q36QI;2!5ZEP Z1T,&#F;Q^T5BO5
M!=UVD(0B@A;=I.U%8B@ 7(@W?CS2^\E+ZDI64A\R,'39(;H9H_DQ!EU"SWFK
M/?E2=P-V[5;WN_5G)9GY<1^=W'G&1LU]'NV82T/_TO#(IRX=/'H3<S[*GJ?&
M;@2]#3(JY'NF]A[QR^Q?=#]1MC<Z"2-@NPD[-^9^)>@ (+A0Q$\!$]B87F+^
M1K4E MF<W:<4%^YNXGE-!L]KRAA9T\V5TXW5^_ X\[B$0?<75AOQ^2^Z[47[
MB(0$1@#QGZGULBUV20\"-(HE/HPZ0CGK 7O!R A_!.#(A@H43D!?1%Z(MJ@J
M<I)%H? Z@(E=HQ1-AB=F1O)I?A%IU-*T.-Z!?M,@4D>CE2>7D:=Q^EPAT\7D
M$C/F^%GIW[0&"$D<X4CJ51HKT>V(OS"R2#5++DOPJ[P\+WT$M0D-[#14$G0P
M@*\6>-H2UO0@4..0C&R"GX" N NAT&#XRQT,01JXL1F**9DA VTN(^\IM(0/
M:T.6.N@*I: 5O9DZF^OS5'"<U*.YL8 *'9%01_,&X1(=QB>6JZE/\Z'R<A2+
M9VP7G2?X2>2#_X<3&HBJ,'J+69EB/*<;*<9#E@+QD.1W. Q4,IM-$ULM:R]'
M^F0,00#4C-E6W,A07$W,%17^+S'W,V(8P<7QF6EZD%@K,U$]'.V)CE7%] "C
M:6:9'B86C"0E XA]&(I[:-%IP0/YKZ>H7J;FBM%=#G?$B7<H'=?C#CL2?ER3
MCS27,IYNA/Q,-\IT(0'<5<""GD5YIK8R#'R>PILQ'M$<D*Q6G2CU/#)<M!!8
M]H^/A[!?W=!K(W8E"A$/ILE XG3(A!2(<G/5Z47$3SDY8@K=Y=2W1'*2O:R(
M71'9C"].":&\;6C:&B9=V+\UV6V';J3&-Z=WLFF<S_I"1@% VUZ,JE,C&)DK
M/#LL$=SDWL&QO*&0J<E:03A3:AOX-#>3-A^=A;3V41HOV2W9$O84K^IPF>#+
M/$8D,<<5,\LSP\K-;N@"MKDVJ;8X/$F(G$3EUY'Y'_.M^PY_Y/-$[20/"PR(
MX-IG8=1WAZE7'$'#8HB\9!UB "I.#T]1"R?NMR[_3&+N!)X347;74%*HLCNR
MGS*X[(\7FQGT(?$E32MWN;UAP^7^HIRS,)'U;&!SY198GQ\,W"XPGQ[+.[%E
MO'6OWLWF/]%HD&,EL#_D>\/1GC==QN#0T:B#(\!$W;,^<7ZJ"BCU>5SC[=4[
M2C;C,;C<>X'#TKAM] %S-8%V'+@X&#T!)+J"I1XAK0V^%N@,J$[ SLC+2KD>
M(Z[*)3=L9)AFUNQ*3*O0X2[CC#$=;8IZMRFV2NYDMP?80'P5]AT0EB:>6ZD+
MRN4-<L8+)BL'E*."0VB7>0]TS5%7Z(6*I!*E+J,Q:8:E;JT[+K?2N>$-OQ K
M&8F!/M_V?S3,[)GE?ZM1Z+M'7[?^.64. P('??HH\'%U=*L#"AX(9)GOGJVU
M6=*F\U8+M2<WT<Z7?FMP<O:Y]ZP\MME8ZEY[8M=N=D>-_LDGKX@A-0DHXP@]
M; FH3 FKEQ!6?6$VQ(%OP$W[C"=G*\9)@[V1OP(O;/T.(GH?%FZ9)ZJ4DWJT
M<..='I&=7,R6G*5JOK63/',^!P^D_E$ NG3C'0]D8M$96?<,)[$Z#/.HN.8O
MG9H@!$:QL$PN1S96E3(>ITR%S9(/J4^ :!NB(L\]9-SB1G2^'+E\P+9(WB)M
M!O\9CXTDB4>359(P>$@5\WED:J/T48*@ZR3."C$M% 4SQ@9!RMH^Q93I&Z@
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MAYUF7,CRB!6[@M??BD\(BJ668_E<0E_.6+1<92Y?X^R%! *'T30#3;%*A%U
M!Z16D7)G1F)5"D,RESEDS6JA0GC*XT*Q PVT:6\+:D**'>541QC:+5IF/[AF
M5YC98Z<J.K2/2I? - IEO"<!W",F_/#\XNP.1:$JYKB$I$#1'E\YX3,]+G!"
M16.+.&&3..&!3RTMSNT;^)!@@O5*'A-,GLPR/UDTE.AN&K8333I.B"XF/D:"
MRIO_C"@+K">]K%0' 8HY\[MCP>5<_L$8/JC[B21_=#/[TQ[7:,U(&*OP[LD0
M)14'8;H6L +/U0L5Y3K8)07;Y>I?%T]P-[$T4$128<*IXD!NCZ=C21:,CC;,
MF,S?*^=!>$,IMDU:XC"K$G)N[OO8G43RX(7\EK-OTM0,Q7.YKTW7.87OE_\U
M9#I+7LBO<UDH+VJECC5R!)U@EP0.#2E%@7R:J<W7!J]=8/D91G=;W9!W)-*N
MXM&PC$>3\59[S7B[YXRWVFO&VVO&VY3'4Q[^=13)$S[TBTI\FXFTT\&JM0>O
MIOIXDLM[FVLB+2K[F!&G*FQK<:HY;[4G=JL5'<0[4?GS TU/W"Q/3?1<3[0%
MT=8H;]*:[\U,B*JTTY[4+W:*EV?U3ZU3[\W[D]/=D];!CKG[_63WZ SP'0GZ
M^/S#[JFY?7%Z"M@-FMW9+N*XP GQ/W\GBO,P4,RS..\=RZ=ZX.V(],1M[%.X
M;0_=F)<CGX0,39B6[Q!&<U1.S+<9I- L:Z1PUZ7;D_)^5#D\^A/O?O^;(=RU
M=Q$@4V9V";(E*]G)IDPZGJH\"AFT$L5IZ2X;JB^Z,]6"X*4.,TESIZU*>W(^
M=O:NSFN?1E?)C'4PZH:>#1\#"F1OWI]M?]C=N3C<-8[WS-OS+P+PK;3IY2]A
M.;W[C1Q6/T/3YE>63(J?,6F;0'O-,%L:W_&<Z<GQQ=F3OV%G")#_?5-ZHRZ@
MTMQI([X7X?_:DUHIOCZ[.6X,#^M9PV*.@9BSJSQ-;8K&%DW$+O*)V%/+SYI#
MO@[H-! Z)0Z=<O]#6&Y<'-?/>^N'3NE^H",'AL=A<JA".:G8%^(@O_%YVSUH
M#^R3W=9Q:]+R67MR<'WF[S%[-[I*IHGGHS(0!D#B,@Q&OH/$$83_F.%EYVVI
M4+%*Y895JE;?O9D:2B\HIH:&ZK3=*?:*9:^Y;:2S$!.KE?Z3?^$9$S;WD_]W
MQIK%6N;QN4/MJ<G"7$BG)]6WHN.>KE*DE(AEY],7M.GT%V<[;]Y7:E:Y5%@X
MEWXN//()[ZD#NI0+Z/JJ@"[5&E:M4;L_2.<2<453]L21*1PP1;1^I^<=??Q8
MN>G^6H%HO_7=F$U3ZFSJI#+I#9OJF,D;+X\]#S>6Q;2E,4%JV#ID;D%DS97O
MOE*V*J7FPKM?=.#'":Q<0BD75@56L=JTZHW2'8&52QU[T]1QX(.!@Z&'*0HI
M?_CXFUV/C@/LB[,&L3:;6%RYI\=P[PI RQ-*N;3RW5>:5K7ZM EE/L#RB:6\
M,L#J%:M26"Q55B"66M:%)LXG!M\(A]H4V9R>%D^O3OL?]X/J0P@6,K?_ZK7/
MALTM**:Z*@+42E:A?-?[?QJ0RR>=E37?8J%J%>MWY36YI+.;XW([QAHJ,-7(
M]39%-5>-QGB_\N/3U[CT0,)&[LL,Q,;X7)2_BA"YL+H%%356Q85JK6[5"N5'
M2T:ZUVTC8MT-]V:C[X(V#<\ RI7<FT[H 0":N"@E]2LWUYV1>6O*+["'XJWO
M1@QTPE,:,(1>M"F<'OW:MDO-5NO#=[9.2:!V0RDXH=K/7\%DW=;,!]/RZ%PI
MKHK.]2:P@<93Q^9*:0W8W%S2RP5W=N"C&\Z]8G-PW#[]-#S_&IY>?JX\"-^>
MZ;P\_7_V8/COCLBP$QO/H8:YCL.YGIK%3LUE<>)V*]W1MY-_D;>@PLKJQDS5
M*E<6*Q@S?+C+0O/IW>2R]%]=1/\K02Z7+12G/0-"(TW'1)75<PZ,(-88@<N^
MGW6^EL+^QWLT>Q9$"?(90HG?_WF '?&7#E$N FUI-:RBUTPG& '-+>7AO>4J
MMS',YUWH+?C!RA[@HE5JEJUJM7)KCE"Z&T=XB7>7:RQ65C80ZH6&5:@N-A!6
MNCG)D41FI)%*0!UZ;BQ['\F\TT*!I^U.I6!I>1^M>GO"HM/^WGC\<W_WF93;
M_XT>"M6I'@K[0>!@HCI@XX$?V_XE%IPNF8Z3BM#<;J'VI'FV;7^/6MOGOZO/
MY$)EGEIE<RI#K=*>7#1'UY]*I<+>3N?-^X.C\];1_L'6X:[(Y* 4C_WCXYUO
M!X>'?SL?K51U_67R:#;XHP^4LOF,\X?T-E1#%B);IR[BHHP&:T;<D!>/XV0+
M48><:5+EH9TP/7 "?Z1.4UH%)'77SDD**UE&W@"E2T':HLA($K=,"+O&[E)8
M+3X6.\72;S[U>!31 )'\8US#7GW8011AZ75ZXX9,H>'%.\E8FU@T,*=!)?EC
MI^1V+2K\I]Y53&12B!\\[!Z1<Y+I:1W&"YC6\1"9H=6I_.<S;&,U\MAQ3TJ.
M64F?NCTSYZWVY*C5F'P\V_]T<?'BTCE+UEQ22&5I/IZ\S#=3R9*[[<GX>K(U
M*$>GA>_.,LF26:&Y5K+X:RF6S4>887G?"8*2HA]OUN1]G[C5[8X&8FS@02(=
M#X,H8@N]&,\'#-SV[8[-<RRV]JB^]^6<GIQ;]YX+N[[<U8HJLDQO9$O,. 'M
M--U.9RK1]UZS*:7L:#:V<ZS1_1!HJ>V>M;NXD4*Q4&QK^<[A8;4__KB]=0XZ
MAQF[,7Y6OFG2JY:YI6K7Q1"7-]D-9G>XE"\HM<%<KT\QS^M37=F#W[0:Y8K5
MJ%8??7YL<J.EG!L]$":&QCL3UGE(MWUTUG;<_!L/6N4/G:_UZN1'4]WX7"Y\
M!P1XNQP&+#S0+;!CY002H/E2U6K4%J<JSKW$=P^$&(TD\BG!*(6()D-FTGUT
M5:B.3@OGC9.ZPH(\(73_ET\QOCE;OL5=W\+_BWV9_O?-QE0J;]$J+Y&@^"AN
M/(\5S+S?[O?3ZT&U\6<2%:?X^MHY^O)76%L]K]BJ-NI6K;PX_+)*"O[Z\ELT
M]NJEE-P[I6<D6%*=Y@MI7BKT@:.9 N)WK_SU]X=^:SBNS50)ID[Q)F^KMXP0
MU^Z8(7)O,"Q-PW">K)T)R8LH.O_YU=^/ADN+VEL!=AD.NZ1,%3ZM$O=IS8JX
MU5;/GK JC9I5J"VN39K#8._I>I<3G<M?LU<??#@_V3[?B=T%LG0]9%-[)&13
MF*FK+@/%Z,SK[G]E.R.?Y4BL^Z"+?+7S3O2P<@3Z'NAAO:;NTJEJ"#MLYM65
M&!_?TH6Q[N2F!$$KTX2_%X1@POLY]+]ONWXB+W-1=MS_TVA<=7Y_&S=G2LIY
MX+F%)^4._*%>6$OBU:.YU:U;2.O%USWCIL>_?K'?>W%SJ[^L)'\$%[]0GWIV
M%Y]SL;,OU1[^=G<^^A/WL+E ;J_O+E<TDE<56/5;*' S3&8 HE6MWS[K;29N
M3=G/?QFM\NSL5?G&Y_W&Z<%I972Q6\E1:AX<K;(:T.)CK81DM_#!/3"2K<'$
M7SZLHH4'5NL$\G T4)X=2-B=H;Z71_WR]F6W_JT\4Q?:Y1,JLCZG>RP@6#ZV
MD(^Y*^OSR\<6GK;,;:T8C]B=:?<=?/]X$/2WKBX;]K*JU7WBT5I#%+E(UEC9
MY]FTZL6BU2PM#E$\6>';7#*L,8,+?6L>EWOGDX_^3FF!2O< .+12I",?96[1
M@F&61"V5K&;Y]BGO3PES<L(C,_#D*NB<_.Z,C^W0R]'+[E5.+6FL-2IK+8^2
MQ0CSBPQVVI.;W9/>^+(1W[#*,TE*?XCDSD9M=G)GMA:@Y3LJ<Q,O95;29STW
MZ7/IU=J3"[:W=73QO=48/% SW,>?#:JE0V,&=%XN]U/)$ZV#M-OM%[<&D\//
MGVO+Y(E.E5P\[X31Y7MRKN8A7Z*<$\>^+$*X-9?G+W[P00+A4GAQ'"\2VHM[
M:CS6;#I=HTCN\1"O,<N%=V_$B#X],<,IY"L?/[J_:D&Y6#FY5+J'.*ME+L:7
MJ52-6W5/E.+IMN=9/J6CL;(-7;/*]:I5:=XQ ^OATD'SD/KA,SX:&IK2[24?
MW.Z#9&%SPZZ-Z\./K=Z//^>-!!OO,]B:OZ-5W(K-E>WFJM6DCD"K="%<G^-P
M&>QY#E'7VO)L=%4W>_&*[>P<[_XZ1P>>0.*_YER_\QE7(HZ[>P@JA;K5:"Y.
M2'A(G_MJ//@IN^3S%)'RG121&2Z0^N&G^'Q\T>\7^W=20];J%6FNT2NB^424
M8<<M,1K"(Y__VY9?OOV<7[V<'6EQ.V/7Y$?._1\QDFX)4+UD>T^W::@GXU*6
MW^W,F)G?+/YG:;,P>:>VU$MSO_- JM%*%N+M5.P\WJLW^-B;S7>/6#S/Y'//
MAL'O;UWORY$WS6P7X<G<)-&YJLC\#2]OTS57KJJI5AI6Y<X=;1]>A9@A[%L#
M[#<Q>8QJMNXNUK<Y[3*>9PZ>W3!V6CSZ^,$MKE5)GK_#E33@U3MYU1I6O?JX
M%-][8XPSU=J[L\;:*JRQK#!.S",*SIINX6CH3?ZP!V5T^4BTLO.J7&\N-1#D
ME='=E=%55V%T4VAW=+1[XW\J_RFQ;I)VHJWVV+A?;D R05U0?E<OI2/^]R22
M[5:T]DL+K?V%@\K6WG4Q0?"]6_#5W9E\]>"\\*MZ<>/^ZCAW4#G_/WO?V9RX
MLB;\G5^A=^K>JIDJS$$BWSD[59A@X[&! 1R_N 02(%M(6!)@_.O?#LH)18+'
M6[M[/(!:W4\_.:;1!#("LW;'^,B#22@RGZT5PJ=11>K_Z)]RT7C^>+B?W$W_
M".P]5_W$*1='YT))[KAM4<IP<&UNRK',3J]+EJ!-_%]KY@L_7 G0%:.(Q'^L
MT?Y:OAI<Z+ER@U=J61W/+U[?!D:M0R?8QG:1<RK"+'JAJ:<PPY.3H8/, =UB
M..@ZRX/.&^/+2J]^WS@"X/K:20"TT4>L>-I)&+3,"@T>@8Y'V&)1)E@!#HCS
M;B:8A6,>E^P$-G/GM\?36G"_PW*Q9Q6B 8N<]^PO<\?@/CT#,G;(OJU8(+G_
M1U0K/XD[.'X/+(:Z!B,MA.'6P?55&U3*J.MH*+=M,&>L6W-3;UT0W)J;9/4P
MG7#K*)OOMWUFZ;6LPNPG,=HNP0[J$CWF)EK390C7K@@A2%;,3_VC/0:_,@2Z
M)LW__0> V@7H$DN_GHU90%A@[26Z,S,VG@R,+?"T:S5N0#"##L(4@\V$S'LC
MY70I-+5#N#5$2[2;<*M[UQIT&IGS3F_8Z+2ZC=8P2W2ZC1SJN#R\/1]VFIWZ
MH-,:[J_C<.J'AFVHA\2H1S1ZW6'ONM.LCUI-HMWIUKN-3OV:&([ !S>M[LAQ
MZ$^!K4EG. -^4/7*<!:G/@9=>Z6L)-:LQ:B]_WU3GZLNJ<])O.;YXVU<JFUN
M\_-.J_:)<Z+-W;15K1,\OS,:#+1/&D;;"[6?LB+1T)8_XSF!)<:TS(&O@3B!
MVATG 3Q1@)8(C965S$Y7/.XG#3B*BXH+T[--UI'SM6!U&( 6D.8XH25I"]5(
M; ZY-*3&@6X.]:K&7;'E8\[3KCY_?-P]O/Y>MB9_^GR0/&W I3JC%G'=N0,L
MRZ5/_DUO,.H\U4>=7I=H/?1;W6'K*Y/;WOLWN#H<L$GI(S!IH$4#<=.,CC&\
MX^:>JOKPHEK;;+8WG_[,?C]N*<@BHQ:$_NLZ(ZD:S,OHPE.[ #JC#<NOV1L
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MMV@H]^O4DO^XG/6C%+M'$0T:5D\E6IC,.9DE%+C!8^!P3G@%1^I2]%ZR5+9
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M!Z$.HEZRD@P[<,*NI K2UE4: \@$&;S  N*289<Y630&*KD-"MDY],H+EOZ
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M>;580"-)F]N*;0@<":%5V)@8K%U?YZR&OF8,PVD1LO>X$B!#H"H/ASNJ\ZN
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M)>'@8FI1X]T_W.MF]AQW#><E.M9@*[G78*N#R(N7I;M5]9S[J!;^FF"K:^,
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MO>M.LSYJ-8EVIUOO-CKU:V(X A_<M+HCQZ$_!;8F/MV-RCL#.BX#V,RZF7D
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MT3$FVH2AK/B)-D!!JNP>A' 2E)5D:_=3::J0.+&*5*%XQ3>%=3>]I@J!K8%
M&3[%H\SP*0;.\#D)VOI<:G<X#^,GX6DG;/1]0>$+"L<-A?TZ 2BMIA#IDJBS
M:Q0G0$I]Y?=36BB;3F\8_5I58>)Z$3GZ\[LKU^1BA0^33 !WYV^X1.ROGY"N
MXX1B7)ND&"_F$=W:/_8A"Y;08#ITL,N\3XTZWMNE]^;V[7VU]K$:/%(73HE$
MTC3FBTF$.Z(8\\=)."'D_&[\L)GS]J9#49+V=R*'EVU(ZIB5GA7/G5]72F7Q
M(C_T"4;:K7@S/>[?BJ\XK?@#74L<X_TX:<E-"!4.7?:3DK=9>'JZNEYOEDPE
M6-7/3L]R0.ZRNPE$L1:V"42HJ6?ZP"'_B4/%YX^^++7X._;FJ<E^XBDF&HQ,
M4S#01!KV?<*O&/;7O__O[(QH<RS/_(_H \;P$ZSTMF*%"5BA1OW$N (6(\[.
M5"IDN'5P>],&E3*:%Q1J"D>PV1IN8XF\K5!P:V[XY)'7AQOYVT9YM,_,D--@
M]I,8;9=@!W6)'G.3GT07\'(,UZX((4A1YJ?^T1Z#7QEHK.'PO_\ 4+L 76+I
MU[,Q"P0*6'N)[LR,C2<#8PL\[;3L!@0SZ"!,,=A,R+RW:3GI4FAJAW!B=<)S
MP(#6TAIT&IGS3F_8Z+2ZC=8P2W2ZC1Q1[S:)X>WYL-/LU >=UG!_$\!2/W2W
M-VH-B5&/:/2ZP]YUIUD?M9I$N].M=QN=^C4Q'($/;EK=D>/04<[LQID"P"'M
M(6='.J4JB>/V!*+-CB4\]D1M>9,EE#E+0&V,%K8$N@9@4W""(A+@K6CRUT;B
M%!2W!RH@TN"([_ 9J/M0^9^WYI_4M9^@+\F?/S(;3ID3]=Q%KI_[I\[S' VE
MQ 4OCFD>B!-)$5A)=E^/E;1%<D1_)<DKZ)L#VX*_=7^I]2QHNPQ\0@;"(IOA
M!((FIIRT0 W#.#S*3YQ. ;"@A\]N5%+F'"<:#I1#LURQ5PW\ ]GH6DG@"*BL
M,K;/U4X-%)G'G1I@?_P(:G #-35#K]14X7/VIO.''[3FYX97!NX,'(+ S<]V
M91>%.(97%T?JC,SK?QDVHF.[5G.P%&\&2C&?]ZA00I2K>VRG9@1 NGGEIVSI
M#X=FT]&3"?X)Q!Y]K!U E.5*FLR!542LE@0F %JS>S)@<3N*-$THTN!I6=:'
M#O:D 30F="@#VPPB*RLW:)YGF?-MBY[,K;]]YCHZZB1@-VT&+_+J[N-WF7<Z
MN#7/'6 5L@IA?\2)?3B/O@96'/)QII5B9MX'QA].L>'+=Y4MZ8P3;IS09DMJ
M'"I+T#*Q 6P&_A<CCQU9JF9^ I?&1-=<0?:#\[#Q=@$_1U_)Z7&2XK93Z0Z8
M>WY2UI&C#I1K"!3 EPUP6%HK[N(N@0Z5,%^)UP:@[(\6]"Z0P!&Q_XB2.P\Q
M<P_XH#M:-(Z)ASA1Y5F6E+.S ?0<X=^B?]_0[]QBM=#0J2'<]:J7W%*6IZ?"
M:YPG!0=[MIS+AFDQ.[U%9D#*G%: \K@EQJR.6PPQWEKU(%:"7R(=*0,E%U$L
MG3'@(1&Y[X@9A ]6ANR/J2MI6I-9%>NIRI&AAT%HX\W:20'0@ Q])? =,Q8L
M(F'5C]9^I=*(A40 $KJOEH4!<$ GUA@3_-5__/0T5]RQ1'5,8X'QMS*9/-%\
M*)7AGS$C\-NGFIT@LK8S12*'74>*1@(VA(^?C$I5W*MU,,XO ?*AR\\1PQ5
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M4[OZC/N@KU*T^6_>8G%'7U[C^/CTQN&UL^M'UYC'TUVY]O16JO7OC0 @WF7
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MM>C"3_TA$A-(GN#=+^@M6%*C1!347RQY#KT2!?7E%: H [5S;B%S#:5<;W[
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M'&*&GLEH8(-6(,UA E+Q -ZN:A>!P\K:'C7<P7 3 #>$DI 'E@5/3%D,F_\
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M'QF@,CCS&>7(;T=.2NIG=#KZ[S[,$N=K-4B;>IOLF:0228]Q0Z)[9/NQ3!U
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MHU%%Y#1_JG:[<7<-*$.9G^]+ 5AS [;?%MXR#8NU@P\#KA);A++F]YUK^S2
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M;E(G1/MSE"=N5@"A"!$$LB8L')!B;>O!T5FH1-TVM5\TPQ3M'P,6ZJ=C5BM
ME*@AN]#=65;O#GH'RON@YI*LAG4Y8.\Z:SZ$Y(<8RJ8KE)1)+LLMA*=+Y+GK
MX3S?F]T,_*)$>TQ'V]*!E=MC<IE%6QI"VF:1I],8#JF@*(L"<&1%G=C4HT#>
MD++Q!EN%+4ZW(LU1+!F_PD+!F(D=XEA'XC!N+T3L<3;U+6/UEU13-,*9:<N0
M7R_^DO+@+U04_H)OU!)+\ _P?C3?4T8%=U"39!<"'E>(6(:NP9J1Q!0G#1<8
MMEH88\:N<+XHFN\F:;7#K(KOQJP+O8U$)3 CD_#?:<WIMJ$;T^8,552%3JI9
M24X"M'15+1O,E\3MD0KK*;H#)9M9R0#@"F+-;YC2>;)^ZNC?KE-'[NB%KF4K
M9@Y08+#(SNUM>46X')[T^=5#,8[-ZUY2;6?ZKQQQZN*?#);\J16B\'V1\N>^
M2#'W1<J?^R*=^R*=^R*=^R*=^R(=A?B,:F C0P,JZ HE&.Y+K07/7-:U5]W@
M)*T5X!.P[L@.41#8K2"F[('J")%HK060M! X+>%+UZ?#12L&AGM6@"KZ4B39
MWEC3TS:"M$&D'+.C$2^@^(Z",FBA^H:V4[XLF\D]JH32R,*]UZHT6R-'V(A(
M:>U&P6AD\21;(&/KAFOL@/)R,)L6#EKU7+5X1Z#Q@'5,/>=(/SD)KS>=LGP'
MK00(UR&4T@I6V:$-2#ZC:S Z&!E..$D%=Y$U5N/;4M8-%V)$Z2D\XMBR"+/M
M4M@R.+M'""G@6N:SAB(!H-/<(1!,J0'0#@.YWN'^>($JT!3'KJQ-6C5X:O#[
MU.KXJ43A23J"V:CFG)-P0 >]ASIWY+$A>4W.GG(1!&@$ARS0YCIR*9NIKV55
M&1%(N"9H.0T!]FEH+960"T@00OM6-WM0]0"4TF%7R(2I8"YO]:,:S8XR^8C-
MCGQJ--2?$[H_N!_?51A7*$U)AW>@;MZ"3^^B3-[=NRA$=45N]SK+C1Y4) JS
MY6\6/RIQ7Q('5LK3;8GP ?4S?.=G1-5P'7C>3"%]P'<;(--/-D.3,5MQG_%
M>'WK%!8KT7+&#XX-;,S]=*S79Q 6<HK3.YWK%E6,CMI%)L1Y$O\G42.#CXOV
MI$_;'I(^-TZ]SXD_\M)-\=5-F^$)TO;LQ,XN;,:(5YW3YN,C2>VFDQ>UEW,J
MASB>AJI>YH:O%[%S8V9PRU >9^P46%W#V *9L9SYA3[YH4R2;B^I!Z3.6W@_
M3RX@DLOJ@(9V&O)]8M=S"HHAE,:.5%IHV SP;$97@!(E[(Y%W 2-M:C/(Y;7
MR_:UW7@^38O!NL<RB-B7BESX*47'0FPGS+4Z*(7B%K*1LPP7 =?U9\'**K&M
M<",_K^X6%0M5F'/SC)"2,<I)YVFT01N%;.9E/?O1[S3%Q21[9W8@K?KLVFO'
M04B_<4E^J$\;J%^X0)5:-K3>HI#/CM9%.K<1J3^-GO?)U-J^F5- 8H!I@^CM
MM<(D#P!/-,&QM@UA+GLEC]D3:BZP(O*I&-%,]"8MT)N2P9A75$+N6C]?4E&U
MZ8F^]3<'<GHGC)CQ&]854J.&_#Q(]SE;U@>RM:194 _5^*2V"=GC)N^RV=%9
MRY*0YM8$(HO'EJA;ID)$4B6@T@',C(LAZ0&JJV,&3]QZ75JII5;5Q)+NQ<92
M43'FT&PW:LX,QKP0:=[\B(=ZD#8":@;6:U;D19SY@'0H/EB'H@:L@,LZE0D
MJD+TT3!+0$6)/&G6+*!13JRR0..X('1-5>>2JEFS("*<FJE!*I:*3-,T9555
MYJ'1BM>*.Z'K*T_YKCP,5/PT2PQX>*,,)D!4L/XF*9_<81MW_]Z\JV6^HX-Z
M'YVO3]O><M&_J;S]OI?UO/FG4N&>I$EG<L+#/I'21NAC *!%J4_S4'2[4A*'
M.#JE<4-BJ.'>!R'8P+]'@?D&=EQ=O:Q?)8G[,;]_5J<%X]0Y7H'Z)@0NW">
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M*7%<$=)SK<!I^94</"UR05-(=]$908Y-+CH0)+(_L92GTYFD,&2[ 1^9E[7
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MPR7HC!KPB)K:"5GUO]J->/>CD>E=K::'0M?[DY3^@''0<C1KG] R?>G5>.%
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MZ.Z[4(?Q$?2XH;['#U .$HX6%R3Y"'G/'+X#S72_Q]U>DR#;\IEL[0]W7D%
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M("V53V3$#)QVS &13?P;K< 'R_ EK)@R8VQ4%RB E2%R(MRKH4(1:8[0^1,
MY$!//FFT;XNI>WSBR+5E.KA,'JHL(,=D(9^"' YR# &PD->PHB@M1&3;X:L5
M^/50]ZB9F$55N^TT57E#@1:J*O B8L1IQ$?AT^8L83BX+JDS@4]-T51/77#8
MRU*_NL@6[6O161GDDBQDC*@>'[OU5 A$H.I+4:')JD6,1G"9[SQ05Q3'*]CL
MA"SZ 0*2U$&Q8QD $K9V+#&%V>T,,W-\*5X>14-N3"Z ;T&<U%@GVM)0@J^
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M3J&\+,TUC&35(Q Y2*8&H2@'9W&?\!GOLX@)YZC8?0?FO#O#;B!Y3DM)GI)
M%&'BHP6*%N$4!X(Z:6>NN!8*2QN!))P2#N0W:*@HZ11)8\<1/"1LT(\#H"Z1
M#D3C6^@2-8.KGQ /J]6=H> \?W8,_SV&7"^MZ3[VR%Y@:JUM""RK3'!S'S%/
M1*0KTR9 ,&)",NFH(G*$BDPB,D;&CY[><ZNA7.J:65D-#9AP%<&9M/":$!E7
M81?DD']A4VDN\O[RC[[,AA& !(-2N!Y,TU8/*!LF8183NGD%G<F<NU?$V[TB
MFSEWKSAWK]@NP'"\_1S.32P^01.+PPV.Q;]1/"#R0AI=+!20PB6CGV#3!WJZ
M>PA]5A9C^"[*B$/<LV-^> \M%H?EHA4/>V9/WO6:-]0=NL">-:E%6%"/ ZT#
M6Y45QB@NH2<N+G!!,I="[=CFAN]88 ?81)%PU(5"PAQ>IOH_ST@=N>-'@.H-
M>:QP-$51>B,/O5D,J,&"%W#=K" -]0P/[?XT51$&*$R:3E59D>58]_:@"H\#
M2/H.B0.90 6\SWD"*NIV(>C-!K%9A\L45%+2@+(/B<T%,>,"?Z &K$(2?Z3%
M>.)9 6?U;(N2GMJ.MH'?;3;[0ZX_"^VBH## :476.ANO:CI[BHV9 I/"CG1M
MBT;B$6ZHB*O.S]DQI[O=+LJRURHP;#BD!5=1K39&-H$7 <%B%-XQRS8LR:$F
M>S#HGN2W^53Z8,I!D4M$/IL+^JPN;$ BD*YRGO55L[6J"-?7O"I82G"V*+=Q
MO&53@8V]/97-]H\<\:;I7)K)T?X56$%U<EY08@PH,01*?<"LY$ZK.UTRR4&)
M,<J0&$\812\G93+I0J'H!R/<,&=..)BP<F"J%;TW%221@E-)SXVVE+,9Q4>.
MACPXPQ!5+,E@@K(447-623D@-\Q'<,VX.[TQ)=O S-YP K@%&E/XA"?& JX"
M%09H27?!C.5%*#DQ*T+A^CZROGTZOI4M4U,C/_)E/>SQ7*\\FO9J@P_L0KT/
MK_=2 \T%2V #Z4@#CJ9"X"0+/>76=37'*[B(%,^:T4.QY$:2X0;?*J"V5L<Q
MM=K HZO\R_KG:)'IMQ<%J*L92 #W.Q=8"&M("^#+]U[UIEY[N*M3[0;U5&]>
MWT"#.E5YK'<KUW6J6[^O-%O-UC5U5Z_TZE2_WKW7H9 HJ7[8C.QR]B]70SX,
MW>W&9OM[.OUFDF"P'.1$;:>:Q!S#\&R/Z5)>7,$Q0/NTI]#HYT3PFL;<9O.0
M\;;=YG.-33^40>/6F5UW )J?P%@Y%I!N<8F"@OKX<4T/7?!/MT_,L)TKFG.J
MG #PE"U?-C61U:)XAM899A1W*>OJ(1MN5VC@Q4'-YS[/?_)Y8<VJ=9P8$(*Y
MLQ<G"L]]/F#XIQ?YZ4>(AKUA=F))I-1YRC0WY?-2O]W*%/QXBET!#4SX#5B(
M9PJ!I\F;W6JPG']>(\W$.%\RW)"=W,NZT;LOW!1&@\?%*9LW7JIQTOW+LSFG
M[&F*J =QGWT/[E9>L\V:\[_M9?W,M9\FOR=_^!)_(E.2C ;DM+L!>?UE/9M?
MK7[(]8?\&_OE>[-5;=]#>ZKRZ\/[C>\#+GY-Q6/'W8(3=TT/"D''*YS98:(F
M_ MN>%@1N0;\'H)@HVO&VHQ_QR=#"I@WA-F?ZG6OQIPP"[/D)1K!LH?+WB5V
MR(P(9+!ODB))-ZA6#W4\5]EWH*4X USY@&)60)"6Q^:&*;RL027W/E],7U>O
M?!@W3+W2Q3Z7KW?M7N]OZJK>:'?K%&$9*<@R3ML#0S*6[+JG#5C?J"#O2^(N
M%OUT<^7RBU?@Y_UW:YHK_.ZNQ7'\_ACTFGA<,,F"IO;B%>WA7Q]__!K5,DR?
M3@0T<7JGMG#X)0O70K)>O?TZ]/9(IY^+] Z<F@AJ&/S!YK0C:M,=5 .0XD<F
M&RW@>]I&1-.A7@%%5[!>9FSSKE%MKZ&H?EF7[]G&XUMK_":;-!.GYT(34@5O
M?ZFMJCL!9^G_^CS3ST_Z-6B\=62H1TM%R&[1TA<UEOB_+Q>N>'LFS63R:9HN
M>#@=MO!P_OWYCB<@!R);WOEPBI!JZ#3#E&(Y&T^NT=B-:VBVF)UIU$ORJ#1E
MY>%]+@+3"(BV.)BXMH!0?'4C)@:S^;"^T.V>E!CN:I")QEER= S(F\D7T\6,
M5Y%3*"$8@LF<CWGC,0=PJ-P6#:']Q <#3[B0I@OYV$_9DUV5=V-7]7=59LF,
M('G55,%,0?W9X9TR-)OAK4V<*ZVH+S/5PL^8*X8;#]K/HU44?A8M?..$%D,P
MNX\:O 1!EHE&!?@VBI,6 P&$$L=;/B4Q$@A[JA%9X1;YGGY4 @5Y@4F7Z/+6
M5,)$YH5G+-@""X(X97YW'"BGRU >9LO;R\,@'-@NVM=X64]:/_XT&[__9'*Y
M$W:5?[),?Z@(I,*GY-M[KUO2IO5H@9%5+8TV]P0P2% ;6W$%1##B?5+XLU=<
M29HVUYE*V0C@-UWO)*T4!N1!@?GJ/@N(R.V+D?O9E=)EVK^B'W>W$JT UO;G
M">!," #SK1>.]ZD!>&^\C7XOYJW>]$/ ',1.=S>-Z72N5$AG"KZY$NF4O5*@
M/P%>P/^JP>)O/![0+SDY[L!JGO8/K"*:E$14@Z"'0ETPWQA4+7H&5;=^ZLOZ
MBOLYI8>U+-L<':B4L"5GY^X:]Z-1FQY<!R9GI]H-RDP9H.J_.O56KTY=U5OU
M1K/?.P<$0Z9C!YO?"<?$:,]PX:^Y^/2K/LW\%+GXO?C>FSN<J(4)G(9GP'"J
M5MA53ZKVAJ^'#9QSR' /(<, 2M;FV/U[5$&V<T@QKI"B-?U00X4&@"MG!3]M
M=,96F_WZU?IY^/:R5I:_AX]Y<?HX+L;J-_NN+2): K/+@>&;NZS]CNH*+OCW
MBPG/01WD7PK"AN'?![( ];@L@F()LM9OH5-T=TG4CW7MN=W6[HDQ53?&X.AM
M1>3NI&%(O*G4I^OG CU=\5&"SC[Q(S/2#/5 U5(E\-'%-P&>L%!0C&;KYB-7
M:?O:NA\<,=ZA^BD$P12#""9*#9!).XP'M]5374-0S56;&>5&\Y;(@D2C%"<:
M@ V-!>4@+ @=Z-I"6XX=<N'<^'$!K9!)!&B>9%1TDY&_!ZV/R4@UR6C&XH\_
MQ GJ-Y)YKN3J@[O[2>)Y##9(.LSQG7P/% X9XE5H@ZBM;C#3_:4YQ+8YG@-%
MRG "-5:O<2'R:.60DO304R3VS$X"U>Y=V4F<ULK!5N8>U&)B+!/^7@,C (F<
M^_< ]WE0BPG40W5(:A;WYE#4C*TUH/1<<_.GEW4[5U!4H=9>+MD3-?X+^>,U
M_@N%!(Q_V@-Q;';K%NA3[*P?"^_\<_Z-VUWWLAO\B=:[AP!]:;]H$_\& BV@
M"+B3]V(ZQ+3< FM^O:MMM7<W:2K"V09.3O\JTB=A \<)N8TF1SB$CI))48PA
MA7=#)D52-GK%@]H#C723SJU&^J_GPML@=UV>,J_':Z2;-CJG0>/4C?30K"8P
M2G$4K"8FH(7B,G&REQCR7O?&7LXV^T&8CV%R0PV>;O+Q_*C\>'/]>,,\1[$7
M0S8*VUQ7$<!S-V/K":3;Q^0,+<:?0AL"]"=8([&W?-QB#'7$D=F\[^EY<9IP
M)0Y7+^OZ/7C,%F_'0Z%TH,FKUN2BCYF81I\GIHGQ3DRCSQ/37,D0GWQBFIM$
MCW=<V'E&VJG/2/.J5(B[^*7DZL9LEJGH-BQ4:RIH[)&"0@?:9"0>*!L+7ZX\
M"U^V>B)JA%KOOOVNER8U^H3U!J\N@H;G"9D_>.:4HDU.L7POF)##DU-X1=5G
M/)#**2AZ#J>CH+M.J/RR?A0SF1+SNW=3"^P>B.J$:O5&O=N%%(\JA2J]7KW?
MP]SNKEFY:MXU^\WZN5[HPQN3.;KDZ75 +-V8/:G\0,U_MD(#9Q40 <CR[7W$
M-$JMJ]MSL\#/7OESC+4N!TQP!TY->QP,4W/K$><\K"B.]))'D-308LV1!9*B
M5%E97HTD><G*G()F)\S86K]RO6YQ:_*QM7Z?WKVL[UO3^F]E52L]C9(HK/%R
M"+2 :AUUBAI3#ZVK=<+I ]H&AHNJA8"\Y[ (3Q=Y*7*^,)U)ETKE=*FP8_7-
MQDJ9TX&^I[N[E(T*_5*ZS!33V6RPEWNW4J#J)M)'W?"U[S37/S+EX-^X,1(T
M;[5(@-*;L#*X8A7 62^H2HIJ\ B-,8SSW6&A^@?0C5(B>5-N$/14:&Y?#-#B
M\&!-?75)Y[AMAVTQ@'H+IK!%L-T9?*%+^72V'-Q>[*-2"P\#[-[<(/JLVG0V
MASA"<'O6:"Q 'UO:U0;9PHW7S#&V57;.J_"9:P-(BI.LB_G"<%";K][H:7(Q
M=30*T&_0KKE$H^?0AV :'B@;&HQ;D.P6@5,[[A1H.LWD@KMF'A3!Q@!&;Q+<
MHA^4$XRY=,9SI'8<91 Z 7KYD)NBRHIC?B" RDR")+7&K,=)@;)*TR.I6WP%
MXST)5G-=%&M9V,?A2WC@A:>[\A;MB1T:7":=IW=EV$<(1D^Z*T<V0_*Y-)T,
MV7D5D9C:OSH!LI/&[D9=YJWZD&<Z<92*X%<<ECJ$E[0%<6S1L-;1LCN3+H:P
M;0Z*.") S9L6(FO?V6PZEP\VQR/00GT3+:#4':(/H[@;*P[!"]]JXK1*!1/'
MK]>V_I%X?T9KN7(E3!O3_1AYOKY4-'23>M.73['Z^EW.H*,K PE(LPQQAEN0
M>>0T2YI)E[+%=#$??]/V\]F%8S:1[08ZDRX7B^E2A#;2.S?<=X&@!=07OM]$
MM3D&EP&M%@,><H7,^@/2N)&WV2./X<C3@,.5RI0S6S=9"95Z>_)@V[J8,8&,
MY<;+^BT+IF_#]EUS.#SAS*,]))B5,UE7@MEB!O>^:H_\PP=^666V=LI;/.9E
MK90'D^Y*?+ZU%".?WH%:4LFH"<O94\&HN:3"U_)0Q5M1"Y47H(F*/!.B.RJ(
MN+4M,G@X:62A!].JV=;KSX>&,FJ$R2QK=^K=2A]-ID6#::EJI=M]IAKM[E.E
M6SOGE'UX_HJ90E6WY)0MA-GZNM]K<:W29TMQ,0%2M.24_?[S-*.[.>Z*3P8@
MYYRR<T[9.:?L$*EI4[?HS>E)$W>!<&6A3B295U>5=UYY>3%M3FT"9Q6:B:J\
MNL<X_K+^^5 2AXL24P51,IFVF4O[Q=EPZF!S9:(E)NF@?O&$M$.QCNPC92"P
M"Z5TH<Q\BK2E:%E*6QU%]*R%4CJ;*Z>+(5S6NR4Q%9/@![9^8K<+F5<X'B]>
MYPS-3+OY.+CM]")-K(ZQ<5BH=FU)$G0 J!SX%-TCB2849]*9$"- XPT<[1W
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M$HS#)KVQ"NP,4$B&B\ N*=UU(=D9+6:2)&"HA05/U W@:S:>T [_X[\WQ9&
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M,#(S,3(S,5]D968N>&UL4$L! A0#%     @ ,Z=Y6!T^?@^ F@   QX) !4
M             ( !&'<  &5N=F(M,C R,S$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( #.G>5@[W&QJX60   KA!@ 5              "  <L1 0!E;G9B+3(P
M,C,Q,C,Q7W!R92YX;6Q02P$"% ,4    "  SIWE8K'5D1/E?  "3)0, "
M            @ '?=@$ 97@Q-"YH=&U02P$"% ,4    "  SIWE8CK* ?$4I
M  ">3@$ "               @ '^U@$ 97@Q.2YH=&U02P$"% ,4    "  S
MIWE8+N!"4(P#  #E#@  "@              @ %I  ( 97@R,RTQ+FAT;5!+
M 0(4 Q0    ( #.G>5@-3BA8H <   @P   *              "  1T$ @!E
M>#,Q+3$N:'1M4$L! A0#%     @ ,Z=Y6*.HYY&C!P  ;S    H
M     ( !Y0L" &5X,S$M,BYH=&U02P$"% ,4    "  SIWE8I9PF=XH$
M(@  "               @ &P$P( 97@S,BYH=&U02P$"% ,4    "  SIWE8
M!=B1, L6  #?V0  "               @ %@& ( 97@Y-RYH=&U02P$"% ,4
M    "  SIWE84C=:K0MM P!*92  #               @ &1+@( 9F]R;3$P
<+6LN:'1M4$L%!@     -  T !0,  ,:;!0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ENVB="http://enveric.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="envb-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesCRedeemablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="From2024-02-012024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2023-06-152023-06-16_custom_KanubaddiSeparationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:KanubaddiSeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-16_custom_KanubaddiSeparationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:KanubaddiSeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-16</instant>
        </period>
    </context>
    <context id="From2023-06-152023-06-16_custom_MrKanubaddiEmploymentAgreementMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:MrKanubaddiEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-16_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-16</instant>
        </period>
    </context>
    <context id="AsOf2023-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2023-11-21</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_country_CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MaximumMember_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:PrefundedCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RestrictedStockUnitsUnvestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RestrictedStockUnitsUnvestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockAwardsVestedAndUnIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockAwardsVestedAndUnIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonStockInAbeyanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:CommonStockInAbeyanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CommonStockInAbeyanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:CommonStockInAbeyanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvstmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvstmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:ComputerEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:ComputerEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-01</instant>
        </period>
    </context>
    <context id="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-01</endDate>
        </period>
    </context>
    <context id="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegistrationRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-03</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-03_custom_RegistrationRightsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegistrationRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-03</instant>
        </period>
    </context>
    <context id="From2022-02-132022-02-15_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-13</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-15_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="From2022-02-132022-02-15_custom_UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENVB:UnderwritersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-13</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENVB:UnderwritersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-21</startDate>
            <endDate>2022-07-22</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-21</startDate>
            <endDate>2022-07-22</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-22_custom_PIPESecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDOfferingAndPIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="From2022-05-022022-05-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2022-05-02</startDate>
            <endDate>2022-05-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-02_custom_TwoThousandTwentyLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-02-102022-02-11_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-11</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-11_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="AsOf2022-02-11_us-gaap_CommonStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="AsOf2022-02-11_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="AsOf2022-02-14_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="AsOf2022-07-22_custom_WarrantAmendmentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="AsOf2022-07-14_custom_WarrantAmendmentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-14</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RDOfferingAndPIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDOfferingAndPIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PIPESecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PIPESecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-07-252022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:PlacementAgentPreferredInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:PlacementAgentPreferredInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="From2023-12-282023-12-28_custom_FebruaryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-28</startDate>
            <endDate>2023-12-28</endDate>
        </period>
    </context>
    <context id="From2023-12-282023-12-28_custom_FebruaryWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-28</startDate>
            <endDate>2023-12-28</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FebruaryWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-28_custom_FebruaryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FebruaryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PreModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputOptionVolatilityMember_custom_PreModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PreModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PreModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PreModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_ExistingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:ExistingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PostModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PostModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_ExistingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:ExistingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PostModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PostModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-12-282023-12-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-12-28</startDate>
            <endDate>2023-12-28</endDate>
        </period>
    </context>
    <context id="From2022-07-132022-07-14_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-13</startDate>
            <endDate>2022-07-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-14_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-14</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:RothAndInducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-28</startDate>
            <endDate>2023-12-28</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-28_custom_RothAndInducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:RothAndInducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENVB:AkosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="From2022-05-042022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENVB:AkosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InitialMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SubsequentMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_custom_MeasurementInputMarketRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ENVB:MeasurementInputMarketRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AvanceClinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AvanceClinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_OneTimeMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:OneTimeMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:VogalNathanPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-25</startDate>
            <endDate>2017-12-26</endDate>
        </period>
    </context>
    <context id="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_AdditionalMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:AdditionalMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:VogalNathanPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-25</startDate>
            <endDate>2017-12-26</endDate>
        </period>
    </context>
    <context id="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:VogalNathanPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-25</startDate>
            <endDate>2017-12-26</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OtherConsultingAndVendorAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:OtherConsultingAndVendorAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-02-292024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-08</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="AUD">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="Fact000005">0000890821</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0071"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0110"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0111"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0135"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0138"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0144"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0145"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0194"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:InducementExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0302"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0438"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0440"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0453"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0455"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0468"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0470"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0540"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0588"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0593"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0594"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0595"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0602"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0603"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0605"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0608"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0620"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0635"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:InducementExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0663"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0665"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:NoncashIncomeTaxExpense
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0668"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0705"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0713"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0717"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0720"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0722"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0743"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0747"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:WarrantsIssuedInConjunctionWithCommonStockIssuance
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0749"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfEmbeddedDerivative
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0752"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockSubscriptionReceivable
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0756"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:OfferingCostsAccruedNotPaid
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0759"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:WarrantsIssuedForOfferingCosts
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0762"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0765"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:InducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0768"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0773"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:ModificationOfWarrantsAsPartOfShareCapitalRaise
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0776"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0816"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember"
      id="xdx2ixbrl0893"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_CommonStockInAbeyanceMember"
      id="xdx2ixbrl0897"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0939"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PrepaidFranchiseTaxReceivable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0942"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0945"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:GoodwillImpairmentLossGross
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0962"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:GoodwillCurrencyTranslationImpairmentLoss
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0966"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:GoodwillForeignCurrencyTranslationGainLossGross
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0970"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0972"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0994"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccruedRestructuringCosts
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1050"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1053"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1180"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1182"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1315"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl1377"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2021-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl1379"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2021-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl1381"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2022-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl1393"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl1405"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl1413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1564"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember"
      id="xdx2ixbrl1582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1585"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember"
      id="xdx2ixbrl1591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember"
      id="xdx2ixbrl1594"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1614"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1616"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_WainwrightInvestmentOptionsMember"
      id="xdx2ixbrl1658"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_RDInvestmentOptionsMember"
      id="xdx2ixbrl1660"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PIPEInvestmentOptionsMember"
      id="xdx2ixbrl1662"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1716"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1718"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1752"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1754"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1756"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      id="xdx2ixbrl1788"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1853"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1854"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1857"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1859"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1860"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1863"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1865"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1866"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1868"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1869"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1871"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1874"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1900"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1901"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:EffectiveIncomeTaxRateReconciliationDeferredTrueup
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1937"
      unitRef="Pure"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="Fact000013">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000014">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000015">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="Fact000016">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="Fact000018">001-38286</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="Fact000019">ENVERIC BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="Fact000021">95-4484725</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="Fact000022">4851                                             Tamiami Trail N</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-12-31" id="Fact000023">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="Fact000024">Naples</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="Fact000025">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="Fact000026">34103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="Fact000027">(239)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="Fact000028">302-1707</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-12-31" id="Fact000029">Common     Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-12-31" id="Fact000030">ENVB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-12-31" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="Fact000032">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="Fact000033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="Fact000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="Fact000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="Fact000036">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="Fact000037">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="Fact000038">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-01-01to2023-12-31" id="Fact000039">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-01-01to2023-12-31" id="Fact000040">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="Fact000041">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-06-30"
      decimals="-5"
      id="Fact000042"
      unitRef="USD">7100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-03-21"
      decimals="INF"
      id="Fact000043"
      unitRef="Shares">7294005</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000045">Portions
of the Company&#x2019;s proxy statement for the Annual Meeting of Stockholders to be held May 28, 2024 are incorporated by reference into
Part III of this report. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s
fiscal year ended December 31, 2023. Additionally, portions of the Annual Report are incorporated by reference in this Form 10-K in response
to Items within Part II.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="Fact000046">688</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="Fact000047">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="Fact000048">East Hanover, New Jersey</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">2287977</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">17723884</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">1293554</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">708053</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000062"
      unitRef="USD">3581531</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">18431937</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">507377</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">677485</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">63817</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">210932</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">379686</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">718309</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">1120988</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">4299840</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">19552925</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">1218783</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">463275</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">1075643</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">1705655</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">63820</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">23608</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">851008</us-gaap:OtherLiabilitiesCurrent>
    <ENVB:WarrantLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">25470</ENVB:WarrantLiabilitiesCurrent>
    <ENVB:WarrantLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">185215</ENVB:WarrantLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">727000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">2343504</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">3995973</us-gaap:LiabilitiesCurrent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000119"
      unitRef="USDPShares">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000121"
      unitRef="USDPShares">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000123"
      unitRef="Shares">100000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000125"
      unitRef="Shares">100000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000127"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000129"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000131"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000133"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000136"
      unitRef="USD">885028</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000139"
      unitRef="USD">885028</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000147"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000149"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000151"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000155"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000157"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000159"
      unitRef="Shares">3600000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000161"
      unitRef="Shares">3600000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000163"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000165"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000167"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000169"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000174"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000176"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000178"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000182"
      unitRef="Shares">2739315</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000184"
      unitRef="Shares">2739315</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000186"
      unitRef="Shares">2078271</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000188"
      unitRef="Shares">2078271</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">27392</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000172"
      unitRef="USD">20782</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000190"
      unitRef="USD">100815851</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">94395662</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000193"
      unitRef="USD">1817640</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000196"
      unitRef="USD">-96499518</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">-79207786</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000199"
      unitRef="USD">-569749</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">-536734</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000202"
      unitRef="USD">1956336</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000203"
      unitRef="USD">14671924</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000205"
      unitRef="USD">4299840</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000206"
      unitRef="USD">19552925</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000211"
      unitRef="USD">8852021</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000212"
      unitRef="USD">11605761</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000214"
      unitRef="USD">7252437</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">8027773</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">7453662</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">343982</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000221"
      unitRef="USD">327910</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">16448440</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000224"
      unitRef="USD">27415106</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-16448440</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">-27415106</us-gaap:OperatingIncomeLoss>
    <ENVB:InducementExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000232"
      unitRef="USD">1848235</ENVB:InducementExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">-94396</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000236"
      unitRef="USD">-4315236</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnInvestments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000238"
      unitRef="USD">208752</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000239"
      unitRef="USD">3472726</us-gaap:GainLossOnInvestments>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000241"
      unitRef="USD">727000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000242"
      unitRef="USD">-325000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000244"
      unitRef="USD">3708</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000245"
      unitRef="USD">-5249</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">-814379</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000248"
      unitRef="USD">7457713</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">-17262819</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000251"
      unitRef="USD">-19957393</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000253"
      unitRef="USD">28913</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000254"
      unitRef="USD">-1486060</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">-17291732</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000257"
      unitRef="USD">-18471333</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000259"
      unitRef="USD">19041</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000260"
      unitRef="USD">33014</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000262"
      unitRef="USD">147988</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000263"
      unitRef="USD">295976</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000265"
      unitRef="USD">-17458761</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000266"
      unitRef="USD">-18800323</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000271"
      unitRef="USD">-33015</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000272"
      unitRef="USD">-505932</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000274"
      unitRef="USD">-17491776</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000275"
      unitRef="USD">-19306255</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000277"
      unitRef="USDPShares">-8.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000279"
      unitRef="USDPShares">-8.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000281"
      unitRef="USDPShares">-13.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000283"
      unitRef="USDPShares">-13.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000285"
      unitRef="Shares">2159063</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000287"
      unitRef="Shares">2159063</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000289"
      unitRef="Shares">1446007</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">1446007</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact000304"
      unitRef="Shares">1000</ENVB:TemporaryEquityShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000295"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000306"
      unitRef="Shares">2078271</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000296"
      unitRef="USD">20782</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000297"
      unitRef="USD">94395662</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000299"
      unitRef="USD">-79207786</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000300"
      unitRef="USD">-536734</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000301"
      unitRef="USD">14671924</us-gaap:StockholdersEquity>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000309"
      unitRef="USD">-19041</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000310"
      unitRef="USD">-19041</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000312"
      unitRef="USD">19041</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000316"
      unitRef="USD">19041</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000319"
      unitRef="USD">-147988</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">-147988</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000322"
      unitRef="USD">147988</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000326"
      unitRef="USD">147988</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact000338"
      unitRef="Shares">-1000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-1052057</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000330"
      unitRef="USD">-1052057</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000344"
      unitRef="USD">2150160</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000348"
      unitRef="USD">2150160</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000360"
      unitRef="Shares">103641</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">1036</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000354"
      unitRef="USD">-1036</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000372"
      unitRef="Shares">139403</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">1394</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000366"
      unitRef="USD">253713</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000370"
      unitRef="USD">255107</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ENVB:NetOfferingCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000384"
      unitRef="USD">239302</ENVB:NetOfferingCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000378"
      unitRef="USD">1967424</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000379"
      unitRef="USD">-280500</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000382"
      unitRef="USD">1686924</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000390"
      unitRef="USD">683997</ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000394"
      unitRef="USD">683997</ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000406"
      unitRef="Shares">418000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000399"
      unitRef="USD">4180</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000400"
      unitRef="USD">1532960</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000401"
      unitRef="USD">-1537140</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000415"
      unitRef="USD">-33015</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000416"
      unitRef="USD">-33015</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">-17291732</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000426"
      unitRef="USD">-17291732</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000442"
      unitRef="Shares">2739315</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000431"
      unitRef="USD">27392</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000432"
      unitRef="USD">100815851</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000433"
      unitRef="USD">-1817640</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000434"
      unitRef="USD">-96499518</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000435"
      unitRef="USD">-569749</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000436"
      unitRef="USD">1956336</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000457"
      unitRef="Shares">651921</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000447"
      unitRef="USD">6519</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000448"
      unitRef="USD">83066656</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000449"
      unitRef="USD">-60736453</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000450"
      unitRef="USD">-30802</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000451"
      unitRef="USD">22305920</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000472"
      unitRef="Shares">651921</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000462"
      unitRef="USD">6519</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000463"
      unitRef="USD">83066656</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000464"
      unitRef="USD">-60736453</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000465"
      unitRef="USD">-30802</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000466"
      unitRef="USD">22305920</us-gaap:StockholdersEquity>
    <ENVB:StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000483"
      unitRef="Shares">400000</ENVB:StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000477"
      unitRef="USD">4000</ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000478"
      unitRef="USD">5798464</ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000481"
      unitRef="USD">5802464</ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000489"
      unitRef="USD">2620671</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000492"
      unitRef="USD">2620671</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000503"
      unitRef="Shares">899</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000497"
      unitRef="USD">9</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000498"
      unitRef="USD">-9</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ENVB:RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000514"
      unitRef="USD">402000</ENVB:RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative>
    <ENVB:RedeemableNoncontrollingInterestIssuanceCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000516"
      unitRef="USD">41962</ENVB:RedeemableNoncontrollingInterestIssuanceCosts>
    <ENVB:RedeemableNoncontrollingInterestShares
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact000518"
      unitRef="Shares">1000</ENVB:RedeemableNoncontrollingInterestShares>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000506"
      unitRef="USD">556038</ENVB:RedeemableNoncontrollingInterestValue>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000507"
      unitRef="USD">556038</ENVB:RedeemableNoncontrollingInterestValue>
    <ENVB:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000529"
      unitRef="Shares">52685</ENVB:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="0"
      id="Fact000520"
      unitRef="USD">527</ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000522"
      unitRef="USD">527</ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000524"
      unitRef="USD">-527</ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000527"
      unitRef="USD">-527</ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000532"
      unitRef="USD">-33014</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000533"
      unitRef="USD">-33014</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000535"
      unitRef="USD">33014</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000538"
      unitRef="USD">33014</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000541"
      unitRef="USD">-295976</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000542"
      unitRef="USD">-295976</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000544"
      unitRef="USD">295976</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000547"
      unitRef="USD">295976</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000558"
      unitRef="Shares">1223</ENVB:StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000552"
      unitRef="USD">12</ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000553"
      unitRef="USD">-12</ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000569"
      unitRef="Shares">1000000</ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000563"
      unitRef="USD">10000</ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000564"
      unitRef="USD">3239124</ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000567"
      unitRef="USD">3249124</ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000580"
      unitRef="Shares">24228</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000574"
      unitRef="USD">242</ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000575"
      unitRef="USD">-242</ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000591"
      unitRef="Shares">-52685</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="0"
      id="Fact000582"
      unitRef="USD">-527</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000584"
      unitRef="USD">-527</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000586"
      unitRef="USD">527</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000589"
      unitRef="USD">527</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000599"
      unitRef="USD">-505932</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000600"
      unitRef="USD">-505932</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000607"
      unitRef="USD">-18471333</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000609"
      unitRef="USD">-18471333</us-gaap:NetIncomeLoss>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact000622"
      unitRef="Shares">1000</ENVB:TemporaryEquityShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000612"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000613"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000624"
      unitRef="Shares">2078271</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000614"
      unitRef="USD">20782</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000615"
      unitRef="USD">94395662</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000616"
      unitRef="USD">-79207786</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000617"
      unitRef="USD">-536734</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000618"
      unitRef="USD">14671924</us-gaap:StockholdersEquity>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact000637"
      unitRef="Shares">1000</ENVB:TemporaryEquityShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000627"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000628"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000639"
      unitRef="Shares">2078271</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000629"
      unitRef="USD">20782</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000630"
      unitRef="USD">94395662</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000631"
      unitRef="USD">-79207786</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000632"
      unitRef="USD">-536734</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000633"
      unitRef="USD">14671924</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000644"
      unitRef="USD">-17291732</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000645"
      unitRef="USD">-18471333</us-gaap:NetIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000650"
      unitRef="USD">-94396</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000651"
      unitRef="USD">-4315236</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnInvestments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000653"
      unitRef="USD">208752</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000654"
      unitRef="USD">3472726</us-gaap:GainLossOnInvestments>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000656"
      unitRef="USD">727000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000657"
      unitRef="USD">-325000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000659"
      unitRef="USD">2150160</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000660"
      unitRef="USD">2620671</us-gaap:ShareBasedCompensation>
    <ENVB:InducementExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000662"
      unitRef="USD">1848235</ENVB:InducementExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000666"
      unitRef="USD">7453662</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <ENVB:NoncashIncomeTaxExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000669"
      unitRef="USD">-1504302</ENVB:NoncashIncomeTaxExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000671"
      unitRef="USD">64048</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000672"
      unitRef="USD">107291</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000674"
      unitRef="USD">168754</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000675"
      unitRef="USD">168750</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000677"
      unitRef="USD">175228</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000678"
      unitRef="USD">159160</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000680"
      unitRef="USD">4206</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000686"
      unitRef="USD">6857</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000687"
      unitRef="USD">374058</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000689"
      unitRef="USD">-103848</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000690"
      unitRef="USD">263686</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000692"
      unitRef="USD">64045</ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation>
    <ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000693"
      unitRef="USD">107288</ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000695"
      unitRef="USD">-14094411</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000696"
      unitRef="USD">-17146723</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000701"
      unitRef="USD">5180</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000702"
      unitRef="USD">584165</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000704"
      unitRef="USD">16847</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000707"
      unitRef="USD">11667</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000708"
      unitRef="USD">-584165</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000714"
      unitRef="USD">17222099</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000716"
      unitRef="USD">291084</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000719"
      unitRef="USD">1052057</us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock>
    <us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000723"
      unitRef="USD">958038</us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000725"
      unitRef="USD">-1343141</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000726"
      unitRef="USD">18180137</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000728"
      unitRef="USD">-10022</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000729"
      unitRef="USD">-81364</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000731"
      unitRef="USD">-15435907</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000732"
      unitRef="USD">367885</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000734"
      unitRef="USD">17723884</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000735"
      unitRef="USD">17355999</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000737"
      unitRef="USD">2287977</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000738"
      unitRef="USD">17723884</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000744"
      unitRef="USD">5249</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000746"
      unitRef="USD">9507</us-gaap:IncomeTaxesPaidNet>
    <ENVB:WarrantsIssuedInConjunctionWithCommonStockIssuance
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000750"
      unitRef="USD">3595420</ENVB:WarrantsIssuedInConjunctionWithCommonStockIssuance>
    <ENVB:IssuanceOfEmbeddedDerivative
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000753"
      unitRef="USD">402000</ENVB:IssuanceOfEmbeddedDerivative>
    <ENVB:StockSubscriptionReceivable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000755"
      unitRef="USD">1817640</ENVB:StockSubscriptionReceivable>
    <ENVB:OfferingCostsAccruedNotPaid
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000758"
      unitRef="USD">182724</ENVB:OfferingCostsAccruedNotPaid>
    <ENVB:WarrantsIssuedForOfferingCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000761"
      unitRef="USD">77991</ENVB:WarrantsIssuedForOfferingCosts>
    <ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000764"
      unitRef="USD">255107</ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts>
    <ENVB:InducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000767"
      unitRef="USD">683997</ENVB:InducedConversionOfWarrantsAndPreferredInvestmentOptions>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000770"
      unitRef="USD">19041</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000771"
      unitRef="USD">33014</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000774"
      unitRef="USD">4323734</ENVB:InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance>
    <ENVB:ModificationOfWarrantsAsPartOfShareCapitalRaise
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000777"
      unitRef="USD">251357</ENVB:ModificationOfWarrantsAsPartOfShareCapitalRaise>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000779"
      unitRef="USD">147988</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000780"
      unitRef="USD">295976</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <us-gaap:NatureOfOperations contextRef="From2023-01-01to2023-12-31" id="Fact000782">&lt;p id="xdx_808_eus-gaap--NatureOfOperations_zcYw7bouB0pi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1. &lt;span id="xdx_827_zeGb70wjgan"&gt;BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nature
of Operations&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Enveric
Biosciences, Inc. (&#x201c;Enveric&#x201d; or the &#x201c;Company&#x201d;) is a biotechnology company developing novel neuroplastogenic small-molecule
therapeutics for the treatment of depression, anxiety, and addiction disorders. The head office of the Company is located in Naples,
Florida. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (&#x201c;Jay Pharma&#x201d;), 1306432 B.C. Ltd. (&#x201c;HoldCo&#x201d;),
MagicMed Industries, Inc. (&#x201c;MagicMed&#x201d;), Enveric Canada Inc., and Enveric Therapeutics, Pty. Ltd. (&#x201c;Enveric Therapeutics&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leveraging
its unique discovery and development platform, The Psybrary&#x2122;, Enveric has created a robust Intellectual Property portfolio of New
Chemical Entities for specific mental health indications. Enveric&#x2019;s lead program, the EVM201 Series, comprises next generation
synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series &#x2013; EB-373
&#x2013; for the treatment of psychiatric disorders. Enveric is also advancing its second program, the EVM301 Series, expected to offer
a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity
without also inducing hallucinations in the patient.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the Company&#x2019;s amalgamation with MagicMed completed in September 2021 (the &#x201c;Amalgamation&#x201d;), the Company has continued
to pursue the development of MagicMed&#x2019;s proprietary Psychedelic Derivatives library, the Psybrary&#x2122; which the Company believes
will help to identify and develop the right drug candidates needed to address mental health challenges, including cancer-related distress.
The Company synthesizes novel versions of classic psychedelics, such as psilocybin, DMT, mescaline and MDMA, using a mixture of chemistry
and synthetic biology, resulting in the expansion of the Psybrary&#x2122;, which includes 15 patent families with over a million potential
variations and hundreds of synthesized molecules. Within the Psybrary&#x2122; the Company has three different types of molecules, Generation
1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). The Company is working to add novel psychedelic
molecular compounds and derivatives (&#x201c;Psychedelic Derivatives&#x201d;) on a regular basis through its work at the Company&#x2019;s
labs in Calgary, Alberta, Canada, where the Company has a team of PhD scientists with expertise in synthetic biology and chemistry. To
date the Company has created over 500 molecules that are housed in the Psybrary&#x2122;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company screens newly synthesized molecules in the Psybrary&#x2122; through PsyAI&#x2122;, a proprietary artificial intelligence (&#x201c;AI&#x201d;)
tool. Leveraging AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. The Company
believes it streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological
effects to help determine ideal drug candidates, tailored to each indication. Each of these molecules that the Company believes are patentable
can then be further screened to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New
compounds of sufficient purity are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal),
and ultimately clinical (human) evaluations. The Company intends to utilize the Psybrary&#x2122; and the AI tool to categorize and characterize
the Psybrary&#x2122; substituents to focus on bringing more psychedelics-inspired molecules from discovery to the clinical phase.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Australian
Subsidiary&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 21, 2023, the Company established Enveric Therapeutics, an Australia-based subsidiary, to support the Company&#x2019;s plans to
advance its lead program, the EVM201 Series, comprised of the next generation synthetic prodrugs of the active metabolite, psilocin (&#x201c;EVM201
Series&#x201d;), towards the clinic. Enveric Therapeutics will oversee the Company&#x2019;s preclinical, clinical, and regulatory activities
in Australia, including ongoing interactions with the local Human Research Ethics Committees (HREC) and the Therapeutic Goods Administration
(TGA), Australia&#x2019;s regulatory authority.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
Concern, Liquidity and Other Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has incurred a loss since inception resulting in an accumulated deficit of $&lt;span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_zeXL2JVUG7I7" title="Accumulated deficit"&gt;96,499,518&lt;/span&gt; as of December 31, 2023 and further losses
are anticipated in the development of its business. Further, the Company has operating cash outflows of $&lt;span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20231231_zC9IEOtZAr8a" title="Net cash used in operating activities"&gt;14,094,411&lt;/span&gt; for the year ended
December 31, 2023. For the year ended December 31, 2023, the Company had a loss from operations of $&lt;span id="xdx_906_eus-gaap--OperatingIncomeLoss_iN_di_c20230101__20231231_zptySDPGyAxb" title="Loss from operations"&gt;16,448,440&lt;/span&gt;. Since inception, being
a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its
operations. The Company&#x2019;s operations have been funded principally through the issuance of equity. These factors raise substantial
doubt about the Company&#x2019;s ability to continue as a going concern for a period of one year from the issuance of these financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
assessing the Company&#x2019;s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate
sufficient cash flow in the future to support its operating and capital expenditure commitments. At December 31, 2023, the Company had
cash of $&lt;span id="xdx_906_eus-gaap--Cash_iI_c20231231_zvJyRYCpQVAi" title="Cash"&gt;2,287,977&lt;/span&gt; and working capital of $&lt;span id="xdx_900_ecustom--WorkingCapital_iI_c20231231_znZyDndGCB39" title="Working capital"&gt;1,238,027&lt;/span&gt;. The Company&#x2019;s current cash on hand is not sufficient enough to satisfy its
operating cash needs for the 12 months from the filing of this Annual Report on Form 10-K. These conditions raise substantial doubt regarding
the Company&#x2019;s ability to continue as a going concern for a period of one year after the date the financial statements are issued.
Management&#x2019;s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public
or private equity or debt financings or other sources, which has included the Equity Distribution Agreement with Canaccord for proceeds
of up to $&lt;span id="xdx_901_eus-gaap--ProceedsFromShortTermDebt_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z37fhioYnxFk" title="Additional working capital"&gt;2.4&lt;/span&gt; million (see Note 7), the Purchase Agreement with Lincoln Park (see Note 7), subject to registration, the Inducement Letters
and resulting sales of common stock under the Existing Warrants for cash proceeds of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zz97PuFdcZcd" title="Warrants for cash proceeds"&gt;1.8&lt;/span&gt; million received in January 2024 (see Note
7), and the exercise of warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBnxG2jQtVMb" title="Exercise of warrants to purchase"&gt;1,954,000&lt;/span&gt; shares of common stock for cash proceeds of approximately $&lt;span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240201__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zck6XEqy8KS5" title="Cash proceeds of warrants"&gt;2.7&lt;/span&gt; million in February
2024 (see Note 12), and may include additional collaborations with third parties as well as disciplined cash spending. Adequate additional
financing may not be available to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital,
the Company may be required to undertake cost-cutting measures including delaying or discontinuing certain operating activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of these factors, management has concluded that there is substantial doubt about the Company&#x2019;s ability to continue as
a going concern for a period of one year after the date of the financial statements are issued. The Company&#x2019;s consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reduction
in Force/Restructuring&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2023, the Company entered into a cost reduction plan, including a reduction in force (&#x201c;RIF&#x201d;) of approximately 35% of
its full-time employees to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that
were focused on the Akos cannabinoid spin-out were terminated. The Company recognized severance charges of approximately $&lt;span id="xdx_909_eus-gaap--SeveranceCosts1_c20230501__20230531_z8D58hHBUYA" title="Severance costs"&gt;453,059&lt;/span&gt; through
December 31, 2023. The plan included a focus on progressing the Company&#x2019;s existing non-cannabinoid pipeline while reducing the
rate of spend and managing cash flow. In June 2023, the Company completed the reduction in force, with such severance expenses recorded
in general and administrative accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 16, 2023, the Company entered into a separation agreement with Avani Kanubaddi, the Company&#x2019;s President and Chief Operating
Officer (the &#x201c;Kanubaddi Separation Agreement&#x201d;). In accordance with the Kanubaddi Separation Agreement, Mr. Kanubaddi&#x2019;s
outstanding restricted stock units (&#x201c;RSUs&#x201d;) will retain their vesting conditions. Mr. Kanubaddi&#x2019;s 2023 salary and benefits
of $&lt;span id="xdx_907_eus-gaap--SalariesAndWages_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_zMaUHcTYjBF4" title="Salaries and benefit"&gt;550,974&lt;/span&gt;, inclusive of the 2023 performance bonus in the amount of $&lt;span id="xdx_90A_eus-gaap--AccruedBonusesCurrent_iI_c20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_ztd6F7MB8w7c" title="Performance bonus"&gt;129,760&lt;/span&gt; were accrued and the salary and benefits, excluding the
2023 performance bonus will be paid out in twelve equal monthly installments beginning in July 2023. As of December 31, 2023, the performance
metrics for the 2023 performance bonus were not achieved and the accrued amount of amount of $&lt;span id="xdx_906_eus-gaap--RestructuringReserve_iI_c20231231_zRuin27dgPvk" title="Reversed amount"&gt;129,760&lt;/span&gt; was reversed. Upon termination,
any unvested time-based RSUs became fully vested. The Company accelerated expense recognized related to these shares that vested was
$&lt;span id="xdx_907_ecustom--ExpenseRelatedToAccelerationOfVesting_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--MrKanubaddiEmploymentAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLAvMlfADMU2" title="Expense related to acceleration of vesting"&gt;231,273&lt;/span&gt;. All of the &lt;span id="xdx_906_ecustom--MarketPerformanceBasedShares_iI_c20230616__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmfQq6R0AFH7" title="Market performance based shares"&gt;11,278&lt;/span&gt; market performance-based RSUs previously granted that were subject to the original terms and conditions of
Mr. Kanubaddi&#x2019;s employment agreement were forfeited during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z5glKSFld41e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_ztulwBwkUNX1" style="display: none"&gt;SCHEDULE
OF RESTRUCTURING COSTS PAYABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accrued&lt;br/&gt;
Restructuring Costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;January 1, 2023 Beginning balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20230101__20231231_zAlZ6w4mtdef" style="text-align: right" title="Restructuring cost payable, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Restructuring costs incurred&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--RestructuringCostsIncurred_c20230101__20231231_zWEiabbndsUi" style="width: 16%; text-align: right" title="Restructuring costs incurred"&gt;1,004,033&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restructuring costs paid&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RestructuringCosts_c20230101__20231231_zH5WzRsnJSdh" style="text-align: right" title="Restructuring costs"&gt;(572,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restructuring costs reversed&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OtherRestructuringCosts_c20230101__20231231_zY0iQ8QQEIX6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Restructuring costs reversed"&gt;(129,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;December 31, 2023 ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20230101__20231231_z5ABeYZz2MK4" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending"&gt;301,645&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zbWxkJfj9qfh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inflation
Risks&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers the current inflationary trend existing in the North American economic environment reasonably likely to have a material
unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price
inflation, have caused a general increase in the cost of labor and materials. In addition, there is an increased risk of the Company
experiencing labor shortages due to a potential inability to attract and retain human resources due to increased labor costs resulting
from the current inflationary environment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nasdaq
Notice&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 21, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that as
of September 30, 2023, the Company did not meet the minimum of $&lt;span id="xdx_90A_ecustom--MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_iI_c20231121_zRjXM8zUUidi" title="Minimum of stockholders equity required for continued listing pursuant to exchange"&gt;2,500,000&lt;/span&gt; in stockholders&#x2019; equity required for continued listing
pursuant to Nasdaq Listing Rule 5550(b)(1). On February 6, 2024, the Company received a letter from Nasdaq, granting the Company an extension
to regain compliance with the minimum stockholders&#x2019; equity requirement by May 20, 2024. If the Company fails to evidence compliance
upon filing its periodic report for June 30, 2024 with the SEC and Nasdaq, the Company may be subject to delisting. The Company plans
to regain and evidence compliance with the Stockholders&#x2019; Equity Requirement by the required deadlines, but it is not assured.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000784"
      unitRef="USD">-96499518</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000786"
      unitRef="USD">-14094411</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000788"
      unitRef="USD">-16448440</us-gaap:OperatingIncomeLoss>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000790"
      unitRef="USD">2287977</us-gaap:Cash>
    <ENVB:WorkingCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000792"
      unitRef="USD">1238027</ENVB:WorkingCapital>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2023-01-012023-12-31_custom_EquityDistributionAgreementMember"
      decimals="-5"
      id="Fact000794"
      unitRef="USD">2400000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-01-31_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000796"
      unitRef="USD">1800000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000798"
      unitRef="Shares">1954000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-02-012024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact000800"
      unitRef="USD">2700000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:SeveranceCosts1
      contextRef="From2023-05-012023-05-31"
      decimals="0"
      id="Fact000802"
      unitRef="USD">453059</us-gaap:SeveranceCosts1>
    <us-gaap:SalariesAndWages
      contextRef="From2023-06-152023-06-16_custom_KanubaddiSeparationAgreementMember"
      decimals="0"
      id="Fact000804"
      unitRef="USD">550974</us-gaap:SalariesAndWages>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2023-06-16_custom_KanubaddiSeparationAgreementMember"
      decimals="0"
      id="Fact000806"
      unitRef="USD">129760</us-gaap:AccruedBonusesCurrent>
    <us-gaap:RestructuringReserve
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000808"
      unitRef="USD">129760</us-gaap:RestructuringReserve>
    <ENVB:ExpenseRelatedToAccelerationOfVesting
      contextRef="From2023-06-152023-06-16_custom_MrKanubaddiEmploymentAgreementMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000810"
      unitRef="USD">231273</ENVB:ExpenseRelatedToAccelerationOfVesting>
    <ENVB:MarketPerformanceBasedShares
      contextRef="AsOf2023-06-16_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000812"
      unitRef="Shares">11278</ENVB:MarketPerformanceBasedShares>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000814">&lt;p id="xdx_896_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z5glKSFld41e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_ztulwBwkUNX1" style="display: none"&gt;SCHEDULE
OF RESTRUCTURING COSTS PAYABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accrued&lt;br/&gt;
Restructuring Costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;January 1, 2023 Beginning balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20230101__20231231_zAlZ6w4mtdef" style="text-align: right" title="Restructuring cost payable, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Restructuring costs incurred&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--RestructuringCostsIncurred_c20230101__20231231_zWEiabbndsUi" style="width: 16%; text-align: right" title="Restructuring costs incurred"&gt;1,004,033&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restructuring costs paid&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RestructuringCosts_c20230101__20231231_zH5WzRsnJSdh" style="text-align: right" title="Restructuring costs"&gt;(572,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restructuring costs reversed&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OtherRestructuringCosts_c20230101__20231231_zY0iQ8QQEIX6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Restructuring costs reversed"&gt;(129,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;December 31, 2023 ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20230101__20231231_z5ABeYZz2MK4" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending"&gt;301,645&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <ENVB:RestructuringCostsIncurred
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000818"
      unitRef="USD">1004033</ENVB:RestructuringCostsIncurred>
    <us-gaap:RestructuringCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000820"
      unitRef="USD">-572628</us-gaap:RestructuringCosts>
    <us-gaap:OtherRestructuringCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000822"
      unitRef="USD">-129760</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000824"
      unitRef="USD">301645</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <ENVB:MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange
      contextRef="AsOf2023-11-21"
      decimals="0"
      id="Fact000826"
      unitRef="USD">2500000</ENVB:MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000828">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_z1Usp4Epnijl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2. &lt;span id="xdx_827_z29VOpGCLrQb"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6VcoZZsSz29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zbIKrsz2JJMb"&gt;Basis
of Presentation and Principal of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance and in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and the applicable rules
and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) regarding consolidated financial information. All intercompany
transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--UseOfEstimates_zLE80GiwQAK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zMMySFR20SIc"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported.
By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such
estimates in future periods could be significant. Significant areas requiring management&#x2019;s estimates and assumptions include determining
the fair value of transactions involving common stock, the valuation of warrants and preferred investment options, and the valuation
of stock-based compensation and accruals associated with third party providers supporting research and development efforts. Actual results
could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z5nptn10VcWl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zFKLsC1vhXHf"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
inception through December 31, 2023, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#x2019;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended December
31, 2023 and 2022, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the consolidated statements of shareholders&#x2019; equity as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the consolidated statements of operations and comprehensive loss as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6AeRnFPvu0k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zNjHpvv4Gia"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The
Company did not have any cash equivalents as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zIej6k2jp2B1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z0Oa78Uy6iHe"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zB4bQGBLtGA6" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; in the United States and Australia and $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zGy542i4yAyf" title="Cash insured amount"&gt;100,000&lt;/span&gt; in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of December 31, 2023, the Company had greater than $&lt;span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zQv2tJGpW28l" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; at United States financial institutions, less than $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--AU_zPZgCdbAQVk7" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt;
at Australian financial institutions, and greater than $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zkz71lJ5798l" title="Cash FDIC insured amount"&gt;100,000&lt;/span&gt; at Canadian financial institutions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zuPlfgRbEyZd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_ztBjC43QkT38"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss consists of two components, net loss and other comprehensive income (loss). Other comprehensive loss refers to revenue, expenses,
gains, and losses that under GAAP are recorded as an element of shareholders&#x2019; equity but are excluded from net loss. Other comprehensive
loss consists of foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziQD2CBAghZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zPkCB4Owiyud"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the Psybrary&#x2122; and Patent Applications, In Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) and license
agreements. Psybrary&#x2122; and Patent Applications intangible assets are valued using the relief from royalty method. The cost of license
agreements is amortized over the economic life of the license. The Company assesses the carrying value of its intangible assets for impairment
each year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IPR&amp;amp;D
intangible assets are acquired in conjunction with the acquisition of a business and are assigned a fair value, using the multi-period
excess earnings method, related to incomplete research projects which, at the time of acquisition, have not reached technological feasibility.
The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion
or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then-useful
life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to
be generated, and begin amortization. The Company tests its intangible assets for impairment at least annually and whenever events or
circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator
of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company&#x2019;s
expected future cash flows; a sustained, significant decline in the Company&#x2019;s stock price and market capitalization; a significant
adverse change in legal factors or in the business climate of the Company&#x2019;s segments; unanticipated competition; and slower growth
rates. If the fair value determined is less than the carrying amount, an impairment loss is recognized in operating results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z32t25Ny06rb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zdX7mG65WS1b"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company tests goodwill for potential impairment at least annually, or more frequently if an event or other circumstance indicates that
the Company may not be able to recover the carrying amount of the net assets of the reporting unit. The Company has determined that the
reporting unit is the entire company, due to the integration of all of the Company&#x2019;s activities. In evaluating goodwill for impairment,
the Company may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that
the fair value of a reporting unit is less than its carrying amount. If the Company bypasses the qualitative assessment, or if the Company
concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company performs
a quantitative impairment test by comparing the fair value of a reporting unit with its carrying amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zNmGyuL93vpj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z622SrpvFB74"&gt;Property
&amp;amp; Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Major property additions, replacements, and betterments are capitalized, while maintenance and repairs
that do not extend the useful lives of an asset or add new functionality are expensed as incurred. Depreciation and amortization are
recorded using the straight-line method over the respective estimated useful lives of the Company&#x2019;s long-lived assets. The estimated
useful lives are typically &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDXlWGeWzm" title="Estimated useful lives"&gt;3&lt;/span&gt; to &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zuaBlK6Ilio2" title="Estimated useful lives"&gt;5&lt;/span&gt; years for office furniture and equipment and are depreciated on a straight-line basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--DeferredOfferingCostsPolicyTextBlock_zI13qPYdFR16" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zmmelDy6vXh3"&gt;Deferred
Offering Costs&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company allocates offering costs to the different components of the capital raise on a pro rata basis. Any offering costs allocated to
common stock are charged directly to additional paid-in capital. Any offering costs allocated to warrant liabilities are charged to general
and administrative expenses on the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the requirements of ASC Topic 340, &lt;i&gt;Other Assets and Deferred Costs&lt;/i&gt; (&#x201c;ASC 340&#x201d;) and SAB 5A &lt;i&gt;-
Expenses of Offering&lt;/i&gt;. Offering costs, which consist mainly of legal, accounting and consulting fees directly attributable to the
issuance of an equity contract to be classified in equity are recorded as a reduction in equity. For the year ended December 31, 2023,
the Company incurred $&lt;span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zOw3Bao897qf" title="Deferred offering costs"&gt;567,603&lt;/span&gt; in deferred offering costs in connection with the Equity Distribution Agreement (the &#x201c;Distribution
Agreement&#x201d;), with Canaccord Genuity LLC (&#x201c;Canaccord&#x201d;) and the Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;)
with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;). These deferred offering costs will be proportionately offset against
the total proceeds from the issuance of common stock available under the agreements and the Company will expense any remaining balance
of deferred offering costs if the agreements are terminated. For the year ended December 31, 2023, there were no issuances of common
stock under the agreements resulting in the deferral of offering costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--WarrantLiabilityPolicyTextBlock_zanLVGGwng9c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zH6VWLIKl02j"&gt;Warrant
Liability and Investment Options&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its financial instruments, including issued stock purchase warrants and investment options, to determine if
such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 &#x201c;Distinguishing
Liabilities from Equity&#x201d; (&#x201c;ASC 480&#x201d;) and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;).
The Company accounts for warrants and investment options for shares of the Company&#x2019;s common stock that are not indexed to its own
stock as derivative liabilities at fair value on the consolidated balance sheets. The Company accounts for common stock warrants and
investment options with put options as liabilities under ASC 480. Such warrants and investment options are subject to remeasurement at
each consolidated balance sheet date and any change in fair value is recognized as a component of other expense on the consolidated statements
of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration
of such common stock warrants and investment options. At that time, the portion of the warrant liability and investment options related
to such common stock warrants will be reclassified to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_zOLylevrf7oj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zHBF6D1y83y9"&gt;Modification
and Inducement of Warrants and Investment Options&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
change in any of the terms or conditions of warrants is accounted for as a modification. For a warrant modification accounted for under
ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over the fair
value of the original warrant immediately before its terms are modified, measured based on the fair value of the shares and other pertinent
factors at the modification date. The accounting for incremental fair value of warrants is based on the specific facts and circumstances
related to the modification. When a modification is directly attributable to equity offerings, the incremental change in fair value of
the warrants are accounted for as equity issuance costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the inducement to exercise warrants in accordance with ASC Subtopic 470-20-40 &#x201c;Debt with Conversion and Other
Options&#x201d; (&#x201c;ASC 470-20-40&#x201d;). ASC 470-20-40 requires the recognition through earnings of an inducement charge equal to
the fair value of the consideration delivered in excess of the consideration issuable under the original conversion terms. Therefore,
the Company recognized a loss on the warrant inducement for the incremental change of the warrants related to the reduced exercise price
and the issuance of new warrants as these components induced the holders to exercise the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_ze8NOutWO18c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zBwpH1gx3ZNb"&gt;Derivative
Liability&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as assets or liabilities, the derivative
instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the
fair value reported in the consolidated statements of operations. The classification of derivative instruments, including whether such
instruments should be recorded as assets or liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion
of the instrument could be required within 12 months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zL6shVmPF5Cf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zsORoSsW5NTg"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#x2019;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liabilities. In management&#x2019;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax
benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The
amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
A liability for &#x201c;unrecognized tax benefits&#x201d; is recorded for any tax benefits claimed in the Company&#x2019;s tax returns that
do not meet these recognition and measurement standards. As of December 31, 2023 and 2022, no liability for unrecognized tax benefits
was required to be recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy for recording interest and penalties associated with tax audits is to record such items as a component of operating
expenses. There were no amounts accrued for penalties and interest for the years ended December 31, 2023 and 2022. The Company does not
expect its uncertain tax positions to change during the next twelve months. Management is currently unaware of any issues under review
that could result in significant payments, accruals or material deviations from its position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has identified its United States, Canadian and Australian federal tax returns, and its state and provincial tax returns in Florida,
Massachusetts, New Jersey, Pennsylvania, and Ontario, CA as its &#x201c;major&#x201d; tax jurisdictions. The Company is in the process
of filing its United States federal and state and Australian federal corporate tax returns for the year ended December 31, 2023. The
Company is in the process of filing its Canadian corporate tax returns for the years ended December 31, 2023 and 2022. Net operating
losses for these periods will not be available to reduce future taxable income until the returns are filed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zEsxkwpAfIyl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zVtfgEZ2LSf1"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows ASC 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions, requiring
such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded at the more
readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The Company uses the Black-Scholes
option-pricing model to determine the grant date fair value of certain stock-based awards under ASC 718. The assumptions used in calculating
the fair value of stock-based awards represent management&#x2019;s reasonable estimates and involve inherent uncertainties and the application
of management&#x2019;s judgment. Fair value of restricted stock units or restricted stock awards is determined by the closing price per
share of the Company&#x2019;s common stock on the date of award grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair value is amortized as a charge to earnings on a straight-line basis, for awards or portions of awards that do not require
specified milestones or performance criteria as a vesting condition and also depending on the terms and conditions of the award, and
the nature of the relationship of the recipient of the award to the Company. The Company records the grant date fair value in line with
the period over which it was earned. For employees and consultants, this is typically considered to be the vesting period of the award.
The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair value of awards that require specified milestones or recipient performance are charged to expense when such milestones
or performance criteria are probable to be met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
stock units, restricted stock awards, and stock options are granted at the discretion of the Compensation Committee of the Company&#x2019;s
board of directors (the &#x201c;Board of Directors&#x201d;). These awards are restricted as to the transfer of ownership and generally
vest over the requisite service periods, typically over a 12 to 48-month period. A significant portion of these awards may include vesting
terms that include, without limitation, defined volume weighted average price levels being achieved by the Company&#x2019;s common stock,
specific performance milestones, employment, or engagement by the Company, with no assurances of achievement of any such vesting conditions,
if applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of RSU&#x2019;s is equal to the product of the number of units awarded, multiplied by the closing price per share of the Company&#x2019;s
common stock on the date of the award. The terms and conditions of each RSU is defined in the RSU agreement and includes vesting terms
that consist of any or all of the following: immediate vesting, vesting over a defined period of time, vesting based on achievement of
a defined volume weighted average price levels at specified times, vesting based on achievement of specific performance milestones within
a specific time frame, change of control, termination of the employee without cause by the Company, resignation of the employee with
good cause. The value assigned to each RSU is charged to expense based on the vesting terms, as follows: value of RSU&#x2019;s that vest
immediately are charged to expense on the date awarded, value of RSU&#x2019;s that vest based upon time, or achievement of stock price
levels over a period of time are charged to expense on a straight line basis over the time frame specified in the RSU and the value of
RSU&#x2019;s that vest based upon achievement of specific performance milestones are charged to expense during the period that such milestone
is achieved. Vested RSU&#x2019;s may be converted to shares of common stock of an equivalent number upon either the termination of the
recipient&#x2019;s employment with the Company, or in the event of a change in control. If the recipient is not an employee, such person&#x2019;s
engagement with the Company must either be terminated prior to such conversion of RSU&#x2019;s to shares of common stock, or in the event
of a change in control. Furthermore, as required by Section 409A of the Internal Revenue Code, if the recipient is a &#x201c;specified
employee&#x201d; (generally, certain officers and highly compensated employees of publicly traded companies), such recipient may only
convert vested RSU&#x2019;s into shares of common stock no earlier than the first day of the seventh month following such recipients termination
of employment with the Company, or the event of change in control.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of RSA&#x2019;s is equal to the product of the number of restricted shares awarded, multiplied by the closing price per share of
the Company&#x2019;s common stock on the date of the award. The terms and conditions of each RSA is defined in the RSA agreement and includes
vesting terms that consist of any or all of the following: immediate vesting, vesting over a defined period of time, or vesting based
on achievement of a defined volume weighted average price levels at specified times. Upon vesting, the recipient may receive restricted
stock which includes a legend prohibiting sale of the shares during a restriction period that is defined in the RSA agreement. Termination
of employment by or engagement with the Company is not required for the recipient to receive restricted shares of common stock. The value
assigned to each RSA is charged to expense based on the vesting terms, as follows: value of RSA&#x2019;s that vest immediately are charged
to expense on the date awarded, value of RSA&#x2019;s that vest based upon time, or achievement of stock price levels over a period of
time are charged to expense on a straight-line basis over the time frame specified in the RSU.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z2bNPdQ0lNxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zX4N0aihbZJi"&gt;Net
Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the years ended December 31, 2023 and 2022 excludes
potentially dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully
diluted. In accordance with ASC 260 &#x201c;Earnings per Share&#x201d; (&#x201c;ASC 260&#x201d;), penny warrants were included in the calculation
of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022 the Company issued &lt;span id="xdx_908_eus-gaap--StockIssued1_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zrEmdvuW4kc3" title="Stock and warrants issued"&gt;767,500&lt;/span&gt; pre-funded common stock warrants, which were exercised on various dates during
the year ended December 31, 2022. The pre-funded common stock warrants became exercisable on July 26, 2022 based on the terms and conditions
of the agreements. As the pre-funded common stock warrants are exercisable for $&lt;span id="xdx_90D_eus-gaap--WarrantExercisePriceDecrease_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zklaTLhZDQRk" title="Warrant exercise price"&gt;0.0001&lt;/span&gt;, these shares are considered outstanding common
shares and are included in the computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants
is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions
were met on July 26, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z3HM0uaIm6yl" style="display: none"&gt;SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Warrants to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,799,213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;655,463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,848&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_z5qaULxH0YR3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock awards - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0893"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;708&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_zqhcUe1s59cj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Common stock in abeyance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;704,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0897"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zq1067Obsksb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment options to purchase shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,070,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zhYSctrl3dxd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,764,881&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,901,045&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zJID65LmxDb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqetmarc655b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_ztG9Z6EAI5m2"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value
Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), approximates the carrying amounts in the balance sheets, excluding the derivative,
warrants, and preferred investment option liabilities, primarily due to their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zWzfZ1GdSou9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zKPLQOyArmx4"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 - Valuations based on quoted prices for identical assets and liabilities in active markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and
liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by
other market participants. These valuations require significant judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain financial instruments, including cash and accounts payable, the carrying amounts approximate their fair values as of December
31, 2023 and 2022 because of their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ziSLQKNyYoCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zuz1Rz8vQhr9"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_zQ7ioewi5Gc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease assets are included within right-of-use operating lease asset and operating lease liabilities are included in current portion of
right-of-use operating lease obligation and non-current portion of right-of-use operating lease obligation on the consolidated balance
sheets as of December 31, 2023 and 2022. The Company has elected not to present short-term leases as these leases have a lease term of
12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise.
Lease payments for short-term leases are recognized on a straight-line basis over the term of the lease. All other lease assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the
Company&#x2019;s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information
available at adoption date in determining the present value of lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain
a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset
and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company
has elected to account for non-lease components associated with its leases and lease components as a single lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes a right-of-use asset, which represents the Company&#x2019;s right to use the underlying asset for the lease term, and
a lease liability, which represents the present value of the Company&#x2019;s obligation to make payments arising over the lease term.
The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing
rate&lt;b&gt;&lt;i&gt;.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of
ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset
that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset,
(iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v)
the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of
the lease term. All other leases are recorded as operating leases. Finance lease payments are bifurcated into (i) a portion that is recorded
as interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did not have any finance
leases as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zxsDQhAmPSMf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_za6xEu8hPKl1"&gt;Redeemable
Non-controlling Interest&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the issuance of Akos Series A Preferred Stock, the Akos Purchase Agreement (as defined below in Note 8) and certificate
of designation contain a put right guaranteed by the Company as defined in Note 8. Applicable accounting guidance requires an equity
instrument that is redeemable for cash or other assets to be classified outside of permanent equity if it is redeemable (a) at a fixed
or determinable price on a fixed or determinable date, (b) at the option of the holder, or (c) upon the occurrence of an event that is
not solely within the control of the issuer. As a result of this feature, the Company recorded the non-controlling interests as Redeemable
Non-Controlling Interests (&#x201c;RNCI&#x201d;) and classified them in mezzanine equity within its consolidated balance sheet initially
at its acquisition-date estimated redemption value or fair value. In addition, the Company has elected to recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument by accreting the embedded derivative at each reporting
period over 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right (as defined below) requiring Akos to force redemption of all of the Akos Series A Preferred Stock. See Note 8.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQ4s5yz0SOx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zww0mCbaLZc1"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines its reporting units in accordance with FASB ASC 280, &#x201c;Segment Reporting&#x201d; (&#x201c;ASC 280&#x201d;). The
Company evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated. The Company has multiple operations related
to psychedelics and cannabinoids. Both of these operations exist under one reporting unit: Enveric. The Company has one operating segment
and reporting unit. The Company is organized and operated as one business. Management reviews its business as a single operating segment,
using financial and other information rendered meaningful only by the fact that such information is presented and reviewed in the aggregate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6VQKIWjEQ2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zwwObdI2aaB5"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU 2020-06, &lt;i&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/i&gt; (Subtopic 470-20) and &lt;i&gt;Derivatives
and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity&lt;/i&gt; (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;) to simplify certain financial
instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features
from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#x2019;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#x2019;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2023, and should be applied on a full or modified retrospective basis. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06
effective January 1, 2023, and has determined that the adoption of this guidance had no impact on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently evaluating ASU 2023-07 to determine its impact on the Company&#x2019;s
disclosures, however, as the Company currently has one reportable segment, the Company does not expect ASU 2023-07 to have a material
impact.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its consolidated financial statements
and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000830">&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6VcoZZsSz29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zbIKrsz2JJMb"&gt;Basis
of Presentation and Principal of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance and in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and the applicable rules
and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) regarding consolidated financial information. All intercompany
transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="Fact000832">&lt;p id="xdx_846_eus-gaap--UseOfEstimates_zLE80GiwQAK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zMMySFR20SIc"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported.
By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such
estimates in future periods could be significant. Significant areas requiring management&#x2019;s estimates and assumptions include determining
the fair value of transactions involving common stock, the valuation of warrants and preferred investment options, and the valuation
of stock-based compensation and accruals associated with third party providers supporting research and development efforts. Actual results
could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000834">&lt;p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z5nptn10VcWl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zFKLsC1vhXHf"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
inception through December 31, 2023, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#x2019;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended December
31, 2023 and 2022, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the consolidated statements of shareholders&#x2019; equity as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the consolidated statements of operations and comprehensive loss as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000836">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6AeRnFPvu0k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zNjHpvv4Gia"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The
Company did not have any cash equivalents as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-01to2023-12-31" id="Fact000838">&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zIej6k2jp2B1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z0Oa78Uy6iHe"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zB4bQGBLtGA6" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; in the United States and Australia and $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zGy542i4yAyf" title="Cash insured amount"&gt;100,000&lt;/span&gt; in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of December 31, 2023, the Company had greater than $&lt;span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zQv2tJGpW28l" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; at United States financial institutions, less than $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--AU_zPZgCdbAQVk7" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt;
at Australian financial institutions, and greater than $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zkz71lJ5798l" title="Cash FDIC insured amount"&gt;100,000&lt;/span&gt; at Canadian financial institutions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31_country_US"
      decimals="0"
      id="Fact000840"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31_country_CA"
      decimals="0"
      id="Fact000842"
      unitRef="USD">100000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31_country_US"
      decimals="0"
      id="Fact000844"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31_country_AU"
      decimals="0"
      id="Fact000846"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31_country_CA"
      decimals="0"
      id="Fact000848"
      unitRef="USD">100000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000850">&lt;p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zuPlfgRbEyZd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_ztBjC43QkT38"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss consists of two components, net loss and other comprehensive income (loss). Other comprehensive loss refers to revenue, expenses,
gains, and losses that under GAAP are recorded as an element of shareholders&#x2019; equity but are excluded from net loss. Other comprehensive
loss consists of foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000852">&lt;p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziQD2CBAghZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zPkCB4Owiyud"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the Psybrary&#x2122; and Patent Applications, In Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) and license
agreements. Psybrary&#x2122; and Patent Applications intangible assets are valued using the relief from royalty method. The cost of license
agreements is amortized over the economic life of the license. The Company assesses the carrying value of its intangible assets for impairment
each year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IPR&amp;amp;D
intangible assets are acquired in conjunction with the acquisition of a business and are assigned a fair value, using the multi-period
excess earnings method, related to incomplete research projects which, at the time of acquisition, have not reached technological feasibility.
The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion
or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then-useful
life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to
be generated, and begin amortization. The Company tests its intangible assets for impairment at least annually and whenever events or
circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator
of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company&#x2019;s
expected future cash flows; a sustained, significant decline in the Company&#x2019;s stock price and market capitalization; a significant
adverse change in legal factors or in the business climate of the Company&#x2019;s segments; unanticipated competition; and slower growth
rates. If the fair value determined is less than the carrying amount, an impairment loss is recognized in operating results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000854">&lt;p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z32t25Ny06rb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zdX7mG65WS1b"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company tests goodwill for potential impairment at least annually, or more frequently if an event or other circumstance indicates that
the Company may not be able to recover the carrying amount of the net assets of the reporting unit. The Company has determined that the
reporting unit is the entire company, due to the integration of all of the Company&#x2019;s activities. In evaluating goodwill for impairment,
the Company may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that
the fair value of a reporting unit is less than its carrying amount. If the Company bypasses the qualitative assessment, or if the Company
concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company performs
a quantitative impairment test by comparing the fair value of a reporting unit with its carrying amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000856">&lt;p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zNmGyuL93vpj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z622SrpvFB74"&gt;Property
&amp;amp; Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Major property additions, replacements, and betterments are capitalized, while maintenance and repairs
that do not extend the useful lives of an asset or add new functionality are expensed as incurred. Depreciation and amortization are
recorded using the straight-line method over the respective estimated useful lives of the Company&#x2019;s long-lived assets. The estimated
useful lives are typically &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDXlWGeWzm" title="Estimated useful lives"&gt;3&lt;/span&gt; to &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zuaBlK6Ilio2" title="Estimated useful lives"&gt;5&lt;/span&gt; years for office furniture and equipment and are depreciated on a straight-line basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_srt_MinimumMember_us-gaap_OfficeEquipmentMember"
      id="Fact000858">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_srt_MaximumMember_us-gaap_OfficeEquipmentMember"
      id="Fact000860">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <ENVB:DeferredOfferingCostsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000862">&lt;p id="xdx_844_ecustom--DeferredOfferingCostsPolicyTextBlock_zI13qPYdFR16" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zmmelDy6vXh3"&gt;Deferred
Offering Costs&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company allocates offering costs to the different components of the capital raise on a pro rata basis. Any offering costs allocated to
common stock are charged directly to additional paid-in capital. Any offering costs allocated to warrant liabilities are charged to general
and administrative expenses on the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the requirements of ASC Topic 340, &lt;i&gt;Other Assets and Deferred Costs&lt;/i&gt; (&#x201c;ASC 340&#x201d;) and SAB 5A &lt;i&gt;-
Expenses of Offering&lt;/i&gt;. Offering costs, which consist mainly of legal, accounting and consulting fees directly attributable to the
issuance of an equity contract to be classified in equity are recorded as a reduction in equity. For the year ended December 31, 2023,
the Company incurred $&lt;span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zOw3Bao897qf" title="Deferred offering costs"&gt;567,603&lt;/span&gt; in deferred offering costs in connection with the Equity Distribution Agreement (the &#x201c;Distribution
Agreement&#x201d;), with Canaccord Genuity LLC (&#x201c;Canaccord&#x201d;) and the Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;)
with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;). These deferred offering costs will be proportionately offset against
the total proceeds from the issuance of common stock available under the agreements and the Company will expense any remaining balance
of deferred offering costs if the agreements are terminated. For the year ended December 31, 2023, there were no issuances of common
stock under the agreements resulting in the deferral of offering costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ENVB:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000864"
      unitRef="USD">567603</us-gaap:DeferredOfferingCosts>
    <ENVB:WarrantLiabilityPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000866">&lt;p id="xdx_84C_ecustom--WarrantLiabilityPolicyTextBlock_zanLVGGwng9c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zH6VWLIKl02j"&gt;Warrant
Liability and Investment Options&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its financial instruments, including issued stock purchase warrants and investment options, to determine if
such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 &#x201c;Distinguishing
Liabilities from Equity&#x201d; (&#x201c;ASC 480&#x201d;) and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;).
The Company accounts for warrants and investment options for shares of the Company&#x2019;s common stock that are not indexed to its own
stock as derivative liabilities at fair value on the consolidated balance sheets. The Company accounts for common stock warrants and
investment options with put options as liabilities under ASC 480. Such warrants and investment options are subject to remeasurement at
each consolidated balance sheet date and any change in fair value is recognized as a component of other expense on the consolidated statements
of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration
of such common stock warrants and investment options. At that time, the portion of the warrant liability and investment options related
to such common stock warrants will be reclassified to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ENVB:WarrantLiabilityPolicyTextBlock>
    <ENVB:ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000868">&lt;p id="xdx_846_ecustom--ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_zOLylevrf7oj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zHBF6D1y83y9"&gt;Modification
and Inducement of Warrants and Investment Options&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
change in any of the terms or conditions of warrants is accounted for as a modification. For a warrant modification accounted for under
ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over the fair
value of the original warrant immediately before its terms are modified, measured based on the fair value of the shares and other pertinent
factors at the modification date. The accounting for incremental fair value of warrants is based on the specific facts and circumstances
related to the modification. When a modification is directly attributable to equity offerings, the incremental change in fair value of
the warrants are accounted for as equity issuance costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the inducement to exercise warrants in accordance with ASC Subtopic 470-20-40 &#x201c;Debt with Conversion and Other
Options&#x201d; (&#x201c;ASC 470-20-40&#x201d;). ASC 470-20-40 requires the recognition through earnings of an inducement charge equal to
the fair value of the consideration delivered in excess of the consideration issuable under the original conversion terms. Therefore,
the Company recognized a loss on the warrant inducement for the incremental change of the warrants related to the reduced exercise price
and the issuance of new warrants as these components induced the holders to exercise the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ENVB:ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000870">&lt;p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_ze8NOutWO18c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zBwpH1gx3ZNb"&gt;Derivative
Liability&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as assets or liabilities, the derivative
instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the
fair value reported in the consolidated statements of operations. The classification of derivative instruments, including whether such
instruments should be recorded as assets or liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion
of the instrument could be required within 12 months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000872">&lt;p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zL6shVmPF5Cf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zsORoSsW5NTg"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#x2019;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liabilities. In management&#x2019;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax
benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The
amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
A liability for &#x201c;unrecognized tax benefits&#x201d; is recorded for any tax benefits claimed in the Company&#x2019;s tax returns that
do not meet these recognition and measurement standards. As of December 31, 2023 and 2022, no liability for unrecognized tax benefits
was required to be recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy for recording interest and penalties associated with tax audits is to record such items as a component of operating
expenses. There were no amounts accrued for penalties and interest for the years ended December 31, 2023 and 2022. The Company does not
expect its uncertain tax positions to change during the next twelve months. Management is currently unaware of any issues under review
that could result in significant payments, accruals or material deviations from its position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has identified its United States, Canadian and Australian federal tax returns, and its state and provincial tax returns in Florida,
Massachusetts, New Jersey, Pennsylvania, and Ontario, CA as its &#x201c;major&#x201d; tax jurisdictions. The Company is in the process
of filing its United States federal and state and Australian federal corporate tax returns for the year ended December 31, 2023. The
Company is in the process of filing its Canadian corporate tax returns for the years ended December 31, 2023 and 2022. Net operating
losses for these periods will not be available to reduce future taxable income until the returns are filed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000874">&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zEsxkwpAfIyl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zVtfgEZ2LSf1"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows ASC 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions, requiring
such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded at the more
readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The Company uses the Black-Scholes
option-pricing model to determine the grant date fair value of certain stock-based awards under ASC 718. The assumptions used in calculating
the fair value of stock-based awards represent management&#x2019;s reasonable estimates and involve inherent uncertainties and the application
of management&#x2019;s judgment. Fair value of restricted stock units or restricted stock awards is determined by the closing price per
share of the Company&#x2019;s common stock on the date of award grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair value is amortized as a charge to earnings on a straight-line basis, for awards or portions of awards that do not require
specified milestones or performance criteria as a vesting condition and also depending on the terms and conditions of the award, and
the nature of the relationship of the recipient of the award to the Company. The Company records the grant date fair value in line with
the period over which it was earned. For employees and consultants, this is typically considered to be the vesting period of the award.
The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair value of awards that require specified milestones or recipient performance are charged to expense when such milestones
or performance criteria are probable to be met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
stock units, restricted stock awards, and stock options are granted at the discretion of the Compensation Committee of the Company&#x2019;s
board of directors (the &#x201c;Board of Directors&#x201d;). These awards are restricted as to the transfer of ownership and generally
vest over the requisite service periods, typically over a 12 to 48-month period. A significant portion of these awards may include vesting
terms that include, without limitation, defined volume weighted average price levels being achieved by the Company&#x2019;s common stock,
specific performance milestones, employment, or engagement by the Company, with no assurances of achievement of any such vesting conditions,
if applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of RSU&#x2019;s is equal to the product of the number of units awarded, multiplied by the closing price per share of the Company&#x2019;s
common stock on the date of the award. The terms and conditions of each RSU is defined in the RSU agreement and includes vesting terms
that consist of any or all of the following: immediate vesting, vesting over a defined period of time, vesting based on achievement of
a defined volume weighted average price levels at specified times, vesting based on achievement of specific performance milestones within
a specific time frame, change of control, termination of the employee without cause by the Company, resignation of the employee with
good cause. The value assigned to each RSU is charged to expense based on the vesting terms, as follows: value of RSU&#x2019;s that vest
immediately are charged to expense on the date awarded, value of RSU&#x2019;s that vest based upon time, or achievement of stock price
levels over a period of time are charged to expense on a straight line basis over the time frame specified in the RSU and the value of
RSU&#x2019;s that vest based upon achievement of specific performance milestones are charged to expense during the period that such milestone
is achieved. Vested RSU&#x2019;s may be converted to shares of common stock of an equivalent number upon either the termination of the
recipient&#x2019;s employment with the Company, or in the event of a change in control. If the recipient is not an employee, such person&#x2019;s
engagement with the Company must either be terminated prior to such conversion of RSU&#x2019;s to shares of common stock, or in the event
of a change in control. Furthermore, as required by Section 409A of the Internal Revenue Code, if the recipient is a &#x201c;specified
employee&#x201d; (generally, certain officers and highly compensated employees of publicly traded companies), such recipient may only
convert vested RSU&#x2019;s into shares of common stock no earlier than the first day of the seventh month following such recipients termination
of employment with the Company, or the event of change in control.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of RSA&#x2019;s is equal to the product of the number of restricted shares awarded, multiplied by the closing price per share of
the Company&#x2019;s common stock on the date of the award. The terms and conditions of each RSA is defined in the RSA agreement and includes
vesting terms that consist of any or all of the following: immediate vesting, vesting over a defined period of time, or vesting based
on achievement of a defined volume weighted average price levels at specified times. Upon vesting, the recipient may receive restricted
stock which includes a legend prohibiting sale of the shares during a restriction period that is defined in the RSA agreement. Termination
of employment by or engagement with the Company is not required for the recipient to receive restricted shares of common stock. The value
assigned to each RSA is charged to expense based on the vesting terms, as follows: value of RSA&#x2019;s that vest immediately are charged
to expense on the date awarded, value of RSA&#x2019;s that vest based upon time, or achievement of stock price levels over a period of
time are charged to expense on a straight-line basis over the time frame specified in the RSU.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000876">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z2bNPdQ0lNxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zX4N0aihbZJi"&gt;Net
Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the years ended December 31, 2023 and 2022 excludes
potentially dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully
diluted. In accordance with ASC 260 &#x201c;Earnings per Share&#x201d; (&#x201c;ASC 260&#x201d;), penny warrants were included in the calculation
of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022 the Company issued &lt;span id="xdx_908_eus-gaap--StockIssued1_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zrEmdvuW4kc3" title="Stock and warrants issued"&gt;767,500&lt;/span&gt; pre-funded common stock warrants, which were exercised on various dates during
the year ended December 31, 2022. The pre-funded common stock warrants became exercisable on July 26, 2022 based on the terms and conditions
of the agreements. As the pre-funded common stock warrants are exercisable for $&lt;span id="xdx_90D_eus-gaap--WarrantExercisePriceDecrease_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zklaTLhZDQRk" title="Warrant exercise price"&gt;0.0001&lt;/span&gt;, these shares are considered outstanding common
shares and are included in the computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants
is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions
were met on July 26, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z3HM0uaIm6yl" style="display: none"&gt;SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Warrants to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,799,213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;655,463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,848&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_z5qaULxH0YR3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock awards - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0893"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;708&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_zqhcUe1s59cj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Common stock in abeyance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;704,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0897"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zq1067Obsksb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment options to purchase shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,070,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zhYSctrl3dxd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,764,881&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,901,045&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zJID65LmxDb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:StockIssued1
      contextRef="From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember"
      decimals="0"
      id="Fact000878"
      unitRef="USD">767500</us-gaap:StockIssued1>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember"
      decimals="INF"
      id="Fact000880"
      unitRef="USDPShares">0.0001</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000882">&lt;p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z3HM0uaIm6yl" style="display: none"&gt;SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Warrants to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,799,213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;655,463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,848&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_z5qaULxH0YR3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock awards - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0893"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;708&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_zqhcUe1s59cj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Common stock in abeyance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;704,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0897"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zq1067Obsksb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment options to purchase shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,070,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zhYSctrl3dxd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,764,881&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,901,045&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact000884"
      unitRef="Shares">2799213</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact000885"
      unitRef="Shares">655463</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember"
      decimals="INF"
      id="Fact000887"
      unitRef="Shares">20848</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Shares">62492</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsUnvestedMember"
      decimals="INF"
      id="Fact000890"
      unitRef="Shares">140491</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockUnitsUnvestedMember"
      decimals="INF"
      id="Fact000891"
      unitRef="Shares">64053</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember"
      decimals="INF"
      id="Fact000894"
      unitRef="Shares">708</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_CommonStockInAbeyanceMember"
      decimals="INF"
      id="Fact000896"
      unitRef="Shares">704000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact000899"
      unitRef="Shares">70000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Shares">1070000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact000902"
      unitRef="Shares">30329</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact000903"
      unitRef="Shares">48329</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000905"
      unitRef="Shares">3764881</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000906"
      unitRef="Shares">1901045</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000908">&lt;p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqetmarc655b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_ztG9Z6EAI5m2"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value
Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), approximates the carrying amounts in the balance sheets, excluding the derivative,
warrants, and preferred investment option liabilities, primarily due to their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000910">&lt;p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zWzfZ1GdSou9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zKPLQOyArmx4"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 - Valuations based on quoted prices for identical assets and liabilities in active markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and
liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by
other market participants. These valuations require significant judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain financial instruments, including cash and accounts payable, the carrying amounts approximate their fair values as of December
31, 2023 and 2022 because of their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-12-31" id="Fact000912">&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ziSLQKNyYoCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zuz1Rz8vQhr9"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000914">&lt;p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_zQ7ioewi5Gc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease assets are included within right-of-use operating lease asset and operating lease liabilities are included in current portion of
right-of-use operating lease obligation and non-current portion of right-of-use operating lease obligation on the consolidated balance
sheets as of December 31, 2023 and 2022. The Company has elected not to present short-term leases as these leases have a lease term of
12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise.
Lease payments for short-term leases are recognized on a straight-line basis over the term of the lease. All other lease assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the
Company&#x2019;s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information
available at adoption date in determining the present value of lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain
a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset
and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company
has elected to account for non-lease components associated with its leases and lease components as a single lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes a right-of-use asset, which represents the Company&#x2019;s right to use the underlying asset for the lease term, and
a lease liability, which represents the present value of the Company&#x2019;s obligation to make payments arising over the lease term.
The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing
rate&lt;b&gt;&lt;i&gt;.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of
ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset
that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset,
(iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v)
the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of
the lease term. All other leases are recorded as operating leases. Finance lease payments are bifurcated into (i) a portion that is recorded
as interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did not have any finance
leases as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <ENVB:RedeemableNoncontrollingInterestPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000916">&lt;p id="xdx_846_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zxsDQhAmPSMf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_za6xEu8hPKl1"&gt;Redeemable
Non-controlling Interest&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the issuance of Akos Series A Preferred Stock, the Akos Purchase Agreement (as defined below in Note 8) and certificate
of designation contain a put right guaranteed by the Company as defined in Note 8. Applicable accounting guidance requires an equity
instrument that is redeemable for cash or other assets to be classified outside of permanent equity if it is redeemable (a) at a fixed
or determinable price on a fixed or determinable date, (b) at the option of the holder, or (c) upon the occurrence of an event that is
not solely within the control of the issuer. As a result of this feature, the Company recorded the non-controlling interests as Redeemable
Non-Controlling Interests (&#x201c;RNCI&#x201d;) and classified them in mezzanine equity within its consolidated balance sheet initially
at its acquisition-date estimated redemption value or fair value. In addition, the Company has elected to recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument by accreting the embedded derivative at each reporting
period over 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right (as defined below) requiring Akos to force redemption of all of the Akos Series A Preferred Stock. See Note 8.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ENVB:RedeemableNoncontrollingInterestPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000918">&lt;p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQ4s5yz0SOx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zww0mCbaLZc1"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines its reporting units in accordance with FASB ASC 280, &#x201c;Segment Reporting&#x201d; (&#x201c;ASC 280&#x201d;). The
Company evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated. The Company has multiple operations related
to psychedelics and cannabinoids. Both of these operations exist under one reporting unit: Enveric. The Company has one operating segment
and reporting unit. The Company is organized and operated as one business. Management reviews its business as a single operating segment,
using financial and other information rendered meaningful only by the fact that such information is presented and reviewed in the aggregate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000920">&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6VQKIWjEQ2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zwwObdI2aaB5"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU 2020-06, &lt;i&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/i&gt; (Subtopic 470-20) and &lt;i&gt;Derivatives
and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity&lt;/i&gt; (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;) to simplify certain financial
instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features
from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#x2019;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#x2019;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2023, and should be applied on a full or modified retrospective basis. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06
effective January 1, 2023, and has determined that the adoption of this guidance had no impact on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently evaluating ASU 2023-07 to determine its impact on the Company&#x2019;s
disclosures, however, as the Company currently has one reportable segment, the Company does not expect ASU 2023-07 to have a material
impact.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its consolidated financial statements
and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000922">&lt;p id="xdx_80C_eus-gaap--OtherCurrentAssetsTextBlock_zaAAsItDs3Mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3.&lt;span&gt; &lt;span id="xdx_82D_z7UD1gS7KARl"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3Gs4LNqtEXh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and 2022, the prepaid expenses and other current assets of the Company consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zTydFvT6Kuv4" style="display: none"&gt;SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_z62twSxO8pL7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_z3hHr38UO7Tf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zIwSnFeaEsv8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;46,320&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;268,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_znbflNJJ4xcj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid value-added taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159,782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_z3HJkewuOo16" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;149,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;174,406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zRR1RvRhJGo5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105,179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_zv88yG4YKVt2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred offering costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;567,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0939"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zujCa29AAHXe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Franchise tax receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0942"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zaRKpTVrRgM4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;R&amp;amp;D tax incentive receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;145,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0945"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zieXSbV2rhJ5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,293,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;708,053&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zesRhFyyZGE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000924">&lt;p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3Gs4LNqtEXh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and 2022, the prepaid expenses and other current assets of the Company consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zTydFvT6Kuv4" style="display: none"&gt;SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_z62twSxO8pL7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_z3hHr38UO7Tf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zIwSnFeaEsv8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;46,320&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;268,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_znbflNJJ4xcj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid value-added taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159,782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_z3HJkewuOo16" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;149,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;174,406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zRR1RvRhJGo5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105,179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_zv88yG4YKVt2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred offering costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;567,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0939"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zujCa29AAHXe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Franchise tax receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0942"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zaRKpTVrRgM4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;R&amp;amp;D tax incentive receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;145,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0945"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zieXSbV2rhJ5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,293,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;708,053&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <ENVB:PrepaidResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000926"
      unitRef="USD">46320</ENVB:PrepaidResearchAndDevelopment>
    <ENVB:PrepaidResearchAndDevelopment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000927"
      unitRef="USD">268686</ENVB:PrepaidResearchAndDevelopment>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000929"
      unitRef="USD">243429</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000930"
      unitRef="USD">159782</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000932"
      unitRef="USD">149559</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000933"
      unitRef="USD">174406</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000935"
      unitRef="USD">62036</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000936"
      unitRef="USD">105179</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000938"
      unitRef="USD">567603</us-gaap:DeferredOfferingCosts>
    <ENVB:PrepaidFranchiseTaxReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000941"
      unitRef="USD">79258</ENVB:PrepaidFranchiseTaxReceivable>
    <ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000944"
      unitRef="USD">145349</ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000947"
      unitRef="USD">1293554</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000948"
      unitRef="USD">708053</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000950">&lt;p id="xdx_804_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_z9SCaXsACTk5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4. &lt;span id="xdx_824_zU9uwK220FDb"&gt;INTANGIBLE ASSETS AND GOODWILL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company performs an annual impairment test at the reporting unit level as of December 31 of each fiscal year. As of December 31, 2022,
the Company&#x2019;s goodwill and intangible assets were fully impaired, and thus no annual impairment test was necessary as of December
31, 2023. The following table provides the Company&#x2019;s goodwill, indefinite and definite lives intangible assets as of December 31,
2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zNA8zJSGKUU" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company&#x2019;s goodwill consisted of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zywzBm3sR0Xd" style="display: none"&gt;SCHEDULE
OF GOODWILL&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated Impairment Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Currency Translation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--GoodwillGross_iS_c20220101__20221231_zrL5hyJCBTck" style="width: 11%; text-align: right" title="Goodwill Gross, Beginning balance"&gt;9,834,855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNS_di_c20220101__20221231_zoA3HbV75zY9" style="width: 11%; text-align: right" title="Accumulated Impairment Losses, Beginning balance"&gt;(8,225,862&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--GoodwillCurrencyTranslation_iS_c20220101__20221231_zsv05uR0T8P7" style="width: 11%; text-align: right" title="Currency Translation, Beginning balance"&gt;(21,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Goodwill_iS_c20220101__20221231_zcXRwm58qzs1" style="width: 11%; text-align: right" title="Goodwill, Beginning balance"&gt;1,587,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Impairment losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--GoodwillImpairmentLossGross_iN_di_c20220101__20221231_zkf3VkHhApy6" style="text-align: right" title="Goodwill Gross, Impairment losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--GoodwillAccumulatedImpairmentLoss_iN_di_c20220101__20221231_zUssTZVnGsp9" style="text-align: right" title="Accumulated Impairment Losses, Impairment losses"&gt;(1,486,060&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--GoodwillCurrencyTranslationImpairmentLoss_iN_di_c20220101__20221231_zl7mHTPCTDti" style="text-align: right" title="Currency Translation, Impairment losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0966"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zsSlcGVeDune" style="text-align: right" title="Goodwill, Impairment losses"&gt;(1,486,060&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loss on currency translation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--GoodwillForeignCurrencyTranslationGainLossGross_c20220101__20221231_zyhq88vbkWy9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill Gross, Loss on currency translation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0970"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_c20220101__20221231_zyyjjekFt9Bh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Impairment Losses, Loss on currency translation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0972"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--GoodwillCurrencyTranslationLoss_c20220101__20221231_zapkiDJnziL9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Currency Translation, Loss on currency translation"&gt;(101,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20220101__20221231_zMG8RIR4uUE4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill, Loss on currency translation"&gt;(101,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--GoodwillGross_iE_c20220101__20221231_zs3uh3Cgc7W3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill Gross, Ending balance"&gt;9,834,855&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNE_di_c20220101__20221231_zIXJIohBvg8a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Impairment Losses, Ending balance"&gt;(9,711,922&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--GoodwillCurrencyTranslation_iE_c20220101__20221231_zW9O3fTzJnD2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Currency Translation, Ending balance"&gt;(122,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zvobPkbyOarl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zxEPfyg8txe4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zUeFBNUXA8mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company&#x2019;s indefinite lived intangible assets consisted of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zWEh1BmzLMM6" style="display: none"&gt;SCHEDULE
OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Indefinite lived intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iS_d0_c20220101__20221231_zYcj6o314Pg" style="width: 16%; text-align: right" title="Balance, Indefinite lived intangible assets"&gt;6,375,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Impairment losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetImpairmentCharges_iN_di_c20220101__20221231_z8wLJAfYqT8g" style="text-align: right" title="Impairment losses"&gt;(5,967,602&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Loss on currency translation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20220101__20221231_z1veDDOEjT78" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loss on currency translation"&gt;(407,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iE_c20220101__20221231_z7LKtTyUhh1h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Balance, Indefinite lived intangible assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0994"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2023 and 2022, the definite lived intangible assets consisted of: &#160; &#160; &#160; &#160;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; width: 80%"&gt;Definite lived intangible assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 16%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20220101__20221231_ziSpokWclQNl" style="text-align: right" title="Balance, Definite lived intangible assets"&gt;548,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20220101__20221231_zSxeeR1NJHi1" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(168,750&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20230101__20231231_zoS9i0Nplzqe" style="text-align: right"&gt;379,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20231231_zNNExnK3q2ec" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization"&gt;(168,754&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20230101__20231231_zIT0j5Uxijbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, Definite lived intangible assets"&gt;210,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zXWcVfQneWi8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
identified definite lived intangible assets, amortization expense amounted to $&lt;span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zk2p8bhGkqR9" title="Intangible assets, amortization expense"&gt;168,754&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zyBCbH7OAWC" title="Intangible assets, amortization expense"&gt;168,750&lt;/span&gt; during the years ended December 31,
2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zqb59wU0hIE9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company amortizes definite lived intangible assets on a&#x202f;straight-line basis over their estimated useful lives. Amortization expense
of identified intangible assets based on the carrying amount as of December 31, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zzVXkKpEcQPl" style="display: none"&gt;SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231_zkDZQgKYy2ck"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzC0U_zTyAhx8Iihm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;168,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzC0U_zWOFDxfsxxFe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;42,182&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzC0U_zC9XwcaOuro6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finite lived assets amortization
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;210,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zPK37hZCJdad" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000952">&lt;p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zNA8zJSGKUU" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company&#x2019;s goodwill consisted of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zywzBm3sR0Xd" style="display: none"&gt;SCHEDULE
OF GOODWILL&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated Impairment Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Currency Translation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--GoodwillGross_iS_c20220101__20221231_zrL5hyJCBTck" style="width: 11%; text-align: right" title="Goodwill Gross, Beginning balance"&gt;9,834,855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNS_di_c20220101__20221231_zoA3HbV75zY9" style="width: 11%; text-align: right" title="Accumulated Impairment Losses, Beginning balance"&gt;(8,225,862&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--GoodwillCurrencyTranslation_iS_c20220101__20221231_zsv05uR0T8P7" style="width: 11%; text-align: right" title="Currency Translation, Beginning balance"&gt;(21,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Goodwill_iS_c20220101__20221231_zcXRwm58qzs1" style="width: 11%; text-align: right" title="Goodwill, Beginning balance"&gt;1,587,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Impairment losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--GoodwillImpairmentLossGross_iN_di_c20220101__20221231_zkf3VkHhApy6" style="text-align: right" title="Goodwill Gross, Impairment losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--GoodwillAccumulatedImpairmentLoss_iN_di_c20220101__20221231_zUssTZVnGsp9" style="text-align: right" title="Accumulated Impairment Losses, Impairment losses"&gt;(1,486,060&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--GoodwillCurrencyTranslationImpairmentLoss_iN_di_c20220101__20221231_zl7mHTPCTDti" style="text-align: right" title="Currency Translation, Impairment losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0966"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zsSlcGVeDune" style="text-align: right" title="Goodwill, Impairment losses"&gt;(1,486,060&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loss on currency translation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--GoodwillForeignCurrencyTranslationGainLossGross_c20220101__20221231_zyhq88vbkWy9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill Gross, Loss on currency translation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0970"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_c20220101__20221231_zyyjjekFt9Bh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Impairment Losses, Loss on currency translation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0972"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--GoodwillCurrencyTranslationLoss_c20220101__20221231_zapkiDJnziL9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Currency Translation, Loss on currency translation"&gt;(101,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20220101__20221231_zMG8RIR4uUE4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill, Loss on currency translation"&gt;(101,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--GoodwillGross_iE_c20220101__20221231_zs3uh3Cgc7W3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill Gross, Ending balance"&gt;9,834,855&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNE_di_c20220101__20221231_zIXJIohBvg8a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Impairment Losses, Ending balance"&gt;(9,711,922&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--GoodwillCurrencyTranslation_iE_c20220101__20221231_zW9O3fTzJnD2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Currency Translation, Ending balance"&gt;(122,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zvobPkbyOarl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:GoodwillGross
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000954"
      unitRef="USD">9834855</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000956"
      unitRef="USD">8225862</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <ENVB:GoodwillCurrencyTranslation
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000958"
      unitRef="USD">-21359</ENVB:GoodwillCurrencyTranslation>
    <us-gaap:Goodwill
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000960"
      unitRef="USD">1587634</us-gaap:Goodwill>
    <ENVB:GoodwillAccumulatedImpairmentLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000964"
      unitRef="USD">1486060</ENVB:GoodwillAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000968"
      unitRef="USD">1486060</us-gaap:GoodwillImpairmentLoss>
    <ENVB:GoodwillCurrencyTranslationLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000974"
      unitRef="USD">-101574</ENVB:GoodwillCurrencyTranslationLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000976"
      unitRef="USD">-101574</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000978"
      unitRef="USD">9834855</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000980"
      unitRef="USD">9711922</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <ENVB:GoodwillCurrencyTranslation
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000982"
      unitRef="USD">-122933</ENVB:GoodwillCurrencyTranslation>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000986">&lt;p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zUeFBNUXA8mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company&#x2019;s indefinite lived intangible assets consisted of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zWEh1BmzLMM6" style="display: none"&gt;SCHEDULE
OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Indefinite lived intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iS_d0_c20220101__20221231_zYcj6o314Pg" style="width: 16%; text-align: right" title="Balance, Indefinite lived intangible assets"&gt;6,375,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Impairment losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetImpairmentCharges_iN_di_c20220101__20221231_z8wLJAfYqT8g" style="text-align: right" title="Impairment losses"&gt;(5,967,602&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Loss on currency translation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20220101__20221231_z1veDDOEjT78" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loss on currency translation"&gt;(407,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iE_c20220101__20221231_z7LKtTyUhh1h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Balance, Indefinite lived intangible assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0994"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2023 and 2022, the definite lived intangible assets consisted of: &#160; &#160; &#160; &#160;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; width: 80%"&gt;Definite lived intangible assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 16%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20220101__20221231_ziSpokWclQNl" style="text-align: right" title="Balance, Definite lived intangible assets"&gt;548,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20220101__20221231_zSxeeR1NJHi1" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(168,750&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20230101__20231231_zoS9i0Nplzqe" style="text-align: right"&gt;379,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20231231_zNNExnK3q2ec" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization"&gt;(168,754&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20230101__20231231_zIT0j5Uxijbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, Definite lived intangible assets"&gt;210,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000988"
      unitRef="USD">6375492</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000990"
      unitRef="USD">5967602</us-gaap:AssetImpairmentCharges>
    <us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000992"
      unitRef="USD">-407890</us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000996"
      unitRef="USD">548436</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000997"
      unitRef="USD">168750</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000998"
      unitRef="USD">379686</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001000"
      unitRef="USD">168754</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001002"
      unitRef="USD">210932</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001004"
      unitRef="USD">168754</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001006"
      unitRef="USD">168750</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001008">&lt;p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zqb59wU0hIE9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company amortizes definite lived intangible assets on a&#x202f;straight-line basis over their estimated useful lives. Amortization expense
of identified intangible assets based on the carrying amount as of December 31, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zzVXkKpEcQPl" style="display: none"&gt;SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231_zkDZQgKYy2ck"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzC0U_zTyAhx8Iihm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;168,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzC0U_zWOFDxfsxxFe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;42,182&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzC0U_zC9XwcaOuro6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finite lived assets amortization
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;210,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001010"
      unitRef="USD">168750</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001012"
      unitRef="USD">42182</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001014"
      unitRef="USD">210932</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001016">&lt;p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXXYZu4HU6c9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5. &lt;span id="xdx_825_zaytaYVEUUm6"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVVGahhpzvNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following assets which are located in Calgary, Canada and placed in service by Enveric Biosciences Canada,
Inc. (&#x201c;EBCI&#x201d;), with all amounts translated into U.S. dollars:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zxF5quYUvBz1" style="display: none"&gt;SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zzCZHNQZFxvd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zvLPGndd0db5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zp4aNQNMWWri" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;836,709&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;831,123&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_z9JhYXtwNtFl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment and leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zPgLn2Oc6tvg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(357,711&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(178,775&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zXt2mt3bMunh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net of accumulated depreciation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;507,377&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;677,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z2MshGQnoZt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense was $&lt;span id="xdx_90D_eus-gaap--Depreciation_c20230101__20231231_zaY42joe7YG7" title="Depreciation"&gt;175,228&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--Depreciation_c20220101__20221231_z0vGnuRplH4c" title="Depreciation"&gt;159,160&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001018">&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVVGahhpzvNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following assets which are located in Calgary, Canada and placed in service by Enveric Biosciences Canada,
Inc. (&#x201c;EBCI&#x201d;), with all amounts translated into U.S. dollars:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zxF5quYUvBz1" style="display: none"&gt;SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zzCZHNQZFxvd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zvLPGndd0db5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zp4aNQNMWWri" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;836,709&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;831,123&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_z9JhYXtwNtFl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment and leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zPgLn2Oc6tvg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(357,711&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(178,775&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zXt2mt3bMunh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net of accumulated depreciation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;507,377&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;677,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_LabEquipmentMember"
      decimals="0"
      id="Fact001020"
      unitRef="USD">836709</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_LabEquipmentMember"
      decimals="0"
      id="Fact001021"
      unitRef="USD">831123</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember"
      decimals="0"
      id="Fact001023"
      unitRef="USD">28379</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember"
      decimals="0"
      id="Fact001024"
      unitRef="USD">25137</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001026"
      unitRef="USD">357711</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001027"
      unitRef="USD">178775</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001029"
      unitRef="USD">507377</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001030"
      unitRef="USD">677485</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001032"
      unitRef="USD">175228</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001034"
      unitRef="USD">159160</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001036">&lt;p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zBePLueQV7ve" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6. &lt;span id="xdx_828_zbdmk1JonaWe"&gt;ACCRUED LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zEC0nxuwQfD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and December 31, 2022, the accrued liabilities of the Company consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_z2CYiR69qip9" style="display: none"&gt;SCHEDULE
OF ACCRUED LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zIdUdedJs0bc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_ztfCG22lB8m6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_zzTIaLc6TzX6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Product development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;139,981&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;195,104&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zxArVFIfjro7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued salaries, wages, and bonuses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,175,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zmvujpsSA58g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;584,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zGJabHMfEVH5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued restructuring costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_z6PA2plzHgPe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued franchise taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1053"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zTXa5jxvaF64" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Patent costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;251,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zHLlMDwwvI65" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,075,643&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,705,655&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zfLwpnfUgaDl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001038">&lt;p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zEC0nxuwQfD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and December 31, 2022, the accrued liabilities of the Company consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_z2CYiR69qip9" style="display: none"&gt;SCHEDULE
OF ACCRUED LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zIdUdedJs0bc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_ztfCG22lB8m6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_zzTIaLc6TzX6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Product development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;139,981&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;195,104&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zxArVFIfjro7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued salaries, wages, and bonuses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,175,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zmvujpsSA58g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;584,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zGJabHMfEVH5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued restructuring costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_z6PA2plzHgPe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued franchise taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1053"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zTXa5jxvaF64" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Patent costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;251,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zHLlMDwwvI65" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,075,643&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,705,655&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ENVB:AccruedProductDevelopmentCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001040"
      unitRef="USD">139981</ENVB:AccruedProductDevelopmentCost>
    <ENVB:AccruedProductDevelopmentCost
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001041"
      unitRef="USD">195104</ENVB:AccruedProductDevelopmentCost>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001043"
      unitRef="USD">8889</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001044"
      unitRef="USD">1175963</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001046"
      unitRef="USD">584810</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001047"
      unitRef="USD">83255</us-gaap:AccruedProfessionalFeesCurrent>
    <ENVB:AccruedRestructuringCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001049"
      unitRef="USD">301645</ENVB:AccruedRestructuringCosts>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001052"
      unitRef="USD">22318</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001055"
      unitRef="USD">18000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001056"
      unitRef="USD">251333</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001058"
      unitRef="USD">1075643</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001059"
      unitRef="USD">1705655</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001061">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zDwGAQBPdjdj" style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7. &lt;span id="xdx_821_zPkNv6EA0ckj"&gt;SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Authorized
Capital&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--CommonStockVotingRights_c20230101__20231231_zyP7HBT2y9O4" title="Common stock voting rights"&gt;The
holders of the Company&#x2019;s common stock are entitled to one vote per share&lt;/span&gt;. Holders of common stock are entitled to receive ratably
such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Upon the liquidation, dissolution,
or winding up of the Company, holders of common stock are entitled to share ratably in all assets of the Company that are legally available
for distribution. As of December 31, 2023, &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_z3kEFDBFbKC" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt; shares of common stock and &lt;span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zBU2P1eYPMuf" title="Preferred stock, shares authorized"&gt;20,000,000&lt;/span&gt; shares of Preferred Stock were authorized
under the Company&#x2019;s articles of incorporation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Equity
Distribution Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 1, 2023, the Company entered into the Distribution Agreement, with Canaccord, pursuant to which the Company may offer and sell
from time to time, through Canaccord as sales agent and/or principal, shares of common stock of the Company, par value $&lt;span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zzPld5phABZh" title="Common stock, par value"&gt;0.01&lt;/span&gt; per share
having an aggregate offering price of up to $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zV61LRnnxsQj" title="Common stock, offering price"&gt;10.0&lt;/span&gt; million. Due to the offering limitations applicable to the Company and in accordance
with the terms of the Distribution Agreement, the Company may offer common stock having an aggregate gross sales price of up to $&lt;span id="xdx_900_ecustom--SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zFsQ1hTkiWgf" title="Aggregate gross sales price"&gt;2,392,514&lt;/span&gt;
pursuant to the prospectus supplement dated September 1, 2023 (the &#x201c;Prospectus Supplement&#x201d;). Subject to the terms and conditions
of the Distribution Agreement, Canaccord may sell the common stock by any method permitted by law deemed to be an &#x201c;at-the-market
offering&#x201d;. The Company will pay Canaccord a commission equal to &lt;span id="xdx_909_ecustom--CommissionPercentage_pid_dp_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zXJHXmkSZzdf" title="Commission percentage"&gt;3.0&lt;/span&gt;% of the gross sales price of the common stock sold through
Canaccord under the Distribution Agreement and has also agreed to reimburse Canaccord for certain expenses. The Company may also sell
common stock to Canaccord as principal for Canaccord&#x2019;s own account at a price agreed upon at the time of sale. Any sale of common stock to Canaccord as principal would be pursuant to the terms of a separate terms agreement between the Company and Canaccord.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Inducement Letters (as defined below within this Note 7) prohibits the Company from entering into any variable rate transaction as defined
in the Inducement Letters, including the issuance of (1) any variable priced debt or equity securities or (2) transactions whereby the
Company may issue securities at a future determined price, such as through an at-the-market offering or an equity line of credit. The
variable rate transaction restriction expires after six-month from the closing date of December 28, 2023 for the Inducement Letters for
an issuance through an at-the-market offering, and one-year for the remaining variable rate transactions. Subsequent to December 31, 2023, the limitation on the at-the-market offering was waived. See Note 12.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Lincoln
Park Equity Line&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 3, 2023, the Company entered into a Purchase Agreement and a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;),
with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $&lt;span id="xdx_904_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zOOeNanEtQna" title="Purchase committment"&gt;10.0&lt;/span&gt; million of the Company&#x2019;s common stock,
par value $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zHrjprwA7De7" title="Common stock, par value"&gt;0.01&lt;/span&gt; per share subject to certain limitations and satisfaction of the conditions set forth in the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln
Park, and Lincoln Park is obligated to purchase up to $&lt;span id="xdx_90A_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zs6V54OtPzKd" title="Purchase committment"&gt;10.0&lt;/span&gt; million of the Company&#x2019;s common stock (the &#x201c;Purchase Shares&#x201d;).
However, such sales of common stock by the Company, if any, will be subject to important limitations set forth in the Purchase Agreement,
including limitations on number of shares that may be sold. Sales may occur from time to time, at the Company&#x2019;s sole discretion,
over the 24-month period commencing on the date that the conditions to Lincoln Park&#x2019;s purchase obligation set forth in the Purchase
Agreement are satisfied, including that a registration statement on Form S-1 covering the resale of the shares of our common stock that
have been and may be issued to Lincoln Park under the Purchase Agreement, which the Company has filed with the SEC pursuant to the Registration
Rights Agreement, is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Because
the purchase price per share to be paid by Lincoln Park for the shares of common stock that we may elect to sell to Lincoln Park under
the Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock at the time we elect to sell shares to
Lincoln Park pursuant to the Purchase Agreement, if any, it is not possible for us to predict the number of shares of Common Stock that
we will sell to Lincoln Park under the Purchase Agreement, the purchase price per share that Lincoln Park will pay for shares purchased
from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by Lincoln Park under
the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company has issued no shares of common stock through the Equity Line or the Distribution Agreement.
The Company had capitalized deferred offering costs of $&lt;span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zKz2gddhOKWe" title="Deferred offering costs"&gt;567,603&lt;/span&gt; related to establishing the Distribution Agreement with Canaccord and
the Purchase Agreement with Lincoln Park and no reductions to additional paid in capital. Of this amount, $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zPkUqxA8u6Vg"&gt;255,107&lt;/span&gt; represents the fair
value of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDJ8hpMn6Hwc"&gt;139,403&lt;/span&gt; shares of common stock issued to Lincoln Park as consideration for its commitment under the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock Activity&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023 a total of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znp99CIqxNdk" title="Issuance of common shares in exchange for RSU conversions, shares"&gt;103,641&lt;/span&gt; shares of common stock were issued pursuant to the conversion of restricted stock
units. During the year ended December 31, 2022, a total of &lt;span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVVRjjZ5Exei" title="Stock issued during period conversion of restricted stock award"&gt;1,223&lt;/span&gt; and &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9r9oyNeumEg"&gt;899&lt;/span&gt; shares of common stock were issued pursuant to the conversion
of restricted stock awards and restricted stock units, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 15, 2022, the Company completed a public offering of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220213__20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zntTgZMDrl9k" title="Public offering"&gt;400,000&lt;/span&gt; shares of common stock and warrants to purchase up to &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTUe4kaUETye" title="Warrants to purchase"&gt;400,000&lt;/span&gt; shares
of common stock for gross proceeds of approximately $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220213__20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6jFxLXor71f" title="Proceeds from common stock"&gt;10.0&lt;/span&gt; million, before deducting underwriting discounts and commissions and other
offering expenses. A.G.P./Alliance Global Partners acted as sole book-running manager for the offering. In addition, Enveric granted
the underwriter a 45-day option to purchase up to an additional &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zq0ZVhdNZHnc" title="Additional shares of common stock purchase"&gt;60,000&lt;/span&gt; shares of common stock and/or warrants to purchase up to an additional
&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zxA8e1kW3047" title="Additional warrants purchase"&gt;60,000&lt;/span&gt; shares of common stock at the public offering price, which the underwriter has partially exercised for warrants to purchase up
to &lt;span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zX7UOxhPkFLc" title="Exercised of warrants"&gt;60,000&lt;/span&gt; shares of common stock. At closing, Enveric received net proceeds from the offering of approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zcX0o9TCANtj" title="Net proceeds from offering"&gt;9.1&lt;/span&gt; million, after deducting
underwriting discounts and commissions and estimated offering expenses with $&lt;span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zwY93X07Ejgd" title="Offering expenses"&gt;5.8&lt;/span&gt; million allocated to equity, $&lt;span id="xdx_905_ecustom--WarrantLiability_iI_pn5n6_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zlHQkuaWT4Ck" title="Warrant liability"&gt;3.6&lt;/span&gt; million to warrant
liability and the remaining $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zNb2KWCaTJi7" title="Warrant expenses"&gt;0.3&lt;/span&gt; million recorded as an expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2022, the Company entered into a securities purchase agreement (the &#x201c;Registered Direct Securities Purchase Agreement&#x201d;)
with an institutional investor for the purchase and sale of &lt;span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zq67jFtpMDv2" title="Sale of stock"&gt;116,500&lt;/span&gt; shares of the Company&#x2019;s common stock, pre-funded warrants to
purchase up to &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zjWAalEsmIM2" title="Purchase of common stock"&gt;258,500&lt;/span&gt; shares of common stock (the &#x201c;RD Pre-Funded Warrants&#x201d;), and unregistered preferred investment options
(the &#x201c;RD Preferred Investment Options&#x201d;) to purchase up to &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_z19ToUBw98Gi" title="Issued shares"&gt;375,000&lt;/span&gt; shares of common stock (the &#x201c;RD Offering&#x201d;).
The gross proceeds from the RD Offering were approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zmk1U6vmH2Ck" title="Proceeds from issuance of warrants"&gt;3,000,000&lt;/span&gt;. Subject to certain ownership limitations, the RD Pre-Funded Warrants
became immediately exercisable at an exercise price equal to $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zsYLFes8tIh5" title="Share price"&gt;0.0001&lt;/span&gt; per share of common stock. On August 3, 2022, all of the issued
RD Pre-Funded Warrants were exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Concurrently
with the RD Offering, the Company entered into a securities purchase agreement (the &#x201c;PIPE Securities Purchase Agreement&#x201d;)
with institutional investors for the purchase and sale of &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zo2AVAUxuI0k" title="Sale of stock"&gt;116,000&lt;/span&gt; shares of common stock, pre-funded warrants to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zjS5ykHZolGe" title="Purchase of common stock"&gt;509,000&lt;/span&gt;
shares of common stock (the &#x201c;PIPE Pre-Funded Warrants&#x201d;), and preferred investment options (the &#x201c;PIPE Preferred Investment
Options&#x201d;) to purchase up to &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zdO9qNgWdtvg" title="Issued shares"&gt;625,000&lt;/span&gt; shares of the common stock in a private placement (the &#x201c;PIPE Offering&#x201d;). The gross
proceeds from the PIPE Offering were approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zcihzISSJtPf" title="Proceeds from issuance of warrants"&gt;5,000,000&lt;/span&gt;. Subject to certain ownership limitations, the PIPE Pre-Funded Warrants
became immediately exercisable at an exercise price equal to $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zaSq53mrSBkh" title="Share price"&gt;0.0001&lt;/span&gt; per share of common stock. All of the issued PIPE Pre-Funded Warrants
were exercised on various dates prior to August 18, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
RD Offering and PIPE Offering closed on July 26, 2022, with aggregate gross proceeds of approximately $&lt;span id="xdx_907_eus-gaap--ProceedsFromOtherEquity_pn6n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zFQmF58p6Dzl" title="Proceeds from RD offerings"&gt;8&lt;/span&gt; million. The aggregate net proceeds
from the offerings, after deducting the placement agent fees and other estimated offering expenses, were approximately $&lt;span id="xdx_90D_ecustom--PaymentsOfStockIssuanceCost_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zUK66EqEgCdh" title="Offerings costs"&gt;7.1&lt;/span&gt; million,
with $&lt;span id="xdx_90F_ecustom--PaymentsOfAllocatedEquity_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_z7bhCebODrmj" title="Payments of allocated equity"&gt;3.2&lt;/span&gt; million allocated to equity, $&lt;span id="xdx_90E_ecustom--PaymentsOfInvestmentOptionLiability_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zSkUFLNUdin9" title="Payments of investment option liability"&gt;4.3&lt;/span&gt; million to investment option liability, and the remaining $&lt;span id="xdx_901_ecustom--PaymentsOfStockIssuanceCostsRecordedExpense_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zmXneHwiVHlh" title="Payments of stock issuance costs recorded expense"&gt;0.4&lt;/span&gt; million recorded as an expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Amendment
to 2020 Long-Term Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 3, 2022, our board of directors (&#x201c;Board&#x201d;) adopted the First Amendment (the &#x201c;Plan Amendment&#x201d;) to the Enveric
Biosciences, Inc. 2020 Long-Term Incentive Plan (the &#x201c;Incentive Plan&#x201d;) to &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220502__20220503_zZJBKbAFKI05" title="Incentive plan description"&gt;(i) increase the aggregate number of shares available
for the grant of awards by 146,083 shares to a total of 200,000 shares, and (ii) add an &#x201c;evergreen&#x201d; provision whereby the
number of shares authorized for issuance pursuant to awards under the Incentive Plan will be automatically increased on the first trading
date immediately following the date the Company issues any share of common stock (defined below) to any person or entity, to the extent
necessary so that the number of shares of the Company&#x2019;s common stock authorized for issuance under the Incentive Plan will equal
the greater of (x) 200,000 shares, and (y) 15% of the total number of shares of the Company&#x2019;s common stock outstanding as of such
issuance date (the &#x201c;Evergreen Provision&#x201d;). The Plan Amendment was approved by the Company&#x2019;s shareholders at a special
meeting of the Company&#x2019;s shareholders held on July 14, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 2, 2023, the shareholders approved the amendments to the 2020 Long-Term Incentive Plan, which was approved by the Board on August
8, 2023 (the &#x201c;Amended Incentive Plan&#x201d;). The Amended Incentive Plan (i) increased the number of authorized shares reserved
for issuance under the Amended Incentive Plan to a maximum of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231102__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zlmk1poNjGA3" title="Authorized shares reserved"&gt;350,000&lt;/span&gt;, subject to adjustment, and (ii) removed the Evergreen Provision
implemented in the Plan Amendment. As of December 31, 2023, the total number of shares available for grant under the Incentive Plan was
&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zwU3zwqNsFga" title="Shares available ofr grant"&gt;107,453&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8YtSqYx16Ag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity under the Company&#x2019;s incentive plan for the years ended December 31, 2023 and 2022 is presented
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zu3hZq6igFI4" style="display: none"&gt;SCHEDULE OF STOCK OPTION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zlfachWgXyo4" style="width: 9%; text-align: right" title="Number of Shares, Outstanding at beginning"&gt;23,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zBHipcjjafJb" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning"&gt;79.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_z3KUiEblBS32" style="width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning"&gt;103.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zc6QHY3pugra" title="Weighted Average Remaining Contractual Term (years)"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zWsvXq7xXltk" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Outstanding"&gt;34,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zUwzel36BOnk" style="text-align: right" title="Number of Shares, Granted"&gt;25,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z5kJ7HfnP6pf" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;3.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znh44xkmKi5a" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;
                                                                          &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zMwQE9ty7cd5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, forfeited"&gt;(1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zODjjvTnFKVd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, forfeited"&gt;175.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znQpNtug7kVc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;140.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_z8a4TyNt1Z85" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Outstanding at beginning"&gt;48,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zg98NijbXZh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning"&gt;37.05&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zIZUyOqQArtj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning"&gt;44.82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5ShG7pIcpf5" title="Weighted Average Remaining Contractual Term (years)"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zfbN7fLAAKpi" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1180"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zvXECFVHHTLj" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1182"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231_z4H5Vu8Biz83" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, forfeited"&gt;(18,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zV15MinWPaA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, forfeited"&gt;3.07&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zMCYL5FZJYyj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;2.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_z0vJtB0G1Poe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Outstanding at end"&gt;30,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zTWGbA0Nvv66" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at end"&gt;57.17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zUfoA887Azb9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at end"&gt;77.22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_za3lss46TUsl" title="Weighted average remaining contractual term, outstanding balance"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231_zN4jPjsgp21g" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable shares at end"&gt;25,677&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_ziRZaH57gja8" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable weighted average price at end"&gt;64.45&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zx8Su3tDvHy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, exercisable"&gt;88.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z4vf0GnUomE9" title="Weighted average remaining contractual term, exercisable"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zXYm0PO3CNlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEutDXJS5oV9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
granted during the years ended December 31, 2022 were valued using the Black Scholes model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zR9P2uQxAng7" style="display: none"&gt;SCHEDULE OF STOCK OPTION ASSUMPTION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zj6iPtU5AHta" title="Term (years)"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20221231_zlKRFdSy2ve2" title="Stock price"&gt;3.07&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231_zX3WUGe0AYX2" title="Exercise price"&gt;3.07&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z5lvwkDplOW2" title="Dividend yield"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_zXidb2KriXN1" title="Expected volatility"&gt;112.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_za8yif42LrIb" title="Risk free interest rate"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zSkXtPvxBb04" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
above assumptions are determined by the Company as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
    price &#x2013; Based on closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    average risk-free interest rate &#x2014; Based on the daily yield curve rates for U.S. Treasury obligations with maturities, which
    correspond to the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield &#x2014; The Company has not paid any dividends on common stock since its inception and does not anticipate paying dividends
    on its common stock in the foreseeable future.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility &#x2014; Based on the historical volatility of comparable companies in a similar industry.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term &#x2014; The Company has had no stock options exercised since inception. The expected option term represents the period that
    stock-based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin (&#x201c;SAB&#x201d;)
    No. 107, Share-Based Payment, which averages an award&#x2019;s weighted-average vesting period and expected term for &#x201c;plain
    vanilla&#x201d; share options.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s stock based compensation expense, recorded within general and administrative expense, related to stock options for the
years ended December 31, 2023 and 2022 was $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zt08RojEH0Xh" title="General and administrative expense"&gt;156,075&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXVmi6fVuBdb" title="General and administrative expense"&gt;180,042&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the Company had $&lt;span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za7OVdVnQO29" title="Unamortized stock option expense"&gt;84,774&lt;/span&gt; in unamortized stock option expense, which will be recognized over a weighted average period
of &lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zN1HXhFc7nl6"&gt;1.00&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Restricted
Stock Awards&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the Company recorded $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoynQV9JMUSl" title="Stock-based compensation expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWmTrUjkTZp7" title="Stock-based compensation expense"&gt;24,363&lt;/span&gt;, respectively, in stock-based compensation expense within
general and administrative expense, related to restricted stock awards. There were no RSA grants during the years ended December 31,
2023 and 2022. As of December 31, 2022, there were no unvested RSA shares. As of December 31, 2023, there were no unamortized stock-based
compensation costs related to restricted share awards. During the year ended December 31, 2023 the Company settled the &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1bnkYOkliK7" title="Common stock , shares issued restricted stock awards"&gt;708&lt;/span&gt; vested and
unissued shares (as of December 31, 2022) for cash of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLFTi9qtv6r6" title="Unissued shares for cash"&gt;14,250&lt;/span&gt;. There are &lt;span id="xdx_900_ecustom--NumberOfVestedAndUnissuedShares_iI_do_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2mtX7G3wVJd" title="Number of vested and unissued shares"&gt;no&lt;/span&gt; restricted stock awards as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Issuance
of Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zeKrkjRh7dje" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activity in restricted stock units was as follows for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_zOnUfbNkVcx6" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average&lt;br/&gt;
 fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Non-vested at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEDhw9y1hxZb" style="width: 16%; text-align: right" title="Number of shares, Non-vested beginning"&gt;62,013&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaILPTwaljuj" style="width: 16%; text-align: right" title="Weighted average fair value, Non-vested beginning"&gt;126.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zirQtPdDJsZi" style="text-align: right" title="Number of shares, Granted"&gt;37,445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUYL7MfjSel" style="text-align: right" title="Weighted average fair value, Granted"&gt;33.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxzxsA9U3MM5" style="text-align: right" title="Number of shares, Forfeited"&gt;(26,772&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoUqJoFo0SPa" style="text-align: right" title="Weighted average fair value, Forfeited"&gt;79.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCGHiACcoei3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Vested"&gt;(8,633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmbvrrJRPdT2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average fair value, Vested"&gt;130.55&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Non-vested at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3a70kwxF3V2" style="text-align: right" title="Number of shares, Non-vested beginning"&gt;64,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLrYNbURiDu7" style="text-align: right" title="Weighted average fair value, Non-vested beginning"&gt;92.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znLFWlg2TGh1" style="text-align: right" title="Number of shares, Granted"&gt;182,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfBGTV22anXd" style="text-align: right" title="Weighted average fair value, Granted"&gt;2.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2mJgukWkvO9" style="text-align: right" title="Number of shares, Forfeited"&gt;(43,426&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxHfzIDptRA4" style="text-align: right" title="Weighted average fair value, Forfeited"&gt;25.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNyxeKRhEEJ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested"&gt;(62,636&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrqPsZk6qtR7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average fair value, Vested"&gt;19.80&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-vested at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIJwWAqEmkx2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, non-vested ending"&gt;140,491&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJYYLsJCm9Q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average fair value, Non-vested ending"&gt;28.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zBLyP5ujOgX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the Company recorded $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaktYeVWKPm1" title="Stock based compensation, expenses"&gt;1,994,085&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJPvzY0F5oTg" title="Stock based compensation, expenses"&gt;2,416,266&lt;/span&gt;, respectively, in stock-based compensation
expense related to restricted stock units, which is a component of both general and administrative and research and development expenses
in the consolidated statement of operations and comprehensive loss. As of December 31, 2023, the Company had unamortized stock-based
compensation costs related to restricted stock units of $&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRBdOX0w06He" title="Stock-based compensation, unamortized"&gt;2,021,021&lt;/span&gt; which will be recognized over a weighted average period of &lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyktIo5qhnf1" title="Weighted average period"&gt;1.9&lt;/span&gt; years
and unamortized stock-based costs related to restricted stock units which will be recognized upon achievement of specified milestones.
As of December 31, 2023, &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxLDWxSkxrQi" title="Common stock vested restricted stock units"&gt;20,848&lt;/span&gt; restricted stock units are vested without shares of common stock being issued, with all of these shares
due as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z3ex9jdX7Hgd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s recognition of stock-based compensation for restricted stock units for the following periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zwVhDWsRp68h" style="display: none"&gt;SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zPQew5K1VjCh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zCbffNV9umPf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense for RSUs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zSOwB6VgYaZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,085,791&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,389,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfdu3M9qPMBi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;908,294&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,026,907&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zcduJChWGdHc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,994,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,416,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_zgOmbiRFAoQe" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock-based compensation expense for RSUs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,994,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,416,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A3_zs23cTYn7Nd8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants
and Preferred Investment Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zCwAZnLGDADf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about shares issuable under warrants outstanding at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_z8ZFdYdYVEvf" style="display: none"&gt;SCHEDULE
OF WARRANTS OUTSTANDING&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrant shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTfdpCfJmiBi" style="width: 11%; text-align: right" title="Warrant shares outstanding at beginning"&gt;195,463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3fi1daRxsLi" style="width: 11%; text-align: right" title="Weighted average exercise Price, Outstanding at beginning"&gt;131.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z54Yv7nvu7W9" title="Weighted average remaining life, Outstanding"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVKnQZX3WT3" style="width: 11%; text-align: right" title="Intrinsic Value, Outstanding beginning"&gt;801,024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoHdcQoSVWS2" style="text-align: right" title="Warrant shares outstanding, Issued"&gt;1,227,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq4CkgY3nmbb" style="text-align: right" title="Weighted average exercise price, Issued"&gt;10.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoCiirvRQcd1" style="text-align: right" title="Warrant shares outstanding, Exercised"&gt;(767,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchanged for common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPYXssDy289d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchanged for common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1315"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziP88dUalGL3" style="text-align: right" title="Warrant shares outstanding at beginning"&gt;655,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgN4PA0LOL52" style="text-align: right" title="Weighted average exercise Price, Outstanding at beginning"&gt;58.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNat7GYdCief" title="Weighted average remaining life, Outstanding"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zif7UujrkK8h" style="text-align: right" title="Intrinsic Value, Outstanding beginning"&gt;5,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF9wfK13hB3a" style="text-align: right" title="Warrant shares outstanding, Issued"&gt;2,311,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzzaBhPs6fcj" style="text-align: right" title="Weighted average exercise price, Issued"&gt;1.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFg4HAtR0Uo3" style="text-align: right" title="Warrant shares outstanding, Exercised"&gt;(122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjBdEmkvsgQ3" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;1.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWsO7MCiRq3g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant shares outstanding, Forfeited"&gt;(45,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0n5xO3Jttvj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Forfeited"&gt;111.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG0zfcvh1EB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant shares outstanding at end"&gt;2,799,213&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVykSWQShf2c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise Price, Outstanding at end"&gt;11.79&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo234JlDnvN9" title="Weighted average remaining life, Outstanding"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TQKNs9s47l" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant shares outstanding, Exercisable"&gt;2,799,213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxF5xDyqxuv9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable"&gt;11.79&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziBL756oG0Sj" title="Weighted average remaining life, Exercisable"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znZZJLvwpd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1349"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A4_zPsrElVeMZDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 11, 2022, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;)
with A.G.P./Alliance Global Partners (the &#x201c;Underwriter&#x201d;). Pursuant to the Underwriting Agreement, the Company agreed to sell,
in a firm commitment offering, &lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220210__20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBeMIQlREhB9" title="Sale of stock"&gt;400,000&lt;/span&gt; shares of the Company&#x2019;s common stock and accompanying warrants to purchase up to an aggregate
of &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwRjsuVzK6ll" title="Warrant exercises, shares"&gt;400,000&lt;/span&gt; shares of its common stock (&#x201c;February 2022 Warrants&#x201d;), as well as up to &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220210__20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4yI7NRdWlc6" title="Additional shares of common stock"&gt;60,000&lt;/span&gt; additional shares of common stock
and/or warrants to purchase an aggregate of up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zCnVO8Hipssf" title="Warrant exercises, shares"&gt;60,000&lt;/span&gt; shares of its common stock that may be purchased by the Underwriter pursuant
to a 45-day option granted to the Underwriter by the Company (the &#x201c;Offering&#x201d;). Each share of common stock was sold together
with a common warrant to purchase one share of common stock, at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt7SQbdnlyZ9" title="Warrant, exercise price"&gt;27.50&lt;/span&gt; per share. Such common warrants were immediately
exercisable and will expire five years from the date of issuance. There is not expected to be any trading market for the common warrants
issued in the Offering. The combined public offering price of each share of common stock and accompanying common warrant sold in the Offering
was $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUsxAEI45Quk" title="Sale of stock, price per share"&gt;25.00&lt;/span&gt;. On February 14, 2022, the Underwriter exercised its option to purchase an additional &lt;span id="xdx_905_ecustom--ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_iI_c20220214__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5i9uo6XMQy" title="Purchase of additional warrants"&gt;60,000&lt;/span&gt; warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Registered Direct (&#x201c;RD&#x201d;) Offering and the Private Investment in Public Entity (&#x201c;PIPE&#x201d;) Offering
entered into on July 22, 2022, the Company entered into Warrant Amendment (the &#x201c;Warrant Amendments&#x201d;) with the investors in
both offerings to amend certain existing warrants to purchase up to an aggregate of &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220722__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zBOpNG8waIyk" title="Purchase of common stock"&gt;122,000&lt;/span&gt; shares of common stock that were previously
issued to the investors, with an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220714__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zphVdaVhW65b" title="Exercise price"&gt;27.50&lt;/span&gt; per share (subsequent to the 1-for-50 reverse stock split that occurred on
July 14, 2022) and expiration date of &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220714__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zgyCnvlpoemb" title="Warrant expiration"&gt;February 15, 2027&lt;/span&gt;. Pursuant to the Warrant Amendments, the previously issued warrants were amended,
effective upon the closing of the offerings, so that the amended warrants have a reduced exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220722__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_znAWYBaoUBq9" title="Exercise price"&gt;7.78&lt;/span&gt; per share and expire
five and one-half years following the closing of the offerings. In connection with this transaction, the Company determined the fair
value of the February 2022 Warrants immediately prior to the Warrant Amendment and the fair value of the amended warrants immediately
after the Warrant Amendment. For the year ended December 31, 2022, the incremental change in fair value was deemed to be $&lt;span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zSNM3dV6YnM1" title="Offerings costs"&gt;251,357&lt;/span&gt;, which was included as equity issuance costs
related to the RD and PIPE financing transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants assumed pursuant to the acquisition of MagicMed contain certain down round features, which were not triggered by the February
2022 and July 2022 public offerings, that would require adjustment to the exercise price upon certain events when the offering price
is less than the stated exercise price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z00XmdXvzoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about investment options outstanding at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zXmcUZK6ggX1" style="display: none"&gt;SCHEDULE
OF WARRANTS  AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Investment options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zEwvcLEoJfDe" style="text-align: right" title="Investment options Outstanding, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1377"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zxaDKk1asuL5" style="text-align: right" title="Weighted average exercise price, Outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1379"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zlJw8znfo0I4" style="text-align: right" title="Intrinsic value, Outstanding beginning"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1381"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; padding-bottom: 1.5pt"&gt;Issued&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zDF48VFSv1A7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Investment options outstanding, Issued"&gt;1,070,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVx10hGW7qx2" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Weighted average exercise price, Issued"&gt;7.93&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zqwHo3jONiyh" style="text-align: right" title="Investment options outstanding, beginning"&gt;1,070,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVu0eC11XHn7" style="text-align: right" title="Weighted average exercise price, Outstanding beginning"&gt;7.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7cYhlQli82i" title="Weighted average remaining life, Outstanding"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zW78kJ5dKbha" style="text-align: right" title="Intrinsic value, Outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1393"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLWd0NriqTJ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Investment options outstanding, Exercised"&gt;(1,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zJbc1b45aUy4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Exercised"&gt;1.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z1lexvtMAU48" style="border-bottom: Black 1.5pt solid; text-align: right" title="Investment options outstanding, end"&gt;70,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z64Vkjb4vBD2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Outstanding end"&gt;10.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zo3u42JYc9hg" title="Weighted average remaining life, Outstanding"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLfLYOEFU04b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic value, Outstanding end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1405"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zSZT9LEs53K1" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment options outstanding, Exercisable"&gt;70,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zaDEqPn9Z6kf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding end"&gt;10.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zyrHBnlcTyT6" title="Weighted average remaining life, Exercisable"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zhirJurCktSd" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1413"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zN7RQXnULVth" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Registered Direct Securities Purchase Agreement the Company issued unregistered preferred investment options to purchase
up to &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zZV69Zq59PW2" title="Issued shares"&gt;375,000&lt;/span&gt; shares of common stock. Subject to certain ownership limitations, the RD Preferred Investment Options became immediately
exercisable at an exercise price equal to $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zntitPn12CAh" title="Exercise price"&gt;7.78&lt;/span&gt; per share of common stock. The RD Preferred Investment Options are exercisable for five
and one-half years from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the PIPE Securities Purchase Agreement the Company issued unregistered preferred investment options to purchase up to
&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zLjlPihd61Y1" title="Issued shares"&gt;625,000&lt;/span&gt; shares of the common stock. Subject to certain ownership limitations, PIPE Preferred Investment Options became immediately exercisable
at an exercise price equal to $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zOI44kWNylt2" title="Exercise price"&gt;7.78&lt;/span&gt; per share of common stock. The PIPE Preferred Investment Options are exercisable for five and one-half
years from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 26, 2022, in connection with the RD Offering and PIPE Offering, the Company issued preferred investment options (the &#x201c;Placement
Agent Preferred Investment Options&#x201d;) to an entity to purchase up to &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220725__20220726__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_z4HuoSUpk0bk" title="Purchase of common stock"&gt;70,000&lt;/span&gt; shares of the common stock for acting as a placement
agent. The Placement Agent Preferred Investment Options have substantially the same terms as the RD Preferred Investment Options and
the PIPE Preferred Investments Options, except the Placement Agent Preferred Investment Options have an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220726__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_zZKCojjEaSb2" title="Exercise price"&gt;10.00&lt;/span&gt; per
share. The Placement Agent Preferred Investment Options are exercisable for five years from the date of the commencement of the RD Offering
and PIPE Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#x201c;Inducement Letters&#x201d;) with
certain holders (the &#x201c;Holders&#x201d;) of the February 2022 Post-Modification Warrants and RD and PIPE preferred investment
options to purchase shares of the Company&#x2019;s common stock (the &#x201c;Existing Warrants and Investment Options&#x201d;) pursuant
to which the Holders agreed to exercise for cash their Existing Warrants and Investment Options to purchase &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_z8kGZoMo5WF2" title="Issued shares"&gt;1,122,000&lt;/span&gt;
shares of the Company&#x2019;s common stock, in the aggregate, at a reduced exercised price of $&lt;span id="xdx_90B_eus-gaap--WarrantExercisePriceDecrease_pid_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MinimumMember_zmre4xpOatuj" title="Share price"&gt;1.37&lt;/span&gt;
per share (from an original exercise price of $&lt;span id="xdx_903_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MaximumMember_zHGTrhQQ6C24" title="Share price"&gt;7.78&lt;/span&gt;
per share), in exchange for the Company&#x2019;s agreement to issue new warrants (the &#x201c;Inducement Warrants&#x201d;) to purchase
up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zZZklwjzMRFc" title="Issued shares"&gt;2,244,000&lt;/span&gt;
shares of the Company&#x2019;s common stock (the &#x201c;Inducement Warrant Shares&#x201d;), and the Holders to make a cash payment of
$&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zLm5mALpc9N2" title="Cash payment"&gt;0.125&lt;/span&gt;
per Inducement Warrant share for total proceeds of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zD00dqXJGv56" title="Proceeds from inducement warrant"&gt;280,500&lt;/span&gt;. In January 2024, the Company received aggregate gross proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGk6Yg4XAvBi" title="Gross proceeds"&gt;1,817,640&lt;/span&gt;
from the exercise of the Existing Warrants and Investment Options by the Holders and the sale of the Inducement Warrants. Because
the Existing Warrants and Investment Options by the Holders and the sale of the Inducement Warrants that exercised on December 28,
2023 and unsettled until January 2024, the proceeds are included in the consolidated balance sheet as a subscription receivable as
of December 31, 2023. As of December 31, 2023, &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOGsXVkNBqP9"&gt;418,000&lt;/span&gt;
shares of the Existing Warrants and Investment Options exercised were considered issued as the Company had the enforceable right to
the obtain the cash proceeds, which were in-transit, and the Holders were no longer able to rescind the exercise election. Due to
the beneficial ownership limitation provisions, &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zhAJrEorEKnf" title="Issued shares"&gt;704,000&lt;/span&gt;
shares of the Existing Warrants and Investment Options exercised were initially unissued and held in abeyance for the benefit of the
Holder until notice is received from the Holder that the shares may be issued in compliance with such limitation. &lt;span id="xdx_903_ecustom--ClassOfWarrantOrRightReasonForIssuing_c20230101__20231231_zwnPNtnbyEcl" title="Warrant issued description"&gt;The
Company engaged Roth Capital Partners, LLC (&#x201c;Roth&#x201d;) to act as its financial advisor in connection with the transactions
summarized above and will pay Roth approximately $144,000 for its services, in addition to reimbursement for certain expenses. Roth
was also issued warrants to purchase up to 67,320 shares of common stock. The Roth Warrants have the same terms as the Inducement
Warrants. The grant date fair value of these Roth Warrants was estimated to be $77,991 on December 28, 2023 and were charged to
additional paid in capital as issuance costs. The Company also incurred legal fees of $17,254 related to the transactions above that
were charged to additional paid in capital as issuance costs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also agreed to file a registration statement on Form S-3 covering the resale of the Inducement Warrant Shares issued or issuable
upon the exercise of the Inducement Warrants (the &#x201c;Resale Registration Statement&#x201d;) by January 8, 2024 (filed January 11,
2024). In the Inducement Letters, the Company agreed not to issue any shares of common stock or common stock equivalents or to file any
other registration statement with the SEC (in each case, subject to certain exceptions) for a period ending on February 26, 2024. The
Company also agreed not to effect or agree to effect any variable rate transaction (as defined in the Inducement Letters) until December
28, 2024. See the &lt;i&gt;Equity Distribution Agreement&lt;/i&gt; section of this Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with this transaction, the Company determined the fair value of the Existing Warrants and Investment Options immediately
prior to the Inducement Letters and the fair value of the amended warrants and investment options immediately after the Inducement
Letters. The pre-modification measurement of fair value of the Existing Warrants and Investment Options were determined utilizing a
Black-Scholes model considering all relevant assumptions current at the date of modification (i.e. for the Existing Warrants share
price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_z4IjDXLBbkR3" title="Warrants share price"&gt;1.56&lt;/span&gt;,
exercise price of $&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zXyDya2udmf7" title="Exercise price"&gt;7.78&lt;/span&gt;,
term of &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_z18G9NhjUGR9" title="Term (years)"&gt;3.6&lt;/span&gt;
years, volatility of &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zAwHYm59mTXh" title="Warrants outstanding, measurement input"&gt;94&lt;/span&gt;%,
risk-free rate of &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zm3bbvuCJqC7" title="Warrants outstanding, measurement input"&gt;3.96&lt;/span&gt;%,
and expected dividend rate of &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zl0yVDmgmajc" title="Warrants outstanding, measurement input"&gt;0&lt;/span&gt;%,
resulting in a fair value per share of $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zhUcl0TXRUT1" title="Warrants outstanding, per share"&gt;.54&lt;/span&gt; and for the Investment Options share price of $&lt;span id="xdx_90D_ecustom--InvestmentOptionSharePrice_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zGpacZ3BNDs9" title="Share price"&gt;1.56&lt;/span&gt;,
exercise price of $&lt;span id="xdx_907_ecustom--InvestmentOptionExercisePrice_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zKnYAoUxhJdj" title="Exercise price"&gt;7.78&lt;/span&gt;,
term of &lt;span id="xdx_903_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zhEXHdObGO13" title="Term (years)"&gt;4.1&lt;/span&gt; years,
volatility of &lt;span id="xdx_907_ecustom--InvestmentOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zYBQ1dLbufLc" title="Investment outstanding, measurement input"&gt;95&lt;/span&gt;%,
risk-free rate of &lt;span id="xdx_90F_ecustom--InvestmentOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zntwM6yIYi33" title="Investment outstanding, measurement input"&gt;3.90&lt;/span&gt;%,
and expected dividend rate of &lt;span id="xdx_90A_ecustom--InvestmentOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zmwuConmHkW8" title="Investment outstanding, measurement input"&gt;0&lt;/span&gt;%,
resulting in a fair value per share of $&lt;span id="xdx_90A_ecustom--SharePriceOption_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zrnS9PJeicn5" title="Investment outstanding, per share"&gt;.62&lt;/span&gt;). The total fair value of the &lt;span id="xdx_907_eus-gaap--SharesOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_z0BA93tLj2hc" title="Shares outstanding"&gt;122,000&lt;/span&gt; Existing Warrants and &lt;span id="xdx_909_eus-gaap--SharesOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_ztD05TA6sohg" title="Shares outstanding"&gt;1,000,000&lt;/span&gt; Investment Options
was $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zVhEgu2qiBfh" title="Intrinsic value"&gt;65,349&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_z5MR6FWFETJg" title="Intrinsic value"&gt;618,648&lt;/span&gt;, respectively. The post-modification fair value was determined using the intrinsic value of $&lt;span id="xdx_909_ecustom--InvestmentIntrinsicValue_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember_zMYFJxOt02R5" title="Intrinsic value"&gt;0.19&lt;/span&gt;
due to the inducement and totaled $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zo6q6Crb4fEc" title="Intrinsic value"&gt;23,180&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_zUN1EbSFyMVk" title="Intrinsic value"&gt;190,000&lt;/span&gt; for the Existing Warrants and Investment Options, respectively. The change in fair value from the date of the modification prior to modification and the fair value on the
date of the modification after the modification, but prior to exercise was $&lt;span id="xdx_903_ecustom--InvestmentInducementGain_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember_zYGxYB7iir1f" title="Inducement gain"&gt;470,817&lt;/span&gt;,
which was reflected as an inducement gain, within other expenses on the Company&#x2019;s consolidated statement of operations and
comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
grant date fair value of these Inducement Warrants was estimated to be $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20231228__20231228_z2x1EoMCFBJl"&gt;2,599,552&lt;/span&gt; on December 28, 2023 and the proceeds of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231228__20231228_zJIFuTKtruIl"&gt;280,500&lt;/span&gt;,
which were received on January 2, 2024, for the issuance of the Inducement Warrants is reflected as inducement expense, within other
expenses on the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfValuationOfWarrantsTextBlock_zjlfMoR7FOl7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its equity classified Inducement Warrants at the date of issuance on December 28, 2023.
The Company used a Black Scholes valuation model in order to determine their value. The key inputs into the Black Scholes valuation model
for the valuation of the warrants are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zy2L3wh6IEsj" style="display: none"&gt;SCHEDULE
OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Roth and Inducement Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 28, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z52K9qwfKrY6" title="Term (years)"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zvpHkwU31FQ6" title="Stock price"&gt;1.56&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zm3vVfJEgZJb" title="Exercise price"&gt;1.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zdaTE0h352rg" title="Dividend yield"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zZ8qJnxEV6V3" title="Expected volatility"&gt;92.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z72dh5NNsTw" title="Risk free interest rate"&gt;3.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Number of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zMzy9I7TxUTl" style="text-align: right" title="Warrants, number of warrants"&gt;2,311,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zBRgEViXl0za" style="text-align: right" title="Value (per share)"&gt;1.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zXHJwPy7aNrd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series
C Preferred Shares&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 3, 2022, the Board of Directors (the &#x201c;Board&#x201d;) declared a dividend of one one-thousandth of a share of the Company&#x2019;s
Series C Preferred Stock (&#x201c;Series C Preferred Stock&#x201d;) for each outstanding share of the Company&#x2019;s common stock held of record as of 5:00 p.m. Eastern Time on May 13, 2022 (the &#x201c;Record Date&#x201d;). This dividend
was based on the number of outstanding shares of common stock prior to the Reverse Stock Split. The outstanding shares of Series C Preferred
Stock were entitled to vote together with the outstanding shares of the Company&#x2019;s common stock, as a single class, exclusively
with respect to a proposal giving the Board the authority, as it determines appropriate, to implement a reverse stock split within twelve
months following the approval of such proposal by the Company&#x2019;s stockholders (the &#x201c;Reverse Stock Split Proposal&#x201d;),
as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split Proposal (the
&#x201c;Adjournment Proposal&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company held a special meeting of stockholders on July 14, 2022 (the &#x201c;Special Meeting&#x201d;) for the purpose of voting on, among
other proposals, a Reverse Stock Split Proposal and an Adjournment Proposal. All shares of Series C Preferred Stock that were not present
in person or by proxy at the Special Meeting were automatically redeemed by the Company immediately prior to the opening of the polls
at Special Meeting (the &#x201c;Initial Redemption&#x201d;). All shares that were not redeemed pursuant to the Initial Redemption were
redeemed automatically upon the approval by the Company&#x2019;s stockholders of the Reverse Stock Split Proposal at the Special Meeting
(the &#x201c;Subsequent Redemption&#x201d; and, together with the Initial Redemption, the &#x201c;Redemption&#x201d;). &lt;span id="xdx_904_eus-gaap--PreferredStockVotingRights_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z5dqYDZjASmi" title="Preferred stock voting rights"&gt;Each share of Series
C Preferred Stock was entitled to receive $0.10 in cash for each 10 whole shares of Series C Preferred Stock immediately prior to the
Redemption. As of June 30, 2022, there were&lt;/span&gt; &lt;span id="xdx_904_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zdUuJvhOW6s9" title="Redeemable preferred stock, shares outstanding"&gt;52,684.548&lt;/span&gt; shares of Series C Preferred Stock issued and outstanding. As of December 31,
2022, both the Initial Redemption and the Subsequent Redemption had occurred. As a result, no shares of Series C Preferred Stock remain
outstanding. As of December 31, 2023 and 2022, there are &lt;span id="xdx_90E_eus-gaap--PreferredStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zjdiSzO1vp5b" title="Preferred Stock authorized for future issuances"&gt;100,000&lt;/span&gt; shares of Series C Preferred Stock authorized for future issuances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights contextRef="From2023-01-01to2023-12-31" id="Fact001063">The
holders of the Company&#x2019;s common stock are entitled to one vote per share</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001065"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001067"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="INF"
      id="Fact001069"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="-5"
      id="Fact001071"
      unitRef="USD">10000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ENVB:SaleOfStockConsiderationExpectedMaximumPriceOnLimitation
      contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="0"
      id="Fact001073"
      unitRef="USD">2392514</ENVB:SaleOfStockConsiderationExpectedMaximumPriceOnLimitation>
    <ENVB:CommissionPercentage
      contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="INF"
      id="Fact001075"
      unitRef="Pure">0.030</ENVB:CommissionPercentage>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember"
      decimals="-5"
      id="Fact001077"
      unitRef="USD">10000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-11-03_custom_RegistrationRightsAgreementMember"
      decimals="INF"
      id="Fact001079"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember"
      decimals="-5"
      id="Fact001081"
      unitRef="USD">10000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001083"
      unitRef="USD">567603</us-gaap:DeferredOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001084"
      unitRef="USD">255107</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001085"
      unitRef="Shares">139403</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001087"
      unitRef="Shares">103641</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <ENVB:StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001089"
      unitRef="Shares">1223</ENVB:StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001090"
      unitRef="Shares">899</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-132022-02-15_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001092"
      unitRef="Shares">400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-02-15_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001094"
      unitRef="Shares">400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-02-132022-02-15_us-gaap_IPOMember"
      decimals="-5"
      id="Fact001096"
      unitRef="USD">10000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-132022-02-15_custom_UnderwritersMember"
      decimals="INF"
      id="Fact001098"
      unitRef="Shares">60000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-02-15_custom_UnderwritersMember"
      decimals="INF"
      id="Fact001100"
      unitRef="Shares">60000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ENVB:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2022-02-132022-02-15_custom_UnderwritersMember"
      decimals="INF"
      id="Fact001102"
      unitRef="Shares">60000</ENVB:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-02-132022-02-15_custom_UnderwritersMember"
      decimals="-5"
      id="Fact001104"
      unitRef="USD">9100000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2022-02-15_custom_UnderwritersMember"
      decimals="-5"
      id="Fact001106"
      unitRef="USD">5800000</us-gaap:DeferredOfferingCosts>
    <ENVB:WarrantLiability
      contextRef="AsOf2022-02-15_custom_UnderwritersMember"
      decimals="-5"
      id="Fact001108"
      unitRef="USD">3600000</ENVB:WarrantLiability>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-02-132022-02-15_custom_UnderwritersMember"
      decimals="-5"
      id="Fact001110"
      unitRef="USD">300000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001112"
      unitRef="Shares">116500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001114"
      unitRef="Shares">258500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001116"
      unitRef="Shares">375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact001118"
      unitRef="USD">3000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001120"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001122"
      unitRef="Shares">116000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-07-22_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001124"
      unitRef="Shares">509000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001126"
      unitRef="Shares">625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact001128"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-22_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001130"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember"
      decimals="-6"
      id="Fact001132"
      unitRef="USD">8000000</us-gaap:ProceedsFromOtherEquity>
    <ENVB:PaymentsOfStockIssuanceCost
      contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember"
      decimals="-5"
      id="Fact001134"
      unitRef="USD">7100000</ENVB:PaymentsOfStockIssuanceCost>
    <ENVB:PaymentsOfAllocatedEquity
      contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember"
      decimals="-5"
      id="Fact001136"
      unitRef="USD">3200000</ENVB:PaymentsOfAllocatedEquity>
    <ENVB:PaymentsOfInvestmentOptionLiability
      contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember"
      decimals="-5"
      id="Fact001138"
      unitRef="USD">4300000</ENVB:PaymentsOfInvestmentOptionLiability>
    <ENVB:PaymentsOfStockIssuanceCostsRecordedExpense
      contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember"
      decimals="-5"
      id="Fact001140"
      unitRef="USD">400000</ENVB:PaymentsOfStockIssuanceCostsRecordedExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-05-022022-05-03" id="Fact001142">(i) increase the aggregate number of shares available
for the grant of awards by 146,083 shares to a total of 200,000 shares, and (ii) add an &#x201c;evergreen&#x201d; provision whereby the
number of shares authorized for issuance pursuant to awards under the Incentive Plan will be automatically increased on the first trading
date immediately following the date the Company issues any share of common stock (defined below) to any person or entity, to the extent
necessary so that the number of shares of the Company&#x2019;s common stock authorized for issuance under the Incentive Plan will equal
the greater of (x) 200,000 shares, and (y) 15% of the total number of shares of the Company&#x2019;s common stock outstanding as of such
issuance date (the &#x201c;Evergreen Provision&#x201d;). The Plan Amendment was approved by the Company&#x2019;s shareholders at a special
meeting of the Company&#x2019;s shareholders held on July 14, 2022.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2023-11-02_custom_TwoThousandTwentyLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact001144"
      unitRef="Shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact001146"
      unitRef="Shares">107453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001148">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8YtSqYx16Ag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity under the Company&#x2019;s incentive plan for the years ended December 31, 2023 and 2022 is presented
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zu3hZq6igFI4" style="display: none"&gt;SCHEDULE OF STOCK OPTION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zlfachWgXyo4" style="width: 9%; text-align: right" title="Number of Shares, Outstanding at beginning"&gt;23,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zBHipcjjafJb" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning"&gt;79.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_z3KUiEblBS32" style="width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning"&gt;103.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zc6QHY3pugra" title="Weighted Average Remaining Contractual Term (years)"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zWsvXq7xXltk" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Outstanding"&gt;34,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zUwzel36BOnk" style="text-align: right" title="Number of Shares, Granted"&gt;25,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z5kJ7HfnP6pf" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;3.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znh44xkmKi5a" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;
                                                                          &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zMwQE9ty7cd5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, forfeited"&gt;(1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zODjjvTnFKVd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, forfeited"&gt;175.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znQpNtug7kVc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;140.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_z8a4TyNt1Z85" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Outstanding at beginning"&gt;48,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zg98NijbXZh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning"&gt;37.05&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zIZUyOqQArtj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning"&gt;44.82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5ShG7pIcpf5" title="Weighted Average Remaining Contractual Term (years)"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zfbN7fLAAKpi" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1180"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zvXECFVHHTLj" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1182"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231_z4H5Vu8Biz83" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, forfeited"&gt;(18,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zV15MinWPaA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, forfeited"&gt;3.07&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zMCYL5FZJYyj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;2.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_z0vJtB0G1Poe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Outstanding at end"&gt;30,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zTWGbA0Nvv66" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at end"&gt;57.17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zUfoA887Azb9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at end"&gt;77.22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_za3lss46TUsl" title="Weighted average remaining contractual term, outstanding balance"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231_zN4jPjsgp21g" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable shares at end"&gt;25,677&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_ziRZaH57gja8" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable weighted average price at end"&gt;64.45&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zx8Su3tDvHy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, exercisable"&gt;88.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z4vf0GnUomE9" title="Weighted average remaining contractual term, exercisable"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact001150"
      unitRef="Shares">23829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact001152"
      unitRef="USDPShares">79.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact001154"
      unitRef="USDPShares">103.50</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31" id="Fact001156">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001158"
      unitRef="USD">34333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001160"
      unitRef="Shares">25500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001162"
      unitRef="USDPShares">3.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001164"
      unitRef="USDPShares">2.58</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001166"
      unitRef="Shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001168"
      unitRef="USDPShares">175.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001170"
      unitRef="USDPShares">140.50</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001172"
      unitRef="Shares">48329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001174"
      unitRef="USDPShares">37.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001176"
      unitRef="USDPShares">44.82</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31" id="Fact001178">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001184"
      unitRef="Shares">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001186"
      unitRef="USDPShares">3.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001188"
      unitRef="USDPShares">2.58</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001190"
      unitRef="Shares">30329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001192"
      unitRef="USDPShares">57.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001194"
      unitRef="USDPShares">77.22</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-01to2023-12-31" id="Fact001196">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001198"
      unitRef="Shares">25677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001200"
      unitRef="USDPShares">64.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001202"
      unitRef="USDPShares">88.72</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-01to2023-12-31" id="Fact001204">P2Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001206">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEutDXJS5oV9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
granted during the years ended December 31, 2022 were valued using the Black Scholes model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zR9P2uQxAng7" style="display: none"&gt;SCHEDULE OF STOCK OPTION ASSUMPTION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zj6iPtU5AHta" title="Term (years)"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20221231_zlKRFdSy2ve2" title="Stock price"&gt;3.07&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231_zX3WUGe0AYX2" title="Exercise price"&gt;3.07&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z5lvwkDplOW2" title="Dividend yield"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_zXidb2KriXN1" title="Expected volatility"&gt;112.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_za8yif42LrIb" title="Risk free interest rate"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31" id="Fact001208">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001210"
      unitRef="USDPShares">3.07</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001212"
      unitRef="USDPShares">3.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001214"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001216"
      unitRef="Pure">1.120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001218"
      unitRef="Pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact001220"
      unitRef="USD">156075</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact001222"
      unitRef="USD">180042</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact001224"
      unitRef="USD">84774</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      id="Fact001225">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001227"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001229"
      unitRef="USD">24363</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001231"
      unitRef="Shares">708</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001233"
      unitRef="USD">14250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid>
    <ENVB:NumberOfVestedAndUnissuedShares
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001235"
      unitRef="Shares">0</ENVB:NumberOfVestedAndUnissuedShares>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001237">&lt;p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zeKrkjRh7dje" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activity in restricted stock units was as follows for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_zOnUfbNkVcx6" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average&lt;br/&gt;
 fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Non-vested at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEDhw9y1hxZb" style="width: 16%; text-align: right" title="Number of shares, Non-vested beginning"&gt;62,013&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaILPTwaljuj" style="width: 16%; text-align: right" title="Weighted average fair value, Non-vested beginning"&gt;126.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zirQtPdDJsZi" style="text-align: right" title="Number of shares, Granted"&gt;37,445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUYL7MfjSel" style="text-align: right" title="Weighted average fair value, Granted"&gt;33.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxzxsA9U3MM5" style="text-align: right" title="Number of shares, Forfeited"&gt;(26,772&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoUqJoFo0SPa" style="text-align: right" title="Weighted average fair value, Forfeited"&gt;79.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCGHiACcoei3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Vested"&gt;(8,633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmbvrrJRPdT2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average fair value, Vested"&gt;130.55&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Non-vested at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3a70kwxF3V2" style="text-align: right" title="Number of shares, Non-vested beginning"&gt;64,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLrYNbURiDu7" style="text-align: right" title="Weighted average fair value, Non-vested beginning"&gt;92.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znLFWlg2TGh1" style="text-align: right" title="Number of shares, Granted"&gt;182,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfBGTV22anXd" style="text-align: right" title="Weighted average fair value, Granted"&gt;2.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2mJgukWkvO9" style="text-align: right" title="Number of shares, Forfeited"&gt;(43,426&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxHfzIDptRA4" style="text-align: right" title="Weighted average fair value, Forfeited"&gt;25.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNyxeKRhEEJ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested"&gt;(62,636&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrqPsZk6qtR7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average fair value, Vested"&gt;19.80&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-vested at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIJwWAqEmkx2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, non-vested ending"&gt;140,491&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJYYLsJCm9Q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average fair value, Non-vested ending"&gt;28.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001239"
      unitRef="Shares">62013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001241"
      unitRef="USDPShares">126.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001243"
      unitRef="Shares">37445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001245"
      unitRef="USDPShares">33.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001247"
      unitRef="Shares">26772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001249"
      unitRef="USDPShares">79.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001251"
      unitRef="Shares">8633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001253"
      unitRef="USDPShares">130.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001255"
      unitRef="Shares">64053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001257"
      unitRef="USDPShares">92.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001259"
      unitRef="Shares">182500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001261"
      unitRef="USDPShares">2.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001263"
      unitRef="Shares">43426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001265"
      unitRef="USDPShares">25.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001267"
      unitRef="Shares">62636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001269"
      unitRef="USDPShares">19.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001271"
      unitRef="Shares">140491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001273"
      unitRef="USDPShares">28.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001275"
      unitRef="USD">1994085</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001277"
      unitRef="USD">2416266</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001279"
      unitRef="USD">2021021</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001281">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001283"
      unitRef="Shares">20848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001285">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z3ex9jdX7Hgd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s recognition of stock-based compensation for restricted stock units for the following periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zwVhDWsRp68h" style="display: none"&gt;SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zPQew5K1VjCh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zCbffNV9umPf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense for RSUs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zSOwB6VgYaZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,085,791&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,389,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfdu3M9qPMBi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;908,294&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,026,907&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zcduJChWGdHc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,994,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,416,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_zgOmbiRFAoQe" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock-based compensation expense for RSUs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,994,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,416,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001287"
      unitRef="USD">1085791</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001288"
      unitRef="USD">1389359</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001290"
      unitRef="USD">908294</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001291"
      unitRef="USD">1026907</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001293"
      unitRef="USD">1994085</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001294"
      unitRef="USD">2416266</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001296"
      unitRef="USD">1994085</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001297"
      unitRef="USD">2416266</us-gaap:AllocatedShareBasedCompensationExpense>
    <ENVB:ScheduleOfWarrantsOutstandingTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001299">&lt;p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zCwAZnLGDADf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about shares issuable under warrants outstanding at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_z8ZFdYdYVEvf" style="display: none"&gt;SCHEDULE
OF WARRANTS OUTSTANDING&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrant shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTfdpCfJmiBi" style="width: 11%; text-align: right" title="Warrant shares outstanding at beginning"&gt;195,463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3fi1daRxsLi" style="width: 11%; text-align: right" title="Weighted average exercise Price, Outstanding at beginning"&gt;131.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z54Yv7nvu7W9" title="Weighted average remaining life, Outstanding"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVKnQZX3WT3" style="width: 11%; text-align: right" title="Intrinsic Value, Outstanding beginning"&gt;801,024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoHdcQoSVWS2" style="text-align: right" title="Warrant shares outstanding, Issued"&gt;1,227,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq4CkgY3nmbb" style="text-align: right" title="Weighted average exercise price, Issued"&gt;10.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoCiirvRQcd1" style="text-align: right" title="Warrant shares outstanding, Exercised"&gt;(767,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchanged for common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPYXssDy289d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchanged for common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1315"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziP88dUalGL3" style="text-align: right" title="Warrant shares outstanding at beginning"&gt;655,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgN4PA0LOL52" style="text-align: right" title="Weighted average exercise Price, Outstanding at beginning"&gt;58.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNat7GYdCief" title="Weighted average remaining life, Outstanding"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zif7UujrkK8h" style="text-align: right" title="Intrinsic Value, Outstanding beginning"&gt;5,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF9wfK13hB3a" style="text-align: right" title="Warrant shares outstanding, Issued"&gt;2,311,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzzaBhPs6fcj" style="text-align: right" title="Weighted average exercise price, Issued"&gt;1.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFg4HAtR0Uo3" style="text-align: right" title="Warrant shares outstanding, Exercised"&gt;(122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjBdEmkvsgQ3" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;1.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWsO7MCiRq3g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant shares outstanding, Forfeited"&gt;(45,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0n5xO3Jttvj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Forfeited"&gt;111.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG0zfcvh1EB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant shares outstanding at end"&gt;2,799,213&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVykSWQShf2c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise Price, Outstanding at end"&gt;11.79&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo234JlDnvN9" title="Weighted average remaining life, Outstanding"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TQKNs9s47l" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant shares outstanding, Exercisable"&gt;2,799,213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxF5xDyqxuv9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable"&gt;11.79&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziBL756oG0Sj" title="Weighted average remaining life, Exercisable"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znZZJLvwpd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1349"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ENVB:ScheduleOfWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001301"
      unitRef="Shares">195463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001303"
      unitRef="USDPShares">131.00</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      id="Fact001305">P3Y4M24D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001307"
      unitRef="USD">801024</ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001309"
      unitRef="Shares">1227500</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001311"
      unitRef="USDPShares">10.31</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001313"
      unitRef="Shares">767500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001317"
      unitRef="Shares">655463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001319"
      unitRef="USDPShares">58.36</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="Fact001321">P3Y7M6D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001323"
      unitRef="USD">5514</ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001325"
      unitRef="Shares">2311320</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001327"
      unitRef="USDPShares">1.37</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001329"
      unitRef="Shares">122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001331"
      unitRef="USDPShares">1.37</ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001333"
      unitRef="Shares">45570</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001335"
      unitRef="USDPShares">111.50</ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001337"
      unitRef="Shares">2799213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001339"
      unitRef="USDPShares">11.79</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact001341">P4Y7M6D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001343"
      unitRef="Shares">2799213</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001345"
      unitRef="USDPShares">11.79</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact001347">P4Y7M6D</ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-02-102022-02-11_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001351"
      unitRef="Shares">400000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-02-11_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001353"
      unitRef="Shares">400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-102022-02-11_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001355"
      unitRef="Shares">60000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-02-11_us-gaap_CommonStockMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001357"
      unitRef="Shares">60000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-02-11_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001359"
      unitRef="USDPShares">27.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-02-11_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001361"
      unitRef="USDPShares">25.00</us-gaap:SaleOfStockPricePerShare>
    <ENVB:ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-02-14_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001363"
      unitRef="Shares">60000</ENVB:ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-07-22_custom_WarrantAmendmentAgreementsMember"
      decimals="INF"
      id="Fact001365"
      unitRef="Shares">122000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-14_custom_WarrantAmendmentAgreementsMember"
      decimals="INF"
      id="Fact001367"
      unitRef="USDPShares">27.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2022-07-14_custom_WarrantAmendmentAgreementsMember"
      id="Fact001369">2027-02-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-22_custom_WarrantAmendmentAgreementsMember"
      decimals="INF"
      id="Fact001371"
      unitRef="USDPShares">7.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-012022-12-31_custom_RDOfferingAndPIPEInvestmentOptionsMember"
      decimals="0"
      id="Fact001373"
      unitRef="USD">251357</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001375">&lt;p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z00XmdXvzoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about investment options outstanding at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zXmcUZK6ggX1" style="display: none"&gt;SCHEDULE
OF WARRANTS  AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Investment options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zEwvcLEoJfDe" style="text-align: right" title="Investment options Outstanding, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1377"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zxaDKk1asuL5" style="text-align: right" title="Weighted average exercise price, Outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1379"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zlJw8znfo0I4" style="text-align: right" title="Intrinsic value, Outstanding beginning"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1381"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; padding-bottom: 1.5pt"&gt;Issued&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zDF48VFSv1A7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Investment options outstanding, Issued"&gt;1,070,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVx10hGW7qx2" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Weighted average exercise price, Issued"&gt;7.93&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zqwHo3jONiyh" style="text-align: right" title="Investment options outstanding, beginning"&gt;1,070,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVu0eC11XHn7" style="text-align: right" title="Weighted average exercise price, Outstanding beginning"&gt;7.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7cYhlQli82i" title="Weighted average remaining life, Outstanding"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zW78kJ5dKbha" style="text-align: right" title="Intrinsic value, Outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1393"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLWd0NriqTJ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Investment options outstanding, Exercised"&gt;(1,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zJbc1b45aUy4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Exercised"&gt;1.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z1lexvtMAU48" style="border-bottom: Black 1.5pt solid; text-align: right" title="Investment options outstanding, end"&gt;70,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z64Vkjb4vBD2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Outstanding end"&gt;10.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zo3u42JYc9hg" title="Weighted average remaining life, Outstanding"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLfLYOEFU04b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic value, Outstanding end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1405"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zSZT9LEs53K1" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment options outstanding, Exercisable"&gt;70,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zaDEqPn9Z6kf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding end"&gt;10.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zyrHBnlcTyT6" title="Weighted average remaining life, Exercisable"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zhirJurCktSd" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1413"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued
      contextRef="From2022-01-012022-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001383"
      unitRef="Shares">1070000</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice
      contextRef="From2022-01-012022-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001385"
      unitRef="USDPShares">7.93</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001387"
      unitRef="Shares">1070000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2022-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001389"
      unitRef="USDPShares">7.93</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_custom_InvestmentOptionsMember"
      id="Fact001391">P5Y1M6D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001395"
      unitRef="Shares">-1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised
      contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001397"
      unitRef="USDPShares">1.37</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001399"
      unitRef="Shares">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001401"
      unitRef="USDPShares">10.00</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember"
      id="Fact001403">P4Y1M6D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001407"
      unitRef="Shares">70000</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001409"
      unitRef="USDPShares">10.00</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption
      contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember"
      id="Fact001411">P4Y1M6D</ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001415"
      unitRef="Shares">375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001417"
      unitRef="USDPShares">7.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001419"
      unitRef="Shares">625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001421"
      unitRef="USDPShares">7.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-252022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember"
      decimals="INF"
      id="Fact001423"
      unitRef="Shares">70000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember"
      decimals="INF"
      id="Fact001425"
      unitRef="USDPShares">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact001427"
      unitRef="Shares">1122000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001429"
      unitRef="USDPShares">1.37</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-01-012023-12-31_custom_FebruaryWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001431"
      unitRef="USDPShares">7.78</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-12-28_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact001433"
      unitRef="Shares">2244000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-28_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact001435"
      unitRef="USDPShares">0.125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember"
      decimals="0"
      id="Fact001437"
      unitRef="USD">280500</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-01-31_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001439"
      unitRef="USD">1817640</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001440"
      unitRef="Shares">418000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-12-31_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact001442"
      unitRef="Shares">704000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <ENVB:ClassOfWarrantOrRightReasonForIssuing contextRef="From2023-01-01to2023-12-31" id="Fact001444">The
Company engaged Roth Capital Partners, LLC (&#x201c;Roth&#x201d;) to act as its financial advisor in connection with the transactions
summarized above and will pay Roth approximately $144,000 for its services, in addition to reimbursement for certain expenses. Roth
was also issued warrants to purchase up to 67,320 shares of common stock. The Roth Warrants have the same terms as the Inducement
Warrants. The grant date fair value of these Roth Warrants was estimated to be $77,991 on December 28, 2023 and were charged to
additional paid in capital as issuance costs. The Company also incurred legal fees of $17,254 related to the transactions above that
were charged to additional paid in capital as issuance costs.</ENVB:ClassOfWarrantOrRightReasonForIssuing>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001446"
      unitRef="USDPShares">1.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001448"
      unitRef="Pure">7.78</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember"
      id="Fact001450">P3Y7M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputOptionVolatilityMember_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001452"
      unitRef="Pure">94</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001454"
      unitRef="Pure">3.96</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001456"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001458"
      unitRef="USDPShares">0.54</us-gaap:SharePrice>
    <ENVB:InvestmentOptionSharePrice
      contextRef="From2023-01-012023-12-31_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001460"
      unitRef="Shares">1.56</ENVB:InvestmentOptionSharePrice>
    <ENVB:InvestmentOptionExercisePrice
      contextRef="From2023-01-012023-12-31_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001462"
      unitRef="USDPShares">7.78</ENVB:InvestmentOptionExercisePrice>
    <ENVB:InvestmentOptionTerm
      contextRef="From2023-01-012023-12-31_custom_PreModificationWarrantsMember"
      id="Fact001464">P4Y1M6D</ENVB:InvestmentOptionTerm>
    <ENVB:InvestmentOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputOptionVolatilityMember_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001466"
      unitRef="Pure">95</ENVB:InvestmentOutstandingMeasurementInput>
    <ENVB:InvestmentOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001468"
      unitRef="Pure">3.90</ENVB:InvestmentOutstandingMeasurementInput>
    <ENVB:InvestmentOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001470"
      unitRef="Pure">0</ENVB:InvestmentOutstandingMeasurementInput>
    <ENVB:SharePriceOption
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001472"
      unitRef="USDPShares">0.62</ENVB:SharePriceOption>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_ExistingWarrantsMember"
      decimals="INF"
      id="Fact001474"
      unitRef="Shares">122000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001476"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_ExistingWarrantsMember"
      decimals="INF"
      id="Fact001478"
      unitRef="USD">65349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001480"
      unitRef="USD">618648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <ENVB:InvestmentIntrinsicValue
      contextRef="From2023-01-012023-12-31_custom_PostModificationWarrantsMember"
      decimals="INF"
      id="Fact001482"
      unitRef="USDPShares">0.19</ENVB:InvestmentIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_ExistingWarrantsMember"
      decimals="INF"
      id="Fact001484"
      unitRef="USD">23180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001486"
      unitRef="USD">190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <ENVB:InvestmentInducementGain
      contextRef="From2023-01-012023-12-31_custom_PostModificationWarrantsMember"
      decimals="0"
      id="Fact001488"
      unitRef="USD">470817</ENVB:InvestmentInducementGain>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-12-282023-12-28"
      decimals="0"
      id="Fact001489"
      unitRef="USD">2599552</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-12-282023-12-28"
      decimals="0"
      id="Fact001490"
      unitRef="USD">280500</us-gaap:ProceedsFromIssuanceOfWarrants>
    <ENVB:ScheduleOfValuationOfWarrantsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001492">&lt;p id="xdx_893_ecustom--ScheduleOfValuationOfWarrantsTextBlock_zjlfMoR7FOl7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its equity classified Inducement Warrants at the date of issuance on December 28, 2023.
The Company used a Black Scholes valuation model in order to determine their value. The key inputs into the Black Scholes valuation model
for the valuation of the warrants are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zy2L3wh6IEsj" style="display: none"&gt;SCHEDULE
OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Roth and Inducement Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 28, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z52K9qwfKrY6" title="Term (years)"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zvpHkwU31FQ6" title="Stock price"&gt;1.56&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zm3vVfJEgZJb" title="Exercise price"&gt;1.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zdaTE0h352rg" title="Dividend yield"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zZ8qJnxEV6V3" title="Expected volatility"&gt;92.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z72dh5NNsTw" title="Risk free interest rate"&gt;3.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Number of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zMzy9I7TxUTl" style="text-align: right" title="Warrants, number of warrants"&gt;2,311,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zBRgEViXl0za" style="text-align: right" title="Value (per share)"&gt;1.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ENVB:ScheduleOfValuationOfWarrantsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember"
      id="Fact001494">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice
      contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001496"
      unitRef="USDPShares">1.56</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001498"
      unitRef="USDPShares">1.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001500"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001502"
      unitRef="Pure">0.920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001504"
      unitRef="Pure">0.0380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001506"
      unitRef="Shares">2311320</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001508"
      unitRef="USDPShares">1.16</us-gaap:SharePrice>
    <us-gaap:PreferredStockVotingRights
      contextRef="From2022-07-132022-07-14_us-gaap_SeriesCPreferredStockMember"
      id="Fact001510">Each share of Series
C Preferred Stock was entitled to receive $0.10 in cash for each 10 whole shares of Series C Preferred Stock immediately prior to the
Redemption. As of June 30, 2022, there were</us-gaap:PreferredStockVotingRights>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2022-07-14_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001512"
      unitRef="Shares">52684.548</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001514"
      unitRef="Shares">100000</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <ENVB:RedeemableNonControllingInterestTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001516">&lt;p id="xdx_80C_ecustom--RedeemableNonControllingInterestTextBlock_zi5Q4GzDPrpf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8. &lt;span id="xdx_820_zpC01KA801s3"&gt;REDEEMABLE NON-CONTROLLING INTEREST&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Spin-Off
and Related Private Placement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Spin-Off, on May 5, 2022, Akos and the Company entered into into a Securities Purchase Agreement (the &#x201c;Akos
Purchase Agreement&#x201d;) with an accredited investor (the &#x201c;Akos Investor&#x201d;), pursuant to which Akos agreed to sell up to
an aggregate of &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zb3OhmPCrJOj" title="Sale of stock"&gt;5,000&lt;/span&gt; shares of Akos Series A Preferred Stock, at price of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zkAv4iFGwlvc" title="Sale of stock price per share"&gt;1,000&lt;/span&gt; per share, and warrants (the &#x201c;Akos Warrants&#x201d;)
to purchase shares of Akos&#x2019; common stock, par value $&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_ziqdyNm1proh" title="Common stock par value"&gt;0.01&lt;/span&gt; per share (the &#x201c;Akos Common Stock&#x201d;), for an aggregate purchase
price of up to $&lt;span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zewKu8BntBy9" title="Sale of stock, value"&gt;5,000,000&lt;/span&gt; (the &#x201c;Akos Private Placement&#x201d;). The Akos Purchase Agreement was guaranteed by the Company. Pursuant
to the Akos Purchase Agreement, Akos issued &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zG8bfr259E7" title="Sale of stock"&gt;1,000&lt;/span&gt; shares of the Akos Series A Preferred Stock to the Akos Investor in exchange for $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7nhFd17DNtk" title="Sale of stock, value"&gt;1,000,000&lt;/span&gt;
on May 5, 2022. The additional $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zxgML5QugCI7" title="Sale of stock, value"&gt;4,000,000&lt;/span&gt; was to be received on or immediately prior to the Spin-Off. The issuance of the Akos Series
A Preferred Stock results in RNCI (see Note 2). Palladium Capital Advisors, LLC (&#x201c;Palladium&#x201d;) acted as placement agent for
the Akos Private Placement. &lt;span id="xdx_90F_ecustom--SpinoffAndRelatedPrivatePlacementDescription_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zdbaTOlv0Foh" title="Spin-off and related private placement, description"&gt;Pursuant to the Akos Purchase Agreement, Akos had agreed to pay Palladium a fee equal to 9% of the aggregate
gross proceeds raised from the sale of the shares of the Akos Series A Preferred Stock and a non-accountable expense allowance of 1%
of the aggregate gross proceeds raised the sale of the Akos Series A Preferred Stock in the Akos Private Placement. The fee due in connection
with the Akos Private Placement to be paid to Palladium in the form of convertible preferred stock and warrants was on similar terms
to the securities issued in the Akos Private Placement.&lt;/span&gt; Palladium was also entitled to warrants to purchase Akos Common Stock in an amount
up to &lt;span id="xdx_908_ecustom--WarrantsToPurchaseCommonStockPercentage_pid_dp_uPure_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_z1kHLnr5gR2h" title="Warrants to purchase common stock, percentage"&gt;8&lt;/span&gt;% of the number of shares of Akos Common Stock underlying the shares issuable upon conversion of the Akos Series A Preferred Stock.
As of December 31, 2023, no accruals are required to be recorded for the fees or warrants since the Akos Series A Preferred Stock has
been redeemed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Terms
of Akos Series A Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the Certificate of the Designations, Preferences, and Rights of Series A Convertible Preferred Stock of Akos (the &#x201c;Akos Series
A Preferred Certificate of Designations&#x201d;), on or immediately prior to the completion of the spin-off of Akos into an independent,
separately traded public company listed on the Nasdaq Stock Market, the outstanding Akos Series A Preferred Stock automatically converted
into a number of shares of Akos Common Stock equal to &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AkosMember_zptxw7wnlvwj" title="Percentage of stock issued and outstanding"&gt;25&lt;/span&gt;% of the then issued and outstanding Akos Common Stock, subject to the Beneficial
Ownership Limitation (as defined in the Akos Purchase Agreement). Cumulative dividends on each share of Akos Series A Preferred Stock
accrue at the rate of &lt;span id="xdx_900_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AkosMember_zqfJDBLNLuU3" title="Dividend rate"&gt;5&lt;/span&gt;% annually.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Akos Series A Preferred Certificate of Designations provided that upon the earlier of (i) the one-year anniversary of May 5, 2022, and
only in the event that the Spin-Off has not occurred; or (ii) such time that Akos and the Company have abandoned the Spin-Off or the
Company is no longer pursuing the Spin-Off in good faith, the holders of the Akos Series A Preferred Stock shall have the right (the
&#x201c;Put Right&#x201d;), but not the obligation, to cause Akos to purchase all or a portion of the Akos Series A Preferred Stock for
a purchase price equal to $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znidGcp5SmHb" title="Sale of stock, price per share"&gt;1,000&lt;/span&gt; per share, subject to certain adjustments as set forth in the Akos Series A Preferred Certificate of
Designations (the &#x201c;Stated Value&#x201d;), plus all the accrued but unpaid dividends per share. In addition, after the one-year anniversary
of May 5, 2022, and only in the event that the Spin-Off has not occurred and Akos is not in material default of any of the transaction
documents, Akos may, at its option, at any time and from time to time, redeem the outstanding shares of Akos Series A Preferred Stock,
in whole or in part, for a purchase price equal to the aggregate Stated Value of the shares of Akos Series A Preferred Stock being redeemed
and the accrued and unpaid dividends on such shares. Pursuant to the Akos Purchase Agreement, the Company has guaranteed the payment
of the purchase price for the shares purchased under the Put Right.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Akos Series A Preferred Certificate of Designations contains limitations that prevent the holder thereof from acquiring shares of Akos
Common Stock upon conversion of the Akos Series A Preferred Stock that would result in the number of shares of Akos Common Stock beneficially
owned by such holder and its affiliates exceeding 9.99% of the total number of shares of Akos Common Stock outstanding immediately after
giving effect to the conversion (the &#x201c;Beneficial Ownership Limitation&#x201d;), except that upon notice from the holder to Akos,
the holder may increase or decrease the limit of the amount of ownership of outstanding shares of Akos Common Stock after converting
the holder&#x2019;s shares of Akos Series A Preferred Stock, provided that any change in the Beneficial Ownership Limitation shall not
be effective until 61 days following notice to Akos.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Redemption
of Akos Series A Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right requiring Akos to force redemption of all of the Akos Series A Preferred Stock for $&lt;span id="xdx_900_eus-gaap--DividendsPayableAmountPerShare_iI_pid_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztQh1TbMgLA2" title="Dividends, per share"&gt;1,000&lt;/span&gt;&#x202f;per share, plus accrued
but unpaid dividends of approximately $&lt;span id="xdx_905_ecustom--UnpaidDividends_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbljvP6uynA2" title="Unpaid dividends"&gt;52,000&lt;/span&gt;&#x202f;for a total of approximately $&lt;span id="xdx_901_eus-gaap--DividendsPreferredStock_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdtM4nK5oH7j" title="Dividends"&gt;1,052,000&lt;/span&gt;. The Company had 20 days following the receipt
of the Put Exercise Notice to make the payment and made payment on May 19, 2023. Upon redemption in May 2023, the Company revalued the
derivative liability and the Company recognized a change in fair value of the derivative liability on the Company&#x2019;s consolidated
statement of operations during the second quarter of 2023 of $&lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20230630_zmKTPInuh3Li" title="Change in fair value of derivative liability"&gt;714,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company, Akos, and the Akos Investor have terminated the Akos Purchase Agreement in connection with the planned Spin-Off and certain
registration rights agreement in connection with the Akos Private Placement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Accounting
for Akos Series A Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
the shares of Akos Series A Preferred Stock were redeemable at the option of the holder and the redemption is not solely in the control
of the Company, the shares of Akos Series A Preferred Stock were accounted for as a redeemable non-controlling interest and classified
within mezzanine equity in the Company&#x2019;s consolidated balance sheets. The redeemable non-controlling interest was initially measured
at fair value. Dividends on the shares of Akos Series A Preferred Stock were recognized as preferred dividends attributable to redeemable
non-controlling interest in the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--TemporaryEquityTableTextBlock_zpIqAAdWohPh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents the reconciliation of changes in redeemable non-controlling interest:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zjoodKpMYtk6" style="display: none"&gt;SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_c20230101__20231231_z2KtOijK4HZ5" style="width: 16%; text-align: right" title="Beginning balance"&gt;885,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Preferred dividends attributable to redeemable non-controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zjwjD9FtrCoi" style="text-align: right" title="Issuance of redeemable noncontrolling Series C preferred stock"&gt;19,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accretion of embedded derivative and transaction costs associated with Akos Series A Preferred Stock to redemption value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zVgFPFbJN1yh" style="text-align: right" title="Accretion of embedded derivative to redemption value"&gt;147,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Redemption of Akos Series A Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_iN_di_c20230101__20231231_z61deouwmhW3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Redemption of Akos Series A Preferred Stock"&gt;(1,052,057&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_c20230101__20231231_z2cCqG7L0c62" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1560"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z5hvmzlTgjq6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2023, the Akos Series A Preferred Stock was redeemed for a total of &lt;span id="xdx_90B_ecustom--RedeemableNoncontrollingInterest_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfzod7fCUkea" title="Redeemable noncontrolling interest"&gt;1,052,057&lt;/span&gt;, and the balance of the redeemable non-controlling
interest is $&lt;span id="xdx_902_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iI_dxL_c20231231_zAeOWuDFnGDk" title="Redeemable non-controlling interest::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1564"&gt;0&lt;/span&gt;&lt;/span&gt; as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ENVB:RedeemableNonControllingInterestTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001518"
      unitRef="Shares">5000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001520"
      unitRef="USDPShares">1000</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001522"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact001524"
      unitRef="USD">5000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001526"
      unitRef="Shares">1000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001528"
      unitRef="USD">1000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact001530"
      unitRef="USD">4000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ENVB:SpinoffAndRelatedPrivatePlacementDescription
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember"
      id="Fact001532">Pursuant to the Akos Purchase Agreement, Akos had agreed to pay Palladium a fee equal to 9% of the aggregate
gross proceeds raised from the sale of the shares of the Akos Series A Preferred Stock and a non-accountable expense allowance of 1%
of the aggregate gross proceeds raised the sale of the Akos Series A Preferred Stock in the Akos Private Placement. The fee due in connection
with the Akos Private Placement to be paid to Palladium in the form of convertible preferred stock and warrants was on similar terms
to the securities issued in the Akos Private Placement.</ENVB:SpinoffAndRelatedPrivatePlacementDescription>
    <ENVB:WarrantsToPurchaseCommonStockPercentage
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001534"
      unitRef="Pure">0.08</ENVB:WarrantsToPurchaseCommonStockPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember"
      decimals="INF"
      id="Fact001536"
      unitRef="Pure">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2022-05-042022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember"
      decimals="INF"
      id="Fact001538"
      unitRef="Pure">0.05</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001540"
      unitRef="USDPShares">1000</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001542"
      unitRef="USDPShares">1000</us-gaap:DividendsPayableAmountPerShare>
    <ENVB:UnpaidDividends
      contextRef="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001544"
      unitRef="USD">52000</ENVB:UnpaidDividends>
    <us-gaap:DividendsPreferredStock
      contextRef="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001546"
      unitRef="USD">1052000</us-gaap:DividendsPreferredStock>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact001548"
      unitRef="USD">714000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001550">&lt;p id="xdx_897_eus-gaap--TemporaryEquityTableTextBlock_zpIqAAdWohPh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents the reconciliation of changes in redeemable non-controlling interest:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zjoodKpMYtk6" style="display: none"&gt;SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_c20230101__20231231_z2KtOijK4HZ5" style="width: 16%; text-align: right" title="Beginning balance"&gt;885,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Preferred dividends attributable to redeemable non-controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zjwjD9FtrCoi" style="text-align: right" title="Issuance of redeemable noncontrolling Series C preferred stock"&gt;19,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accretion of embedded derivative and transaction costs associated with Akos Series A Preferred Stock to redemption value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zVgFPFbJN1yh" style="text-align: right" title="Accretion of embedded derivative to redemption value"&gt;147,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Redemption of Akos Series A Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_iN_di_c20230101__20231231_z61deouwmhW3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Redemption of Akos Series A Preferred Stock"&gt;(1,052,057&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_c20230101__20231231_z2cCqG7L0c62" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1560"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001552"
      unitRef="USD">885028</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001554"
      unitRef="USD">19041</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001556"
      unitRef="USD">147988</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001558"
      unitRef="USD">1052057</us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock>
    <ENVB:RedeemableNoncontrollingInterest
      contextRef="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001562"
      unitRef="USD">1052057</ENVB:RedeemableNoncontrollingInterest>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001566">&lt;p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zzc4DQdOVCk6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9. &lt;span id="xdx_82E_zsrUTbzuipf3"&gt;FAIR VALUE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z7nYIEKnfDSb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides the financial liabilities measured on a recurring basis and reported at fair value on the balance sheet as of
December 31, 2023 and 2022, and indicates the fair value of the valuation inputs the Company utilized to determine such fair value of
warrant liabilities, derivative liability, and investment options:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B1_zv5Cq3TrTwbh" style="display: none"&gt;SCHEDULE
OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zwa6pMcie7mj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_ztyBGagJWl2d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zluQ4KiXC6C8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Warrant liabilities - January 2021 Warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;81&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zbxFjRea6mu7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrant liabilities - February 2021 Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdwlc80Umupj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrant liabilities - February 2022 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;185,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zsQK5dRZG5R2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;185,215&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zBIbM8e99NVb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_z7y8UeEVWOR7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zqJ0MJeu0Ymi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Derivative liability - May 2022&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 10%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1582"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;727,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zR1tqPhaDMu9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1585"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;727,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231_z7T84h3p4yAc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zY86vTWnoNeh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_znMNJ66bvtl9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Wainwright investment options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;23,608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;44,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zeZJIMkg8nk6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;RD investment options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1591"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;302,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zOFVpVS8Jrzb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;PIPE investment options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1594"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;503,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdfcDlytmmXj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Fair value of investment option liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,608&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;851,008&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zlaHAKR4Y6A2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrant liabilities, derivative liability, and investment options are all classified as Level 3, for which there is no current market
for these securities such as the determination of fair value requires significant judgment or estimation. Changes in fair value measurement
categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded
within other income (expense) on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Initial
measurement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--InitialMeasurementMember_z1QM2DVjkmSk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the warrant liabilities are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BA_zyGP5uMpiwf9" style="display: none"&gt;SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;February 2022 Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;February 2022 Post-Modification Warrants (See Note 7)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February 15, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zkRE5qfbxQV" title="Warrants term"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_ztVxTxKwnXvb" title="Warrants term"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zg4vc6tNjoU6" style="text-align: right" title="Warrants, stock price"&gt;15.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zUD00iEXtF7c" style="text-align: right" title="Warrants, stock price"&gt;6.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMKqRGglU068" style="text-align: right" title="Warrants, exercise price"&gt;27.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKSgY0wy0iyh" style="text-align: right" title="Warrants, exercise price"&gt;7.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVyprhikOUP2" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1614"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zFsXu3HGkuPe" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1616"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zcJF7D6miHg7" title="Warrants, measurement input"&gt;74.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zXulwjEnomb2" title="Warrants, measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zDHnLKF0SByk" title="Warrants, measurement input"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_znzQkLQw96rk" title="Warrants, measurement input"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Number of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z4cDZMXOyqyk" style="text-align: right" title="Warrants, number of warrants"&gt;460,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zw9U56dyLJU3" style="text-align: right" title="Warrants, number of warrants"&gt;122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zSrYFRvG1GD9" style="text-align: right" title="Value (per share)"&gt;8.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zc94NSTnQNmh" style="text-align: right" title="Value (per share)"&gt;4.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its derivative liability at the respective date of issuance. The Company used a Weighted
Expected Return valuation model in order to determine their value. The key inputs into the Weighted Expected Return valuation model for
the initial valuations of the warrant liabilities are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;May 2022 Derivative Liability&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;May 5, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 73%"&gt;Principal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ConvertiblePreferredStockPrincipalValue_iI_pid_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zA97NpTGuk22" style="width: 23%; text-align: right" title="Principal"&gt;1,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMajfNXiCdV7" style="text-align: right" title="Dividend rate"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Market rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketRateMember_zwinaaQECZ11" style="text-align: right" title="Market rate"&gt;4.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its investment options at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the investment options are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Wainwright Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;RD Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;PIPE Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zRRpPgv5agTj" title="Investment option term"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zdhDz6mJGNJ" title="Investment option term"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zfSptC7W7KEg" title="Investment option term"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zPlSJf5eL0A6" style="text-align: right" title="Investment, stock price"&gt;6.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zqYpSozvjjQ8" style="text-align: right" title="Investment, stock price"&gt;6.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zDLPZtQBQ3f2" style="text-align: right" title="Investment, stock price"&gt;6.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYWvEhjRG27a" style="text-align: right" title="Investment, exercise price"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zidSfPnMN3kc" style="text-align: right" title="Investment, exercise price"&gt;7.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z4ui6DjkSRej" style="text-align: right" title="Investment, exercise price"&gt;7.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zQ8wA9rqzTjb" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1658"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zO3qrym8KSpa" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1660"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvzToWtaoU02" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1662"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_ziabNgPIphZ3" title="Investment, measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zofjONCNkiQb" title="Investment, measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvIEEezFwTO9" title="Investment, measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z0rmtJQWmDCi" title="Investment, measurement input"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zKeYY8MkDdMi" title="Investment, measurement input"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z9Fo5tlv9cUh" title="Investment, measurement input"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Number of investment options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYbQQoJTqgg2" style="text-align: right" title="Number of investment options"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zwzPQkiN0jy2" style="text-align: right" title="Number of investment options"&gt;375,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFk1flldufk" style="text-align: right" title="Number of investment options"&gt;625,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zwdNPoSCez9h" style="text-align: right" title="Value (per share)"&gt;3.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zCIxDRegUmw8" style="text-align: right" title="Value (per share)"&gt;4.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFdwm4V6zmKk" style="text-align: right" title="Value (per share)"&gt;4.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zqJvQKCnT5l7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Subsequent
measurement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zyPosEMl6298" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the changes in fair value of the warrant liabilities, derivative liability, and investment options that are
classified as Level 3:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B3_zf0YvucZm167" style="display: none"&gt;SCHEDULE
OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total Warrant Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 73%"&gt;Fair value as of December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfWR0eRZvVP5" style="width: 23%; text-align: right" title="Total beginning balance"&gt;653,674&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance of February 2022 warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXGaIgmvYyJi" style="text-align: right" title="Issuance of equity"&gt;3,595,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value due to modification of February 2022 warrants as part of July 2022 raise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFIntmBPaxCj" style="text-align: right" title="Change in fair value, modification"&gt;251,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE0CYMPIHUj4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value"&gt;(4,315,236&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfghil2mtthe" style="text-align: right" title="Total beginning balance"&gt;185,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkAmp56BB0z3" style="text-align: right" title="Change in fair value"&gt;(94,396&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDN8OycYqdhb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise of warrants"&gt;(65,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zme9nFXE8ezh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total beginning balance"&gt;25,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total Derivative Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Fair value as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFGDcN74hZH" style="padding-bottom: 1.5pt; text-align: right" title="Total beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1706"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 73%; text-align: left; padding-bottom: 1.5pt"&gt;Issuance of May 2022 convertible preferred stock&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPpeS4e84xo4" style="padding-bottom: 1.5pt; width: 23%; text-align: right" title="Issuance of equity"&gt;402,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSM8F2xaqSZb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value"&gt;325,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaWdjbixGpx4" style="text-align: right" title="Total beginning balance"&gt;727,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value arising from redemption of Akos Series A Preferred Stock - See Note 8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEhyNzluaeM9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value"&gt;(727,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of derivative liability as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqz7o8NCcsD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1716"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total Investment Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkafZlF2mmd8" style="text-align: right" title="Total beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1718"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 73%"&gt;Issuance of July 2022 investment options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJCC3dQ45BP1" style="width: 23%; text-align: right" title="Issuance of equity"&gt;4,323,734&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAP0ZMaOKtx2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value"&gt;(3,472,726&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsspxHsvJgQ5" style="text-align: right" title="Total beginning balance"&gt;851,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2wRFtIor8lj" style="text-align: right" title="Change in fair value"&gt;(208,752&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of investment options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmmwHeZhV8Fi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise of investment options"&gt;(618,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of investment option liability as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwfYpkEyGifd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance"&gt;23,608&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zTDiFxmrLd74" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zVmNi2ZEtwR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the warrant liabilities as of December 31, 2023 are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zGwJ3NUryGMb" style="display: none"&gt;SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 2021 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February 2021 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February 2022 Warrants Unmodified&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_z6UybGHOxEm9" title="Warrants term"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z8aHZ5nk0zCe" title="Warrants term"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zUoJTl1pinb3" title="Warrants term"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z5f7OPJrG5A" style="text-align: right" title="Warrant measurement input"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z43IGWEMy7mi" style="text-align: right" title="Warrant measurement input"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPFDp0gpvu1f" style="text-align: right" title="Warrant measurement input"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zzQ4UuJKdZN" style="text-align: right" title="Warrant measurement input"&gt;247.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zh3valY73Qz2" style="text-align: right" title="Warrant measurement input"&gt;245.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zI70P4KFepEe" style="text-align: right" title="Warrant measurement input"&gt;27.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zXom3SuDcJeh" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1752"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmrl5hHMBCm2" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1754"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zrAdZu39f75a" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1756"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zGbl4bmvxqsh" style="text-align: right" title="Warrants, measurement input"&gt;89.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUtVZGZgnQkc" style="text-align: right" title="Warrants, measurement input"&gt;88.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUdeTyuL8oac" style="text-align: right" title="Warrants, measurement input"&gt;87.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVAXZdk6d31h" style="text-align: right" title="Warrants, measurement input"&gt;4.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zXrUSp9jZPD9" style="text-align: right" title="Warrants, measurement input"&gt;4.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMV40M3mGbVf" style="text-align: right" title="Warrants, measurement input"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Number of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zn6PP51bQ6m" style="text-align: right" title="Warrants, number of warrants"&gt;36,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z5JR5WBgvpN8" style="text-align: right" title="Warrants, number of warrants"&gt;34,281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z7TkfR5O3yy9" style="text-align: right" title="Warrants, number of warrants"&gt;338,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zOg7y7IDF7R5" style="text-align: right" title="Value (per share)"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_zAR75z9wv3J9" style="text-align: right" title="Value (per share)"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zeqE92vGMb9d" style="text-align: right" title="Value (per share)"&gt;0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the investment options as of December 31, 2023 are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;H.C. Wainwright &amp;amp; Co., LLC Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zoMuNWVyzAm" title="Investment option term"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zUboA7OQUpLa" style="text-align: right" title="Investment, stock price"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--StockOptionExercisePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zgo6KhIG3Ijf" style="text-align: right" title="Investment, exercise price"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zN9N15RArLo6" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1788"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zA3LphOX94wg" title="Investment, measurement input"&gt;94.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zOhw3RzTphsk" title="Investment, measurement input"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Number of investment options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2nEB216o2a" style="text-align: right" title="Number of investment options"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zucFVItplnkl" style="text-align: right" title="Value (per share)"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zrbMv2JczZWj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the date of the redemption of the of Akos Series A Preferred Stock in May 2023, the derivative liability fair value was $&lt;span id="xdx_905_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBe0f08cNDD6" title="Derivative liability fair value"&gt;0&lt;/span&gt; due to the
probability of a spin-off occurring was zero. See Note 8.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001568">&lt;p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z7nYIEKnfDSb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides the financial liabilities measured on a recurring basis and reported at fair value on the balance sheet as of
December 31, 2023 and 2022, and indicates the fair value of the valuation inputs the Company utilized to determine such fair value of
warrant liabilities, derivative liability, and investment options:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B1_zv5Cq3TrTwbh" style="display: none"&gt;SCHEDULE
OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zwa6pMcie7mj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_ztyBGagJWl2d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zluQ4KiXC6C8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Warrant liabilities - January 2021 Warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;81&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zbxFjRea6mu7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrant liabilities - February 2021 Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdwlc80Umupj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrant liabilities - February 2022 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;185,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zsQK5dRZG5R2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;185,215&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zBIbM8e99NVb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_z7y8UeEVWOR7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zqJ0MJeu0Ymi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Derivative liability - May 2022&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 10%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1582"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;727,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zR1tqPhaDMu9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1585"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;727,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231_z7T84h3p4yAc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zY86vTWnoNeh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_znMNJ66bvtl9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Wainwright investment options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;23,608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;44,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zeZJIMkg8nk6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;RD investment options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1591"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;302,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zOFVpVS8Jrzb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;PIPE investment options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1594"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;503,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdfcDlytmmXj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Fair value of investment option liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,608&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;851,008&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001570"
      unitRef="USD">4</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001571"
      unitRef="USD">81</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001573"
      unitRef="USD">4</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001574"
      unitRef="USD">79</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001576"
      unitRef="USD">25462</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001577"
      unitRef="USD">185055</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001579"
      unitRef="USD">25470</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001580"
      unitRef="USD">185215</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember"
      decimals="0"
      id="Fact001583"
      unitRef="USD">727000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001586"
      unitRef="USD">727000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember"
      decimals="0"
      id="Fact001588"
      unitRef="USD">23608</us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember"
      decimals="0"
      id="Fact001589"
      unitRef="USD">44904</us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember"
      decimals="0"
      id="Fact001592"
      unitRef="USD">302289</us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember"
      decimals="0"
      id="Fact001595"
      unitRef="USD">503815</us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001597"
      unitRef="USD">23608</us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001598"
      unitRef="USD">851008</us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_InitialMeasurementMember"
      id="Fact001600">&lt;p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--InitialMeasurementMember_z1QM2DVjkmSk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the warrant liabilities are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BA_zyGP5uMpiwf9" style="display: none"&gt;SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;February 2022 Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;February 2022 Post-Modification Warrants (See Note 7)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February 15, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zkRE5qfbxQV" title="Warrants term"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_ztVxTxKwnXvb" title="Warrants term"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zg4vc6tNjoU6" style="text-align: right" title="Warrants, stock price"&gt;15.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zUD00iEXtF7c" style="text-align: right" title="Warrants, stock price"&gt;6.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMKqRGglU068" style="text-align: right" title="Warrants, exercise price"&gt;27.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKSgY0wy0iyh" style="text-align: right" title="Warrants, exercise price"&gt;7.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVyprhikOUP2" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1614"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zFsXu3HGkuPe" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1616"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zcJF7D6miHg7" title="Warrants, measurement input"&gt;74.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zXulwjEnomb2" title="Warrants, measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zDHnLKF0SByk" title="Warrants, measurement input"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_znzQkLQw96rk" title="Warrants, measurement input"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Number of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z4cDZMXOyqyk" style="text-align: right" title="Warrants, number of warrants"&gt;460,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zw9U56dyLJU3" style="text-align: right" title="Warrants, number of warrants"&gt;122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zSrYFRvG1GD9" style="text-align: right" title="Value (per share)"&gt;8.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zc94NSTnQNmh" style="text-align: right" title="Value (per share)"&gt;4.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its derivative liability at the respective date of issuance. The Company used a Weighted
Expected Return valuation model in order to determine their value. The key inputs into the Weighted Expected Return valuation model for
the initial valuations of the warrant liabilities are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;May 2022 Derivative Liability&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;May 5, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 73%"&gt;Principal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ConvertiblePreferredStockPrincipalValue_iI_pid_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zA97NpTGuk22" style="width: 23%; text-align: right" title="Principal"&gt;1,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMajfNXiCdV7" style="text-align: right" title="Dividend rate"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Market rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketRateMember_zwinaaQECZ11" style="text-align: right" title="Market rate"&gt;4.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its investment options at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the investment options are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Wainwright Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;RD Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;PIPE Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zRRpPgv5agTj" title="Investment option term"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zdhDz6mJGNJ" title="Investment option term"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zfSptC7W7KEg" title="Investment option term"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zPlSJf5eL0A6" style="text-align: right" title="Investment, stock price"&gt;6.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zqYpSozvjjQ8" style="text-align: right" title="Investment, stock price"&gt;6.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zDLPZtQBQ3f2" style="text-align: right" title="Investment, stock price"&gt;6.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYWvEhjRG27a" style="text-align: right" title="Investment, exercise price"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zidSfPnMN3kc" style="text-align: right" title="Investment, exercise price"&gt;7.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z4ui6DjkSRej" style="text-align: right" title="Investment, exercise price"&gt;7.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zQ8wA9rqzTjb" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1658"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zO3qrym8KSpa" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1660"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvzToWtaoU02" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1662"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_ziabNgPIphZ3" title="Investment, measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zofjONCNkiQb" title="Investment, measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvIEEezFwTO9" title="Investment, measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z0rmtJQWmDCi" title="Investment, measurement input"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zKeYY8MkDdMi" title="Investment, measurement input"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z9Fo5tlv9cUh" title="Investment, measurement input"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Number of investment options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYbQQoJTqgg2" style="text-align: right" title="Number of investment options"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zwzPQkiN0jy2" style="text-align: right" title="Number of investment options"&gt;375,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFk1flldufk" style="text-align: right" title="Number of investment options"&gt;625,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zwdNPoSCez9h" style="text-align: right" title="Value (per share)"&gt;3.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zCIxDRegUmw8" style="text-align: right" title="Value (per share)"&gt;4.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFdwm4V6zmKk" style="text-align: right" title="Value (per share)"&gt;4.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember"
      id="Fact001602">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember"
      id="Fact001604">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ENVB:WarrantsAndRightsOutstandingStockPrice
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001606"
      unitRef="USDPShares">15.75</ENVB:WarrantsAndRightsOutstandingStockPrice>
    <ENVB:WarrantsAndRightsOutstandingStockPrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001608"
      unitRef="USDPShares">6.33</ENVB:WarrantsAndRightsOutstandingStockPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001610"
      unitRef="USDPShares">27.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001612"
      unitRef="USDPShares">7.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact001618"
      unitRef="Pure">74.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact001620"
      unitRef="Pure">80.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001622"
      unitRef="Pure">1.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001624"
      unitRef="Pure">2.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact001626"
      unitRef="Shares">460000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember"
      decimals="INF"
      id="Fact001628"
      unitRef="Shares">122000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact001630"
      unitRef="USDPShares">8.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember"
      decimals="INF"
      id="Fact001632"
      unitRef="USDPShares">4.07</us-gaap:SharePrice>
    <ENVB:ConvertiblePreferredStockPrincipalValue
      contextRef="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember"
      decimals="INF"
      id="Fact001634"
      unitRef="USD">1000000</ENVB:ConvertiblePreferredStockPrincipalValue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001636"
      unitRef="Pure">5.0</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_custom_MeasurementInputMarketRateMember"
      decimals="INF"
      id="Fact001638"
      unitRef="Pure">4.4</us-gaap:AlternativeInvestmentMeasurementInput>
    <ENVB:InvestmentOptionTerm
      contextRef="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember"
      id="Fact001640">P5Y</ENVB:InvestmentOptionTerm>
    <ENVB:InvestmentOptionTerm
      contextRef="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember"
      id="Fact001642">P5Y6M</ENVB:InvestmentOptionTerm>
    <ENVB:InvestmentOptionTerm
      contextRef="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember"
      id="Fact001644">P5Y6M</ENVB:InvestmentOptionTerm>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_WainwrightInvestmentOptionsMember"
      decimals="INF"
      id="Fact001646"
      unitRef="USDPShares">6.33</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_RDInvestmentOptionsMember"
      decimals="INF"
      id="Fact001648"
      unitRef="USDPShares">6.33</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_PIPEInvestmentOptionsMember"
      decimals="INF"
      id="Fact001650"
      unitRef="USDPShares">6.33</us-gaap:SaleOfStockPricePerShare>
    <ENVB:StockOptionExercisePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_WainwrightInvestmentOptionsMember"
      decimals="INF"
      id="Fact001652"
      unitRef="USDPShares">10.00</ENVB:StockOptionExercisePrice>
    <ENVB:StockOptionExercisePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_RDInvestmentOptionsMember"
      decimals="INF"
      id="Fact001654"
      unitRef="USDPShares">7.78</ENVB:StockOptionExercisePrice>
    <ENVB:StockOptionExercisePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_PIPEInvestmentOptionsMember"
      decimals="INF"
      id="Fact001656"
      unitRef="USDPShares">7.78</ENVB:StockOptionExercisePrice>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_WainwrightInvestmentOptionsMember"
      decimals="INF"
      id="Fact001664"
      unitRef="Pure">80.0</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_RDInvestmentOptionsMember"
      decimals="INF"
      id="Fact001666"
      unitRef="Pure">80.0</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_PIPEInvestmentOptionsMember"
      decimals="INF"
      id="Fact001668"
      unitRef="Pure">80.0</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WainwrightInvestmentOptionsMember"
      decimals="INF"
      id="Fact001670"
      unitRef="Pure">2.9</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_RDInvestmentOptionsMember"
      decimals="INF"
      id="Fact001672"
      unitRef="Pure">2.9</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PIPEInvestmentOptionsMember"
      decimals="INF"
      id="Fact001674"
      unitRef="Pure">2.9</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember"
      decimals="INF"
      id="Fact001676"
      unitRef="Shares">70000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember"
      decimals="INF"
      id="Fact001678"
      unitRef="Shares">375000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember"
      decimals="INF"
      id="Fact001680"
      unitRef="Shares">625000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember"
      decimals="INF"
      id="Fact001682"
      unitRef="USDPShares">3.60</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember"
      decimals="INF"
      id="Fact001684"
      unitRef="USDPShares">4.07</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember"
      decimals="INF"
      id="Fact001686"
      unitRef="USDPShares">4.07</us-gaap:SharePrice>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_SubsequentMeasurementMember"
      id="Fact001688">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zyPosEMl6298" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the changes in fair value of the warrant liabilities, derivative liability, and investment options that are
classified as Level 3:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B3_zf0YvucZm167" style="display: none"&gt;SCHEDULE
OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total Warrant Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 73%"&gt;Fair value as of December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfWR0eRZvVP5" style="width: 23%; text-align: right" title="Total beginning balance"&gt;653,674&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance of February 2022 warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXGaIgmvYyJi" style="text-align: right" title="Issuance of equity"&gt;3,595,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value due to modification of February 2022 warrants as part of July 2022 raise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFIntmBPaxCj" style="text-align: right" title="Change in fair value, modification"&gt;251,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE0CYMPIHUj4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value"&gt;(4,315,236&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfghil2mtthe" style="text-align: right" title="Total beginning balance"&gt;185,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkAmp56BB0z3" style="text-align: right" title="Change in fair value"&gt;(94,396&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDN8OycYqdhb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise of warrants"&gt;(65,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zme9nFXE8ezh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total beginning balance"&gt;25,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total Derivative Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Fair value as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFGDcN74hZH" style="padding-bottom: 1.5pt; text-align: right" title="Total beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1706"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 73%; text-align: left; padding-bottom: 1.5pt"&gt;Issuance of May 2022 convertible preferred stock&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPpeS4e84xo4" style="padding-bottom: 1.5pt; width: 23%; text-align: right" title="Issuance of equity"&gt;402,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSM8F2xaqSZb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value"&gt;325,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaWdjbixGpx4" style="text-align: right" title="Total beginning balance"&gt;727,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value arising from redemption of Akos Series A Preferred Stock - See Note 8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEhyNzluaeM9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value"&gt;(727,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of derivative liability as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqz7o8NCcsD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1716"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total Investment Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkafZlF2mmd8" style="text-align: right" title="Total beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1718"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 73%"&gt;Issuance of July 2022 investment options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJCC3dQ45BP1" style="width: 23%; text-align: right" title="Issuance of equity"&gt;4,323,734&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAP0ZMaOKtx2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value"&gt;(3,472,726&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsspxHsvJgQ5" style="text-align: right" title="Total beginning balance"&gt;851,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2wRFtIor8lj" style="text-align: right" title="Change in fair value"&gt;(208,752&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of investment options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmmwHeZhV8Fi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise of investment options"&gt;(618,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of investment option liability as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwfYpkEyGifd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance"&gt;23,608&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001690"
      unitRef="USD">653674</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001692"
      unitRef="USD">3595420</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001694"
      unitRef="USD">251357</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001696"
      unitRef="USD">4315236</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001698"
      unitRef="USD">185215</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001700"
      unitRef="USD">94396</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <ENVB:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001702"
      unitRef="USD">65349</ENVB:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001704"
      unitRef="USD">25470</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001708"
      unitRef="USD">402000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001710"
      unitRef="USD">-325000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001712"
      unitRef="USD">727000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001714"
      unitRef="USD">727000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2022-01-012022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001720"
      unitRef="USD">4323734</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2022-01-012022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001722"
      unitRef="USD">3472726</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001724"
      unitRef="USD">851008</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001726"
      unitRef="USD">208752</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <ENVB:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions
      contextRef="From2023-01-012023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001728"
      unitRef="USD">618648</ENVB:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001730"
      unitRef="USD">23608</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_SubsequentMeasurementMember"
      id="Fact001732">&lt;p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zVmNi2ZEtwR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the warrant liabilities as of December 31, 2023 are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zGwJ3NUryGMb" style="display: none"&gt;SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 2021 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February 2021 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February 2022 Warrants Unmodified&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_z6UybGHOxEm9" title="Warrants term"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z8aHZ5nk0zCe" title="Warrants term"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zUoJTl1pinb3" title="Warrants term"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z5f7OPJrG5A" style="text-align: right" title="Warrant measurement input"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z43IGWEMy7mi" style="text-align: right" title="Warrant measurement input"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPFDp0gpvu1f" style="text-align: right" title="Warrant measurement input"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zzQ4UuJKdZN" style="text-align: right" title="Warrant measurement input"&gt;247.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zh3valY73Qz2" style="text-align: right" title="Warrant measurement input"&gt;245.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zI70P4KFepEe" style="text-align: right" title="Warrant measurement input"&gt;27.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zXom3SuDcJeh" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1752"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmrl5hHMBCm2" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1754"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zrAdZu39f75a" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1756"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zGbl4bmvxqsh" style="text-align: right" title="Warrants, measurement input"&gt;89.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUtVZGZgnQkc" style="text-align: right" title="Warrants, measurement input"&gt;88.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUdeTyuL8oac" style="text-align: right" title="Warrants, measurement input"&gt;87.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVAXZdk6d31h" style="text-align: right" title="Warrants, measurement input"&gt;4.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zXrUSp9jZPD9" style="text-align: right" title="Warrants, measurement input"&gt;4.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMV40M3mGbVf" style="text-align: right" title="Warrants, measurement input"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Number of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zn6PP51bQ6m" style="text-align: right" title="Warrants, number of warrants"&gt;36,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z5JR5WBgvpN8" style="text-align: right" title="Warrants, number of warrants"&gt;34,281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z7TkfR5O3yy9" style="text-align: right" title="Warrants, number of warrants"&gt;338,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zOg7y7IDF7R5" style="text-align: right" title="Value (per share)"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_zAR75z9wv3J9" style="text-align: right" title="Value (per share)"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zeqE92vGMb9d" style="text-align: right" title="Value (per share)"&gt;0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the investment options as of December 31, 2023 are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;H.C. Wainwright &amp;amp; Co., LLC Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zoMuNWVyzAm" title="Investment option term"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zUboA7OQUpLa" style="text-align: right" title="Investment, stock price"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--StockOptionExercisePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zgo6KhIG3Ijf" style="text-align: right" title="Investment, exercise price"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zN9N15RArLo6" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1788"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zA3LphOX94wg" title="Investment, measurement input"&gt;94.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zOhw3RzTphsk" title="Investment, measurement input"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Number of investment options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2nEB216o2a" style="text-align: right" title="Number of investment options"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zucFVItplnkl" style="text-align: right" title="Value (per share)"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember"
      id="Fact001734">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember"
      id="Fact001736">P2Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember"
      id="Fact001738">P3Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ENVB:WarrantsAndRightsOutstandingStockPrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001740"
      unitRef="USDPShares">1.30</ENVB:WarrantsAndRightsOutstandingStockPrice>
    <ENVB:WarrantsAndRightsOutstandingStockPrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001742"
      unitRef="USDPShares">1.30</ENVB:WarrantsAndRightsOutstandingStockPrice>
    <ENVB:WarrantsAndRightsOutstandingStockPrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001744"
      unitRef="USDPShares">1.30</ENVB:WarrantsAndRightsOutstandingStockPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001746"
      unitRef="USDPShares">247.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001748"
      unitRef="USDPShares">245.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001750"
      unitRef="USDPShares">27.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact001758"
      unitRef="Pure">89.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact001760"
      unitRef="Pure">88.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact001762"
      unitRef="Pure">87.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001764"
      unitRef="Pure">4.20</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001766"
      unitRef="Pure">4.20</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001768"
      unitRef="Pure">4.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember"
      decimals="INF"
      id="Fact001770"
      unitRef="Shares">36429</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember"
      decimals="INF"
      id="Fact001772"
      unitRef="Shares">34281</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact001774"
      unitRef="Shares">338000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember"
      decimals="INF"
      id="Fact001776"
      unitRef="USDPShares">0.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember"
      decimals="INF"
      id="Fact001778"
      unitRef="USDPShares">0.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact001780"
      unitRef="USDPShares">0.08</us-gaap:SharePrice>
    <ENVB:InvestmentOptionTerm
      contextRef="From2023-01-012023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      id="Fact001782">P3Y7M6D</ENVB:InvestmentOptionTerm>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      decimals="INF"
      id="Fact001784"
      unitRef="USDPShares">1.30</us-gaap:SaleOfStockPricePerShare>
    <ENVB:StockOptionExercisePrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      decimals="INF"
      id="Fact001786"
      unitRef="USDPShares">10.00</ENVB:StockOptionExercisePrice>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      decimals="INF"
      id="Fact001790"
      unitRef="Pure">94.0</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      decimals="INF"
      id="Fact001792"
      unitRef="Pure">4.00</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      decimals="INF"
      id="Fact001794"
      unitRef="Shares">70000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      decimals="INF"
      id="Fact001796"
      unitRef="USDPShares">0.34</us-gaap:SharePrice>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001798"
      unitRef="USD">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001800">&lt;p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJzHQhc2S99e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10. &lt;span id="xdx_824_zLAtIowfPq7c"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is periodically involved in legal proceedings, legal actions and claims arising in the normal course of business. Management
believes that the outcome of such legal proceedings, legal actions and claims will not have a significant adverse effect on the Company&#x2019;s
financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Australian
Subsidiary Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 23, 2023, the Company issued a press release announcing the selection of Australian CRO, Avance Clinical, in preparation for Phase
1 Study of EB-373, the Company&#x2019;s lead candidate targeting the treatment of anxiety disorders. Under the agreement, Avance Clinical
will manage the Phase 1 clinical trial of EB-373 in coordination with the Company&#x2019;s newly established Australian subsidiary, Enveric
Therapeutics Pty, Ltd. The Phase 1 clinical trial is designed as a multi-cohort, dose-ascending study to measure the safety and tolerability
of EB-373. EB-373, a next-generation proprietary psilocin prodrug, has been recognized as a New Chemical Entity (NCE) by Australia&#x2019;s
Therapeutic Goods Administration (TGA) and is currently in preclinical development targeting the treatment of anxiety disorder. The total
cost of the Avance Clinical contract is approximately &lt;span id="xdx_902_eus-gaap--CapitalizedContractCostNet_iI_uAUD_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zP5GfH9I9BH2" title="Contract cost"&gt;3,000,000&lt;/span&gt; AUD, which translates to approximately $&lt;span id="xdx_905_eus-gaap--CapitalizedContractCostNet_iI_uUSD_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zh1rCXdtro0i" title="Contract cost"&gt;2,000,000&lt;/span&gt; USD as of December
31, 2023. As of December 31, 2023, the Company has paid approximately $&lt;span id="xdx_904_eus-gaap--ConstructionContractCostProgressPaymentOffset_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zBWqr4Io24Ge" title="Payment of contract cost"&gt;1,036,940&lt;/span&gt; of the Avance Clinical contract costs and has accrued
$&lt;span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_z3EcyGn4t8s5" title="Accrued liabilities"&gt;523,284&lt;/span&gt; recorded as accrued liabilities and $&lt;span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zYKiKTtPTDXc" title="Accounts payable"&gt;239,320&lt;/span&gt; as accounts payable on the accompanying consolidated balance sheet. For the year
ended December 31, 2023, the Company has expensed $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_ztSbfQPHmw17" title="Research and development expenses"&gt;1,751,444&lt;/span&gt; in research and development expenses within the accompanying consolidated
statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Development
and Clinical Supply Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 22, 2021, the Company entered into a Development and Clinical Supply Agreement (the &#x201c;PureForm Agreement&#x201d;) with PureForm
Global, Inc. (&#x201c;PureForm&#x201d;), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&#x201c;API&#x201d;)
for the Company&#x2019;s development plans for cancer treatment and supportive care. Under the terms of the PureForm Agreement, PureForm
has granted the Company the exclusive right to purchase API and related product for cancer treatment and supportive care during the term
of the Agreement (contingent upon an initial minimum order of 1 kilogram during the first thirty (30) days from the effective date) and
has agreed to manufacture, package and test the API and related product in accordance with specifications established by the parties.
All inventions that are developed jointly by the parties in the course of performing activities under the PureForm Agreement will be
owned jointly by the parties in accordance with applicable law; however, if the Company funds additional research and development efforts
by PureForm, the parties may enter into a further agreement whereby PureForm would assign any resulting inventions or technical information
to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
initial term of the PureForm Agreement is three (3) years commencing on the effective date of the PureForm Agreement, subject to extension
by mutual agreement of the parties. The Company has met the minimum purchase requirement of 1 kilogram during the first thirty days of
the PureForm Agreement&#x2019;s effectiveness. The Company did not pursue an extension of the PureForm Agreement beyond the initial term
and the agreement terminated in 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Purchase
agreement with Prof. Zvi Vogel and Dr. Ilana Nathan &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 26, 2017, Jay Pharma entered into a purchase agreement with Prof. Zvi Vogel and Dr. Ilana Nathan (the &#x201c;Vogel-Nathan Purchase
Agreement&#x201d;), pursuant to which Jay Pharma was assigned ownership rights to certain patents, which were filed and unissued as of
the date of the Vogel-Nathan Purchase Agreement. The Vogel-Nathan Purchase Agreement includes a commitment to pay a one-time milestone
totaling $&lt;span id="xdx_909_eus-gaap--LongTermPurchaseCommitmentAmount_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember__srt--StatementScenarioAxis__custom--OneTimeMilestoneMember_zowhwjN3UqGl" title="Long-term purchase commitment, amount"&gt;200,000&lt;/span&gt; upon the issuance of a utility patent in the United States or by the European Patent Office, as defined in the agreement.
The Company has accrued such amount as of December 31, 2021, as a result of the milestone criteria being achieved. Payment was made during
January 2022. In addition, a milestone payment totaling $&lt;span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember__srt--StatementScenarioAxis__custom--AdditionalMilestoneMember_zj2RHyb06Cu7" title="Long-term purchase commitment, amount"&gt;300,000&lt;/span&gt; is due upon initiation of a Phase II(b) study. Research activities related
to the relevant patents are still in pre-clinical stage, and accordingly, this milestone has not been achieved. The Vogel-Nathan Purchase
Agreement contains a commitment for payment of royalties equaling &lt;span id="xdx_90E_ecustom--RoyaltiesPercentage_pid_dp_uPure_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember_zeaJzpkABMv3" title="Royalties percentage"&gt;2&lt;/span&gt;% of the first $&lt;span id="xdx_90D_eus-gaap--PaymentsForRoyalties_pn6n6_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember_zoZY67IeTyk6" title="Payments for royalties"&gt;20&lt;/span&gt; million in net sales derived from the commercialization
of products utilizing the relevant patent. As these products are still in the preclinical phase of development, no royalties have been
earned.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
Consulting and Vendor Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into a number of agreements and work orders for future consulting, clinical trial support, and testing services,
with terms ranging between 1 and 18 months. These agreements, in aggregate, commit the Company to approximately $&lt;span id="xdx_906_eus-gaap--Cash_iI_pn5n6_c20231231__us-gaap--TypeOfArrangementAxis__custom--OtherConsultingAndVendorAgreementsMember_zXfWx4ycr8Rc" title="Future cash"&gt;1.3&lt;/span&gt; million in future
cash payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Right-of-use
lease&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2021, MagicMed entered into a lease agreement (the &#x201c;LSIH Lease&#x201d;) with the University of Calgary for the use and
occupation of lab and office space at the University of Calgary&#x2019;s Life Science Innovation Hub building located in Calgary, Alberta,
Canada (the &#x201c;LSIH Facility&#x201d;). The lease expired in July 2023, and was extended on a month-to-month basis through December
31, 2023. Accordingly, no operating lease liability or right-of-use asset is recorded as of December 31, 2023. The Company terminated
this lease effective in March 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rent
expense is recorded on the straight-line basis. Rent expense under the LSIH Lease for the years ended December 31, 2023 and 2022 was
$&lt;span id="xdx_902_eus-gaap--PaymentsForRent_c20230101__20231231_zBINyAlGGitl" title="Rent expenses"&gt;114,241&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--PaymentsForRent_c20220101__20221231_zTe2yrPNRkw2" title="Rent expenses"&gt;120,667&lt;/span&gt;, respectively. Rent expense is recorded in research and development costs on the consolidated statements of operations
and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_zcSidS9fkSDb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average remaining lease term and the weighted-average discount rate of the lease was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_zQfu0TOu6lia" style="display: none"&gt;SCHEDULE OF WEIGHTED
AVERAGE REMAINING LEASE TERM&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Remaining lease term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231_zuiWJW2cO47k" title="Operating leases remaining lease term"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20221231_zk4ki5oTON06" title="Operating lease discount rate"&gt;12.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zFSM6H6fbVub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CapitalizedContractCostNet
      contextRef="AsOf2023-12-31_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact001802"
      unitRef="AUD">3000000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="AsOf2023-12-31_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact001804"
      unitRef="USD">2000000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:ConstructionContractCostProgressPaymentOffset
      contextRef="AsOf2023-12-31_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact001806"
      unitRef="USD">1036940</us-gaap:ConstructionContractCostProgressPaymentOffset>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2023-12-31_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact001808"
      unitRef="USD">523284</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2023-12-31_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact001810"
      unitRef="USD">239320</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact001812"
      unitRef="USD">1751444</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_OneTimeMilestoneMember"
      decimals="0"
      id="Fact001814"
      unitRef="USD">200000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_AdditionalMilestoneMember"
      decimals="0"
      id="Fact001816"
      unitRef="USD">300000</us-gaap:LongTermPurchaseCommitmentAmount>
    <ENVB:RoyaltiesPercentage
      contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember"
      decimals="INF"
      id="Fact001818"
      unitRef="Pure">0.02</ENVB:RoyaltiesPercentage>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember"
      decimals="-6"
      id="Fact001820"
      unitRef="USD">20000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31_custom_OtherConsultingAndVendorAgreementsMember"
      decimals="-5"
      id="Fact001822"
      unitRef="USD">1300000</us-gaap:Cash>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001824"
      unitRef="USD">114241</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001826"
      unitRef="USD">120667</us-gaap:PaymentsForRent>
    <ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001828">&lt;p id="xdx_89C_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_zcSidS9fkSDb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average remaining lease term and the weighted-average discount rate of the lease was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_zQfu0TOu6lia" style="display: none"&gt;SCHEDULE OF WEIGHTED
AVERAGE REMAINING LEASE TERM&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Remaining lease term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231_zuiWJW2cO47k" title="Operating leases remaining lease term"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20221231_zk4ki5oTON06" title="Operating lease discount rate"&gt;12.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2022-12-31" id="Fact001830">P0Y7M6D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001832"
      unitRef="Pure">0.120</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001834">&lt;p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zYdOWhZhqi8i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11. &lt;span id="xdx_82E_zmpByKrEU5va"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYpFlmqCGSD2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s U.S. and foreign loss before income taxes are set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zeA4xpukjyji" style="display: none"&gt;SCHEDULE OF EARNING (LOSS) BEFORE INCOME
TAX&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zxZNk46ZRzng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20221231_zijVKXfD02T1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzlef_z9MaFVvNgvr6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(10,205,116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(7,251,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzlef_zE8rf8karcM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,057,703&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12,706,165&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_mtILFCOzlef_z2B2dgbOYfy4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,262,819&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(19,957,393&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zhNKqIFZq044" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the Company recorded income tax expense of $&lt;span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20231231_z3Bd8okIz0A9" title="Income tax expenses and benefits"&gt;28,913&lt;/span&gt; and an income tax benefit of $&lt;span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zTxFvfZupNSk" title="Income tax expenses and benefits"&gt;1,486,060&lt;/span&gt;,
respectively. The income tax benefit (expense) is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zBdQk1cD3aIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_z4LFMffO1bGa" style="display: none"&gt;SCHEDULE
OF INCOME TAX EXPENSE BENEFITS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20231231_zXpnWXEk0Qnd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_zktAaySoCScj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Current:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_iN_di_maCITEBzYcv_zswZcV5nkVg7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1853"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maCITEBzYcv_zAEkzY61kyi6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;State&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(28,913&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maCITEBzYcv_zBO2f4fpNnae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1860"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iNT_di_mtCITEBzYcv_maITEBzKnh_zBI0YA4EbLMh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; Total
    current income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,913&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1863"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zO46stlDOwwa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1865"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1866"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_z7PzV6xiY5vd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1869"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zXxtOtSLhIsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1871"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,486,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDFITEzdpW_maITEBzKnh_zXY6vb4G9k2j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1874"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,486,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzKnh_z5f9VHGVH2Ya" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total income tax (expense) benefit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(28,913&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,486,060&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zEMeV37Jgcl8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFSERvZE8hD1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s deferred tax assets and deferred tax liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zVn0082ZSHDi" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zXa1FmWtibt5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zwvxf2F8NBJ1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNdz_maDTANzxkL_zMNkEZsyD8Wf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;10,889,863&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,927,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzxkL_zg5Rc6Cqe1F8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,185,399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,348,928&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ResearchAndDevelopmentCapitalizedExpenses_iI_maDTANzxkL_z756cbDpyv1k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development capitalized expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;611,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;614,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsAndIntangibleAmortization_iI_maDTANzxkL_zrt11foR7jeg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOther_iI_maDTANzxkL_zLfR2vCU52Pd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzXjO_msDTANzxkL_zMfzrABlkFk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowances&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12,837,755&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,977,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzxkL_zeNN2eU460z" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1900"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1901"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zv3ekvcOLIcc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zs9bhRynYJsl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following potentially utilizable net operating loss tax carryforwards:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zt3NjQUFsfF" style="display: none"&gt;SCHEDULE
OF OPERATING LOSS CARRY FORWARDS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zulmzGTSNdN8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231_zZqWm1R4dBi8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zQU8ncu82Cef" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;24,268,692&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;18,349,753&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zI0OIVbJPSr6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,220,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,892,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zzjfJ55ZT1Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,672,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,377,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zSAitNKZZYjl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Net operating loss tax carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,672,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,377,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A8_z7S3r24z5eD4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Tax Cuts and Jobs Act of 2017 (the &#x201c;Act&#x201d;) limits the net operating loss deduction to 80% of taxable income for losses
arising in tax years beginning after December 31, 2017. As of December 31, 2023, the Company had federal net operating loss
carryforwards and state net operating loss carryforwards of $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zMyXJ1gm3FJ8"&gt;24,268,692&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zH57liFWfGbk" title="Net operating loss carryforwards"&gt;11,220,065&lt;/span&gt;,
respectively, both of which can be carried forward indefinitely and Canadian net operating loss carryforwards of $&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zr2nJ9Kzy0j6" title="Net operating loss carryforwards"&gt;17,672,420&lt;/span&gt;,
which will begin to expire in 2040.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzVMVNGeNJec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s effective tax rate varied from the statutory rate as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B8_z6qq60Xq2gJ2" style="display: none"&gt;SCHEDULE
OF EFFECTIVE STATUTORY INCOME TAX RATE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zcnUsjwkXjAj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_z6WLN5u7FCy" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maALCzr1A_zmTBblmRYrR1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Federal income tax at the statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 3%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 3%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maALCzr1A_zYGRPLUj28i3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax rate (net of federal)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maALCzr1A_z9kt9Ydnzk1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign tax rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_pid_dp_uPure_maALCzr1A_zTghWy4U2b78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueup_pid_dp_uPure_maALCzr1A_zw7LHgBY8Yg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred true-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1937"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maALCzr1A_ztmgY4wYYHoh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23.3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtALCzr1A_zWrMtwwBJC36" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zsa35ks9ndR2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those temporary differences become deductible. The valuation allowance increased by
$&lt;span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_znu1AgEoYdYj" title="Valuation allowance"&gt;1,859,862&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zQeSg7kdYWS3" title="Valuation allowance"&gt;4,429,869&lt;/span&gt; during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files U.S. federal and state returns. The Company&#x2019;s foreign subsidiary also files a local tax return in their local jurisdiction.
From a U.S. federal, state and Canadian perspective the years that remain open to examination are consistent with each jurisdiction&#x2019;s
statute of limitations. As of December 31, 2023, the Company has not filed tax returns for the fiscal year 2023 and Canadian corporate
tax returns for fiscal year 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Section
382&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
utilization of the Company&#x2019;s net operating losses may be subject to a substantial limitation in the event of any significant future
changes in its ownership structure under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result
in the expiration of the net operating loss carryforwards before their utilization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Section
174&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beginning
in 2022, the Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;) eliminated the option to deduct research and development expenditures
in the current year and requires taxpayers to amortize US expenses over five years and foreign expense over fifteen years pursuant to
IRC Section 174. During the years ended December 31, 2023 and 2022, the Company has estimated and capitalized gross $&lt;span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20230101__20231231_z0NaECqIR2Wg" title="Research and development expense gross"&gt;463,696&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20220101__20221231_zOGeQR7Krns5" title="Research and development expense gross"&gt;2,684,319&lt;/span&gt;,
respectively, of research and development expenditures that will be amortized primarily over five years. This did not have a material
impact on the Company&#x2019;s tax liability for the years ended December 31, 2023 and 2022. The Company will continue to evaluate the
impact of these tax law changes on the current and future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inflation
Reduction Act&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 16, 2022, President Joe Biden signed the Inflation Reduction Act of 2022 (the &#x201c;Act&#x201d;) into law. The Act includes a
new 15% corporate minimum tax and a 1% excise tax on the value of corporate stock repurchases, net of new share issuances, after December
31, 2022. These provisions did not have a material impact on the Company&#x2019;s consolidated financial position as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001836">&lt;p id="xdx_89E_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYpFlmqCGSD2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s U.S. and foreign loss before income taxes are set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zeA4xpukjyji" style="display: none"&gt;SCHEDULE OF EARNING (LOSS) BEFORE INCOME
TAX&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zxZNk46ZRzng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20221231_zijVKXfD02T1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzlef_z9MaFVvNgvr6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(10,205,116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(7,251,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzlef_zE8rf8karcM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,057,703&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12,706,165&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_mtILFCOzlef_z2B2dgbOYfy4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,262,819&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(19,957,393&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001838"
      unitRef="USD">-10205116</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001839"
      unitRef="USD">-7251228</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001841"
      unitRef="USD">-7057703</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001842"
      unitRef="USD">-12706165</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001844"
      unitRef="USD">-17262819</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001845"
      unitRef="USD">-19957393</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001847"
      unitRef="USD">28913</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001849"
      unitRef="USD">-1486060</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001851">&lt;p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zBdQk1cD3aIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_z4LFMffO1bGa" style="display: none"&gt;SCHEDULE
OF INCOME TAX EXPENSE BENEFITS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20231231_zXpnWXEk0Qnd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_zktAaySoCScj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Current:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_iN_di_maCITEBzYcv_zswZcV5nkVg7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1853"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maCITEBzYcv_zAEkzY61kyi6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;State&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(28,913&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maCITEBzYcv_zBO2f4fpNnae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1860"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iNT_di_mtCITEBzYcv_maITEBzKnh_zBI0YA4EbLMh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; Total
    current income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,913&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1863"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zO46stlDOwwa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1865"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1866"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_z7PzV6xiY5vd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1869"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zXxtOtSLhIsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1871"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,486,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDFITEzdpW_maITEBzKnh_zXY6vb4G9k2j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1874"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,486,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzKnh_z5f9VHGVH2Ya" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total income tax (expense) benefit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(28,913&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,486,060&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001856"
      unitRef="USD">28913</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001862"
      unitRef="USD">28913</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001872"
      unitRef="USD">-1486060</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001875"
      unitRef="USD">-1486060</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001877"
      unitRef="USD">28913</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001878"
      unitRef="USD">-1486060</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001880">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFSERvZE8hD1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s deferred tax assets and deferred tax liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zVn0082ZSHDi" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zXa1FmWtibt5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zwvxf2F8NBJ1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNdz_maDTANzxkL_zMNkEZsyD8Wf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;10,889,863&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,927,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzxkL_zg5Rc6Cqe1F8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,185,399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,348,928&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ResearchAndDevelopmentCapitalizedExpenses_iI_maDTANzxkL_z756cbDpyv1k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development capitalized expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;611,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;614,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsAndIntangibleAmortization_iI_maDTANzxkL_zrt11foR7jeg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOther_iI_maDTANzxkL_zLfR2vCU52Pd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzXjO_msDTANzxkL_zMfzrABlkFk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowances&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12,837,755&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,977,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzxkL_zeNN2eU460z" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1900"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1901"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001882"
      unitRef="USD">10889863</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001883"
      unitRef="USD">8927330</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001885"
      unitRef="USD">1185399</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001886"
      unitRef="USD">1348928</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ENVB:ResearchAndDevelopmentCapitalizedExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001888"
      unitRef="USD">611245</ENVB:ResearchAndDevelopmentCapitalizedExpenses>
    <ENVB:ResearchAndDevelopmentCapitalizedExpenses
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001889"
      unitRef="USD">614041</ENVB:ResearchAndDevelopmentCapitalizedExpenses>
    <ENVB:DeferredTaxAssetsAndIntangibleAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001891"
      unitRef="USD">80518</ENVB:DeferredTaxAssetsAndIntangibleAmortization>
    <ENVB:DeferredTaxAssetsAndIntangibleAmortization
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001892"
      unitRef="USD">54141</ENVB:DeferredTaxAssetsAndIntangibleAmortization>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001894"
      unitRef="USD">70730</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001895"
      unitRef="USD">33453</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001897"
      unitRef="USD">12837755</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001898"
      unitRef="USD">10977893</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001903">&lt;p id="xdx_897_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zs9bhRynYJsl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following potentially utilizable net operating loss tax carryforwards:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zt3NjQUFsfF" style="display: none"&gt;SCHEDULE
OF OPERATING LOSS CARRY FORWARDS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zulmzGTSNdN8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231_zZqWm1R4dBi8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zQU8ncu82Cef" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;24,268,692&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;18,349,753&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zI0OIVbJPSr6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,220,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,892,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zzjfJ55ZT1Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,672,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,377,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zSAitNKZZYjl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Net operating loss tax carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,672,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,377,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001905"
      unitRef="USD">24268692</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001906"
      unitRef="USD">18349753</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact001908"
      unitRef="USD">11220065</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact001909"
      unitRef="USD">16892754</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      decimals="0"
      id="Fact001911"
      unitRef="USD">17672420</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_ForeignCountryMember"
      decimals="0"
      id="Fact001912"
      unitRef="USD">16377435</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      decimals="0"
      id="Fact001914"
      unitRef="USD">17672420</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_ForeignCountryMember"
      decimals="0"
      id="Fact001915"
      unitRef="USD">16377435</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001916"
      unitRef="USD">24268692</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact001918"
      unitRef="USD">11220065</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      decimals="0"
      id="Fact001920"
      unitRef="USD">17672420</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001922">&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzVMVNGeNJec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s effective tax rate varied from the statutory rate as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B8_z6qq60Xq2gJ2" style="display: none"&gt;SCHEDULE
OF EFFECTIVE STATUTORY INCOME TAX RATE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zcnUsjwkXjAj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_z6WLN5u7FCy" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maALCzr1A_zmTBblmRYrR1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Federal income tax at the statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 3%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 3%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maALCzr1A_zYGRPLUj28i3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax rate (net of federal)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maALCzr1A_z9kt9Ydnzk1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign tax rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_pid_dp_uPure_maALCzr1A_zTghWy4U2b78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueup_pid_dp_uPure_maALCzr1A_zw7LHgBY8Yg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred true-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1937"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maALCzr1A_ztmgY4wYYHoh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23.3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtALCzr1A_zWrMtwwBJC36" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001924"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001925"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001927"
      unitRef="Pure">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001928"
      unitRef="Pure">-0.026</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001930"
      unitRef="Pure">-0.030</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001931"
      unitRef="Pure">-0.031</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001933"
      unitRef="Pure">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001934"
      unitRef="Pure">-0.040</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation>
    <ENVB:EffectiveIncomeTaxRateReconciliationDeferredTrueup
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001936"
      unitRef="Pure">0.132</ENVB:EffectiveIncomeTaxRateReconciliationDeferredTrueup>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001939"
      unitRef="Pure">0.108</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001940"
      unitRef="Pure">0.233</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001942"
      unitRef="Pure">0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001943"
      unitRef="Pure">-0.074</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001945"
      unitRef="USD">1859862</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001947"
      unitRef="USD">4429869</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001949"
      unitRef="USD">463696</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001951"
      unitRef="USD">2684319</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001953">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z18CjkrOmpN9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12. &lt;span id="xdx_820_zNqnVHMzgyjl"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Through
February 29, 2024, the Company issued all &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztZQSzRfQhgf" title="Number of common stock issued"&gt;704,000&lt;/span&gt; shares of common stock of the &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVMa1cegYz64" title="Existing Warrants"&gt;704,000&lt;/span&gt; shares of Existing Warrants and Investment Options
exercised that were held in abeyance due to the beneficial ownership limitation provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 29, 2024, one investor exercised the Inducement Warrants to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKrULxjy5eIa" title="Warrants to purchase shares of common stock"&gt;1,954,000&lt;/span&gt; shares of common stock for cash proceeds of approximately
$&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl177HQBwHH" title="Cash proceeds"&gt;2.7&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 8, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct offering
of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zxqKyTLmS3hh"&gt;228,690
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock, par
value $&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z4fZ2TTDwlU6"&gt;0.01
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share to the Holders of the Inducement Warrants.
The issuance was made in exchange for the permanent and irrevocable waiver of the variable rate transaction limitation solely with respect
to the entry into and/or issuance of shares of common stock in an at the market offering contained in the Inducement Letters.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to December 31, 2023, the Company sold an aggregate of &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zZl25kVUlsV1" title="Number of shares sold"&gt;1,668,000&lt;/span&gt; shares of common stock for aggregate gross proceeds of $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zP6ktUIcIwx3" title="Gross proceeds from sale of shares"&gt;2,392,502&lt;/span&gt; and
net proceeds of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zBs01OrWOijg" title="Net Proceeds from sale of shares"&gt;2,320,707&lt;/span&gt; under the Distribution Agreement with Canaccord.&#x201d;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-292024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001955"
      unitRef="Shares">704000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001957"
      unitRef="Shares">704000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001959"
      unitRef="Shares">1954000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-02-292024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001961"
      unitRef="USD">2700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001962"
      unitRef="Shares">228690</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001963"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember"
      decimals="INF"
      id="Fact001965"
      unitRef="Shares">1668000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember"
      decimals="0"
      id="Fact001967"
      unitRef="USD">2392502</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember"
      decimals="0"
      id="Fact001969"
      unitRef="USD">2320707</us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
